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Abstract
Implantable cardioverter defibrillators for the treatment of
arrhythmias and cardiac resynchronisation therapy for
the treatment of heart failure: systematic review and
economic evaluation
Jill L Colquitt,* Diana Mendes, Andrew J Clegg, Petra Harris,
Keith Cooper, Joanna Picot and Jackie Bryant
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton,
Southampton, UK
*Corresponding author*Corresponding author
Background: This assessment updates and expands on two previous technology assessments that
evaluated implantable cardioverter defibrillators (ICDs) for arrhythmias and cardiac resynchronisation
therapy (CRT) for heart failure (HF).
Objectives: To assess the clinical effectiveness and cost-effectiveness of ICDs in addition to optimal
pharmacological therapy (OPT) for people at increased risk of sudden cardiac death (SCD) as a result of
ventricular arrhythmias despite receiving OPT; to assess CRT with or without a defibrillator (CRT-D or
CRT-P) in addition to OPT for people with HF as a result of left ventricular systolic dysfunction (LVSD) and
cardiac dyssynchrony despite receiving OPT; and to assess CRT-D in addition to OPT for people with
both conditions.
Data sources: Electronic resources including MEDLINE, EMBASE and The Cochrane Library were searched
from inception to November 2012. Additional studies were sought from reference lists, clinical experts and
manufacturers’ submissions to the National Institute for Health and Care Excellence.
Review methods: Inclusion criteria were applied by two reviewers independently. Data extraction and
quality assessment were undertaken by one reviewer and checked by a second. Data were synthesised
through narrative review and meta-analyses. For the three populations above, randomised controlled trials
(RCTs) comparing (1) ICD with standard therapy, (2) CRT-P or CRT-D with each other or with OPT and
(3) CRT-D with OPT, CRT-P or ICD were eligible. Outcomes included mortality, adverse events and quality
of life. A previously developed Markov model was adapted to estimate the cost-effectiveness of OPT, ICDs,
CRT-P and CRT-D in the three populations by simulating disease progression calculated at 4-weekly cycles
over a lifetime horizon.
Results: A total of 4556 references were identified, of which 26 RCTs were included in the review:
13 compared ICD with medical therapy, four compared CRT-P/CRT-D with OPT and nine compared CRT-D
with ICD. ICDs reduced all-cause mortality in people at increased risk of SCD, defined in trials as those
with previous ventricular arrhythmias/cardiac arrest, myocardial infarction (MI) > 3 weeks previously,
non-ischaemic cardiomyopathy (depending on data included) or ischaemic/non-ischaemic HF and left
ventricular ejection fraction ≤ 35%. There was no benefit in people scheduled for coronary artery bypass
graft. A reduction in SCD but not all-cause mortality was found in people with recent MI. Incremental
cost-effectiveness ratios (ICERs) ranged from £14,231 per quality-adjusted life-year (QALY) to £29,756 per
QALY for the scenarios modelled. CRT-P and CRT-D reduced mortality and HF hospitalisations, and
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improved other outcomes, in people with HF as a result of LVSD and cardiac dyssynchrony when compared
with OPT. The rate of SCD was lower with CRT-D than with CRT-P but other outcomes were similar. CRT-P
and CRT-D compared with OPT produced ICERs of £27,584 per QALY and £27,899 per QALY respectively.
The ICER for CRT-D compared with CRT-P was £28,420 per QALY. In people with both conditions, CRT-D
reduced the risk of all-cause mortality and HF hospitalisation, and improved other outcomes, compared
with ICDs. Complications were more common with CRT-D. Initial management with OPT alone was most
cost-effective (ICER £2824 per QALY compared with ICD) when health-related quality of life was kept
constant over time. Costs and QALYs for CRT-D and CRT-P were similar. The ICER for CRT-D compared
with ICD was £27,195 per QALY and that for CRT-D compared with OPT was £35,193 per QALY.
Limitations: Limitations of the model include the structural assumptions made about disease progression
and treatment provision, the extrapolation of trial survival estimates over time and the assumptions made
around parameter values when evidence was not available for specific patient groups.
Conclusions: In people at risk of SCD as a result of ventricular arrhythmias and in those with HF as a result
of LVSD and cardiac dyssynchrony, the interventions modelled produced ICERs of < £30,000 per QALY
gained. In people with both conditions, the ICER for CRT-D compared with ICD, but not CRT-D compared
with OPT, was < £30,000 per QALY, and the costs and QALYs for CRT-D and CRT-P were similar. A RCT
comparing CRT-D and CRT-P in people with HF as a result of LVSD and cardiac dyssynchrony is required,
for both those with and those without an ICD indication. A RCT is also needed into the benefits of ICD in
non-ischaemic cardiomyopathy in the absence of dyssynchrony.
Study registration: This study is registered as PROSPERO number CRD42012002062.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
CONTAK-CD Randomised controlled trial of the CONTAK-CD device.
QRS interval An electrocardiogram trace pattern (comprising three electrocardiogram waves: Q, R and S)
corresponding to the depolarisation of the right and left ventricles of the heart. The duration or ‘width’ of
the QRS interval is an indicator of ventricular dyssynchrony.
QT Q and T wave on an electrocardiogram.
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by the Appraisal Committee at NICE in their deliberations. The full report with each
piece of commercial-in-confidence data removed and replaced by the statement
‘commercial-in-confidence information (or data) removed’ is available on the NICE website:
www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Scientific summary
Background
Management of people at increased risk of sudden cardiac death (SCD) as a result of ventricular
arrhythmias and of people with heart failure (HF) due to left ventricular systolic dysfunction (LVSD) and
cardiac dyssynchrony has continued to evolve. Implantable cardioverter defibrillators (ICDs), which can
restore normal heart rhythm using pacing, cardioversion or defibrillation, and cardiac resynchronisation
therapy (CRT), which resynchronises the contraction of the heart using biventricular pacing [CRT-pacer
(CRT-P)] or combines the functionality of CRT-P and an ICD (known as CRT-defibrillator CRT-D), are used
to manage these conditions. Given the considerable overlap in the conditions experienced by the different
patient groups, some uncertainty remains as to which device(s) provide the most effective option(s) for
their treatment.
Objectives
To assess the clinical effectiveness and cost-effectiveness of:
l ICDs in addition to optimal pharmacological therapy (OPT) for people who are at increased risk of SCD
as a result of ventricular arrhythmias despite receiving OPT
l CRT-P or CRT-D in addition to OPT for people with HF as a result of LVSD and cardiac dyssynchrony
despite receiving OPT
l CRT-D in addition to OPT for people with both conditions.
Methods
Data sources
Electronic bibliographic databases including MEDLINE, EMBASE and The Cochrane Library were searched
from inception to November 2012 for English-language articles. Bibliographies of included articles and
manufacturers’ submissions to the National Institute for Health and Care Excellence (NICE) were searched.
Experts in the field were asked to identify additional published and unpublished references.
Study selection
Titles and abstracts were screened for eligibility by two reviewers independently. Inclusion criteria were
applied to the full text of retrieved papers by one reviewer and checked independently by a second
reviewer. Inclusion criteria were as follows:
l people at increased risk of SCD as a result of ventricular arrhythmias despite receiving OPT
(studies comparing ICD with OPT)
l people with HF as a result of LVSD and cardiac dyssynchrony despite receiving OPT (studies comparing
CRT-P or CRT-D with each other or with OPT)
l people with both conditions described above (studies comparing CRT-D with ICD, CRT-P or OPT)
l outcome measures: mortality, adverse effects of treatment, health-related quality of life (HRQoL),
symptoms and complications related to tachyarrhythmias and/or HF, HF hospitalisations, change in New
York Heart Association (NYHA) class and change in left ventricular ejection fraction (LVEF)
l only randomised controlled trials (RCTs) or full economic evaluations were eligible.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxix
Data extraction and quality assessment
Data extraction and quality assessment were undertaken by one reviewer and checked by a second
reviewer. Differences in opinion were resolved through discussion at each stage. The manufacturer’s
submission to NICE was reviewed.
Data synthesis
Studies were synthesised through a narrative review with full tabulation of results. Where appropriate,
studies were combined in a meta-analysis.
Economic model
The model previously developed for the technology assessment of CRT for HF was adapted to estimate
the cost-effectiveness of ICDs, CRT-P and CRT-D in the scoped populations. The Markov state transition
model simulated disease progression in a cohort of patients who moved between distinct health states
over their lifetime. Disease progression varied according to the characteristics of the population group
and the care pathway that they follow. The key events modelled were hospitalisation because of HF or
arrhythmia, transplant, surgical failure, death, perioperative complications of the implant procedure,
routine device replacements, lead displacement, infections and device upgrades. Utility values for the
several health states modelled were used to estimate the benefit of each intervention in terms of
quality-adjusted life-years (QALYs). Resource use and cost estimation aimed to cost all relevant resources
consumed in the care of patients in the three populations. The resources considered in the current model
included medication, resources involved in device implantation, device-related complications and
maintenance, hospitalisation because of HF or severe arrhythmia, and heart transplantation. Costs and
benefits were discounted at 3.5% per annum. The perspective of the cost-effectiveness analysis was that
of the NHS and Personal Social Services. Uncertainty was explored through deterministic and probabilistic
sensitivity analysis.
Results
Clinical effectiveness
A total of 4556 references were identified, of which 26 RCTs were included in the review: 13 compared
ICDs with medical therapy in people at risk of SCD as a result of ventricular arrhythmias; four compared
CRT-P (and CRT-D in one RCT) with OPT in people at risk of HF because of LVSD and cardiac
dyssynchrony; and nine compared CRT-D with ICD in people with both conditions.
People at risk of sudden cardiac death as a result of ventricular arrhythmias
Previous ventricular arrhythmia/cardiac arrest (secondary prevention)
Compared with antiarrhythmic drugs, ICDs reduced the risk of all-cause mortality [four RCTs; risk ratio (RR)
0.75, 95% confidence interval (CI) 0.61 to 0.93, p= 0.01]. One RCT found no significant differences in
quality of life (QoL), whereas a second RCT found improvements with ICD but not in the control group.
Prespecified subgroups did not differ significantly.
Recent myocardial infarction (within 6–41 days or ≤ 31 days)
Meta-analysis found no difference in all-cause mortality between the groups (two RCTs; RR 1.04, 95% CI
0.86 to 1.25, p= 0.69). QoL was not reported. No significant differences in all-cause mortality were found
for 13 prespecified subgroups in one RCT.
Remote myocardial infarction (> 3 weeks or > 1 month previously)
Meta-analysis found a reduction in all-cause mortality with the use of ICDs (two RCTs; RR 0.57, 95% CI
0.33 to 0.97, p= 0.04). One RCT reporting hospitalisations found higher rates per 1000 months’ follow-up
among people receiving an ICD (11.3 vs. 9.4, p= 0.09), with higher HF hospitalisations (19.9% vs. 14.9%).
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Differences in QoL measured using the Health Utilities Index 3 (HUI3) were not statistically significant
between groups. All-cause mortality for 12 prespecified subgroups was similar.
Non-ischaemic or idiopathic dilated cardiomyopathy
Meta-analysis found no significant difference in all-cause mortality between the groups (three RCTs; RR
0.77, 95% CI 0.52 to 1.15, p= 0.20). Two trials reported no significant differences in QoL. One trial
reported no statistically significant differences in six prespecified subgroup analyses for all-cause mortality.
Meta-analysis of the three cardiomyopathy trials and the non-ischaemic congestive HF subgroup of the
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) found a statistically significant reduction in
all-cause mortality with ICD therapy (RR 0.74, 95% CI 0.58 to 0.93, p= 0.01).
Scheduled for coronary artery bypass graft
One RCT found no difference in all-cause mortality between the groups (RR 1.08, 95% CI 0.85 to
1.38, p= 0.53).
Health-related quality of life was significantly better among people receiving OPT for some measures.
There was no difference in all-cause mortality among 10 prespecified subgroups.
A broad population with mild to moderate ischaemic/non-ischaemic
heart failure and a left ventricular ejection fraction of ≤ 35%
One three-arm trial compared ICDs, amiodarone and placebo. Compared with placebo, ICDs reduced the
risk of all-cause mortality [hazard ratio (HR) 0.77, 97.5% CI 0.62 to 0.96, p= 0.007]. No significant
difference was found in QoL. QoL was lower in people who had had an ICD shock within the previous
month than in those who had not received a shock. There was no interaction of ICD therapy with the
cause of congestive HF. Compared with placebo, ICDs reduced the risk of all-cause mortality in those in
NYHA class II but not in NYHA class III.
Adverse events
Between 5% and 61% of people with an ICD experienced an adverse event, depending on the definition
of adverse event and length of follow-up. Three trials reporting adverse event rates for the comparator
treatment found rates between 12% and 55%. Lead-, electrode- or defibrillator generator-related
problems affected 1.8–14% of people in five trials reporting this.
People with heart failure as a result of left ventricular systolic dysfunction
and cardiac dyssynchrony
Compared with OPT, CRT-P reduced the risk of all-cause mortality (four RCTs; RR 0.75, 95% CI 0.58 to
0.96, p= 0.02). An improvement in NYHA class (three RCTs; RR 1.68, 95% CI 1.52 to 1.86, p< 0.00001),
LVEF (one RCT; p< 0.001), exercise capacity (three RCTs) and QoL [four RCTs; Minnesota Living with
Heart Failure Questionnaire (MLWHFQ) score mean difference (MD) –10.33, 95% CI –13.31 to –7.36,
p< 0.00001] was also found with CRT-P. Prespecified subgroup analysis found that people with
non-ischaemic heart disease had a greater change in LVEF, but there was little difference in the effect of
CRT-P on the composite outcome for 16 subgroups.
One RCT found that CRT-D reduced the risk of all-cause mortality compared with OPT (HR 0.64, 95% CI
0.48 to 0.86, p= 0.003). Improvements in NYHA class (57% vs. 38%, p< 0.001), exercise capacity
(6-minute walk distance 46m vs. 1m) and QoL (MLWHFQ score –26 vs. –12, p< 0.001) were also found
with CRT-D at 6 months.
The rate of SCD was higher with CRT-P than with CRT-D (RR 2.72, 95% CI 1.58 to 4.68, p= 0.0003), but
all-cause mortality (RR 1.20, 95% CI 0.96 to 1.52, p= 0.12), HF hospitalisations (28% vs. 29%) and
changes in NYHA class, exercise capacity and QoL were similar for CRT-P and CRT-D.
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Adverse events
The rate of device-related deaths was between 0.2% and 0.8% for CRT-P (two trials) and 0.5% for
CRT-D. The rate of moderate or severe adverse events related to the implantation procedure was 10% for
CRT-P and 8% for CRT-D in one trial, with 13% and 9% of CRT-P and CRT-D implantations, respectively,
unsuccessful. Moderate or severe adverse events from any cause were more common with CRT-D than
with OPT (CRT-D 69%, CRT-P 66%, OPT 61%, CRT-D vs. OPT: p= 0.03; CRT-P vs. OPT: p= 0.15).
Reported complications included lead displacements, infections and coronary sinus dissections.
People with both conditions
Compared with ICDs, CRT-D reduced the risk of all-cause mortality (eight RCTs; RR 0.84, 95% CI 0.73 to
0.96, p= 0.01) and HF hospitalisation (three RCTs; RR 0.75, 95% CI 0.64 to 0.88, p= 0.0005). No
difference in the proportion of people experiencing at least one episode of ventricular tachycardia or
ventricular fibrillation was found (four RCTs; RR 0.90, 95% CI 0.71 to 1.14, p= 0.38). An improvement in
mean NYHA class (two RCTs; MD –0.19, 95% CI –0.34 to –0.05, p= 0.008) but not in the proportion of
people who improved by one or more NYHA classes (three RCTs; RR 1.81, 95% CI 0.91 to 3.60, p= 0.09)
was found with CRT-D. Improvements in LVEF (eight RCTs; MD 2.15, 95% CI 0.45 to 3.86, p= 0.01),
exercise capacity and QoL (six RCTs; MLWHFQ score MD –6.9, 95% CI –10.4 to –3.4, p= 0.0001) were
found with CRT-D compared with ICDs. Prespecified subgroup analyses found that longer QRS duration,
women, left bundle branch block and non-ischaemic cardiomyopathy were associated with greater benefit
from CRT-D for certain outcomes. One large RCT found significantly higher device- or implantation-related
complications (13.3% vs. 6.8%, p< 0.001) and device-related hospitalisation (20% vs. 12.2%, HR 1.68,
95% CI 1.32 to 2.13, p< 0.001) with CRT-D than with ICDs.
Cost-effectiveness
A total of 1410 references were identified of which 51 economic evaluations were included in the review
of cost-effectiveness (34 reported on ICDs, 15 reported on CRT and two reported on both ICDs and CRT).
ICDs were reported to be cost-effective in almost half of the ICD studies. One relevant UK study reported
a mean incremental cost-effectiveness ratio (ICER) for an average UK secondary prevention patient of
£76,139 per QALY gained. Almost all CRT studies reported that CRT was cost-effective. One relevant UK
study estimated an ICER of £16,735 per QALY gained for CRT-P compared with OPT and an ICER of
£40,160 per QALY gained for CRT-D compared with CRT-P.
Six HRQoL studies were found. Two included people with an ICD; one found that the mean European
Quality of Life-5 Dimensions (EQ-5D) score did not change with time after implant and the other reported
no difference between EQ-5D scores of primary and secondary prevention patients and that QoL for ICD
patients was similar to that of the general population. Four cohort studies reported EQ-5D scores in HF
and the overall results showed decreased EQ-5D scores compared with scores in the general population,
particularly in NYHA classes III and IV.
One joint manufacturer’s submission was received from the Association of British Healthcare Industries
(ABHI). The general approach taken in the manufacturer’s submission seems reasonable although it is not
clear whether or not uncertainty is properly assessed. Subgroups specified by ABHI do not directly address
those scoped by NICE. Overall, the results show that for most subgroups there is at least one device with
an ICER of < £30,000 per QALY gained, and in some cases a different device might have an ICER of
< £20,000 per QALY gained.
Independent economic evaluation
People at risk of sudden cardiac death as a result of ventricular arrhythmias
The addition of ICD to OPT for the secondary prevention of SCD has an ICER of £19,479 per QALY gained
compared with OPT alone. The probability of it being cost-effective at a willingness to pay (WTP) of
£20,000 and £30,000 per QALY gained is 51% and 82% respectively. The ICER for the mixed-age cohort
is slightly higher (£24,967 per QALY), as the ICER increased with age and 52% of these patients are
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expected to be aged > 65 years. Subgroup analyses for ICD+OPT compared with OPT alone produced
ICERs of £14,231 per QALY for people with remote myocardial infarction (MI), £29,756 per QALY for a
broad population with mild to moderate HF and £26,028 per QALY for non-ischaemic cardiomyopathy.
The parameters with the greatest impact on the ICER were the time horizon, the HR for all-cause mortality
associated with the ICD+OPT arm, the risk of surgical death during ICD implantation and the lifetime of
the device.
People with heart failure as a result of left ventricular systolic dysfunction
and cardiac dyssynchrony
The addition of CRT-P to OPT (in the initial stage of management of HF) resulted in an estimated ICER of
£27,584 per QALY gained compared with initial management with OPT alone (allowing for the
subsequent implants). Similarly, the initial implant of CRT-D alongside OPT resulted in an ICER of £27,899
per QALY gained compared with OPT alone. When comparing CRT-D+OPT with CRT-P+OPT, a slightly
higher ICER was estimated for CRT-D+OPT (£28,420 per QALY gained). At a WTP of £20,000 per QALY
gained, initial management with OPT alone followed by implantation of the clinically necessary device is
the strategy with the highest probability of being cost-effective (83%). Above a WTP of £28,000 per
QALY, the strategy with the highest probability of being cost-effective is CRT-D+OPT (38%). The
incremental cost-effectiveness results for the comparisons seem to be sensitive mainly to device-related
costs and to parameters that determine the incremental benefit of the devices for patients’ survival, such
as the RRs of SCD and HF death for CRT-P. The device lifetime of CRT-D also was particularly influential
because of the incremental costs incurred when it became shorter. In a scenario assuming the upper limit
estimates of device-related costs or lower estimates for the longevity of all devices, both CRT-P+OPT and
CRT-D+OPT became non-cost-effective compared with initial management with OPT alone (followed by
the subsequent upgrades).
People with both conditions
The most cost-effective strategy for people with both conditions at a WTP range of £20,000–30,000 per
QALY is initial management with OPT alone (followed by device implantation and subsequent upgrades as
necessary). Both strategies with the initial implantation of CRT devices have ICERs of > £30,000 per QALY
compared with OPT alone (CRT-D £35,193 per QALY; CRT-P £41,414 per QALY). Costs and QALYs for
CRT-D and CRT-P are similar, as the effectiveness of CRT-P was assumed to be the same as for CRT-D.
CRT-D+OPT has an ICER of £27,195 per QALY compared with ICD+OPT. At a WTP of £30,000 per
QALY, OPT alone, ICD+OPT, CRT-D+OPT and CRT-P+OPT have a 44%, 31%, 15% and 10%
probability of being cost-effective respectively. CRT-D+OPT becomes the intervention with the highest
probability of being cost-effective above a WTP of £42,000 per QALY. Assuming the same HF progression
as used in the model for people with HF and no ICD indication gives an ICER of £27,396 per QALY for
CRT-D compared with OPT. The cost-effectiveness results for the comparison of CRT-D+OPT with
ICD+OPT were fairly robust to the variation of input parameters. The most influential parameters were the
RR of all-cause mortality for ICDs and the lifetime of the CRT-D and ICD devices.
Discussion
A de novo economic model was developed for the current appraisal following recognised guidelines, and
systematic searches were conducted to identify the data inputs for the model. The independent model was
adapted from the model structure used in the previous appraisal of CRT for HF [NICE technology appraisal
(TA)120], providing a consistent approach and enabling comparability.
Despite following recognised guidance on developing economic models, the evaluation has some
limitations. These include the use of structural assumptions about the risks and timing of reimplantation of
devices and treatment options following occurrence of a major event from previous models; the
extrapolation of trial survival estimates over time; and assumptions around parameter values when
evidence was not available for specific patient groups, particularly for CRT-P in people with both
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conditions. When limitations have arisen in the evaluation, these have been identified in the report.
Assumptions made or data identified from alternative sources have been checked by seeking clinical advice
and the effects of parameters thought to be influential to the results have been assessed through
sensitivity analyses.
In general, the independent models were relatively robust to changes in the assumptions and data
parameter values. Those parameters with the greatest impact on the cost-effectiveness results were the
time horizon, the HR for all-cause mortality associated with the devices, and the lifetime of the devices.
Conclusions
Implantable cardiac defibrillators reduced all-cause mortality in people at increased risk of SCD, defined
in trials as those with previous ventricular arrhythmias/cardiac arrest, remote MI, non-ischaemic
cardiomyopathy (depending on data included) or ischaemic/non-ischaemic HF and LVEF ≤ 35%, but not in
people scheduled for coronary artery bypass grafting or with recent MI. The addition of ICD to OPT was
cost-effective at a WTP threshold of £30,000 for the scenarios modelled, and in some cases at a WTP
threshold of £20,000, in patients at risk of SCD. CRT-P and CRT-D reduced all-cause mortality and HF
hospitalisations and improved other outcomes in people with HF as a result of LVSD and cardiac
dyssynchrony when compared with OPT. The rate of SCD was lower with CRT-D than with CRT-P, but
other outcomes, including all-cause mortality, were similar. Both CRT-P and CRT-D had an ICER of
< £30,000 per QALY gained compared with OPT, as did the comparison between CRT-D and CRT-P in
people with HF as a result of LVSD and cardiac dyssynchrony. In people with both conditions, CRT-D
reduced the risk of all-cause mortality and HF hospitalisation, and improved other outcomes, compared
with ICD. The ICER for the comparison of CRT-D+OPT with ICD+OPT but not with initial management
with OPT alone was < £30,000 per QALY (unless no difference in all-cause mortality was assumed).
The costs and QALYs for CRT-D and CRT-P were similar.
A RCT comparing CRT-D and CRT-P in people with HF due to LVSD and cardiac dyssynchrony is required,
for both those with and those without an ICD indication. A trial is needed of the benefits of ICD in
non-ischaemic cardiomyopathy in the absence of dyssynchrony.
Study registration
This study is registered as PROSPERO number CRD42012002062.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
This technology assessment has been undertaken on the request of the National Institute for HealthResearch (NIHR) Health Technology Assessment (HTA) programme to inform the National Institute for
Health and Care Excellence (NICE) appraisal Implantable Cardioverter Defibrillators for the Treatment of
Arrhythmias and Cardiac Resynchronisation Therapy for the Treatment of Heart Failure (Review of TA95
and TA120).1
Description of the underlying health problem
This assessment encompasses people at risk of sudden cardiac death (SCD) as a result of ventricular
arrhythmias (abnormal heart rhythms) and people with heart failure (HF) as a result of left ventricular
systolic dysfunction (LVSD) and cardiac dyssynchrony. For the purposes of this assessment, and in line with
the NICE scope,1 three populations are considered:
1. people at increased risk of SCD as a result of ventricular arrhythmias despite receiving optimal
pharmacological therapy (OPT)
2. people with HF as a result of LVSD and cardiac dyssynchrony despite receiving OPT
3. people with both conditions described above.
In practice, however, these are not distinct populations and there is considerable overlap between the
groups, such that people with HF from LVSD are at risk of SCD from ventricular arrhythmia.
Sudden cardiac death
The widely accepted definition of SCD is a sudden and unexpected death from cardiac causes within an
hour of the onset of symptoms.2 Coronary heart disease (CHD) (narrowing or blocking of the coronary
arteries) is the most common clinical finding associated with SCD, with about 80% of such deaths linked
to this condition (Figure 1). CHD causes SCD mainly because it can lead to ventricular tachycardia (VT),
which is an abnormally fast heart rhythm originating in one of the ventricles, and ventricular fibrillation
(VF), which is an unco-ordinated and erratic contraction of the heart muscle of the ventricles. Patients with
cardiomyopathies (diseases of heart muscle) account for a further 10–15% of cases of SCD and there is
likely to be significant overlap between this group and those with CHD (i.e. some patients will have both
conditions). The remaining 5–10% of SCD cases are associated with other disorders, either structurally
abnormal congenital cardiac conditions or structurally normal but electrically abnormal hearts.3
Deaths in England and Wales from CHD in 2010 numbered 140,301 (Table 1). It is thought that
approximately 50% of all CHD-related deaths are SCDs.6 The cause of SCD is frequently VT or VF, but may
also be due to asystole (cessation of electrical activity in the heart) or causes other than arrhythmias
(e.g. ischaemia)8,9 Commonly, VT develops initially followed by degeneration to VF, which then leads to the
development of asystole.10 According to guidelines of the American College of Cardiology, the American
Heart Association and the European Society of Cardiology for the management of patients with ventricular
arrhythmias and the prevention of SCD,7 VF is the rhythm recorded at the time of sudden cardiac arrest in
75–80% of cases. There is evidence that the incidence of VT/VF events has declined over time, perhaps
reflecting an impact of treatment strategies targeted at coronary artery disease.11–14
People known to be at risk of SCD include those who have experienced a previous event that they
survived, such as life-threatening arrhythmia (accounting for 5–10% of SCDs), haemodynamic
abnormalities including HF (7–15% of SCDs) and acute coronary syndromes such as myocardial infarction
(MI) and angina pectoris (≤ 20% of SCDs).6 However, in ≥ 30% of SCDs, CHD had not been previously
diagnosed in the patient, and in one-third of SCDs the patients were known to have cardiac disease but
were considered to be at low risk for SCD.6
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A recent systematic review of 67 studies worldwide15 estimated that the average survival rate for adults
following an out-of-hospital cardiac arrest was 7%. Depending on the clinical scenario, a small proportion
of people who do survive a first life-threatening cardiac episode may remain at high risk of further
episodes (e.g. if VF is due to left ventricular dysfunction). Secondary prevention (prevention of an
additional life-threatening event) may therefore be required. When appropriate treatment and secondary
preventative strategies are implemented, recent studies have reported 5-year survival ranging from 69% to
100%,16,17 although these may overestimate survival. It is important to recognise the multiple causes of the
electrical process of VF, as not all patients with VF will be amenable to implantable cardiac defibrillator
(ICD) therapy. For example, VF or VT occurring as a primary electrical process in Brugada syndrome would
be expected to respond well to ICD therapy, whereas VF due to massive heart damage in a major acute MI
may not. Deciding on the rational use of ICD therapy can be complex, as the risk of arrhythmic death and
therefore the potential benefit from ICD therapy varies between pathologies (e.g. ischaemic heart disease,
non-ischaemic cardiomyopathy or electrical disease) and also with the progression of the disease
(e.g. the impact of ICD may vary depending on the time after an MI that the therapy is started).
Preventing a first life-threatening event (primary prevention of SCD) is challenging because it requires
identifying people with a sufficient level of risk for primary prevention to be appropriate. There are multiple
risk factors for SCD, which include increasing age, hereditary factors, being in the top 10% of risk for
coronary atherogenesis, the presence of inflammatory markers (e.g. C-reactive protein), hypertension, left
ventricular hypertrophy, intraventricular conduction abnormalities [e.g. left bundle branch block (LBBB)],
obesity, diabetes and lifestyle factors (e.g. smoking, excessive alcohol consumption, lack of physical activity,
social and economic stressors).7 Currently no optimal strategy for risk stratification exists.18
TABLE 1 Deaths in England and Wales from CHD and SCD in 2010
Cause of death Total Men Women
aCHD4 140,301 81,405 58,896
SCDb 70,151 40,703 29,448
VFc 52,613–56,121 30,527–32,562 22,086–23,558
a Deaths from CHD defined as International Classification of Diseases codes I20–I25 inclusive.5
b Estimated as 50% of deaths from CHD.6
c Estimated as 75–80% of SCDs.7
Coronary disease (80%)
Cardiomyopathies (10 – 15%)
Other (5 – 10%)
FIGURE 1 Proportions of SCD by different aetiologies.3
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Heart failure
Heart failure is a clinical syndrome characterised by symptoms (breathlessness and fatigue) and signs
(fluid retention) caused by failure of the heart to pump adequately. It is usually a chronic condition
predominantly affecting people aged > 50 years and has a poor prognosis.19 Coronary artery disease
(ischaemic heart disease) has been identified as the most common cause of HF in two UK studies.20,21
Other causes of HF are LVSD, hypertension, valve disease, atrial fibrillation or flutter, cardiomyopathy
(either hypertrophic or restrictive) or cor pulmonale (pulmonary heart disease). The cause of HF was
unknown in approximately one-third of cases in the two UK studies.20,21 The NICE scope for this appraisal1
focuses on HF that is a result of LVSD. LVSD is an impairment in the ability of the left ventricle to pump
blood into the circulation during contraction (systole).19
The prognosis for HF patients is poor, with deterioration in quality of life (QoL) and reduced life
expectancy.19 In addition, HF patients may also be at risk of SCD. Patients with HF and LVSD from the
Echocardiographic Heart of England Screening Study (ECHOES) cohort had a 5-year survival rate of 53%,22
and 3.8% of the deaths that occurred among those with HF and LVSD were sudden deaths,22 although
SCD may be underestimated in this study. The 10-year survival in this study for those with HF and LVSD
was 27.4%.23 The severity of HF graded according to the New York Heart Association (NYHA) classification
system is an indicator of prognosis.24–27 This system has four classes to which patients can be assigned,
with severity increasing with class number from I to IV (Table 2); however, it is worth noting that clinicians
may differ in the way that they interpret and assign these classes.28
The most recent estimates for the incidence of HF in the UK come from the General Practice Research
Database (GPRD).29 In 2009 these data indicated that the incidence of HF was higher in Wales
(men 44.6 and women 24.9 per 100,000 person-years) than in England (men 37.5 and women 23.0 per
100,000 person-years). The incidence of HF increased with age, being highest in those aged > 75 years
(e.g. in England, men 326.0 and women 256.2 per 100,000 person-years), and incidence rates are higher
in men than in women at all ages. From these data and those for Scotland and Northern Ireland, it has
been estimated that there are > 27,000 new cases of HF in the UK each year.29
The corresponding estimates for the prevalence of HF in the UK derived from the GPRD29 are similar in
England and Wales (for all ages in men: 0.9% in England and 1.0% in Wales; for all ages in women:
0.7% in England and Wales). In total, this corresponds to almost 160,000 cases in England and Wales in
2009. Data from the ECHOES cohort have indicated that, of the total number of HF cases identified,
approximately 50% have HF with LVSD.22 Applying this proportion to the prevalence data for England and
Wales from the GRPD would suggest that there were approximately 80,000 cases of HF with LVSD
in 2009.
TABLE 2 The NYHA HF classification system
Class Comfort at rest?
Limitation to
physical activity? Effect of physical activity
I Yes None No undue fatigue, palpitations, dyspnoea or
angina pain
II Yes Slight Ordinary physical activity can result in fatigue,
palpitations, dyspnoea or angina pain
III Yes Marked Less than ordinary activity causes fatigue, palpitations,
dyspnoea or angina pain
IV May have HF or angina
symptoms even at rest
Always Unable to carry out any physical activity without new
or increasing discomfort
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Description of the technology under assessment
The current technology assessment concerns specific types of cardiac implantable electronic devices for the
prophylaxis and/or treatment of conduction system disease that use one or more of the following
approaches to restore normal heart rhythm:
l ‘pacing’ – a series of low-voltage electrical impulses delivered at a fast rate to correct the heart rhythm
l cardioversion’ – one or more small electric shocks delivered to the heart to restore a normal rhythm
l ‘defibrillation’ – one or more large electric shocks delivered to the heart to restore a normal rhythm.
Cardiac resynchronisation therapy (CRT) devices are a specific type of cardiac pacemaker that have three
conducting leads (connected to the right atrium and both ventricles) and are used to correct inconsistency
of the heartbeat between the right and left sides of the heart (dyssynchrony), referred to as biventricular
pacing. These devices are known as CRT-pacers (CRT-Ps) (or biventricular pacers).
Implantable cardioverter defibrillators are used to provide cardioversion and/or defibrillation shocks to
correct more serious dysfunction of the heart rhythm, including VT, VF and asystole, any one of which may
be associated with SCD. ‘Single chamber’ ICDs have a single conducting lead connected only to the right
ventricle; ‘dual chamber’ ICDs have two leads connected to the right atrium and the right ventricle.
In addition to their cardioversion and defibrillation ability, modern ICDs provide the functionality of a
standard pacemaker to treat slow heart rhythms (if necessary) by pacing the right-hand chamber(s) of
the heart.
Modern types of CRT device may combine the functionality of both a CRT-P and an ICD and these are
referred to as CRT-defibrillators (CRT-Ds).
Cardiac resynchronisation therapy is aimed at a specific subset of the HF population with evidence of
delayed left ventricular activation (as manifest by prolongation of the QRS complex). Because this
population is a priori at risk of arrhythmic death, CRT can be combined with an ICD. ICDs and CRT-D
devices are appropriate for patients with a high risk of SCD, whereas CRT-P devices are appropriate in
patients with less serious cardiac arrhythmias. However, as noted earlier, heart disease is a complex and
progressive condition and patients who are initially implanted with a CRT-P may subsequently develop
heart disease and be at risk of SCD, and an upgrade from a CRT-P to a CRT-D or an ICD may
be appropriate.30
Although they may differ in function, CRT and ICD devices are similar in size and structure – about the size
of a pocket watch (capacity 30–40ml, weight around 70 g, thickness approximately 13mm) – and consist
of a battery-powered pulse generator controlled by a microcomputer. They are implanted under the skin,
typically just below the collar bone on the left or right side of the chest, and (depending on the device
type) have one or more leads (tiny wires) that are routed through veins to the heart’s chambers for sensing
electrical activity and for providing the corrective pacing, cardioversion and/or defibrillation impulses.
Modern CRT and ICD devices store a record of the heart’s electrical activity and contain a wireless
transmitter/receiver to enable the device to be programmed and interrogated from an external computer
using wireless telemetry. Readings from a device may be transmitted by telephone, enabling the
cardiologist to remotely check the performance of the device while the patient is at home.
Early devices were implanted using the transthoracic method, but current CRT and ICD devices are placed
under the skin in the pectoral region with transvenous insertion of the leads into the heart under local
anaesthesia, using high-resolution X-ray angiography to guide the placing of the leads. The procedure for
primary prevention typically requires a maximum of a 1-night stay in hospital. For secondary prevention the
length of stay will depend on any underlying health problems. The longevity of CRT and ICD devices is
limited by their battery life, which is in the range of 4–7 years, depending on a number of factors including
the pacing mode, pacing percentage and capacitor recharge interval.31–33 Replacement of batteries alone is
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not feasible, so when the battery is due for renewal the pulse generator unit has to be replaced, in a
minor surgical procedure. When possible the connecting leads are left in situ and only the generator unit
itself is replaced, although eventually one or more of the connecting leads may also require replacement.
Modern devices can be specifically programmed to deliver resynchronisation pacing independently to the
atria and ventricles of the heart to maximise synchronisation. The devices can also be programmed
according to which of the heart’s chambers they monitor (sense) to detect existing electrical activity. The
ability of CRT and ICD devices to recognise different types of arrhythmia may enable them to deliver more
appropriate therapy, in particular lessening the incidence of inappropriate shocks. Several coding systems
(typically comprising three to five letters) have been developed to indicate the programmed pacing/sensing
modes. A widely used code developed by the Heart Rhythm Society (HRS) and the British Pacing and
Electrophysiology Group (BPEG) consists of three letters to describe the pacing chamber [atrium, A;
ventricle, V; or dual (i.e. both), D], three letters to describe the sensed chamber (A, V or D) and a further
three letters to describe whether pacing is inhibited (I) or triggered (T) in response to the sensed beat or,
if dual pacing and sensing are programmed, whether dual (D) inhibition and triggering (for the different
chambers) occurs. As an example, the code ‘VVI’ would indicate ventricular pacing (shocks are delivered to
the ventricle), ventricular sensing (electrical activity is monitored in the ventricle) and that pacing is
inhibited if an electrical beat is sensed in the ventricle. To illustrate a more complex example, the code
‘DDD’ would indicate a device programmed for dual-chamber pacing and sensing. In this case the atrium
would be stimulated if sinus bradycardia is detected. Both atrium and ventricle would be stimulated if
bradycardia exists independently in both chambers. If heart block exists with normal sinus function the
ventricle would be paced in synchrony with the atrium and, if sinus rhythm exists, pacing would be
totally inhibited.
The most recent development in cardiac implantable electronic devices is the subcutaneous ICD (S-ICD),
which was approved by the US Food and Drug Administration (FDA) in April 2012. The S-ICD is positioned
just under the skin, outside the rib cage, and can be implanted under local anaesthesia. The electronics
and batteries of the S-ICD enable it to deliver enough energy to defibrillate the heart without the need for
a connecting lead to the heart, which avoids lead-related complications including the risk of dangerous
infections (other potential procedural complications are considered below). A disadvantage of the S-ICD,
however, is that it cannot provide long-term pacing. A RCT comparing S-ICD with transvenous ICD
(ClinicalTrials.gov identifier NCT01296022)34 is currently under way and is due to complete in March 2015
and a registry study of S-ICD (ClinicalTrials.gov identifier NCT01085435)35 is due to complete in
December 2016.
Potential procedural complications
The most challenging technical aspect of a CRT device implantation is the optimal placement of the third
lead in the coronary sinus vein. The final position of the left ventricular pacing lead depends on the
anatomy of the cardiac venous system, as well as the performance and stability of the pacing lead and
the need to avoid phrenic nerve stimulation.36 The left phrenic nerve (which sends signals between the
brain and the diaphragm) may be stimulated by the left ventricular pacing lead, causing uncomfortable
diaphragmatic twitch, which could prevent optimal left ventricular lead placement and can hinder left
ventricular stimulation. Phrenic nerve stimulation occurs in around 20% of patients with bipolar leads.37
A recent systematic review of implantation-related complications in 11 ICD and seven CRT trials suggests
that the most common complications include coronary vein dissection (1.3%) and coronary vein
perforation (1.3%), with coronary vein-related complications occurring in only 2.0% of patients.38 This low
rate is attributed to the growing experience of physicians combined with technical progress. The overall
incidence of lead dislodgement for non-thoracotomy ICDs was 1.8%, with higher rates of lead
dislodgement in the CRT trials, which varied from 2.9% to 10.6%. The reported overall rate of leads
dislodged during and after 3095 successful implantations was 5.9%. A recent study in the USA,39 which
was based on the National Cardiovascular Data Registry, found that, after adjusting for diagnostic test
results and comorbidities, dual-chamber ICDs were associated with a 40% greater odds of procedural
complications and a 45% greater odds of mortality than single-chamber ICDs, illustrating a greater risk of
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procedural complications with the more complex types of ICD device. Another recent study in the USA40
examined 16-year trends from 1993 to 2008 in the incidence of infections related to cardiac implantable
electronic devices, based on data from the National Inpatient Sample (NIS). There has been a marked
increase in infection incidence, notably since 2004, and this has been associated with an increase in
in-hospital mortality and increased treatment costs. The reasons for the increased incidence of
device-related infections are unclear, but could be related to the increased use of ICD and CRT devices
relative to traditional pacemakers. Because of the demands placed on the battery, the longevity of ICD
and CRT devices is lower than that of traditional pacemakers, and the need for more frequent surgical
replacement of ICD and CRT devices might at least in part explain why the number of device-related
infections has increased.40
Setting, cost and equipment
Cardiac resynchronisation therapy and ICD device implants are carried out in local hospital or cardiac
centres and can take from 1 to 3 hours depending on the type of device. Implantation of biventricular
or resynchronisation devices is more complicated and takes longer than implantation of other ICDs.
Implantation procedures are usually performed by senior cardiologists with specialist training in the
technique, supported by cardiac technicians and nurses. Follow-up visits for patients can be as often as
every 3–12 months, requiring support from senior cardiologists, cardiac nurses and technicians. According
to the HRS/European Heart Rhythm Association (EHRA) Expert Consensus on the Monitoring of
Cardiovascular Implantable Electronic Devices,41 whereas neither direct nor remote monitoring follow-up
visits should be longer than 12 months, 6-monthly follow-up for ICD and CRT-D devices is recommended.
The increasing complexity of devices could impact on the time needed for follow-up visits.
The average cost of the devices, including leads, has been estimated at £9692 for the ICD device, £3411
for CRT-P and £12,293 for CRT-D (see Chapter 5, Parameters common to all populations, and see
Table 109 for further details). In addition to the cost of the device itself, high-quality digital X-ray
equipment is necessary for coronary sinus angiography and positioning of the left ventricular pacing lead,
as well as an external ICD programmer (a telemetry computer commercially produced and marketed for
use with the device41) to enable the cardiologist to adjust the settings of the ICD after surgery or at
follow-up visits as required.
Management of the disease
Existing guidelines for SCD and HF include NICE guidance on ICDs for arrhythmias42 and CRT for HF,43
and a NICE clinical guideline on the management of chronic HF.44 Guidelines on the use of CRT have also
been published by the European Society of Cardiology,45 the Heart Failure Society of America46 and the
American College of Cardiology Foundation and the American Heart Association.47 A 10-year National
Service Framework for Coronary Heart Disease was published by the UK Department of Health in 2000,48
but this did not make specific recommendations on the use of CRT or ICD devices and is now out of date.
Given the absence of a national framework, Heart Rhythm UK has recently developed standards for the
implantation and follow-up of CRT devices.49
Sudden cardiac death
Diagnosis of sudden cardiac death
As SCD can happen without warning, it is important for general practitioners and secondary care providers
to be aware of risk factors so that patients at high risk of SCD can be identified and referred for cardiac
evaluation. A range of diagnostic tests may be used to identify risk of SCD. An electrocardiogram (ECG)
can detect abnormalities in the heart’s electrical activity and may reveal evidence of heart damage from
CHD, or signs of a previous or current heart attack. Electrophysiological testing is sometimes used to
identify the origins of an arrhythmia and programmed electrical stimulation (PES) of the heart may be used
to stimulate the heart to induce the arrhythmia. An electrophysiological or PES study may be used before
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implantation of an ICD to confirm the need for an ICD or for diagnostic work-up. Other tests that may be
used to identify SCD risk include ultrasound echocardiography and cardiac magnetic resonance imaging
(to image or film different parts or the whole of the heart), blood tests (to check concentrations of
chemicals involved in heart function, e.g. potassium and magnesium) and cardiac catheterisation
(e.g. if blood samples from within the heart are required, or to inject dye for angiographic studies).
Implantable devices for sudden cardiac death
Ventricular arrhythmias, particularly sustained VT and VF, are life-threatening events. For patients who
meet specified treatment criteria, the NICE guidance issued in 2006 [technology appraisal (TA)9542]
recommends that ICD (or CRT-D) therapy is recommended for primary prevention (prevention of a first
life-threatening arrhythmic event) and secondary prevention (prevention of an additional life-threatening
event in survivors of sudden cardiac events or patients with recurrent unstable rhythms) of SCD. Patients
with sustained ventricular arrhythmias associated with haemodynamic compromise in the presence of LVSD
should be considered for ICD therapy after reversible factors are addressed. Patients with LVSD and who
have recently had a MI or patients who have a cardiac condition that is associated with a high risk of
sudden death should also be considered for ICD therapy in addition to OPT. OPT (as described below) is
used as an adjunct or provided for those patients for whom an ICD would not be appropriate
(e.g. those with a severely limited prognosis).
Specific recommendations of the NICE guidance42 (which does not cover non-ischaemic dilated
cardiomyopathy) are that ICDs may be used as primary prevention for patients who have a history of
previous (≤ 4 weeks) MI and either left ventricular dysfunction with a left ventricular ejection fraction (LVEF)
< 35% (no worse than NYHA class III) and non-sustained VT on Holter (24-hour ECG) monitoring and
inducible VT on electrophysiological testing or left ventricular dysfunction with a LVEF of < 30% (no worse
than NYHA class III) and a QRS duration of ≥ 120 milliseconds; or who have a familial cardiac condition
with a high risk of sudden death, including long QT syndrome, hypertrophic cardiomyopathy, Brugada
syndrome or arrhythmogenic right ventricular dysplasia, or have undergone surgical repair of congenital
heart disease.
Implantable cardioverter defibrillators as secondary prevention for arrhythmias are recommended for
individuals who present, in the absence of a treatable cause, with one of the following: survived a cardiac
arrest due to either VT or VF; spontaneous sustained VT causing syncope or significant haemodynamic
compromise; sustained VT without syncope or cardiac arrest and who have an associated reduction in
ejection fraction (LVEF < 35%) (no worse than NYHA class III).42
Optimal pharmacological therapy for sudden cardiac death
Chronic prophylactic antiarrhythmic drug (AAD) therapy is aimed at suppressing the development of
arrhythmias in patients at high risk of SCD. The class III drugs such as amiodarone are used for specific
indications. These drugs may enhance the maintenance of sinus rhythm but cannot terminate an
arrhythmia once it is initiated. A meta-analysis based on 8522 patients from 15 trials found that
amiodarone reduced the risk of SCD by 29% and cardiovascular death (CVD) by 18% in patients at risk of
SCD.50 However, amiodarone therapy was neutral with respect to all-cause mortality and was associated
with a high discontinuation rate and significant end-organ adverse reactions including hepatic, pulmonary
and thyroid toxicity, with a two- and fivefold increased risk of pulmonary and thyroid toxicity respectively50
Other drugs that may be included in the OPT of SCD are angiotensin-converting enzyme (ACE) inhibitors
(recommended for all patients with LVSD to improve ventricular geometry and function), aldosterone
receptor antagonists (for people resistant to other drug therapy) and beta-blockers (to reverse ventricular
remodelling) among others.51
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Heart failure
Diagnosis of heart failure
The NICE clinical guideline CG108, Chronic Heart Failure: Management of Chronic Heart Failure in Adults
in Primary and Secondary Care,44 provides a diagnostic pathway for HF, the key elements of which are
shown in Figure 2. Serum natriuretic peptides (SNPs; protein substances secreted by the wall of the heart
when it is stretched or under increased pressure) should be measured in people with suspected HF without
MI, although the guideline cautions that levels of SNPs can be reduced by certain conditions (e.g. obesity)
or treatments (e.g. diuretics, ACE inhibitors, beta-blockers). Conversely, other conditions [e.g. left
ventricular hypertropy, renal dysfunction, chronic obstructive pulmonary disease (COPD)] can cause high
levels of SNPs. Therefore, an ECG and other tests (e.g. chest radiography, blood tests, urinalysis,
spirometry) may be required to evaluate other possible diagnoses. Transthoracic Doppler two-dimensional
echocardiography is used to assess the function (systolic and diastolic) of the left ventricle, to detect
intracardiac shunts and to exclude important valve disease. If a poor image is obtained, other imaging
methods (e.g. radionuclide angiography, cardiac magnetic resonance imaging or transoesophageal Doppler
two-dimensional echocardiography) can be considered.
Management of heart failure
A patient presenting with the typical signs and symptoms of HF should receive specialist assessment
including echocardiography.44 If HF is diagnosed the goals of treatment are to reduce mortality and
improve the health outcome of the patient. In clinical practice, pharmacological agents are routinely used
as the first-line therapy in managing HF44 (details of OPT for HF are given in Optimal pharmacological
therapy for heart failure).
Patient with
suspected HF
and previous MI
Urgent referral
within 2 weeks
Referral within
6 weeks
Doppler 2D echocardiography
and specialist assessment
Patient with
suspected HF
without previous MI
Measure serum natriuretic peptides:
•
or
•
 
BNP
NTproBNP
BNP > 400 pg/ml
(116 pmol/l)
or
NTproBNP > 2000 pg/ml
(236 pmol/l)
BNP 100 – 400 pg/ml
(29 – 116 pmol/l)
or
NTproBNP 400 – 2000 pg/ml
(47 – 236 pmol/l)
FIGURE 2 Key elements in the NICE HF guideline diagnostic pathway.52 BNP, B-type natriuretic peptide;
NTproBNP, N-terminal pro-B-type natriuretic peptide.
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In addition to drug therapy, according to the NICE clinical guideline,44 individuals should be encouraged to
participate in exercise-based cardiac rehabilitation (including a psychological and educational component),
to give up smoking if applicable or be referred to a smoking cessation service, and to abstain from alcohol
consumption if they have alcohol-related HF. Similarly, the European Society of Cardiology recommends
that individuals with HF should be enrolled in a multidisciplinary care management programme.53
Implantable devices for heart failure
As the severity of HF symptoms increases, a patient’s symptoms may no longer be controlled by OPT or
lifestyle changes. There are multiple syndromes associated with HF that could predispose patients to the
need for further intervention. In patients with HF, the existence of a modifiable risk factor such as
arrhythmias may constitute a rationale for the use of multiple interventions. The NICE pathway for chronic
HF52 indicates that, when symptoms are not controlled by OPT, treatment with CRT-P or CRT-D can be
considered for patients meeting specific criteria.
Current NICE guidance issued in 2007 (TA12043) recommends CRT-P as a treatment option for individuals
with HF who fulfil all of the following criteria: are currently experiencing or have recently experienced NYHA
class III–IV symptoms; are in sinus rhythm – either with a QRS duration of ≥ 150milliseconds estimated by
standard ECG or with a QRS duration of 120–149milliseconds estimated by ECG and mechanical
dyssynchrony that is confirmed by echocardiography; have a LVEF of ≤ 35%; are receiving OPT. CRT-D may
be considered for individuals who fulfil the criteria for implantation of a CRT-P device and who also
separately fulfil the criteria for the use of an ICD device (see Implantable devices for sudden cardiac death).
Comments received from a clinical expert indicate that CRT is increasingly being considered for people
without symptoms with the aim of improving prognosis by modifying the natural history of HF. Another
interventional procedure that may be considered for patients with severe refractory symptoms is cardiac
transplant. For those awaiting a donor heart, short-term circulatory support with a left ventricular assist
device may be indicated.54
Optimal pharmacological therapy for heart failure
Optimal medical drug therapy for HF can include ACE inhibitors, diuretics (for the relief of congestive
symptoms and fluid retention), beta-blockers, aldosterone antagonists, digoxin (if symptoms continue
despite the use of ACE inhibitors), amiodarone, anticoagulants (to reduce the risk of stroke), aspirin
(to reduce the risk of vascular events), statins (to reduce the risk of MI and stroke), inotropic agents
(to stimulate the heart muscle) and calcium channel blockers (for comorbid hypertension and angina).
The NICE 2010 clinical guideline44 suggests that medical drug therapy for HF has two aims – first, to
improve morbidity (by reducing symptoms, improving exercise tolerance, reducing hospital admissions and
improving QoL) and, second, to improve prognosis (by reducing all-cause mortality or HF-related mortality).
According to the guideline, first-line treatment should include both ACE inhibitors and beta-blockers
licensed for HF for all individuals with HF due to LVSD.
If an individual remains symptomatic despite optimal therapy with an ACE inhibitor and a beta-blocker,
second-line treatment recommendations are to add one of the following: an aldosterone antagonist
licensed for HF [especially if the patient has moderate to severe HF (NYHA class III–IV) or has had an MI
within the past month] or an angiotensin II receptor antagonist (also known as an angiotensin receptor
blocker or ARB) licensed for HF [especially if the patient has mild to moderate HF (NYHA class II–III)] or
hydralazine in combination with nitrate [especially if the patient is of African or Caribbean origin and has
moderate to severe HF (NYHA class III–IV)].44
Pharmacological recommendations for all types of HF include diuretics, calcium channel blockers,
amiodarone, anticoagulants, aspirin and inotropic agents (such as dobutamine, milrinone or enoximone).
ACE inhibitor therapy should not be initiated in individuals with a clinical suspicion of haemodynamically
significant valve disease.44
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Current service provision
Current service provision is difficult to ascertain as the most recent audits of the use of CRT devices and
ICDs in England and Wales55,56 suggest that there is considerable regional variation in implant rates. There
is also a lack of information on patient referral patterns for the receipt of resynchronisation and
defibrillation devices in the NHS.57
The National Heart Failure Audit April 2010–March 201158 did not capture any information on the use of
CRT devices or ICDs, but recommended that such data should be collected in future audits.
The most recent study to have reported the use of CRT devices and ICDs was the Cardiac Rhythm
Management: UK National Clinical Audit 2010,55 which compared the rates of implantation of bradycardia
pacemakers, ICDs and CRT devices during 2000–10 in comparison with national targets (a recent update
of the audit56 provides additional data for January–December 2011 but is an interim version pending final
publication). The audit collected data from 28 cardiac networks (regional groups of hospitals providing
implants of pacemakers, CRT devices and ICDs) in England. There is clearly wide regional variation in the
rates of implantation, with some cardiovascular networks having achieved or exceeded national target
implant rates during 2010 and other networks not (Table 3). However, there is some debate about what
the national targets should be. For example, a target of 100 ICD implants per million patients per annum
has been proposed55 but other estimates that assume adherence to published guidelines suggest that the
annual implant rate for ICDs should be higher, between 105 and 504 per million patients.57 The wide
regional variation in implant rates appears to suggest underuse in those regions with low implant rates.57
The audit55 noted that the ratio of CRT-P implants to CRT-D implants and the ratio of ICD to CRT-D
implants were highly variable among the cardiac networks in England, but it is not possible to determine
the extent to which this variation reflects differences in local clinical practice and/or differences between
patient populations. A study of ICD referral patterns in a single cardiac network in southern England57
found that implant rates were higher in areas where the local hospital was a regional cardiac centre
compared with district general hospitals (with or without a device specialist), suggesting that some of the
observed regional variation may reflect the structure of cardiac networks (the number and type of hospitals
they include) and their patient referral pathways.57 The discrepancy observed within the study of cardiac
networks was greatest with respect to the use of ICDs for coronary artery disease primary prevention
indications, and the authors suggested that this most likely reflects underuse of the therapy in the district
hospitals rather than overuse in the regional cardiac centre.57 A related study in the same cardiac network
retrospectively investigated the management of ICD-implanted patients who developed HF.59 Such patients
may potentially benefit by being upgraded from an ICD to a CRT device. However, only a low proportion
of these patients were found to have received an upgrade, raising the question of whether a CRT device
might have been a more appropriate initial choice than an ICD for this patient subgroup.59
TABLE 3 Device implant rates in England during 2010 compared with national targets55
Device type
Averagea (range) no. of implants
per million patients, adjusted for
age and sex
National target (no. of implants
per million patients, adjusted for
age and sex)
ICD 72 (34–131) 100
All CRT devices (CRT-P+CRT-D) 114 (68–182) 130
All defibrillator devices (ICD+CRT-D) 131 (81–197) Not reported
a Not explicitly stated whether mean or median.
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The audit55 reported data on the types of physiological pacing that were employed and also some data
on the presenting symptoms and ECG patterns in patients with implants. As there is substantial overlap in
the indications for resynchronisation and defibrillation devices,59 the choice of clinicians between ICD,
CRT-D and CRT-P devices may in some cases have been arbitrary,55 and the audit did not discriminate
between all of the possible pacing and defibrillation modes that can be programmed in modern
implantable devices. Overall, in England during 2010, an ICD was the device type employed most
frequently for syncope/cardiac arrest with VT/VF; CRT-D devices were the most frequent type implanted
for HF with VT/VF; and CRT-P devices were the most frequent type employed in patients who had HF
without VT/VF. Both CRT-D and ICD devices, but rarely CRT-P devices, were used for prophylaxis (Table 4).
All device types were implanted more often in men than in women (80.1% of ICD, 83.4% of CRT-D and
68.4% of CRT-P devices were implanted in men). In 2011, a much higher proportion of CRT-D devices
were implanted for primary prevention than for secondary prevention (78.3% vs. 21.7% respectively),
although the proportions of ICDs implanted for primary and secondary prevention were similar (48.3%
and 51.4% respectively).55
The demand for device implants will increase because of a growing ageing population. In addition, there
are increasing demands to expand the use of CRT devices, that is, to include individuals with NYHA
class I–II symptoms, an ejection fraction of < 30% and a QRS interval wider than 130milliseconds. This will
increase the burden on existing services within cardiology, as well as raising the importance of device
costs. The UK National Clinical Audit55 confirms that there has been a substantial increase in the number
of CRT and ICD devices implanted in England and Wales during 2000–10. The interim update of the
audit56 suggests, however, that, although more ICDs per million patients were implanted in England in
2011 than in 2010, the rate of increase has slowed and, overall, the total number of CRT implants per
million patients was similar during 2010 and 2011.
In addition to the variation within the UK (see Table 3), there is considerable variation in the utilisation of
implantable defibrillators across Europe,55 and ICD/CRT-D implant rates are considerably higher in the
USA than in Europe.60 The UK has approximately 0.7 ICD implant centres per million population, which is
lower than in France, Germany, Italy and the USA.60 It has been suggested that lower utilisation rates may
reflect three main factors: a shortage of implant centres and electrophysiologists; poorly developed referral
strategies/care pathways; and problems with specialist health-care investment.60 The recently collected
data55,60 suggest that systematic planning of ICD services is lacking in the UK, with underutilisation of CRT
and ICD devices, although it is unclear if this impacts on the equality of service provision.
TABLE 4 Combinations of presenting symptoms and ECGs in resynchronisation and defibrillation device implant
patients in England, 201055
Presenting symptom and ECG ICD (%) CRT-D (%) CRT-P (%) Total (rounded) (%)
Syncope/cardiac arrest and VT/VF 79.3 20.4 0.2 100
HF and VT/VF 29.8 68.2 1.9 100
HF and any rhythm except VT/VF 3.9 20.6 75.5 100
Prophylactic (no symptoms) – all presenting ECGs 48.5 48.8 2.7 100
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Chapter 2 Definition of the decision problem
This chapter states the key factors that will be addressed by this assessment and defines the scope of theassessment in terms of these key factors in line with the definitions provided in the NICE scope.61 This
assessment updates and expands on two previous technology assessment reports (TARs), The Clinical and
Cost-Effectiveness of Implantable Cardioverter Defibrillators: a Systematic Review62 (which itself was an
update of a TAR published in 200063) and The Clinical Effectiveness and Cost-Effectiveness of Cardiac
Resynchronisation (Biventricular Pacing) for Heart Failure: Systematic Review and Economic Model.64 The
key differences between the present assessment and the previous assessments are outlined below and
summarised in Appendix 1.
Decision problem
The interventions included within the scope of this assessment are ICD, CRT-P and CRT-D devices, each in
addition to OPT.
Three populations are defined by the NICE scope:61
1. people at increased risk of SCD as a result of ventricular arrhythmias despite OPT
2. people with HF as a result of LVSD and cardiac dyssynchrony despite OPT
3. people with both conditions described above.
The first group, people at risk of SCD as a result of ventricular arrhythmias, includes and expands on the
population considered in the previous ICD TAR.62 For the present assessment this population is not
restricted by NYHA classification and there is no specified cut-off for LVEF. The second group, people with
HF as a result of LVSD and cardiac dyssynchrony, includes and expands on the population considered
in the previous CRT TAR.64 As in the previous TAR, this population is not restricted by NYHA classification
in the present assessment, but unlike the previous TAR there is no specified cut-off for LVEF. The third
group, people with both conditions, was not considered in the previous TARs.62,64 People with
cardiomyopathy are not excluded from consideration in this assessment.
Although the three populations are considered separately within the report for the purposes of this
assessment, it is acknowledged that in practice these are not distinct groupings and there is considerable
overlap between the groups: people with HF due to LVSD are at risk of SCD from ventricular arrhythmia.
The NICE scope61 did not indicate whether any subgroups of patients were of interest. No subgroups were
predefined in the earlier guidance (TA9542), but subgroup analyses were reported in some included studies
by LVEF, QRS duration and history of HF requiring treatment. Subgroups that were thought to be
of interest in TA12043 and were therefore predefined were age, atrial fibrillation, NYHA class, degree of
LVSD, degree of dyssynchrony and ischaemic and non-ischaemic HF. Relevant subgroups for the current
assessment may also include renal failure. If sufficient evidence is available, consideration will be given to
these subgroups.
The relevant comparisons for this assessment are as follows:
l for people at increased risk of SCD as a result of ventricular arrhythmias despite OPT, ICD will be
compared with standard care (OPT without ICD)
l for people with HF as a result of LVSD and cardiac dyssynchrony despite OPT, CRT-P and CRT-D will be
compared with each other or with standard care (OPT without CRT)
l for people with both conditions described above, CRT-D will be compared with ICD, CRT-P or standard
care (OPT alone).
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The clinical outcomes of interest include mortality (including progressive HF mortality, non-HF mortality,
all-cause mortality and SCD), health-related quality of life (HRQoL), symptoms and complications related to
tachyarrhythmias and/or HF, HF hospitalisations, change in NYHA class, change in LVEF, and adverse
effects of treatment. Outcomes for the assessment of cost-effectiveness will include direct costs based on
estimates of health-care resources associated with the interventions as well as consequences of the
interventions, such as treatment of adverse events.
Overall aims and objectives of the assessment
The aims of this health technology assessment are threefold:
l to assess the clinical effectiveness and cost-effectiveness of ICDs in addition to OPT for the treatment of
people who are at increased risk of SCD as a result of ventricular arrhythmias despite receiving OPT
l to assess the clinical effectiveness and cost-effectiveness of CRT-P or CRT-D in addition to OPT for the
treatment of people with HF as a result of LVSD and cardiac dyssynchrony despite receiving OPT
l to assess the clinical effectiveness and cost-effectiveness of CRT-D in addition to OPT for the treatment
of people who have an increased risk of both SCD as a result of ventricular arrhythmias and HF as a
result of LVSD and cardiac dyssynchrony despite OPT.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Methods for the systematic reviews of
clinical effectiveness and cost-effectiveness
The a priori methods for systematically reviewing the evidence of clinical effectiveness andcost-effectiveness were described in the research protocol, which was sent to the advisory group and to
NICE for comment. Although helpful comments were received relating to the general content of the
research protocol, there were none that identified specific problems with the methodology of the review.
The methods outlined in the protocol are briefly summarised below.
Identification of studies
A search strategy was developed, tested and refined by an experienced information scientist. The strategy
identified clinical effectiveness studies of ICDs for arrhythmias and CRT for the treatment of HF. Additional
search strategies identified studies reporting on the cost-effectiveness of ICDs and CRT, and studies
reporting on the epidemiology and natural history of arrhythmias and HF. Searches to inform
cost-effectiveness modelling were also conducted. Sources of information and search terms are provided in
Appendix 2. The most recent search was carried out in November 2012.
The following electronic databases were searched: The Cochrane Library including the Cochrane Database
of Systematic Reviews (CDSR), the Cochrane Central Register of Controlled Trials, the Centre for Reviews
and Dissemination (CRD) (University of York) Database of Abstracts of Reviews of Effectiveness (DARE), the
NHS Economic Evaluation Database (NHS EED) and the Health Technology Assessment (HTA) database;
MEDLINE (Ovid); EMBASE (Ovid); MEDLINE In-Process and Other Non-Indexed Citations (Ovid); Web of
Science with Conference Proceedings: Science Citation Index Expanded (SCIE) and Conference Proceedings
Citation Index – Science (CPCI) (ISI Web of Knowledge); Biosis Previews (ISI Web of Knowledge); Zetoc
(Mimas); NIHR Clinical Research Network Portfolio; ClinicalTrials.gov; and Current Controlled Trials.
Searches were carried out from database inception to the present for studies in the English language.
Searches were limited to randomised controlled trials (RCTs) for the assessment of clinical effectiveness and
to full economic evaluations for the assessment of cost-effectiveness. Bibliographies of retrieved papers
and the manufacturers’ submission (MS) to NICE were assessed for relevant studies that met the inclusion
criteria, and the expert advisory group was contacted to identify additional published and
unpublished evidence.
Inclusion and exclusion criteria
The inclusion criteria for population, interventions and comparators are summarised in Table 5.
Population
l People at increased risk of SCD as a result of ventricular arrhythmias despite OPT.
l People with HF as a result of LVSD and cardiac dyssynchrony despite OPT.
l People with both conditions described above.
Left ventricular systolic dysfunction was defined as a reduced LVEF using the cut-off provided by the
publications (an arbitrary cut-off was not imposed by this review). Similarly, cardiac dyssynchrony was as
defined by the publications, usually a prolonged QRS interval. Trials clearly stating that participants had a
reduced LVEF, cardiac dyssynchrony and an indication for an ICD were considered as having
both conditions.
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Interventions
The interventions under consideration for each patient group are:
l for people at increased risk of SCD: ICDs in addition to OPT
l for people with HF: CRT-P or CRT-D in addition to OPT
l for people with both conditions: CRT-D in addition to OPT.
Comparators
The comparators under consideration for each patient group are:
l for people at increased risk of SCD: standard care (OPT without ICD)
l for people with HF: CRT-P or CRT-D were compared with each other; standard care (OPT without CRT)
l for people with both conditions: ICDs; CRT-P; standard care (OPT alone).
When screening studies for inclusion it became apparent that the pharmacological therapy in some of the
older studies might not be considered optimal by current standards. After consultation with NICE and
clinical experts, it was decided that trials in which the pharmacological therapy in either the intervention
arm or the comparator arm was not optimal (i.e. was not current best practice based on clinical opinion)
would be included in the systematic review.
Outcomes
Studies must have included one or more of the following outcome measures to be eligible for inclusion in
this review:
l mortality (including progressive HF mortality, non-HF mortality, all-cause mortality and SCD)
l adverse effects of treatment
l HRQoL
l symptoms and complications related to tachyarrhythmias and/or HF
l HF hospitalisations
l change in NYHA class
l change in LVEF.
Study design
l For the systematic review of clinical effectiveness, only RCTs were eligible.
l Studies published as abstracts or conference presentations from 2010 onwards were included only if
sufficient details were presented to allow an appraisal of the methodology and the assessment of
results to be undertaken.
l Systematic reviews of the clinical effectiveness of ICDs and CRT were used as a source of references.
l For the systematic review of cost-effectiveness, studies were included only if they reported the results
of full economic evaluations [cost-effectiveness analyses (reporting cost per life-year gained), cost–utility
analyses or cost–benefit analyses].
TABLE 5 Summary of inclusion criteria
Population People at increased risk of SCD as a
result of ventricular arrhythmias
despite OPT
People with HF as a result of
LVSD and cardiac dyssynchrony
despite OPT
People with both conditions
described to the left
Interventions ICD in addition to OPT CRT-P or CRT-D in addition
to OPT
CRT-D in addition to OPT
Comparators Standard care (OPT without ICD) CRT-P vs. CRT-D; standard care
(OPT without CRT)
ICDs; CRT-P; standard care
(OPT alone)
METHODS FOR THE SYSTEMATIC REVIEWS OF CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS
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l For the systematic review of QoL, primary studies or QoL data collected as part of a trial using the
European Quality of Life-5 Dimensions (EQ-5D) (not visual analogue scale), and specified by NYHA class
for people with HF, were included.
l Non-English-language studies were excluded.
Screening and data extraction process
Studies were selected for inclusion in the systematic review of clinical effectiveness through a two-stage
process using the criteria defined earlier. The titles and abstracts of studies identified by the search strategy
were screened by two reviewers to identify all citations that potentially met the inclusion criteria. Full
papers of potentially relevant studies were retrieved and assessed by two independent reviewers using a
standardised eligibility form. Full papers or abstracts describing the same study were linked together, with
the article reporting key outcomes designated as the primary publication. Data from included studies were
extracted by one reviewer using a standardised data extraction form and checked by a second reviewer.
At each stage, any disagreements were resolved by discussion, with the involvement of a third reviewer
when necessary.
Titles and abstracts identified by the search strategies for the systematic reviews of cost-effectiveness and
QoL were assessed for potential eligibility by two health economists using predetermined inclusion criteria.
Full papers were assessed for inclusion by two reviewers.
Critical appraisal
The risk of bias of the clinical effectiveness studies was assessed according to criteria devised by The
Cochrane Collaboration.65 Criteria were applied by one reviewer and checked by a second reviewer, with
differences in opinion resolved by consensus and by consultation with a third reviewer if necessary.
Economic evaluations were appraised using criteria based on those recommended by Drummond and
Jefferson,66 the requirements of the NICE reference case67 and the suggested guideline for good practice in
decision-analytic modelling by Philips and colleagues68 (see Appendix 3). Published studies carried out from
the UK NHS and Personal Social Services (PSS) perspective were examined in more detail.
Method of data synthesis
Clinical effectiveness data were synthesised through a narrative review with tabulation of the results of
included studies. When data were of sufficient quality and homogeneity, meta-analysis of the clinical
effectiveness studies was performed to estimate the risk ratio (RR) and 95% confidence intervals (CIs) for
relevant outcomes. The random-effects method was used. Meta-analysis was performed using Review
Manager 5 (RevMan; The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark).
Statistical heterogeneity was assessed using the chi-squared test and degrees of freedom (df), and the I2
statistic. When standard deviations (SDs) were not presented in the published papers, these were
calculated from the available statistics [CIs, standard errors (SEs) or p-values].65 A minority of papers
reported median values with 95% CIs; in these cases, rather than omitting the trial from a meta-analysis, it
was assumed that the data were symmetrical (and so the median would be similar to the mean value) and
the median was used directly in the meta-analysis.
This report contains reference to confidential information provided as part of the NICE appraisal
process. This information has been removed from the report and the results, discussions and conclusions of
the report do not include the confidential information. These sections are clearly marked in the report.
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Chapter 4 Clinical effectiveness
Overall quantity of evidence identified
Searches identified a total of 4556 references after deduplication and full texts of 222 references were
retrieved after screening titles and abstracts. The number of references excluded at each stage of the
systematic review is shown in Figure 3. Selected references that were retrieved but later excluded are listed
in Appendix 4 with reasons for exclusion. Papers were often excluded for more than one reason, with the
most common reason being study design (70 papers), followed by comparator (40 papers) and outcomes
(32 papers). Although not formally assessed, the level of agreement between reviewers for screening was
considered good.
Searches identified five relevant trials in progress, summaries of which can be found in Appendix 5.
Twenty-six eligible RCTs were identified (Table 6); many of these trials were reported in several publications
(a total of 78 papers). Thirteen RCTs were considered to involve people at increased risk of SCD as a result
of ventricular arrhythmias (see People at risk of sudden cardiac death as a result of ventricular arrhythmias),
four trials were considered to involve people with HF as a result of LVSD and cardiac dyssynchrony (see
People with heart failure as a result of left ventricular systolic dysfunction and cardiac dyssynchrony) and
nine RCTs were considered to involve people with both of these conditions (see People with both
conditions). Further details on the quantity and quality of research for each of these populations are
described in the following sections.
People at risk of sudden cardiac death as a result of
ventricular arrhythmias
Quantity and quality of research available
Eleven of the 13 RCTs included reported their findings in more than one paper; a summary of the included
papers for each trial can be seen in Table 7. Seven of these RCTs plus one additional RCT [the Multicenter
Unsustained Tachycardia Trial (MUSTT)146] were included in the 2005 TAR,62 as can be seen in Table 7. One
further RCT [the Midlands Trial of Empirical Amiodarone versus Electrophysiology-Guided Interventions and
Implantable Cardioverter-Defibrillators (MAVERIC)147] was noted in the 2005 TAR62 as in progress at that time.
The interventions in the MUSTT146 and MAVERIC147 trials did not meet the scope of the present review; however,
as these were included in the previous TARs62,63 they are discussed in Subgroup analyses reported by included
randomised controlled trials. A list of other excluded studies can be seen in Appendix 4.
The RCTs used different criteria to identify groups at ‘high risk’ of SCD from ventricular arrhythmia. The
Antiarrhythmics Versus Implantable Defibrillators (AVID),71 Cardiac Arrest Study Hamburg (CASH),81 Canadian
Implantable Defibrillator Study (CIDS)84 and Defibrillator versus Beta-Blockers for Unexplained Death in Thailand
(DEBUT)89 trials included people who had had a previous ventricular arrhythmia or who had been resuscitated
from cardiac arrest. Four studies included people with either a recent MI [Defibrillator in Acute Myocardial
Infarction Trial (DINAMIT)95 and the Immediate Risk Stratification Improves Survival (IRIS) trial97] or a
MI > 3–4 weeks before study entry [Multicenter Automatic Defibrillator Implantation Trial I (MADIT I),99
MADIT II101]. The Amiodarone Versus Implantable Cardioverter-Defibrillator Randomized Trial (AMIOVIRT),69
Cardiomyopathy Trial (CAT)82 and Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation
(DEFINITE)90 trial included people with cardiomyopathy. The Coronary Artery Bypass Graft Patch (CABG Patch)
trial75 recruited patients scheduled for coronary artery bypass graft surgery and at high risk for sudden death,
and the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)105 recruited a broad population of patients
with mild to moderate HF. The results will be discussed according to the ‘high-risk’ group of the participants.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
Identified through database
searching after deduplication
(n = 4546)
Additional records identified through
other sources
(n = 10)
RCTs included in qualitative
synthesis and meta-analysis
(n = 26) (reported in 78 publications):
Arrhythmias, n = 13 (40 publications)
HF, n = 4 (18 publications)
Both conditions, n = 9 (20 publications)
Records excluded
(n = 4334)
Full texts assessed for eligibility
(n = 222)
Full text records excluded
(n = 143)
Reasons for exclusion:a
• Reviews, n = 2
• Abstracts, n = 16b
• Population, n = 10
• Intervention, n = 9
• Comparator, n = 40
• Outcomes, n = 32
• Study design, n = 70
Unobtainable
(n = 1)
Total records screened
(n = 4556)
FIGURE 3 Flow chart of identification of studies. a, Studies could be excluded for more than one reason;
b, 16 of the abstracts/conference presentations were published from 2010 onwards (see Appendix 4) and were
excluded as there were insufficient details included to allow an appraisal of the methodology and an assessment
of the results as per the protocol.
TABLE 6 List of RCTs included in the systematic review of clinical effectiveness
Study Publicationa
People at increased risk of SCD as a result of ventricular arrhythmias
AMIOVIRT Strickberger et al. 2003,69 Wijetunga and Strickberger 200370
AVID AVID investigators 199771 and 1999,72 Hallstrom 1995,73 Schron et al. 200274
CABG Patch Bigger 1997,75 CABG Patch Trial Investigators and Coordinators 1993,76 Bigger et al. 199877 and
1999,78 Spotnitz et al.1998,79 Namerow et al. 199980
CASH Kuck et al. 200081
CAT Bänsch et al. 2002,82 German Dilated Cardiomyopathy Study investigators 199283
CIDS Connolly et al. 200084 and 1993,85 Sheldon et al. 2000,86 Irvine et al. 2002,87 Bokhari et al. 200488
DEBUT Nademanee et al. 200389
DEFINITE Kadish et al. 200490 and 2000,91 Schaechter et al. 2003,92 Ellenbogen et al. 2006,93
Passman et al. 200794
DINAMIT Hohnloser et al. 200495 and 200096
IRIS Steinbeck et al. 200997 and 200498
MADIT I Moss et al. 1996,99 MADIT Executive Committee 1991100
MADIT II Moss et al. 2002101 and 1999,102 Greenberg et al. 2004,103 Noyes et al. 2007104
SCD-HeFT Bardy et al. 2005,105 Mitchell et al. 2008,106 Mark et al. 2008,107 Packer et al. 2009108
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TABLE 6 List of RCTs included in the systematic review of clinical effectiveness (continued )
Study Publicationa
People with HF as a result of LVSD and cardiac dyssynchrony
CARE-HF Cleland et al. 2005,109 2001,110 2006,111 2007112 and 2009,113 Gras et al. 2007,36
Gervais et al. 2009,114 Ghio et al. 2009115
COMPANION Bristow et al. 2004116 and 2000,117 US Food and Drug Administration 2004,118 Carson et al. 2005,119
Anand et al. 2009120
MIRACLE Abraham et al. 2002121 and 2000,122 US Food and Drug Administration 2001,123
St John Sutton et al. 2003124
MUSTIC Cazeau et al. 2001125
People with both conditions described above
CONTAK-CD Higgins et al. 2003,126 Saxon et al. 1999,127 Lozano et al. 2000,128 US Food and Drug
Administration 2002129
MADIT-CRT Moss et al. 2009130 and 2005,131 Solomon et al. 2010,132 Goldenberg et al. 2011,133,134
Arshad et al. 2011135
MIRACLE ICD Young et al. 2003136
MIRACLE ICD II Abraham et al. 2004137
Piccirillo 2006 Piccirillo et al. 2006138
Pinter 2009 Pinter et al. 2009139
RAFT Tang et al. 2010140 and 2009141
RethinQ Beshai et al. 2007,142 Beshai and Grimm 2007143
RHYTHM ICD US Food and Drug Administration 2004144 and 2005145
AMIOVIRT, Amiodarone Versus Implantable Cardioverter-Defibrillator Randomized Trial; AVID, Antiarrhythmics Versus
Implantable Defibrillators; CABG Patch, Coronary Artery Bypass Graft Patch; CARE-HF, CArdiac REsynchronization in Heart
Failure; CASH, Cardiac Arrest Study Hamburg; CAT, Cardiomyopathy Trial; CIDS, Canadian Implantable Defibrillator Study;
COMPANION, Comparison of Medical Therapy, Pacing, and Defibrillation in Patients with Left Ventricular Systolic
Dysfunction; CONTAK-CD, RCT of the CONTAK-CD device; DEBUT, Defibrillator versus Beta-Blockers for Unexplained Death
in Thailand; DEFINITE, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; DINAMIT, Defibrillator in Acute
Myocardial Infarction Trial; IRIS, Immediate Risk Stratification Improves Survival; MADIT, Multicenter Automatic Defibrillator
Implantation Trial; MADIT-CRT, Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization
Therapy; MIRACLE, Multicenter InSync Randomized Clinical Evaluation; MIRACLE ICD, Multicenter InSync ICD Randomized
Clinical Evaluation; MUSTIC, Multisite Stimulation in Cardiomyopathies; RAFT, Resynchronization-Defibrillation for
Ambulatory Heart Failure Trial; RethinQ, Cardiac Resynchronization Therapy in Patients with Heart Failure and Narrow QRS;
RHYTHM ICD, Resynchronization for the HemodYnamic Treatment for Heart failure Management Implantable Cardioverter
Defibrillator; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
a Bold text indicates primary or key publication.
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TABLE 7 Comparison of included studies in the previous and present TARs: people at risk of SCD as a result of
ventricular arrhythmia
Study
2005 TAR62
(reason for
exclusion)
Present
TAR (participants) Publicationa
Secondary prevention
AVID Included Included (cardiac arrest) AVID investigators 199771 and 1999,72 Hallstrom 1995,73
Schron et al. 200274
CASH Included Included (cardiac arrest) Kuck et al. 200081
CIDS Included Included (cardiac arrest) Connolly et al. 200084 and 1993,85 Sheldon et al. 2000,86
Irvine et al. 2002,87 Bokhari et al. 200488
DEBUT Excluded
(participants)
Included (sudden
unexpected
death syndrome)
Nademanee et al. 200389
Primary prevention
DINAMIT In progress Included (early post MI) Hohnloser et al. 200495 and 200096
IRIS New Included (early post MI) Steinbeck et al. 200997 and 200498
MADIT I Included Included (remote
from MI)
Moss et al. 1996,99 MADIT Executive Committee 1991100
MADIT II Included Included (remote
from MI)
Moss et al. 2002101 and 1999,102 Greenberg et al. 2004,103
Noyes et al. 2007104
AMIOVIRT Excluded
(participants)
Included
(cardiomyopathy)
Strickberger et al. 2003,69 Wijetunga and Strickberger 200370
CAT Included Included
(cardiomyopathy)
Bänsch et al. 2002,82 German Dilated Cardiomyopathy Study
investigators 199283
DEFINITE Excluded
(participants)
Included
(cardiomyopathy)
Kadish et al. 200490 and 2000,91 Schaechter et al. 2003,92
Ellenbogen et al. 2006,93 Passman et al. 200794
CABG
Patch
Included Included (need
for CABG)
Bigger 1997,75 CABG Patch Trial Investigators and
Coordinators 1993;76 Bigger et al. 199877 and 1999,78
Spotnitz et al.1998,79 Namerow et al. 199980
MUSTT Included Excluded because
of intervention
Buxton et al. 1999,146 Lee et al. 2002148
SCD-HeFT In progress, in
NICE TA9542
Included (HF) Bardy et al. 2005,105 Mitchell et al. 2008,106
Mark et al. 2008,107 Packer et al. 2009108
AMIOVIRT, Amiodarone Versus Implantable Cardioverter-Defibrillator Randomized Trial; AVID, Antiarrhythmics Versus
Implantable Defibrillators; CABG Patch, Coronary Artery Bypass Graft Patch; CASH, Cardiac Arrest Study Hamburg;
CAT, Cardiomyopathy Trial; CIDS, Canadian Implantable Defibrillator Study; DEBUT, Defibrillator versus Beta-Blockers for
Unexplained Death in Thailand; DEFINITE, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation;
DINAMIT, Defibrillator in Acute Myocardial Infarction Trial; IRIS, Immediate Risk Stratification Improves Survival;
MADIT, Multicenter Automatic Defibrillator Implantation Trial; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
a Bold text indicates primary or key publication.
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Characteristics of the included studies
Study characteristics are summarised in Tables 8–10 and participant characteristics are summarised in
Tables 11–13. Additional details can be found in Appendix 7.
TABLE 8 Study characteristics: cardiac arrest survivors/ventricular arrhythmia – secondary prevention
Parameter AVID71 CASH81 CIDS84 DEBUT89
Study design RCT RCT RCT RCT (pilot and
main study)
Target
population
Resuscitated from
near-fatal VF; or
symptomatic
sustained VT with
haemodynamic
compromise
Resuscitated from
cardiac arrest
secondary to
documented
sustained
ventricular arrhythmia
Previous sustained
ventricular arrhythmia
SUDS survivors or
probable survivors
Intervention ICD+medical therapy ICD+medical therapy ICD+AAD for
symptomatic VT
ICD+ beta-blocker or
amiodarone if
frequent shocks
Comparator AAD+medical therapy AAD (amiodarone or
metoprolol)+medical
therapy
Amiodarone+AAD for
symptomatic VT
Beta-blocker
(long-acting
propranolol); other
beta-blockers if
intolerable side effects
Country
(no. of
centres)
USA (53), Canada (3) Germany (multicentre,
number unclear)
Canada (19),
Australia (3), USA (2)
Thailand (unclear)
Sample
size
(randomised)
1016 288 659 Pilot 20, main trial 66
Length of
follow-up
Mean 18.2
(SD 12.2) months
Mean 57
(SD 34) months
Mean 3 years Maximum 3 years
Key
inclusion
criteria
VF, VT with syncope or
VT without syncope but
with ejection fraction
≤ 0.40 and systolic blood
pressure < 80mmHg;
chest pain or near
syncope.73 If patients
underwent
revascularisation their
ejection fraction had to
be ≤ 0.40
Not reported. Rate
was the only criterion
selected for detection
of a sustained
ventricular arrhythmia
Any of following in the
absence of either recent
acute MI (≤ 72 hours) or
electrolyte imbalance:
documented VF;
out-of-hospital cardiac
arrest requiring
defibrillation or
cardioversion;
documented, sustained
VT causing syncope;
other documented
sustained VT at a rate
≥ 150 bpm causing
presyncope or angina in
a patient with a LVEF
≤ 35%; or unmonitored
syncope with
subsequent
documentation of either
spontaneous VT
≥ 10 seconds or
sustained (≥ 30 seconds)
monomorphic VT
induced by programmed
ventricular stimulation
SUDS survivor: a healthy
subject without
structural heart disease
who had survived
unexpected VF or
cardiac arrest after
successful resuscitation
Probable SUDS survivor:
a subject without
structural heart disease
who experienced
symptoms indicative of
the clinical presentation
of SUDs, especially
during sleep. ECG
abnormalities showing
RBBB-like pattern with
ST elevation in right
precordial leads and
inducible VT/VF in
electrophysiological
testing
bpm, beats per minute; RBBB, right bundle branch block; SUDS, sudden unexplained death syndrome.
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TABLE 9 Study characteristics: post MI – primary prevention
Parameter DINAMIT95 IRIS97 MADIT I99 MADIT II101
Target
population
Recent MI (6–40 days);
reduced LVEF and
impaired cardiac
autonomic function
Recent MI (≤ 31 days)
and predefined markers
of elevated risk
Previous MI and left
ventricular dysfunction
High-risk cardiac
patients with
previous MI and
advanced left
ventricular
dysfunction
Study
design
RCT RCT RCT RCT
Intervention ICD+OPT ICD+OPT ICD+ conventional
medical therapy
ICD+ conventional
medical therapy
Comparator OPT OPT Conventional
medical therapy
Conventional
medical therapy
Country
(no. of
centres)
Canada (25), Germany
(21), France, (8), UK (4),
Poland (4), Slovakia (2),
Austria (2), Sweden (2),
USA (2), the Czech
Republic (1), Switzerland
(1), Italy (1)
Austria, the Czech
Republic, Germany,
Hungary, Poland, the
Russian Federation,
Slovakia (total 92)
USA (30), Europe (2) USA (71),
Europe (5)
Sample size 674 898 196 1232
Length of
follow-up
Mean 30 (SD 13) months Average 37 (range 0 to
106) months
Average 27 (range < 1 to
60) months
Average 20 months
(range 6 days to
53 months)
Key
inclusion
criteria
Recent MI (6–40 days
previously); LVEF ≤ 0.35;
SD of normal-to-normal
RR intervals of
≤ 70milliseconds or a
mean R–R interval of
≤ 750milliseconds
(heart rate ≥ 80 bpm)
over a 24-hour period as
assessed by 24-hour
Holter monitoring
performed at least 3 days
after the infarction
Predefined markers of
elevated risk – at least
one of heart rate ≥ 90
bpm on first available
ECG (within 48 hours of
MI) and LVEF ≤ 40% (on
one of days 5–31 after
the MI); non-sustained
VT of three or more
consecutive ventricular
premature beats during
Holter ECG monitoring,
with a heart rate
≥ 150 bpm (on days 5–31)
NYHA class I, II or III;
LVEF ≤ 0.35; Q-wave
or enzyme-positive
MI> 3 weeks before
entry; a documented
episode of asymptomatic,
unsustained VT unrelated
to an acute MI; no
indications for CABG or
coronary angioplasty
within past 3 months;
sustained VT or fibrillation
reproducibly induced and
not suppressed after the
intravenous administration
of procainamide
(or equivalent)
LVEF ≤ 0.30 in
last 3 months;
MI> 1 month
before study entry
bpm, beats per minute.
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TABLE 10 Study characteristics: cardiomyopathy, CABG surgery and HF – primary prevention
Parameter
Cardiomyopathy CABG surgery HF
AMIOVIRT69 CAT82 DEFINITE90 CABG Patch75 SCD-HeFT105
Target
population
Non-ischaemic
(DCM) and
asymptomatic
non-sustained VT
Recent-onset
idiopathic
DCM and
impaired LVEF
and without
documented
symptomatic
VT
Non-ischaemic
cardiomyopathy
and moderate to
severe left
ventricular
dysfunction
Patients
scheduled for
CABG surgery
and at risk for
sudden death
(LVEF < 0.36 and
abnormalities
on ECG)
Broad population of
patients with mild to
moderate HF
Study
design
RCT RCT (pilot) RCT RCT RCT
Intervention ICD+OPT ICD+OPT ICD+OPT ICD+OPT ICD+OPT
Comparator Amiodarone+OPT OPT OPTa OPT; no specific
therapy for
ventricular
arrhythmia
Amiodarone or placebo
(two groups)+OPT
Country
(no. of
centres)
USA (10) Germany (15) USA (44),
Israel (4)
USA (35),
Germany (2)
USA (99%), Canada,
New Zealand (total 148)
Sample size 103 104 458 900 2521
Length of
follow-up
Mean 2
(SD 1.3) years
2 years Mean 29
(SD 14.4)
months
Mean 32 months Median 45.5 (range
24 to 72.6) months
Key
inclusion
criteria
Non-ischaemic DCM
(left ventricular
dysfunction in the
absence of, or
disproportionate to
the severity of,
CAD); LVEF ≤ 0.35;
asymptomatic
non-sustained VT;
NYHA class I–III
NYHA class II
or III; LVEF
≤ 30%; aged
18–70 years;
symptomatic
DCM
≤ 9 months
LVEF < 36%;
presence of
ambient
arrhythmias;
history of
symptomatic HF;
presence of
non-ischaemic
DCM
Scheduled for
CABG surgery;
LVEF < 0.36;
marker of
arrhythmia:
abnormalities
on ECG
NYHA class II or III;
chronic, stable CHF
from ischaemic or
non-ischaemic causes;
LVEF ≤ 35%; ischaemic
CHF defined as LVSD
associated with marked
stenosis or a
documented history of
MI; non-ischaemic CHF
defined as LVSD
without marked stenosis
CAD, coronary artery disease; CHF, congestive heart failure; DCM, dilated cardiomyopathy.
a AADs discouraged but allowed for symptomatic atrial fibrillation or supraventricular arrhythmias.
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TABLE 12 Key participant characteristics: MI
Parameter
DINAMIT95 IRIS97 MADIT I99 MADIT II101
ICD OPT ICD OPT ICD OPT ICD OPT
Sample size, n 332 342 445 453 95 101 742 490
Age (years),
mean (SD)
61.5 (10.9) 62.1 (10.6) 62.8 (10.5) 62.4 (10.6) 62 (9) 64 (9) 64 (10) 65 (10)
Sex, % male 75.9 76.6 77.5 75.9 92 92 84 85
Arrhythmia, % NR NR NSVT 22.2 NSVT 24.1 VT 100 VT
100
NR NR
NYHA I, % 13.5 12.0 28a 37 33 35 39
NYHA II, % 60.9 58.7 60a 63 67 35 34
NYHA III, % 25.6 29.3 12a 25 23
NYHA IV, % 0 0 0.1a 0 0 5 4
LVEF (%),
mean (SD)
28 (5) 28 (5) 34.6 (9.3) 34.5 (9.4) 27 (7) 25 (7) 23 (5) 23 (6)
QRS interval
(milliseconds),
mean (SD)
107 (24) 105 (23) NR NR NR NR 50%
≥ 120
milliseconds
51%
≥ 120
milliseconds
LBBB/RBBB, % NR NR 10.1/NR 6.4/NR 7/NR 8/NR 19/9 18/7
NR, not reported; NSVT, non-sustained ventricular tachycardia; RBBB, right bundle branch block.
a At discharge for 885 surviving patients.
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Intervention and comparators
The NICE scope and systematic review protocol defined the intervention for this group of people as ‘ICDs
in addition to OPT’ and the comparator as ‘standard care (OPT without an ICD)’. Concepts of OPT have
changed over time and OPT varies depending on the population (e.g. previous VF, post MI, HF), making a
standard definition of OPT difficult. Standards of reporting have also changed, making it difficult in some
instances to be clear what participants have received. As a consequence it was decided, and agreed with
NICE, to include studies that compared ICDs (with or without OPT) with the different types of medical
therapy, reporting the details of the pharmacological therapy used. The studies included were eligible on
all other selection criteria.
The trials of people with previous VF or cardiac arrest compared ICDs with AADs, including either
amiodarone or a beta-blocker (sotalol) (AVID71), amiodarone or a beta-blocker (metoprolol) in separate
groups (CASH81) or amiodarone (CIDS84), or with a beta-blocker (propranolol) (DEBUT89). Use of other
medication was permitted in these trials. AVID71 permitted the use of aspirin, beta-blockers and ACE
inhibitors when clinically appropriate in both groups. CASH81 reported concurrent therapies at discharge
(see Pharmacological therapy for further details of pharmacological therapy received by participants in all
included trials). CIDS84 stated that AADs could be used in both groups to control supraventricular or
non-sustained VTs that were symptomatic or might cause discharge of the ICD. DEBUT89 permitted other
beta-blocking agents or amiodarone if intolerable side effects developed from propranolol or if frequent
shocks from recurrent VF occurred, but did not provide additional data.
Trials of people with recent (IRIS,97 DINAMIT95) or remote (MADIT I,99 MADIT II)101 MI compared ICDs+OPT
with OPT, although the pharmacological therapy in MADIT may not be considered optimal by
current standards.
The trials of people with cardiomyopathy compared ICDs+OPT with amiodarone+OPT (AMIOVIRT69) or
ICDs+OPT with OPT (CAT,82 DEFINITE90).
The CABG Patch trial75 included people scheduled for CABG surgery and compared ICDs+OPT with OPT
(the trial protocol prohibited use of AADs for asymptomatic ventricular arrhythmias), although the
pharmacological therapy may not be considered optimal by current standards. The ICDs used in this trial
were epicardial defibrillators, mostly committed devices (i.e. they deliver a shock even if the arrhythmia
stops before the end of charging) that were not capable of storing electrograms.
The SCD-HeFT trial105 was a three-arm trial comparing ICDs, amiodarone and placebo in a broad
population of patients with mild-to moderate HF. All participants received OPT.
Participants
Cardiac arrest The DEBUT trial89 differed notably from the other three trials (AVID,71 CASH81 and CIDS84)
of people resuscitated from cardiac arrest as participants in the DEBUT trial89 were survivors or probable
survivors (symptoms indicative of the clinical presentation) of sudden unexplained death syndrome (SUDS)
with otherwise normal hearts. All participants in the DEBUT study89 were of Thai origin and were similar to
people with Brugada syndrome (a genetic disorder characterised by abnormal ECG findings and increased
risk of cardiac death); as such the trial findings should also apply to this group of people.
The majority of participants in the AVID,71 CASH81 and CIDS84 trials had ischaemic heart disease (70–83%).
A small proportion of those in the CASH81 and CIDS84 trials had dilated cardiomyopathy. Two-thirds of
participants in the AVID trial71 and around three-quarters of those in the CIDS trial84 had a previous MI.
All participants in the CASH81 and DEBUT89 trials, 60% in the AVID trial71 and 50% in the CIDS trial84 had
congestive heart failure (CHF). The majority (approximately 87%) of people in the CASH trial81 had NYHA
class I or class II HF, whereas about 40% of those in the CIDS trial84 and half of those in the AVID trial71
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fell into these categories. Only 10–11% of participants in the AVID71 and CIDS84 trials had moderate to
severe HF (NYHA class III and IV), whereas 16% of people in the CASH trial81 had NYHA class III HF and
none had NYHA class IV HF. Mean LVEF was higher in the CASH trial81 (46%) than in the AVID trial71
(32%) or the CIDS trial84 (34%), suggesting that there may have been a disproportionate representation of
relatively healthy participants in the CASH trial.81 The mean QT interval ranged from 387milliseconds
(DEBUT89) to 445milliseconds (AVID).71
The participants in the DEBUT trial89 were younger (mean age 40–48 years) than those in the other
three trials (mean age 56–65 years) and all had NYHA class I HF. LVEF was higher in the DEBUT trial89
(mean LVEF 66–69%) than in the AVID,71 CASH81 and CIDS84 trials.
Myocardial infarction The MADIT I99 and MADIT II101 trials included people who had had a MI > 3 weeks
or > 1 month previously. Participants in MADIT I99 were also required to have a LVEF of ≤ 35%, whereas
the MADIT II trial101 required advanced left ventricular dysfunction (LVEF ≤ 30%). The DINAMIT95 and IRIS97
trials recruited participants with a recent MI (within 6–40 days and 5–31 days respectively). DINAMIT95
required participants to have a LVEF of ≤ 35% and a SD of normal-to-normal R–R intervals of
≤ 70milliseconds or a mean R–R interval of ≤ 750milliseconds (heart rate ≥ 80 beats per minute) over
24 hours. The IRIS trial97 included people with at least one of the following markers of risk: heart rate
≥ 90 beats per minute on the first available ECG and LVEF ≤ 40%; or non-sustained ventricular tachycardia
(NSVT) of ≤ 3 consecutive ventricular premature beats during Holter ECG monitoring with a heart rate of
≥ 150 beats per minute.
The DINAMIT trial95 had the greatest majority of participants in NYHA class II or III (around 88%); the
corresponding percentages in the IRIS,97 MADIT I99 and MADIT II101 trials were 27%, 63–67% and 60%
respectively. The trials had either no or very few participants in NYHA class IV. Mean LVEF ranged from
23%101 to 35%,97 reflecting the different inclusion criteria of the studies.
The mean age of the participants in these trials was similar, ranging from 61.5 years in the DINAMIT trial95
to 65 years in MADIT II.101 The majority of participants (from 76% in DINAMIT95 to 92% in MADIT I99)
were men.
Cardiomyopathy The AMIOVIRT69 and DEFINITE90 trials recruited people with non-ischaemic dilated
cardiomyopathy, NSVT and a LVEF of ≤ 35%. CAT82 enrolled people with recent-onset (< 9 months)
idiopathic dilated cardiomyopathy and a LVEF of ≤ 30%, but without documented symptomatic ventricular
arrhythmias. Note that despite participants not having suffered ventricular arrhythmias, the low LVEF
indicates a risk of ventricular arrhythmias and SCD and CAT82 was therefore judged eligible for inclusion in
this review. Also, NSVT was identified with Holter ECG in over half of participants at baseline.
The majority of participants in these trials were in NYHA class II or III, with none in NYHA class IV. The
AMIOVIRT69 (13–18%) and DEFINITE90 (18–25%) trials included more people in NYHA class I than the CAT
trial,82 as this was an exclusion criteria of CAT.82 Despite the lower cut-off for LVEF for inclusion in CAT,82
the mean LVEF at baseline was similar or slightly higher than in the other two trials (CAT82 24–25%,
AMIOVIRT69 22–23%, DEFINITE90 21–22%). The mean QRS interval was similar between CAT82 [ICD 102
(SD 29)milliseconds, OPT 114 (SD 29) milliseconds] and DEFINITE90 [115 (range 78–196) milliseconds],
although the measures of variance suggest that some participants had cardiac dyssynchrony.
Participants in CAT82 had a median duration of symptoms of just 3 months, compared with around 3 years
in AMIOVIRT69 and DEFINITE.90 The participants in CAT82 were also slightly younger (mean age 52 years)
than in AMIOVIRT69 (mean age 59 years) or DEFINITE90 (mean age 58 years). The majority of participants
(approximately 71% in AMIOVIRT69 and DEFINITE90 and 80% in CAT82) were men.
Coronary artery bypass graft surgery Participants in CABG Patch75 were scheduled for CABG surgery
and at risk for SCD (LVEF < 36%) with abnormalities on ECG. People with a history of sustained VT or VF
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were excluded. The majority of participants (71–74%) were in NYHA class II or III with a mean LVEF of
27%. Most participants (83%) had had a previous MI. Mean age was about 64 years and 82–87%
of participants were men.
Mild to moderate heart failure SCD-HeFT105 included a broad population of people with mild to
moderate HF from ischaemic or non-ischaemic causes and a LVEF of ≤ 35%. Ischaemic CHF was defined as
LVSD associated with a ≥ 75% narrowing of at least one of three major coronary arteries (marked stenosis)
or a documented history of MI. Non-ischaemic CHF was defined as LVSD without marked stenosis. Overall,
70% of participants were in NYHA class II and 30% were in class III. Median LVEF was 24–25% and less
than one-quarter of participants had NSVT. The median age was 60 years and most participants (77%)
were men.
Pharmacological therapy
Tables 14 and 15 display medication at hospital discharge.
Cardiac arrest Two-thirds of participants in the AVID trial71 were receiving ACE inhibitors. Only 6% of the
ICD group received AADs at discharge. Beta-blockers were more common among the ICD group (42.3%)
than among the AAD group (16.5%) (p< 0.001), which may have resulted in some bias towards ICD.
Aspirin was received by around 60% of participants in the AVID trial71 and warfarin was received by a
greater proportion of participants in the AAD arm (35%) than in the ICD arm (22%). Half of the
participants in the AVID trial71 received diuretics, around 37% received nitrates and 12% (AAD arm) and
18% (ICD arm) received calcium channel blockers. Digitalis was received by 41% (AAD arm) and 47%
(ICD arm) of participants (p= 0.04). The pharmacological therapy provided in the AVID trial71 would have
been considered optimal at the time that the trial was conducted, although current standards would
include less digitalis and more ACE inhibitors and beta-blocker therapy.
Less than half of participants in the CASH trial81 received ACE inhibitors at hospital discharge. The ICD and
metoprolol groups did not receive any AADs, and the ICD and amiodarone groups did not receive any
beta-blockers. Aspirin was received by around 60% of participants in the ICD group, but by fewer
participants in the amiodarone (45%) and metoprolol (41%) arms. Less than 10% of participants in the
CASH trial81 received warfarin, less than one-third received diuretics, around 30% received nitrates and
12% (metoprolol arm) to 26% (ICD arm) received calcium channel blockers. Digitalis was received by
15% (metoprolol arm) to 26% (ICD arm) of participants. The pharmacological therapy provided in the
CASH trial81 would have been considered optimal at the time that the trial was conducted. However,
beta-blocker treatment was an active comparator in this trial and was not used with ICDs, which may
have resulted in bias against the ICD. ACE inhibitor use is low in this trial but the patients did not have
indications for these at the time that the trial was undertaken.
None of the participants in the CIDS trial84 received ACE inhibitors at hospital discharge. Class I
antiarrhythmics were received by just 2.4% (amiodarone arm) and 5.5% (ICD arm) of participants.
A greater proportion of the ICD group than the amiodarone group received the beta-blocker sotalol
(19.8% vs. 1.5%), beta-blockers other than solatol (33.5% vs. 21.4%) and digoxin (29.6% vs. 22.7%).
No other drugs were reported. The pharmacological therapy provided in the CIDS trial84 would not be
considered optimal by current standards and the higher use of beta-blockers in the ICD group may bias
the trial in favour of ICDs.
Medication at hospital discharge is not reported in the DEBUT trial;89 however, use of beta-blockers was
low in the ICD group (8/47 in main trial and pilot study combined).
Myocardial infarction Both groups in the DINAMIT trial95 were given ‘best conventional medical
therapy’. ACE inhibitors were taken by around 95% of participants at baseline, antiplatelet agents by
92%, beta-blockers by 87% and lipid-lowering agents by 78%. The IRIS trial97 had a similarly high usage
of ACE inhibitors (91%), antiplatelet agents (96%), beta-blockers (96%) and statins (92%).
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TABLE 15 Medication at discharge: cardiomyopathy, CABG surgery and HF
Medication
Cardiomyopathy
CABG
surgery HF
aAMIOVIRT69 CAT82 DEFINITE90
CABG
Patch75 bSCD-HeFT105
ICD Amiodarone ICD OPT ICD OPT ICD OPT ICD Amiodarone Placebo
Sample size, n 51 52 50 54 229 229 430 442 829 845 847
ACE inhibitor, % 90 81 94.0 98.1 83.8 87.3 54.7 53.8 83 87 85
ACE inhibitor/
ARB, %
94 97 98
ARB, % 13.5 8.7 14 14 16
Amiodarone, % 3.9 6.6 3.7 3.2
Class I
antiarrhythmic, %
16.7 12.0
Anticoagulants, % 15.3 14.7
Antiplatelets, % 82.8 85.1
Acetylsalicylic
acid (aspirin)
58 55 56
Warfarin 24.0 35.2 32 37 33
Beta-blockers, % 53 50 4.0 3.7 85.6 84.3 69 69 69
Carvedilol 56.3 58.5
Metoprolol 25.8 18.8
Sotalol 0.5 0.2
Other 3.5 7.0 17.9 24.0
Calcium channel
blockers, %
16.0 7.4 10.5 7.0
Diuretics, % 71 67 88.0 85.2 87.3 86.0 57.2 47.1
Loop 82 82 82
Potassium
sparing
20 21 19
Thiazide 8 6 7
Spironolactone 20 19
Nitrates, % 32.0 25.9 9.2 13.1 8.1 8.1
Digitalis, % 68.6 64.5
Digoxin, % 71 67 41.5 42.4 67 73 70
Lipid-lowering
agents, %
9.5 8.4
Statins, % 38 40 38
a Concomitant drug therapy at last follow-up.
b At enrolment.
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Antiarrhythmics (mainly amiodarone) were taken by a small proportion of participants (ICD arm 13.4% vs.
OPT arm 17.4%, p= 0.11). Pharmacological therapy is considered optimal by current standards in both the
DINAMIT trial95 and the IRIS trial.97
The MADIT I trial99 presents data on drug use at 1 month (see Table 14) and last contact (see Appendix 7).
Usage of ACE inhibitors (ICD arm 60%, medical therapy arm 55%) and beta-blockers (beta-blockers or
sotalol: ICD arm 27%, medical therapy arm 15%) was low in this trial at 1 month and beta-blocker use
was not balanced between the groups. Three-quarters of the medical therapy group received amiodarone
at 1 month compared with 2% of the ICD group, but use of class I antiarrythmics was similar (ICD arm
12% vs. medical therapy arm 10%). At 1 month, 56% of the ICD patients and 8% of the medical therapy
patients had no antiarrhythmic medication. Approximately half of the participants were receiving
diuretics. Digitalis use was high by current standards (ICD arm 58%, medical therapy arm 38%).
The pharmacological therapy provided in the MADIT I trial99 would not be considered optimal by
current standards.
The MADIT II trial101 did not report medication at discharge but presented medication at last contact,
which was a mean of 18 months (ICD arm) and 17 months (OPT arm) from enrolment. About 70% of
participants received ACE inhibitors, about 10–13% received amiodarone and 2–3% received class I AADs.
Beta-blockers were taken by 70% of participants, diuretics by 72% of the ICD group and 81% of the OPT
group, digitalis by 57% of participants and statins by about two-thirds of participants. The pharmacological
therapy provided in the MADIT II trial101 would be considered optimal by current standards.
Cardiomyopathy The AMIOVIRT trial69 reports that OPT was encouraged in both the ICD group and the
amiodarone group. Therapy at discharge was not reported but concomitant drug therapy was presented
(see Table 15), with no statistically significant differences between the groups. A high proportion
(81–90%) of participants received ACE inhibitors and approximately half received beta-blockers. Over
two-thirds received diuretics and/or digoxin and one-fifth received spironolactone. Beta-blocker use is
slightly lower in this trial than in current standards, but the pharmacological therapy is close to optimal.
About 96% of participants took ACE inhibitors at baseline in CAT,82 but beta-blocker use was low
(4% of participants). Diuretics were taken by the majority of participants (85–88%), warfarin was received
by 24–35% of participants, nitrates were taken by 26–32% of participants and calcium channel blockers
were taken by 7–16% of participants. Observed differences between the groups were not statistically
significant. Although acceptable at the time, the pharmacological therapy in this trial would not be
considered optimal by current standards because of the low beta-blocker use.
Optimal pharmacological therapy was described for both groups in the DEFINITE trial.90 A high proportion
(about 86%) of participants received ACE inhibitors and a small proportion (8.7–13.5%) received ARBs.
Beta-blockers were taken by 85%, diuretics by 87% and digoxin by 42%. A small proportion of each
group received amiodarone (ICD arm 3.9%, OPT arm 6.6%) and nitrates (ICD arm 9.2%, OPT arm
13.1%). The pharmacological therapy in this trial would be considered optimal by current standards.
Coronary artery bypass graft surgery ACE inhibitors were taken by over half of the participants in the
CABG Patch trial.75 In total, 63.3% of the ICD group and 65.2% of the control group received no oral
AADs. Class I antiarrythmics were taken by 16.7% (ICD arm) and 12.0% (OPT arm) of participants,
amiodarone by 3.7% (ICD arm) and 3.2% (OPT arm) and beta-blockers (other than sotalol) by 17.9%
(ICD arm) and 24% (OPT arm). There is an excess of AAD use in the ICD arm, which may paradoxically
offset some of the ICD benefit. The majority of participants received antiplatelet drugs (84%), two-thirds
received digitalis and around half received diuretics (47–57%). The pharmacological therapy provided in
this trial would have been considered optimal at the time that the trial was conducted but use is low by
current standards.
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Mild to moderate heart failure A high proportion (94–98%) of participants in SCD-HeFT105 were taking
ACE inhibitors or an ARB at enrolment. Beta-blockers were taken by 69% of participants, digoxin by about
70%, aspirin by about 56%, warfarin by about 35% and statins by about 40%. Most (82%) received loop
diuretics and 20% received potassium-sparing diuretics and a minority received thiazide (7%). This trial
also reported medication at last follow-up, for which there was a statistically significant (p< 0.001)
difference in beta-blocker use between groups (ICD arm 82%, amiodarone arm 72%, placebo arm 79%)
(see Appendix 7). The pharmacological therapy in this trial would be considered optimal by
current standards.
Outcomes
All-cause mortality was the primary outcome in all 13 trials in people at risk of SCD from ventricular
arrhythmias.69,71,78,81,82,84,89,90,95,97,99,101,105 Secondary outcomes tended to focus on other measures of
mortality or survival. Ten RCTs assessed total cardiac deaths,69,72,78,82,84,95,97,99,103,108 13 RCTs assessed
sudden cardiac and arrhythmic deaths,69,72,78,81,82,84,89,90,95,97,99,103,108 11 RCTs assessed cardiac
non-arrhythmic deaths,69,72,78,82,84,90,95,97,99,103,108 10 RCTs assessed other non-cardiac causes of
death,69,72,78,82,84,95,97,99,103,108 five RCTs assessed cumulative mortality75,84,90,97,105 and four RCTs assessed
survival.69,71,81,82 Other secondary outcome measures included heart hospitalisations (two RCTs71,101),
symptoms and complications related to arrhythmias (three RCTs69,82,103), QoL (seven RCTs69,74,80,87,94,104,107)
and adverse events (13 RCTs69,71,75,81,82,84,89,90,95,97,99,101,105).
Setting
The AVID,71 CASH81 and CIDS84 trials were multicentre studies, with the majority of the centres in the
USA71 or Canada84 or in Germany.81 The DEBUT study89 was conducted in Thailand but the number of
centres was not reported. The number of participants ranged from 66 (DEBUT main study89) to
1016 (AVID71). The DEBUT trial89 also included a pilot study in which 20 participants were randomised.
Length of follow-up ranged from a mean of 18.2 months (SD 12.2 months) in the AVID trial71 to
57 months (SD 34 months) in the CASH trial.81
The DINAMIT,95 IRIS,97 MADIT I99 and MADIT II101 trials were multicentre studies. The majority of centres
for the DINAMIT trial95 were in Canada, Germany and Europe (four UK centres) and the IRIS trial97 was
conducted in Europe (not the UK) and the Russian Federation. The majority of centres for the MADIT I99
and MADIT II101 trials were in the USA. Sample size ranged from 196 (MADIT I99) to 1232 (MADIT II101).
Mean follow-up ranged from 20 months in the MADIT II trial101 to 37 months in the IRIS trial.97
The AMIOVIRT69 and DEFINITE90 trials were multicentre studies with the majority of centres in the USA,
whereas CAT82 was a multicentre study conducted in Germany. Sample size was relatively small in
AMIOVIRT69 and CAT82 (103 and 104 participants randomised respectively), with CAT82 designed as a pilot
study. The DEFINITE trial90 randomised 458 participants. The trials had similar lengths of follow-up: a mean
of 2 years in the AMIOVIRT69 and CAT82 trials and a mean of 2.4 years in the DEFINITE trial.90
The CABG Patch trial75 was a multicentre study conducted primarily in the USA, with 900 participants
randomised. Mean follow-up was 32 months. SCD-HeFT105 was also a multicentre study conducted mainly
in the USA, with 2521 participants randomised. Median follow-up was 45.5 months.
Risk of bias
The risk of bias in the included trials is summarised in Table 16 and further details for each trial can be
found in the data extraction tables in Appendix 7. All 13 trials were unclear on risk of bias associated with
randomisation. In fact eight trials did not report details of either randomisation or allocation concealment;
therefore, the risk of selection bias (differences between known and unknown baseline characteristics of
the groups) is unclear. Five trials (CIDS,84 MADIT I,99 IRIS,97 DINAMIT,95 CABG Patch75) did not report the
randomisation method, although sufficient details were reported to establish that the allocation sequence
was adequately concealed and they were judged to have a low risk of selection bias.
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It was not possible to blind participants and personnel (health-care providers) in these trials as one group
received surgery. This could bias the results because of differences in behaviours across intervention groups
or differences in the care provided, such as administration of co-interventions. The trials were therefore
judged to have a high risk of performance bias. Cause of death was determined or reviewed by a
committee blinded to treatment group in the AVID,71 DEFINITE,90 DINAMIT, 95 AMIOVIRT,69 IRIS97 and
SCD-HeFT105 trials. Outcome assessors were not blinded in the other trials but mortality was judged
unlikely to be influenced by lack of blinding and so the trials were considered to have a low risk of
detection bias for this outcome. Unblinded trials reporting QoL69,71,75,84,90,101,105 were judged to have a high
risk of detection bias for this outcome.
Risk of attrition bias (differences between groups in withdrawals from the study) was low in seven of the
trials69,81,90,95,97,99,101 and unclear in three trials.82,84,89 In the AVID,71 CABG Patch75 and SCD-HeFT105 trials,
risk of attrition bias was judged to be low for mortality but high or unclear for QoL outcomes.
Risk of selective reporting bias (differences between reported and unreported findings) was considered to
be low in six studies.69,71,81,89,99,105 Five studies listed outcomes in a protocol or methods section that were
not then reported.82,84,90,95,97 Risk of selective reporting bias was unclear in two studies (MADIT II,101
CABG Patch75).
Risk of other sources of bias was judged to be high in DINAMIT95 as block randomisation in an unblinded
trial can lead to prediction of allocation. The authors of the CASH study81 note that centres were reluctant
to enrol patients for potential ICD therapy in the early phase of the study and to deny ICD therapy in the
late phase of the study. The effect of this is unclear. Seven of the trials were stopped early;69,71,75,82,89,99,101
however, simulation evidence suggests that inclusion of stopped-early trials in meta-analyses does not lead
to substantial bias.65
Methodological comments
Similarity of groups at baseline
Although it was evident that there were differences between the 13 trials in the types of participants
included (see earlier section on participants), within the trials participants appeared generally to be well
balanced at baseline. However, some differences were evident. In the IRIS97 trial the ICD group had a
higher proportion than the OPT group of people with LBBB (10.1% vs. 6.4%, p= 0.05) and diabetes
mellitus (37.2% vs. 30.2%, p= 0.03). The CAT82 trial found a higher occurrence of bradycardias among
the OPT group (18.8%) than among the ICD group (2.1%, p= 0.015). The DEFINITE90 trial noted that
the OPT group (3.27 years) had a significantly longer mean duration of HF than the ICD+OPT group
(2.39 years) (p= 0.04).
Sample size
All 13 trials included a calculation of sample size or statistical power based on the primary outcome
measure of all-cause mortality. The CIDS (n= 659),84 DINAMIT (n= 674),95 DEFINITE (n= 458),90
CABG-Patch (n= 900)75 and SCD-HeFT (n= 2521)105 trials appeared to be adequately powered to detect a
difference in all-cause mortality. In contrast, the CASH (n= 288),81 DEBUT (n= 66),89 MADIT II (n= 1232)101
and CAT (n= 104)82 trials were thought to be underpowered based on reported sample size calculations.
Five trials were stopped early because they achieved an a priori stopping rule concerning crossing of
efficacy boundaries [AVID (n= 1016),71 MADIT I (n= 196),99 MADIT II (n= 1232)101] or because interim
analysis showed low event rates, which meant that further recruitment would not achieve adequate
statistical power [AMIOVIRT (n= 103),69 CAT (n= 104)82]. Because of lower than anticipated mortality
in the IRIS trial,97 an increase in sample size (n= 900) was recommended by the data and safety
monitoring board.
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Other issues
The CASH trial81 was designed as a four-arm trial (ICD, amiodarone, metoprolol, propafenone);
however, the propafenone arm was terminated early after the interim analysis had been carried out.
The DEBUT trial89 reports the results of a pilot study and the main trial, although both were small.
During the course of the MADIT I trial,99 a change was made from transthoracic to transvenous leads.
The authors of this trial note that this altered the type of patient referred for entry to the trial.
Funding
The AVID71 and CIDS84 trials received funding from the National Heart, Lung, and Blood Institute and the
Medical Research Council of Canada respectively. All of the other RCTs69,75,81,82,89,90,95,97,99,101,105 received
some or all of their funding from the ICD manufacturers, which may represent a potential conflict
of interests.
Assessment of effectiveness
All-cause mortality
All 13 trials comparing the use of ICDs with the use of AADs in people at increased risk of SCD
from ventricular arrhythmias reported measures of all-cause mortality as their primary outcome
measure.69,71,75,81,82,84,89,90,95,97,99,101,105 Four trials71,81,84,89 assessed the use of ICDs compared with the use
of AADs in people at increased risk of SCD from previous ventricular arrhythmias. All four trials showed
beneficial effects on crude mortality rates for those receiving an ICD, although only the AVID trial71
(ICD arm 15.8%, AAD arm 24.0%, p< 0.012, follow-up 18.2 months) and the main DEBUT trial89
(ICD arm 0%, AAD arm 13.8%, p< 0.02, follow-up 3 years) found statistically significant differences. A
separate pilot study for the DEBUT trial89 had previously shown no significant difference between the ICD
arm and the AAD arm (ICD arm 0%, AAD arm 30.0%, p= 0.07, follow-up maximum 3 years). In the other
two studies differences were either not statistically significant or not assessed. The CASH trial81 reported an
all-cause mortality rate of 36.4% for the ICD group compared with 44.4% for the AAD group (p-value not
stated, follow-up 57 months). The CIDS trial84 reported a crude mortality rate of 25.3% for the ICD group
and 29.6% for the AAD group over the 3-year follow-up, equating to an annual crude mortality rate of
8.3% for the ICD group and 10.2% for the AAD group, a risk ratio reduction (RRR) of 19.7% (95% CI
–7.7% to 40.0%, p= 0.142) (Table 17). A meta-analysis of the four studies (including the DEBUT pilot
study89) using a random-effects model showed a statistically significant benefit for ICDs compared with
AADs with a RR of 0.75 (95% CI 0.61 to 0.93, p= 0.010), with limited heterogeneity (χ2= 5.89, df= 4,
I2= 32%) (Figure 4).
Of the nine trials69,75,82,90,95,97,99,101,105,146 including people who had not suffered a life-threatening
arrhythmia but who were at increased risk, three showed statistically significant benefits for all-cause
mortality in the ICD+OPT group compared with the different comparators (see Table 17). In the MADIT I
trial,99 15.8% of participants receiving an ICD+OPT died compared with 38.6% of participants receiving
OPT (mean follow-up 27 months), equating to a hazard ratio (HR) of 0.46 (95% CI 0.26 to 0.82,
p= 0.009) (see Table 17). The MADIT II trial101 also found significant benefits, with 14.2% of those with an
ICD+OPT dying compared with 19.8% of those who received OPT only (mean follow-up 20 months), a
HR of 0.69 (95% CI 0.51 to 0.93, p= 0.016). Post-trial follow-up in the MADIT II study101 found continued
benefit of ICDs at 8 years (HR 0.66, 95% CI 0.56 to 0.78, p= 0.001); analysis was undertaken on an
efficacy basis by including data on crossovers and validated in an intention-to-treat (ITT) analysis.149 The
SCD-HeFT trial,105 which had a longer follow-up period (mean 45.5 months), reported that 22.0% of
people who received an ICD+OPT died compared with 28.4% of those receiving amiodarone+OPT and
28.8% of those receiving placebo+OPT. HRs showed that the difference between the ICD+OPT group
and the placebo+OPT group was statistically significant (HR 0.77, 97.5% CI 0.62 to 0.96, p= 0.007),
whereas that between the amiodarone+OPT group and the placebo+OPT group was not statistically
significant (HR 1.06, 97.5% CI 0.86 to 1.30, p= 0.53).105 A meta-analysis of the two MADIT trials99,101
using a random-effects model showed a statistically significant benefit for those receiving ICDs+OPT
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TABLE 17 All-cause mortality
Study Follow-up
ICD, n/N (%)
[rate/year, %]
OPT, n/N (%)
[rate/year, %] Effect
95% CI,
p-value
Cardiac arrest
AVID71 Mean 18.2
(SD 12.2) months
80/507
(15.8, ± 95% CI 12.6
to 19)
AAD: 122/509
(24.0, ± 95% CI 20.3
to 27.7)
< 0.012
CASH81 57 (SD 34) months 36/99 (36.4, 95%
CI 26.9 to 46.6)a
Amiodarone: 40/92
(43.5, 95% CI 33.2
to 54.2)a
Metoprolol: 44/97
(45.4, 95% CI 35.2
to 55.8)a
Both:b 84/189
(44.4, 95% CI 37.2
to 51.8)a
CIDS84c Mean 3 years 83/328 (25.3) [8.3] Amiodarone: 98/331
(29.6) [10.2]
RRR 19.7 –7.7 to 40.0,
0.142
DEBUT89
pilot study
Max. 3 years
after randomisation
0/10 (0) Propranolol: 3/10
(30.0)
0.07
DEBUT89
main study
3 years 0/37 (0) Propranolol: 4/29
(13.8)
0.02
Early post MI
DINAMIT95 Average 30
(SD 13) months
62/332 (18.7) [7.5] 58/342 (17.0) [6.9] HR 1.08 0.76 to 1.55,
0.66
IRIS97 Average 37 months 116/445 (26.1) 117/453 (25.8) HR 1.04 0.81 to 1.35,
0.15
Remote from MI
MADIT I99 Average 27 months 15/95 (15.8) 39/101 (38.6) HR 0.46 0.26 to 0.82,
0.009
MADIT II101 Average 20 months 105/742 (14.2) 97/490 (19.8) HR 0.69 0.51 to 0.93,
0.016
Cardiomyopathy
AMIOVIRT69 Mean 2.0
(SD 1.3) years
6/51 (11.8) Amiodarone+OPT:
7/52 (13.5)
0.8
CAT82 1 year
(primary end point)
4/50 (8.0) 2/54 (3.7) 0.3672
Mean 5.5
(SD 2.2) years
13/50 (26.0) 17/54 (31.5)
DEFINITE90 Mean 29.0
(SD 14.4) months
28/229 (12.2) 40/229 (17.5) HR 0.65 0.40 to 1.06,
0.08
CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
compared with OPT alone, with a RR of 0.57 (95% CI 0.33 to 0.97, p= 0.04), although there was some
apparent heterogeneity (χ2= 3.54, df= 1, I2= 72%), which may reflect differences in disease severity
(see Figure 4).
The other six trials, which included people with cardiomyopathy,69,82,90 in the early period post MI95,97 or
scheduled for a CABG,78 found no statistically significant differences between groups for all-cause
mortality. The AMIOVIRT trial69 reported all-cause mortality after a mean follow-up of 2 years, finding that
11.8% of those with an ICD+OPT had died compared with 13.5% of those receiving amiodarone+OPT
(p= 0.8). The CAT trial82 reported all-cause mortality at 1 year, showing no significant difference between
groups (ICD+OPT 8% vs. OPT 3.7%, p= 0.3672). Longer mean follow-up to 5.5 years showed a limited
difference between groups, with 26% of the ICD+OPT group and 31.5% of the OPT group dying
(p-value not stated). The DEFINITE trial90 found that 12.2% of participants receiving an ICD+OPT and
17.5% of those receiving OPT had died at a mean follow-up of 29 months, a HR of 0.65 (95% CI 0.40
to 1.06, p= 0.08) (see Table 17). Combining these three cardiomyopathy trials using random-effects
meta-analysis confirmed that there was no significant difference between the treatments, with a RR of
0.77 (95% CI 0.52 to 1.15, p= 0.20), with no heterogeneity (χ2= 1.73, df= 2, I2= 0%) (see Figure 4).
The effect of combining the three cardiomyopathy trials with the non-ischaemic CHF subgroup of the
SCD-HeFT trial105 is assessed in Subgroup analyses reported by included randomised controlled trials. The
DINAMIT95 and IRIS97 trials assessed the effects of ICDs+OPT compared with OPT in those who were in
the early period post MI. The DINAMIT trial95 reported that 18.7% of participants receiving an ICD+OPT
and 17.0% of those receiving OPT had died by 30 months’ follow-up, resulting in a HR of 1.08 (95% CI
0.76 to 1.55, p= 0.66). Similarly, the IRIS trial97 found no significant difference in all-cause mortality
between the ICD+OPT group (26.1%) and the OPT group (25.8%), reflected in a HR of 1.04 (95% CI
0.81 to 1.35, p= 0.15). Meta-analysis of the DINAMIT95 and IRIS97 trials confirmed that there was no
significant difference between the treatments, with a RR of 1.04 (95% CI 0.86 to 1.25, p= 0.69), with no
heterogeneity (χ2= 0.19, df= 1, I2= 0%) (see Figure 4). The CABG Patch trial,78 which included people
who were scheduled for a CABG, reported a mortality rate of 22.9% for those receiving an ICD+OPT
compared with 21.2% for those receiving OPT (p-value not stated), a RR of 1.08 (95% CI 0.85 to 1.38,
p= 0.53) (see Figure 4).
TABLE 17 All-cause mortality (continued )
Study Follow-up
ICD, n/N (%)
[rate/year, %]
OPT, n/N (%)
[rate/year, %] Effect
95% CI,
p-value
Scheduled for CABG
CABG Patch78 Mean 32
(SD 16) months
102/446 (22.9) 96/454 (21.1)
HF
SCD-HeFT105 Median for surviving
patients 45.5
(range 24–72.6)
months
182/829 (22.0) Amiodarone+OPT:b
240/845 (28.4)
Placebo+OPT:b
244/847 (28.8)
HR 0.77d 0.62 to 0.96,e
0.007
HR, hazard ratio; max, maximum.
a Probability level for CI around crude death rate not reported in CASH.81
b The CASH81 and SCD-HeFT105 trials are three-arm trials; however, the two control arms have been combined to provide a
single pairwise comparison for the meta-analysis (see Cochrane Handbook section 16.5.465) (see Figure 4).
c Longer-term follow-up (5.6 years) from one centre of the CIDS study84 has been excluded from the meta-analysis to
avoid double counting of participants.
d HRs for amiodarone vs. placebo are not presented in the summary tables (see Appendix 7).
e 97.5% CI.
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Total cardiac deaths
Only two trials in people at increased risk of SCD due to previous ventricular arrhythmias, specifically the
AVID72 and CIDS84 trials, assessed the effects of ICDs compared with AADs on total cardiac deaths
(Table 18). Although both studies found lower crude rates for those receiving an ICD, neither reported
whether the effect was statistically significant (AVID:72 ICD 12.4%, AAD 18.5%, p-value not stated;
CIDS:84 ICD 20.4%, AAD 25.1%; p-value not stated). In addition, the CIDS trial84 found no statistically
significant difference between the interventions with regard to annual crude mortality rates (ICD 6.7%,
AAD 8.6%, RRR 23.4%, 95% CI –5.7 to 44.5, p= 0.104). However, a meta-analysis of the two studies
using a random-effects model showed that ICDs had a statistically significant effect compared with AADs,
Study or subgroup
Cardiac arrest (secondary prevention)
AVID71–74
CASH81
CIDS84–88
DEBUT pilot89
DEBUT main89
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.02; χ2 = 5.89, df = 4 (p = 0.21); I2 = 32%
Test for overall effect: z = 2.59 (p = 0.010)
Recent MI
DINAMIT95,96
IRIS97,98
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.19, df = 1 (p = 0.66); I2 = 0%
Test for overall effect: z = 0.40 (p = 0.69)
Remote MI
MADIT I99,100
MADIT II101–104
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.11; χ2 = 3.54, df = 1 (p = 0.06); I2 = 72%
Test for overall effect: z = 2.06 (p = 0.04)
Cardiomyopathy
AMIOVIRT69,70
CAT82,83
DEFINITE90–94
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.73, df = 2 (p = 0.42); I2 = 0%
Test for overall effect: z = 1.27 (p = 0.20)
CABG surgery
CABG Patch75–80
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.62 (p = 0.53)
Mild to moderate HF
SCD HeFT105–108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 3.49 (p = 0.0005)
Events
80
36
83
0
0
199
62
116
178
15
105
120
6
4
28
38
102
102
182
182
Total
507
99
328
10
37
981
332
445
777
95
742
837
51
50
229
330
446
446
829
829
122
84
98
3
4
311
58
117
175
39
97
136
7
2
40
49
96
96
484
484
Events Total
509
189
331
10
29
1068
342
453
795
101
490
591
52
54
229
335
454
454
1692
1692
Weight
34.9%
28.6%
35.5%
0.6%
0.5%
100.0%
31.7%
68.3%
100.0%
41.1%
58.9%
100.0%
15.2%
5.8%
79.0%
100.0%
100.0%
100.0%
100.0%
100.0%
0.66 (0.51 to 0.85)
0.82 (0.60 to 1.11)
0.85 (0.67 to 1.10)
0.14 (0.01 to 2.45)
0.09 (0.00 to 1.57)
0.75 (0.61 to 0.93)
1.10 (0.80 to 1.52)
1.01 (0.81 to 1.26)
1.04 (0.86 to 1.25)
0.41 (0.24 to 0.69)
0.71 (0.56 to 0.92)
0.57 (0.33 to 0.97)
0.87 (0.32 to 2.42)
2.16 (0.41 to 11.28)
0.70 (0.45 to 1.09)
0.77 (0.52 to 1.15)
1.08 (0.85 to 1.38)
1.08 (0.85 to 1.38)
0.77 (0.66 to 0.89)
0.77 (0.66 to 0.89)
ICD No ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
0.1 0.2 0.5 1 2 5 10
Favours ICD Favours no ICD
Test for subgroup difference: χ2 = 13.63, df = 5 (p = 0.02); I2 = 63.3%
FIGURE 4 All-cause mortality.
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with a RR of 0.74 (95% CI 0.61 to 0.91, p= 0.004) and no apparent heterogeneity (χ2= 0.84, df= 1,
I2= 0%) (Figure 5).
Eight trials69,78,82,95,97,99,101,108 in people who had not suffered a life-threatening arrhythmia but who were
at increased risk assessed the effects of ICDs+OPT compared with either OPT, amiodarone+OPT or
placebo+OPT on total cardiac deaths (see Table 18). Of these, only the MADIT II trial,103 which included
people remote from MI (ICD+OPT 10.6%, OPT 16.3%, p< 0.01), and the SCD-HeFT trial,108 which
included people with mild to moderate HF (ICD+OPT 14.7%, placebo+OPT 19.7%, amiodarone+OPT
19.2%; HR 0.76, 95% CI 0.60 to 0.95, p= 0.018), found statistically significant benefit for those receiving
an ICD+OPT. A similar difference was identified in the MADIT I trial,99 which included people remote from
MI (ICD+OPT 11.6%, OPT 26.7%); however, statistical significance was not stated. A meta-analysis of the
MADIT I99 and II103 trials using a random-effects model showed a statistically significant benefit for
ICDs+OPT, with a RR of 0.59 (95% CI 0.42 to 0.83, p= 0.003) and limited heterogeneity (χ2= 1.3, df= 1,
I2= 23%) (see Figure 5).
The DINAMIT95 (ICD+OPT 13.9%, OPT 14.3%, p-value not stated) and IRIS97 (ICD+OPT 21.3%, OPT
21.9%, p-value not stated) trials, which included those with a recent MI, the AMIOVIRT trial,69 which
included those with cardiomyopathy (ICD+OPT 7.8%, amiodarone+OPT 9.6%, p-value not stated) and
the CABG Patch trial,78 which included people scheduled for a CABG (ICD+OPT 17.0%, OPT 17.4%;
HR 0.97, 95% CI 0.71 to 1.33, p= 0.84) found limited differences in total cardiac deaths between those
receiving ICD+OPT and those receiving either OPT or amiodarone+OPT (see Table 18). In contrast,
TABLE 18 Total cardiac deaths
Study Follow-up
ICD, n/N (%)
[rate/year, %]
OPT, n/N (%)
[rate/year, %] Effect
95% CI,
p-value
Cardiac arrest
AVID72 Mean 18.2 (SD 12.2) months 63/507 (12.4) AAD: 94/509 (18.5)
CIDS84 Mean 3 years 67/328 (20.4) [6.7] Amiodarone:
83/331 (25.1) [8.6]
RRR 23.4 –5.7 to
44.5, 1.04
Early post MI
DINAMIT95 Average 30 (SD 13) months 46/332 (13.9) 49/342 (14.3)
IRIS97 Average 37 months 95/445 (21.3) 99/453 (21.9)
Remote from MI
MADIT I99 Average 27 months 11/95 (11.6) 27/101 (26.7)
MADIT II103 Average 20 months 79/742 (10.6) 80/490 (16.3) < 0.01
Cardiomyopathy
AMIOVIRT69 Mean 2.0 (SD 1.3) years 4/51 (7.8) Amiodarone+OPT:
5/52 (9.6)
CAT82 1 year (primary end point) 4/50 (8.0) 0/54 (0)
Scheduled for CABG
CABG
Patch78
Mean 32 (SD 16) months 76/446 (17.0) 79/454 (17.4) HR 0.97 0.71 to
1.33, 0.84
HF
SCD-HeFT108 Median for surviving patients
45.5 (range 24 to 72.6) months
122/829 (14.7) Amiodarone+OPT:
162/845 (19.2),
placebo+OPT:
167/847 (19.7)
HR 0.76 0.60 to
0.95, 0.018
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the CAT trial,82 which included people with cardiomyopathy, reported higher total cardiac mortality among
those receiving an ICD+OPT than among those receiving OPT (ICD+OPT 8%, OPT 0%), although the
statistical significance was not stated. When these trials were meta-analysed by patient group using
random-effects models, the lack of any statistically significant benefit was evident. Combining the
DINAMIT95 and IRIS97 trials produced a RR of 0.97 (95% CI 0.79 to 1.20, p= 0.8) with no apparent
heterogeneity (χ2= 0, df= 1, I2= 0%) (see Figure 5). The meta-analysis of the AMIOVIRT69 and CAT82 trials
resulted in a RR of 2.03 (95% CI 0.17 to 23.62, p= 0.57) with some moderate heterogeneity (χ2= 2.59,
df= 1, I2= 61%) (see Figure 5).
Sudden cardiac death/arrhythmic deaths
Sudden cardiac and arrhythmic death rates were lower among people receiving an ICD than among those
receiving AADs in the four trials72,81,84,89 that included people at increased risk of SCD as a result of
Study or subgroup Events Total Events Total Weight
ICD No ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
Cardiac arrest (secondary prevention)
AVID71–74
CIDS84–88
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.84, df = 1 (p = 0.36); I2 = 0%
Test for overall effect: z = 2.85 (p = 0.004)
Recent MI
DINAMIT95,96
IRIS97,98
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.00, df = 1 (p = 0.96); I2 = 0%
Test for overall effect: z = 0.25 (p = 0.80)
Remote MI
MADIT I99,100
MADIT II101–104
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.02; χ2 = 1.30, df = 1 (p = 0.25); I2 = 23%
Test for overall effect: z = 3.00 (p = 0.003)
Cardiomyopathy
AMIOVIRT69,70
CAT82,83
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 2.07; χ2 = 2.59, df = 1 (p = 0.11); I2 = 61%
Test for overall effect: z = 0.57 (p = 0.57)
CABG surgery
CABG Patch75–80
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.14 (p = 0.89)
Mild to moderate HF
SCD HeFT105–108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.87 (p = 0.004)
63
67
130
46
95
141
11
79
90
4
4
8
76
76
122
122
507
328
835
332
445
777
95
742
837
51
50
101
446
446
829
829
94
83
177
49
99
148
27
80
107
5
0
5
79
79
329
329
509
331
840
342
453
795
101
490
591
52
54
106
454
454
1692
1692
48.1%
51.9%
100.0%
30.9%
69.1%
100.0%
24.4%
75.6%
100.0%
63.2%
36.8%
100.0%
100.0%
100.0%
100.0%
100.0%
0.67 (0.50 to 0.90)
0.81 (0.61 to 1.08)
0.74 (0.61 to 0.91)
0.97 (0.67 to 1.40)
0.98 (0.76 to 1.25)
0.97 (0.79 to 1.20)
0.43 (0.23 to 0.82)
0.65 (0.49 to 0.87)
0.59 (0.42 to 0.83)
0.82 (0.23 to 2.87)
9.71 (0.54 to 175.83)
2.03 (0.17 to 23.62)
0.98 (0.74 to 1.30)
0.98 (0.74 to 1.30)
0.76 (0.63 to 0.92)
0.76 (0.63 to 0.92)
0.1 0.2 0.5 1 2 5 10
Favours ICD Favours no ICD
Test for subgroup difference: χ2 = 9.67, df = 5 (p = 0.09); I2 = 48.3%
FIGURE 5 Total cardiac deaths.
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previous ventricular arrhythmias (Table 19). Both the CASH81 [ICD 13.0%, 95% CI 7.9 to 19.6; AAD
(either amiodarone or metoprolol) 32.8%, 95% CI 27.2 to 41.8] and DEBUT89 (ICD 0%; AAD 13.8%) trials
reported lower rates of SCD for those receiving an ICD than for those receiving AADs, although only the
CASH trial81 showed a statistically significant difference. Similarly, the AVID72 and CIDS84 studies showed
benefit for people receiving an ICD compared with AADs with regard to crude rate of arrhythmic deaths
(AVID:72 ICD 4.7%, AAD 10.8%; CIDS84: ICD 9.2%, AAD 13.0%), although neither demonstrated a
statistically significant difference. The CIDS trial84 also showed no statistically significant difference when
comparing the interventions for annual crude mortality rate [ICD 3.0%, AAD 4.5%, RRR 32.8%; 95% CI
–7.2 to 57.8, p= 0.094]. Combining the four studies through a random-effects meta-analysis showed a
statistically significant benefit for the ICD group compared with the AAD group, with a RR of 0.49
(95% CI 0.34 to 0.69, p< 0.0001) and limited heterogeneity (χ2= 5.47, df= 4, I2= 27%) (Figure 6).
All nine trials69,78,82,90,95,97,99,103,108 that included people who had not suffered a life-threatening arrhythmia
but who were at increased risk reported sudden cardiac or arrhythmic death as an outcome (see Table 19).
Although eight of the trials69,78,90,95,97,99,103,108 showed benefit for those receiving an ICD+OPT compared
with OPT, amiodarone+OPT or placebo+OPT, only four90,95,97,103 identified showed a statistically
significant effect. The DINAMIT95 and IRIS97 trials highlighted the benefits of ICDs+OPT compared with
OPT for people who had had a recent MI, reporting HRs of 0.42 (95% CI 0.22 to 0.83, p= 0.009) and
0.55 (95% CI 0.31 to 1.00, p= 0.049) respectively (see Table 19). When meta-analysed, a combined RR of
0.45 (95% CI 0.31 to 0.64, p< 0.0001) resulted, with no heterogeneity reported (χ2= 0.03, df= 1,
I2= 0%) (see Figure 6).
The MADIT I99 (ICD+OPT 3.2%, OPT 12.9%, p-value not stated) and MADIT II103 (ICD+OPT 3.8%, OPT
10.0%, p< 0.01) trials, which included people remote from MI, showed lower rates of sudden cardiac or
arrhythmic death among those receiving an ICD+OPT than among those receiving OPT. Meta-analysis
using a random-effects model showed a significant benefit for ICDs+OPT with a RR of 0.36 (95% CI 0.23
to 0.55, p< 0.00001) and no heterogeneity (χ2= 0.42, df= 1, I2= 0%) (see Figure 6).
The AMIOVIRT,69 CAT82 and DEFINITE90 trials, which included people with cardiomyopathy, reported
differing outcomes. The DEFINITE trial90 found that significantly fewer people who received an ICD+OPT
(1.3%) died from sudden cardiac or arrhythmic death than those receiving OPT (6.1%), reflected in a HR
of 0.20 (95% CI 0.06 to 0.71, p= 0.006) (see Table 19). Although the AMIOVIRT trial69 also found benefit
for those receiving an ICD+OPT (2.0%) compared with those receiving amiodarone+OPT (3.8%), the
benefit was not statistically significant (p= 0.7). The CAT trial82 reported no sudden cardiac or arrhythmic
deaths in either the ICD+OPT group or the OPT group. A random-effects meta-analysis of the three trials
showed an overall statistically significant benefit for participants who received an ICD+OPT compared
with the comparator treatment, with a RR of 0.26 (95% CI 0.09 to 0.77, p= 0.02) and no heterogeneity
(χ2= 0.41, df= 1, I2= 0%) (see Figure 6).
The CABG Patch trial,78 which included people who were scheduled for CABG surgery, reported lower
rates of sudden cardiac and arrhythmic death in the ICD+OPT group (3.4%) than in the OPT (6.2%),
although the difference was marginally insignificant (HR 0.55, 95% CI 0.29 to 1.03, p= 0.06)
(see Table 19). In contrast, the SCD-HeFT trial108 found significantly lower sudden cardiac or arrhythmic
mortality in the group receiving an ICD+OPT (4.6%) than in the group receiving amiodarone+OPT
(9.5%) or the group receiving placebo+OPT (11.6%), with a RR of 0.44 (95% CI 0.31 to 0.61,
p< 0.00001) (see Figure 6).
Non-arrhythmic cardiac deaths
Two trials72,84 that included people at increased risk of SCD because of previous ventricular arrhythmias
reported rates of non-arrhythmic deaths. The AVID72 and CIDS84 trials assessed the effects of ICDs
compared with the effects of AADs on crude non-arrhythmic cardiac deaths, with neither stating whether
there was any statistically significant benefit (AVID72: ICDs 7.7%, AAD 7.7%; CIDS84: ICDs 11.3%,
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TABLE 19 Sudden cardiac deaths/arrhythmic deaths
Study Follow-up
ICD, n/N (%)
[rate/year, %]
OPT, n/N (%)
[rate/year, %] Effect
95% CI,
p-value
Cardiac arrest
AVID72 Mean 18.2 (SD 12.2)
months
24/507 (4.7) AAD: 55/509 (10.8)
CASH81 57 (SD 34) months 13/99 (13.1,
95% CI 7.9 to
19.6)a
Amiodarone: 27/92
(29.3, CI 19.4 to 40.8)b
Metoprolol: 34/97
(35.1, CI 25.2 to 48.8)b
Both: 62/189
(32.8, CI 27.2 to 41.8)a
CIDS84 Mean 3 years 30/328 (9.1) [3.0] Amiodarone: 43/331
(13.0) [4.5]
RRR 32.8% –7.2 to
57.8, 0.094
DEBUT89
pilot study
Max. 3 years after
randomisation
0/10 (0) Propranolol: 3/10
(30.0)
DEBUT89
main study
3 years 0/37 (0) Propranolol: 4/29
(13.8)
Early post MI
DINAMIT95 Average 30 (SD 13)
months
12/332 (3.6) [1.5] OPT: 29/342 (8.5) [3.5] HR 0.42 0.22 to
0.83, 0.009
IRIS97 Average 37 months 27/445 (6.1) OPT: 60/453 (13.2) HR 0.55 0.31 to
1.00, 0.049
Remote from MI
MADIT I99 Average 27 months 3/95 (3.2) OPT: 13/101 (12.9)
MADIT II103 Average 20 months 28/742 (3.8) OPT: 49/490 (10.0) < 0.01
Cardiomyopathy
AMIOVIRT69 Mean 2.0 (SD 1.3) years 1/51 (2.0) Amiodarone+OPT:
2/52 (3.8)
0.7
CAT82 1 year (primary end point) 0/50 (0) OPT: 0/54 (0)
DEFINITE90 Mean 29.0 (SD 14.4)
months
3/229 (1.3) OPT: 14/229 (6.1) HR 0.20 0.06 to
0.71, 0.006
Scheduled for CABG
CABG
Patch78
Mean 32 (SD 16) months 15/446 (3.4) OPT: 28/454 (6.2) 0.55 0.29 to
1.03, 0.06
HF
SCD-HeFT108 Median for surviving
patients 45.5 (range 24
to 72.6) months
38/829 (4.6) Amiodarone+OPT:
80/845 (9.5)
Placebo+OPT:
98/847 (11.6)
a Crude death rate.
b Level of CI not reported.
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AAD 12.1%) (Table 20). The CIDS trial84 also reported annual crude mortality rates (ICDs 3.7%,
AAD 4.2%), which resulted in a non-significant RRR of 13.5% (95% CI –35.4 to 44.7, p= 0.526).
A random-effects meta-analysis confirmed the lack of a statistically significant difference between the
groups, reporting a RR of 0.97 (95% CI 0.72 to 1.31, p= 0.83) and no heterogeneity (χ2= 0.06, df= 1,
I2= 0%) (Figure 7).
Implantable cardiac defibrillator+OPT appeared to have a limited effect on the occurrence of
non-arrhythmic cardiac deaths compared with OPT, amiodarone+OPT or placebo+OPT in people who
had not suffered a life-threatening arrhythmia but who were at increased risk (see Table 20). In people
Study or subgroup Events Total Events Total Weight
ICD No ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
Cardiac arrest (secondary prevention)
AVID71–74
CASH81
CIDS84–88
DEBUT pilot89
DEBUT main89
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.04; χ2 = 5.47, df = 4 (p = 0.24); I2 = 27%
Test for overall effect: z = 3.96 (p < 0.0001)
Recent MI
DINAMIT95,96
IRIS97,98
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.03, df = 1 (p = 0.86); I2 = 0%
Test for overall effect: z = 4.34 (p < 0.0001)
Remote MI
MADIT I99,100
MADIT II101–104
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.42, df = 1 (p = 0.52); I2 = 0%
Test for overall effect: z = 4.76 ( p < 0.00001)
Cardiomyopathy
AMIOVIRT69,70
CAT82,83
DEFINITE90–94
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.41, df = 1 (p = 0.52); I2 = 0%
Test for overall effect: z = 2.43 (p = 0.02)
CABG surgery
CABG Patch75–80
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.94 (p = 0.05)
Mild to moderate HF
SCD HeFT105–108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 4.79 ( p < 0.00001)
24
13
30
0
0
67
12
27
39
3
28
31
1
0
3
4
15
15
38
38
507
99
328
10
37
981
332
445
777
95
742
837
51
50
229
330
446
446
829
829
55
62
43
3
4
167
29
60
89
13
49
62
2
0
14
16
28
28
178
178
509
189
331
10
29
1068
342
453
795
101
490
591
52
54
229
335
454
454
1692
1692
33.7%
27.6%
35.6%
1.5%
1.5%
100.0%
30.6%
69.4%
100.0%
11.9%
88.1%
100.0%
21.3%
78.7%
100.0%
100.0%
100.0%
100.0%
100.0%
0.44 (0.28 to 0.70)
0.40 (0.23 to 0.69)
0.70 (0.45 to 1.09)
0.14 (0.01 to 2.45)
0.09 (0.00 to 1.57)
0.49 (0.34 to 0.69)
0.43 (0.22 to 0.82)
0.46 (0.30 to 0.71)
0.45 (0.31 to 0.64)
0.25 (0.07 to 0.83)
0.38 (0.24 to 0.59)
0.36 (0.23 to 0.55)
0.51 (0.05 to 5.45)
Not estimable
0.21 (0.06 to 0.74)
0.26 (0.09 to 0.77)
0.55 (0.30 to 1.01)
0.55 (0.30 to 1.01)
0.44 (0.31 to 0.61)
0.44 (0.31 to 0.61)
0.05 0.2 1 5 20
Favours ICD Favours no ICD
Test for subgroup difference: χ2 = 2.59, df = 5 (p = 0.06); I2 = 0%
FIGURE 6 Sudden cardiac deaths/arrhythmic deaths.
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who had had a recent MI, the DINAMIT95 and IRIS trials97 found a statistically significant benefit for those
receiving OPT only compared with those receiving an ICD+OPT, reporting HRs of 1.72 (95% CI 0.99 to
2.99, p= 0.05) and 1.92 (95% CI 1.29 to 2.84, p= 0.001) respectively. Combining the studies using a
random-effects meta-analysis confirmed the statistically significant benefit for people receiving OPT, with a
RR of 1.77 (95% CI 1.30 to 2.40, p= 0.0002) and no apparent heterogeneity (χ2= 0, df= 1, I2= 0%)
(see Figure 7).
The effect of the different interventions on non-arrhythmic cardiac deaths in other patient subgroups was
more equivocal. The MADIT I99 and MADIT II103 trials, which included people remote from MI, reported
contrasting mortality rates (MADIT I:99 ICD+OPT 7.4%, OPT 12.9%; MADIT II:103 ICD+OPT 5.8%,
OPT 4.3%). Meta-analysing these data using a random-effects model showed no statistically significant
difference between the ICD+OPT group and the OPT group (RR 0.95, 95% CI 0.41 to 2.18, p= 0.9;
χ2= 2.77, df= 1, I2= 64%) (see Figure 7). Similar variation was reported by the three trials assessing
non-arrhythmic cardiac deaths among people with cardiomyopathy. The AMIOVIRT69 (ICD+OPT 5.9%,
amiodarone+OPT 5.8%), CAT82 (ICD+OPT 8%, OPT 0%) and DEFINITE90 (ICD+OPT 3.9%, OPT 4.8%)
trials reported differing mortality rates; when these data were meta-analysed there were no statistically
significant differences between the groups (RR 1.13, 95% CI 0.42 to 3.03, p= 0.81; χ2= 2.71, df= 2,
I2= 26%) (see Figure 7). Similarly, the CABG Patch trial,78 which included those who were scheduled for
CABG surgery (RR 1.26, 95% CI 0.87 to 1.82, p= 0.21), and the SCD-HeFT trial,108 which included those
TABLE 20 Non-arrhythmic cardiac deaths
Study Follow-up
ICD, n/N (%)
[rate/year, %]
OPT, n/N (%)
[rate/year, %] Effect
95% CI,
p-value
AVID72 Mean 18.2 (SD 12.2) months 39/507 (7.7) AAD: 39/509 (7.7)
CIDS84 Mean 3 years 37/328 (11.3) [3.7] Amiodarone:
40/331 (12.1) [4.2]
RRR
13.5%
–35.4 to
44.7, 0.526
Early post MI
DINAMIT95 Average 30 (SD 13) months 34/332 (10.2) [4.1] 20/342 (5.8) [2.4] HR 1.72 0.99 to
2.99, 0.05
IRIS97 Average 37 months 68/445 (15.3) 39/453 (8.6) HR 1.92 1.29 to
2.84, 0.001
Remote from MI
MADIT I99 Average 27 months 7/95 (7.4) 13/101 (12.9)
MADIT II103 Average 20 months 43/742 (5.8) 21/490 (4.3)
Cardiomyopathy
AMIOVIRT69 Mean 2.0 (SD 1.3) years 3/51 (5.9) Amiodarone+OPT:
3/52 (5.8)
0.7
CAT82 1 year (primary end point) 4/50 (8.0) 0/54 (0)
DEFINITE90 Mean 29.0 (SD 14.4) months 9a/229 (3.9) 11a/229 (4.8)
Scheduled for CABG
CABG
Patch78
Mean 32 (SD 16) months 57/446 (12.8) 46/454 (10.1) HR 1.24 0.84 to
1.84, 0.28
HF
SCD-HeFT108 Median for surviving patients
45.5 (range 24 to 72.6) months
81/829 (9.8) Amiodarone+OPT:
77/845 (9.1),
placebo+OPT:
68/847 (8.0)
a Deaths from HF reported only.
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with mild to moderate HF (RR 1.14, 95% CI 0.88 to 1.48, p= 0.32) found no statistically significant
differences between the groups (see Figure 7).
Other causes of death: non-cardiac deaths
Two trials72,84 in people at increased risk of SCD because of previous ventricular arrhythmias assessed
non-cardiac causes of death as an outcome (Table 21). The AVID72 and CIDS84 trials found no statistically
significant difference between ICDs and AADs for the outcome of other non-cardiac causes of death
(AVID:72 ICD 3.4%, AAD 5.5%, RR 1.78, 95% CI 0.98 to 3.26, p= 0.053; CIDS:84 non-cardiac vascular:
ICD 0.9%, AAD 0.6%, RRR –36.6%, 95% CI –719.8 to 77.2, p= 0.732; non-vascular: ICD 4.0%, AAD
3.9%, RRR 4.5%, 95% CI –106.1 to 55.7, p= 0.908) (see Table 21), reflected in a random-effects
meta-analysis (RR 0.79, 95% CI 0.45 to 1.37, p= 0.40; χ2= 1.51, df= 1, I2= 34%) (Figure 8). The CIDS
Study or subgroup Events Total Events Total Weight
ICD No ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
Cardiac arrest (secondary prevention)
AVID71–74
CIDS84–88
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.06, df = 1 (p = 0.81); I2 = 0%
Test for overall effect: z = 0.22 (p = 0.83)
Recent MI
DINAMIT95,96
IRIS97,98
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.00, df = 1 (p = 0.97); I2 = 0%
Test for overall effect: z = 3.67 (p = 0.0002)
Remote MI
MADIT I99,100
MADIT II101–104
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.24; χ2 = 2.77, df = 1 (p = 0.10); I 2 = 64%
Test for overall effect: z = 0.12 (p = 0.90)
Cardiomyopathy
AMIOVIRT69,70
CAT82,83
DEFINITE90–94
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.23; χ2 = 2.71, df = 2 (p = 0.26); I2 = 26%
Test for overall effect: z = 0.25 (p = 0.81)
CABG surgery
CABG Patch75–80
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.24 (p = 0.21)
Mild to moderate HF
SCD HeFT105–108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.99 (p = 0.32)
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102
7
43
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3
4
9
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81
507
328
835
332
445
777
95
742
837
51
50
229
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446
446
829
829
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40
79
20
39
59
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34
3
0
11
14
46
46
145
145
509
331
840
342
453
795
101
490
591
52
54
229
335
454
454
1692
1692
49.3%
50.7%
100.0%
32.8%
67.2%
100.0%
41.1%
58.9%
100.0%
29.5%
10.5%
60.0%
100.0%
100.0%
100.0%
100.0%
100.0%
1.00 (0.66 to 1.54)
0.93 (0.61 to 1.42)
0.97 (0.72 to 1.31)
1.75 (1.03 to 2.98)
1.77 (1.22 to 2.57)
1.77 (1.30 to 2.40)
0.57 (0.24 to 1.37)
1.35 (0.81 to 2.25)
0.95 (0.41 to 2.18)
1.02 (0.22 to 4.82)
9.71 (0.54 to 175.83)
0.82 (0.35 to 1.94)
1.13 (0.42 to 3.03)
1.26 (0.87 to 1.82)
1.26 (0.87 to 1.82)
1.14 (0.88 to 1.48)
1.14 (0.88 to 1.48)
0.05 0.2 1 5 20
Favours ICD Favours no ICD
Test for subgroup difference: χ2 = 8.66, df = 5 (p = 0.12); I2 = 42.3%
FIGURE 7 Non-arrhythmic cardiac deaths.
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TABLE 21 Other causes of death (non-cardiac)
Study Outcome and follow-up
ICD, n/N (%)
[rate/year, %]
OPT, n/N (%)
[rate/year, %] Effect
95% CI,
p-value
Cardiac arrest
AVID72 Mean 18.2 (SD 12.2) months 17/507 (3.4) AAD: 28/509a (5.5) RR 1.78 0.98 to
3.26, 0.053
CIDS84 Non-cardiac vascular deaths,
mean 3 years
3/328 (0.9) [0.3] Amiodarone: 2/331
(0.6) [0.2]
RRR –36.6% –719.8 to
77.2, 0.732
Non-vascular deaths, mean
3 years
13/328 (4.0) [1.3] 13/331 (3.9) [1.4] RRR 4.5% –106.1 to
55.7, 0.908
Early post MI
DINAMIT95 Non-cardiac vascular deaths,
average 30 (SD 13) months
5/332 (1.5) [0.6] 3/342 (0.9) [0.4] HR 1.69 0.40 to
7.06, 0.47
Non vascular deaths,
average 30 (SD 13) months
11/332 (3.3) [1.3] 6/342 (1.8) [0.7] HR 1.85 0.68 to
5.01, 0.22
IRIS97 Average 37 months 21/445 (4.7) 18/453 (4.0) HR 1.23 0.51
Remote from MI
MADIT I99 Non-cardiac deaths, average
27 months
4/95 (4.2) 6/101 (5.9)
Unknown (cardiac or non-cardiac
deaths), average 27 months
0/95 (0) 6/101 (5.9)
MADIT II103 Non-cardiac deaths, average
20 months
22/742 (3.0) 12/490 (2.4)
Unknown (cardiac or non-cardiac
deaths), average 20 months
4/742 (0.5) 5/490 (1.0)
Cardiomyopathy
AMIOVIRT69 Mean 2.0 (SD 1.3) years 2/51 (3.9) Amiodarone+OPT:
2/52 (3.8)
0.9
CAT82 1 year (primary end point) 0/50 (0) 2/54 (3.7)
Scheduled for CABG
CABG
Patch78
Non-cardiac deaths,
mean 32 (SD 16) months
25/446 (5.6) 17/454 (3.7) HR 1.49 0.80 to
2.76, 21
Unknown deaths 1/446 (0.2) 0/454 (0)
HF
SCD-HeFT108 Non-cardiac deaths, median
for surviving patients 45.5
(range 24–72.6) months
48/829 (5.8) Amiodarone+OPT:
54/845 (6.4)
Placebo+OPT:
53/847 (6.3)
HR 0.80b 0.57 to
1.12, NS
Unknown deaths, median for
surviving patients 45.5
(range 24–72.6) months
12/829 (1.4) Amiodarone+OPT:
24/845 (2.8)
NS
Placebo+OPT
24/847 (2.8)
NS, not significant.
a Three attributed to amiodarone pulmonary toxicity.
b Comparison for non-cardiac deaths between ICD+OPT and placebo+OPT.
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trial84 presented annual crude death rates for the ICD and AAD groups for non-cardiac vascular (ICD 0.3%,
AAD 0.2%) and non-vascular (ICD 1.3%, AAD 1.4%) causes,84 finding limited differences.
Eight trials69,78,82,95,97,99,103,108 in people who had not suffered a life-threatening arrhythmia but who were at
increased risk assessed the effects of ICDs+OPT on other non-cardiac causes of death compared with the
different comparator treatments, finding no statistically significant benefit (see Table 21). Meta-analyses
using random-effects models of the DINAMIT95 and IRIS97 trials in people with a recent MI (RR 1.39, 95%
CI 0.86 to 2.27, p= 0.18; χ2= 0.70, df= 1, I2= 0%), the MADIT I99 and MADIT II103 trials in people remote
from MI (RR 1.06, 95% CI 0.58 to 1.95, p= 0.84; χ2= 0.55, df= 1, I2= 0%) and the AMIOVIRT69 and
CAT82 trials in people with cardiomyopathy (RR 0.65, 95% CI 0.13 to 3.29, p= 0.60; χ2= 0.75, df= 1,
I2= 0%) all found no statistically significant effects (see Figure 8). Similarly, the CABG Patch trial78 in
people who were scheduled for CABG surgery (RR 1.50, 95% CI 0.82 to 2.73, p= 0.19) and the
Study or subgroup Events Total Events Total Weight
ICD No ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
Cardiac arrest (secondary prevention)
AVID71–74
CIDS84–88
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.05; χ2 = 1.51, df = 1 ( p = 0.22); I 2 = 34%
Test for overall effect: z = 0.85 ( p = 0.40)
Recent MI
DINAMIT95,96
IRIS97,98
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.70, df = 1 ( p = 0.40); I 2 = 0%
Test for overall effect: z = 1.33 ( p = 0.18)
Remote MI
MADIT I99,100
MADIT II101–104
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.55, df = 1 ( p = 0.46); I 2 = 0%
Test for overall effect: z = 0.20 ( p = 0.84)
Cardiomyopathy
AMIOVIRT69,70
CAT82,83
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.75, df = 1 ( p = 0.39); I 2 = 0%
Test for overall effect: z = 0.52 ( p = 0.60)
CABG surgery
CABG Patch75–80
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.31 ( p = 0.19)
Mild to moderate HF
SCD HeFT105–108
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.52 ( p = 0.60)
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0.61 (0.34 to 1.10)
1.08 (0.54 to 2.14)
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1.83 (0.82 to 4.09)
1.19 (0.64 to 2.20)
1.39 (0.86 to 2.27)
0.71 (0.21 to 2.43)
1.21 (0.60 to 2.42)
1.06 (0.58 to 1.95)
1.02 (0.15 to 6.97)
0.22 (0.01 to 4.39)
0.65 (0.13 to 3.29)
1.50 (0.82 to 2.73)
1.50 (0.82 to 2.73)
0.92 (0.66 to 1.27)
0.92 (0.66 to 1.27)
0.05 0.2 1 5 20
Favours ICD Favours no ICD
Test for subgroup difference: χ2 = 4.66, df = 5 (p = 0.46); I2 = 0%
FIGURE 8 Other causes of death: non-cardiac deaths.
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SCD-HeFT108 trial, which included people with mild-to moderate HF (RR 0.92, 95% CI 0.66 to 1.27,
p= 0.60), reported no statistically significant differences between groups in deaths from other non-cardiac
causes (see Figure 8).
Cumulative mortality
The cumulative mortality risk for both total and arrhythmic mortality was assessed annually for up to
3 years’ follow-up in the CIDS trial in people at increased risk of sudden cardiac death as a result of previous
ventricular arrhythmias.84 Rates were consistently lower for those receiving an ICD compared with those
receiving AADs, with a RRR for total mortality of 15.4% in year 1, 29.7% in year 2 and 13.7% in year 3 and
a RRR for arrhythmic mortality of 29.9% in year 1, 31.4% in year 2 and 17.8% in year 3 (Table 22).
Four trials in people who had not suffered a life-threatening arrhythmia but who were at increased risk
reported other mortality outcomes.75,90,97,105 The IRIS trial97 in people with a recent MI presented cumulative
death rates annually up to 3 years (see Table 22). Although this trial found lower mortality rates for those
TABLE 22 Cumulative mortality
Study Outcome ICD OPT Effect
Cardiac arrest
CIDS84 Cumulative risks over time, total mortality, % Amiodarone:
1 year 9.46 11.18 ARR 1.72, RRR 15.4
2 years 14.75 20.97 ARR 6.22, RRR 29.7
3 years 23.32 27.03 ARR 3.71, RRR 13.7
Cumulative risks over time, arrhythmic mortality, %
1 year 4.37 6.23 ARR 1.86, RRR 29.9
2 years 6.68 9.74 ARR 3.06, RRR 31.4
3 years 9.77 11.88 ARR 2.11, RRR 17.8
Cardiomyopathy
DEFINITE90 All-cause mortality rate at 1 year, % 2.6 6.2
All-cause mortality rate at 2 years, % 7.9 14.1
Early post MI
IRIS97 Cumulative 1-year death rate, %a 10.6 12.5
Cumulative 2-year death rate, %a 15.4 18.2
Cumulative 3-year death rate, %a 22.4 22.9
Scheduled for CABG
CABG
Patch75
Actuarial mortality by 4 years’ follow-up, % 27 24 p-value 0.64
HR for death per unit time 1.07
(95% CI 0.81 to 1.42)
HF
SCD-
HeFT105
Kaplan–Meier estimates of death from any cause,
5-year event rate
0.289 Amiodarone+OPT:
0.340
Placebo+OPT:
0.361
ARR, absolute risk reduction.
a States that no significant difference in survival was detected between the groups; p-value of 0.76 given, which may
relate to these data but reporting is unclear.
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receiving an ICD+OPT (year 1 10.6%, year 2 15.4%, year 3 22.4%) than for those receiving OPT
(year 1 12.5%, year 2 18.2%, year 3 22.9%), the differences were not found to be statistically significant
(p= 0.76). Similarly, the DEFINITE trial,90 which included people with cardiomyopathy (year 1: ICD+OPT
2.6%, OPT 6.2%; year 2: ICD+OPT 7.9%, OPT 14.1%), and the SCD-HeFT trial,105 which included people
with mild to moderate HF (Kaplan–Meier estimate, 5 years: ICD+OPT 0.289; amiodarone+OPT 0.340;
placebo+OPT 0.361), also reported lower all-cause mortality following implantation of an ICD (p-values
not stated). In contrast, the CABG Patch trial,75 which included people scheduled for CABG surgery,
reported higher actuarial mortality at 4 years’ follow-up in those receiving an ICD+OPT (27%) than in
those receiving OPT (24%), although the difference was not statistically significant (HR 1.07, 95% CI 0.81
to 1.42, p= 0.64) (see Table 22).
Survival
Differences in mortality were reflected in the survival outcomes reported by the AVID71,72 and CASH81 trials
in people at increased risk of SCD as a result of previous ventricular arrhythmias. The AVID trial reported
statistically significant differences in overall survival during the 3 years of follow-up (p< 0.02),71 survival
free of cardiac death at 2 years (p= 0.0042)72 and survival to arrhythmic death at 2 years (p= 0.0002),72
favouring ICDs compared with AAD (Table 23). Survival free of non-arrhythmic cardiac death did not differ
significantly between those receiving ICDs and those receiving AADs (p= 0.8039).72 Despite the CASH
trial81 finding benefits for ICDs compared with AADs for overall survival (HR 0.766, p= 0.081) and survival
free of cardiac arrest (HR 0.481, p= 0.072), the differences were not statistically significant. In contrast, the
CASH trial81 did report a significant benefit for survival free of sudden death for people who received an
ICD compared with those who received AADs (HR 0.423, p= 0.005). The DEBUT trial89 reported a mean
survival time for the AAD group of 26.2 [standard error of the mean (SEM) 1.4] months (no deaths in the
ICD group).
Only the AMIOVIRT69 and CAT82 trials, which included people with cardiomyopathy, reported survival
(see Table 23). The AMIOVIRT trial69 presented overall and arrhythmia-free survival rates for the ICD+OPT
group and the amiodarone+OPT group at 1 and 3 years’ follow-up, showing no statistically significant
difference (overall survival p= 0.1, arrhythmia-free survival p= 0.8). The CAT trial82 presented cumulative
survival data for the ICD+OPT group and the OPT group for up to 6 years’ follow-up, finding no
statistically significant difference between the groups (p= 0.554) (see Table 23).
Heart failure hospitalisations
Only the AVID study,71 which included people at increased risk of SCD because of previous ventricular
arrhythmias, reported the proportion of patients rehospitalised annually for up to 3 years’ follow-up.
Significantly higher rates were reported for the ICD group than for the AAD group (p= 0.04) (Table 24).
For both groups, the rehospitalisation rate was > 55% at year 1, > 65% at year 2 and > 75% at year 3.
The MADIT II trial,101 which included people remote from MI, reported the proportion of hospitalisations
because of HF (ICD+OPT 19.9%, OPT 14.9%, p-value not stated) and the number of patients hospitalised
per 1000 months of follow-up (ICD+OPT 11.3, OPT 9.4, p= 0.09), with higher rates among those
receiving an ICD+OPT (see Table 24).
Symptoms/complications related to arrhythmias
The CAT82 and AMIOVIRT69 trials, which included people with cardiomyopathy, reported the occurrence of
syncope. Some 12% of people with an ICD+OPT had syncope during VTs in the CAT trial82 and 3.9%
of ICD+OPT patients and 5.8% of amiodarone+OPT patients had syncope in the AMIOVIRT study69
(Table 25). The MADIT II trial,103 which included people remote from MI, reported the number of adverse
cardiac events in the week before SCD (ICD+OPT 28, OPT 49), with comparable rates of syncope and
angina pectoris (4% for both), lower rates of MI for the ICD+OPT group (ICD+OPT 4%, OPT 10%) and
higher rates of ventricular arrhythmia (ICD+OPT 25%, OPT 10%) and CHF (ICD+OPT 43%, OPT 16%)
for the ICD+OPT group.
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TABLE 23 Survival
Study Outcome and follow-up ICD, n/N (%) OPT, n/N (%) p-value
Cardiac arrest
AVID71 Overall survival, %, mean 18.2
(SD 12.2) months
AAD: < 0.02
1 year 89.3 82.3
2 years 81.6 74.7
3 years 75.4 64.1
aSurvival free of cardiac death, %72 0.0042
At 1 year 90.9 85.1
At 2 years 85.0 81.2
bSurvival to arrhythmic death, %72 0.0002
At 1 year 96.6 91.9
At 2 years 94.2 89.1
Survival free of non-arrhythmic
cardiac deathc
Presented in
figure only
Presented in
figure only
0.8039
CASH81 57 (SD 34) months AAD:
Overall survival, ICD vs.
amiodarone/metoprolol
HR 0.766 97.5% CI
upper bound
1.112, 0.081
Survival free of sudden death,
ICD vs. amiodarone/metoprolol
HR 0.423 97.5% CI
upper bound
0.721, 0.005
Survival free of cardiac arrest,
ICD vs. amiodarone/metoprolol
HR 0.481 97.5% CI
upper bound
1.338, 0.072
DEBUT89 main study 3 years
Mean (SEM) survival (months) 26.2 (1.4)
Cardiomyopathy
AMIOVIRT69 Survival rate, % 0.8d
1 year 96 Amiodarone+OPT: 90
3 years 88 Amiodarone+OPT: 87
Arrhythmia-free survival rate, % 0.1e
1 year 78 82
3 years 63 73
CAT82 Cumulative survival, % 0.554
2 years 92 93
4 years 86 80
6 years 73 68
a Non-cardiac deaths censored.
b Non-cardiac and non-arrhythmic deaths censored.
c Non-cardiac and arrhythmic deaths censored.
d Survival rates at 1 and 3 years.
e Arrhythmic-free survival rates at 1 and 3 years.
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Quality of life
Two trials in people at increased risk of SCD because of previous ventricular arrhythmias, the AVID74 and
CIDS87 trials, reported results from substudies using a range of generic and condition-specific measures of
QoL (Table 26). The AVID trial74 assessed QoL using the Short Form questionnaire-36 items (SF-36) physical
component summary (PCS) and mental component summary (MCS), the 46-item patient concerns checklist
and the cardiac version of the QL index. Follow-up was for 12 months and assessments were made of the
impact of adverse symptoms and ICD shocks. Comparison of PCS scores at baseline and 12 months’
follow-up showed no statistically significant differences between the ICD group and the AAD group
(baseline: ICD 37.4, AAD 36.5, p= 0.3; 12 months: ICD 40.0, AAD 38.0, p= 0.3). In contrast, the ICD
group had a lower (worse) mean score on the MCS at baseline than the AAD group, which was
statistically significant (p= 0.006), although any difference had disappeared by 12 months’ follow-up.
Scores on the patient concerns checklist did not differ significantly between the ICD group and the AAD
group at baseline (ICD 15.9, AAD 16.2, p= 0.06) or at 12 months’ follow-up (p= 0.1). On the QL index
the scores for the ICD and AAD groups were similar at baseline (ICD 22.1, AAD 21.9, p-value not stated)
and at 12 months’ follow-up (scores and p-values not stated).
TABLE 24 Hospitalisations
Study Outcome ICD OPT p-value
Cardiac arrest
AVID71 % of patients rehospitalised
(patients at risk N= 1011)
0.04
At 1 year 59.5 55.6
At 2 years 74.8 64.7
At 3 years 83.3 75.5
Remote from MI
MADIT II101 Hospitalisation because of HF, n (%) 148 (19.9) 73 (14.9)
Patients hospitalised per 1000 months of
active follow-up
11.3 9.4 0.09
TABLE 25 Symptoms/complications related to arrhythmia
Study Outcome ICD OPT Effect (HR)
Cardiomyopathy
CAT82 Syncope during VT, n/N (%) 6/50 (12)
AMIOVIRT69 Syncope, % 3.9a 5.8 0.7
Remote from MI
MADIT II103 Adverse cardiac events in week before
SCD, n
28 49
Syncope, % 4 4
Angina pectoris, % 4 4
MI, % 4 10
Ventricular arrhythmia, % 25 10
CHF, % 43 16
a VT or VF was the cause of syncope in each ICD patient in whom it occurred.
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TABLE 26 Quality-of-life outcomes
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
Cardiac arrest (secondary prevention)
AVID74 1 year (n= 416) AAD (n= 384)
SF-36 PCS score, mean (SD)
Baseline 37.4 (10.9) 36.5 (11.2) 0.3
12 months 40 (10.5)a 38 (17)a
SF-36 MCS score, mean (SD)
Baseline 45.9 (11.8) 47.5 (11.5) 0.006
12 months 49 (16.5)a 48 (17)a
Patient concerns checklist, mean (SD)
Baseline 15.9 (8.6) 16.2 (8.9) 0.06
12 months NR NR 0.1
QL index, mean (SD)
Baseline 22.1 (4.9) 21.9 (5.0)
Impact of adverse symptoms on QoLb
SF-36 PCS score –2.25 (–3.32 to –1.18), p< 0.001 –1.64 (–2.89 to
–0.41), p= 0.009
SF-36 MCS score –2.32 (–3.76 to –0.88), p= 0.002 –0.51 (–1.97 to
0.94), p= 0.5
Patient concerns 1.84 (0.91 to 2.76), p< 0.001 0.91 (0.07 to
1.75), p= 0.03
Impact of ICD shocks on QoLb
SF-36 PCS score –1.45 (–2.74 to –0.18), p= 0.03
SF-36 MCS score –1.82 (–3.56 to –0.08), p= 0.04
Patient concerns 2.15 (1.07 to 3.23), p< 0.001
CIDS87 (n= 86) Amiodarone
(n= 92)
Time by group
p-value
Domains of MHI, mean (SD)
Total indexc
Baseline 173.2 (25.5) 180.4 (27.8)
6 months 183.1 (30.2) 180.2 (31.1)
12 months 184.3 (27.9) 178.3 (28.7) 0.001
Psychological distressd
Baseline 51.3 (14.1) 47.8 (16.5)
6 months 45.1 (17.6) 47.6 (18.3)
12 months 43.4 (15.9) 48.8 (16.8) 0.001
Psychological well-beingc
Baseline 58.5 (12.7) 62.2 (12.3)
6 months 62.2 (13.4) 61.8 (14.1)
12 months 61.7 (13.2) 61.3 (13.3) 0.03
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TABLE 26 Quality-of-life outcomes (continued )
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
Domains of Nottingham Health Profile, mean (SD)
Energy leveld (n= 83) (n= 88)
Baseline 27.5 (32.2) 24.4 (32.4)
6 months 18.6 (30.1) 27.8 (32.1)
12 months 17.7 (26.1) 36.8 (37.3) 0.0001
Physical mobility (n= 84) (n= 90)
Baseline 10.9 (12.0) 13.2 (20.5)
6 months 10.5 (13.7) 15.1 (19.2)
12 months 9.1 (13.6) 17.7 (19.2) 0.002
Social isolationd (n= 81) (n= 88)
Baseline 8.5 (15.4) 9.9 (17.7)
6 months 9.8 (18.6) 12.2 (22.4)
12 months 8.5 (18.4) 11.1 (22.6) 0.9
Emotional reactionsd (n= 76) (n= 86)
Baseline 17.3 (18.1) 14.3 (20.1)
6 months 11.1 (18.2) 15.3 (22.4)
12 months 8.3 (16.6) 14.5 (19.6) 0.002
Paind (n= 83) (n= 90)
Baseline 4.4 (7.9) 7.5 (15.1)
6 months 7.5 (17.1) 6.3 (13.6)
12 months 4.5 (9.9) 8.2 (15.4) 0.52
Sleep disturbanced (n= 78) (n= 88)
Baseline 31.4 (27.4) 29.6 (31.5)
6 months 25.0 (29.7) 30.8 (31.0)
12 months 23.9 (29.4) 30.2 (32.4) 0.02
Life impairmentd (n= 78) (n= 83)
Baseline 2.0 (1.9) 1.6 (1.7)
6 months 1.6 (1.8) 1.9 (1.9)
12 months 1.6 (1.3) 1.8 (1.9) 0.005
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TABLE 26 Quality-of-life outcomes (continued )
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
Effects of ICD shocks
on HRQoL scores87
ICDs: no
shocks (n= 66)
ICDs: 1–4
shocks
(n= 27)
ICDs:
≥ 5
shocks
(n= 15)
Amiodarone
(n= 95)
Between-
group p-value
Domains of MHI, mean (SD)
Total indexc
Baseline 175.9 (26.5) 171.7
(22.7)
171.2
(32.0)
177.9 (27.1)
12 months 186.2
(26.9)e,f
186.6
(21.7)e,f
168.8
(41.2)
175.6 (29.2) 0.001
Within-group
p-value
0.001 0.001 0.725
Psychological distressd
Baseline 50.2 (15.2) 50.8
(12.3)
51.9
(18.1)
49.8 (16.3)
12 months 42.5 (15.3)e,f 41.4
(11.7)e,f
52.7
(25.2)
50.9 (17.5) 0.001
Within-group
p-value
0.001 0.001 0.833
Psychological well-beingc
Baseline 60.1 (12.5) 56.6
(11.6)
57.1
(15.0)
61.7 (12.0)
12 months 62.8 (13.1) 62.1
(10.9)f
55.6
(16.8)
60.6 (13.3) 0.02
Within-group
p-value
0.074 0.004 0.642
Domains of NHP, mean (SD)
Energy leveld (n= 64) (n= 27) (n= 15) (n= 90)
Baseline 28.6 (32.5) 28.5
(30.5)
22.6
(34.2)
24.3 (30.8)
12 months 19.5 (27.1)e 24.8
(33.4)e
23.5
(29.5)
37.0 (37.6) 0.003
Within-group
p-value
0.02 0.115 0.859
Physical mobilityd (n= 65) (n= 27) (n= 15) (n= 93)
Baseline 13.1 (15.0) 12.4
(10.2)
7.1
(9.8)
13.18 (20.1)
12 months 9.3 (12.4)e 15.5
(17.3)
8.0
(13.3)
17.2 (19.1) 0.02
Within-group
p-value
0.05 0.638 0.747
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TABLE 26 Quality-of-life outcomes (continued )
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
Social isolationd (n= 66) (n= 27) (n= 15) (n= 92)
Baseline 10.6 (16.7) 4.3 (9.2) 8.9
(16.1)
11.8 (18.5)
12 months 8.8 (19.5) 6.4 (15.5) 12.8
(23.9)
12.5 (23.0) 0.57
Within-group
p-value
0.03 0.991 0.817
Emotional reactionsd (n= 61) (n= 27) (n= 14) (n= 90)
Baseline 16.2 (17.4) 16.3
(17.1)
21.6
(21.1)
16.3 (19.8)
12 months 7.1 (14.6)e,f 6.8 (10.2)e 22.0
(31.0)
15.9 (20.3) 0.001
Within-group
p-value
0.001 0.02 0.886
Paind (n= 66) (n= 27) (n= 15) (n= 92)
Baseline 6.8 (11.8) 4.0 (8.5) 5.3
(8.3)
8.5 (15.6)
12 months 6.4 (14.7) 5.4 (11.7) 5.5
(7.1)
7.7 (14.5) 0.71
Within-group
p-value
0.086 0.710 0.721
Sleep disturbanced (n= 62) (n= 27) (n= 14) (n= 89)
Baseline 30.0 (26.9) 36.3
(31.4)
27.3
(27.1)
30.4 (30.5)
12 months 22.1 (28.1) 29.1
(33.9)
34.6
(35.4)
30.1 (33.6) 0.3
Within-group
p-value
0.002 0.042 0.680
Lifestyle impairmentd (n= 65) (n= 26) (n= 14) (n= 82)
Baseline 2.0 (2.0) 2.4 (1.9) 2.2
(1.9)
1.7 (1.6)
12 months 1.3 (1.5)e 1.4 (1.5)e 1.4
(1.6)
1.9 (1.9) 0.03
Within-group
p-value
0.061 0.033 0.334
Remote from MI
MADIT II104 HUI3 scores while alive,
36 months
(n= 658) (n= 431)
Baseline mean 0.637 0.646
Baseline overall
mean score
including deathg
0.637 0.646
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TABLE 26 Quality-of-life outcomes (continued )
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
Year 1,
proportion alive
0.93 0.903
Mean 0.627 0.659
Mean
annual changeh
–0.019 –0.012
Overall mean score
including deathg
0.584 0.595
Year 2,
proportion alive
0.846 0.792
Mean 0.622 0.667
Mean
annual changeh
–0.027i –0.011
Overall mean
score including
deathg
0.526 0.529
Year 3,
proportion alive
0.767 0.667
Mean 0.601 0.678
Mean
annual changeh
–0.019j –0.013
Overall mean
score including
deathg
0.461 0.452
Cardiomyopathy
AMIOVIRT69 1 year (n= 51) Amiodarone+OPT
(n= 52)
QWBS, mean (SD) 74 (19) 70 (22) 0.5k
State–Trait Anxiety
Inventory, mean (SD)
61 (17) 67 (20) 0.4k
DEFINITE94 (n= 227) (n= 226)
SF-12
Long-term
MCS scores
0.89
Long-term
PCS scores
NS
Long-term MLWHFQ
subscale scores
NS
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TABLE 26 Quality-of-life outcomes (continued )
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
Scheduled for CABG
CABG
Patch80
6 months (n= 262) (n= 228) p-valuel
HRQoL, mean (SD)
Perception of health
General health
status
54.8 (22.9) 58.3 (23.6) NS
Perception of
health transitionm
2.4 (1.2) 2.1 (1.2) 0.030
Physical limitations 41.7 (42.3) 49.2 (42.8) 0.055
Bodily pain 57.4 (24.6) 58.8 (24.8) NS
Ability to function
Employment
status
0.25 (0.4) 0.29 (0.5) NS
Physical role
functioning
58.3 (27.5) 61.8 (28.3) NS
Emotional role
functioning
55.4 (43.4) 67.3 (39.9) 0.003
Social functioning 70.5 (27.2) 70.8 (26.4) NS
Psychological well-being
Mental health 72.5 (18.3) 77.2 (17.0) 0.004
Satisfaction with
appearance
6.0 (1.3) 6.3 (1.1) 0.008
Satisfaction
with scar
7.0 (1.2) 7.2 (1.1) 0.040
Received a shock prior
to completing the
6-month QoL
instrument, n/N (%)
101/262 (38.5)
ICD device did not
fire (n= 161)
ICD device
fired
(n= 101)
OPT (n= 228) OPT vs. ICD
fired (95% CI)n
HRQoL, mean (SD)
Perception of health
General health
status
56.6 (23.3) 52.1 (22.1) 58.3 (23.6) NS
Perception of
health transitionm
2.3 (1.2) 2.5 (1.3) 2.1 (1.2) (–0.73 to
–0.01)o
Physical limitations 44.8 (42.9) 36.8 (41.1) 49.2 (42.8) (0.31 to 24.6)p
Bodily pain 57.8 (24.1) 56.8 (25.3) 58.8 (24.8) NS
Ability to function
Employment
status
0.30 (0.5) 0.18 (0.4) 0.29 (0.5) NS
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TABLE 26 Quality-of-life outcomes (continued )
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
Physical
role functioning
61.5 (27.5) 53.2 (27.0) 61.8 (28.3) (0.7 to 16.6)
Emotional
role functioning
59.5 (43.4) 49.1 (42.8) 67.3 (39.9) (6.2 to 30.1)
Social functioning 71.6 (26.9) 68.8 (27.7) 70.8 (26.4) NS
Psychological
well-being
Mental health 73.6 (43.4) 70.6 (18.5) 77.2 (17.0) (1.5 to 11.6)
Satisfaction
with appearance
6.0 (1.3) 6.0 (1.4) 6.3 (1.1) (–0.01 to 0.71)
Satisfaction
with scar
7.0 (1.2) 7.1 (1.2) 7.2 (1.1) NS
Rate of
rehospitalisation prior
to completing the
6-month QoL
instrument (%)
36.0 55.5 33.8
HF
SCD-HeFT107 ICD+OPT (n= 816) Amiodarone+OPT
(n= 830),
placebo+OPT (n= 833)
Difference
(95% CI)q
DASI, mean score (SD)
Baseline (n= 814) 24.6 (13.6) (n= 825) 25.3 (14.1),
(n= 829) 24.9 (14.1)
–0.34
(–1.68 to 1.00)
3 months (n= 766) 26.9 (14.1) (n= 756) 26.2 (14.7),
(n= 768) 26.2 (14.3)
–0.69
(–0.73 to 2.11)
12 months (n= 734) 26.8 (14.4) (n= 676) 26.1 (14.5),
(n= 697) 26.6 (14.8)
0.16
(–1.35 to 1.68)
30 months (n= 665) 26.8 (14.3) (n= 575) 27.1 (15.3),
(n= 585) 25.9 (15.3)
0.89
(–0.75 to 2.53)
ICD+OPT (n= 816) Amiodarone+OPT
(n= 830),
placebo+OPT (n= 833)
Difference
(95% CI),q
p-value
MHI-5
Baseline (n= 814) 71.7 (20.5) (n= 827) 72.1 (20.1),
(n= 830) 70.0 (21.4)
1.64
(–0.39 to 3.67)
3 months (n= 764) 74.4 (19.3) (n= 759) 72.9 (20.6),
(n= 767) 71.3 (21.5)
3.15
(1.10 to 5.19),
≤0.05
12 months (n= 734) 74.5 (18.9) (n= 674) 72.9 (20.5),
(n= 693) 70.9 (21.5)
3.68
(1.58 to 5.78),
≤0.05
30 months (n= 654) 72.2 (19.1) (n= 560) 73.2 (20.3),
(n= 564) 71.0 (21.7)
1.24
(–1.06 to 3.53)
ICD+OPT Placebo+OPT p-value
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TABLE 26 Quality-of-life outcomes (continued )
Study
Outcome and
follow-up Intervention Comparator(s)
95% CI,
p-value
MLWHFQ, median
Baseline 41 43 0.77
3 months 30 36 0.006
12 months 32 36 0.07
30 months 32 36 0.05
ICD+OPT Placebo+OPT p-value
Global health status, median
3 months 75 70 0.002
12 months 75 70 0.05
30 months 70 70 0.18
ICD+OPT (n= 816) p-value
Received shock
within 1 month
before a
scheduled QoL
assessment
(n= 49)
No shock
SF-36 score, mean change
General health
perceptions
–6.3 3.4 0.002
Physical function –8 10.9 < 0.001
Emotional function –11 4.5 0.02
Social function –5.3 4.6 0.009
Self-related health –3.2 6.6 0.009
DASI, Duke Activity Status Index; HUI3, Health Utilities Index 3; MHI, Mental Health Index; MHI-5, Mental Health Index-5;
MLWHFQ, Minnesota Living with Heart Failure Questionnaire; NHP, Nottingham Health Profile; QWBS, Quality of
Well-Being Scale; NR, not reported; NS, not significant; SF-12, Short Form questionnaire-12 items.
a Values in italics obtained from figure in paper using Engauge Digitizer free software version 5.1 (see http://digitizer.
sourceforge.net/).
b Unit for outcome not given; assumed to be mean impact (change) in QoL score with 95% CI.
c Higher values represents better functioning.
d Higher values represents poorer functioning.
e Groups that differed significantly from amiodarone without ICD group (p< 0.05).
f Groups that differed from the ICD≥ 5 shocks group (p< 0.05).
g Mean HRQoL score (among n patients) after setting score for death to 0.
h Equals (difference from baseline)/y.
i p< 0.05.
j p< 0.10.
k p-values were also reported within groups (not data extracted).
l p-values for QoL outcomes represent significance of t-tests comparing mean scores of control vs. ICD patients.
m Lower score reflects a tendency to rate heath as better now relative to 1 year ago. For all other QoL measures higher
scores represent a more favourable score.
n 95% CIs control the experiment-wise type 1 error rate to be 0.5 using Tukey’s method.
o F-test for analysis of variance has p-value of 0.0507.
p F-test for analysis of variance has p-value of 0.0549.
q ICD vs. placebo reported here. Amiodarone vs. placebo can be viewed in data extraction forms (see Appendix 7).
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The effects of adverse symptoms and ICD shocks were assessed in the AVID trial74 using PCS scores, MCS
scores and patient concerns using multivariate analysis including age, sex, race, index arrhythmia, ejection
fraction, history of HF and use of beta-blockers at hospital discharge (see Table 26). Adverse symptoms led
to a statistically significant worsening of PCS scores (p< 0.001), MCS scores (p= 0.002) and patient
concern scores (p< 0.001) for the ICD group and PCS scores (p= 0.009) and patient concern scores
(p= 0.03) for the AAD group. The occurrence of ICD shocks had a similar adverse effect on QoL, with
statistically significant worsening of PCS scores (p= 0.03), MCS scores (p= 0.04) and patient concern
scores (p< 0.001).
A substudy of the CIDS trial87 reported the effects of ICDs and AADs on three domains of the Mental
Health Inventory (MHI) and seven domains of the Nottingham Health Profile (NHP), with an additional
assessment of the consequences of ICD shocks on these measures (see Table 26). At 12 months’ follow-up
the ICD group had shown a significantly greater improvement than the AAD group on the MHI domains of
‘total index’ (p= 0.001), ‘psychological distress’ (p= 0.001) and ‘psychological well-being’ (p= 0.03) and
the NHP domains of ‘energy level’ (p= 0.0001), ‘physical mobility’ (p= 0.002), ‘emotional reactions’
(p= 0.002), ‘sleep disturbance’ (p= 0.02) and ‘lifestyle impairment’ (p= 0.005). It was notable that none of
the domains on the MHI and the NHP improved for the AAD group between baseline and 12 months’
follow-up, with the domains of ‘energy level’ and ‘physical mobility’ deteriorating.
The effects of ICD shocks on QoL were assessed in the CIDS trial87 on the different domains of the MHI
and the NHP through univariate comparisons between groups in terms of the numbers of shocks
(i.e. ICD no shocks, ICD one to four shocks, ICD five or more shocks and AAD group without an ICD)
(see Table 26). It was evident that the ICD five or more shocks group, like the AAD group without an ICD,
did not experience the significant improvements in QoL that were reported by the ICD groups with less
than five shocks. At 12 months’ follow-up the ICD five or more shocks group scored significantly worse
(p< 0.05) than both the ICD no shocks group and the ICD one to four shocks group on the MHI ‘total
index’ and ‘psychological distress’ domains, than the ICD one to four shocks group on the MHI
‘psychological well-being‘ domain and than the ICD no shocks group on the NHP ‘emotional reactions’
domain. Although the ICD five or more shocks group did not differ significantly from the AAD group
without an ICD on any of the MHI and NHP domains, the ICD no shocks and ICD one to four shocks
groups had significantly better (p< 0.05) QoL than the AAD group without an ICD on the MHI ‘total index’
and ‘psychological distress’ domains and the NHP ‘energy level’, ‘physical mobility’ (ICD no shocks only),
‘emotional reactions’ and ‘lifestyle impairment’ domains.
Five trials69,80,94,104,107 in people who had not suffered a life-threatening arrhythmia but who were at
increased risk assessed QoL. The MADIT II trial104 assessed QoL in those remote from their MI through the
Health Utilities Index 3 (HUI3), reporting the mean score, mean annual change and overall mean score
(including death) for those alive at assessment annually to 3 years’ follow-up (see Table 26). The mean
annual change in HUI3 scores showed a worsening in HRQoL for the ICD+OPT group compared with the
OPT group annually, with a statistically significantly change in years 2 (p= 0.05) and 3 (p= 0.10).104
Despite these changes, comparison of the HUI3 scores for the different interventions showed that they
were not significantly different during follow-up, even when mortality was taken into account (valuing
death as 0).104
The AMIOVIRT study69 in people with cardiomyopathy assessed changes in QoL using the Quality of
Well-Being Scale (QWBS) and the State–Trait Anxiety Inventory (STAI) (see Table 26). Comparison of the
ICD+OPT group with the amiodarone+OPT group at 1 year of follow-up showed no statistically
significant difference between the groups for well-being on the QWBS (p= 0.5) or for anxiety on the STAI
(p= 0.4). Although the DEFINITE trial94 in people with cardiomyopathy assessed QoL using the Short Form
questionnaire-12 items (SF-12) MCS and PCS and the Minnesota Living with Heart Failure Questionnaire
(MLWHFQ), stating that no statistically significant differences were found between the ICD+OPT group
and the OPT group, no data were reported.
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The CABG Patch trial80 in people scheduled for a CABG assessed HRQoL using measures of perception of
health, ability to function and psychological well-being at 6 months’ follow-up (see Table 26). On all
measures of HRQoL the group receiving OPT reported a higher QoL than the ICD+OPT group, with
statistically significant differences for the measures of perception of health transition (p= 0.030), emotional
role function (p= 0.003), mental health (p= 0.004), satisfaction with appearance (p= 0.008) and
satisfaction with scar (p= 0.040).80 With 38.5% of people with an ICD+OPT having received a shock in
the 6 months before completing the QoL instrument, the CABG Patch trial80 assessed the effects on QoL
scores. On 10 of the 12 measures the OPT group had a higher QoL than the ICD+OPT group when the
device either fired or did not fire. The scores for the ICD+OPT group when the device did not fire were
similar to those of the OPT group, with no statistically significant differences (p-values not stated). In
contrast, the ICD+OPT group when the device did fire had a lower QoL, with statistically significant
differences (p= 0.05) for perception of health transition, physical limitations, physical role functioning,
emotional role functioning, mental health and satisfaction with appearance.
The SCD-HeFT trial107 in people with HF reported QoL through a comparison of the Duke Activity Status
Index (DASI), the Mental Health Inventory 5 (MHI-5), the MLWHFQ and the global health status of the
ICD+OPT, amiodarone+OPT and placebo+OPT groups at baseline and 3, 12 and 30 months’ follow-up
(see Table 26). The effects on QoL were compared between those experiencing shocks and those not
receiving a shock in the ICD+OPT group using the SF-36. Using the DASI there were no clinical
(4-point difference) or statistically significant differences in median or mean scores between the groups
at baseline and 3, 12 and 30 months. On the MHI-5, outcomes were more equivocal. Although the
differences in the median and mean scores comparing the ICD+OPT group and amiodarone+OPT group
separately with the placebo+OPT group were below clinically meaningful levels (i.e. 5-point difference),
some were statistically significant. Comparison of the median scores showed that the ICD+OPT group
had significantly better scores than the placebo+OPT group at 3 months (p= 0.01) and 12 months
(p= 0.003). By 30 months the scores for the ICD+OPT group had declined to baseline levels. Similarly,
the mean scores for the ICD+OPT group differed significantly from those for the placebo+OPT group
at 3 and 12 months (p= 0.05). Although the amiodarone+OPT group had a significantly higher MHI-5
score at baseline than the placebo+OPT group (p= 0.05), these differences disappeared during
subsequent follow-up.
Similar improvements for the ICD+OPT group were reported on the MLWHFQ in the SCD-HeFT trial,107
resulting in significantly better scores for the ICD+OPT group than for the placebo+OPT group at 3
(p= 0.006) and 30 (p= 0.05) months (see Table 26). However, these differences were thought to be
clinically insignificant (5-point change). In contrast, a comparison using a time trade-off utility measure
showed that the health status of the ICD+OPT group and the placebo+OPT group declined from
baseline with no statistically significant difference at 30 months’ follow-up (p= 0.18).
The effects of ICD shocks on QoL were assessed in the SCD-HeFT trial using the SF-36 (see Table 26).107
A comparison of the changes in scores for those who had received a shock within 1 month of a scheduled
QoL assessment and those who had not received a shock showed a significant decrease in the QoL of
those who received a shock with regard to their relative perceptions of general health (p= 0.002), physical
function (p< 0.001), emotional function (p= 0.02), social function (p= 0.009) and self-related
health (p= 0.009).107
Adverse events
All four trials71,81,84,89 comparing the use of ICDs with AADs in people at increased risk of SCD because of
previous ventricular arrhythmias reported adverse events (Table 27). Reported adverse events differed
between the trials, limiting comparisons. Only the total number of adverse events and mortality rates were
compared between the interventions in the DEBUT trial89 and the AVID71 and CASH81 trials respectively.
The DEBUT trial89 reported that 29.7% of the ICD group and 13.8% of the AAD group suffered adverse
events (p-value not stated). The AVID trial71 compared deaths within 30 days of initiation of therapy or by
hospital discharge if 30 days after therapy began, finding no statistically significant difference between the
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TABLE 27 Adverse events
Study Outcome and follow-up ICD, n/N (%) OPT, n/N (%) p-value
Cardiac arrest (secondary prevention)
AVID71 Non-fatal torsade de pointes VT 1/509 (0.2)
Suspected pulmonary
toxicity, %
At 1 year 3
At 2 years 5
Death from pulmonary toxicity 1/509 (0.2)
Thyroid replacement
medication, %
At 1 year 1 10
At 2 years 1 16
Death within 30 days of
initiation of therapya
12/507 (2.4) 18/509 (3.5) 0.27
Bleeding requiring reoperation
or transfusion
6/507 (1.2)
Serious haematoma 13/507 (2.6)
Infection 10/507 (2.0)
Pneumothorax 8/507 (1.6)
Cardiac perforation 1/507 (0.2)
Early dislodgement or migration
of leads
3/507 (0.6)
Unsuccessful first attempt at
ICD implantation
without thoracotomy
5/507 (1.0)
Overall rate of non-fatal
complications of
implantation, %
5.7
CASH81 Amiodarone Metoprolol
Drug-related pulmonary toxicity 0/92 (0)
Hyperthyroidism 3/92 (3.3)
Drug discontinuation required 9/92 (9.8) 10/97 (10.3)
Perioperative deaths or, for
drug arms, deaths within the
same time frame
All ICDs 5/99 (5.1)
[epicardial ICDs 3/55
(5.4), endocardial ICDs
2/44 (4.5)]
AADs: 2/189 (1.1)
[amiodarone 2/92 (2.2),
metoprolol 0/97 (0)]
0.029
Other complications
Infection 3/99 (3.0) (explantation
required for two)
Haematoma or seroma 6/99 (6.1)
Pericardial effusion 1/99 (1.0)
Pleural effusion 3/99 (3.0)
Pneumothorax 1/99 (1.0)
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TABLE 27 Adverse events (continued )
Study Outcome and follow-up ICD, n/N (%) OPT, n/N (%) p-value
Dislodgement or migration of
system leads
3/99 (3.0)
Device dysfunction 5/99 (5.1)
Overall complication rate, % 23.0 (including an
explantation rate
of 2.1)
CIDS84 30-day mortality in implanted patients (n= 310)
In patients with
thoracotomy (n= 33)
1/33 (3.0)
In patients with
non-thoracotomy lead
system (n= 277)
1/277 (0.4)
ICD permanently or temporarily
explanted because of infection,
heart transplantation or patient
preference
16/310 (5.2)
Adverse experiences ever reported
Pulmonary infiltrate 18/331 (5.7)
(1.9% per year)b
Visual symptoms (blurred,
halo or decreased)
48/331 (14.5)
Bradycardia 10/331 (3.0)
Skin discolouration 21/331 (6.3)
Photosensitivity 34/331 (10.3)
Ataxia 97/331 (17.2)b
Tremor 91/331 (15.4)b
Insomnia 64/331 (19.3)
Peripheral neuropathy 1/331 (0.3)
ICD product discomfort 25/328 (7.6)
ICD malfunction 2/328 (0.6)
ICD pocket infection 15/328 (4.6)
(1.4% per year)
ICD dislodgement/fracture 8/328 (2.4)
DEBUT
(pilot
study)89
Operative mortality 0/0 (0)
Adverse effects 2/10 (20.0)
Defibrillation discharges
caused by supraventricular
tachycardia or sinus
tachycardia
1/10 (10.0)
T-wave oversensing 0/0 (0)
ICD replaced because of
insulation break
1/10 (10.0)
continued
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TABLE 27 Adverse events (continued )
Study Outcome and follow-up ICD, n/N (%) OPT, n/N (%) p-value
DEBUT
(main
study)89
Operative mortality 0/0 (0)
Adverse effects 11/37 (29.7) 4/29 (13.8)
Minor complications, corrected by reprogramming devices without major intervention
Defibrillation discharges
caused by supraventricular
tachycardia or
sinus tachycardia
7/37 (19.0)
T-wave oversensing 3/37 (8.1)
Pocket erosion requiring
removal of ICD
1/37 (2.7)
Side-effects in beta-blocker group
Impotence/decrease
in libido
1/29 (3.4)
Fatigue 1/29 (3.4)
Profound bradycardia 1/29 (3.4)
Hypotension plus central
nervous system side effect
1/29 (3.4)
Early post MI
DINAMIT95 Number of deaths related to
device implantation
0/310 (0)
In-hospital device-
related complications
25/310 (8.1)
IRIS97 Died within 30 days
of implantation
7/415 (1.7)
(n= 4 MI, n= 3 HF)
Died within 30 days
of randomisation
9/415 (2.2) 11/453 (2.4)
Number of ICDs actually
implanted
415 39 (median 7.6 months
after randomisation)
Inserted lead entangled in
tricuspid valve, removed
surgically
1/415 (0.2)
ICD explanted or permanently
deactivated during follow-up
(median 6.8 months after
implantation)
14/415 (3.4)
Clinically significant
complications requiring
hospitalisation, surgical
correction or intravenous
drug administration
65/415 (15.7),
76 complications
Up to 30 days
after implantation
19/415 (4.6)
During follow-up 48/415 (11.6)
Lead-related problems requiring
surgical revision (included in
the above complications)
10/415 (2.4)
(four had
lead replacements)
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TABLE 27 Adverse events (continued )
Study Outcome and follow-up ICD, n/N (%) OPT, n/N (%) p-value
Remote from MI
MADIT I99 Operative deaths in the first
30 days
0/95 (0) 0/101 (0)
Hypotension 0/95 (0) 1/101 (1.0)
Syncope 1/95 (1.1) 5/101 (5.0)
Hypothyroidism 0/95 (0) 1/101 (1.0)
Sinus bradycardia 3/95 (3.2) 3/101 (3.0)
Pulmonary fibrosis 0/95 (0) 3/101 (3.0)
Pulmonary embolism 1/95 (1.1) 1/101 (1.0)
Atrial fibrillation 4/95 (4.2) 0/101 (0)
Pneumothorax 2/95 (2.1) 0/101 (0)
Bleeding 1/95 (1.1) 0/101 (0)
Venous thrombosis 1/95 (1.1) 0/101 (0)
Surgical infection 2/95 (2.1) 0/101 (0)
Problems with defibrillator lead 7/95 (7.4) 0/101 (0)
Malfunction of defibrillator
generator
3/95 (3.2) 2/101 (2.0)
Total no. of patients with
adverse events
19/95 (20.0) 12/101 (11.9)
MADIT II101 Adverse effects of treatment,
death during implantation
0/742 (0)
Lead problems 13/742 (1.8)
Non-fatal infections requiring
surgical intervention
5/742 (0.7)
Cardiomyopathy
AMIOVIRT69 Discontinued amiodarone
because of adverse effects,
mean follow-up 17.8
(SD 13.3) months
25/52 (48.1)
CAT82 Complications caused by ICD therapy
Death within 30 days of
ICD implantation
0/50 (0)
Device dislocation and
bleeding requiring revision
2/50 (4.0)
Electrode dislocation
requiring revision
2/50 (4.0)
Complications in 24 months of
follow-up
10 in seven patients
Electrode dislocation and
sensing/isolation defects
7/50 (14.0)
Infection with total
device replacement
2/50 (4.0)
Perforation 1/50 (2.0)
continued
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TABLE 27 Adverse events (continued )
Study Outcome and follow-up ICD, n/N (%) OPT, n/N (%) p-value
DEFINITE90 Complications during
implantation of ICD
3/229 (1.3)
Haemothorax 1/229 (0.4)
Pneumothorax 1/229 (0.4)
Cardiac tamponade 1/229 (0.4)
Procedure-related deaths 0/229 (0)
Complications during follow-up 10/229 (4.4)
Lead dislodgement
or fracture
6/229 (2.6)
Venous thrombosis 3/229 (1.3)
Infection 1/229 (0.4)
Receipt of ICD upgrade during
follow-up
13/229 (5.7)
Dual chamber ICD because
of development of sinus
node dysfunction
2/229 (0.9)
Biventricular devices for
NYHA class III or IV HF and
prolonged QRS interval
11/229 (4.8)
Scheduled for CABG
CABG
Patch75
Death in the first 30 days
after randomisation
24/446 (5.4) 20/454 (4.4) 0.60
Postoperative complications
MI 18c/446 (4.0) 16c/454 (3.5)
Sustained VT 26c/446 (5.8) 31c/454 (6.8)
VF 15c/446 (3.4) 24c/454 (5.3)
Bradycardia 13c/446 (2.9) 20c/454 (4.4)
Atrial fibrillation 102c/446 (22.9) 94c/454 (20.7)
Shock 41c/446 (9.2) 34c/454 (7.5)
New or more severe HF 70c/446 (15.7) 57c/454 (12.6)
Conduction defect 63c/446 (14.1) 66c/454 (14.5)
Residual central nervous
system deficit
16c/446 (3.6) 9c/454 (2.0)
Bleeding treated with surgery 22c/446 (4.9) 14c/454 (3.1)
Postpericardiotomy syndrome 4c/446 (0.9) 3c/454 (0.7)
Deep sternal
wound infection
12c/446 (2.7) 2c/454 (0.4) 0.01< p< 0.05
Infection at wound or
catheter site
55c/446 (12.3) 27c/454 (5.9) 0.01< p< 0.05
Pneumonia 38c/446 (8.5) 18c/454 (4.0) 0.01< p< 0.05
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TABLE 27 Adverse events (continued )
Study Outcome and follow-up ICD, n/N (%) OPT, n/N (%) p-value
Other infection 28c/446 (6.3) 15c/454 (3.3)
Renal failure 30c/446 (6.7) 22c/454 (4.8)
Events during long-term follow-up
Angina pectoris 120c/446 (27.0) 125c/454 (27.5)
MI 2c/446 (0.5) 19c/454 (4.2) 0.01< p< 0.05
New or worsening HF 190c/446 (42.5) 193c/454 (42.5)
Ventricular arrhythmias 87c/446 (19.4) 65c/454 (14.3)
Atrial fibrillation 66c/446 (14.7) 46c/454 (10.1)
Hospitalisation 274c/446 (61.4) 251c/454 (55.2)
Repeat CABG surgery 0/446 (0.0) 3c/454 (0.7)
PTCA or atherectomy 13c/446 (2.9) 10c/454 (2.1)
Permanent
cardiac pacemaker
13c/446 (2.9) 22c/454 (4.9)
ICD removed 40/446 (9.0)
Infection 19/446 (4.3)
ICD reached end of service
period and not replaced
5/446 (1.1)
Patient request 5/446 (1.1)
HF
SCD-
HeFT105
(n= 829) Amiodarone+OPT
(n= 845),
placebo+OPT (n= 847)
Implantation was unsuccessful 1/829 (0.1)
ICD removed during follow-up 32/829 (3.9)
Clinically significant ICD
complications, %d
At time of implantation 5
Later in the course of
follow-up
9
Increased tremor (amiodarone
vs. placebo) at time of last
follow-up, %
4
Increased hypothyroidism
(amiodarone vs. placebo) at
time of last follow-up, %
6
PTCA, percutaneous transluminal coronary angioplasty.
a Or by the time of hospital discharge if discharge occurred later than 30 days after therapy began.
b The numerator, denominator and percentages as reported by the primary publication are incorrect; however, it is not
clear where the error lies.
c Calculated from percentages by reviewer.
d Defined as clinical events requiring surgical correction, hospitalisation or new and otherwise unanticipated drug therapy.
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ICD group (2.4%) and the AAD group (3.5%) (p= 0.27). In contrast, the CASH trial81 found significantly
(p= 0.029) higher mortality rates during the perioperative period for the ICD group (5.1%) than for the
AAD group (1.1%). The only other comparison between interventions was in the AVID trial,71 finding that
the use of thyroid replacement medication was higher for the AAD group at year 1 (10.0%) and year 2
(16.0%) than in the ICD group (1.0% years 1 and 2) (p-value not stated).
Analysis of the adverse events reported for the ICD groups in the four trials71,81,84,89 showed that these
tended to be limited in occurrence (see Table 27). The most frequent were those related to the placement
and operation of the device itself, including defibrillation discharges caused by superventricular tachycardia
or sinus tachycardia (19.0%);89 T-wave oversensing (8.1%);89 ICD product discomfort (7.6%);84 ICD
permanently or temporarily explanted because of infection, heart transplantation or patient preference
(5.2%);84 device dysfunction (5.1%);81 pocket erosion requiring removal of the ICD (2.7%);89 dislodgement
or migration of system leads (3.0%);81 ICD dislodgement/fracture (2.4%);84 bleeding requiring reoperation
or transfusion (1.2%);71 and unsuccessful first attempt at ICD implantation without thoracotomy (1.0%).71
Other adverse events included haematoma or seroma (6.1%);81 serious haematoma (2.6%);71 pleural
effusion (3.0%);81 infection (2.0–4.6%);71,84 and pneumothorax (1.6%).71
Adverse events reported for the AAD groups differed between the four trials (see Table 27).71,81,84,89
The CIDs trial84 found that > 10% of people receiving amiodarone reported insomnia (19.3%), ataxia
(17.2%), tremor (15.4%), visual symptoms (14.5%) or photosensitivity (10.3%). Other adverse events
reported in the CIDs trial84 included skin discolouration (6.3%) and pulmonary infiltrate (5.7%). In the
CASH trial81 10% of people receiving amiodarone (9.8%) or metoprolol (10.3%) had to discontinue drug
treatment. The AVID trial71 reported that 5% of the AAD group had suspected pulmonary toxicity at
2 years. Other adverse events reported by the AVID,71 CASH81 and DEBUT89 trials affected < 5% of
participants (see Table 27).
All nine trials69,75,82,90,95,97,99,101,105 comparing ICDs+OPT with the differing comparator treatments in people
who had not suffered a life-threatening arrhythmia but who were at increased risk reported adverse
events, with six trials69,82,90,95,97,101 focused predominantly on those related to the placement of ICDs (see
Table 27). The type of adverse events reported differed between the trials, making comparisons difficult.
Adverse events were thought to affect between 5%105 and 61%75 of people receiving an ICD, depending
on the definition of an adverse event or complication and the period of follow-up. Only three trials75,99,105
reported adverse events for the different comparator treatments, with rates varying from 11.9% to 55%.
Mortality rates associated with implantation of an ICD appeared low, with no deaths reported by
four trials82,95,99,101 and crude death rates ranging from 1.6% to 5.4% in the IRIS97 and CABG Patch75 trials
respectively. Deaths among those receiving the comparator treatments were reported only in the CABG
Patch trial,75 with a crude death rate for the OPT group of 4.4%.
Lead-, electrode- or defibrillator generator-related problems were reported in five trials,82,90,97,99,101 affecting
between 1.8% and 14.0% of people. In the IRIS trial,97 these led to a surgical revision rate of 2.4%.
Surgical or device-related infections were reported in four trials,75,82,90,99 affecting between 0.4% and
12.3% of people in the ICD group. A further three trials81,82,101 reported infection leading to surgical
intervention or device removal/replacement, which occurred in 0.7–4% of people.
Other non-device-specific adverse events were reported by four trials.75,82,90,99 In the MADIT I99 and
SCD-HeFT75 trials only syncope (5%) and hypothyroidism (6%) affected ≥ 5% of people in the comparator
groups. The CABG Patch trial75 reported adverse events in the postoperative period and during long-term
follow-up for both the ICD+OPT group and the OPT group, focusing predominantly on changes in
underlying cardiac conditions. In the postoperative period the CABG Patch trial75 reported event rates of
≥ 5% for the ICD+OPT group and ≥ 4% for the OPT group for atrial fibrillation (ICD+OPT 22.9%, OPT
20.7%), new or severe HF (ICD+OPT 15.7%, OPT 12.6%), conduction defect (ICD+OPT 14.1%, OPT
14.5%), sustained VT (ICD+OPT 5.8%, OPT 6.8%), shock (ICD+OPT 9.2%, OPT 7.5%), pneumonia
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(ICD+OPT 8.5%, OPT 4.0%) and renal failure (ICD+OPT 6.7%, OPT 4.8%).75 Events during long-term
follow-up that affected ≥ 5% of the ICD+OPT group and the OPT group included new or worsening HF
(ICD+OPT 42.5%, OPT 42.5%), angina pectoris (ICD+OPT 27.0%, OPT 27.5%), ventricular arrhythmias
(ICD+OPT 19.4%, OPT 14.3%) and atrial fibrillation (ICD+OPT 14.7%, OPT 10.1%).
Subgroup analyses reported by included randomised controlled trials
Six trials71,75,90,97,103,105 reported prespecified subgroup analyses, although it should be noted that the trials
were not powered to detect differences in subgroups.
The report of the AVID trial,71 which included people at increased risk of SCD because of previous
ventricular arrhythmias, presented in a figure four prespecified subgroup analyses for all-cause mortality
(age, LVEF, cause of arrhythmia and qualifying arrhythmia). No subgroup differed significantly from the
others or the overall population. For most of the subgroups the 95% CIs crossed 1.0, apart from those for
LVEF ≤ 35%, cause of arrhythmia coronary artery disease and VF rhythm, which favoured ICD. Subgroup
analyses for the index arrhythmia were also reported (baseline: VF n= 455; VT n= 561).72 ICDs improved
survival free of arrhythmic death for people whose presenting arrhythmia was VT (p= 0.025) or VF
(p= 0.0019). For non-arrhythmic cardiac death there were no statistically significant differences in survival
between the ICD group and the AAD group for people presenting with either VT (p= 0.72) or
VF (p= 0.98).
The IRIS trial,97 which included people in the early period post MI, prespecified 13 subgroup analyses for
all-cause mortality, nine of which were presented in a figure [age, sex, CHF on admission, criterion of
inclusion (for definitions see Appendix 7), ST-elevation MI, early reperfusion for ST-elevation MI, number of
vessels, smoking and NYHA class at discharge] and four of which were not presented but described as
similar in the two study groups (diabetes, hypertension, lipid abnormalities and number of risk factors).
For most of the subgroups the 95% CIs crossed 1.0, apart from those for thrombolytic therapy for early
reperfusion for ST-elevation MI (favoured control, data in figure only) and left main artery (favoured ICD,
data in figure only).
In people remote from their MI, the MADIT II trial103 reported prespecified subgroup analyses for all-cause
mortality using baseline characteristics, five of which were presented in a figure only (age, sex, ejection
fraction, NYHA class or QRS interval) and seven of which were not presented (hypertension, diabetes,
LBBB, atrial fibrillation, the interval since the most recent MI, type of ICD, and blood urea nitrogen level).
The HRs in all of the subgroups were similar, with no statistically significant interactions.
The DEFINITE trial,90 which included people with cardiomyopathy, presented six prespecified subgroup
analyses for all-cause mortality in a figure only (age, sex, LVEF, QRS interval, NHYA class and history of
atrial fibrillation). None of the differences between subgroups were statistically significant. For most of the
subgroups the 95% CIs crossed 1.0, apart from those for men (RR 0.49, 95% CI 0.27 to 0.90, p= 0.018),
NYHA class III (RR 0.37, 95% CI 0.15 to 0.90, p= 0.02) and LVEF ≥ 20% (favoured ICD, data in
figure only).
The CABG Patch trial,75 which included people who were scheduled for CABG surgery, evaluated 10
prespecified subgroups (age, sex, HF, NYHA class, LVEF, diabetes mellitus, QRS complex duration, use of
ACE inhibitors, use of class I or class III AADs and use of beta-adrenergic-blocking drugs). HRs for the ICD
group compared with the control group were found to be similar among the subgroups for all-cause
mortality (data not reported).
The SCD-HeFT trial, which included people with mild to moderate HF, reported prespecified subgroup
analyses for all-cause mortality105 and cause of death108 according to cause of CHF (ischaemic or
non-ischaemic) and NYHA class (II or III) and for all-cause mortality according to race.106 Table 28 presents
the results for ICDs compared with placebo; subgroup results for the comparisons between amiodarone
and placebo are reported in Appendix 7.
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There was no significant interaction between ICD therapy and the cause of CHF for all-cause mortality
(p= 0.68).105 The HRs for those with ischaemic and non-ischaemic CHF were 0.79 (97.5% CI 0.60 to
1.04, p= 0.05) and 0.73 (97.5% CI 0.50 to 1.07, p= 0.06) respectively. Similarly, there was no significant
interaction between ICD therapy and the cause of CHF for each of the specified modes of death108
(see Table 28). A significant reduction in sudden death presumed to be ventricular tachyarrhythmic was
found for both ischaemic (HR 0.43, 95% CI 0.27 to 0.67) and non-ischaemic (HR 0.34, 95% CI 0.17 to
0.70) causes of CHF, whereas no significant reduction in other modes of death was found for either
subgroup (see Table 28).
TABLE 28 Subgroups in the SCD-HeFT trial
Subgroup and outcome ICD vs. placebo HR (95% CI), p-value
Ischaemic CHF
All-cause mortality105 0.79 (0.60 to 1.04a), 0.05
Cause of death108
Cardiac 0.80 (0.60 to 1.05)
Sudden tachyarrhythmic 0.43 (0.27 to 0.67)
HF 1.11 (0.74 to 1.67)
Non-cardiac 0.79 (0.50 to 1.22)
Non-ischaemic CHF
All-cause mortality105 0.73 (0.50 to 1.07a), 0.06
Cause of death108
Cardiac 0.68 (0.44 to 1.03)
Sudden tachyarrhythmic 0.34 (0.17 to 0.70)
HF 1.21 (0.67 to 2.18)
Non-cardiac 0.81 (0.48 to 1.37)
NYHA class II
All-cause mortality105 0.54 (0.40 to 0.74a),< 0.001
Cause of death108
Cardiac 0.50 (0.36 to 0.70)
Sudden tachyarrhythmic 0.26 (0.15 to 0.44)
HF 0.93 (0.56 to 1.54)
Non-cardiac 0.63 (0.40 to 0.99)
NYHA class III
All-cause mortality105 1.16 (0.84 to 1.61a), 0.30
Cause of death108
Cardiac 1.17 (0.84 to 1.64)
Sudden tachyarrhythmic 0.73 (0.41 to 1.29)
HF 1.34 (0.86 to 2.09)
Non-cardiac 1.10 (0.66 to 1.85)
Race African American
All-cause mortality106 0.65 (95% CI 0.43 to 0.99)
Race white
All-cause mortality106 0.73 (95% CI 0.58 to 0.90)
a 97.5% CI.
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There was a statistically significant interaction between ICD therapy and NYHA class (p< 0.001).105
Compared with placebo, ICDs reduced the risk of death in people in NYHA class II (HR 0.54, 97.5% CI
0.40 to 0.74, p< 0.001), but not in those in NYHA class III (HR 1.16, 97.5% CI 0.84 to 1.61, p= 0.30).
The interaction between ICD therapy and NYHA class was statistically significant for cardiac mortality
(p= 0.0004) and sudden death presumed to be ventricular tachyarrhythmic (p= 0.0091), but not for HF
(p= 0.29) or non-cardiac (p= 0.11) deaths.108 ICD therapy reduced the risk of cardiac mortality (HR 0.50,
95% CI 0.36 to 0.70) and sudden tachyarrhythmic death (HR 0.26, 95% CI 0.15 to 0.44) in people in
NYHA class II, but not in those in NYHA class III (HR 1.17, 95% CI 0.84 to 1.64, and HR 0.73, 95% CI
0.41 to 1.29 respectively).
There was no significant interaction between ICD therapy and race (p= 0.53); ICD therapy reduced the risk
of death in both racial groups (African American: HR 0.65, 95% CI 0.43 to 0.99; white: HR 0.73
95% CI 0.58 to 0.90).106
Combining data from the SCD-HeFT105 non-ischaemic CHF subgroup with data from the three
cardiomyopathy trials (AMIOVIRT,69 CAT,82 DEFINITE90) was considered appropriate by clinical experts.
SCD-HeFT105 did not report the number of events for all-cause mortality occurring in each of the ischaemic
and non-ischaemic subgroups; therefore, these were estimated by reviewers and data from the
non-ischaemic subgroup were combined in a meta-analysis (Figure 9). The SCD-HeFT non-ischaemic
subgroup strongly influenced the analysis and a statistically significant effect in favour of ICD therapy with
no statistical heterogeneity was found (RR 0.74, 95% CI 0.58 to 0.93, p= 0.01). This is in contrast to the
non-significant result of the meta-analysis of the three cardiomyopathy trials alone (see Figure 4).
Other relevant trials
Two trials146,147 were excluded as the intervention did not meet the scope of the present review (many
participants in the intervention arm did not receive an ICD); however, these trials presented subgroup data
comparing ICD therapy with no ICD therapy that may be considered relevant. The MUSTT146 and
MAVERIC147 trials have not undergone formal data extraction and quality assessment but the data are
presented here for information.
The MUSTT study was included in the previous TARs62,63 although the authors noted that it did not meet their
inclusion criteria if strictly applied (in that randomisation determined electrophysiology-guided therapy not ICD
therapy). The authors also state that caution should be used when assessing the results as the study did not
randomise participants to drug therapy or ICD and has the potential for bias and confounding of results.62
The MUSTT study was designed to test the hypothesis that electrophysiology-guided antiarrhythmic
therapy reduces SCD. People with sustained, monomorphic VT induced by any method of stimulation and
those with sustained polymorphic VT (including ventricular flutter and fibrillation) induced by one or
two extra stimuli were randomly assigned in equal numbers to receive either antiarrhythmic therapy
guided by the results of electrophysiological testing or no antiarrhythmic therapy. ICD therapy could be
recommended for people randomised to electrophysiological testing after at least one unsuccessful drug
Study or subgroup Events Total Events Total Weight
ICD No ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
AMIOVIRT69,70
CAT82,83
DEFINITE90–94
SCD HeFT105–108
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.82, df = 3 ( p = 0.61); I 2 = 0%
Test for overall effect: z = 2.55 ( p = 0.01)
6
4
28
63
101
51
50
229
398
728
7
2
40
87
136
52
54
229
394
729
5.3%
2.0%
27.8%
64.8%
100.0%
0.87 (0.32 to 2.42)
2.16 (0.41 to 11.28)
0.70 (0.45 to 1.09)
0.72 (0.53 to 0.96)
0.74 (0.58 to 0.93)
0.05 0.2 1 5 20
Favours ICD Favours no ICD
Test for subgroup difference: χ2 = 2.36, df = 1 (p = 0.12); I2 = 57.6%
FIGURE 9 All-cause mortality, cardiomyopathy RCTs and SCD-HeFT non-ischaemic CHF subgroup.
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test. Median follow-up was 39 months. Beta-blocker use was significantly higher in the no therapy group
(electrophysiological testing 29%, no therapy 51%, p= 0.001).
All-cause mortality was significantly reduced in the ICD group compared with the electrophysiology-guided
therapy without a defibrillator group (RR 0.42, 95% CI 0.29 to 0.61, p< 0.001) and the no therapy group
(RR 0.49, 95% CI 0.35 to 0.69, p< 0.001).146 The overall mortality rate at 5 years was 24% among
patients who received a defibrillator and 55% among those who did not.
The risk of death from cardiac arrest or arrhythmia was significantly reduced in patients who received an ICD
compared with those receiving electrophysiology-guided therapy without a defibrillator (RR 0.24, 95% CI
0.13 to 0.43, p< 0.001) and those receiving no therapy (RR 0.28, 95% CI 0.16 to 0.49, p< 0.001).146
The MAVERIC trial was in progress at the time of the previous TAR.62 This multicentre UK study was
designed to test the possibility of prospectively identifying, using electrophysiological testing, patients who
would benefit most from ICD therapy in the context of the secondary prevention of SCD. Survivors of
sustained VT, VF or SCD were randomised to electrophysiology-guided interventions (AADs, coronary
revascularisation and ICD therapy) or empirical amiodarone therapy, with prestratification for
haemodynamic status at the index event. Median follow-up was 60 months.
Subgroup analysis was presented for ICD recipients compared with non-ICD recipients, regardless of
allocated treatment. As with the MUSTT trial, these results must be viewed with caution because of the
lack of randomisation and the possibility of bias and confounding. An ICD was received by 31 of 108
(29%) patients randomised to electrophysiological testing [14/60 (23%) patients haemodynamically stable
and 17/48 (35%) patients haemodynamically unstable at the index event] and 5 of 106 (5%) patients
randomised to amiodarone [4/62 (6%) patients haemodynamically stable and 1/44 (2%) patients
haemodynamically unstable at the index event]. ICD recipients were significantly younger [62.7 (SD 9.0)
years vs. 68.1 (SD 9.8) years, p= 0.002] and less likely to have diabetes (5.3% vs. 18.8%, p= 0.042) than
non-ICD recipients; other baseline characteristic were similar.
Survival was significantly better in ICD recipients than in non-ICD recipients [HR 0.54, 0.30 to 0.97
(definition of interval not stated), p= 0.0391]. Comparisons between ICD recipients and non-ICD recipients
were also presented separately for haemodynamically stable patients [HR 0.71, 0.29 to 1.75 (definition of
interval not stated), p= 0.4537] and haemodynamically unstable patients [HR 0.42, 0.20 to 0.92 (definition
of interval not stated), p= 0.0299] at the index event. Multivariate analysis of factors affecting survival
found that ICD implantation was associated with a non-statistically significant reduction in the risk of
death [OR 0.43, 0.17 to 1.11 (definition of interval not stated), p= 0.080].
Summary of clinical effectiveness: people at risk of sudden cardiac death
as a result of ventricular arrhythmias
l A total of 13 RCTs were included that compared ICDs with medical therapy in people at risk of SCD
because of arrhythmias. The trials were synthesised according to the criteria that they used to identify
people at risk of SCD.
l Risk of bias – As it was not possible to blind participants and personnel in these trials, they were judged
to have a high risk of performance bias. Trials were judged to have a low risk of detection bias as
assessment of mortality is unlikely to be influenced by lack of blinding; however, the risk of detection
bias is high for QoL outcomes. Five trials were judged to have a low risk of selection bias, but this was
unclear in eight trials because of inadequate reporting.
Ventricular arrhythmia/cardiac arrest (secondary prevention)
l Four RCTs compared the effectiveness of ICDs and AADs. Average length of follow-up ranged from
18 months to 57 months and sample size ranged from 66 to 1016. The proportion of participants with
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CHF differed in the trials. In two trials 100% of participants had CHF, with> 80% in NYHA classes I
and II. In the other two trials between 60% and 90% had CHF with approximately 50% in both trials
in NYHA classes I and II. LVEF also varied, ranging from 30% to 70% across all four studies.
l All four RCTs assessed all-cause mortality as the primary outcome measure, which when combined
through meta-analysis showed a statistically significant benefit for ICDs compared with AADs (RR 0.75,
95% CI 0.61 to 0.93, p= 0.01). Differences were found in the four RCTs for the outcome of sudden
cardiac/arrhythmic deaths, with a statistically significant benefit for ICDs compared with AADs when
combined through meta-analysis (RR 0.49, 95% CI 0.34 to 0.69, p< 0.0001).
l Meta-analysis of two trials showed a statistically significant benefit for ICDs compared with AAD for the
outcome of total cardiac deaths (RR 0.74, 95% CI 0.61 to 0.91, p= 0.004); however, no differences
were found for the outcomes of non-arrhythmic cardiac deaths (RR 0.97, 95% CI 0.72 to 1.31,
p= 0.83) or other non-cardiac causes of death (RR 0.79, 95% CI 0.45 to 1.37, p= 0.40). Two RCTs
reported different measures of survival, finding a statistically significant benefit for ICDs compared with
AADs for overall survival at 3 years (difference 11%, p< 0.02), survival free of cardiac death at 2 years
(difference 4%, p= 0.004), survival to arrhythmic death at 2 years in one trial (difference 5%,
p= 0.0002) and survival free of sudden death at 57 months in the other trial (HR 0.423, p= 0.005).
One RCT found lower cumulative mortality annually over 3 years’ follow-up with ICDs (difference: year
1 14.5%, year 2 1.7%, year 3 4.1%).
l Two RCTs assessed QoL through separate substudies using a range of measures. In one RCT there
were no significant between-group differences at follow-up. A second RCT found that QoL improved
significantly in the ICD group on three domains of the MHI and five domains of the NHP, whereas
there were no changes in the OPT group. In this trial the QoL of those experiencing five or more ICD
shocks did not differ significantly from that of the OPT group when analysed using the MHI and the
NHP. The no shocks and one to four shocks ICD groups showed significant improvements on the MHI
and NHP compared with the OPT group.
l One trial reported prespecified subgroup analyses for all-cause mortality. The subgroups for age, LVEF,
cause of arrhythmia and qualifying arrhythmia did not differ significantly from each other or the overall
population for all-cause mortality.
People with a recent myocardial infarction (within 6–41 days or ≤ 31 days)
l Two RCTs compared ICDs+OPT with OPT. Length of follow-up was 30 or 37 months and sample size
ranged from 674 to 898. About 60% of participants in both trials were in NYHA class II, but the
majority of the remaining participants had NYHA class III symptoms in one trial and NYHA class I
symptoms in the other trial. Similarly, mean LVEF differed between the studies (28% and 35%),
reflecting different eligibility criteria.
l Meta-analysis of the two trials found no difference between the groups in all-cause mortality (RR 1.04,
95% CI 0.86 to 1.25, p= 0.69), total cardiac deaths (RR 0.97, 95% CI 0.79 to 1.20, p= 0.8) and
non-cardiac deaths (RR 1.39, 95% CI 0.86 to 2.27, p= 0.18). Those who received an ICD+OPT had a
lower risk of SCD (RR 0.45, 95% CI 0.31 to 0.64, p< 0.0001) but a higher risk of non-arrhythmic
cardiac death (RR 1.77, 95% CI 1.30 to 2.40, p= 0.0002). One trial reporting cumulative mortality
found no statistically significant difference between the groups. QoL was not reported.
l One trial reported prespecified subgroup analyses for all cause-mortality. No significant differences
were found for the 13 prespecified subgroups.
People with remote myocardial infarction (> 3 weeks or > 1 month previously)
l Two RCTs compared ICDs+OPT with OPT, although the pharmacological therapy in one of these may
not be considered optimal by current standards. Average length of follow-up was 27 and 20 months
and sample size was 196 and 1232 respectively. About two-thirds of participants had NYHA class II or
III symptoms and one-third had NYHA class I symptoms. Mean LVEF differed between the studies
(about 26% and 23%), reflecting different eligibility criteria.
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l Meta-analysis of the two trials found a reduction in all-cause mortality (RR 0.57, 95% CI 0.33 to 0.97,
p= 0.04), total cardiac deaths (RR 0.59, 95% CI 0.42 to 0.83, p= 0.003) and SCD (RR 0.36, 95% CI
0.23 to 0.55, p< 0.00001) in the ICD+OPT group compared with the OPT group. There was no
difference in non-arrhythmic cardiac death (RR 0.95, 95% CI 0.41 to 2.18, p= 0.9) or non-cardiac
death (RR 1.06, 95% CI 0.58 to 1.95, p= 0.84) between the groups. One trial reporting
hospitalisations found a higher rate per 1000 months’ follow-up among those who received an ICD
(11.3 vs. 9.4, p= 0.09), with higher HF hospitalisations (19.9% vs. 14.9%, p-value not reported).
l In one trial that assessed QoL using the HUI3, scores were lower in the ICD+OPT group than
in the OPT group at baseline. Differences between the groups were not statistically significant at
3 years’ follow-up.
l One trial reported prespecified subgroup analyses for all-cause mortality. The HRs in all 12 of the
subgroups were similar, with no statistically significant interactions.
People with non-ischaemic or idiopathic dilated cardiomyopathy
l Three RCTs compared ICD+OPT with OPT or ICD+OPT with amiodarone+OPT. Mean follow-up was
between 24 months (two RCTs) and 29 months and sample size ranged from 103 to 458. One trial
enrolled people with recent onset of disease. Over half to two-thirds of participants were in NYHA
class II; in one trial the remaining participants were in NYHA class III, but in two trials around 15–21%
were in NYHA class I. Mean LVEF ranged from 21% to 25%.
l Meta-analysis found no significant difference between ICDs and OPT or amiodarone in all-cause
mortality (RR 0.77, 95% CI 0.52 to 1.15, p= 0.20), total cardiac deaths (RR 2.03, 95% CI 0.17 to
23.62, p= 0.57), non-arrhythmic cardiac death (RR 1.13, 95% CI 0.42 to 3.03, p= 0.81) or non-cardiac
death (RR 0.65, 95% CI 0.13 to 3.29, p= 0.60). However a reduction was found in rate of SCDs
(RR 0.26, 95% CI 0.09 to 0.77, p= 0.02) with ICDs.
l Two trials reported no significant difference in survival between groups.
l Two trials reported no significant differences in QoL, assessed using the QWBS and STAI or the SF-12
MCS and PCS and MLWHFQ.
l One trial reported six prespecified subgroup analyses for all-cause mortality. None of the differences
between subgroups was statistically significant.
l Meta-analysis of the three cardiomyopathy trials and the non-ischaemic CHF subgroup of the
SCD-HeFT trial found a statistically significant reduction in all-cause mortality (RR 0.74, 95% CI 0.58 to
0.93, p= 0.01) with ICDs compared with OPT or amiodarone.
People scheduled for coronary artery bypass graft surgery
l One trial compared ICD+OPT with OPT, although the pharmacological therapy would not be
considered optimal by current standards. Mean follow-up was 32 months and 900 participants were
randomised. The majority of participants were in NYHA class II or III and mean LVEF was 27%.
l No significant difference was found between groups in all-cause mortality (RR 1.08, 95% CI 0.85 to
1.38, p= 0.53), total cardiac deaths (HR 0.97, 95% CI 0.71 to 1.33, p= 0.84), non-arrhythmic cardiac
death (HR 1.24, 95% CI 0.84 to 1.84, p= 0.28), non-cardiac death (RR 1.50, 95% CI 0.82 to 2.73,
p= 0.19) or actuarial mortality at 4 years’ follow-up (HR 1.07, 95% CI 0.81 to 1.42, p= 0.64). The rate
of SCD was lower in the ICD group but this did not reach statistical significance (HR 0.55, 95% CI 0.29
to 1.03, p= 0.06).
l HRQoL was higher among those receiving OPT than among those receiving an ICD+OPT for all
measures and this was statistically significant for some perception of health transition, emotional role
function, mental health, satisfaction with appearance and satisfaction with scar.
l HRs for the ICD group compared with the control group for all-cause mortality were found to be
similar among 10 prespecified subgroups.
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A broad population of people with mild to moderate heart failure
l One three-arm trial compared ICDs, amiodarone and placebo; all participants received OPT. Mean
follow-up was 46 months and 2521 participants were randomised. Over two-thirds of participants were
in NYHA class II, with the remaining participants in NYHA class III. Mean LVEF was 25%.
l All-cause mortality was significantly lower in the ICD+OPT group than in the placebo+OPT group
(HR 0.77, 97.5% CI 0.62 to 0.96, p= 0.007). A significant reduction in total cardiac deaths (HR 0.76,
95% CI 0.60 to 0.95, p= 0.018) and SCD (compared with the placebo and amiodarone groups
combined, RR 0.44, 95% CI 0.31 to 0.61, p< 0.00001) in favour of ICD was also found. There was no
statistically significant difference between the ICD group and the placebo and amiodarone groups
combined in the number of non-arrhythmic cardiac deaths (RR 1.14, 95% CI 0.88 to 1.48, p= 0.32) or
deaths from non-cardiac causes (RR 0.92, 95% CI 0.66 to 1.27, p= 0.60).
l Little difference was found in QoL assessed using the DASI. Statistically significant differences in MHI
scores and global health status at 3 and 12 months were not maintained at 30 months, and the
difference in MHI score was not clinically meaningful. A significant decrease in perceptions of QoL was
found using the SF-36 among people who had received an ICD shock within the previous month
compared with those who had not received a shock.
l There was no interaction between ICD therapy (p= 0.68) and the cause of CHF (ischaemic or
non-ischaemic) for all-cause mortality or other specified modes of death. There was a statistically
significant interaction between ICD therapy and NYHA class: compared with placebo, ICDs reduced the
risk of all-cause mortality, cardiac mortality and sudden death presumed to be ventricular tachyarrhythmic
in people with NYHA class II, but not in those with NYHA class III. The interaction between ICD therapy
and NYHA class was not statistically significant for HF (p= 0.29) or non-cardiac (p= 0.11) deaths.
Adverse events
l Adverse events were reported by all four RCTs that included those with previous ventricular
arrhythmias. Up to 30% of people in the ICD groups reported adverse events, with most related to the
placement and operation of the device. Rates in the OPT group appeared lower.
l The nine RCTs that included people who had not suffered a life-threating arrhythmia reported
adverse event rates in the ICD group of between 5% and 61%, depending on the definition of adverse
event and length of follow-up. Adverse event rates for the comparator treatment group were between
11.9% and 55% in the three RCTs reporting this. Lead-, electrode- or defibrillator generator-related
problems affected 1.8–14% of people in the five trials that reported this.
People with heart failure as a result of left ventricular systolic
dysfunction and cardiac dyssynchrony
Quantity and quality of research available
Four RCTs109,116,121,125 comparing CRT-P and OPT in people with HF as a result of LVSD and cardiac
dyssynchrony despite receiving OPT met the inclusion criteria. In addition, one of these RCTs, the
Comparison of Medical Therapy, Pacing, and Defibrillation in Patients with Left Ventricular Systolic
Dysfunction (COMPANION) trial,116 compared CRT-P and CRT-D with OPT.
Three of the trials reported their findings in more than one paper; a summary of the included papers for
each trial can be seen in Table 29. All of these studies were included in the 2007 TAR,64 which also
included the RCT of the CONTAK-CD device.126 This trial is discussed later in People with both conditions.
Characteristics of the included studies
Study characteristics are summarised in Table 30 and participant characteristics are summarised in
Table 31. Further details can be found in the data extraction forms in Appendix 8.
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TABLE 29 Included RCTs for people with HF
Study Publicationa
CARE-HF Cleland et al. 2005,109 2001,110 2006,111 2008112 and 2009,113 Gras et al. 2007,36 Gervais et al. 2009,114
Ghio et al. 2009115
COMPANION Bristow et al. 2004116 and 2000,117 US Food and Drug Administration 2004,118 Carson et al. 2005,119
Anand et al. 2009120
MIRACLE Abraham et al. 2002121 and 2000,122 US Food and Drug Administration 2001,123 St John Sutton
et al. 2003124
MUSTIC Cazeau et al. 2001125
CARE-HF, CArdiac REsynchronization in Heart Failure; MIRACLE, Multicenter InSync Randomized Clinical Evaluation;
MUSTIC, Multisite Stimulation in Cardiomyopathies.
a Bold text indicates primary or key publication.
TABLE 30 Study characteristics
Parameter CARE-HF109 COMPANION116 MIRACLE121 MUSTIC125
Study design RCT RCT RCT Randomised
crossover trial
Target
population
NYHA class III or IV as a
result of LVSD and
cardiac dyssynchrony
Advanced chronic HF
and intraventricular
conduction delays
Moderate to severe HF Severe HF and major
intraventricular delay
Intervention CRT-P+medical therapy CRT-P or CRT-D
and OPT
CRT-P on and OPT CRT-P on and OPT
Comparator Standard medical therapy OPT CRT-P off and OPT CRT-P off and OPT
Country (no.
of centres)
Europe (82) (including
France, Germany, Italy,
Switzerland and the UK)
USA (128) USA and Canada (45) Europe (15) (France,
Germany, Italy, Sweden,
Switzerland and the UK)
Sample
size
(randomised)
813 1520 453 58
Length of
follow-up
Mean 29.4 months (mean
37.4 months with
8-month extension)
Primary end point,
median
11.9–16.2 months
6 months 3 months
Key
inclusion
criteria
HF for ≥ 6 weeks; NYHA
class III or IV despite
standard pharmacological
therapy; LVEF ≤ 35%;
LVEDD ≥ 30mm;a QRS
interval ≥ 120milliseconds;b
aortic pre-ejection delay
> 140milliseconds,
interventricular mechanical
delay> 40milliseconds,
delayed activation of
posterolateral left
ventricular wall
Sinus rhythm; NYHA
class III or IV; LVEF
≤ 35%; LVEDD
≥ 60mm; QRS
≥ 120milliseconds;
PR interval
> 150milliseconds
HF due to ischaemic or
non-ischaemic
cardiomyopathy for
> 1 month; NYHA class
III or IV; LVEF ≤ 35%;
LVEDD ≥ 55mm;
QRS interval
≥ 130milliseconds;
6-minute walk
distance ≤ 450m
Severe HF due to
idiopathic or ischaemic
LVSD; sinus rhythm;
NYHA class III for
≥ 1 month whilst on
OPT; LVEF< 35%;
LVEDD> 60mm;
QRS interval
> 150milliseconds;
No standard indication
for a pacemaker
CARE-HF, CArdiac REsynchronization in Heart Failure; LVEDD, left ventricular end-diastolic diameter; MIRACLE, Multicenter
InSync Randomized Clinical Evaluation; MUSTIC, Multisite Stimulation in Cardiomyopathies.
a Indexed to height.
b QRS interval of 120–149milliseconds: patients need to meet two-thirds of additional criteria for dyssynchrony.
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Intervention and comparators
In the Multicenter InSync Randomized Clinical Evaluation (MIRACLE)121 and Multisite Stimulation in
Cardiomyopathies (MUSTIC)125 trials, all participants were implanted with a CRT-P device and pacing was
inactivated in the control group. Participants in the CArdiac REsynchronization in Heart Failure (CARE-HF)109
and COMPANION116 trials received either a device+OPT or OPT only. Pharmacological therapy in all
four trials would be considered optimal by current standards.
Participants
The trials included people with NYHA class III or IV HF, with the majority of participants in NYHA class III
(ranging from 82% in CARE-HF109 to 100% in MUSTIC125). All of the trials included participants with LVEF
< 35%; average LVEF was about 22% in the MIRACLE121 and COMPANION trials116 and 25% in the
CARE-HF trial.109
The trials differed in their eligibility criteria with regard to the QRS interval, with the CARE-HF109 and
COMPANION116 trials requiring a QRS interval of ≥ 120milliseconds, the MIRACLE trial121 requiring a QRS
TABLE 31 Key participant characteristics
Parameter
CARE-HF109 COMPANION116 MIRACLE121 MUSTIC125
CRT-P OPT CRT-P CRT-D OPT CRT-P on CRT-P off CRT-P on CRT-P off
Sample size, n 409 404 617 595 308 228 225 29 29
Age (years),
mean (SD)
67
(60–73)a
66
(59–72)a
67b 66b 68b 63.9
(10.7)
64.7
(11.2)
64
(11)
64
(8)
Sex, % male 74 73 67 67 69 68 68 66 83
Ischaemic heart
disease, %
40 36 54 55 59 50 58
Dilated
cardiomyopathy, %
43 48
NYHA class, %
I 0 0 0 0 0 0 0 0 0
II 0 0 0 0 0 0 0 0 0
III 94 93 87 86 82 90 91 100 100
IV 6 7 13 14 18 10 9 0 0
LVEF (%), mean (SD) 25b 25b 20b 22b 22b 21.8
(6.3)
21.6
(6.2)
QRS interval
(milliseconds),
mean (SD)
160b
(152–180)a
160b
(152–180)a
160b 160b 158b 167
(21)
165
(20)
172
(22)
175
(19)
LBBB/RBBB, % 69/12 73/10 70/9
6-minute walk
test (m), mean
274b 258b 244b 305 291 354
(110)
346
(111)
Peak VO2
(ml/kg/minute),
mean (SD)
14.0 13.7 13.5
(8.4)
14.1
(4.6)
Heart rate (bpm),
mean (SD)
69b 70b 72b 72b 72b 73
(13)
75
(13)
75
(12)
75
(14)
bpm, beats per minute; RBBB, right bundle branch block; VO2, oxygen consumption.
a Range.
b Median.
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interval of ≥ 130milliseconds and the MUSTIC trial125 requiring a QR interval of > 150milliseconds. This is
reflected in the average QRS interval at baseline in these studies, with the longest average QRS interval
seen in the MUSTIC trial125 (see Table 31). When reported, the proportion of participants with ischaemic
heart disease ranged from 36% (CARE-HF109) to 59% (COMPANION116).
The mean age of the participants in the studies was similar, ranging from around 64 years in the
MIRACLE121 and MUSTIC125 trials to 68 years in the COMPANION trial116 (see Table 31). The majority of
participants were men (73% and 74% in the CARE-HF trial arms,109 67%, 67% and 69% in the three
COMPANION trial arms,116 68% in both of the MIRACLE trial arms121 and 66% and 83% in the MUSTIC
trial arms125).
Pharmacological therapy
Optimal pharmacological therapy was used in all of the trials (Table 32). At least 90% of all participants
received ACE inhibitors or ARBs. Less than one-third (28%) of participants used beta-blockers in the
MUSTIC study,125 between 55% and 62% used beta-blockers in the MIRACLE trial,121 between 66% and
68% used beta-blockers in the COMPANION trial116 and between 70% and 74% used beta-blockers in
the CARE-HF trial.109 Spironolactone use was not reported by the MIRACLE study121 but was 22% in the
MUSTIC trial,125 and between 53% and 55% in the COMPANION trial109 and between 54% and 59% in
the CARE-HF trial.109 Less than half of the participants in the CARE-HF trial109 used diuretics, with around
94% of participants in the other studies using them. Both the CARE-HF trial109 and the MUSTIC trial125
reported that less than half of the participants used digoxin, and around one-third of participants in the
MUSTIC trial125 used amiodarone. In the MIRACLE trial121 around three-quarters of participants used
digitalis medication.
Outcomes
Although all four trials reported all-cause mortality, it was not a primary outcome. The primary outcome of
two trials was a composite end point: all-cause mortality and all-cause hospitalisation in the COMPANION
trial116 and all-cause mortality and unplanned hospitalisation for a major cardiovascular event in the
CARE-HF trial.109 Composite outcomes can be seen in the data extraction forms (see Appendix 8) but have
not been discussed in this report. The primary outcome of the MIRACLE121 and MUSTIC125 trials was
distance walked in 6 minutes; changes in NYHA class and QoL were also primary outcomes in the
MIRACLE trial.125
TABLE 32 Medication at baseline
Medication
CARE-HF109 COMPANION116 MIRACLE121 MUSTIC125
CRT-P OPT CRT-P CRT-D OPT CRT-P on CRT-P off CRT-P on CRT-P off
Sample size, n 409 404 617 595 308 228 225 67a
Aldosterone antagonist
(spironolactone), %
54 59 53 55 55 22
Amiodarone, % 31
ACE inhibitor, % 70 69 69
ACE inhibitor or ARB, % 95 95 89 90 89 93 90 96
Beta-blockers, % 70 74 68 68 66 62 55 28
Digitalis, % 78 79
Diuretic, % 94 94 93 94
Loop diuretic, % 43 44 94 97
Digoxin, % 40 45 48
a n= 67 enrolled, n= 58 randomised.
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All four trials reported mortality from SCD. In addition, the COMPANION116 and MUSTIC125 trials reported
total cardiac deaths and the CARE-HF109 and COMPANION116 trials reported death from HF. HF
hospitalisation was reported by all four trials. The CARE-HF,109 MIRACLE121 and MUSTIC125 trials reported
details on worsening HF whereas arrhythmias were reported by the CARE-HF109 and MUSTIC125 trials.
All trials except for the MUSTIC trial125 reported change in NYHA class, but only the CARE-HF109 and
MIRACLE121 trials reported changes in LVEF. HRQoL and adverse events were reported by all trials.
Setting
All four studies were multicentre trials, with the number of centres ranging from 15 (MUSTIC125) to
128 (COMPANION116). The CARE-HF109 and MUSTIC125 trials were undertaken in Europe, with both
including centres in the UK. The COMPANION study116 was undertaken in the USA whereas the
MIRACLE121 trial included centres in the USA and Canada.
The MUSTIC study125 used a randomised crossover design, with 3 months’ follow-up for each of the two
crossover periods. The length of follow-up for the MIRACLE study121 was 6 months. The mean length of
follow-up in the CARE-HF study109 was 29.4 months, plus an 8-month extension (total mean follow-up
37.4 months). The COMPANION trial116 reported a median follow-up for the composite end point of
11.9 months for OPT, 15.7 months for CRT-D and 16.2 months for CRT-P. Median follow-up for mortality
was also reported as 14.8 months for OPT, 16.0 months for CRT-D and 16.5 months for CRT-P.
Risk of bias
Details of the risk of bias for each study can be found in the data extraction tables in Appendix 8, with a
summary in Table 33.
TABLE 33 Risk of bias
Domain
Judgement
CARE-HF109 COMPANION116 MIRACLE121 MUSTIC125
Selection bias
Random sequence generation Low Unclear Unclear Unclear
Allocation concealment Low Unclear Unclear Unclear
Performance bias
Blinding of participants and
personnel
High High Low High
Detection bias
Blinding of outcome
assessment
Compositea – low; secondaryb – high
or unclear
Low Low High
Attrition bias
Incomplete outcome
data addressed
Compositea and echocardiographic
outcomes – low; left ventricular
remodelling outcomes – unclear
Low Unclear Low
Reporting bias
Selective reporting Low Low High High
Other bias
Other sources of bias Low Low Low High
a Morality and hospitalisation.
b Echocardiographic outcomes – high risk; adverse events – unclear risk.
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Because of a lack of reported details on randomisation methods and allocation concealment methods, the
risk of selection bias for the COMPANION,116 MIRACLE121 and MUSTIC125 trials was unclear. The risk of
selection bias was low in the CARE-HF trial.109
The MIRACLE trial121 appeared to be at low risk of performance and detection bias, with both patients and
physician unaware of treatment assignment (CRT-P on or off). The MUSTIC trial125 was at high risk of
performance and detection bias, with only participants blinded to the treatment order (CRT-P on or off).
Both the CARE-HF trial109 and the COMPANION trial116 were unblinded trials, placing them at high risk of
performance bias. For detection bias, the CARE-HF trial109 was judged to be at low risk of bias for the
composite end point of mortality and hospitalisation, using an end-points committee unaware of treatment
assignment. However, without blinding, the trial was at high risk of detection bias for echocardiographic
outcomes. The risk of detection bias for adverse events was unclear, with some adverse events classified by
the end-points committee but others by an unblinded independent expert. The risk of detection bias in the
COMPANION trial116 was low, with a steering committee and end-points committee unaware of
treatment assignment.
Both the COMPANION trial116 and the MUSTIC trial125 were at low risk of attrition bias. The MUSTIC trial125
reported both numbers and reasons for withdrawals, whereas the COMPANION trial116 censored data in
the ITT analysis for participants who withdrew and for whom data could not be obtained. The CARE-HF
trial109 also reported ITT analyses and was at low risk of bias for mortality, hospitalisation and
echocardiographic outcomes; however, the risk of bias for QoL and left ventricular reverse remodelling was
unclear because of unexplained differences in numbers. The risk of attrition bias in the MIRACLE study121
was unclear for both primary and secondary outcomes. Although ITT analysis was used and attrition
reported, the low numbers reported for the primary outcome of NYHA class and differences in sample size
between the primary outcome and the secondary outcome were unexplained. Both the CARE-HF trial109
and the COMPANION study116 were at low risk of selective reporting bias. For both studies the protocol or
rationale/design papers have been published and there was no evidence of missing outcomes. However,
the MIRACLE121 and MUSTIC125 trials were at high risk of selective reporting bias. The MIRACLE trial121
assessed change in NYHA class but failed to report the data, and the MUSTIC trial125 included the SF-36 in
the study protocol122 but did not report any data.
There was an additional risk of bias in the MUSTIC trial125 because of the use of block randomisation
without blinding. However, the use of the crossover design appears appropriate.
Methodological comments
Similarity of groups at baseline
The groups in the four studies were generally well balanced at baseline.
Sample size
All four of the trials included a statistical power calculation. The CARE-HF,109 MIRACLE121 and MUSTIC125
trials appeared to be adequately powered to detect a difference in the relevant primary outcome measure.
The MUSTIC trial125 randomised 58 participants, the MIRACLE trial121 randomised 453 participants
and the CARE-HF trial109 randomised 813 participants. The COMPANION trial116 was stopped early when
pre-established boundaries had been crossed, with 1520 participants randomised and 1000 primary
end points already or almost met. The trial was designed with 2200 participants to detect a reduction of
25% in the primary end point.
Crossovers
By the end of the extension period in the CARE-HF trial,109 24% of participants in the OPT group had a
CRT device implanted and activated and 2% of participants in the CRT-P treatment arm received a CRT-D
device. The MIRACLE trial121 reported that 4% of participants crossed over from OPT to the CRT-P
treatment group, but reported no details for the CRT-P treatment group. The COMPANION trial120 reported
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that, out of 78 cardiac procedures in the OPT group, 33 (42%) were for CRT implants. In addition, this trial
reported that there were substantial withdrawals in the OPT group (26%) to receive commercially available
implants, whereas the withdrawal rates in the CRT-P and CRT-D groups were 6% and 7% respectively.
ITT analysis was performed in the trials.
Other issues
Studies differed in the timing of implantation, baseline evaluation and randomisation. Two studies
randomised participants before implantation. In the CARE-HF study109 baseline measures were taken
before randomisation and implantation, whereas in the COMPANION study116 randomisation occurred
before implantation but baseline measures were taken 1 week after successful implantation. The
remaining two studies (MIRACLE121 and MUSTIC125) randomised participants after implantation. In the
MIRACLE study121 baseline measures were taken before implantation and randomisation whereas in
the MUSTIC study125 baseline measures were taken after randomisation, which occurred 2 weeks after
implantation. Thus, only those participants with a successful implantation underwent randomisation in
both studies, limiting the generalisability of these studies. These differences may affect comparability
between the studies.
The MUSTIC trial125 does not report all outcomes for both crossover periods. In addition, 10 participants
did not complete both crossover periods (including five who did not complete the first period).
The COMPANION trial116 had substantial withdrawals from the OPT group (see Crossovers).
Funding
All four trials received funding grants from the device manufacturers, with three trials funded by
Medtronic109,121,125 and one by the Guidant Corporation.116 In addition, three of the trials, the MIRACLE,121
MUSTIC125 and CARE-HF109 trials, reported conflicts of interests, as some/all authors were consultants or
investigators for, or employees of, the company providing the funding. Both the CARE-HF trial109 and the
COMPANION trial116 stated that sponsors had no role in data analysis, whereas the MIRACLE trial121 stated
that sponsors placed no restrictions or limitation on the investigators performing the data analyses.
Assessment of effectiveness
All-cause mortality
All four studies reported all-cause mortality (Table 34), although it was not the primary outcome of
the trials.
CRT-P compared with optimal pharmacological therapy
The CARE-HF trial109 reported a statistically significant difference in all-cause mortality between the groups
after a mean follow-up of 37.4 months, which included an 8-month extension period (CRT-P 24.7% vs.
OPT 38.1%, HR 0.60, 95% CI 0.47 to 0.77, p< 0.0001). Mortality rates at year 3 were 11.5 percentage
points lower for the CRT-P group (CRT-P 23.6% vs. OPT 35.1%), although no statistical comparison
was reported. After completion of the CARE-HF trial, long-term follow-up of people who survived and
reconsented (343 of 813 originally enrolled) found that the effect of CRT persisted (HR 0.77, 95% CI 0.63
to 0.93, p= 0.007), despite implantation of CRT devices in > 95% of those originally assigned to the
control group (ITT analysis undertaken, with participants remaining in their assigned group regardless of
subsequent treatment).150 In contrast, the MIRACLE trial121 found no statistically significant difference in
all-cause mortality between the groups after 6 months’ follow-up (CRT-P 5.3% vs. OPT 7.1%, HR 0.73,
95% CI 0.34 to 1.54, p= 0.40), and the difference in the 12-month all-cause mortality rate between the
CRT-P and OPT groups in the COMPANION trial116 did not reach statistical significance (CRT-P 15% vs. OPT
19%, HR 0.76, 95% CI 0.58 to 1.01, p= 0.059). The MUSTIC trial125 reported one death in the first
crossover period (1/29, 3.4%) and two in the second crossover period (2/29, 6.9%) among those receiving
CRT-P and none during the OPT period. No statistical comparison was reported.
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The studies were considered sufficiently similar to combine in a meta-analysis (Figure 10). For meta-analysis
of the MUSTIC crossover trial,125 all deaths in those receiving CRT-P or OPT from both crossover periods
were included. This method provides a conservative analysis, with the study being underweighted rather
than overweighted.65 There was evidence of moderate statistical heterogeneity between the studies
(χ2= 4.99, df= 3, I2= 40%). The RR for CRT-P compared with OPT for all-cause mortality using the
random-effects method was 0.75 (95% CI 0.58 to 0.96, p= 0.02) (see Figure 10). Excluding the MUSTIC
trial125 from the meta-analysis had little effect (RR 0.73, 95% CI 0.60 to 0.89, p= 0.002).
TABLE 34 All-cause mortality
Study Follow-up CRT-P, n/N (%) OPT, n/N (%) Effect
95% CI,
p-value
CARE-HF109 First 90 days of trial 12/409 (2.9) 15/404 (3.7)
29.4 monthsa 82/409 (20.0) 120/404 (29.7) HR
0.64
0.48 to
0.85,
< 0.002
a37.4 months111 101/409 (24.7) 154/404 (38.1) HR
0.60
0.47 to
0.77,
< 0.0001
Mortality rate
1 year,111 %
9.7 12.6
Mortality rate
2 year, %
18 25.1
Mortality rate
3 year, %
23.6 35.1
MIRACLE121 6 months 12/228 (5.3) 16/225 (7.1) HR
0.73
0.34 to
1.54, 0.40
MUSTIC125 6 months First period: 1/29 (3.4b),
second period: 2/29 (6.9b)
First period: 0/29 (0),
second period: 0/29 (0)
RR
7.00b
0.37 to
132.56,
0.19b
CRT-P, n/N (%) OPT, n/N (%)
COMPANION116 CRT-P 16.5 months,
OPT 14.8 monthsc
131/617 (21.2) 77/308 (25.0)
12-month rate 93b/617 (15) 59b/308 (19) HR
0.76
0.58 to
1.01, 0.059
CRT-D, n/N (%) OPT, n/N (%)
CRT-D 16.0 months,
OPT 14.8 monthsc
105/595 (17.6) 77/308 (25.0) RR
0.71b
0.54 to
0.92, 0.009b
12-month rate 71b/595 (12) 59b/308 (19) HR
0.64
0.48 to
0.86, 0.003
CRT-P, n/N (%) CRT-D, n/N (%)
CRT-P 16.5 months,
CRT-D 16.0 monthsc
131/617 (21) 105/595 (18) RR
1.20b
0.96 to
1.52, 0.12b
a Mean.
b Calculated by reviewer.
c Median.
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CRT-D compared with optimal pharmacological therapy
The COMPANION trial116 found a statistically significant reduction in mortality with CRT-D at 12 months
(CRT-D 12% vs. OPT 19%, HR 0.64, 95% CI 0.48 to 0.86, p= 0.003), giving a reduction in risk of 36%
for all-cause mortality.
CRT-P pacer compared with CRT-D
The COMPANION trial116 included three treatment arms (CRT-P, CRT-D and OPT). The difference in
all-cause mortality between the CRT-P group (21%) and the CRT-D group (18%) was not statistically
significant (RR 1.20, 95% CI 0.96 to 1.52, p= 0.12). However, all comparisons between CRT-P and CRT-D
should be treated with caution as the trial was not powered for this comparison.
Total cardiac deaths
Both the COMPANION trial119 and the MUSTIC trial125 reported total cardiac deaths.
CRT-P compared with optimal pharmacological therapy
The COMPANION trial119 found no statistically significant difference in total cardiac deaths between CRT-P
and OPT (CRT-P 17.7% vs. OPT 18.8%, p= 0.334), with a median follow-up of 16.5 months for CRT-P
and 14.8 months for OPT (RR 0.94, 95% CI 0.70 to 1.25, p= 0.66) (Table 35). The three deaths that
occurred in the MUSTIC trial125 were from cardiac causes, with no significant differences between
treatment arms (CRT-P 5.2% vs. 0% OPT, RR 7.00, 95% CI 0.37 to 132.56, p= 0.19).
CRT-D compared with optimal pharmacological therapy
The COMPANION trial119 found that the number of cardiac deaths was statistically significantly lower
in the CRT-D group than in the OPT group (12.8% vs. 18.8% respectively, p= 0.006), with a median
follow-up of 16.0 months for CRT-D and 14.8 months for OPT (RR 0.68, 95% CI 0.50 to 0.93, p= 0.02)
(see Table 35).
CRT-P compared with CRT-D
The number of cardiac deaths in the COMPANION trial119 was statistically significantly higher in the CRT-P
group than in the CRT-D (RR 1.38, 95% CI 1.06 to 1.81, p= 0.02). However, all comparisons between
CRT-P and CRT-D should be treated with caution as the trial was not powered for this comparison.
Study or subgroup Events Total Events Total Weight
CRT-P OPT RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
CARE-HF36,109–115
COMPANION116–120
MIRACLE121–124
MUSTIC125
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.02; χ2 = 4.99, df = 3 ( p = 0.17); I 2 = 40%
Test for overall effect: z = 2.26 ( p = 0.02)
101
131
12
3
247
409
617
228
58
1312
154
77
16
0
247
404
308
225
58
995
47.1%
41.9%
10.3%
0.7%
100.0%
0.65 (0.53 to 0.80)
0.85 (0.66 to 1.09)
0.74 (0.36 to 1.53)
7.00 (0.37 to 132.56)
0.75 (0.58 to 0.96)
0.01 0.1 1 10 100
CRT-P OPT
FIGURE 10 All-cause mortality: CRT-P vs. OPT.
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Heart failure deaths
Both the CARE-HF trial109 and the COMPANION trial119 reported mortality from HF.
CRT-P compared with optimal pharmacological therapy
The CARE-HF trial109 found that mortality attributed to worsening HF was statistically significantly lower
in the CRT-P group than in the OPT group (around 9% vs. 16% respectively), with a risk reduction of 45%
(HR 0.55, 95% CI 0.37 to 0.82, p= 0.003) at 37.4 months’ follow-up. The risk of HF was reported to be
3.0% per annum for those receiving CRT-P compared with 5.1% per annum for those receiving OPT.
The COMPANION trial119 found no statistically significant differences between those receiving CRT-P and
those receiving OPT (8.6% vs. 11.0% respectively, HR 0.71, 95% CI 0.46 to 1.09, p= 0.112), with
follow-up of 16.5 months for those receiving CRT-P and 14.8 months for those receiving OPT (Table 36).
The studies were considered sufficiently similar to combine in a meta-analysis. There was no evidence of
statistical heterogeneity between the studies (χ2= 0.99, df= 1, I2= 0%). The random-effects RR for HF
deaths for the comparison between CRT-P and OPT was 0.67 (95% CI 0.51 to 0.88, p= 0.004)
(Figure 11).
CRT-D compared with optimal pharmacological therapy
The COMPANION trial119 found no statistically significant difference in HF deaths between CRT-D (8.7%)
and OPT (11.0%), with a HR of 0.73 (95% CI 0.47 to 1.11, p= 0.143) at 16.0 months’ follow-up for
those receiving CRT-D and 14.8 months’ follow-up for those receiving OPT (see Table 36).
CRT-P compared with CRT-D
The HF death rates in the CRT-P and CRT-D groups in the COMPANION trial119 were similar (8.6% vs.
8.7% respectively), with a RR of 0.98 (95% CI 0.68 to 1.42, p= 0.93).
TABLE 35 Total cardiac deaths
Study Follow-up CRT-P, n/N (%) OPT, n/N (%) Effect
95% CI,
p-value
MUSTIC125 6 months First period: 1/29 (3.4a),
second period: 2/29 (6.9a)
First period 0/29 (0),
second period 0/29 (0)
RR
7.00a
0.37 to
132.56, 0.19a
COMPANION119 CRT-P 16.5 months,
OPT 14.8 monthsb
109/617 (17.7c) 58d/308 (18.8) RR
0.94a
0.70 to 1.25,
0.66a (0.334e)
% of deaths 83.2 75.3
CRT-D, n/N (%) OPT, n/N (%)
CRT-D 16.0 months,
OPT 14.8 monthsb
76/595 (12.8) 58d/308 (18.8) RR
0.68a
0.50 to 0.93,
0.02a (0.006e)
% of deaths 72.4 75.3
CRT-P, n/N (%) CRT-D, n/N (%)
CRT-P 16.5 months,
CRT-D 16.0 monthsb
109/617 (17.7c) 76/595 (12.8) RR
1.38a
1.06 to
1.81, 0.02a
% of deaths 83.2 72.4
a Calculated by reviewer.
b Median.
c States 109/617= 17.1% in paper.
d States 54/308 (18.8%) in paper, but cardiac causes total 58.
e Statistical analysis reported by trial.
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Sudden cardiac death
All trials reported SCDs, although there were uncertainties within the MIRACLE trial data.121
CRT-P compared with optimal pharmacological therapy
The CARE-HF trial109 found the rate of SCDs to be statistically significantly lower in the CRT-P group than
in the OPT group (7.8% vs. 13.4% respectively, HR 0.54, 95% CI 0.35 to 0.84, p= 0.005) at a mean
follow-up of 37.4 months. The proportion of SCDs per year was reported to be 2.5% for those receiving
CRT-P and 4.3% for those receiving OPT. There were two reported SCDs in the MUSTIC trial,125 one (1/29,
3.4%) in the first crossover period (after 26 days of active pacing) and one (1/29, 3.4%) in the second
crossover period (2 hours after switching from inactive to active pacing). No statistical comparison was
reported. CRT-P failed to reduce the risk of SCD in the COMPANION trial,119 with more sudden deaths in
the group receiving CRT-P than in the group receiving OPT (7.8% vs. 5.8% respectively; HR 1.21, 95% CI
0.70 to 2.07, p= 0.485) at 16.5 months’ follow-up for those receiving CRT-P and 14.8 months’ follow-up
TABLE 36 Heart failure deaths
Study Follow-up
CRT-P,
n/N (%) OPT, n/N (%) Effect 95% CI, p-value
CARE-HF109 29.4 monthsa 33/409 (8.1) 56/404 (13.9) RR 0.58 0.39 to
0.87, 0.009
a37.4 months (with extension)111 38/409 (9.3) 64/404 (15.8) HR 0.55 0.37 to
0.82, 0.003
Per annum (%) 3.0 5.1
COMPANION119 CRT-P 16.5 months, OPT
14.8 monthsb
53/617 (8.6) 34/308 (11.0) HR 0.71 0.46 to
1.09, 0.112
% of deaths 40.5 44.2
CRT-D,
n/N (%) OPT, n/N (%)
CRT-D 16.0 months, OPT
14.8 monthsb
52/595 (8.7) 34/308 (11.0) HR 0.73 0.47 to
1.11, 0.143
% of deaths 49.5 44.2
CRT-P,
n/N (%)
CRT-D,
n/N (%)
CRT-P 16.5 months, CRT-D
16.0 monthsb
53/617 (8.6) 52/595 (8.7) RR
0.98c
0.68 to
1.42, 0.93c
% of deaths 40.5 49.5
a Mean.
b Median.
c Calculated by reviewer.
Study or subgroup Events Total Events Total Weight
CRT-P OPT RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
CARE-HF36,109–115
COMPANION116–120
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.99, df = 1 ( p = 0.32); I 2 = 0%
Test for overall effect: z = 2.85 ( p = 0.004)
38
53
91
409
617
1026
64
34
98
404
308
712
54.0%
46.0%
100.0%
0.59 (0.40 to 0.86)
0.78 (0.52 to 1.17)
0.67 (0.51 to 0.88)
0.01 0.1 1 10 100
CRT-P OPT
FIGURE 11 Heart failure deaths: CRT-P vs. OPT.
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for those receiving OPT. The study also reported the proportion of deaths classified as SCD as 36.6% for
those receiving CRT-P and 23.4% for those receiving OPT (Table 37).
Meta-analysis of the three trials found evidence of substantial statistical heterogeneity between the studies
(χ2= 7.22, df= 2, I2= 72%). Differences in the rates of SCD between CRT-P and OPT were not statistically
significant, with a random-effects RR of 0.97 (95% CI 0.44 to 2.14, p= 0.94) (Figure 12).
TABLE 37 Sudden cardiac death
Study Follow-up CRT-P, n/N (%) OPT, n/N (%) Effect 95% CI, p-value
CARE-HF109 29.4 monthsa 29/409 (7.1) 38/404 (9.4) RR 0.75b 0.47 to 1.20, 0.23b
a37.4 months111 32/409 (7.8) 54/404 (13.4) HR 0.54 0.35 to 0.84, 0.005
Per annum (%) 2.5 4.3
MUSTIC125 6 months First crossover:
1/29 (3.4b),
second crossover:
1/29 (3.4b)
First crossover:
0/29 (0),
second crossover:
0/29 (0)
RR 5.00b 0.25 to 99.82, 0.29b
COMPANION119 CRT-P 16.5 months,
OPT 14.8 monthsc
48/617 (7.8) 18/308 (5.8) HR 1.21 0.70 to 2.07, 0.485
% of deaths 36.6 23.4
CRT-D, n/N (%) OPT, n/N (%)
CRT-D 16.0 months,
OPT 14.8 monthsc
17/595 (2.9) 18/308 (5.8) HR 0.44 0.23 to 0.86, 0.020
% of deaths 16.2 23.4
CRT-P, n/N (%) CRT-D, n/N (%)
CRT-P 16.5 months,
CTR-D 16.0 monthsc
48/617 (7.8) 17/595 (2.9) RR 2.72b 1.58 to 4.68, 0.0003b
% of deaths 36.6 16.2
a Mean.
b Calculated by reviewer.
c Median.
Study or subgroup Events Total Events Total Weight
CRT-P OPT RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
CARE-HF36,109–115
COMPANION116–120
MUSTIC125
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.29; χ2 = 7.22, df = 2 ( p = 0.03); I 2 = 72%
Test for overall effect: z = 0.08 ( p = 0.94)
32
48
2
82
409
617
58
1084
54
18
0
72
404
308
58
770
48.7%
45.1%
6.2%
100.0%
0.59 (0.39 to 0.89)
1.33 (0.79 to 2.25)
5.00 (0.25 to 101.93)
0.97 (0.44 to 2.14)
0.01 0.1 1 10 100
CRT-P OPT
FIGURE 12 Sudden cardiac death: CRT-P vs. OPT.
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The FDA report123 associated with the MIRACLE trial reported the numbers of SCDs in each arm at
9 months’ follow-up (CRT-P n= 7, OPT n= 5) (the main publication121 reported outcomes at 6 months);
however, the numbers in each arm were not reported and the total sample size in the FDA report
(n= 536) differed from the number randomised in the main publication (n= 453).121 If the sample size in
each arm is assumed to be the same as the main publication, the RR for the trial is 1.38 (95% CI 0.45 to
4.29). Combining these data with the CARE-HF, COMPANION and MUSTIC data in a meta-analysis gives
an overall RR of 1.02 (95% CI 0.54 to 1.94).
CRT-D compared with optimal pharmacological therapy
The COMPANION trial119 found the rate of SCD to be statistically significantly lower in the group receiving
CRT-D than in the group receiving OPT (2.9% vs. 5.8% respectively), with a HR of 0.44 (95% CI 0.23 to
0.86, p= 0.020) at 16.0 months’ follow-up for those receiving CRT-D and 14.8 months’ follow-up for
those receiving OPT.
CRT-P compared with CRT-D
In the COMPANION trial119 the rate of SCD was statistically significantly higher in the group receiving
CRT-P than in the group receiving CRT-D (7.8% vs. 2.9% respectively; RR 2.72, 95% CI 1.58 to 4.68,
p= 0.0003). However, all comparisons between CRT-P and CRT-D should be treated with caution as the
trial was not powered for this comparison.
Other causes of death
The COMPANION trial119 found no statistically significant difference in the number of non-cardiac deaths
between those receiving CRT-P and those receiving OPT (p= 0.122) or between those receiving CRT-D and
those receiving OPT (p= 0.717). The numbers of vascular, non-cardiac and unknown deaths appear to be
similar between those receiving CRT-P and those receiving CRT-D (Table 38).
Hospitalisations because of heart failure
All four trials reported hospitalisations because of HF. Additional hospitalisation outcomes reported by the
trials, including cardiac and non-cardiac hospitalisations, are summarised in Appendix 6.
Number of people hospitalised because of heart failure
CRT-P compared with optimal pharmacological therapy The CARE-HF trial109 found that fewer people
were hospitalised because of HF in the CRT-P group (CRT-P 17.9% vs. OPT 32.9%; HR 0.48, 95% CI 0.36
to 0.64, p< 0.001) at 29.4 months’ mean follow-up. Similar results were found in the MIRACLE trial121 at
6 months’ follow-up (CRT-P 7.9% vs. OPT 15.1%, HR 0.50, 95% CI 0.28 to 0.88, p= 0.02) and in the
COMPANION trial116 at 16.2 months’ follow-up for CRT-P and 11.9 months’ follow-up for OPT (CRT-P
29% vs. OPT 36%, RR 0.80, 95% CI 0.66 to 0.97, p= 0.02) (Table 39). In the MUSTIC trial,125
hospitalisations related to decompensated HF were lower in the group receiving CRT-P (CRT-P 10.3% vs.
OPT 31.0%), but this failed to reach statistical significance (RR 0.33, 95% CI 0.10 to 1.11, p< 0.07).
The trials were combined in meta-analysis; however, the MUSTIC trial125 reported data for the first
crossover period only. There was evidence of substantial statistical heterogeneity between the studies
(χ2= 8.50, df= 3, I2= 65%), but the direction of effect is consistent. The RR of hospitalisation because of
HF for CRT-P compared with OPT was 0.61 (95% CI 0.44 to 0.83, p= 0.002), giving a RRR for
hospitalisation related to HF with CRT-P of 39% (Figure 13).
CRT-D compared with optimal pharmacological therapy In the COMPANION trial119 there were
significantly fewer people admitted to hospital with HF in the CRT-D group than in the OPT group
(28% vs. 36% respectively), with a RR of 0.77 (95% CI 0.63 to 0.93, p= 0.008) at a median follow-up
of 15.7 months for those receiving CTR-D and 11.9 months for those receiving OPT.
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TABLE 38 Other causes of death
Study Outcome and follow-up
CRT-P,
n/N (%)
OPT,
n/N (%) Effect
95% CI,
p-value
COMPANION119 Vascular deaths, CRT-P 16.5 months,
OPT 14.8 monthsa
5/617 (0.8) 0
% of deaths 3.8
Non-cardiac deaths 14/617 (2.3) 11/308 (3.6) 0.122
% of deaths 10.7 14.3
Unknown deaths 3/617 (0.5) 8/308 (2.6)
% of deaths 2.3 10.4
CRT-D,
n/N (%) OPT, n/N (%)
Vascular deaths, CRT-D 16.0,
OPT 14.8 monthsa
3/595 (0.5) 0
% of deaths 2.8
Non-cardiac deaths 21/595 (3.5) 11/308 (3.6) 0.717
% of deaths 10.7 14.3
Unknown deaths 5/595 (0.8) 8/308 (2.6)
% of deaths 4.8 10.4
a Median.
TABLE 39 Hospitalisations related to HF
Study Outcome and follow-up
CRT-P,
n/N (%)
OPT,
n/N (%) Effect
95% CI,
p-value
CARE-HF109 Unplanned hospitalisation with
worsening HF, 29.4 monthsa
72/409 (17.6) 133/404 (32.9) HR 0.48 0.36 to 0.64,
< 0.001
MIRACLE121 Hospitalisation for worsening HF,
6 months
18/228 (7.9) 34/225 (15.1) HR 0.50 0.28 to 0.88,
0.02
MUSTIC125 Hospital admission because of
decompensated HF, 3 monthsb
3/29 (10.3) 9/29 (31.0) RR 0.33c 0.10 to 1.11,
0.07c,d
COMPANION116 Hospitalised one or more times with HF,
CRT-P 16.2 months, OPT 11.9 monthse
179/617 (29) 112/308 (36) RR 0.80c 0.66 to 0.97,
0.02c
CRT-D,
n/N (%) OPT, n/N (%)
Hospitalised one or more times with HF,
CRT-D 15.7 months, OPT 11.9 monthse
166/595 (28) 112/308 (36) RR 0.77c 0.63 to 0.93,
0.008c
a Mean.
b Data reported for first crossover period only.
c Calculated by the reviewer.
d Analyses reported by paper, p< 0.05.125
e Median.
Note: The COMPANION trial116 states that no significant differences were found for any of the end points between CRT-P
and CRT-D (no p-values reported).
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CRT-P compared with CRT-D The COMPANION trial report116 states that no significant differences were
found in any of the end points between those receiving CRT-P and those receiving CRT-D. In addition, the
proportions of people hospitalised at least once with HF were similar in the two groups (28% vs.
29% respectively).
Number of hospitalisation events for heart failure
The CARE-HF,109 COMPANION120 and MIRACLE121 trials reported the number of hospitalisation events
and/or number of days hospitalised because of HF. The CARE-HF trial109 reported the number of
unplanned hospitalisations of patients because of worsening HF. The COMPANION trial120 reported the
number of admissions, the percentage of total admissions and the average number of days hospitalised
per patient year of follow-up, whereas the MIRACLE trial121 reported the total number of days hospitalised
because of HF (Table 40).
Study or subgroup Events Total Events Total Weight
CRT-P OPT RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
CARE-HF36,109–115
COMPANION116–120
MIRACLE121–124
MUSTIC125
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.06; χ2 = 8.50, df = 3 ( p = 0.04); I 2 = 65%
Test for overall effect: z = 3.14 ( p = 0.002)
72
179
18
3
272
409
617
228
29
1283
133
112
34
9
288
404
308
225
29
966
35.5%
39.2%
19.4%
5.9%
100.0%
0.53 (0.42 to 0.69)
0.80 (0.66 to 0.97)
0.52 (0.30 to 0.90)
0.33 (0.10 to 1.11)
0.61 (0.44 to 0.83)
0.01 0.1 1 10 100
CRT-P OPT
FIGURE 13 Hospitalisations related to HF: CRT-P vs. OPT.
TABLE 40 Hospitalisations related to HF: number of events and/or days of admission
Study Outcome and follow-up CRT-P OPT Effect
95% CI,
p-value
CARE-HF109 Hospitalisation events, 29.4 monthsa 122 252
MIRACLE121 Total no. of days hospitalised, 6 months 83 363
No. of hospitalisations 25 50
COMPANION120 CRT-P 16.2 months, OPT 11.9 monthsb
No. of admissions (% of total admissions) 329 (33) 235 (46)
Average no. of admissions per patient year of follow-up 0.41 0.73
Average days per patient year of follow-up (average
length of stay per admission)
3.6 (8.6) 5.9 (8.2)
CRT-D OPT
CRT-D 15.7 months, OPT 11.9 monthsb
No. of admissions (% of total admissions) 333 (36) 235 (46)
Average no. of admissions per patient year of follow-up 0.43 0.73
Average days per patient year of follow-up (average
length of stay per admission)
3.8 (8.8) 5.9 (8.2)
a Mean.
b Median.
Note: The COMPANION trial116 reports that no significant differences were found in any of the hospitalisation end points
between the CRT-P group and the CRT-D group (no p-values reported).
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CRT-P compared with optimal pharmacological therapy In the CARE-HF trial,109 the 72 participants in
the CRT-P group (n= 409) who were hospitalised with worsening HF had a total of 122 hospitalisations,
compared with a total of 252 hospitalisations for 133 patients in the OPT group (n= 404). In the
COMPANION trial,120 33% of the total admissions were due to HF among patients receiving CRT-P
compared with 46% of the total admissions among patients receiving OPT, at a median 16.2 months’
follow-up for those with CRT-P and median 11.9 months’ follow-up for those with OPT. The average
number of admissions per patient year of follow-up was also lower in the group receiving CRT-P (CRT-P
0.41 vs. OPT 0.73). The average length of stay per admission was similar between the treatment groups
(CRT-P 8.6 days vs. OPT 8.2 days). Similarly, the MIRACLE trial121 found that the total number of days
hospitalised because of HF was lower in the CRT-P group than in the OPT group at 6 months’ follow-up
(83 days vs. 363 days respectively), but no statistical comparison was reported. However, hospitalisation
occurred twice as often in those receiving OPT (OPT 50 events vs. CRT-P 25 events) (see Table 40).
The rate of events was calculated for each trial (no. of events/N × follow-up) and combined in a
meta-analysis using the inverse variance method. Although statistical heterogeneity was present
(χ2= 28.27, df= 3, I2= 89%), the direction of the effect was fairly consistent (Figure 14). A significant
reduction in the rate of HF hospitalisations was found in the CRT-P group (RR 0.58, 95% CI 0.35 to
0.96, p= 0.03).
CRT-D compared with optimal pharmacological therapy In the COMPANION trial120 the proportion of
admissions that were related to HF was lower in the CRT-D group (CRT-P 36% vs. OPT 46%), at a median
of 15.7 months’ follow-up for those receiving CRT-P and 11.9 months’ follow-up for those receiving OPT.
The average number of admissions per patient year of follow-up was lower in those receiving CRT-D
(CRT-D 0.43 vs. OPT 0.73). The average length of stay per admission was similar in both treatment groups
(CRT-D 8.8 days vs. OPT 8.2 days) (see Table 40).
CRT-P compared with CRT-D The COMPANION trial120 found that there were no significant differences
between those receiving CRT-P and those receiving CRT-D for any of the hospitalisation end points; in
addition, the proportion of admissions that were related to HF was similar between the groups (33% vs.
36% respectively). This was reflected in both the average number of admissions per patient year of
follow-up (CRT-P 0.41 vs. CRT-D 0.43) and the average length of stay per admission (CRT-P 8.6 days vs.
8.8 CRT-D days) (see Table 40).
Study or subgroup
CARE-HF36,109–115
COMPANION116–120
MIRACLE121–124
MUSTIC125
Total (95% CI)
Heterogeneity: τ2 = 0.19; χ2 = 28.27, df = 3 ( p < 0.00001); I 2 = 89%
Test for overall effect: z = 2.13 ( p = 0.03)
log(RR)
– 0.738
– 0.0498
– 0.706
– 1.099
SE
0.11
0.085
0.245
0.667
Weight
31.7%
32.4%
25.7%
10.2%
100.0%
0.48 (0.39 to 0.59)
0.95 (0.81 to 1.12)
0.49 (0.31 to 0.80)
0.33 (0.09 to 1.23)
0.58 (0.35 to 0.96)
RR, IV,
random (95% CI)
RR, IV,
random (95% CI)
0.1 0.2 0.5 1 2 5 10
Favours CRT-P Favours OPT
FIGURE 14 Number of hospitalisations because of HF: CRT-P vs. OPT.
CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
Arrhythmias
The CARE-HF trial109 reported atrial arrhythmias or ectopy whereas the MUSTIC trial125 reported
decompensation due to persistent atrial fibrillation. Because of the different outcome measures used in the
two trials, data were not pooled. No comparisons between CRT-D and OPT or between CRT-P and CRT-D
were reported.
CRT-P compared with optimal pharmacological therapy
In the CARE-HF trial,109 the risk of arrhythmias or ectopy was significantly higher in the CRT-P group
than in the OPT group (15.6% vs. 10.1% respectively; RR 1.54, 95% CI 1.07 to 2.23, p= 0.02). One case
of decompensation due to persistent atrial fibrillation occurred in the OPT treatment group during the first
crossover period of the MUSTIC trial125 (RR 0.33, 95% CI 0.01 to 8.02, p= 0.50) (Table 41).
Worsening heart failure
Three of the trials reported data on worsening HF (not defined by NYHA class), but outcome
definitions differed.
CRT-P compared with optimal pharmacological therapy
In the CARE-HF trial,109 fewer people receiving CRT-P experienced worsening HF than those receiving OPT
(CRT-P 46.7% vs. OPT 64.9%; RR 0.72, 95% CI 0.63 to 0.82, p< 0.001) (Table 42). In the MIRACLE trial,121
there were fewer people with HF requiring intravenous diuretics (CRT-P 5.7% vs. OPT 10.7%; HR 0.51,
95% CI 0.26 to 1.00, p= 0.05), vasodilators or positive inotropic agents (CRT-P 2.6% vs. OPT 6.2%; HR
0.41, 95% CI 0.16 to 1.08, p= 0.06) or medication for HF (CRT-P 7.0% vs. OPT 15.6%; HR 0.43, 95% CI
0.24 to 0.77, p= 0.004) in the CRT-P group than in the OPT group (see Table 42). The MUSTIC trial125
reported one case of severe decompensation in the CRT-P off group, leading to a premature switch to
active pacing (RR 0.33, 95% CI 0.01 to 8.02, p= 0.50). Despite the different definitions used by the trials,
the risk of worsening HF was reduced with CRT-P when the trials were combined in a meta-analysis
(RR 0.71, 95% CI 0.63 to 0.80, p< 0.00001) (Figure 15). No significant statistical heterogeneity
was observed.
Change in New York Heart Association class
The CARE-HF,109 COMPANION116 and MIRACLE121 trials reported improvement in NYHA class. The
three trials included people in NYHA classes III and IV at baseline. The CARE-HF trial109 reported NYHA
class at 18 months and mean NYHA class at 90 days; the MIRACLE trial121 reported improvements in
NYHA class at 6 months; and the COMPANION trial116 reported NYHA class at 3 and 6 months. NYHA
class was one of three reported primary end points in the MIRACLE trial.121
TABLE 41 Arrhythmias
Study Outcome and follow-up CRT-P, n/N (%) OPT, n/N (%) Effect 95% CI, p-value
CARE-HF109 Atrial arrhythmias or
ectopy, 29.4 monthsa
64/409 (15.6) 41/404 (10.1) RR 1.54b 1.07 to 2.23, 0.02b
MUSTIC125 Decompensation due to
persistent atrial fibrillation,
6 months
First period: 0/29,
second period: 0/29
First period: 1/29 (3.4),
second period: 0/29
RR 0.33b 0.01 to 8.02, 0.50b
a Mean.
b Calculated by reviewer.
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CRT-P compared with optimal pharmacological therapy
All three trials reported a statistically significant greater proportion of participants with improvement in
NYHA class with CRT-P than with OPT (Table 43). The CARE-HF trial109 also reported an improvement
in mean NYHA class with CRT-P [CRT-P 2.1 (SD 1.0) vs. OPT 2.7 (SD 0.9), p< 0.001]. There was no
evidence of statistical heterogeneity between the studies when the data were pooled in a random-effects
meta-analysis (χ2= 70, df= 2, I2= 0%) (Figure 16). The pooled data from all three trials showed an
increase in the proportion of people with an improvement of one or more NYHA class in the CRT-P group
compared with the OPT group (RR 1.68, 95% CI 1.52 to 1.86, p< 0.00001).
CRT-D compared with optimal pharmacological therapy
In the COMPANION trial,116 the proportion of people with an improvement in NYHA class was statistically
significantly greater in the CRT-D group than in the OPT group at both 3 months (CRT-D 55% vs. OPT
24%, p< 0.001) and 6 months (CRT-D 57% vs. OPT 38%, p< 0.001) (see Table 43).
CRT-P compared with CRT-D
In the COMPANION trial116 the proportion of people with an improvement in NYHA class was similar
between the CRT-P group and the CRT-D group at both 3 months (58% vs. 55% respectively) and
6 months (61% vs. 57% respectively; RR 0.93, 95% CI 0.84 to 1.04, p= 0.20) (see Table 43). However,
this comparison should be treated with caution as the trial was not powered for this comparison.
Study or subgroup Events Total Events Total Weight
CRT-P OPT RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
CARE-HF36,109–115
MIRACLE121–124
MUSTIC125
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.03, df = 2 ( p = 0.60); I 2 = 0%
Test for overall effect: z = 5.42 ( p < 0.00001)
191
13
0
204
409
228
58
695
263
24
1
288
405
225
58
688
96.2%
3.6%
0.2%
100.0%
0.72 (0.63 to 0.82)
0.53 (0.28 to 1.02)
0.33 (0.01 to 8.02)
0.71 (0.63 to 0.80)
0.05 0.2 1 5 20
CRT-P OPT
FIGURE 15 Worsening HF: CRT-P vs. OPT.
TABLE 42 Worsening HF
Study Outcome and follow-up CRT-P, n/N (%) OPT, n/N (%) Effect
95% CI,
p-value
CARE-HF109 Worsening HF, 29.4 monthsa 191/409 (46.7) 263/405 (64.9) RR 0.72b 0.63 to 0.82,b
< 0.001
MIRACLE121 HF requiring intravenous
medication, 6 months
Diuretic agents 13/228 (5.7) 24/225 (10.7) HR 0.51 0.26 to
1.00, 0.05
Vasodilators or positive
inotropic agents
6/228 (2.6) 14/225 (6.2) HR 0.41 0.16 to
1.08, 0.06
Medication for HF 16/228 (7.0) 35/225 (15.6) HR 0.43 0.24 to
0.77, 0.004
MUSTIC125 Severe decompensation,
6 months
First period: 0/29 (0),
second period: 0/29 (0)
First period: 1/29 (3.4),
second period: 0/29 (0)
RR 0.33b 0.01 to
8.02, 0.50b
a Mean.
b Calculated by reviewer.
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TABLE 43 Changes in NYHA class
Study
Outcome and
follow-up CRT-P, n/N (%) OPT, n/N (%) Effect 95% CI, p-value
CARE-HF109 NYHA class, 18 months
Class I 105/409 (25.7) 39/404 (9.7) RR 1.67a,b 1.44 to 1.93,
< 0.00001a,b
Class II 150/409 (36.7) 112/404 (27.7)
Class III or IV 80/409 (19.6) 152/404 (37.6)
NYHA class at 90 days,
mean (SD)
2.1 (1.0) 2.7 (0.9) MD 0.6 0.4 to 0.7,
< 0.001
MIRACLE121 6 months
Improved by two or
more classes
34/211 (16) 12/196 (6) RR 1.80b 1.47 to 2.20,
< 0.00001b
Improved by one class 109/211 (52) 62/196 (32)
No change 64/211 (30) 115/196 (59)
Worsened 4/211 (2) 7/196 (4)
COMPANION116 Improvement in NYHA class symptoms
3 months 320c/551 (58) 58c/242 (24) < 0.001
6 months 298c/489 (61) 76b/199 (38) RR 1.60b 1.32 to 1.93,
< 0.00001b,d
CRT-D OPT
3 months 299c/543 (55) 58c/242 (24) < 0.001
6 months 283c/497 (57) 76c/199 (38) RR 2.14b 2.14 to 1.53,
< 0.00001b,d
CRT-P CRT-D
3 months 320c/551 (58) 299c/543 (55)
6 months 298c/489 (61) 283c/497 (57) RR 0.93b 0.84 to 1.04, 0.20b
MD, mean difference.
a RR, 95% CI and p-value for classes I and II combined.
b Calculated by reviewer.
c Numerators calculated by reviewer.
d Analysis reported in paper: p< 0.001.116
Study or subgroup Events Total Events Total Weight
CRT-P OPT RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
CARE-HF36,109–115
COMPANION116–120
MIRACLE121–124
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.70, df = 2 ( p = 0.70); I 2 = 0%
Test for overall effect: z = 10.05 ( p < 0.00001)
255
298
143
696
409
489
211
1109
151
76
74
301
404
199
196
799
47.1%
28.1%
24.8%
100.0%
1.67 (1.44 to 1.93)
1.60 (1.32 to 1.93)
1.80 (1.47 to 2.20)
1.68 (1.52 to 1.86)
0.2 0.5 1 2 5
OPT CRT-P
FIGURE 16 Participants with improvement by one or more NYHA class: CRT-P vs. OPT.
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Change in left ventricular ejaculation fraction
Only one trial reported LVEF. The MIRACLE trial121 reported absolute change in median LVEF at 6 months
for those receiving CRT-P and those receiving OPT. No comparisons between CRT-D and OPT or between
CRT-P and CRT-D were reported.
CRT-P compared with optimal pharmacological therapy
The MIRACLE trial121 reported an improvement in median LVEF with CRT-P (+4.6, 95% CI 3.2 to 6.4), but
LVEF decreased with OPT (–0.2, 95% CI –1.0 to 1.5). The difference between the two changes was
statistically significant at 6 months’ follow-up (p< 0.001).
Exercise capacity
The COMPANION trial116 reported the mean increase in 6-minute walk distance at 3 and 6 months,
whereas the MIRACLE trial121 reported the median change from baseline in 6-minute walk distance
and median change in total exercise time. Change in 6-minute walk distance was one of three primary
end points in this trial. The MUSTIC trial125 reported mean distance walked in 6 minutes at 3 months
(Table 44). The CARE-HF trial109 did not report 6-minute walk distance. Only two trials reported change in
peak oxygen consumption. The MIRACLE trial121 reported the median change in oxygen consumption (VO2)
and the MUSTIC trial125 reported mean VO2 (Table 45). No comparisons between CRT-D and OPT or
between CRT-P and CRT-D were reported.
CRT-P compared with optimal pharmacological therapy
In all three trials, the distance walked in 6 minutes was statistically significantly greater for the CRT-P group
than the OPT group (see Table 44). In the MIRACLE trial,121 the CRT-P group also had a superior outcome
for change in total exercise time (CRT-P 81 seconds vs. OPT 19 seconds, p= 0.001).
The trials were combined in a meta-analysis. For meta-analysis of the MUSTIC crossover trial,125 data were
combined from both periods. This method provides a conservative analysis, with the study being
underweighted rather than overweighted.65 Trials reporting change values and final values were included
in separate subgroups. There was some evidence of statistical heterogeneity between the studies with the
inclusion of the MUSTIC trial125 (χ2= 2.93, df= 2, I2= 32%). The improvement in distance walked in
6 minutes was statistically significantly greater for those receiving CRT-P than for those receiving OPT
[mean difference (MD) 38.14, 95% CI 21.74 to 54.54, p< 0.00001] (Figure 17).
The MIRACLE trial121 reported statistically significantly greater improvements in VO2 with CRT-P than with
OPT (+1.1 units vs. +0.2 units respectively, p= 0.009). In the MUSTIC trial,125 the authors combined the
data from both crossover periods for the statistical analysis, which demonstrated a significantly greater VO2
in those receiving CRT-P (CRT-P 16.2 units vs. OPT 15 units, p= 0.029).
CRT-D compared with optimal pharmacological therapy
In the COMPANION trial,116 the improvement in 6-minute walk distance was statistically significantly
greater with CRT-D than with OPT at 3 months (44m vs. 9m respectively, p< 0.001) and 6 months
(46m vs. 1m respectively, p< 0.001).
CRT-D compared with CRT-P
There were no statistically significant differences in 6-minute walk distance between those receiving CRT-D
and those receiving CRT-P (MD –6.0, 95% CI –19.87 to 7.87, p= 0.40). However, all comparisons
between CRT-P and CRT-D should be treated with caution, as the trial was not powered for
this comparison.
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TABLE 44 Change in 6-minute walk distance
Study Outcome and follow-up CRT-P OPT Effect
95% CI,
p-value
MIRACLE121 6 months
Change in 6-minute walk
distance (m), median (95% CI, SD)
+39 (26 to 54,
103.9a) (n= 214)
+10 (0 to 25,
89.2a) (n= 198)
0.005
Change in total exercise
time (seconds), median (95% CI)
+81 (62 to 119)
(n= 159)
+19 (–1 to 47)
(n= 146)
0.001
MUSTIC125 Distance walked in 6 minutes (m),
mean (SD)
Group 1 (CRT-P on, CTR-P off)
(n= 22)
384.1 (78.9) 336.1 (128.3)
Group 2 (CRT-P off, CRT-P on)
(n= 24)
412.9 (116.9) 316.2 (141.8)
Both groups (n= 46) 399.2 (100.5) 325.7 (134.4) < 0.001
COMPANION116 Change in 6-minute walk
distance (m), mean (SD)
3 months 33 (99) (n= 422) 9 (84) (n= 170) < 0.001
6 months 40 (96) (n= 373) 1 (93) (n= 142) < 0.001
CRT-D OPT
Change in 6-minute walk distance (m), mean (SD)
3 months 44 (109) (n= 420) 9 (84) (n= 170) < 0.001
6 months 46 (98) (n= 378) 1 (93) (n= 142) < 0.001
CRT-P CRT-D
Change in 6-minute walk, m, mean change (SD)
3 months 33 (99) (n= 422) 44 (109)
(n= 420)
6 months 40 (96) (n= 373) 46 (98)
(n= 378)
MD –6.0a –19.87 to
7.87, 0.40a
a Calculated by reviewer.
TABLE 45 Change in VO2
Study Outcome and follow-up CRT-P OPT Effect p-value
MIRACLE121 Change in VO2 (ml/kg/minute),
median (95% CI), 6 months
+1.1 (0.6 to 1.7)
(n= 158)
+0.2 (–0.2 to
0.8) (n= 145)
0.009
MUSTIC125 VO2 (ml/kg/minute), mean (SD),
3 months
Group 1 (CRT-P on,
CTR-P off) (n= 18)
15.9 (5.8) 15.3 (5.9)
Group 2 (CRT-P off,
CRT-P on) (n= 20)
16.4 (3.6) 14.8 (3.9)
Both groups (n= 38) 16.2 (4.7) 15 (4.9) 0.029
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Quality of life
All four studies reported change in QoL assessed using the MLWHFQ. Change in MLWHFQ score was
the primary outcome in the MUSTIC trial.125 The CARE-HF trial113 also reported EQ-5D scores, mean
quality-adjusted life-years (QALYs) and mean life-years (Table 46).
TABLE 46 Quality-of-life measures
Study
Outcome and
follow-up CRT-P OPT MD (95% CI), p-value
CARE-HF113 QALYs, mean
(95% CI)
(n= 409) (n= 404)
3 months 0.16 (0.15 to 0.16) 0.15 (0.14 to 0.15) 0.01 (0.001 to 0.018),
0.285
18 months 0.95 (0.91 to 0.99) 0.82 (0.78 to 0.86) 0.13 (0.07 to 0.018),
< 0.0001
End of study,
mean 37.4 months
1.45 (1.38 to 1.53) 1.22 (1.15 to 1.29) 0.23 (0.13 to 0.33),
< 0.0001
Life-years, mean (95% CI)
3 months 0.241 (0.238 to 0.244) 0.241 (0.238 to 0.244) 0.0003 (–0.004 to 0.0045),
0.90
18 months 1.37 (1.34 to 1.40) 1.33 (1.29 to 1.37) 0.04 (–0.01 to 0.09), 0.13
End of study,
mean 37.4 months
2.07 (1.99 to 2.15) 1.96 (1.88 to 2.05) 0.10 (–0.01 to 0.22), 0.07a
EQ-5D, mean (95% CI)
Baseline 0.60 (0.58 to 0.63) 0.60 (0.57 to 0.63) –
90 days109 0.70 (SD 28) 0.63 (SD 0.29) 0.08 (0.04 to 0.12),
0.001
3 months 0.69 (0.66 to 0.72) 0.61 (0.59 to 0.64) 0.08 (0.04 to 0.11),
< 0.0001
18 months 0.61 (0.58 to 0.64) 0.51 (0.48 to 0.54) 0.10 (0.06 to 0.15),
< 0.0001
End of study,
mean 37.4 months
0.56 (0.52 to 0.59) 0.43 (0.39 to 0.46) 0.13 (0.08 to 0.18),
< 0.0001b
MLWHFQ,c mean (95% CI)
Baseline 44.6 (42.5 to 46.7) 43.7 (41.5 to 45.8) –
90 days109 31 (SD 22) 40 (SD 22) –10 (–8 to –12),
< 0.001
3 months 30.1 (27.9 to 32.3) 38.9 (36.6 to 41.2) –10.6 (–8.1 to –13.1),
< 0.0001d
18 months 28.4 (26.2 to 30.5) 36.0 (33.5 to 38.5) –10.7 (–7.6 to –13.8),
< 0.0001d
End of study,
mean 37.4 months
27.2 (24.9–29.5)
(SD 23.7)
35.1 (32.6–37.6)
(SD 25.6)
–10.1 (–6.8 to –13.3),
< 0.0001d
continued
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TABLE 46 Quality-of-life measures (continued )
Study
Outcome and
follow-up CRT-P OPT MD (95% CI), p-value
MIRACLE121 Change in
MLWHFQ scorec
(n= 213) (n= 193)
6 months, median
(95% CI), SD
–18 (–22 to –12), 37 –9 (–12 to –5), 24.7 0.001
MUSTIC125 MLWHFQ score,c mean (SD)
Group 1 (CRT-P
on, CRT-P off)
(n= 23)
33.3 (22) 42.6 (20.9)
Group 2 (CRT-P
off, CRT-P on)
(n= 22)
25.7 (20.4) 44.0 (25)
Both groups
(n= 45)
29.6 (21.3) 43.2 (22.8) < 0.001
COMPANION116 MLWHFQ (% increase), mean (SD)
3 months –24 (27) (n= 510) –9 (21) (n= 243) < 0.001
6 months –25 (26) (n= 460) –12 (23) (n= 207) < 0.001
CRT-D OPT
3 months –24 (28) (n= 514) –9 (21) (n= 243) < 0.001
6 months –26 (28) (n= 478) –12 (23) (n= 207) < 0.001
CRT-P CRT-D
3 months –24 (27) (n= 510) –24 (28) (n= 514)
6 months –25 (26) (n= 460) –26 (28) (n= 478) 1.00 (2.46 to 4.46), 0.57e
a Calculated by reviewer.
b p-value based on restricted mean survival used to estimate QALYs. This is not the best estimator of survival differences
between groups (statistically inefficient); see instead section on all-cause mortality.
c MLWHFQ includes 21 questions rated on a 6-point scale (total score 105), with higher scores indicating poorer QoL.
d Decline in EQ-5D despite maintained effect on MLWHFQ is because death has a score of 0 on the EQ-5D and is not
included in the MLWHFQ.
e MLWHFQ scores include last value carried forward for missing items. Patients who died were not included. Difference
between groups accounts for baseline NYHA class and MLWHFQ score.
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CRT-P compared with optimal pharmacological therapy
All four trials showed statistically significant improvements in MLWHFQ scores in the CRT-P group
compared with the OPT group (lower scores indicate better QoL). The trials were combined in a
meta-analysis. The COMPANION trial116 and the MIRACLE trial121 reported mean change in MLWHFQ
score from baseline whereas the CARE-HF trial113 and the MUSTIC trial125 reported final mean values.
The MUSTIC trial125 reported data per crossover period and combined data for both crossover
periods (Figure 18).
For meta-analysis of the MUSTIC crossover trial,125 the combined data from both crossover periods were
included, as this method provides a conservative analysis, with the study being underweighted rather than
overweighted.65 There was some evidence of statistical heterogeneity between the studies (χ2= 4.39,
df= 3, I2= 32%), but the direction of effect was consistent. The MD was –10.33 (95% CI –13.31 to –7.36)
and MLWHFQ scores were statistically significantly lower in the CRT-P group than in the OPT group
(p= 0.00001), indicating improved QoL.
Other QoL measures with statistically significant improvements in the CARE-HF trial113 were the EQ-5D and
QALYs. The mean value of the EQ-5D was statistically significantly higher in the CRT-P group at each
follow-up (90 days: CRT-P 0.70 vs. OPT 0.63, p< 0.001; 3 months: CRT-P 0.69 vs. OPT 0.61, p< 0.0001;
18 months: CRT-P 0.61 vs. OPT 0.51, p< 0.0001; end of study CRT-P 0.56 vs. OPT 0.43, p< 0.0001),
although scores appeared to be lower by the end of the study (37.4 months) than at baseline in both
treatment arms. The mean QALYs were statistically significantly higher in the CRT-P group at 18 months
(CRT-P 0.95 vs. OPT 0.82, p< 0.0001) and at the end of the study (CRT-P 1.45 vs. OPT 1.22, p< 0.0001).
CRT-D compared with optimal pharmacological therapy
The reduction in MLWHFQ score, indicating improved QoL, in the COMPANION trial116 was statistically
significantly greater in the CRT-D group at both 3 months (CRT-D –24 vs. OPT –9, p< 0.001) and
6 months (CRT-D –26 vs. OPT –12, p< 0.001).
CRT-P compared with CRT-D
In the COMPANION trial,116 improvements in MLWHFQ scores were similar in the CRT-P group and the
CRT-D group at 6 months (–25 vs. –26 respectively, MD 1.00, 95% CI –2.46 to 4.46, p= 0.57).
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Adverse events
Reporting of adverse events was limited, as can be seen in Tables 47 and 48. All participants in the
MIRACLE trial121 and the MUSTIC trial125 were implanted with a CRT-P device, with pacing inactive in the
control (OPT) group. Both trials randomised only those people who had a successful implantation,
although the MIRACLE trial121 also reported adverse events for all enrolled participants (including 71
participants who were part of a pilot phase and not included in the effectiveness results) (see Table 47).
TABLE 47 Adverse events in participants with a CRT device (randomised to CRT-P on or off)
Study Adverse events
CRT device,
n/N (%)
MIRACLE121 (enrolled n= 571; successfully
implanted n= 528; randomised n= 453:
CRT-P n= 228, OPT n= 225)
All participants undergoing implantation (n= 571)
Unsuccessful implantation 43/571 (7.5)
Complete heart block requiring permanent
cardiac pacing
2/571 (0.4)
Death from clinical events during implant
procedure (progressive hypotension; asytole)
2/571 (0.4)
Coronary sinus dissection 23/571 (4.0)
Cardiac vein or coronary sinus perforationa 12/571 (2.1)
Participants who had successful implantation (n= 528)
Left ventricular lead repositioned 20/528 (3.8)
Left ventricular lead replaced 10/528 (1.9)
Pacemaker-related infection requiring explantation 7/528 (1.3)
Hospitalised for repositioning/replacement of left
ventricular lead
CRT-P on 11/228 (4.8)
CRT-P off 3/225 (1.3)
MUSTIC125 (enrolled n= 67; randomised n= 58:
CRT-P on, CRT-P off n= 29; CRT-P off,
CRT-P on n= 29)
Unsuccessful implantation 5/64 (7.8)
Early lead dislodgement 8/58 (13.8)
CRT-P on
Uncorrectable loss of left ventricular
pacing efficacy
2/58 (3.4)
Decompensation attributed to rapidly
progressive aortic stenosis
1/58 (1.7)
CRT-P off
Severe decompensating leading to a
premature switch to active pacing
1/58 (1.7)
Decompensation due to persistent atrial fibrillation 1/58 (1.7)
a Three of these participants recovered and continued in the study.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105
TABLE 48 Adverse events in participants randomised to CRT-P or OPT (no device)
Study Adverse events
CRT-P,
n/N (%)
OPT,
n/N (%)
RR (95% CI),
p-value
CARE-HF109
[enrolled and randomised
n= 813: CRT-P n= 409,
OPT n= 404 (CRT-P off)]
Unsuccessful implantation 19/409 (4.6)
Device-related death
HF aggravated by
lead displacement
1/409 (0.2)
Septicaemia after
receiving a device
1/404 (0.2)
Most common
adverse device- or
procedure-related events
Lead displacement 24/409 (5.9)
Coronary sinus dissection 10/409 (2.4)
Pocket erosion 8/409 (2.0)
Pneumothorax 6/409 (1.5)
Device-related infection 3/409 (0.7)
COMPANION116
(enrolled and randomised
n= 1520: CRT-P n= 617,
CRT-D n= 595,
OPT n= 308)
Unsuccessful implantation 78/617 (12.6)
Deaths from procedural
complications
5/615 (0.8)
Mortality rate 30 days
after randomisation
6b/617 (1.0) 4b/308 (1.3) 0.34
Moderate or severe
adverse event from
any cause
407b/617 (66) 188b/308 (61) 0.15
Moderate or severe
adverse event related to
implantation procedure
62b/617 (10)
Coronary
venous dissection
2b/617 (0.3)
Coronary
venous perforation
7b/617 (1.1)
Coronary
venous tamponade
3b/617 (0.5)
CRT-D,
n/N (%) OPT, n/N (%)
Unsuccessful implantation 54/595 (9.1)
Deaths from procedural
complications
3/595 (0.5)
Mortality rate 30 days
after randomisation
11b/595 (1.8) 4/308 (1.3) 0.97
Moderate or severe adverse
event from any cause
411b/595 (69) 188/308 (61) 0.03
Moderate or severe
adverse event related to
implantation procedure
48b/595 (8)
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The CARE-HF109 and COMPANION116 trials randomised participants to receive either a CRT-P (or CRT-D)
device or OPT only (see Table 48). However, the CARE-HF109 trial limited reporting of adverse events
to device-related complications. Only the COMPANION trial116 reported any statistical comparison between
CRT-P or CRT-D and OPT for adverse events.
Between 4.6%109 and 12.6%116 of device implantations were unsuccessful in the trials (see Tables 47 and
48). Death from adverse clinical events during the implantation procedure occurred among 0.4% of all
participants in the MIRACLE trial,121 whereas in the COMPANION trial116 0.8% of CRT-P recipients and
0.5% of CRT-D recipients died from procedural complications. The mortality rate 30 days after
randomisation was not statistically significantly different between the OPT group (1.2%), the CRT-P group
(1.0%, p= 0.34) and the CRT-D group (1.8%, p= 0.97),116 or between CRT-P and CRT-D (RR 0.53,
95% CI 0.20 to 4.41, p= 0.2). Device-related deaths occurred among 0.2% of participants randomised to
CRT-P in the CARE-HF trial109 and among 0.2% of those randomised to OPT (after receiving a device),
although the time period was not reported.
Moderate or severe adverse events related to the implantation procedure occurred in 10% of the CRT-P
group and 8% of the CRT-D group in the COMPANION trial.116 The most commonly reported adverse
events were coronary sinus/venous dissection (0.3% CRT-P, 0.5% CRT-D;116 4.0%;121 2.4%109) or
perforation (1.1% CRT-P, 0.8% CRT-D;116 2.1%121) and lead-related events (6%;109,121 13.8%125). In the
MIRACLE trial,121 hospitalisation for repositioning or replacement of the left ventricular lead was more
frequent in those in the CRT-P on group (4.8%) than those in the CRT-P off group (1.3%).
In the COMPANION trial,116 the proportion of moderate or severe adverse events from any cause was
statistically significantly higher in the CRT-D group than in the OPT group (69% vs. 61% respectively,
p= 0.03), but there was no statistically significant difference between the CRT-P group and the OPT group
(66% vs. 61% respectively, p= 0.15) or between the CRT-P group and the CRT-D group (RR 0.95,
95% CI 0.88 to 1.03, p= 0.25). The CARE-HF trial109 reported that the frequency of respiratory tract
infections, hypotension, falls or syncope, acute coronary syndromes, renal dysfunction, ventricular
arrhythmias or ectopy, and neurological events was similar in the CRT-P and OPT only groups.
TABLE 48 Adverse events in participants randomised to CRT-P or OPT (no device) (continued )
Study Adverse events
CRT-P,
n/N (%)
OPT,
n/N (%)
RR (95% CI),
p-value
Coronary venous
dissection
3b/595 (0.5)
Coronary venous
perforation
5b/595 (0.8)
Coronary venous
tamponade
2b/595 (0.3)
CRT-P,
n/N (%)
CRT-D,
n/N (%)
Mortality rate 30 days
after randomisation
6b/617 (1.0) 11b/595 (1.8) 0.53 (0.20, 1.41),
0.20b
Moderate or severe adverse
event from any cause
407b/617 (66) 411b/595 (69) 0.95 (0.88, 1.03),
0.25b
a Number of patients per treatment arm not reported.
b Calculated by reviewer.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
Subgroup analyses reported by included randomised control trials
Only the CARE-HF trial109 presented subgroup analyses that were clearly predefined (Tables 49 and 50).
The trial reported LVEF in people with or without ischaemic heart disease. A statistically significant
interaction between CRT-P and aetiology was found (p= 0.003), whereby people with non-ischaemic heart
disease experienced a greater change in LVEF (see Table 49).
The effect of CRT-P on the composite end point (death from any cause or unplanned hospitalisation for a
major cardiovascular event) in predefined subgroups with analysis stratified for NYHA class (except the
subgroup analysis of NYHA class) can be seen in Table 50. The overall effect of CRT-P on the composite
end point was a HR of 0.63 (95% CI 0.51 to 0.77) and there was little difference in this outcome for any
of the predefined subgroups.
Summary of clinical effectiveness: people with heart failure as a result of
left ventricular systolic dysfunction and cardiac dyssynchrony
l Four RCTs, with a combined total of 2844 participants, comparing CRT-P (and CRT-D in one trial) with
OPT in people with HF as a result of LVSD and cardiac dyssynchrony were included. The trial comparing
CRT-P and CRT-D with OPT randomised participants to each of the three groups but did not perform a
direct comparison between CRT-D and CRT-P.
l There was some risk of bias in the trials in relation to performance, detection and reporting bias,
although risk was unclear in some cases because of inadequate reporting.
l Length of follow-up in the trials varied and included 3 months, 6 months, a median of 11.9–15.7 months
and a mean of 37.4 months (including an extension period). Sample size ranged from 58 to
1520 participants. The majority of participants had NYHA class III symptoms; the remaining few had
NYHA class IV symptoms.
CRT-P compared with optimal pharmacological therapy
l Meta-analysis found that CRT-P significantly reduced the risk of all-cause mortality (four trials; RR 0.75,
95% CI 0.58 to 0.96, p= 0.02), HF deaths (two trials; RR 0.67, 95% CI 0.51 to 0.88, p= 0.004) and
HF hospitalisations (four trials; RR 0.61, 95% CI 0.44 to 0.83, p= 0.002).
l Combining three RCTs in a meta-analysis demonstrated no significant difference in number of SCDs
between the groups (RR 0.97, 95% CI 0.44 to 2.14, p= 0.94). One RCT (COMPANION) reported no
statistically significant difference in total cardiac deaths (CRT-P 17.7% vs. OPT 18.8%, p= 0.334) or
non-cardiac deaths (CRT-P 2.3% vs. OPT 3.6%, p= 0.122).
l More people receiving CRT-P had an improvement of one or more NYHA class (RR 1.68, 95% CI 1.52
to 1.86, p< 0.00001) in the three trials reporting this outcome.
TABLE 49 Changes in LVEF for ischaemic or non-ischaemic heart disease
Study Outcome and follow-up
CRT-P OPT
p-value
IHD
(n= 168)
non-IHD
(n= 197)
IHD
(n= 135)
non-IHD
(n= 235)
CARE-HF115 LVEF (%) at baseline,
median (IQR)
25
(22 to 29)
24
(21 to 29)
26
(22 to 30)
24
(21 to 29)
0.1867
(IHD vs. non-IHD)
Mean (SD) change in
LVEF at 18 months (%)a
6.1 (1.2) 10.9 (1.5) 1.3 (0.7) 2.4 (1.7) 0.003 for interaction
between CRT
and aetiology
IHD, ischaemic heart disease; IQR, interquartile range.
a Values estimated by reviewer from figure using Engauge digitising software (not stated but error bars presumed to
show SD).115
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TABLE 50 Effect of CRT-P on death from any cause or unplanned hospitalisation for a major cardiovascular event
in predefined subgroups
Study Subgroup
Patients with event/total
no. of patientsa HR (95% CI)
CARE-HF109 Overall with primary end point 383/813 0.63 (0.51 to 0.77)
Age (years)b
< 66.4 163/406 0.55 (0.40 to 0.75)
≥ 66.4 220/407 0.68 (0.52 to 0.89)
Sex
Male 290/597 0.62 (0.49 to 0.79)
Female 93/215 0.64 (0.42 to 0.97)
NYHA class
III 349/763 0.64 (0.52 to 0.80)
IV 34/50 0.50 (0.25 to 1.01)
Dilated cardiomyopathy
No 238/443 0.68 (0.53 to 0.88)
Yes 145/370 0.51 (0.36 to 0.73)
Systolic blood pressure (mmHg)b
< 117 208/401 0.60 (0.46 to 0.80)
≥ 117 170/402 0.66 (0.48 to 0.89)
NT-proBNP (pg/ml)c
< 214.5 122/366 0.53 (0.36 to 0.76)
≥ 214.5 224/366 0.70 (0.54 to 0.91)
Ejection fraction (%)b
< 24.7 205/372 0.65 (0.49 to 0.86)
≥ 24.7 152/373 0.62 (0.44 to 0.85)
End-systolic volume index (ml/m2)b
< 119.2 156/366 0.71 (0.52 to 0.98)
≥ 119.2 193/366 0.54 (0.40 to 0.73)
QRS interval (milliseconds)
< 160 152/290 0.74 (0.54 to 1.02)
≥ 160 222/505 0.60 (0.46 to 0.79)
Interventricular mechanical delay (milliseconds)b
< 49.2 199/367 0.77 (0.58 to 1.02)
≥ 49.2 147/368 0.50 (0.36 to 0.70)
Mitral regurgitation area (cm2)b
< 0.218 114/302 0.86 (0.60 to 1.25)
≥ 0.218 175/303 0.56 (0.41 to 0.75)
continued
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l One RCT reported change in LVEF, showing a statistically significant improvement in LVEF with CRT-P
compared with OPT (4.6% vs. –0.2%, p< 0.001) at 6 months.
l There was a greater improvement in exercise capacity with CRT-P, as measured by the distance walked
in 6 minutes (meta-analysis of three trials; change from baseline or final values, MD 38.14m, 95% CI
21.74 to 54.54m, p< 0.00001). A statistically significant improvement in peak oxygen consumption
was also reported by two of the RCTs.
l All four RCTs found statistically significant improvements in QoL (MLWHFQ) in the CRT-P group
(change scores or final values, MD –10.33, 95% CI –13.31 to –7.36). One trial (CARE-HF) also reported
statistically significant improvements in the CRT-P group in the EQ-5D (MD 0.13, 95% CI 0.08 to 0.18,
p< 0.0001) and in QALYs (MD 0.23, 95% CI 0.13 to 0.33, p< 0.00001) at the end of the study (mean
37.4 months).
l One trial reported prespecified subgroup analysis. A significant interaction between CRT-P and
aetiology was found, whereby people with non-ischaemic heart disease had a greater change in LVEF.
There was little difference in the effect of CRT-P on the composite outcome (death from any cause or
unplanned hospitalisation for a major cardiovascular event) for 16 predefined subgroups.
TABLE 50 Effect of CRT-P on death from any cause or unplanned hospitalisation for a major cardiovascular event
in predefined subgroups (continued )
Study Subgroup
Patients with event/total
no. of patientsa HR (95% CI)
Glomerular filtration rate (ml/minute/1.73m2)b
< 60.3 196/369 0.67 (0.50 to 0.89)
≥ 60.3 142/370 0.57 (0.40 to 0.80)
Beta-blockers
No 131/227 0.72 (0.51 to 1.02)
Yes 252/586 0.59 (0.46 to 0.76)
Spironolactone
No 166/356 0.58 (0.43 to 0.79)
Yes 217/457 0.67 (0.51 to 0.88)
Loop diuretics
< 80mg of furosemide
or equivalent
181/461 0.56 (0.42 to 0.76)
≥ 80mg of furosemide
or equivalent
202/352 0.69 (0.53 to 0.92)
Digoxin
No 218/467 0.66 (0.50 to 0.86)
Yes 165/346 0.59 (0.43 to 0.81)
NT-proBNP, N-terminal pro-B-type natriuretic peptide.
a Authors state that, because of missing baseline data, not all subgroup numbers sum to 813.
b Divided according to the median value in the study population; this lead to some inequality in the sizes of
the subgroups.
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CRT-D compared with optimal pharmacological therapy
l One trial compared CRT-D with OPT. All-cause mortality (HR 0.64, 95% CI 0.48 to 0.86, p= 0.003),
total cardiac deaths (RR 0.68, 95% CI 0.50 to 0.93, p= 0.02), SCDs (HR 0.44, 95% CI 0.23 to 0.86,
p= 0.02) and HF hospitalisations (RR 0.77, 95% CI 0.63 to 0.93, p= 0.008) were reduced with CRT-D
compared with OPT.
l There were no significant differences in HF deaths (HR 0.73, 95% CI 0.47 to 1.11, p= 0.143) or
non-cardiac deaths (CRT-D 2.3% vs. OPT 3.6%, p= 0.717) between the groups.
l The proportions of people with an improvement of one or more NYHA class (CRT-D 57% vs. OPT
38%, p< 0.001), improvement in exercise capacity (change in 6-minute walk distance: CRT-D 46m
vs. OPT 1m, p< 0.001) and improvement in QoL (MLWHFQ) score (CRT-D –26 vs. OPT –12, p< 0.001)
at 6 months were statistically significantly greater in the CRT-D group.
CRT-P compared with CRT-D
l One three-arm trial compared both CRT-P and CRT-D with OPT, but the trial was not powered for a
statistical comparison between CRT-P and CRT-D. Statistical comparisons between CRT-P and CRT-D
have been undertaken for the purposes of this review but should be viewed with caution.
l Total cardiac deaths (RR 1.38, 95% CI 1.06 to 1.81, p= 0.02) and SCDs (RR 2.72, 95% CI 1.58 to
4.68, p= 0.0003) were higher in the CRT-P group than in the CRT-D group. All-cause mortality
(RR 1.20, 95% CI 0.96 to 1.52, p= 0.12), HF deaths (RR 0.98, 95% CI 0.68 to 1.42, p= 0.93) and HF
hospitalisations (28% vs. 29%) were similar in the CRT-P group and the CRT-D group.
l Changes in NYHA class, exercise capacity and QoL were similar in the CRT-P group and the CRT-D group.
Adverse events
l Two trials randomised people with successful implantation only. The other two trials reported
device-related deaths of between 0.2% and 0.8% for those receiving CRT-P and 0.5% for those
receiving CRT-D. Moderate or severe adverse events related to the implantation procedure were
reported in 10% of the CRT-P group and 8% of the CRT-D group in one trial, with 13% and 9% of
CRT-P and CRT-D implantations, respectively, unsuccessful. Moderate or severe adverse events from
any cause were more common among those receiving CRT-D than among those receiving OPT (CRT-D
69%, CRT-P 66%, OPT 61%; CRT-D vs. OPT p= 0.03, CRT-P vs. OPT p= 0.15). Reported complications
included lead displacements, infections and coronary sinus dissections.
People with both conditions
Quantity and quality of research available
Nine RCTs comparing CRT-D and ICDs in people at risk of SCD as a result of ventricular arrhythmias and
with HF as a result of LVSD and cardiac dyssynchrony met the inclusion criteria. Five of these trials reported
their findings in more than one paper; a summary of the included papers for each trial can be seen in
Table 51.
One of these studies (CONTAK-CD126) was included in the 2007 TAR on CRT;64 however, participants in
the CONTAK-CD trial126 were required to have VT as an indication for ICD and defibrillating capacity was
available to the control group and it is therefore discussed here rather than in the previous section.
No trials comparing CRT-D with OPT or CRT-D with CRT-P were identified for this population.
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Characteristics of the included studies
Study characteristics are summarised in Table 52 and participant characteristics are summarised in
Table 53. Further details can be found in the data extraction forms in Appendix 9.
Intervention and comparators
The participants in six of these trials126,136,137,139,142,144 were implanted with a device that could provide
both CRT and ICD therapy, and the devices in the comparator groups provided back-up ventricular
pacing and active ICD therapy only (CRT off). In three of the trials130,138,140 the comparator group received
an ICD only device. Participants in both groups of all trials also received OPT (discussed further in
Pharmacological therapy).
Participants
Participants in eight of these studies were required to have guideline indications for ICD therapy (see
Table 52). Piccirillo and colleagues138 state that the participants were undergoing prophylactic treatment
with the ICD or CRT-D. Pinter and colleagues139 enrolled people who ‘were not candidates for CRT therapy
based on guidelines at the time of the study’ (p. 1510); however, such patients would now be considered
to have a conventional indication for CRT.
The trials differed in their eligibility criteria for severity of HF (see Table 52). The majority of participants in
the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy
(MADIT-CRT),130 the Multicenter InSync ICD II Randomized Clinical Evaluation (MIRACLE ICD II)137 and
the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT)140 were in NYHA class II;
in the CONTAK-CD RCT,126 the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD),136
the Cardiac Resynchronization Therapy in Patients with Heart Failure and Narrow QRS (RethinQ) trial142
and the Resynchronization for the HemodYnamic Treatment for Heart failure Management Implantable
Cardioverter Defibrillator (RHYTHM ICD) trial144 the majority of participants were in NYHA class III; and the
majority of participants in the study by Piccirillo and colleagues138 were in NYHA class IV (see Table 53).
NYHA class was not reported by Pinter and colleagues139 although the eligibility criteria required mild to
moderate HF. The proportion of participants with ischaemic heart disease varied between the trials, from
TABLE 51 Included RCTs for people with both conditions
Study Publicationa
CONTAK-CD Higgins et al. 2003,126 Lozano et al. 2000,128 US Food and Drug Administration 2002,129
Saxon et al. 1999127
MADIT-CRT Moss et al. 2009130 and 2005,131 Solomon et al. 2010,132 Goldenberg et al. 2011,134,145
Arshad et al. 2011135
MIRACLE ICD Young et al. 2003136
MIRACLE ICD II Abraham et al. 2004137
Piccirillo 2006 Piccirillo et al. 2006138
Pinter 2009 Pinter et al. 2009139
RAFT Tang et al. 2010140 and 2009141
RethinQ Beshai et al. 2007,142 Beshai and Grimm 2007143
RHYTHM ICD US Food and Drug Administration 2004,144 US Food and Drug Administration 2005145
MADIT-CRT, Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy;
MIRACLE ICD, Multicenter InSync ICD Randomized Clinical Evaluation; RAFT, Resynchronization-Defibrillation for
Ambulatory Heart Failure Trial; RethinQ, Cardiac Resynchronization Therapy in Patients with Heart Failure and Narrow QRS;
RHYTHM ICD, Resynchronization for the HemodYnamic Treatment for Heart failure Management Implantable
Cardioverter Defibrillator.
Bold text indicates primary or key publication.
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around 52% (RethinQ142) to 100% (Piccirillo and colleagues138). The RethinQ trial142 enrolled people with
ischaemic or non-ischaemic cardiomyopathy and the study by Piccirillo and colleagues138 enrolled people
with ischaemic dilated cardiomyopathy.
The RethinQ trial142 differed from the other trials in the criteria used to define cardiac dyssynchrony.
Conventionally, a wide QRS interval indicates electrical dyssynchrony. This trial, however, recruited
people with a narrow QRS interval (< 130milliseconds) and evidence of mechanical dyssynchrony on
echocardiography. Mean QRS interval in this trial was about 107milliseconds and approximately
one-quarter of participants had a QRS duration of ≥ 120milliseconds.
Mean QRS interval in the other eight trials, when reported, ranged from 156milliseconds (CONTAK-CD126)
to 169milliseconds (RHYTHM ICD144). Pinter and colleagues139 did not report baseline QRS duration but
required a minimum duration of 120milliseconds for study eligibility. The Multicenter Automatic Defibrillator
Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT trial)130 required participants to have
a QRS duration of at least 130milliseconds and reported that around 65% of participants had a QRS interval
of ≥ 150milliseconds at baseline. Mean LVEF ranged from 21% (CONTAK-CD126) to 26% (RethinQ142).
The mean age of the participants in the trials was similar, ranging from 63 years (MIRACLE ICD II137) to
67 years (MIRACLE ICD136). The majority of participants (from 75% in MADIT-CRT130 to 90% in MIRACLE
ICD II137) were men.
Pharmacological therapy
Table 54 displays medication at baseline. The majority of participants in all studies received ACE inhibitors
and/or ARBs, although the proportion receiving beta-blockers varied between studies. Less than half of
participants in the CONTAK-CD study,126 around 60% of participants in the MIRACLE ICD136 and MIRACLE
ICD II137 trials and around 80–95% of participants in the MADIT-CRT,130 Piccirillo and colleagues,138
RAFT,140 RethinQ142 and RHYTHM ICD144 trials received beta-blockers. AAD use also varied between
the studies: around 33–35% of participants in the MIRACLE ICD II study,137 33–42% of participants in the
MIRACLE ICD study,136 less than one-quarter of participants in the RHYTHM ICD trial,144 around 15% of
participants in the RAFT trial,140 8–12% in the RethinQ trial142 and around 7% in the MADIT-CRT trial130
were receiving AADs. Pharmacological therapy in each of these trials would be considered optimal or close
to optimal by current standards, although beta-blocker use in the MIRACLE ICD trials was slightly low.
Key outcomes
The primary outcomes differed between the trials. All nine trials reported all-cause mortality but none
as a primary outcome. Also reported were total cardiac deaths (seven trials126,137–140,142,144), death from HF
(four trials126,137–139), SCD (six trials126,136–138,142,144) and death from other causes (six trials126,137–139,142,144).
Three trials126,138,140 reported hospitalisation because of HF, six trials126,136–138,142,144 reported NYHA class and
eight trials126,130,136–139,142,144 reported LVEF. Six trials126,136,137,139,142,144 reported exercise capacity assessed by
the 6-minute walk test and/or peak oxygen consumption, and QoL assessed by the MLWHFQ. The primary
outcome of three trials126,130,140 was a composite outcome; these can be seen in the data extraction forms
in Appendix 9 but have not been presented here.
Setting
Other than the single-centre study by Piccirillo and colleagues,138 the trials were multicentre with the
majority of the centres in the USA and Canada. Only one of the studies130 had a centre in the UK.
The number of participants randomised ranged from 31138 to 1820.130 The length of follow-up was
6 months in the CONTAK-CD,126 MIRACE ICD,136 MIRACLE ICD II,137 Pinter and colleagues139 and
RethinQ142 studies, 12 months in the Piccirillo and colleagues139 and RHYTHM ICD144 studies and an
average of 2.4 years in the MADIT-CRT study130 and 40 months in the RAFT study.140
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Risk of bias
The risk of bias in the included studies is summarised in Table 55 and further details for each study can be
found in the data extraction tables in Appendix 9. Only three of the studies136,137,142 were at low risk of
selection bias. The MADIT-CRT study130 did not report the randomisation method used, although sufficient
details were reported to establish that the allocation sequence was adequately concealed. The remaining
studies did not report details of the randomisation method or allocation sequence concealment; therefore,
the risk of selection bias is unclear.
There is a high risk of performance bias and detection bias in the MADIT-CRT study;130 treating physicians
were aware of study group assignments, and diagnosis of HF and decisions about therapy or hospital
admission were made by physicians aware of assignments, although members of the mortality and HF
committees were unaware of study group assignments. Details of blinding of participants and personnel
were not reported by Piccirillo and colleagues138 and, although spectral recording assessment was blinded,
details of blinding of other outcomes were not reported. The RethinQ142 and RHYTHM ICD144 studies are
described as ‘double blind’ but further details such as who was blinded and how this was maintained were
not reported. However, outcome assessors were unaware of treatment assignment in the RethinQ trial.142
There was a low risk of performance bias and detection bias in the other studies.126,136,137,139,140
Risk of attrition bias in the CONTAK-CD trial126 was low for the primary outcome but high for other
outcomes. MADIT-CRT130 was judged to have a low risk of bias for survival but a high risk of bias
for ventricular remodelling outcomes. Risk of attrition bias was unclear for primary outcomes and high for
secondary outcomes in MIRACLE ICD136 and unclear in MIRACLE ICD II.137 The RethinQ trial142 was judged
to have a low risk of attrition bias for primary and secondary outcomes but a high risk of bias for
additional outcomes when missing data were not accounted for. The other studies138–140,144 had a low risk
of attrition bias.
The RAFT study140 was considered to have a high risk of selective reporting bias as outcomes included
in the protocol (e.g. QoL) were not reported in the trial publication. However, it is noted that this was a
recent study and data may have been published after the completion of this report. The RHYTHM ICD
study report was available only from the FDA website and does not appear to have been published in a
journal. It is not clear whether selected outcomes have been presented to meet the needs of the FDA
approval process. The other studies126,130,136–139,142 were judged to have a low risk of selective
reporting bias.
The risks of other sources of bias were unclear in three studies. The study design, primary outcome
measure and length of follow-up were changed during the course of the CONTAK-CD study,126 but the
potential for these issues to introduce bias into the results is unknown. Because of a lack of details in
the RHYTHM ICD report,144 the risk of other sources of bias is unclear. The sponsors (Medtronic Inc.)
of the MIRACLE ICD study136 appear to have been involved in all aspects of the study, although the risk
of bias from this is unclear. The other studies130,137–140,142 were judged to have a low risk of bias.
Methodological comments
Similarity of groups at baseline
The groups were generally well balanced at baseline (see Table 53). However, the ICD group of
the MIRACLE ICD study136 had a higher proportion of participants with ischaemic heart disease. In the
RHYTHM ICD study,144 the ICD group performed significantly better in the exercise test for peak VO2
(a primary outcome) and included a lower proportion of men, although the authors state that none of the
differences was significant (statistical analysis not presented).
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Sample size
Four of the trials were adequately powered to show a difference in their primary outcome(s). These were
the MIRACLE ICD trial136 (a difference in NYHA class of 0.75, in QoL of 13 points or in 6-minute walk
distance of 50m), the trial by Pinter and colleagues139 (a 12% decrease in end-systolic volume), the RAFT
study140 (a 25% relative reduction in the composite outcome) and the RethinQ trial142 (a difference of 23%
in the proportion of patients who achieved the primary end point).
The actual event rate observed in the CONTAK-CD trial126 was approximately half that expected in the
original study design and consequently the authors state that the study was not adequately powered to
detect a statistically significant difference in HF events. The MADIT-CRT study130 was stopped on the
recommendation of the independent data and safety monitoring board when the monitoring statistic
reached the prespecified efficacy boundary. The study was then unblinded and analyses were limited to
events occurring before trial termination. The MIRACLE ICD study136 was not powered to detect a
morbidity or mortality difference. The study by Piccirillo and colleagues138 was a small study of
31 participants. The study report does not include details of a sample size calculation, and mortality and
NYHA were not primary outcomes and therefore it is assumed that the trial was not powered to detect
these outcomes. The MIRACLE ICD II137 and RHYTHM ICD144 studies do not report sample size calculations.
Crossovers
Crossovers between groups were reported by six of the trials. Crossover from the ICD group to the CRT-D
group occurred in 2.8%139–12.4%130 of participants, the most common reason being for HF events
(Table 56). Crossover from the CRT-D group to the ICD group occurred in 0%142–7.5%130 of participants,
most commonly because of difficulties with the left ventricular/CRT pacing lead (see Table 56).
Other issues
There were some differences between studies in the timing of implantation, baseline evaluation and
randomisation. The MADIT-CRT,130 Piccirillo and colleagues138 and RAFT140 studies randomised participants
before or at the time of implantation. The CONTAK-CD trial126 implanted the device first because of the
immediate need for ICD therapy and then programmed the randomised therapy after a minimum 30-day
period with no CRT, during which time investigators were permitted to optimise pharmacological therapy.
The other studies136,137,139,142,144 randomised only those participants who were successfully implanted. In the
MIRACLE ICD study136 randomisation occurred within 7 days of successful implantation; in the study by
Pinter and colleagues139 participants were randomly assigned following completion of baseline procedures
TABLE 56 Crossovers to the alternative device
Study CRT-D, n/N (%) ICD, n/N (%)
MADIT-CRT130 82/1089 (7.5) (technical difficulties positioning
CRT pacing lead)
91/731 (12.4) (30 before reaching an end point,
61 after HF event)
MIRACLE ICD136 10/187 (5) (two ventricular lead dislodgement,
two diaphragmatic stimulation, six
programming errors)
14/182 (8) (11 worsening HF, two bradycardia,
one programming error)
MIRACLE ICD II137 2/85 (2) (left ventricular lead dislodgement in one
patient and diaphragmatic stimulation in
biventricular and right ventricular pacing modes in
one patient)
5/101 (5) (bradycardia in three patients, centre
error in one patient and pacemaker dependency
after atrioventricular node ablation for atrial
flutter in one patient)
Pinter139 1/36 (2.8) (late left ventricular capture failure) 1/36 (2.8) (worsening CHF)
RAFT140 Not reported 96/904 (10.6) (36 before primary outcome,
60 after HF hospitalisation)
RethinQ142 0/87 (0) 3/85 (3.5) (because of worsening HF)
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14–28 days post implant; and in the RethinQ142 and RHYTHM ICD144 studies baseline evaluation occurred
14 days post implant, followed by randomisation.
The study design of the CONTAK-CD trial126 was modified because of regulatory concerns about morbidity
and mortality associated with CRT and the length of follow-up in the randomised mode. This meant that
the design changed from a randomised crossover design with crossover to occur after 3 months of
randomised therapy (Phase I) to a parallel RCT design with 6 months of follow-up (Phase II). Data from
both phases are reported.
The study by Piccarillo and colleagues138 was a small study that aimed to assess whether spectral indexes
obtained by power spectral analysis of heart rate variability could predict malignant ventricular arrhythmias
in patients. These data are beyond the scope of this report and have not been included. The study also
reported mortality and NYHA class although these were not specified as primary or secondary outcomes.
The RAFT study140 initially enrolled both NYHA class II and NYHA class III patients; however, after a
protocol revision in February 2006 the study enrolled only NYHA class II patients. Primary and secondary
outcomes for patients with NYHA class II or NYHA class III HF were therefore analysed separately.
The RHYTHM ICD study144 has not been published in a journal. Data have been extracted from the FDA
report but limited methodological details are reported.
Funding
Eight of the trials received funding from the device manufacturers. The RHYTHM ICD study144 formed the
basis of a FDA report by St Jude Medical (Sunnyvale, CA, USA). The study by Piccarillo and colleagues138
did not report funding or competing interests.
Assessment of effectiveness
All-cause mortality
All nine trials reported data on all-cause mortality, although only two130,140 compared events between
groups statistically (Table 57). The MADIT-CRT study130 found no statistically significant difference in
all-cause mortality after an average follow-up of 2.4 years (CRT-D 6.8% vs. ICD 7.3%, HR 1.00, 95% CI
0.69 to 1.44, p= 0.99), whereas the RAFT study140 found a statistically significant reduction in mortality
with CRT-D (CRT-D 20.8% vs. ICD 26.1%, HR 0.75, 95% CI 0.62 to 0.91, p= 0.003). Analysis of the
remaining trials (CONTAK-CD:126 CRT-D 4.5% vs. ICD 6.5%, RR 0.69, 95% CI 0.33 to 1.45, p= 0.33;
TABLE 57 All-cause mortality
Study Follow-up (months) CRT-D n/N (%) ICD n/N (%) Effect 95% CI, p-value
CONTAK-CD126 3–6 11/245 (4.5) 16/245 (6.5) RR 0.69a 0.33 to 1.45,a 0.33
MADIT-CRT130 Average 2.4 years 74/1089 (6.8) 53/731 (7.3) HR 1.00 0.69 to 1.44, 0.99
MIRACLE ICD136 6 14/187 (7.5) 15/182 (8.2) RR 0.91a 0.45 to 1.83, 0.79a
MIRACLE ICD II137 6 2/85 (2.4) 2/101 (2.0) RR 1.19a 0.17 to 8.26, 0.86a
Piccirillo138 12 0/16 (0) 0/15 (0)
Pinter139 6 1/36 (2.8) 1/36 (2.8) RR 1.00a 0.07 to 15.38, 1.00a
RAFT140 Mean 40 (SD 20) 186/894 (20.8) 236/904 (26.1) HR 0.75 0.62 to 0.91, 0.003
RethinQ142 6 5/87 (5.7) 1/85 (1.2) RR 4.89a 0.58 to 40.95, 0.14a
RHYTHM ICD144 6 9/83 (10.8) 3/43 (7.0) RR 1.55a 0.44 to 5.44, 0.49a
a Calculated by reviewer.
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MIRACLE ICD:136 CRT-D 7.5% vs. ICD 8.2%, RR 0.91, 95% CI 0.45 to 1.83, p= 0.79; MIRACLE ICD II:137
CRT-D 2.4% vs. ICD 2.0%, RR 1.19, 95% CI 0.17 to 8.26, p= 0.86; Piccirillo and colleagues:138 CRT-D 0%
vs. ICD 0%; Pinter and colleagues:139 CRT-D 2.8% vs. ICD 2.8%, RR 1.00, 95% CI 0.07 to 15.38,
p= 1.00; RethinQ:142 CRT-D 5.7% vs. ICD 1.2%, RR 4.89, 95% CI 0.58 to 40.95, p= 0.14; RHYTHM
ICD:144 CRT-D 10.8% vs. ICD 7.0%, RR 1.55, 95% CI 0.44 to 5.44, p= 0.49) demonstrated no statistically
significant difference in all-cause mortality between devices in each of the trials. Length of follow-up was
up to 6 months in six of the studies,126,136,137,139,142,144 12 months in the study by Piccirillo and colleagues138
and an average of 28.8 months in the MADIT-CRT study130 and 40 months in the RAFT study.140
The trials were considered sufficiently similar to combine in a random-effects meta-analysis and were
grouped according to the NYHA class of the majority of the participants in each trial. There was no
evidence of significant statistical heterogeneity between the studies (χ2= 4.82, df= 7, I2= 0%). Note that
the study by Piccirillo and colleagues138 was not estimable within the meta-analysis as zero events were
observed in both groups. The RR for CRT-D compared with ICD was 0.84 (95% CI 0.73 to 0.96, p= 0.01)
(Figure 19), giving a RRR of 16% with CRT-D for all-cause mortality. The results were strongly influenced
by the large RAFT study140 with 40 months’ follow-up and when this study was removed from the analysis
the results were no longer statistically significant (RR 0.95, 95% CI 0.72 to 1.24, p= 0.69).
Study or subgroup Events Total Events Total Weight
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Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.84, df = 2 (p = 0.66); I2 = 0%
Test for overall effect: z = 2.51 (p = 0.01)
Class III
Pinter 2009139
CONTAK-CD126 –129
RHYTHM ICD144,145
MIRACLE ICD136
RethinQ142,143
Subtotal (95% CI)
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Heterogeneity: τ2 = 0.00; χ2 = 3.64, df = 4 (p = 0.46); I2 = 0%
Test for overall effect: z = 0.21 (p = 0.83)
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Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI)
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Heterogeneity: τ2 = 0.00; χ2 =  4.82, df = 7 (p = 0.68); I2 = 0%
Test for overall effect: z = 2.45 (p = 0.01)
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0.95 (0.60 to 1.50)
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Test for subgroup difference: χ2 = 0.35, df = 1 (p = 0.56); I2 = 0%
FIGURE 19 All-cause mortality.
CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
122
Total cardiac deaths
Seven trials reported data on total cardiac deaths, although only one of these compared events between
groups statistically (Table 58). The RAFT study140 found that CRT-D was associated with a statistically
significant reduction in cardiac deaths (CRT-D 14.5% vs. ICD 17.9%, HR 0.76, 95% CI 0.60 to 0.96,
p= 0.02). When these trials were combined in a meta-analysis (random effects) the overall RR was 0.82
(95% CI 0.67 to 1.00, p= 0.05) in favour of CRT-D (Figure 20). There was no statistically significant
heterogeneity (χ2= 2.38, df= 5, I2= 0%). Again these results were strongly influenced by the large RAFT
study140 and when this was omitted from the analysis there was little difference between the interventions
(RR 0.92, 95% CI 0.44 to 1.92, p= 0.83).
TABLE 58 Total cardiac deaths
Study Follow-up (months) CRT-D, n/N (%) ICD, n/N (%) Effect 95% CI, p-value
CONTAK-CD126 3–6 7/245 (2.9) 10/245 (4.1) RR 0.70a 0.27 to 1.81a
MIRACLE ICD II137 6 2/85 (2.4) 2/101 (2.0) RR 1.19a 0.17 to 8.26a
Piccirillo138 12 0/16 (0) 0/15 (0)
Pinter139 6 1/36 (2.8) 1/36 (2.8) RR 1.00a 0.07 to 15.38a
RAFT140 Mean 40 (SD 20) 130/894 (14.5) 162/904 (17.9) HR 0.76 0.60 to 0.96, 0.02
RethinQ142 6 4/87 (4.6) 1/85 (1.2) RR 3.91a 0.45 to 34.26a
RHYTHM ICD144 6 1/83 (1.2) 1/43 (2.3) RR 0.52a 0.03 to 8.08a
a Calculated by reviewer.
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FIGURE 20 Total cardiac deaths.
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Heart failure deaths
There were no deaths from HF in the MIRACLE ICD II study137 of people with mild NYHA class II HF or in
the small study by Piccirillo and colleagues138 of people in NYHA class IV or III. The CONTAK-CD study,126
in which the majority of participants had NYHA class III or II HF, reported deaths from HF in 1.6% and
3.7% of the CRT-D and ICD groups respectively. Two (2.3%) people in the CRT-D group and one person
(1.2%) in the ICD group of the RethinQ trial142 died from HF (Table 59). Combining these trials in a
random-effects meta-analysis gave an overall RR of 0.64 (95% CI 0.18 to 2.22, p= 0.48) (Figure 21).
TABLE 59 Heart failure deaths
Study Follow-up (months) CRT-D, n/N (%) ICD, n/N (%) Effect 95% CI, p-value
CONTAK-CD126 3–6 4/245 (1.6) 9/245 (3.7) RR 0.44a 0.14 to 1.42, 0.17a
MIRACLE ICD II137 6 0/85 (0) 0/101 (0)
Piccirillo138 12 0/16 (0) 0/15 (0)
RethinQ142 6 2/87 (2.3) 1/85 (1.2) RR 1.95a 0.18 to 21.15, 0.58a
a Calculated by reviewer.
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FIGURE 21 Heart failure deaths.
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Sudden cardiac death
Six trials reported data on SCD (Table 60). No SCDs occurred in the small study by Piccirillo and
colleagues138 or in the RethinQ142 or RHYTHM ICD144 studies. Combining the other three trials129,136,137 in a
meta-analysis gives an overall RR of 1.45 (95% CI 0.43 to 4.92, p= 0.55), with no important statistical
heterogeneity (χ2= 0.61, df= 2, I2= 0) (Figure 22).
TABLE 60 Sudden cardiac death
Study Follow-up (months) CRT-D, n/N (%) ICD, n/N (%) Effect 95% CI, p-value
CONTAK-CD129 3–6 1/245 (0.4) 0/245 (0) RR 3.00 0.12 to 73.28, 0.5a
MIRACLE ICD136 6 3/187 (1.6) 3/182 (1.6) RR 0.97 0.2 to 4.76, 0.97a
MIRACLE ICD II137 6 2/85 (2.4) 1/101 (1.0) RR 2.38 0.22 to 25.76, 0.48a
Piccirillo138 12 0/16 (0) 0/15 (0)
RethinQ143 6 0/87 (0) 0/85 (0)
RHYTHM ICD144 6 0/83 (0) 0/43 (0)
a Calculated by reviewer.
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FIGURE 22 Sudden cardiac deaths.
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Other causes of death
Deaths from non-cardiac causes were reported in the CONTAK-CD trial129 (CRT-D 0.8% vs. ICD 1.2%)
and the RHYTHM ICD study144 (CRT-D 8.4% vs. ICD 4.7%). One (1.1%) death of unknown cause occurred
in the CRT-D group of the RethinQ trial.142 No deaths from non-cardiac causes occurred in the studies by
Piccirillo and colleagues138 or Pinter and colleagues139 (Table 61).
Survival
No statistically significant difference in 6-month cumulative survival was found in the MIRACLE ICD study136
(CRT-D 92.4% vs. ICD 92.2%, p= 0.96) or the RethinQ study142 (CRT-D 94.2% vs. ICD 98.8%, p= 0.11),
or in cumulative freedom from death caused by worsening HF in the RethinQ study142 (CRT-D 97.7% vs.
98.9%, p= 0.58) (Table 62). The probability of event-free survival at 5 years was 57.6% in the CRT-D
group and 48.7% in the ICD group of the RAFT study;140 statistical significance was not reported.
TABLE 61 Other causes of death
Study Follow-up (months) Cause of death CRT-D, n/N (%) ICD, n/N (%)
CONTAK-CD129 3–6 Cardiac (not pump failure or arrhythmic) 2/245 (0.8) 1/245 (0.4)
Non-cardiac 2/245 (0.8) 3/245 (1.2)
Unknown 2/245 (0.8) 3/245 (1.2)
MIRACLE ICD II137 6 MI with cardiogenic shock 0/85 (0) 1/101 (1.0)
Piccirillo138 12 Non-cardiac 0/16 (0) 0/15 (0)
Pinter139 6 Non-cardiac 0/36 (0) 0/36 (0)
RethinQ142 6 Unknown 1/87 (1.1) 0/85 (0)
Unknown cardiac 1/87 (1.1) 0/85 (0)
RHYTHM ICD144 6 Cardiac non-arrhythmic 1/83 (1.2) 1/43 (2.3)
Cardiac unknown 0/83 (0) 0/43 (0)
Non-cardiac 7/83 (8.4) 2/43 (4.7)
Unknown 1/83 (1.2) 0/43 (0)
TABLE 62 Survival
Study Outcome and follow-up CRT-D ICD p-value
MIRACLE ICD136 6-month cumulative survival (95% CI), % 92.4 (87.5 to 95.4) 92.2 (87.2 to 95.3) 0.96
RAFT140 Probability of event-free survival at
5 years, %
57.6 48.7
5-year actuarial rate of death, % 28.6 34.6
RethinQ142 Cumulative overall survival at 6 months
(95% CI), %
94.2 (86.7 to 97.6) 98.8 (91.9 to 99.8) 0.11
Cumulative freedom from death caused
by worsening HF (95% CI), %
97.7 (91.1 to 99.4) 98.9 (91.9 to 99.8) 0.58
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Hospitalisations related to heart failure
The CONTAK-CD,126 Piccirillo and colleagues138 and RAFT140 studies reported hospitalisations related
to HF (Table 63); the MIRACLE ICD,136 Pinter and colleagues139 and RAFT140 studies reported all-cause
hospitalisations (see Appendix 6). The RAFT study140 found a statistically significant reduction in
hospitalisations for HF in the CRT-D group (CRT-D 19.5% vs. ICD 26.1%, HR 0.68, 95% CI 0.56 to 0.83,
p< 0.001). The CONTAK-CD study126 reported that 13.1% of the CRT-D group were hospitalised because
of HF compared with 15.9% of the ICD group. Two people (13.3%) with an ICD and none of the CRT-D
group were hospitalised because of HF in the small study by Piccirillo and colleagues.138 When the studies
were combined in a random-effects meta-analysis, CRT-D reduced the RR of HF hospitalisation by 25%
compared with ICD therapy (RR 0.75, 95% CI 0.64 to 0.88, p= 0.0005) (Figure 23).
TABLE 63 Hospitalisation related to HF
Study Outcome and follow-up
CRT-D,
n/N (%) ICD, n/N (%) Effect
95% CI,
p-value
CONTAK-CD126 At least one HF hospitalisation,
6 months
32/245 (13.1) 39/245 (15.9) RR 0.82a 0.53 to
1.26, 0.37a
Piccirillo138 Hospitalisation because of
worsening HF,
0/16 (0) 2/15 (13.3) RR 0.19a 0.01 to
3.63, 0.27a
RAFT140 Hospitalisation for HF, mean
40 (SD 20) months
174/894 (19.5) 236/904 (26.1) HR 0.68 0.56 to
0.83, < 0.001
a Calculated by reviewer.
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Test for overall effect: z = 3.48 (p = 0.0005)
174
174
32
32
0
0
206
894
894
245
245
16
16
1155
236
236
39
39
2
2
277
904
904
245
245
15
15
1164
86.0%
86.0%
13.7%
13.7%
0.3%
0.3%
100.0%
0.75 (0.63 to 0.89)
0.75 (0.63 to 0.89)
0.82 (0.53 to 1.26)
0.82 (0.53 to 1.26)
0.19 (0.01 to 3.63)
0.19 (0.01 to 3.63)
0.75 (0.64 to 0.88)
0.01 0.1 1 10 100
Favours CRT-D Favours ICD
Test for subgroup difference: χ2 = 1.01, df = 2 (p = 0.60); I2 = 0%
FIGURE 23 Heart failure hospitalisations.
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Arrhythmias
The number of participants experiencing at least one episode of VT or VF can be seen in Table 64. The
proportions appear similar between groups. Random-effects meta-analysis demonstrated no statistically
significant difference between the groups in the number of people experiencing at least one arrhythmia
(RR 0.90, 95% CI 0.71 to 1.14, p= 0.38) (Figure 24).
TABLE 64 Arrhythmias
Study Outcome and follow-up
CRT-D,
n/N (%) ICD, n/N (%) Effect
95% CI,
p-value
CONTAK-CD126 At least one VT/VF event,
6 months
36/245 (14.7) 39/245 (15.9) RR 0.92a 0.61 to 1.40,
0.71a
MIRACLE ICD136 At least one spontaneous
episode of VT or VF, 6 months
42/187 (22) 47/182 (26) RR 0.87a 0.61 to 1.25,
0.45,a 0.47b
MIRACLE ICD II137 At least one appropriately
detected spontaneous episode
of VT or VF, 6 months
19/85 (22) 26/101 (26) RR 0.87a 0.52 to 1.46,
0.59,a 0.61b
Pinter139 VT event requiring therapy from
the device, 6 months
7/36 (19.4) 6/36 (16.7) RR 1.17a 0.43 to 3.13,
0.76,a NSb
NS, not significant.
a Calculated by reviewer.
b Statistical analysis reported in study report.
Study or subgroup Events Total Events Total Weight
CRT-D ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
MIRACLE ICD II137
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.54 (p = 0.59)
Class III
Class II
Pinter 2009139
CONTAK-CD126–129
MIRACLE ICD136
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.31, df = 2 ( p = 0.86); I2 = 0%
Test for overall effect: z = 0.70 (p = 0.48)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.33, df = 3 (p = 0.95); I2 = 0%
Test for overall effect: z = 0.87 (p = 0.38)
19
19
7
36
42
85
104
85
85
36
245
187
468
553
26
26
6
39
47
92
118
101
101
36
245
182
463
564
20.7%
20.7%
5.7%
31.7%
41.9%
79.3%
100.0%
0.87 (0.52 to 1.46)
0.87 (0.52 to 1.46)
1.17 (0.43 to 3.13)
0.92 (0.61 to 1.40)
0.87 (0.61 to 1.25)
0.91 (0.70 to 1.18)
0.90 (0.71 to 1.14)
0.5 0.7 1 1.5 2
Favours CRT-D Favours ICD
Test for subgroup difference: χ2 = 0.02, df = 1 (p = 0.88); I2 = 0%
FIGURE 24 Arrhythmias.
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New York Heart Association class
Six trials reported change in NYHA class; three reported mean or median change and three reported
the number of participants who improved. The MIRACLE ICD,136 MIRACLE ICD II137 and RHYTHM ICD144
trials reported a statistically significant improvement in mean or median NYHA class among people
receiving CRT-D compared with people receiving and ICD (Table 65). Combining these studies in a
random-effects meta-analysis gives a MD of –0.19 (95% CI –0.34 to –0.05, p= 0.008), although note that
the MIRACLE ICD136 trial is not estimable (Figure 25). A significantly greater proportion of the CRT-D group
improved by one class or more in the RethinQ trial142 (CRT-D 54% vs. ICD 29%, p= 0.006), and the
majority (81%) of the participants in the CRT-D group in the study by Piccirillo and colleagues138 showed
an improvement in NYHA class, compared with only 7% of those in the ICD group (see Table 65);
however, there is some uncertainty surrounding these data because of a discrepancy in reporting in the
paper (see Appendix 9). In the CONTAK-CD trial126 there was no statistically significant difference in the
number of people who showed an improvement in NYHA class. Substantial heterogeneity was evident
when these studies were combined in a random-effects meta-analysis (χ2= 8.57, df= 2, I2= 77%)
and, although the direction of effect favoured CRT-D, this was not statistically significant (RR 1.81,
95% CI 0.91 to 3.60, p= 0.09) (Figure 26).
TABLE 65 New York Heart Association class
Study Outcome and follow-up CRT-D, n/N (%) ICD, n/N (%) p-value
CONTAK-CD126 6 months
Improved by two classes 12a/109 (11) 2a/116 (2)
Improved by one class 27a/109 (25) 35a/116 (30) 0.1
No change 56a/109 (51) 59a/116 (51)
Worsened 14a/109 (13) 20a/116 (17)
MIRACLE ICD136 Change in NYHA class,
6 months
(n= 165) median –1
(95% CI –1 to –1, SD 0)
(n= 162) median 0
(95% CI –1 to 0, SD 3.2)
0.007
MIRACLE ICD II137 Change in NYHA class,
6 months
(n= 82) mean –0.18
(SD 0.61)
(n= 98) mean 0.01 (SD 0.63) 0.05
Piccirillo138 12 months
Improved by two classesb 5/16 (31.3) 0/15 (0)
Improved by one classb 8/16 (50.0) 1/15 (6.7)
No changeb 3/16 (18.8) 11/15 (73.3)
Worsenedb 0/16 (0) 3/15 (20.0)
RethinQ142 6 months
Improved by one or
more class
41/76 (54) 23/80 (29) 0.006
No change 31/76 (41) 51/80 (64)
Worsened 4/76 (5) 6/80 (8)
RHYTHM ICD144 Change in NYHA class,
6 months
(n= 83) mean –0.48
(SD 0.65)
(n= 43) mean –0.28
(SD 0.63)
0.048
a Calculated by reviewer.
b Calculated by reviewer from information in text of paper; note that text does not correspond with table in paper.
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Worsening heart failure
The MADIT-CRT trial130 reported a statistically significant reduction in the number of people experiencing a
non-fatal HF event in the CRT-D group compared with the ICD group (CRT-D 13.9% vs. ICD 22.8%,
HR 0.59, 95% CI 0.47 to 0.74, p< 0.001). Fewer HF events requiring intravenous therapy occurred in the
CRT-D group (24 events in 16.1% of patients) than in the ICD group (41 events in 22.3% of patients) in
the RethinQ trial.142 Worsening HF (other than that defined by change in NYHA class; see previous section)
was not reported by the other trials.
Left ventricular ejection fraction
Three126,130,137 of the eight trials reporting LVEF described a statistically significant improvement in mean
LVEF among people receiving CRT-D compared with those receiving an ICD, whereas three136,139,142 trials
reported no statistically significant difference between the groups in change from baseline (Table 66).
The study by Piccirillo and colleagues138 and the RHYTHM ICD study144 did not provide a statistical
comparison. Combining the trials in a meta-analysis showed a statistically significant improvement in LVEF
in the CRT-D group compared with the ICD group (MD 2.15, 95% CI 0.45 to 3.86, p= 0.01) (Figure 27).
There is substantial statistical heterogeneity (χ2= 21.12, df= 7, I2= 67%); however, the direction of the
effect is fairly consistent between studies.
Study or subgroup Events Total Events Total Weight
CRT-D ICD RR, M–H,
random (95% CI)
RR, M–H,
random (95% CI)
Class III
CONTAK-CD126 –129
RethinQ142,143
Subtotal (95% CI)
Total events
Heterogeneity: τ2 = 0.09; χ2 = 3.43, df = 1 (p = 0.06); I2 = 71%
Test for overall effect: z = 1.42 ( p = 0.16)
Class IV
Piccirillo 2006138
Subtotal (95% CI)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.57 ( p = 0.01)
Total (95% CI)
Total events
Heterogeneity: τ2 = 0.24; χ2 = 8.57, df = 2 (p = 0.01); I 2 = 77%
Test for overall effect: z = 1.68 ( p = 0.09)
39
41
80
13
13
93
109
76
185
16
16
201
37
23
60
1
1
61
116
80
196
15
15
211
45.4%
44.2%
89.5%
10.5%
10.5%
100.0%
1.12 (0.78 to 1.62)
1.88 (1.25 to 2.81)
1.44 (0.87 to 2.38)
12.19 (1.81 to 82.15)
12.19 (1.81 to 82.15)
1.81 (0.91 to 3.60)
0.01 0.1 1 10 100
Favours ICD
Test for subgroup difference: χ2 = 4.50, df = 1 (p = 0.03); I2 = 77.8%
Favours CRT-D
FIGURE 26 Proportion of people with improvement in NYHA class.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131
TABLE 66 Left ventricular ejection fraction
Study
Outcome and
follow-up CRT-D ICD Effect 95% CI, p-value
CONTAK-CD126 Change in LVEF (%),
6 months
(n= 222) mean 5.1
(SE 0.7; SD 10.4a)
(n= 216) mean 2.8
(SE 0.7; SD 10.3a)
MD
2.30b
0.36 to 4.24,
0.02,b 0.020c
MADIT-CRT130 Change in LVEF (%),
average 2.4 years
(n= 746) mean 11
(SD 44.6a)
(n= 620) mean 3
(SD 44.6a)
MD
8.00b
3.25 to 12.57,
0.001,b < 0.001c
MIRACLE ICD136 Change in LVEF (%),
6 months
(n= 132) median
1.2 (95% CI 1.2 to
4.1; SD 8.4a)
(n= 133) median
1.7 (95% CI 0.7 to
2.4; SD 5.0a)
MD
–0.50b
–2.17 to 1.17,
0.56,b 0.12c
MIRACLE ICD II137 Change in LVEF (%),
6 months
(n= 68) mean 3.8
(SD 8.0)
(n= 85) mean 0.8
(SD 6.2)
MD
3.00b
0.69 to 5.31,
0.01,b 0.02c
Piccirillo138 LVEF (%) at
12 months
(n= 16) mean 28
(SD 4)
(n= 15) mean 22
(SD 8)
MD
6.00b
1.50 to
10.50, 0.009b
Pinter139 Change in LVEF (%), 6 months
Measured
by MUGA
(n= 36) mean 1.7
(SD 5.4)
(n= 36) mean 0.6
(SD 6.8)
NS
Measured by ECG (n= 36) mean 3.9
(SD 8.9)
(n= 36) mean 1.9
(SD 6.8)
MD
2.00b
–1.66 to 5.66,
0.28,b NSc
RethinQ142 Change in LVEF (%),
6 months
(n= 68) median 1.2
(95% CI –0.4 to
4.4; SD 9.9a)
(n= 74) median 2.0
(95% CI 0.3 to 4.2;
SD 4.2a)
MD
0.80b
3.83 to 2.23,
0.61,b 0.83c
RHYTHM ICD144 Change in LVEF (%),
6 months
(n= 83) mean 4.3
(SD 9.9)
(n= 43) mean 2.9
(SD 6.2)
MD
1.4b
–1.42 to
4.22, 0.33b
MUGA, multigated acquisition; NS, not significant.
a SD calculated by reviewer.
b Calculated by reviewer.
c Statistical analysis reported in trial.
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Exercise capacity
Exercise capacity was reported by six of the eight trials, with six studies measuring distance walked in
6 minutes and two trials measuring exercise duration, five trials measuring peak VO2 and one trial
reporting the proportion of participants with an increase of at least 1.0ml/kg body weight/minute in peak
oxygen consumption (Table 67). The CONTAK-CD trial126 found improvements in both peak VO2 and
distance walked in 6 minutes, which were statistically significantly greater in the CRT-D group than in the
ICD group. The MIRACLE ICD136 and RHYTHM ICD144 trials found statistically significant improvements in
peak VO2 but not distance walked in 6 minutes; the MIRACLE ICD136 trial also found significant
improvements in exercise duration in favour of CRT-D. The MIRACLE ICD II trial137 (mild HF) found no
statistically significant differences in change in peak VO2 or exercise duration, but found a significant
improvement in ventilatory response to exercise with CRT-D compared with ICD. The RethinQ trial142 found
no statistically significant differences in distance walked in 6 minutes or the proportion of participants with
TABLE 67 Exercise capacity
Study Outcome and follow-up CRT-D ICD p-value
CONTAK-CD126 Change in peak VO2
(ml/kg/minute), 3–6 months
(n= 216) mean 0.8
(SE 0.3; SD 4.4a)
(n= 201) mean 0.0
(SE 0.3; SD 4.3a)
0.03
Change in 6-minute walk
distance (m), 3–6 months
(n= 224) mean 35
(SE 7; SD 104.8a)
(n= 220) mean 15
(SE 7; SD 103.8a)
0.043
MIRACLE ICD136 Change in 6-minute walk
distance (m), 6 months
(n= 152) median 55
(95% CI 44 to 79)
(SD 109.2a)
(n= 153) median 53
(95% CI 43 to 75)
(SD 100.2a)
0.36
Change in peak VO2
(ml/kg/minute), 6 months
(n= 120) median 1.1
(95% CI 0.7 to 1.6)
(SD 2.5a)
(n= 121) median 0.1
(95% CI –0.1 to 0.8)
(SD 2.5a)
0.04
Change in exercise duration
(seconds), 6 months
(n= 120) median 55.5
(95% CI 30 to 79)
(SD 135.5a)
(n= 123) median –11
(95% CI –55 to 12)
(SD 187.7a)
< 0.001
MIRACLE ICD II137 Change in peak VO2
(ml/kg/minute), 6 months
(n= 66) mean 0.5
(SD 3.2)
(n= 79) mean 0.2
(SD 3.2)
0.87
Change in exercise duration
(seconds), 6 months
(n= 66) mean 42
(SD 167)
(n= 79) mean 37
(SD 186)
0.56
Change in VE/VCO2
(ml/minute), 6 months
(n= 66) mean –1.8
(SD 6.2)
(n= 78) mean 0.5
(SD 5.2)
0.01
Change in 6-minute walk
distance (m), 6 months
(n= 78) mean 38
(SD 109)
(n= 93) mean 33
(SD 98)
0.59
Pinter139 Change in 6-minute walk
distance (m), 6 monthsb
(n= 36) mean 53.3
(SD 113.3)
(n= 36) mean 27.3
(SD 71.1)
NS
RethinQ142 Change in peak VO2
(ml/kg/minute), 6 months
(n= 76) median 0.4
(95% CI –0.6 to 1.2)
(SD 3.9a)
(n= 80) median 0.5
(95% CI –0.3 to 1.1)
(SD 3.1a)
Peak VO2, increase ≥1.0ml/
kg/minute, n/N (%), 6 months
(n= 76) 35/76 (46) (n= 80) 33/80 (41) 0.63
Change in 6-minute walk
distance (m), 6 months
(n= 75) median 26
(95% CI 0 to 46)
(SD 100a)
(n= 79) median 6
(95% CI –17 to 30)
(SD 104.9a)
0.23
RHYTHM ICD144 Change in peak VO2
(ml/kg/minute), 6 months
(n= 83) mean 0.52
(SD 2.5)
(n= 43) mean –1.41
(SD 4.6)
0.001
Change in 6-minute walk
distance (m), 6 months
(n= 83) mean 13
(SD 74)
(n= 43) mean –15
(SD 142)
0.07
NS, not significant; VE/VCO2, ventilatory response to exercise (minute ventilation/minute carbon dioxide production).
a SD calculated by reviewer.
b Assumed values are mean (SD) but this is not specified in the paper.
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an increase of at least 1.0ml/kg body weight/minute in peak VO2. There was no statistically significant
difference in the change in 6 minute-walk distance in the study by Pinter and colleagues.139
Meta-analysis of these trials demonstrated that the change from baseline in peak VO2 (MD 0.75ml/kg/
minute, 95% CI 0.23 to 1.27ml/kg/minute, p= 0.005) (Figure 28) and distance walked in 6 minutes
(MD 14.5m, 95% CI 2.9 to 26.1m, p= 0.01) (Figure 29) were statistically significantly greater in the
CRT-D group than in the ICD group. There was little statistical heterogeneity in these studies and,
although the MIRACLE ICD136 and RethinQ142 trials report medians and not means, the difference remains
statistically significant when these studies are omitted.
Quality of life
Six126,136,137,139,142,144 of the eight trials reported change in QoL at 6 months, assessed using the MLWHFQ
(Table 68). An improvement in QoL score was seen with CRT-D when the trials were pooled (MD –6.9,
95% CI –10.4 to –3.4, p= 0.0001) (Figure 30). Pinter and colleagues139 also reported the DASI, the
one-item Global Visual Analogue Scale and the SF-36. Comparisons of baseline to 6-month changes
were statistically significantly different for the general health component of the SF-36 only [CRT-D –5.8
(SD 14.9) vs. ICD –5.8 (SD 13.6), p= 0.02].
Adverse events
As described earlier, three130,138,140 of the trials compared CRT-D and ICD devices whereas all participants in
the six remaining trials126,136,137,139,142,144 were implanted with a device that could provide both CRT and ICD
therapy (CRT off in the comparator group). Differences in adverse events relating to the CRT-D device can
therefore be assessed only in the former three trials and, of these, only the MADIT-CRT130 and RAFT140
trials provided adverse event data.
Reporting of adverse events by the included trials was limited and inconsistent. As can be seen in Table 69,
in some of the trials the number of participants randomised differed from the number of people enrolled
and who had implantation attempted, as in six of the trials only those with successful implantation were
randomised. However, adverse event data were reported for all participants who underwent implantation
or attempted implantation in the CONTAK-CD,126 MADIT-CRT,130 MIRACLE ICD,136 MIRACLE ICD II,137
RAFT140 and RHYTHM ICD144 studies. The MIRACLE ICD136 and MIRACLE ICD II137 studies also reported
total complications for those with successful implants.
Five125,136,137,142,144 of the trials using the same device in all participants, that is, CRT on compared with CRT
off, reported adverse events for both interventions combined (Table 70). The MIRACLE ICD trial136 also
reported adverse events separately for the CRT on and CRT off groups, as did the MADIT-CRT130 and
RAFT140 trials for the CRT-D and ICD groups (Table 71). Adverse events were not reported in the study by
Pinter and colleagues,139 and Piccirillo and colleagues138 stated that there no major complications following
implantation but provided no further information.
Between 83.3% and 99.4% of people undergoing an implantation attempt received an implanted device
(see Table 69). Four of these studies136,137,139,144 clearly described the implantations as successful
(83.3–91%).
Perioperative deaths occurred in between 0.1% (MADIT-CRT130) and 2.4% (RHYTHM ICD144) of
participants (see Tables 70 and 71), although it is not clear whether or not the time period of reporting is
consistent between studies. Lead-related complications with CRT-D were experienced by around 7% of
participants in three trials,140,142,144 and the overall lead-related adverse event rate was 14.5% in the
CONTAK-CD trial.126 The MIRACLE ICD136 and MIRACLE ICD II137 trials reported the proportion
of complications that were related to the left ventricular lead before hospital discharge (23% of 159
complications and 34% of 56 complications respectively). In total, 4% of people receiving CRT-D in the
MADIT-CRT trial130 had the left ventricular lead repositioned during the first 30 days (see Table 71).
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TABLE 68 Quality of life
Study
Outcomea and
follow-up CRT-D ICD p-value
CONTAK-CD126 Change in MLWHFQ
score, 6 months
(n= 234) mean –7 (SE 2)
(SD 30.6b)
(n= 255) mean 5 (SE 2)
(SD 31.9b)
0.39c
MIRACLE ICD136 Change in MLWHFQ
score, 6 months
(n= 162) median –17.5
(95% CI –21 to –14) (SD 22.6b)
(n= 157) median –11
(95% CI –16 to –7) (SD 28.5b)
0.02
MIRACLE ICD II137 Change in MLWHFQ
score, 6 months
(n= 81) mean –13.3 (SD 25.1) (n= 96) mean –10.7 (SD 21.7) 0.49
Pinter139 Change in score, 6 monthsd
DASI (n= 36) mean 4.63 (SD 9.20) (n= 36) mean 1.08 (SD 7.02) NS
Global Visual
Analogue Scale
(n= 36) mean –0.07 (SD 2.22) (n= 36) mean –0.17 (SD 1.64) NS
MLWHFQ, 6 months
Total score (n= 36) mean –7.8 (SD 20.1) (n= 36) mean –0.2 (SD 13.5) NS
Physical dimension (n= 36) mean –5.0 (SD 12.4) (n= 36) mean –0.6 (SD 7.9) NS
Emotional
dimension
(n= 36) mean –1.3 (SD 5.0) (n= 36) mean 0.3 (SD 3.4) NS
SF-36, change to 6 monthsd
Physical
functioning
(n= 36) mean 11.2 (SD 24.2) (n= 36) mean 6.3 (SD 21.2) NS
Role physical (n= 36) mean 19.6 (SD 43.2) (n= 36) mean 21.6 (SD 38.1) NS
Bodily pain (n= 36) mean –3.3 (SD 16.6) (n= 36) mean –2.3 (SD 13.1) NS
General health (n= 36) mean –5.8 (SD 14.9) (n= 36) mean –5.8 (SD 13.6) 0.02
PCS (n= 36) mean 1.4 (SD 6.4) (n= 36) mean 1.3 (SD 4.8) NS
Vitality (n= 36) mean 4.7 (SD 22.7) (n= 36) mean 2.6 (SD 15.7) NS
Social functioning (n= 36) mean 12.5 (SD 23.3) (n= 36) mean 5.4 (SD 32.6) NS
Role emotional (n= 36) mean 29.5 (SD 48.4) (n= 36) mean 3.3 (SD 48.2) NS
Mental health (n= 36) mean 4.5 (SD 14.5) (n= 36) mean 0.1 (SD 21.8) NS
MCS (n= 36) mean 5.1 (SD 10.1) (n= 36) mean 0.5 (SD 12.4) NS
RethinQ142 Change in MLWHFQ
score, 6 months
(n= 76) median –8
(95% CI –10 to –1) (SD 19.7b)
(n= 80) median –7
(95% CI –11 to 3) (SD 31.5b)
0.91
RHYTHM ICD144 Change in MLWHFQ
score, 6 months
(n= 83) mean –7.8 (SD 22) (n= 43) mean 3.4 (SD 31) 0.009
NS, not significant.
a For the MLWHFQ, more negative change scores indicate greater improvement.
b SD calculated by reviewer.
c Reported as not statistically significant in the paper but statistically significant in meta-analysis (p< 0.0001).126
d Assumed values are mean (SD) but not always stated.
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TABLE 70 Adverse events reported for study population
Study Adverse events n/N (%) (95% CI)
CONTAK-CD126,129
Attempted implantation
(n= 567)
Operative mortality 12/567 (2.1) (0.9 to 3.3)
Overall lead-related adverse
event rate
75/517a (14.5) (11.5 to 17.5)
Severe device-related events 7/567 (1.2)
Device-related complications
(occurring in > 1% of
patients): infections
7/517a (1.4)
MIRACLE ICD136
Attempted implantation
(n= 429)
Experienced complication from
implant to hospital discharge
120/429 (28) (159 complications)
Complication related to left
ventricular lead
37/159 (23% of complications) (included
15 coronary sinus dissections and
four cardiac perforations)
HF decompensation 6/429 (received intravenous medication)
Heart block 3/429 (required bradycardia pacing support)
Muscle stimulation 4/429 (required either lead repositioning
or replacement)
Pericardial effusion 2/429 (treated with a pericardiocentesis)
Pericarditis 1/429 (received intravenous medication)
Haemo/pneumothorax 3/429 (placement of chest tube)
VT and VF 5/429 (three received external defibrillation,
two received intravenous medication)
Elevated pacing thresholds or
loss of capture
7/429 (six received lead repositioning, one had
set screw tightened in connector block)
Died within 30 days of latest
implant attempt
5/429 (1.2)
Successful implantation
(n= 379)
From hospital discharge to the
6-month follow-up,
total complications
175/379 (46) (398 complications)
MIRACLE ICD II137
Attempted implantation
(n= 210)
Died (before randomisation) 1/210
From implant to
hospital discharge
46/210 (22) (56 complications)
Complications related to
placement of left
ventricular lead
19/56 (34% of complications) (including
three coronary sinus dissections, three cardiac
perforations and five lead dislodgements)
Failed initial implant attemptb 23/210
Successful implantation
(n= 191)b
From hospital discharge to
6 months
66/191 (35) (109 complications)
Complications related to left
ventricular lead
19/109 (17) (including 11 lead dislodgements,
one cardiac perforation, three with
diaphragmatic muscle stimulation and four
elevated pacing thresholds)
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TABLE 70 Adverse events reported for study population (continued )
Study Adverse events n/N (%) (95% CI)
RethinQ142
Randomised patients (n= 172) Lead dislodgement 13/172 (7.6)
Involving left ventricular lead 5/172 (2.9)
Infection 6/172 (3.5)
Bleeding or haematoma 2/172 (1.2)
Loss of pacemaker lead capture 2/172 (1.2)
Phrenic nerve stimulation 3/172 (1.7)
Deep venous thrombosis 3/172 (1.7)
Pneumothorax 2/172 (1.2)
Pericarditis 2/172 (1.2)
Coronary sinus perforation 1/172 (0.6)
RHYTHM ICD144
Enrolled patients (n= 205),
average 12.1 (SD 3.4)
patient-months’ follow-up
Death (before randomisation or
unsuccessful implant)
5/205 (2.4)
Total complications
(adverse events requiring
invasive intervention)
21/205 (10.2) (29 events)
Coronary sinus
perforation/dissection
2 (1.0) (two events)
Diaphragmatic/phrenic
nerve stimulation
3 (1.5) (three events)
Lead dislodgement
or migration
8 (3.9) (nine events)
Bleeding/haematoma 6 (2.9) (six events)
Blood clot/thrombosis 1 (0.5) (one event)
High defibrillation/
cardioversion requirements
2 (1.0) (two events)
Infection 1 (0.5) (one event)
Noise on EGM post shock
(non-SJM right
ventricular lead)
1 (0.5) (one event)
Pneumothorax 2 (1.0) (two events)
Retained foreign body
(surgical sponge)
1 (0.5) (one event)
Elevated pacing threshold –
left ventricular lead
1 (0.5) (one event)
Total observations (adverse
events managed without
invasive intervention)
57 (27.8) (68 events)
Asystolic episode during left
ventricular lead placement
1 (0.5) (one event)
Bleeding/haematoma 10 (4.9) (10 events)
Blood clot/thrombosis 2 (1.0) (two events)
continued
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TABLE 70 Adverse events reported for study population (continued )
Study Adverse events n/N (%) (95% CI)
Coronary sinus
perforation/dissection
6 (2.9) (six events)
Diaphragmatic/phrenic nerve
stimulation – left ventricular
lead
10 (4.9) (10 events)
Diaphragmatic/phrenic nerve
stimulation – right ventricular
lead
2 (1.0) (two events)
Elevated pacing thresholds –
left ventricular lead
10 (4.9) (10 events)
Elevated pacing thresholds –
right ventricular lead
2 (1.0) (two events)
Heart block at implant 2 (1.0) (two events)
High defibrillation/
cardioversion requirements
1 (0.5) (one event)
Hypotension requiring
ventilator support
1 (0.5) (one event)
Inappropriate therapy for SVT 10 (4.9) (13 events)
Infection 3 (1.5) (three events)
Possible pulmonary embolism 1 (0.5) (one event)
T-wave sensing 2 (1.0) (three events)
Pocket inflammation/seroma 1 (0.5) (one event)
Left ventricular lead-related
complications at 6 months
11/155 (7.1) patients, 13 complications
Epic HF system-related
complications at 6 months
13/182 (7.1) patients, 16 complications
Total adverse events
(29 complications and
68 observations)
70 patients, 97 events
Enrolled patients (n= 205),
average 15.1 (SD 4.1)
patient-months’ follow-up
Total complicationsc 22/205 (10.7) (31events)
Lead dislodgement
or migration
9 (4.4) (10 events)
Infection 2 (1.0) (two events)
Total observationsc 59 (28.8) (76 events)
Diaphragmatic/phrenic nerve
stimulation – left
ventricular lead
14 (6.8) (14 events)
Elevated pacing
thresholds – left
ventricular lead
12 (5.9) (12 events)
Inappropriate therapy for SVT 11 (5.4) (14 events)
Infection 4 (2.0) (four events)
EGM, electrogram; SJM, St Jude Medical; SVT, supraventricular tachycardia.
a 517 patients who had an attempted implant procedure with EASYTRAK leads, 448 with successful EASYTRAK
lead implant.
b Paper states that 191/210 (91%) patients were successfully implanted, but also states that 23/210 failed the initial
implant (210–23= 187); there were also four patients with left ventricular lead dislodgements that were not corrected
and were therefore not randomised.
c Only those observations with added data detailed here.145
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TABLE 71 Adverse events reported by intervention
Study Adverse event CRT-D, n/N (%) ICD, n/N (%) Effect
95% CI,
p-value
MADIT-CRT130
Enrolled and
randomised
(n= 1820; CRT-D
n= 1089,
ICD n= 731)
Death in hospital after
device implantation
1/1089
(pulmonary
embolus)
0/731
Serious adverse events within 30 days of implantation
Pneumothorax (1.7) (0.8)
Infection (1.1) (0.7)
Pocket haematoma
requiring evacuation
(3.3) (2.5)
Coronary venous dissection
with pericardial effusion
during CRT-ICD
implantation
5/1089 (0.5) NA
Left ventricular coronary
vein lead repositioned
during first 30 days
44/1089 (4.0) NA
Frequency of serious
device-related adverse
events during long-term
follow-up after the first
30 days
4.5 per 100
device-months
5.2 per 100
device-months
Removal of device 14/1089 (1.3) 5/731 (0.7)
MIRACLE ICD136
CRT on, n/N (%) CRT off, n/N (%)
Successful
implantation and
randomised
(n= 369; CRT-D
n= 187, CRT-off
n= 182)
Complications after hospital discharge to 6 months
Left ventricular lead-
related complication
20 (11) (21 events) 13 (7) (14 events)
ICD system related 9 (5) (9 events) 13 (8) (14 events)
Procedure related 10 (5) (10 events) 11 (6) (13 events)
HF decompensation 36 (19) (63 events) 40 (22) (71 events)
Other 45 (24) (81 events) 44 (24) (74 events)
Total 88 (47) (184 events) 80 (44) (186 events)
continued
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The RAFT trial140 compared adverse events statistically between the CRT-D group and the ICD group
(see Table 71). The rate of device- or implantation-related complications within 30 days of implantation
was significantly higher in the CRT-D group than in the ICD group (CRT-D 13.3% vs. ICD 6.8%,
p< 0.001), as were the rates of device-related hospitalisations (CRT-D 20% vs. ICD 12.2%, HR 1.68,
95% CI 1.32 to 2.13, p< 0.001), lead dislodgement requiring intervention (CRT-D 6.9% vs. ICD 2.2%)
and coronary sinus dissection (CRT-D 1.2% vs. ICD 0%). After the first 30 days, the MADIT-CRT trial130
reported 4.5 (CRT-D group) and 5.2 (ICD group) serious device-related adverse events per 100
device-months.
Subgroup analyses reported by included randomised control trials
Three trials reported prespecified subgroup analysis. The MADIT-CRT trial130 presented prespecified
stratified analysis according to ischaemic or non-ischaemic cardiomyopathy classification. A similar benefit
from CRT-D was found in those with ischaemic or non-ischaemic cardiomyopathy (Table 72). Subgroup
analysis of risk of death or HF according to selected clinical characteristics found that CRT-D was
associated with a greater benefit in people with a QRS duration of ≥ 150milliseconds than in those with a
QRS duration of < 150milliseconds (p= 0.001 for interaction), and with a greater benefit in women than
in men (p= 0.01 for interaction). There were no statistically significant interactions for the other subgroups
(age, NYHA class, LVEF, left ventricular end-diastolic volume and left ventricular end-systolic volume)
(see Table 72). Additional analysis stratified by men and women reported in a secondary publication135
is presented in Table 73 and shows that women achieved significantly better results from CRT-D than men.
TABLE 71 Adverse events reported by intervention (continued )
Study Adverse event CRT-D, n/N (%) ICD, n/N (%) Effect
95% CI,
p-value
RAFT140
CRT-D, n/N (%) ICD, n/N (%)
Implanted
(n= 1787;
CRT-D n= 888,
ICD n= 899)
Death from worsening
HF within 24 hours
of implantation
0/888 1/899 (0.1)
Device-related
hospitalisation
179/888 (20) 110/899 (12.2) HR 1.68 1.32 to 2.13,
< 0.001
Adverse events within
30 days of implantationa
124/888 (14.0) 58/899 (6.5) < 0.001
Haemothorax or
pneumothorax
11/888 (1.2) 8/899 (0.9) 0.47
Device pocket haematoma
requiring intervention
14/888 (1.6) 11/899 (1.2) 0.53
Device pocket infection
requiring intervention
21/888 (2.4) 16/899 (1.8) 0.39
Lead dislodgement
requiring intervention
61/888 (6.9) 20/899 (2.2) 0.0001
Device-pocket problems
requiring revision
4/888 (0.5) 1/899 (0.1) 0.22
Coronary sinus dissection 11/888 (1.2) 0/899 (0) 0.0004
Tamponade 2/888 (0.2) 2/899 (0.2) 1
NA, not applicable.
a Also reports device- or implantation-related complications within 30 days of implantation: CRT-D 118/888 (13.3%),
ICD 61/899 (6.8%) (p< 0.001); not clear what this includes and how it differs from ‘adverse events’ at 30 days.
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TABLE 72 Subgroup analysis: MADIT-CRT trial130
Subgroup CRT-ICD ICD only Effect 95% CI, p-value
Patients with ischaemic cardiomyopathy (NYHA class I or II)
(n= 598) (n= 401)
Death from any cause or non-fatal HF event, n/N (%) 122/598
(20.4)
117/401
(29.2)
HR 0.67 0.52 to 0.88, 0.003
HF events only, n/N (%) 96/598
(16.1)
105/401
(26.2)
HR 0.58 0.44 to 0.78, < 0.001
Death at any time, n/N (%) 53/598
(8.9)
35/401
(8.7)
HR 1.06 0.68 to 1.64, 0.80
Patients with non-ischaemic cardiomyopathy (NYHA class I or II)
(n= 491) (n= 330)
Death from any cause or non-fatal HF event, n (%) 65 (13.2) 68 (20.6) HR 0.62 0.44 to 0.89, 0.01
HF events only, n (%) 55 (11.2) 62 (18.8) HR 0.59 0.41 to 0.87, 0.01
Death at any time, n (%) 21 (4.3) 18 (5.5) HR 0.87 0.44 to 1.70, 0.68
Risk of death or HF according to selected clinical characteristics
No. of events/
no. of patients Effect
95% CI, p-value
for interaction
Age (years)
< 65 years 142/852 HR 0.80a
≥ 65 years 230/968 HR 0.60a
Sex
Male 294/1367 HR 0.76 0.59 to 0.97
Female 78/453 HR 0.37 0.22 to 0.61, 0.01
NYHA class
Ischaemic I 53/265 HR 0.76a
Ischaemic II 186/734 HR 0.62a
Non-ischaemic II 133/821 HR 0.60a
QRS duration (milliseconds)
< 150 147/645 HR 1.06 0.74 to 1.52
≥ 150 225/1175 HR 0.48 0.37 to 0.64, 0.001
LVEF (%)
≤ 25 101/646 HR 0.70a
> 25 271/1174 HR 0.60a
LVEDV (ml)
≤ 240 184/828 HR 0.70a
> 240 184/969 HR 0.62a
LVESV (ml)
≤ 170 190/835 HR 0.66a
> 170 178/962 HR 0.70a
All patients 372/1820 HR 0.66
LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume.
a HRs estimated from figure by reviewer.
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The RAFT trial140 reported an analysis of 11 prespecified subgroups (Table 74) and presented outcomes
separately for the NYHA class II and III subgroups (Table 75). CRT-D and ICD were associated with a similar
reduction in the composite primary outcome of death or hospitalisation for HF (p= 0.91 for interaction),
death from any cause and hospitalisation for HF for NYHA classes II and III. A statistically significant
interaction was found between treatment and QRS duration (p= 0.003), with CRT-D more effective in
people with an intrinsic QRS duration of ≥ 150milliseconds (HR 0.59, 95% CI 0.48 to 0.73) than in those
with an intrinsic QRS duration of < 150milliseconds (HR 0.99, 95% CI 0.77 to 1.27, p= 0.002 for
interaction) or those with a paced QRS duration of ≥200milliseconds (HR 1.07, 95% CI 0.63 to 1.84,
p= 0.03 for interaction). A statistically significant interaction (p= 0.046) between treatment and QRS
morphological type was also found, with CRT-D more effective in people with LBBB than in those with
non-specific intraventricular conduction delay.
The RethinQ trial142 presented prespecified stratified analysis according to QRS interval (≥ 120milliseconds
or < 120milliseconds) and cardiomyopathy classification (ischaemic or non-ischaemic) (Table 76).
A statistically significant improvement in the proportion of people with an increase of at least 1ml/kg
body weight/minute in peak oxygen consumption was found with CRT-D for people with a QRS
interval of ≥ 120milliseconds (58.9% vs. 19.7%, p= 0.02), but not for those with a QRS interval of
< 120milliseconds (42.2% vs. 51.2%, p= 0.45). There was a statistically significant increase in the
proportion with an improvement in NYHA class with CRT-D for both a QRS interval ≥ 120milliseconds
(70.7% vs. 28.0%, p= 0.01) and a QRS interval < 120milliseconds (49.4 vs. 29.3%, p= 0.04). There
was no statistically significant difference between CRT-D and ICD in QoL or distance walked in 6 minutes
for either QRS interval subgroup. Analysis stratified by ischaemic or non-ischaemic cardiomyopathy
classification reflected the results for the whole group for peak oxygen consumption, NYHA class and QoL.
However, a statistically significant difference between CRT-D and ICD in change in distance walked in
6 minutes was found for those with non-ischaemic cardiomyopathy (55.0m vs. 2.5m, p= 0.01), but not
for those with ischaemic cardiomyopathy (4.2m vs. 5.8m, p= 0.57).
TABLE 73 Outcomes by sex: MADIT-CRT trial135
Outcome
Women (n= 453) Men (n= 1367)
p-value for
interactionCRT-D ICD CRT-D ICD
HF or death
(primary end point),
n/N (%)
29/275 (11) 51/178 (29) 159/814 (20) 137/553 (25)
CRT-D vs. ICD HR 0.31, 95% CI
0.19 to 0.50, p< 0.001
CRT-D vs. ICD HR 0.72, 95% CI 0.57
to 0.92, p< 0.01
< 0.01
HF only n= 73 events, CRT-D vs. ICD HR
0.30, 95% CI 0.18 to 0.50,
p< 0.001
n= 249 events, CRT-D vs. ICD HR
0.65, 95% CI 0.50 to 0.84,
p= 0.001
< 0.01
Death at any time n= 20 events, CRT-D vs. ICD HR
0.28, 95% CI 0.10 to 0.79,
p= 0.02
n= 107 events, CRT-D vs. ICD HR
1.05, 95% CI 0.70 to 1.57, p= 0.83
< 0.03
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TABLE 74 Subgroup analysis: RAFT trial140
Subgroup HR (95% CI)
p-value
for interaction
Age: < 65 years vs. ≥ 65 years 0.75
Sex: male vs. female 0.09
NYHA class: II vs. III 0.91
Underlying heart disease: ischaemic vs. non-ischaemic 0.90
QRS duration
Intrinsic QRS < 150milliseconds vs. 0.99 (0.77 to 1.27) 0.003,a 0.002,b 0.003c
Intrinsic QRS ≥ 150milliseconds vs. 0.59 (0.48 to 0.73)
Paced QRS ≥ 200milliseconds 1.07 (0.63 to 1.84)
LVEF (%): < 20 vs. ≥ 20 0.05
QRS morphological features: RBBB vs. LBBB vs. NIVCD vs. paced 0.046
Atrial rhythm: permanent atrial fibrillations or flutter vs. sinus or
atrial paced
0.14
Diabetes: yes vs. no 0.22
Hypertension: yes vs. no 0.84
Estimated GFR (ml/minute/1.73m2): < 60 vs. ≥ 60 0.70
GFR, glomerular filtration rate; NIVCD, non-specific intraventricular conduction delay.
a Interaction between treatment and QRS duration.
b More effective in those with an intrinsic QRS duration of ≥ 150milliseconds (HR 0.59; 95% CI 0.48 to 0.73) than in
those with an intrinsic QRS duration of < 150milliseconds (HR 0.99, 95% CI 0.77 to 1.27, p= 0.002 for interaction).
c More effective in those with an intrinsic QRS duration of ≥ 150milliseconds (HR 0.59, 95% CI 0.48 to 0.73) than in
those with a paced QRS duration of ≥ 200milliseconds (HR 1.07, 95% CI 0.63 to 1.84, p= 0.03 for interaction).
TABLE 75 New York Heart Association subgroup analysis: RAFT trial140
Subgroup CRT-D, n/N (%) ICD, n/N (%) Effect 95% CI, p-value
NYHA class II
(n= 708) (n= 730)
Primary outcome: death or hospitalisation for HF 193/708 (27.3) 253/730 (34.7) HR 0.73 0.61 to 0.88, 0.001
Secondary outcomes
Death from any cause 110/708 (15.5) 154/730 (21.1) HR 0.71 0.56 to 0.91, 0.006
Death from cardiovascular cause 74/708 (10.5) 100/730 (13.7) HR 0.73 0.54 to 0.99, 0.04
Hospitalisation for HF 115/708 (16.2) 159/730 (21.8) HR 0.70 0.55 to 0.89, 0.003
NYHA class III
(n= 186) (n= 174)
Primary outcome: death or hospitalisation for HF 104/186 (55.9) 111/174 (63.8) HR 0.76 0.58 to 0.99, 0.04
Secondary outcomes
Death from any cause 76/186 (40.9) 82/174 (47.1) HR 0.79 0.58 to 1.08, 0.14
Death from cardiovascular cause 56/186 (30.1) 62/174 (35.6) HR 0.77 0.54 to 1.10, 0.15
Hospitalisation for HF 59/186 (31.7) 77/174 (44.3) HR 0.63 0.45 to 0.88, 0.006
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Summary of clinical effectiveness: people with both conditions
l Nine RCTs were included comparing CRT-D with ICD in people both at risk of SCD as a result of
ventricular arrhythmias and with HF as a result of LVSD and cardiac dyssynchrony.
l No RCTs comparing CRT-D with OPT or CRT-D with CRT-P were identified for this population.
l The risk of bias was low in some of the trials but unclear in others because of inadequate reporting.
l Length of follow-up was 6 months in five trials, 1 year in two trials and an average of 2.4 years and
3.3 years in the remaining trials. Sample size ranged from 31 to 1820 participants.
TABLE 76 Subgroup analysis: RethinQ trial142
Subgroup
CRT-D on+OPT
(QRS ≥ 120milliseconds, n= 17;
QRS < 120milliseconds, n= 59)
ICD+OPT
(QRS ≥ 120milliseconds, n= 25;
QRS < 120milliseconds, n= 55) p-value
QRS interval at 6 monthsa
Peak oxygen consumption, increase of ≥ 1ml/kg/minute
QRS
≥ 120milliseconds
58.9 19.7 0.02
QRS
< 120milliseconds
42.2 51.2 0.45
Proportion of patients improved by one or more NYHA class
QRS
≥ 120milliseconds
70.7 28.0 0.01
QRS
< 120milliseconds
49.4 29.3 0.04
QoL, median change (%)
QRS
≥ 120milliseconds
0 –3.7 0.24
QRS
< 120milliseconds
–8.9 –7.0 0.63
6-minute walk distance (m), median change
QRS
≥ 120milliseconds
0.0 –19.1 0.86
QRS
< 120milliseconds
33.7 10.3 0.31
CRT-D on+OPT (ischaemic,
n= 40; non-ischaemic, n= 36)
ICD+OPT (ischaemic,
n= 41; non-ischaemic, n= 39) p-value
Cardiomyopathy classification at 6 monthsa
Peak oxygen consumption, increase of ≥ 1ml/kg/minute
Ischaemic 40.0 44.2 0.82
Non-ischaemic 52.6 38.4 0.25
Proportion of patients improved by one or more NYHA class
Ischaemic 55.3 29.5 0.02
Non-ischaemic 53.2 28.4 0.04
QoL, median change (%)
Ischaemic –5.9 –3.6 0.68
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l The trials differed in their eligibility criteria for HF; the majority of participants were in NYHA class II in
three trials, in NYHA class III in four trials, described as ‘mild to moderate’ in one trial and in NYHA
class IV in one trial. One trial differed from the others in the criteria used to define cardiac
dyssynchrony, recruiting people with a narrow QRS interval (< 130milliseconds) and evidence of
mechanical dyssynchrony on ECG. Trials were similar in other key characteristics. LVEF ranged from
21% to 26%.
l Meta-analysis found that CRT-D reduced the risk of all-cause mortality (eight RCTs; RR 0.84, 95% CI
0.73 to 0.96, p= 0.01) and total cardiac deaths (six RCTs; RR 0.82, 95% CI 0.67 to 1.00, p= 0.05).
These results were strongly influenced by the large RAFT trial, which included people with mild to
moderate HF despite OPT, a LVEF ≤ 30% from ischaemic or non-ischaemic causes, a wide QRS interval
and planned ICD implantation for indicated primary or secondary prevention of SCD.
l Fewer trials reported HF deaths or SCDs separately, and there were no HF deaths or SCDs in some of
these trials. Combining three RCTs in a meta-analysis found little difference in the rate of SCD between
the CRT-D group and the ICD group (RR 1.45, 95% CI 0.43 to 4.92, p= 0.55).
l The RAFT trial found a statistically significant reduction in the rate of HF hospitalisations with CRT-D.
Two small trials found no significant difference between the groups for this outcome. Combining these
trials in a meta-analysis demonstrated that CRT-D reduced the RR of hospitalisation by 25% compared
with ICD (RR 0.75, 95% CI 0.64 to 0.88, p= 0.0005).
l Meta-analysis of four trials found no statistically significant difference between the groups in the
proportion of people experiencing at least one episode of VT or VF (RR 0.90, 95% CI 0.71 to
1.14, p= 0.38).
l An improvement in NYHA class was found with CRT-D among two trials reporting mean or median
change (MD –0.19, 95% CI –0.34 to –0.05, p= 0.008). The results were more heterogeneous among
the three trials reporting the proportion of people who improved by one or more NYHA class: two trials
found a statistically significant improvement with CRT-D but one trial found no difference between the
groups (meta-analysis RR 1.81, 95% CI 0.91 to 3.60, p= 0.09).
l There was substantial statistical heterogeneity in LVEF among the trials, although the direction of effect
was fairly consistent. Meta-analysis found a significant improvement in LVEF with CRT-D compared
with ICD (eight RCTs; MD 2.15%, 95% CI 0.45% to 3.86%, p= 0.01).
l There was a greater improvement in exercise capacity in the CRT-D group than in the ICD group, as
demonstrated by change from baseline in peak VO2 (five RCTs; MD 0.75, 95% CI 0.23 to 1.27,
p= 0.005) and 6-minute walk distance (six RCTs, MD 14.5m, 95% CI 2.9 to 26.1m, p= 0.01).
l An improvement in QoL (MLWHFQ) score was seen with CRT-D when six trials were pooled in a
meta-analysis (MD –6.9, 95% CI –10.4 to –3.4, p= 0.0001). One trial reporting other measures of QoL
(DASI, one-item Global Visual Analogue Scale and SF-36) found that differences between the groups in
baseline to 6-month changes were statistically significant for the general health component of the
SF-36 only.
l Reporting of adverse events was inconsistent between the trials. The large RAFT trial found that the
rate of device- or implantation-related complications within 30 days of implantation was significantly
higher in the CRT-D group than in the ICD group (13.3% vs. 6.8%, p< 0.001), as was the rate of
device-related hospitalisations (20% vs. 12.2%, HR 1.68, 95% CI 1.32 to 2.13, p< 0.001).
l Three trials reported prespecified subgroup analysis. Two trials reported that CRT-D was associated
with a greater benefit in people with a QRS duration of ≥ 150milliseconds than in those with a QRS
duration of < 150milliseconds, and the third trial found a significant increase in the proportion of
people with an improvement in peak oxygen uptake among those with a QRS interval of
≥ 120milliseconds but not among those with a QRS interval of < 120milliseconds. CRT-D was
associated with greater benefit in women than in men (one trial) and with greater benefit in people
with LBBB than in those with non-specific intraventricular conduction delay (one trial). One trial found a
statistically significant improvement with CRT-D for distance walked in 6 minutes for those with
non-ischaemic cardiomyopathy (55.0m vs. 2.5m, p= 0.01) but not for those with ischaemic
cardiomyopathy (4.2m vs. 5.8m, p= 0.57). Other evaluated subgroups showed no statistically
significant effects.
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Summary of Southampton Health Technology Assessments
Centre’s peer review of clinical effectiveness in the Association
of British Healthcare Industries joint submission
A joint report on behalf of Biotronik UK, Boston Scientific, Medtronic UK, Sorin Group and St Jude Medical
was submitted by the Association of British Healthcare Industries (ABHI) to NICE.151 The clinical
effectiveness evidence presented in this MS has been briefly appraised (see Appendix 10). The MS also
presented individual patient data (IPD) network meta-analysis (NMA) (see following section) and an
economic model (see Chapter 5, Review of the manufacturers’ submission).
A systematic review of clinical effectiveness was undertaken in the MS.151 Details of the searches were
reported and the search strategies were supplied. Details and results of studies included in the systematic
review were tabulated. Risk of bias was assessed, although no narrative discussion of risk of bias
was provided.
The inclusion criteria for the MS systematic review differed from those in the NICE scope61 and the results
were not presented according to the population groups defined in the NICE scope. As a result of this, the
MS and the Southampton Health Technology Assessments Centre’s (SHTAC) systematic reviews differ in
the evidence included (see Appendix 10).
The MS does not explicitly report the conclusions from the systematic review of clinical effectiveness in the
main body of the submission. The executive summary states that ‘there is a large body of RCT evidence
confirming the efficacy and safety of ICD, CRT-P and CRT-D in patients with HF’ (p. 4);151 however, there is
no comment regarding the comparative effectiveness of the interventions for each of the populations
defined in the NICE scope. Further conclusions are presented in the MS based on the IPD NMA, which is
discussed in the following section.
Individual patient data network meta-analysis: a critical appraisal
The joint submission from the manufacturers presents an IPD NMA using meta-regression to assess the
effectiveness of ICDs, CRT-P and CRT-D in the different subgroups of people who have HF.151 The intention
was for the IPD NMA to inform the cost-effectiveness model produced on behalf of the manufacturers. As
such, it focuses on the outcomes of all-cause mortality, all-cause hospitalisation and HRQoL. In undertaking
the IPD NMA, the MS recognises the heterogeneous nature of patients with HF and the likelihood that the
interventions may have differing effects. It also changes the focus of the assessment from an evaluation of
the effectiveness of the devices for specific subgroups of patients as identified in the scope for the NICE
appraisal, to trying to establish which subgroups of patients the different devices appear to benefit.
Inevitably, these may not be the same groups. With limited published evidence on the effectiveness of
devices in different patient subgroups with HF, the availability of IPD from the manufacturers makes a NMA
meta-regression possible and justified.
This section presents a critical appraisal of the IPD NMA using a structured approach (see Appendix 10).
It provides an assessment of the appropriateness of the methods used and of the results and
conclusions presented.
Methods
Network of evidence
The systematic review of clinical effectiveness reported in the MS included a comprehensive and
transparent search strategy, the criteria and reasons for study selection, extraction of baseline data on
patient characteristics and study outcomes, quality assessment of studies and the process followed to
complete these stages. The studies identified in the systematic review provided the basis for developing the
network of evidence for the IPD NMA. However, the IPD NMA included only a subset of those studies
identified in the systematic review for which the manufacturers provided IPD (13 of 22 trials; 95% of
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patients from the evidence network). Also, the evidence network excluded seven trials71,75,81,84,89,95,97
identified by the SHTAC systematic review (see earlier in this chapter). The extent of the evidence base for
the NMA varied for the different outcomes assessed, with 13 trials (n= 12,638) for all-cause mortality,
11 trials for all-cause hospitalisation (n= uncertain as it refers to studies not included in the NMA) and
three trials (n= 4432) for HRQoL. The MS outlines reasons for excluding specific studies from the overall
evidence network, the approach taken to allocating trials to different comparisons and the basis for
handling data (i.e. separating or aggregating trial arms or phases) from the trials. The effects of a more
limited evidence base and the manipulation of data are discussed. For all-cause mortality, NMAs were
produced to compare outcomes using aggregate data from all trials in the network with outcomes using
data from the trials included in the IPD only, finding no significant differences. Similar comparisons were
not produced for the other outcomes.
Issues relating to differences in the 13 IPD trials were also considered. The effects of length of follow-up,
trial crossover, missing data and data handling were discussed in the MS, particularly with relation
to all-cause mortality. Length of follow-up was restricted to that specified in trial protocols
(commercial-in-confidence information has been removed) to limit the effects of trial crossover at the
longest follow-up time (commercial-in-confidence information has been removed). Missing data for
the covariables appeared limited (commercial-in-confidence information has been removed), with data
imputed through multiple imputations when necessary (details provided in appendix 6 of the MS151).
The covariables used to capture baseline risk and treatment effect modifiers in the NMA were outlined
for the different outcomes assessed, with the rationale for their inclusion and for any data manipulation
(i.e. continuous to categorical) discussed.
Statistical analysis
The IPD NMA adopted a multivariate approach through meta-regression to assess the effects of the
different interventions on HF patients for the outcomes of all-cause mortality, all-cause hospitalisation and
HRQoL, taking into account the impact of different patient characteristics. Although different types of
regression were used for analysing the three outcomes, all analyses followed a similar two-stage approach.
First, a baseline rate was estimated for each outcome independent of the treatment effects of the devices.
This used the pooled data from the relevant IPD trials for all patients randomised to OPT (i.e. all IPD trials
assessing the specific outcome irrespective of the device assessed), which was the comparator treatment
for the appraisal. Second, device-specific treatment effects were estimated using all available data from the
relevant IPD trials (i.e. trials focusing on the specific outcome for all of the interventions compared). In both
stages of the analyses, patient characteristics were included as covariables to incorporate baseline risk and
treatment effect modifiers. This allowed subgroup-specific treatment effects to be estimated and provided
the opportunity to identify groups of patients for whom the treatment provided significant benefit. In
using a NMA approach, all interventions included can be compared relative to each other, when direct and
indirect evidence is available. This is important in the current assessment when direct evidence may be
limited (e.g. CRT-D vs. CRT-P and CRT-D vs. OPT). However, it is important to note that the findings of
NMA may be affected by limitations in the network of evidence, whether direct or indirect evidence, as will
be evident from the appraisal of the NMA.
For the analysis of all-cause mortality, a parametric survival analysis was undertaken to generate estimates
of baseline mortality for all patients randomised to OPT (n= 3477). Several parametric distributions were
used (i.e. exponential, Gompertz, log-logistic, log-normal and Weibull) in models both with and without
covariables (i.e. patient characteristics) to ascertain which provided the most realistic predictions of survival.
It also allowed the effects of covariables to be considered and, when necessary, the approach to their
inclusion to be altered (e.g. age as a time-dependent covariable). The MS states that these were assessed
through visual comparisons of the fitted and Kaplan–Meier survival curves within the trial follow-up, visual
review of the extrapolations and of the shape of the instantaneous hazard over time, the Akaike
information criterion (AIC), Cox–Snell residuals, tests of the acceptability of the proportional hazards
assumption or accelerated failure time assumption, comparison against external data and review by clinical
experts. Although these methods appear appropriate, the MS presents only the AIC statistics, a
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Kaplan–Meier plot for the Weibull model (distribution selected for the analyses) showing risk quintiles and
an assessment of the proportional hazards assumption. As such, it is not possible to comment with
certainty whether or not the approach was suitable. IPD NMAs using meta-regression were undertaken to
estimate the relative treatment effects (i.e. HRs) of the different devices compared with each other and
with OPT, taking account of factors that may influence their effectiveness (i.e. covariables). An initial
set of NMAs excluding the covariables were conducted at the aggregate level (i.e. trial). This allowed a
comparison of the unadjusted efficacy estimates from the NMAs with those produced by pairwise
meta-analyses from aggregate trial data and with the individual trial estimates. This enabled an assessment
of whether the IPD NMA appeared representative or whether differences existed that required further
examination. It also provided an opportunity to assess the type of analysis that should be undertaken
(i.e. fixed vs. random effects). Although the MS reports that caterpillar plots, Brooks–Gelman–Rubin
statistics, autocorrelation and deviance information criteria (DIC) were assessed, only the DIC are reported.
A second set of analyses, incorporating the covariables from the IPD, were estimated using fixed-effects
models. These analyses used the Cox proportional hazards approach and were stratified by study to allow
the baseline hazard for each study to be independent. A rationale for using fixed-effects models and
for the selection of covariables is presented and appeared appropriate. The MS states that proportional
hazards tests and Schoenfeld residual-based tests were used to assess the models; however, these are
not reported.
The analysis of all-cause hospitalisation focused on the expected number of events per month and the
expected number of days per month spent in hospital (excluding events in the 60 days post randomisation
as these were accounted for separately in the MS economic model). The analysis used a negative binomial
regression model (NBRM) to estimate both the baseline hospitalisation rate for patients on OPT and the
effect of the different treatments on hospitalisation rates. The modelling approach was decided through a
comparison with Poisson regression using measures of goodness of fit [i.e. Bayesian information criterion
(BIC), AIC and two times log-likelihood score] and the covariates were incorporated into the analyses
through a stepwise process (included at a significance level of p= 0.05). Limited data availability meant
that some categorical variables were pooled (e.g. NYHA) and for some subgroups estimates were either
not calculated or considered unreliable. In such cases, adjustments were made and justifications provided.
Although limited information on the specific elements of the process is provided, comparisons are made
with previous evaluations when available. It is evident from the analysis that it is likely that the limited
evidence base affects the results and, although adjustments are made, uncertainty remains.
Health-related quality of life was assessed using the EQ-5D. UK age- and gender-specific utilities152 were
adjusted using disease- and treatment-specific decrements/increments estimated from the three IPD trials
reporting EQ-5D data and were varied over time. Baseline HRQoL taking account of disease severity was
estimated using the NBRM, following a similar procedure to that for all-cause hospitalisation (justification
for approach is provided). Prior to the analysis the raw data had been transformed as they appeared
skewed (commercial-in-confidence information has been removed). Derived values were checked against
population norms and trial-specific values to ascertain whether clinically plausible, reflecting the
uncertainties resulting from the limited IPD available. The impact of treatment on HRQoL was estimated
using the MD from baseline to first follow-up (assumed as 180 days). With only three studies in the
evidence network (n= 3736), observations were limited for ICDs and CRT-D and were skewed by NYHA
groups. This weakened evidence network affected the regression analysis, producing counterintuitive
results. Exploratory analysis using MLWHFQ data at 6 months, the MS systematic review of clinical
effectiveness and a correction for a placebo effect was used to adjust the estimates for use in the MS
cost-effectiveness model. Duration of benefit was estimated by comparing the mean device value with that
for OPT and judging when no further difference occurred. Justification is provided for the decisions made.
Although it is not possible to provide a detailed critique of each stage in the three analyses (given the
partial reporting of the exploratory and confirmatory analyses undertaken) or to replicate the NMA
as the IPD remains unpublished, the steps taken seem appropriate and the results presented appear
reasonable given the note of caution provided in the MS throughout all three analyses.
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Results
All-cause mortality
The baseline Weibull survival model for patients randomised to OPT was shown, through Kaplan–Meier
curves, to differentiate between patients with varying risk profiles and to demonstrate the heterogeneity in
the IPD population. Predicted survival rates were reported to (commercial-in-confidence information has
been removed). The baseline risk model was used in the MS cost-effectiveness model for the baseline
survival curve (see Table 37, p. 121, in the MS151). Covariables included in the model with a statistically
significant effect were age, sex, ischaemic aetiology, LVEF, NYHA class (I/II, III/IV) and QRS duration
(< 120milliseconds, ≥ 120milliseconds).
Exploratory NMA models without the covariables were fitted for the different comparisons of the
interventions using the trials identified in the evidence network (13 trials, 12,638 patients). These
showed limited differences in the HRs for fixed- and random-effects models and for IPD compared with
aggregate data for all trials in the network and for the pairwise meta-analyses. As such, it was considered
appropriate to use the IPD for the NMA and to use fixed-effects models. The fixed-effects IPD NMA
without the covariables estimated the HRs compared with (commercial-in-confidence information has
been removed) for CRT-D, (commercial-in-confidence information has been removed) for CRT-P and
(commercial-in-confidence information has been removed) for ICDs. HRs were presented for CRT-D
compared with CRT-P (commercial-in-confidence information has been removed) and for CRT-D compared
with ICD (commercial-in-confidence information has been removed). The MS states that proportional
hazards tests showed that the benefits were maintained over time [global p-value for device terms
(commercial-in-confidence information has been removed)].
Univariate analyses and multivariate stepwise selection procedures were used to explore the covariables
for inclusion in the final NMA model as treatment effect modifiers. Rationales were provided for the
covariables included for the different comparisons made. The final NMA model was used in the
cost-effectiveness model presented in the MS (see table 39, p. 132, in the MS151). The final NMA model
was used to show the predicted treatment effect for different subgroups, presented as HRs with CIs
(assumed to be 95% CIs although not stated in the MS) (Table 77). Importantly, the MS warns that the
analysis presented is ‘inherently more uncertain than the analysis without covariables’ and that ‘caution
should be taken not to over-interpret individual subgroups since anomalies may arise as a result of patient
level characteristics not accounted for’ (p. 130).151 This is particularly important in relating the broad
conclusions made to the results presented in the MS. The analyses highlighted that age, sex, QRS duration
and LBBB pattern were significant predictors of benefit from the different devices.
It is evident from the forest plots presented in the MS (see figure 19, pp. 133–4151) and from HRs
presented in Table 77 that for the majority of subgroups the devices provide some benefit for all-cause
mortality compared with OPT (49 of 52 comparisons). However, the benefit provided by the devices is
rarely statistically significant (14 of 52 comparisons show significant benefit; four of 52 comparisons are of
borderline significance) and, as indicated in the MS, should be considered with some caution. Despite this,
it is possible to highlight the main findings for the different subgroups for which the benefit is statistically
significant or on the margins of statistical significance. ICDs provided a statistically significant benefit
compared with OPT for men aged < 60 years irrespective of QRS duration or LBBB status and were
marginally insignificant for both men aged ≥ 60 years and women aged < 60 years with a QRS duration
from ≥ 120milliseconds to < 150milliseconds and without LBBB. CRT-D benefited a wider group of
patients compared with OPT. Benefits that were statistically significant or on the margins of statistical
significance were reported for men and women of all ages with a QRS duration of ≥ 150milliseconds and
for women of all ages with a QRS duration from ≥ 120milliseconds to < 150milliseconds. In contrast,
CRT-P had a statistically significant effect only for women aged ≥ 60 years with a QRS duration of
≥ 150milliseconds and with LBBB.
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TABLE 77 Hazard ratios (95% CIs) for all-cause mortality from the NMA with covariables for the comparisons
between the different devices and OPT
QRS
(milliseconds) Device
Sex and age group
Male < 60 years Male ≥ 60 years Female < 60 years Female ≥ 60 years
Non-LBBB
< 120 ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
≥ 120 to < 150 ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
CRT-D Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
CRT-P Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
≥ 150 ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
CRT-D Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
CRT-P Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
LBBB
≥ 120 to < 150 ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
CRT-D Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
CRT-P Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
≥ 150 ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
CRT-D Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
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Post-submission note Following submission of this report we were informed of an error in the ABHI
submission that had led to incomplete accounting of the covariance between the model parameters.
Correcting the error resulted in a narrowing of the CIs around the HRs for the comparisons with OPT.
As SHTAC did not have access to the IPD analyses, the error cannot be verified. Although this increased
the number of comparisons for which there was a statistically significant benefit (28/52), the groups
identified differed little from those that were shown to benefit significantly or that were on the margins of
statistical significance in the previous SHTAC assessment. In the reanalysis ICDs were shown to provide a
statistically significant benefit for all men irrespective of age, QRS duration or LBBB status and for women
aged < 60 years with a QRS duration from ≥ 120milliseconds to < 150milliseconds and without LBBB.
CRT-D benefited a wider group of patients. Benefits that were statistically significant or on the
margins of statistical significance were reported for men and women of all ages with a QRS duration
≥ 120milliseconds and with or without LBBB. In contrast, CRT-P had a statistically significant effect only for
men and women aged ≥ 60 years with a QRS duration of ≥ 150milliseconds and with LBBB.
All-cause hospitalisation
The baseline regression model (see table 40, p. 139, in the MS151) for patients randomised to OPT
produced monthly probabilities of hospitalisation for the different subgroups (Table 78). These were used
for the baseline assessment. When data allowed, treatment effects were estimated using a process similar
TABLE 77 Hazard ratios (95% CIs) for all-cause mortality from the NMA with covariables for the comparisons
between the different devices and OPT (continued )
QRS
(milliseconds) Device
Sex and age group
Male < 60 years Male ≥ 60 years Female < 60 years Female ≥ 60 years
CRT-P Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Source: figure 19, pp. 133–4, in the MS.151
TABLE 78 Baseline monthly probabilities of hospitalisation by covariate pattern (patient receiving OPT)
NYHA class I/II NYHA class III NYHA class IV
Non-ischaemic aetiology
QRS
< 120milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS
120–149milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS
≥ 150milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Ischaemic aetiology
QRS
< 120milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS
120–149milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS
≥ 150milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Assumed starting age 66 years.
Source: table 41, p. 140, in the MS.151
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to a fixed-effects NMA (see table 42, p. 142, in the MS151) and are presented in Table 79. Limited data
meant that estimates could not be provided for some groups (i.e. ICD NYHA class IV and CRT-P NYHA
class I/II) and are thought unreliable for others (i.e. CRT-D NYHA classes III and IV). Alternative values have
been put forward in the MS with justifications (see Table 79), which appear reasonable. The effects of the
devices on all-cause hospitalisations were translated into monthly transition probabilities (Tables 80–82),
which were used in the economic model presented in the MS.
Health-related quality of life
The NBRM (see table 52, p. 152, in the MS151) for patients randomised to OPT was used to generate
baseline results for the different subgroups (Table 83). Given the limitations of the data set used, the
estimates were checked with population norms and with the mean values from the three trials included in
the IPD. Although variations were evident, the MS stated that they were felt to be within acceptable
tolerance levels. Treatment effects on HRQoL were estimated as mean change from baseline using the IPD
(Table 84). As several estimates appeared counterintuitive, reflecting the limited and skewed data available,
the MS adjusted the values based on IPD analysis of MLWHFQ 6-month data and a systematic review
(see Table 84). As a result, the MS suggests that caution should be used when interpreting the results.
TABLE 79 All-cause hospitalisation treatment effects derived from the NMA and used in the MS economic model
(events per month)
Derived value Value used in model Justification
ICD
NYHA class I/II Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Results from IPD analysis clinically plausible
NYHA class III Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Results from IPD analysis clinically plausible
NYHA class IV Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Device not assessed in this patient group
CRT-P
NYHA class I/II Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Device not assessed in this patient group
NYHA class III Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Results from IPD analysis clinically plausible
NYHA class IV Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Results from IPD analysis clinically plausible
CRT-D
NYHA class I/II Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Results from IPD analysis clinically plausible
NYHA class III Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Results from IPD analysis not clinically plausible.
Assumed same as CRT-P-value given common
component (CRT)
NYHA class IV Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Results from IPD analysis not clinically plausible.
Assumed same as CRT-P-value given common
component (CRT)
Source: tables 43 and 44, pp. 142–3, in the MS.151
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TABLE 80 Monthly all-cause hospitalisation transition probabilities (ICD, events per month)
NYHA class I/II NYHA class III NYHA class IV
Non-ischaemic aetiology
QRS < 120milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
NA
QRS 120–149milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
NA
QRS ≥ 150milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
NA
Ischaemic aetiology
QRS < 120milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
NA
QRS 120–149milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
NA
QRS ≥ 150milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
NA
NA, not applicable.
Source: table 45, p. 144, in the MS.151
TABLE 81 Monthly all-cause hospitalisation transition probabilities (CRT-P, events per month)
NYHA class I/II NYHA class III NYHA class IV
Non-ischaemic aetiology
QRS < 120milliseconds NA NA NA
QRS 120–149milliseconds NA Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS ≥ 150milliseconds NA Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Ischaemic aetiology
QRS < 120milliseconds NA NA NA
QRS 120–149milliseconds NA Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS ≥ 150milliseconds NA Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
NA, not applicable.
Source: table 46, p. 144, of the MS.151
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TABLE 82 Monthly all-cause hospitalisation transition probabilities (CRT-D, events per month)
NYHA class I/II NYHA class III NYHA class IV
Non-ischaemic aetiology
QRS < 120milliseconds NA NA NA
QRS
120–149milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS ≥ 150milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Ischaemic aetiology
QRS < 120milliseconds NA NA NA
QRS
120–149milliseconds
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
QRS ≥ 150milliseconds Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
N/A, not applicable.
Source: table 47, p. 145, in the MS.151
TABLE 83 Comparison of indicative individuals with population equivalents
NYHA
class Sex
Decrements from unity
Population
norm Derived Disease-specific componenta
Non-ischaemic aetiology
I/II Male 0.2100 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
I/II Female 0.2098 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
III Male 0.2100 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
III Female 0.2098 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
IV Male 0.2100 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
IV Female 0.2098 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
Ischaemic aetiology
I/II Male 0.2100 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
I/II Female 0.2098 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
III Male 0.2100 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
III Female 0.2098 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
IV Male 0.2100 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
IV Female 0.2098 Commercial-in-confidence information
has been removed
Commercial-in-confidence information
has been removed
a Corresponds to difference between population norm and derived value and is to be interpreted as the impact of the
disease above and beyond what would naturally occur.
Assumed starting age 66 years.
Source: tables 53 and 54, p. 153, in the MS.151
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TABLE 84 Treatment-specific utility increments by device and NYHA group from the IPD analysis and adjusted
values for use in the MS economic model
IPD analysis Economic model
Justification for value used in
economic modeln
Utility value
(mean, SE)a Utility valueb
NYHA class I/II
OPT Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
No clinical reason why person already
receiving OPT would have a change
in utility
ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Value derived from IPD analysis
(commercial-in-confidence information has
been removed). Systematic review
suggests ICDs have a positive impact
CRT-P Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Cost-effectiveness results not generated
for this treatment option
CRT-D Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Value derived from IPD analysis
(commercial-in-confidence information has
been removed). Systematic review and
MLWHFQ analysis suggest that CRT-D has
a positive impact
NYHA class III
OPT Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
No clinical reason why person already
receiving OPT would have a change
in utility
ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Results from IPD analysis not significantly
different from zero. Literature review
suggests that ICDs have no benefit in
this group
CRT-P Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Value derived from IPD analysis
(commercial-in-confidence information has
been removed). Literature review and
MLWHFQ analysis suggest that CRT-P has
a benefit in this group
CRT-D Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Assumed same as CRT-P as not thought
clinically different. IPD results derived from
small patient numbers. Literature review
and MLWHFQ analysis suggest that CRT-D
has a benefit in this group
NYHA class IV
OPT Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
No clinical reason why person already
receiving OPT would have a change
in utility
ICD Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Cost-effectiveness results not generated
for this treatment option
CRT-P Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Not enough information available.
Assumed same as for NYHA class III.
Analysis of MLWHFQ data supports
this assumption
continued
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Validation of the adjusted values provided in the MS is difficult because of the lack of published evidence;
as such, the increments presented should be viewed with caution. (Commercial-in-confidence information
has been removed) and so this was applied in the economic model presented in the MS.
Discussion
The MS presented an IPD NMA using meta-regression to assess the effectiveness of ICDs, CRT-P and
CRT-D for different subgroups of people with HF. As part of the NMA, the MS used a systematic review to
identify the network of evidence for which IPD were available. It provided an outline of the methods used
in the systematic review and in the different stages of the NMA. The effects of different decisions were
discussed and comparisons made, although analyses used to underpin many decisions were not presented.
Limitations in the underlying IPD and uncertainties in the analyses were outlined, with the MS suggesting
caution when interpreting and using the results. Importantly, the IPD NMA presented in the MS did not
take account of the subgroups identified by the scope for the NICE appraisal.61 Instead, it looked for
subgroups of HF patients for whom the different devices appeared to have some benefit. Although
challenging in terms of developing guidance, it reflects the opinion of part of the clinical community. Given
the lack of published evidence on subgroups of HF patients, the IPD NMA provides a useful source of
evidence. However, it should be used cautiously given the uncertainties in the methods used in the
NMA, the limitations in the evidence base (weak and imbalanced data), the assumptions used and the
adjustments made to some counterintuitive results, and the possibility that some of the findings may be
the result of chance.
All-cause mortality
Fixed-effects IPD NMA without covariables showed that CRT-D, CRT-P and ICDs provided a statistically
significant benefit compared with OPT for all-cause mortality. Comparison of CRT-D with both CRT-P
and ICDs showed a statistically significant benefit for CRT-D. These results appeared appropriate when
compared with the original trial results and the pairwise meta-analyses undertaken in the SHTAC
systematic review (see earlier in this chapter) and the MS. When including covariates to identify subgroups
that benefited from the different devices, the outcomes were less clear and the MS advises that the results
should be interpreted with caution. It was evident that all of the devices appeared beneficial compared
with OPT; however, rarely were differences statistically significant. CRT-D appeared to have a statistically
significant benefit for people of all ages with a QRS duration of ≥ 150milliseconds and for women of all
ages with a QRS duration from ≥ 120milliseconds to < 150milliseconds. Although CRT-D showed benefit
for men of all ages, its effects were marginally insignificant. ICDs appeared to have a statistically significant
benefit for men aged < 60 years for all QRS durations and for men aged ≥ 60 years with a QRS duration
from ≥ 120milliseconds to < 150milliseconds and without LBBB. CRT-P showed a statistically significant
benefit only for women with a QRS duration of ≥ 150milliseconds and with LBBB.
TABLE 84 Treatment-specific utility increments by device and NYHA group from the IPD analysis and adjusted
values for use in the MS economic model (continued )
IPD analysis Economic model
Justification for value used in
economic modeln
Utility value
(mean, SE)a Utility valueb
CRT-D Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Commercial-in-
confidence
information has
been removed
Not enough information available.
Assumed same as for NYHA class III.
Analysis of MLWHFQ data supports
this assumption
a Mean changes from baseline in EQ-5D at 6 months.
b All utility values for the economic model have the value for OPT NYHA class III from the IPD analysis deducted to remove
any placebo effect.
Source: tables 56 and 58, pp. 155 and 157, in the MS.151
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All-cause hospitalisations
Estimates of the effects of the different devices on all-cause hospitalisations showed that all were
beneficial. ICDs reduced hospitalisations in people in NYHA groups I–III (commercial-in-confidence
information has been removed) and CRD-P in NYHA groups III and IV (commercial-in-confidence
information has been removed). Estimates for CRT-D suggested a constant effect for all NYHA groups
(commercial-in-confidence information has been removed) and so were adjusted in the MS to reflect
those of CRT-P.
Health-related quality of life
Baseline estimates of HRQoL from the IPD using the EQ-5D showed that patients in NYHA class I/II had
similar values to population norms, whereas patients in NYHA classes III and IV had values that were
progressively lower. Treatment estimates were counterintuitive, reflecting the limited IPD available. As a
consequence, adjustments were made which assumed that CRT-P and CRT–D had the same effect on
EQ-5D values and ICDs had an effect on NYHA class I/II only. Benefits were thought to last for a fixed
period of (commercial-in-confidence information has been removed).
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Chapter 5 Economic analysis
The aim of this section is to assess the cost-effectiveness of:
l ICDs in addition to OPT for the treatment of people who are at increased risk of SCD as a result of
ventricular arrhythmias despite receiving OPT
l CRT-P or CRT-D in addition to OPT for the treatment of people with HF as a result of LVSD and cardiac
dyssynchrony despite receiving OPT
l CRT-D in addition to OPT for the treatment of people with both conditions.
The economic analysis comprises:
l a systematic review of the literature on the cost-effectiveness of ICDs for people at risk of SCD and CRT
for people with HF
l a systematic review of studies of the HRQoL of people at risk of SCD or with HF
l a review of the MS to NICE151
l an independent economic model and cost-effectiveness evaluation (the SHTAC model).
Systematic review of existing cost-effectiveness evidence
A systematic review of the literature was conducted to summarise the existing evidence on the
cost-effectiveness of ICDs for the treatment of arrhythmias and CRT for the treatment of HF. The quality
of the included publications was assessed and those of relevance to the UK are discussed in greater detail
in terms of the methodology used and the potential generalisability of their results.
The methods and inclusion criteria considered for this review of economic evaluations are presented in
Chapter 3 and details of the search strategy are documented in Appendix 2. Given the volume of studies
meeting the inclusion criteria, data extraction was undertaken as follows: for studies included in previous
assessments, data extraction was derived from these reports and checked against original publications; for
newly identified evidence, data were extracted directly from the original publications.
Quantity and quality of research available
The literature searches identified 1410 studies that potentially met the inclusion criteria set out in
Chapter 3 (see Inclusion and exclusion criteria). From screening titles and abstracts, 1334 publications were
excluded and 76 were retrieved for full screening. Of these, 22 did not meet the inclusion criteria:
l six were found not to be full economic evaluations
l six were abstracts (five from 2010 and 2011 and one study treated as an abstract as it did not report
sufficient details for inclusion)
l three references were unobtainable and thus did not provide sufficient details for inclusion
l three had a different comparator from that specified in the research protocol
l two had a different population from that specified in the research protocol
l one had a different intervention from that specified in the research protocol
l one was a non-English-language report.
A list of relevant excluded studies is provided in Appendix 11.
A total of 54 papers met the inclusion criteria.63,64,149,153–203 Three studies were each reported in two
publications; therefore, 51 separate economic evaluations were included in this review. A flow chart
describing the identification of the included studies is provided in Figure 31.
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The included economic evaluations were categorised according to the type of the interventions that they
assessed. Thirty-six63,149,153–186 of the included studies assessed ICDs and 1764,155,172,187–200 assessed CRT.
Two155,172 of these studies assessed both ICDs and CRT; details of these two studies have been included
within both the ICD and the CRT sections.
Economic evaluations of implantable cardiac defibrillators
Most of the economic evaluations identified in the systematic review were for the use of ICDs in patients
at increased risk of SCD. Table 85 provides an overview of these studies.
Nineteen economic evaluations were conducted in the USA,154,157–159,162,165–170,176,177,179–182,184,186 five in
Canada,161,163,171,183,185 three in the UK,63,153,175 three elsewhere in Europe,160,164,174 two in Brazil155,178
and one each in Australia172 and Japan.149 Two studies were conducted in two countries (one in the UK
and France156 and one in Germany and the USA173). Study type was predominantly cost–utility
analysis149,153,155,157–160,162–165,170,174,176–182,185 and cost-effectiveness analysis63,154,166–169,171–173,175,183,184,186 with
two cost–benefit analyses.156,161 Most studies used a Markov model149,153,155,157–160,162–164,166–168,171,174,176–182,185
with five studies using a trial-based analysis169,170,173,183,186 and the remaining studies using a variety of
methods. Most studies used a long-term time horizon of > 20 years,149,153–155,157–160,162,164–166,168,172,174–182,185
six studies had a short time horizon of < 7 years63,156,161,167,169,173 and six studies had a medium time
horizon of between 8 and 19 years.163,170,171,183,184,186 Fourteen studies were based on a single
trial63,154,156,157,161,164,169–171,173,174,180,183,186 with the MADIT II trial101 (six studies154,157,164,171,180,186) and the
SCD-HeFT trial105 (four studies156,161,170,174) the most commonly used. Ten studies used more than one trial,
through meta-analysis, systematic review or different trial populations,149,153,155,160,163,172,176,177,181,182
eleven studies used other sources of evidence to model the intervention effect158,162,165–168,175,178,179,184,185
and one study did not state the source of data.159 Almost half of the studies (n= 15) reported that ICDs
were cost-effective,149,154–156,160,161,166–170,172,175,180,185 with an additional six finding ICDs cost-effective for
high-risk groups according to study definitions.158,165,173,176,177,181 Nine studies did not find ICDs
cost-effective153,157,159,162,163,174,178,183,186 and six studies were unclear whether ICDs were cost effective
or not.63,164,171,179,182,184
The judgements of the methodological quality assessment of the studies on ICDs are summarised in
Table 86. The studies vary in their quality and relevance to the UK NHS. As already described, many studies
were conducted in countries outside the UK and it is unclear how generalisable their results are to the UK
Total identified from searching
(n = 1487)
Titles and abstracts inspected
(n = 1410)
Excluded
(n = 1334)
Papers meeting inclusion criteria
(n = 54)
(Note: three studies are reported
in two papers)
Studies included in this review
(n = 51)
References for retrieval of full paper
(n = 76)
Excluded
(n = 22)
• Population, n = 3
• Intervention, n = 1
• Comparator, n = 3
• Study type, n = 5
• Language, n = 1
• Abstracts, n = 6
• Unobtainable, n = 3
Duplicates excluded
(n = 77)
FIGURE 31 Flow chart of identification of studies for inclusion in the review of cost-effectiveness.
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TABLE 85 Summary of the characteristics of the economic evaluations of ICD vs. OPT
Study Country Population Study type
Main source of
effectiveness data
Authors’
conclusion (ICER)
Al-Khatib
et al. 2005154
USA Adults with a history
of MI and a
LVEF ≤ 30%
Survival MADIT II101 Cost-effective
(US$50,500 per LYG)
Bertoldi et al.
2011155
Brazil HF NYHA class II, III
or IV; EF ≤ 35%
Markov Meta-analysis of trials Marginally cost-effective
(INT$32,663 per QALY)
Buxton et al.
2006153
UK Secondary prevention
patients at risk of
SCD with previous
CA or VT
Markov Observational data
and CIDS84
Not cost-effective
(£76,139 per QALY)
Caro et al.
2007156
UK and
France
HF NYHA
class II or III; LV
dysfunction ≤ 35%
DES SCD-HeFT105 Cost-effective
(cost–benefit ratio
0.17 UK)
Chan et al.
2006157
USA Ischaemic heart
disease and
LVEF ≤ 30%
Markov MADIT II101 Not cost-effective in all
MADIT II patients
(US$55,800 per QALY);
risk stratification with
MTWA improves
cost-effectiveness
(US$48,800 per QALY)
Chan et al.
2009158
USA Cardiomyopathy
(EF ≤ 35%) and no
previous VA
Markov Prospective cohort Cost-effective for
high-risk groups
(US$70,881 per QALY)
Chen and
Hay 2004159
USA Newly diagnosed HF
NYHA class II or III
Markov Not stated Not cost-effective
(US$97,863 per QALY)
Cowie et al.
2009160
Belgium LVEF ≤ 35%; HF
NYHA class II or III; or
previous MI
Markov AMIOVIRT,69 CAT,82
DEFINITE,90 MADIT I,99
MADIT II,101
SCD-HeFT105
Cost-effective
(€29,530 per QALY)
Deniz et al.
2009161
Canada HF NYHA
class II or II; LV
dysfunction ≤ 35%
DES SCD-HeFT105 Cost-effective
(cost–benefit ratio
of 0.05)
Feingold
et al. 2010162
USA Children (10–15
years) with dilated
cardiomyopathy
and HF
Markov Paediatric cardiology
prospective studies
Not cost-effective
(US$281,622 per QALY)
Filion et al.
2009163
Canada Severe LV
dysfunction at risk
of SCD
Markov Meta-analysis of trials Not cost-effective
(CAD$108,900 per QALY)
Gandjour
et al. 2011164
Germany EF ≤ 30% or
< 1 month after MI
Markov MADIT II101 Unclear (€44,736
per QALY)
Goldenberg
et al. 2005165
USA Inherited cardiac
disorders with high
risk of SCD; patients
aged 10–75 years
Survival Several sources Cost-effective in
selected high-risk
patients with inherited
cardiac disorders
because of gained
productivity
over lifetime
(US$3328–600,000
per QALY)
Kupersmith
et al. 1995167
USA High-risk patients
with VT/VF with
ICD implant
from 1980–7
Markov Retrospective study
with historical
control subjects
Cost-effective (epicardial
ICD US$31,100 per
LYG; endocardial ICD
US$25,700 per LYG)
continued
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TABLE 85 Summary of the characteristics of the economic evaluations of ICD vs. OPT (continued )
Study Country Population Study type
Main source of
effectiveness data
Authors’
conclusion (ICER)
Kuppermann
et al. 1990166
USA CA survivors, not
associated with MI,
and persistent VT/VF
Decision
tree+Markov
Several ICD
case series
Cost-effective
(US$15,600–29,600
per LYG)
Larsen et al.
1992168
USA Patients with
sustained VT/VF
Markov Case series of
ICD patients
Cost-effective
(US$29,244 per LYG)
Larsen et al.
2002169
USA EF ≤ 40%; sustained
VT or resuscitated
from CA
Trial AVID71 Moderately cost-effective
(US$66,677 per LYG)
Mark et al.
2006170
USA HF NYHA
class II or III; LV
dysfunction ≤ 35%
Trial SCD-HeFT105 Cost-effective
(US$41,530 per QALY)
McGregor and
Chen 2004171
Canada Adults with a history
of MI and a
LVEF ≤ 30%
Markov MADIT II101 Unclear (CAD$47,458
per LYG)
Medical Services
Advisory
Committee
2006172
Australia Adults with a history
of MI and a LVEF
≤ 30%; or HF NYHA
class II or III and LV
dysfunction ≤ 35%
Decision tree SCD-HeFT,105
COMPANION116
Cost-effective in patients
with moderate to severe
symptoms of CHF
(AUS$39,885 per LYG)
Mushlin et al.
1998173
Germany
and USA
Adults with a history
of MI and a
LVEF ≤ 30%
Trial MADIT99 Cost-effective in selected
high-risk patients
(US$27,000 per LYG)
Neyt et al.
2008174
Belgium HF NYHA
class II or II; LV
dysfunction ≤ 35%
Markov SCD-HeFT105 Not cost-effective
(€132,100 per QALY)
O’Brien et al.
1992175
UK Patients at high risk
of SCD
Simple
calculation
model
ICD case series Cost-effective
(£15,400 per LYG)
Owens et al.
1997176
USA CA survivors at high
risk of SCD
Markov CASH,81 MADIT99 Cost-effective for
high-risk groups
(US$74,400 per QALY)
Owens et al.
2002177
USA Patients at risk
of SCD (trial
characteristics)
Markov MADIT,99 AVID,71
CIDS, CASH,81
MUSTT,146
CABG Patch75
Cost-effective in
high-risk groups
(US$54,700 per QALY)
Parkes et al.
200063
UK Patients at risk
of SCD from
arrhythmias
Survival
calculation
AVID71 Unclear
(£40,500–87,000
per LYG)
Ribeiro et al.
2010178,201
Brazil HF NYHA class II and
III; LVEF ≤ 35%
Markov Several sources;
scenario with
MADIT I99
Not cost-effective
(R$68,318 per QALY)
Sanders et al.
2001179
USA Patients with MI who
did not have
sustained VA
Markov Range of ICD
efficacies evaluated
Unclear (US$71,800 per
QALY –US$557,900 per
QALY for moderate
efficacy and EF <0.3 to
EF >0.4)
Sanders et al.
2004180
USA Adults with a history
of MI and a
LVEF ≤ 30%
Markov MADIT II101 Cost-effective
(US$50,900 per QALY)
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TABLE 85 Summary of the characteristics of the economic evaluations of ICD vs. OPT (continued )
Study Country Population Study type
Main source of
effectiveness data
Authors’
conclusion (ICER)
Sanders et al.
2005181
USA Patients at risk
of SCD (trial
characteristics)
Markov MADIT,99 CABG
Patch,75 MUSTT,146
MADIT II,101
DEFINITE,90
DINAMIT,95
COMPANION,116
SCD-HeFT105
Cost-effective in selected
high-risk patients
(US$34,000–70,200
per QALY)
Sanders et al.
2010182
USA Patients with
LV dysfunction
Markov MADIT,99
MADIT II,101
DEFINITE,90 MUSTT,146
SCD-HeFT105
Unclear, varies widely
among trials
(US$37,031–138,458
per QALY)
Sheldon et al.
2001183 and
O’Brien et al.
2001202
Canada Secondary prevention
patients at risk of
SCD with previous
CA or VT
Trial CIDS84 Not cost-effective
(CAD$213,543 per LYG)
but more attractive in
patients with at least
two risk factors for SCD
(CAD$65,195 per LYG)
Wang et al.
2008149
Japan Brugada syndrome
with abnormal heart
Markov Several trials
including DEBUT89
Cost-effective
(US$14,667 per QALY)
Weiss et al.
2002184
USA VT or VF Retrospective
cohort study
Unclear
(US$78,400 per LYG)
You et al.
2007185
Canada Hypertrophic
cardiomyopathy at
risk of SCD (no
previous CA)
Markov ICD registries and
cohort studies
Cost-effective
(US$19,400 per QALY)
Zwanziger
et al. 2006186
USA Adults with a history
of MI and a
LVEF ≤ 30%
Trial MADIT II101 Not cost-effective for
trial, 3.5 years time
horizon (US$235,000
per LYG)
CA, cardiac arrest; DES, discrete event simulation; EF, ejection fraction; ICER, incremental cost-effectiveness ratio;
LV, Left ventricular; LYG, life-year gained; MTWA, microvolt T-wave alternants; VA, ventricular arrhythmia.
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NHS. Generally, the later studies are of higher quality. Earlier studies were less likely to include QALYs,
long-term life horizons or all relevant costs and consequences.
Five studies153,155,160,178,182 were considered to be of high methodological quality by meeting all or all but
one (‘Setting comparable to the UK’) of the recognised criteria.38,66 Of these, only one study153 was
conducted for a UK setting and perspective and is considered of most relevance. However, it should be
noted that this study, published in 2006, used data from patients mostly implanted before 2002 and
therefore may not be generalisable to current practice. We describe this study in more detail in the
following section.
Buxton and colleagues153
Buxton and colleagues153 developed a Markov model to estimate the cost-effectiveness of ICDs compared
with AAD treatment in the UK in secondary prevention patients at risk of SCD (see Appendix 12 for data
extraction). The economic evaluation was part of a wider study of the clinical characteristics, survival, QoL
and costs of ICD patients in the UK. The model combined patient data from two major UK implanting
centres with data from three published RCTs.71,81,84 The Markov model had daily cycles and eight states:
out of hospital (well); in hospital: arrhythmic, other cardiac, other non-cardiac, ICD maintenance, ICD
replacement and amiodarone problems; and death.
UK-specific survival and admission rates were estimated from the UK sampled observational data for ICD
patients, with data from the Canadian ICD trial84 used to estimate the relative survival and admission rates
between ICD and amiodarone patients. The review of clinical characteristics included 535 UK patients
implanted between 1991 and 2002. Mean actuarial survival at 1, 3 and 5 years was 92%, 86% and
71% respectively.
A cross-sectional survey collected HRQoL data using various QoL measures, including the EQ-5D, from a
sample of 229 patients. The levels of most of the HRQoL measures were lower in the cohort than in the
UK general population. There was no evidence of a change in QoL with time from implantation although
length of follow-up is not clear. Patients who had suffered ICD shocks had significantly poorer HRQoL.
Most patients nevertheless expressed a high level of satisfaction with ICD therapy. Based on the HRQoL
data, the model base case assumes a constant utility value of 0.75 for all patients. Sensitivity analyses used
utility estimates of 0.75 for ICD patients with 0.65 for patients receiving AADs and 0.83 for ICD patients
with 0.80 for patients receiving AADs.
Buxton and colleagues153 collected resource and cost data for 211 patients from Papworth NHS Trust and
167 patients from Liverpool NHS Trust. In addition to the costs of the implantation, post-discharge costs
(tests, medications and follow-up consultation) and costs of additional hospitalisations were also
calculated. The mean initial cost of implantation showed little variation between centres or between earlier
and more recent implants, and the model assumed a cost of £16,402 for the ICD device (with leads) and
an implantation cost of £23,608 (device cost, implantation cost, associated tests and hospital stay).
Buxton and colleagues153 concluded that the benefit from an ICD may not be sufficient to make the
technology cost-effective in the UK. The mean incremental cost-effectiveness ratio (ICER) for an average
UK patient over a 20-year time horizon was £76,139 per QALY gained. Cost-effectiveness was most
favourable for men aged > 70 years with a LVEF of < 35%. Patients with a LVEF of < 35% had an ICER of
£72,000 per QALY over 20 years. Extrapolating over the lifetime of the patients with a low LVEF gave an
ICER of £48,372 per QALY. A reduction in the cost of the implant/replacement and improvements in the
reliability of ICDs (repair/replacement of 3% per patient-year instead of 6% in the base case) would reduce
the ICER to £35,500 per QALY.
As noted earlier, this study used costs and resources associated with patients implanted between 1991 and
2002, which may not reflect current practice and could mean that the ICERs reported are no longer
appropriate. The other high-quality studies, all published since this study was published and for slightly
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different populations and different settings, present a range of conclusions about the cost-effectiveness of
ICDs, from not cost-effective178 to uncertain if cost-effective,182 marginally cost-effective155 and
cost-effective.160
Economic evaluations of cardiac resynchronisation therapy
Seventeen economic evaluations of the use of CRT concern patients with HF.64,155,172,187–200 Table 87
provides an overview of these studies. Four studies were conducted in the UK64,189,190,198 with six
conducted elsewhere in Europe.187,188,191,193,196,199 Two studies were carried out in Australia,172,195 two in the
USA,192,197 and one each in Canada,194 Brazil155 and Argentina.200 The study type was mostly cost–utility
analysis (n= 16) with one cost-effectiveness analysis.172 Most studies used a Markov model
(n= 11),64,155,187,188,193,194,196–200 with six studies using other methodology172,190–192,195 and one using
trial-based analysis.189 Twelve studies used a long-term time horizon of > 20 years64,155,172,188,189,191,194–198,200
and five studies had a short time horizon of < 8 years.187,190,192,193,199 Eight studies were based on a single
trial, with the CARE-HF109 (five studies188–191,198) and COMPANION116 (three studies172,192,196) trials the
most commonly used. Five studies used more than one trial, through meta-analysis, systematic review
or different trial populations155,194,195,197,200 and four studies used other sources of evidence to
model the intervention effect.64,130,193,199 The majority of the studies (n= 15) reported that CRT was
cost-effective.64,155,172,187–193,195,196,198–200 Two studies (conducted in the USA197 and Canada194) in patients in
NYHA class III and with a prolonged QRS duration were uncertain whether or not CRT was cost-effective.
The judgements of the methodological quality assessment of the studies on CRT are summarised in
Table 88. The studies vary in their quality and relevance to the UK NHS. As mentioned earlier, some studies
are conducted in countries outside the UK and it is unclear how generalisable their results are to the UK
NHS. The studies have been conducted in the last 10 years and generally are of fairly high quality.
However, some studies have used a short time horizon and some have not included justification for the
selection of effectiveness data sources or details of all costs and consequences. For one study the focus
was patients with mild HF, which may limit relevance to the UK.
Six studies64,155,188,194,196,197 were considered to be of high methodological quality by meeting all or all
but one (‘Setting comparable to the UK’) of the recognised criteria.38,66 Of these, one study,64 conducted
for a UK setting, is considered to be of most relevance. We describe this study in more detail in the
following section.
Fox and colleagues64
Fox and colleagues64 (also reported in Bond and colleagues203) developed a Markov model to compare
CRT-P and CRT-D with OPT in patients with HF in the UK (see Appendix 12 for data extraction). The model
followed a mixed-age cohort of people (start age from 30 to 90 years) with HF (NYHA class III and IV)
because of LVSD (with LVEF ≤ 35%) and electrical dyssynchrony (QRS duration > 120milliseconds) over
their lifetime. A cycle length of 4 weeks was used and a lifetime time horizon.
The model had the following health states: surgery (original implant, upgrade, routine maintenance),
postoperative complication, stable with device, stable with OPT, infection (CRT or ICD related), hospitalised
(HF, HF and heart transplant) and death (sudden cardiac cause, HF, non-cardiac related).
The baseline population mortality in the OPT arm was taken from the CARE-HF trial109 as this was a large
UK-based trial. The mortality benefit of CRT over time was calculated using the survival curve from the OPT
group in the CARE-HF trial with the pooled HR, estimated in their systematic review of the clinical
effectiveness of cardiac resynchronisation in HF. The model used QoL estimates related to NYHA class
(class I 0.93 and class II 0.78 from Kirsch and McGuire;210 class III 0.61 and class IV 0.44 from Calvert and
colleagues211) and utility for hospitalisation with HF (0.57 from McAllister and colleagues194). Patients were
distributed across NYHA classes according to the data from the CARE-HF trial at baseline, 90 days and
18 months. The costs of the devices were obtained from a sample of 61 NHS ‘buying units’ (either
individual health service trusts or purchasing consortia of trusts) during 2004 and 2005. Costing year and
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TABLE 87 Summary of characteristics of economic evaluations of CRT vs. OPT
Study Country Population
Study
type
Main source of
effectiveness data Authors’ conclusion (ICER)
CRT-P vs. OPT
Banz 2005187 Germany Patients
with HF
Markov Several publications and
expert opinion
Cost-effective
(€36,600 per QALY)
Bertoldi
et al. 2011155
Brazil HF NYHA
class II, III or
IV; EF ≤ 35%
Markov Meta-analyses Cost-effective
(INT$15,723 per QALY)
Blomstrom
et al. 2008191
Denmark,
Finland,
Sweden
HF NYHA
class III or IV;
LVEF < 35%
Survival CARE-HF109 Cost-effective (Denmark
€4759 per QALY; Finland
€3571 per QALY; Sweden
€6493 per QALY)
Bond et al.
2009203
and Fox
et al. 200764
UK HF NYHA
class III or IV;
LVEF < 35%;
QRS > 120
milliseconds
Markov Systematic review and
other published sources
Cost-effective
(£16,738 per QALY)
Callejo et al.
2010188
Spain HF NYHA
class III or IV;
LVEF < 35%
Markov CARE-HF109 Cost-effective
(€28,612 per QALY)
Calvert et al.
2005189
UK HF NYHA
class III or IV;
LVEF < 35%
Trial-
based
CARE-HF109 Cost-effective
(€19,319 per QALY)
Caro et al.
2006190
UK HF NYHA class III
or IV;
LVEF < 35%
DES CARE-HF109 Cost-effective
(£15,247 per QALY)
Feldman et al.
2005192
USA HF NYHA
class III or IV;
LVEF ≤ 35%; QRS
> 120milliseconds
Survival COMPANION116 Cost-effective
(US$19,600 per QALY)
Heerey et al.
2006193
Ireland HF NYHA
class III or IV;
QRS interval
> 130milliseconds
Markov Retrospective
cohort study
Cost-effective (dominant)
McAlister
et al. 2004194
Canada HF NYHA
class III and
prolonged
QRS duration
Markov Systematic review (nine
RCTs: MIRACLE,121
MIRACLE ICD,136
PATH-CHF,204
COMPANION,116
MUSTIC-SR,125
MUSTIC-AF,205
Garrigue et al.,206
CONTAK-CD,126
RD-CHF207)
Uncertain
(US$90,700 per QALY)
Medical
Services
Advisory
Committee
2006195
Australia HF NYHA
class III or IV;
LVEF < 35%
Decision
tree
CARE-HF,109 MIRACLE121 Cost-effective for patients
with moderate to severe
chronic HF (NYHA classes III
and IV) (Aus$12,257 per
QALY for a public hospital)
Neyt et al.
2011196
Belgium HF NYHA
class III or IV;
LVEF ≤ 35%;
QRS interval
> 120milliseconds
Markov COMPANION116 Cost-effective
(€11,200 per QALY)
continued
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TABLE 87 Summary of characteristics of economic evaluations of CRT vs. OPT (continued )
Study Country Population
Study
type
Main source of
effectiveness data Authors’ conclusion (ICER)
Nichol et al.
2004197
USA HF NYHA
class III and
prolonged
QRS duration
Markov MUSTIC-SR,125 MUSTIC-
AF,205 Path-CHF,204
CONTAK-CD,126
MIRACLE,121 MIRACLE
ICD,136 COMPANION,116
Garrigue et al.,206
RD-CHF207
Uncertain
(US$107,800 per QALY)
Poggia et al.
2012200
Argentina HF NYHA
class I or II;
LVEF ≤ 40%;
QRS interval
≥ 120milliseconds
Markov Meta-analysis of
REVERSE,208 MADIT-
CRT,209 RAFT140
Cost-effective
(INT$34,185 per QALY)
Yao et al.
2007198
UK HF NYHA
class III or IV;
LVEF < 35%
Markov CARE-HF109 Cost-effective
(€7538 per QALY)
CRT-D vs. OPT
Aidelsburger
et al. 2008199
Germany HF NYHA
class III or IV
Markov COMPANION116
and Banz187
May be cost-effective for
NYHA classes III and IV
depending on device
longevity (€88,143 per QALY)
Feldman et al.
2005192
USA HF NYHA
class III or IV; LVEF
≤ 35%; QRS
> 120milliseconds
Survival COMPANION116 Cost-effective
(US$43,000 per QALY)
Medical
Services
Advisory
Committee
2006172
Australia HF NYHA
class III or IV;
LVEF ≤ 35%; QRS
> 120milliseconds
Decision
tree
COMPANION116 Cost-effective for patients
with CHF NYHA III or IV,
sinus rhythm, LVEF ≤ 35%
and a QRS duration
≥ 120 milliseconds despite
OPT (Aus$22,944/LYG for a
public hospital)
Yao et al.
2007198
UK HF NYHA
class III or IV;
LVEF < 35%
Markov CARE-HF109 Cost-effective at WTP of
€44,100 per QALY
CRT-D vs. CRT-P
Bertoldi et al.
2011155
Brazil HF NYHA
class II, III or IV;
EF ≤ 35%
Markov Meta-analyses Not cost-effective
(INT$84,345 per QALY)
Bond et al.
2009203 and
Fox et al.
200764
UK HF NYHA
class III or IV;
LVEF < 35%;
QRS interval
> 120milliseconds
Markov Systematic review and
other published sources
Not cost-effective
(£40,160 per QALY)
Callejo et al.
2010188
Spain HF NYHA
class III or IV;
LVEF < 35%
Markov CARE-HF109 Not cost-effective
(€53,547 per QALY)
Neyt et al.
2011196
Belgium HF NYHA
class III or IV;
LVEF ≤ 35%;
QRS interval
> 120milliseconds
Markov COMPANION116 Not cost-effective
(€57,000 per QALY)
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currency for the analysis were 2005 and UK pounds, except for drug costs, which were 2006 and
UK pounds.
Compared with OPT, the model base-case analysis estimated that CRT-P conferred an additional 0.70
QALYs for an additional £11,630 per person, giving an estimated ICER of £16,735 per QALY gained for a
mixed age cohort (range £14,630–20,333).64,203 CRT-D compared with CRT-P conferred an additional 0.29
QALYs for an additional £11,689 per QALY, giving an ICER of £40,160 per QALY for a mixed-age cohort
(range £26,645–59,391). Sensitivity analyses showed that, in comparison to CRT-P, CRT–D devices were
most likely to be cost-effective when implanted in younger individuals and in those with a high risk
of SCD.
Of the other five high-quality studies, the three studies155,188,196 with the patient group most comparable to
that of Fox and colleagues64 also found that CRT-P was cost-effective when compared with OPT, whereas
the other two studies were uncertain about cost-effectiveness.194,197 Three of these high-quality
studies155,188,196 also compared CRT-D with CRT-P and found it not to be cost-effective.
Summary of published economic evaluations
l A systematic review of the cost-effectiveness of ICDs for the treatment of arrhythmias and CRT for the
treatment of HF identified 51 studies (36 studies of ICDs63,149,153–186 and 17 of CRT64,155,172,187–200).
Two studies55,172 analysed the cost-effectiveness of both ICD and CRT.
l The evaluations were published between 1990 and 2012 and the majority were conducted in
North America, but there were also several UK studies.
l Most of the evaluations employed state transition models to estimate long-term outcomes extrapolated
from short-term outcomes in the trials. Time horizons varied between 3 years and lifetime.
l Many of the studies were based on a single trial, with the MADIT II and SCD-HeFT trials the most
common ICD trials and the CARE-HF and COMPANION trials the most common CRT trials. There were
also several evaluations that used results from systematic reviews and meta-analyses of different
combinations of trials.
l Almost half of the studies reported that ICDs were cost-effective, with the others either finding that
ICDs were cost-effective only in high-risk groups or were not cost-effective or being uncertain about
cost-effectiveness. Five studies153,155,160,178,182 were considered to be of high methodological quality;
these studies report different conclusions about cost-effectiveness. Of these, only one study was
conducted for a UK setting and perspective and is considered to be of most relevance.153 This study
reported a mean ICER of £76,139 per QALY gained for an average UK secondary prevention patient
over a 20-year time horizon and therefore concluded that the benefit from ICDs may not be sufficient
to make the technology cost-effective as used in the UK (in 2006). However, these results may not be
applicable to current UK practice as some data used in the model came from patients implanted
between 1990 and 2002, which is now out of date.
TABLE 87 Summary of characteristics of economic evaluations of CRT vs. OPT (continued )
Study Country Population
Study
type
Main source of
effectiveness data Authors’ conclusion (ICER)
Yao et al.
2007198
UK HF NYHA
class III or IV;
LVEF < 35%
Markov CARE-HF109 Cost-effective
(€18,017 per QALY)
CRT-D vs. ICD
Bertoldi et al.
2011155
Brazil HF NYHA
class II, III or
IV; EF ≤ 35%
Markov Meta-analyses Marginally cost-effective
(INT$36,940 per QALY)
EF, ejection fraction; Int$, international dollars; LV, left ventricular; LYG, life-year gained; REVERSE, REsynchronization
reVErses Remodeling in Systolic left vEntricular dysfunction; WTP willingness to pay.
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l Almost all studies reported that CRT was cost-effective, with only two studies194,197 being uncertain
whether CRT was cost-effective. Six studies64,155,188,194,196,197 were considered to be of high methodological
quality, two of which were the studies reporting uncertainty about cost-effectiveness.194,197 One of the
high-quality studies64 was conducted for a UK setting and is considered to be of most relevance to the
UK NHS. This study estimated an ICER of £16,735 per QALY gained for CRT-P compared with OPT and
an ICER of £40,160 per QALY gained for CRT-D compared with CRT-P. The authors concluded that
CRT-D is not cost-effective for left ventricular dysfunction and that CRT alone is the most cost-effective
option in the population of patients evaluated (NYHA class III and IV with LVEF ≤ 35% and QRS duration
> 120milliseconds). CRT-D is more likely to be cost-effective in subgroups of younger patients or those
with a high risk of SCD who would qualify for CRT.
l Two of the included economic evaluations analysed both CRT and ICD, neither of which was
conducted in the UK.155,172 Both found that ICD was cost-effective compared with OPT, one172 found
that CRT-D was cost-effective compared with OPT and the other155 found that CRT-D was marginally
cost-effective compared with ICD.
Systematic review of health-related quality-of-life studies
A systematic review was undertaken to assess the HRQoL of people eligible for ICD or CRT devices.
The aims of the review were to provide data to populate the lifetime economic model with utilities to
calculate QALYs and to provide estimates of HRQoL by NYHA class for those with HF.
For adults, the NICE preferred measure of HRQoL is the EQ-5D212 and this was used in the previous ICD153
and CRT64 TARs. We were interested in HRQoL data of similar or better quality than that used in previous
studies and therefore filtered the results of our searches to include studies using the EQ-5D (index not
visual analogue scale). The search strategies used are described in Appendix 2. The inclusion and exclusion
criteria for the review are shown in Chapter 3 (see Inclusion and exclusion criteria).
The search strategy identified 6696 references, which after filtering for the EQ-5D resulted in 218
potentially relevant papers. Titles and abstracts were screened and the full texts of 22 papers were
retrieved for further inspection. After examining the retrieved papers, six studies met the inclusion
criteria.27,153,211,213–215 A summary of the selection process and the reasons for exclusion are presented in
Figure 32. Most studies were excluded because they did not use the EQ-5D or did not report it in the
required format. A list of the excluded studies is provided in Appendix 13.
References for retrieval
and screening
(n = 22)
Titles and abstracts
inspected after filtering
(n = 218)
Total identified from
searching (after
deduplication)
(n = 6696)
Excluded
(n = 196)
Excluded
(n = 16)
(14 with different QoL
 measure or in different
format, two abstracts with
insufficient details)
Studies included in
systematic review
(n = 6)
FIGURE 32 Flow chart of identification of studies for inclusion in the review of HRQoL.
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Health-related quality of life was assessed using the EQ-5D in four studies of patients with HF27,211,213,214
and two studies153,215 of patients who had received an ICD (Table 89). Three studies were cohort
studies153,213,215 and three studies were observational analyses based on RCTs.27,211,214
TABLE 89 Characteristics of included QoL studies
Study Country Study type
Study
population
Patient
characteristics
QoL
instrument
and
methodology Results
Buxton et al.
2006153
UK Retrospective
cohort study
229 patients
who had
received an ICD
Mean age
60 years, 81%
male; NYHA
class ≥ III 26%
EQ-5D
using UK
population
preferences
Mean EQ-5D was
reported by time
since ICD
implantation
(up to ≥ 6 years)
and ranged from
0.69 to 0.78
Calvert et al.
2005211
UK CARE-HF
RCT109
813 patients
with chronic
HF because of
LVSD and
dyssynchrony
Mean age
65 years; 74%
male; NYHA
class III 94%,
class IV 6%
EQ-5D
using UK
population
preferences
Mean EQ-5D: 0.60
(95% CI 0.58 to
0.62). NYHA class III
0.61, class IV 0.44
Eurich et al.
2006213
USA/
Canada
Cohort study 298 patients
with HF
with LVSD
Mean age
60 years; male
75%; NYHA
class I 11%,
class II 43%,
class III 41%,
class IV 4%
EQ-5D with
UK scoring at
baseline and
after 6 weeks
Mean EQ-5D: 0.66
(SD 0.26). Mean
EQ-5D at 6 weeks:
0.71 (SD 0.22) for
those with no
change in NYHA
Gohler et al.
2009214
USA EPHESUS
RCT214
1395 patients
with chronic HF
after acute MI
Mean age
64 years; male
71%; patient
origin: US 31%,
Europe 52%,
Latin America 14%
EQ-5D
weighted
by the
appropriate
preference
weight based
on the
subject’s origin
Mean EQ-5D by
NYHA class: I 0.855
(95% CI 0.845 to
0.864), II 0.771
(95% CI 0.761 to
0.781), III 0.673
(95% CI 0.727 to
0.765), IV 0.532
(0.480 to 0.584)
Groeneveld
et al. 2007215
USA Cohort study Patients who
had previously
received ICD
therapy for
primary (n= 45)
and secondary
(n= 75)
prevention
Mean age
60 years; male
73%; years
since ICD
implantation 2
EQ-5D
(country of
population
preferences
not reported)
Median EQ-5D
score: primary
prevention: 0.84
(IQR 0.77, 1),
secondary
prevention: 0.84
(IQR 0.78–1)
Holland et al.
201027
UK Cohort
analysis
within
HeartMed
RCT216
293 patients
with HF
following
emergency
hospital
admission
Mean age
77 years; male
64%; SA
NYHA class I/II
33%, class III
34%, class
IV 33%
EQ-5D using
UK population
preferences at
baseline and
6 months’
follow-up
Mean baseline
EQ-5D for SA NYHA
class: I/II 0.72
(SD 0.25), III 0.53
(SD 0.32), IV 0.47
(SD 0.35). Mean
6-month EQ-5D for
SA NYHA: I/II 0.6
(SD 0.25), III 0.38
(SD 0.32), IV 0.34
(SD 0.35)
EPHESUS, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; IQR, interquartile range;
SA NYHA, self-assigned New York Heart Association.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
Buxton and colleagues153 conducted a retrospective postal survey of patients in the UK who had received
an ICD between 1991 and 2002 as part of a wider review of ICD therapy. Based on the responses from
229 patients, they analysed the effect of time since implantation and age on HRQoL. Their analyses
showed that there was no evidence that the time since implantation affects HRQoL substantially over time,
with values similar at 1 year (0.78) and at > 6 years (0.77). However, there are limitations with the type of
study used (cross-sectional survey) and results should be viewed with caution.
Groeneveld and colleagues215 measured and compared HRQoL among primary and secondary prevention
ICD recipients in the USA. They recruited 120 patients undergoing clinical evaluation at cardiac
electrophysiology clinics who had previously received an ICD. The average duration since ICD implantation
was 2 years. The authors found no difference between the EQ-5D values of primary and secondary
patients, with health state utility values of 0.84 for both groups. They concluded that the QoL in patients
with ICDs was similar to that of similarly aged adults in the general population. This study also had
limitations in terms of methodology because of the convenience sampling technique used.
Calvert and colleagues211 investigated the HRQoL of 813 patients with chronic HF because of LVSD and
dyssynchrony (NYHA class III or IV) in the CARE-HF RCT109 in the UK. CARE-HF was a trial to investigate the
effects of CRT-P on the mortality and morbidity of patients already receiving OPT. Baseline EQ-5D data
were collected for 740 patients primarily (94%) in NYHA class III. The authors found that the mean
baseline health state utility value was 0.6 and that HF had an important impact on all aspects of QoL,
which was independent of age. A limitation of the study was that patients were not a random sample of
patients with HF but were patients enrolled in a study who were already receiving OPT.
Eurich and colleagues213 compared several HRQoL measures in 298 people with HF. Patients were recruited
across 14 medical centre outpatient departments in the USA and Canada. HRQoL was assessed at baseline
and at 6 weeks. EQ-5D health state valuations were completed for both UK and US population valuations.
Mean EQ-5D (UK valuation) was 0.66 at baseline and 0.71 at 6 weeks for those with no change in NYHA
status (70% of patients). This was a cohort study that evaluated the random changes observed in HF
patients in the outpatient setting with no specific intervention during the follow-up period.
Gohler and colleagues214 estimated utilities for NYHA classification and number of cardiovascular
rehospitalisations for patients with chronic HF after acute MI in the Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study (EPHESUS) RCT. The EPHESUS trial was a multicentre
RCT that investigated the effect of the aldosterone antagonist eplerenone. HRQoL was investigated in a
subset of 1395 patients at months 0, 3, 6, 12 and 18 using the EQ-5D. The health state utility values were
weighted by the appropriate preference weight based on a subject’s specific region of origin (USA 31%,
Western Europe 52%, Latin America 14%). The study used univariate and multivariate linear regression
analyses with independent variables for NYHA classification, number of cardiovascular hospitalisations
between study intake and the follow-up time point, age, sex and cardiovascular morbidities. In univariate
analyses, utilities associated with NYHA class were 0.85 for class I, 0.77 for class II, 0.67 for class III and
0.53 for class IV.
Holland and colleagues27 conducted a cohort analysis within the HeartMed RCT. A total of 293 adults with
HF were included from three large district general hospitals in the UK after an emergency admission and
were followed up for 6 months. The analysis aimed to test whether patients’ self-assigned NYHA class at
baseline predicted outcomes. Patients classified themselves into one of four self-assigned NYHA classes
using a questionnaire that described their functional status. Mean baseline EQ-5D scores were 0.72, 0.53
and 0.47 for self-assigned NYHA classes I/II, III and IV, respectively, and mean 6-month EQ-5D scores were
0.6, 0.38 and 0.34 respectively. The authors concluded that HF patients’ own assessment of their NYHA
class is a predictor of outcomes in HF, in the same way as clinician-assigned NYHA classes are a predictor
of outcomes; however, the study was limited by there being no clinician assessment to compare with
patients’ own assessment.
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Both studies in patients who had received an ICD had methodological limitations, with a key one being the
selection of participants, who were a small number of volunteers attending a single defibrillator clinic in
the USA215 and survey respondents at two centres in the UK.153 This may have biased the results by not
including patients who were representative of elsewhere with different experiences. However, in the
absence of more rigorous information these studies supply some information of relevance. One of the
studies suggests that there is no difference between the EQ-5D scores of primary and secondary
prevention patients and that QoL for ICD patients was similar to that of the general population of similar
age,215 and the other shows no evidence that QoL changes over time since implant.153
Four cohort studies reported utility estimates for HF patients, with two conducted in the UK27,153 and two
in the USA.213,214 Patient characteristics were generally similar across studies in terms of sex and age,
except for one study27 in which the mean age was greater (77 years compared with 60–65 years). The
severity of HF as measured by NYHA class differed between the studies, with the percentage of NYHA
class III participants ranging from 34%27 to 94%.211 Mean baseline EQ-5D scores were similar in the two
studies that reported this (0.60211 and 0.66213). Three studies reported mean baseline EQ-5D score by
NYHA class. Mean baseline EQ-5D scores for NYHA class III were 0.61,211 0.63214 and 0.53 in the study in
which patients self-assigned NYHA class.27 For NYHA class IV, mean baseline EQ-5D scores were 0.44,211
0.53214 and 0.47.27 Overall, the results suggest that HF has a significant effect on HRQoL. One study
reports random changes in utility after 6 weeks in patients with no change in NYHA class213 and another,
which used a self-assigned NYHA classification, showed decreased EQ-5D scores in each NYHA class after
6 months.27
Summary of the health-related quality-of-life review
l The systematic review found six relevant HRQoL studies that measured EQ-5D in HF,27,153,211,213–215
stratified by NYHA class, or that reported on patients who had previously received an ICD.
l Two studies153,215 were conducted in patients who had received an ICD, one in the UK153 of patients at
two hospitals who were implanted between 1991 and 2002 and who responded to a postal
questionnaire and one215 of volunteers attending a defibrillator clinic in the USA.
l The UK ICD study reported that the mean EQ-5D score did not change with time after implantation
(mean EQ-5D score ranged from 0.69 to 0.78 for the years up to ≥ 6 years since implantation). The US
study reported no difference between the EQ-5D scores of primary and secondary prevention patients
(median EQ-5D score 0.84) and that QoL for ICD patients was similar to that of the general population.
l Four cohort studies reported EQ-5D scores in HF, two127,153 in the UK (one of which was based on the
CARE-HF trial) and two213,214 in the USA (one based on the EPHESUS trial).
l Two studies reported similar mean baseline EQ-5D scores of 0.60 (UK RCT-based study211) and 0.66
(US cohort study213).
l Three studies27,211,214 reported mean baseline EQ-5D score by NYHA class. Mean baseline EQ-5D scores
for NYHA class III were 0.61211 and 0.53214 (UK studies) and 0.63 (US study).214 The lowest value was
reported in the study27 in which patients self-assigned NYHA class. Mean baseline EQ-5D scores for
NYHA class IV were 0.44211 and 0.4727 (UK studies) and 0.53214 (US study).
l One US study213 reported random changes in utility after 6 weeks in patients with no change in NYHA
class and one UK study27 (which used a self-assigned NYHA classification) showed decreased EQ-5D
scores in each NYHA class after 6 months.
l Overall, the results show decreased EQ-5D scores in HF compared with those of the general
population, particularly in NYHA classes III and IV.
Review of the manufacturers’ submission
As described in Chapter 4 (see Summary of Southampton Health Technology Assessments Centre’s peer
review of clinical effectiveness in the Association of British Healthcare Industries joint submission), one MS
consisting of a written report and an electronic model supporting the reported cost-effectiveness analyses
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was submitted to NICE.151 Further details on the submission and a discussion of the clinical data reviewed
and presented can be found in Chapter 4 and Appendix 10.
The review of the economic assessment within the MS consists of a brief overview of the cost-effectiveness
analysis, including the approach taken to modelling disease progression and the effects of treatment,
followed by a critical appraisal of the cost-effectiveness analysis.
Review of the cost-effectiveness analysis in the manufacturers’ submission
A structured data extraction form was used to guide the review of the MS (see Appendix 10),151 jointly
submitted by the ABHI on behalf of Biotronik, Boston Scientific, Medtronic, Sorin and St Jude Medical. The
submission includes a review of published clinical effectiveness studies of OPT, ICD, CRT-P and CRT-D for
the treatment of cardiac arrhythmias and HF, a NMA of IPD and a report of an economic evaluation
undertaken for the NICE multiple technology appraisal process.
The cost-effectiveness analysis uses a survival-based model to estimate the relative cost-effectiveness of
OPT, ICD, CRT-P and CRT-D (compared with each other) in 48 subgroups of patients. IPD from 12,638
patients from 13 RCTs were used to inform the economic model. All individuals are adults with HF, with a
LVEF ≤ 35% and/or at risk of SCD. This heterogeneous group of patients was split into 48 subgroups
according to their NYHA class, QRS duration, LBBB status and aetiology of heart disease, and
cost-effectiveness results are reported for each subgroup.
The perspective adopted for the economic evaluation is that of the UK NHS and PSS. General UK
population utilities were used at baseline to which disease-specific decrements were applied. The impact of
each intervention on HRQoL was incorporated as an intervention-specific increment. These estimates were
derived from published sources and IPD from the trials included in the systematic review of clinical
effectiveness studies in the MS.
For each subgroup, cost-effectiveness results were presented per intervention as incremental cost per
QALY relative to the intervention immediately less effective.
The interventions compared in the MS consist of those included in the NICE scope.61 However, not all of
them were included as comparators for all patient subgroups in the MS, as no patients were identified for
the following combinations:
l ICD excluded for NYHA class IV
l CRT-P excluded for NYHA class I/II and QRS duration < 120milliseconds
l CRT-D excluded for QRS duration < 120milliseconds.
Clinical advice indicated that these exclusions are reasonable.
Modelling approach
A cohort survival model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA)
with two states for alive and dead. Death is modelled using a series of covariate-based regression
equations for baseline risk and treatment effect using long-term IPD. Based on the numbers of patients
alive, the model also estimates the numbers of patients hospitalised in each cycle. The model had monthly
cycles and a lifetime time horizon. Costs and health benefits in the model were discounted at 3.5%.
The baseline probability of death is for patients who receive OPT but no device, based on a range of
clinical covariates. These probabilities are used in combination with device-specific treatment effects,
derived from the NMAs. For the model baseline survival curve, a Weibull distribution was used with the
parameters of the risk model shown in Appendix 10. A similar approach is taken to estimate the
probability of all-cause hospitalisation. HRQoL utilities are applied to patients in the model according to
their treatment and clinical characteristics.
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The model does not include short-term device-related adverse events as the costing approach used to
derive total implant costs covers additional costs such as those of short-term adverse events.
Results were generated in a two-stage process. In the first, cost and QALY estimates were derived for all
relevant comparators for all 4992 patient profiles [four NYHA classes, two aetiology status groups
(ischaemic/non-ischaemic), three QRS categories, four LVEF categories, LBBB status (yes/no), two gender
groups, 13 age categories]. In the second stage, results were aggregated over LVEF and age and gender
categories, reducing the subgroups to 48, defined by NYHA class, QRS duration, LBBB status and aetiology.
Assumptions
The following additional assumptions are made in the model:
l The effects of treatment on HRQoL diminish over time. The model assumes that the benefit observed at
6 months is maintained for up to 5 years and thereafter begins to recede in a linear manner over the
time period from 5 to 10 years. After 10 years an individual with a device will have no additional
HRQoL benefit over an identical person receiving OPT.
l HRQoL increments were assumed to be associated with device implantation.
l Reduction in all-cause hospitalisation varied according to the device implanted and NYHA class of the patient.
Estimation of effectiveness
The clinical effectiveness estimates were based on a NMA of IPD from 13 clinical trials (12,638 patients,
followed up for up to 7.5 years). The clinical trials were CARE-HF,109 COMPANION,116 CONTAK-CD,126
DEFINITE,90 MADIT,99 MADIT II,103 MADIT-CRT,130 MIRACLE,121 MIRACLE ICD,136 RAFT,140 RethinQ,142
REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE)208 and
SCD-HeFT.105 These trials were identified through a systematic review of the clinical effectiveness of all of
the interventions. A further nine trials69,82,125,138,139,144,241,244 were also identified in the review but IPD were
not available for these trials (see Chapter 4 and Appendix 10 for further discussion on the clinical
effectiveness data included in the MS).
The NMA enabled the combination of trials that compared different sets of treatments within a single
analysis, and also allowed the available direct and indirect evidence to be used to inform comparisons
between possible treatments. The analysis assessed the outcomes of all-cause mortality, all-cause
hospitalisation and HRQoL, using the results to inform the economic model developed as part of the MS.
A critique of the IPD NMA is presented later in this chapter.
The IPD NMA showed that ICDs, CRT-D and CRT-P were significantly more effective than OPT for people
with HF when assessed for all-cause mortality, with CRT-D also providing statistically significant benefit
compared with ICDs and CRT-P. The results of the analysis of those subgroups that benefited from
the different interventions compared with OPT were less clear. CRT-D had a statistically significant
benefit for all people with a QRS≥ duration of ≥ 150milliseconds and all women with a QRS ≥ duration
from ≥ 120milliseconds to < 150milliseconds and a marginally insignificant effect for all men with
a QRS duration from ≥ 120milliseconds to < 150milliseconds. ICDs had a significant benefit for men
aged < 60 years and for men aged ≥ 60 years with a QRS duration from ≥ 120milliseconds to
< 150milliseconds and without LBBB. CRT-P had a significant benefit for women with a QRS duration
≥ 150milliseconds and LBBB. The NMA found that CRT-D had the strongest effect on all-cause mortality
(commercial-in-confidence information has been removed). Treatment effects for the individual devices
were also statistically significant (commercial-in-confidence information has been removed).
All devices reduced the rate of all-cause hospitalisations compared with OPT, with rates decreasing for
NYHA classes I–III with ICDs (commercial-in-confidence information has been removed), for NYHA classes III
(commercial-in-confidence information has been removed) and IV (commercial-in-confidence information
has been removed) with CRT-P and for all NYHA classes with CRT-D (commercial-in-confidence information
has been removed). HRQoL was assessed using the EQ-5D, showing counterintuitive results for the effects
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of treatment. Adjustments were made assuming that CRT-P and CRT-D would have the same effects and
that ICDs would have an effect only on NYHA classes I and II. Benefits were thought to last for
(commercial-in-confidence information has been removed) years.
UK device longevity estimates were derived from NHS data from the Central Cardiac Audit Database
(CCAD)217 on all implants with verified life status from 2000 to 2011 (∼ 40,000 implants). The MS considers
that these device longevity estimates represent the best currently available estimates as CCAD contains data
on a large number of implants and it is run by the NHS Information Centre. Device-specific median survival
estimates were obtained by fitting Weibull curves to the data. The Weibull curve was chosen as it is commonly
used to model such data and it was considered a good fit (in terms of both within-data accuracy and
long-term predictive plausibility). Median time to device failure in the model was 7.1 years for ICDs, 10.4 years
for CRT-P and 5.8 years for CRT-D. The methodology used by the manufacturers to estimate device longevity
is commonly used; however, clinical advice indicated that these figures seem to be overestimated.
Critical appraisal of the cost-effectiveness analysis in the
manufacturers’ submission
The MS was appraised for methodological quality and generalisability to the UK NHS using a checklist
adapted from the NICE reference case requirements67 and the Philips and colleagues’ checklist.68 Overall,
the submission meets all of the requirements for methodological quality and generalisability except that it
did not provide evidence that the economic model had been validated, and the model assumptions were
not listed and justified. Table 90 provides a summary of the critical appraisal of the MS.
TABLE 90 Critical appraisal of the economic evaluationa
No. Item MS Comments
1 Is there a clear statement of the decision problem? Yes
2 Is the comparator routinely used in the UK NHS? Yes
3 Is the patient group in the study similar to those of interest in the UK NHS? Yes
4 Is the health-care system comparable to that in the UK? Yes
5 Is the setting comparable to that in the UK? Yes
6 Is the perspective of the model clearly stated? Yes
7 Is the study type appropriate? Yes
8 Is the modelling methodology appropriate? Yes
9 Is the model structure described and does it reflect the disease process? Yes
10 Are assumptions about the model structure listed and justified? No
11 Are the data inputs for the model described and justified? Yes
12 Is the effectiveness of the intervention established based on a
systematic review?
Yes
13 Are health benefits measured in QALYs? Yes
14 Are health benefits measured using a standardised and validated
generic instrument?
Yes
15 Are the resource costs described and justified? Yes
16 Have the costs and outcomes been discounted? Yes
17 Has uncertainty been assessed? Yes Limited to few parameters
18 Has the model been validated? ? Limited reporting
of validation
?, unclear.
a Questions in this checklist based on checklist in Philips et al.67
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The model structure is consistent with the currently accepted theory of HF and ventricular arrhythmia.
The MS does not describe the sources of evidence used to develop and inform the model structure but
provides a brief justification for the choice of evidence (related to the large amount of IPD being available).
The MS also does not include a review of economic evaluations of the scoped interventions and
comparators. Other structures could have been adopted, but the fundamental features of the condition
and the impact of the interventions seem to be captured. Adverse effects of treatment, such as
perioperative complications, were not explicitly incorporated in the model. The model was populated with
data from the systematic review of clinical effectiveness studies in the MS. A monthly cycle length and a
lifetime horizon were appropriately used, and Weibull models were used to extrapolate all-cause mortality
beyond trial duration. There is no reference to the internal validation of the model in the MS. Overall, the
model results make intuitive sense and the conclusions seem valid. In addition, a comparison has been
made between the results of the MS and results generated in previous appraisals and reasons have been
given for any differences.
Estimation of quality-adjusted life-years
The approach taken for HRQoL was (1) to estimate UK-specific age and gender population utilities,
(2) derive disease-specific decrements using IPD EQ-5D data and (3) derive treatment-specific increments
associated with each device at first follow-up visit by NYHA class.
UK-specific age and gender population utilities were taken from a study by Kind and colleagues152 of 3395
individuals resident in the UK. Disease-specific decrements were taken from the CARE-HF,109 MADIT-CRT209
and RAFT140 trials. For the impact of treatment, the utility increments were calculated as the difference
between baseline and first follow-up period. The health state utility values used in the model are presented
in the data extraction form in Appendix 10.
The health state utility values used are derived from the patient-level EQ-5D data. The MS reports that
some of the results were highly counterintuitive given the nature of the underlying disease and the
interventions, for example the results for CRT-D for NYHA class III/IV showed a utility decrement, in
contrast to those for CRT-P. The MS has dealt with these inconsistencies in the patient-level data by using
several assumptions: CRT-D is assumed to have the same utility increment as CRT-P for NYHA class III/IV,
ICDs are assumed to have (commercial-in-confidence information has been removed) for NYHA class III.
ICDs are associated with a utility increment of (commercial-in-confidence information has been removed)
for NYHA class I/II. CRT-D has a utility increment of (commercial-in-confidence information has been
removed) for NYHA class I/II and (commercial-in-confidence information has been removed) for NYHA class
III/IV. These values for ICDs and CRT-P were derived from the IPD analysis after subtracting the OPT NYHA
class III value (commercial-in-confidence information has been removed). The values used for CRT-P were
of a similar magnitude to those reported in the CARE-HF study, which gave a utility increment of 0.1 at
18 months after implantation compared with OPT patients.
In the model, the HRQoL benefit observed at 6 months is maintained up to 5 years and thereafter begins
to recede in a linear manner over a time period of 5–10 years. After 10 years the model assumed that the
individual with a CRT or an ICD device will have no additional HRQoL benefit over an identical person
receiving OPT.
The MS does not report a systematic review of HRQoL studies. A review of utility values used in previous
economic evaluations is reported but no details of how these were obtained are provided. The MS
approach differs from that of most previous models (including those of Buxton and colleagues153
and Fox and colleagues64), in which no benefit from the interventions was assumed. However, the
device-specific increments used in the MS are similar to those used in some of the previous
models.177,192,196 The impact on HRQoL of treatment-related adverse events (such as infection and
perioperative complications), considered in previous models, was not included in the MS.
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Estimation of costs
The resource use accounted for in the MS included device-related resources, medication and resources
related to disease progression. IPD from the trials were used to estimate the mean number of all-cause
hospitalisation events per month and the mean number of days hospitalised per month. Hospital costs
were derived from the NHS reference costs218 and combined with the average mean length of stay. The HF
hospitalisation event cost was £2295 and the non-HF hospitalisation event cost was £2448.
Device costs were sourced from the average selling prices obtained from the manufacturers via the ABHI.
These prices are an aggregate across all sponsors (manufacturers) for ICD, CRT-P and CRT-D devices and
leads sold in the UK to the NHS. The implantation costs were taken from the Healthcare Resource Group
(HRG) tariff values.218 Device-related infection costs were derived by inflating values in the previous TAR on
CRT64 to £3139. Device costs, with implantation costs, were £15,248, £8281 and £17,849 for ICDs, CRT-P
and CRT-D respectively. Further device costs are shown in Appendix 10.
The manufacturers assumed that an OPT regimen is taken by all patients for HF treatment, regardless of
whether or not they receive a device in addition, and the drug cost allocated in any given month to each
patient alive is based on his or her baseline NYHA class. The proportions of patients using a range of HF
medications, by NYHA class, were derived from a combination of the clinical studies identified in the
systematic review and expert opinion. The recommended daily dose for each commonly used drug was
sourced from the British National Formulary (BNF).219 The total cost of treatment per 1-month cycle was
£14.28 for NYHA class I and between £22.13 and £22.30 for NYHA classes II–IV.
Overall, the derivation of costs and assumptions presented in the MS seems appropriate and consistent
with previous approaches. However, specific searches for resource use or cost studies in the UK are not
reported in the MS, and the impact of changes to the values and assumptions used was not analysed in
the MS. The estimates in the model seem to cover the relevant resource use, including complications,
non-HF hospitalisations and outpatient visits.
Cost-effectiveness results
The base-case deterministic results are presented for 48 subgroups defined by NYHA class, QRS duration,
LBBB status and aetiology, but not for the population as a whole or according to the population groups
scoped by NICE, and it is unclear how these results could be aggregated.
The base-case results can be found in the data extraction form (see Appendix 10) and are summarised in
Table 91. The MS provides limited reporting of the results and sensitivity analyses. Generally, only the
ICERs are presented for each of the base-case results, rather than a more detailed breakdown of costs and
QALYs, and incremental costs and QALYs between competing interventions. For the base case, fully
aggregated results with reporting of total costs and QALYs are presented only for subgroups of NYHA III
class patients comparing CRT-D with OPT. Overall, the results show that for most subgroups there is at
least one device with an ICER of < £30,000 per QALY and that, in some cases, a different device might be
cost-effective if a £20,000 per QALY threshold is considered.
The manufacturers conclude that, in many cases in which there are small differences in cost-effectiveness
between devices and high uncertainty as to which is the preferred device, NICE recommendations should
allow for clinical flexibility.
The MS explores model uncertainty through deterministic and probabilistic sensitivity analyses, with most
deterministic sensitivity analyses reported in the MS consisting of scenario analyses. Not all forms of
uncertainty were explored, only uncertainty associated with a few methodological assumptions. The MS
does not report the ranges used for the sensitivity analyses, only the different scenarios tested, and does
not identify the model parameters with the greatest influence on the results. The MS does not report the
assessment of uncertainty associated with resource use and cost parameters, and structural assumptions
have not been tested. For instance, a scenario of reduced device longevity was not analysed nor one
assuming no HRQoL benefit from the interventions.
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The following scenarios were tested in sensitivity analyses: removal of treatment effect tapering (mortality
and HRQoL), use of alternative NYHA-based IPD results and increase in device longevity. The base case
assumed that treatment effects on mortality or HRQoL are not constant but diminish over time. When
constant treatment effects for mortality and HRQoL were explored, ICERs in all patient groups were lower
than in the base case.
According to the MS, there may be a lower mortality treatment effect in patients in NYHA class IV than in
patients in NYHA classes I/II/III for CRT-D. The economic model was run using the estimated all-cause
mortality treatment effects based on the grouping of NYHA class IV compared with NYHA class I–III
patients. This analysis results in CRT-D becoming dominated in all NYHA class IV groups. The ICERs for all
other groups are lower than in the base case. Device longevity was investigated by increasing time to
device failure by 10%. There were only minimal changes to the cost-effectiveness results.
Probabilistic sensitivity analyses were conducted for a few subgroups, selected to reflect the baseline
characteristics of participants in the MADIT-CRT trial, but no overall population analysis was performed.
Because of the complexity of patient-level heterogeneity, the MS reported that a full probabilistic sensitivity
analysis would take several months to execute. Results were presented graphically for four subgroups, men
and women with and without LBBB, for patients of 65 years, NYHA class II, ischaemic, QRS duration
> 150milliseconds and LVEF between 20% and 25% patients. For these subgroups, CRT-D and OPT
showed a similar probability of being cost-effective at a willingness-to-pay (WTP) threshold of £20,000 per
QALY. The manufacturers concluded that the results suggested that the deterministic and probabilistic
sensitivity analyses were broadly aligned.
The MS does not provide any details of the variables included in the probabilistic sensitivity analysis, such
as mean values, distributions and variability of those variables. Credible intervals for the mean ICERs of the
most cost-effective intervention were not reported either. It is therefore not clear whether the methods of
assessment of parameter uncertainty are appropriate and whether the estimates of variation in the
probabilistic sensitivity analysis are appropriate to reflect uncertainty in parameter estimates.
TABLE 91 Summary of the base-case deterministic results
HF
severity
QRS
duration
(milliseconds) Results summary
NYHA
class I/II
< 120 The ICERs for ICD vs. OPT are < £25,200 per QALY gained
120–149 ICD is a cost-effective treatment optiona (ICER < £17,000 per QALY) for patients with no
LBBB. For CRT-D, all ICERs are < £25,000 per QALY gained in LBBB
patients (£20,608–24,343)
≥ 150 CRT-D is cost-effective treatmenta with an ICER of < £28,000 per QALY gained for
all options
NYHA
class III
< 120 ICD vs. OPT generates ICERs of < £30,000 per QALY
120–149 CRT-P is cost-effective.a CRT-D generates ICERs between £23,900 and £27,400 per QALY
gained relative to CRT-P
≥ 150 CRT-P is cost-effective vs. OPT (ICER < £20,000 per QALY). Compared with CRT-P, CRT-D
generates ICERs of < £30,000 per QALY gained. ICD is either dominated or
extendedly dominated
NYHA
class IV
< 120 No comparative analysis was possible in this patient group as no patients were identified
for this combination
≥ 120 For CRT-P compared with OPT, all ICERs are close to or < £20,000 per QALY gained. For
the comparison between CRT-D and CRT-P, all ICERs are > £30,000 per QALY gained
a According to willingness-to-pay threshold of £20,000–30,000 per QALY gained.
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The MS compares the cost-effectiveness estimates with those produced in the previous appraisals of CRT
in patients with NYHA class III/IV HF developed by Fox and colleagues64 and the review of ICDs in primary
prevention.153 The estimates from the MS model are markedly lower than those that were generated in the
models developed for TA9542 and TA120.43 The following reasons are given for the differences: real-time
reduction in production costs, increases in device longevity compared with values used in previous models,
better estimates of the impact of treatment on mortality and better understanding of the impact of
treatment on HRQoL.
Summary of the Association of British Healthcare Industries submission
l The ABHI submission was jointed submitted by the ABHI on behalf of five manufacturers.
l The submission includes a NMA of IPD from over 12,000 patients and 13 RCTs.
l The ABHI economic model is a survival model, based on IPD data according to patient
clinical characteristics.
l The model compared ICDs, CRT-P and CRT-D with OPT.
l The model met all but two of the criteria for methodological quality.
l The cost-effectiveness results are presented in the submission for subgroups according to NYHA class,
QRS duration, LBBB status and aetiology.
l The cost-effectiveness results do not directly address questions posed in the scope from NICE as it is
unclear how the subgroups selected relate to the groups scoped by NICE.
l Overall, ABHI’s results show that for most subgroups there is at least one device with an ICER of
< £30,000 per QALY gained and in some cases a different device might have an ICER of < £20,000 per
QALY gained.
Critique of the Association of British Healthcare Industries submission
The ABHI economic model is a cohort survival model with survival based on a series of covariate-based
regression equations. The model includes the costs and HRQoL of associated events related to
hospitalisation and device implantation. The general approach taken by the manufacturer seems
reasonable and the model structure is consistent with the current understanding of HF and ventricular
arrhythmia. Generally, the model meets most criteria for methodological quality, although there is limited
reporting in the MS on the sources of evidence used to develop and inform the model structure, the
assumptions used in the model have not been fully reported and explained and there is no evidence given
in the MS for internal validation of the model.
The manufacturers’ joint submission presented an IPD NMA to assess the effectiveness of the different
interventions for people with HF. It used meta-regression, allowing the effects of various patient
characteristics on treatment outcomes to be assessed and any subgroups who may benefit differently to be
identified. The analysis assessed the outcomes of all-cause mortality, all-cause hospitalisation and HRQoL,
using the results to inform the economic model developed as part of the MS. As an appraisal of the IPD
NMA is presented in Chapter 4 (see Individual patient data network meta-analysis: a critical appraisal), this
section provides a brief summary of the limitations and findings that are relevant to the economic model
produced as part of the MS.
The data sources used to populate the model for effectiveness are based on IPD data from over 12,000
patients and 13 RCTs and are of high quality; as stated by the MS151 this ‘represent[s] the first analysis of
its kind and magnitude’ (p. 2). Although the NMA appeared to follow established methods and had access
to unpublished IPD, aspects of the reporting of the analysis and apparent limitations in the data meant
that there was uncertainty in the findings presented. Despite the IPD including 13 of the 22 trials
(95% of patients) in the evidence network, data appeared limited given the covariables included
(i.e. number of variables and subcategories) and the lack of data for specific outcomes assessed. As a
consequence, the MS suggests that the analyses for all-cause mortality which include treatment effect
modifiers (i.e. subgroups) should be interpreted cautiously, and it makes adjustments to counterintuitive
results in the analyses of all-cause hospitalisations and HRQoL. The methods used in the NMA are
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discussed; however, the exploratory and confirmatory analyses used to determine the approach taken are
not fully reported. Inevitably, these may affect the results and, although some comparisons are made with
other evidence, a degree of uncertainty remains. Importantly, the IPD NMA has a different focus from that
identified in the scope for the NICE appraisal.61 Rather than assessing the effectiveness of the technologies
in specific groups of patients, it tries to identify which patients the different technologies benefit. As these
groups may not be the same, it is difficult to use the findings to address the original decision problem.
The assumptions made over costing and resource use are similar to the approach used by Fox and
colleagues64 and are consistent with current clinical practice. However, specific searches for resource use
or cost studies in the UK are not reported in the MS, and the impact of changes to the values and
assumptions used was not analysed in the MS. The estimates in the model seem to cover the relevant
resource use, including complications, non-HF hospitalisations and outpatient visits. In addition, the
sources used appear reasonable. The UK device longevity estimates are based on all available implant
data from CCAD and, as stated by the manufacturer, represent the best device longevity estimates
currently available.
The MS does not report a systematic review of HRQoL studies. A review of utility values used in previous
economic evaluations is reported but no details of how these were obtained are provided. The MS
approach differs from that of most previous models (including those of Buxton and colleagues153 and Fox
and colleagues64), in which no benefit from the interventions was assumed. However, the approach
appears reasonable and intuitive and the device-specific increments used in the MS are similar to those
used in some of the previous models177,192,196 and are of a similar magnitude to those reported in the
CARE-HF study.109
The model presents results according to subgroups defined by the manufacturers (NYHA class, QRS
duration, LBBB status and aetiology) and it is not clear how subgroups defined in the MS relate to the
populations scoped by NICE. Furthermore, the results have not been aggregated across subgroups and it
is unclear how the results compare with those from previously developed economic models. Uncertainty is
not comprehensively assessed in the MS as the sensitivity analyses presented are limited to a few scenarios.
The methodology used in the MS for the probabilistic sensitivity analysis is not described in sufficient detail
to determine whether or not joint parameter uncertainty was properly assessed.
Independent economic evaluation
Statement of the decision problem and perspective for the
cost-effectiveness analysis
In accordance with the NICE scope,61 we developed an economic model to estimate the
cost-effectiveness of:
l ICDs for people at risk of SCD as a result of ventricular arrhythmias compared with standard care
without an ICD
l CRT-P or CRT-D for people with HF as a result of LVSD and cardiac dyssynchrony compared with each
other and with standard care without CRT
l CRT-D for people with both conditions compared with CRT-P, ICDs and OPT.
The perspective of the analysis was that of the NHS and PSS. A 3.5% rate was used to discount future
health gains and costs.
Strategies and comparators
The scope for the appraisal as defined by NICE61 stated that the interventions to be considered are ICDs for
patients at risk of SCD and CRT for patients with HF as a result of LVSD and cardiac dyssynchrony,
alongside standard care (also referred to as OPT).
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The scoped population groups are eligible for different interventions and comparators; hence, the
cost-effectiveness analyses were performed specifically for each population group. Table 92 presents
the relevant comparisons for each group, as per the scope61 developed by NICE for this assessment.
1. For people at increased risk of SCD as a result of ventricular arrhythmias despite OPT, an ICD with
OPT will be compared with standard care (OPT without an ICD).
2. For people with HF as a result of LVSD and cardiac dyssynchrony despite OPT, CRT-P and CRT-D
(both with OPT) will be compared with each other or with standard care (OPT without CRT).
3. For people with both conditions described above, CRT-D with OPT will be compared with an ICD with
OPT, CRT-P with OPT or standard care (OPT alone).
Methods for the economic analysis
Model type and rationale for the model structure
All-cause mortality, SCD, HF mortality and death from other causes were key outcomes in the clinical trials
reviewed in Chapter 4. Secondary outcomes included hospitalisation from HF, NYHA class and QoL.
To estimate the impact of changes in these outcomes we required an appropriate model of disease
progression and its effect on patient HRQoL. We conducted a systematic search of the literature to identify
source material on the natural history, epidemiology and treatment of SCD and HF (see Appendix 2).
References identified by these searches, along with previous economic evaluations reviewed earlier
(see Systematic review of existing cost-effectiveness evidence), informed the development of a Markov
state transition model.
A Markov model developed in Microsoft Excel (2010) was used to simulate disease progression in a cohort
of patients, who move between distinct health states over their lifetime. The probability of being in a given
health state or moving to a different one (experiencing an event) is calculated repeatedly over 4-weekly
cycles. Disease progression varies according to the characteristics of the population group and the care
pathway that they follow. Each care pathway represents a distinct possible sequence of interventions. As
patients are modelled moving between health states over a lifetime, the respective health outcomes and
costs can be estimated for a given population following each care pathway. Utility values for the several
health states modelled were used to estimate the benefit of each intervention in terms of QALYs.
The adaptation of the model developed by Fox and colleagues64 for TA12043 was found appropriate for
the analysis of the cost-effectiveness of ICDs for the treatment of arrhythmias and the cost-effectiveness of
CRT devices for the treatment of HF. For patients with HF as a result of LVSD and cardiac dyssynchrony
considered as candidates for CRT, we based the pathways on those included in the model developed
TABLE 92 Treatment strategies being compared for each population group
Population
Comparisons
Intervention Comparator
Population 1 ICD+OPT OPT
Population 2 CRT-P+OPT OPT
CRT-D+OPT OPT
CRT-P+OPT CRT-D+OPT
Population 3 CRT-D+OPT OPT
CRT-D+OPT CRT-P+OPT
CRT-D+OPT ICD+OPT
Note: in OPT strategies patients are treated initially with OPT and subsequently receive devices as clinically necessary.
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for TA120.64 For patients at increased risk of SCD as a result of ventricular arrhythmias we adapted the
pathways based on our review of previous models developed for this population and expert opinion.
Further details on the development of the model can be found in Appendix 14.
Our model structure is similar to that of the model developed by Fox and colleagues.64 The key events
modelled were hospitalisation because of HF or arrhythmias, transplantation, surgical failure, death,
perioperative complications of the implant procedure, routine device replacement, lead displacement,
infections and device upgrades.
Figure 33 provides a general schematic of the health states that patients can experience and the possible
transitions from one health state to another. Patients being managed with OPT enter the model in the
stable health state of the OPT submodel, whereas patients undergoing management with a device enter in
the implant surgery state and will typically transition to stable in the device submodel.
Patients in a stable health state (either receiving OPT or with a device) can remain stable, be hospitalised
because of HF or arrhythmia or die from a variety of causes. In addition, patients in a stable health state
with a device may experience device-related adverse events (infection or lead displacement/failure) or may
require maintenance/replacement of their current device. Patients who are hospitalised because of HF may
be referred for heart transplantation. Patients in any of the live health states (stable, hospitalised and
transplanted) can die from arrhythmia (SCD), HF or any other cause (cardiac or non-cardiac). Transitions
between health states vary according to the population group and the treatment received.
The model structure was developed to reflect the management of patients under current clinical practice,
consisting of a simplistic approximation of the clinically plausible care pathways. Therefore, the model
allows patients initially managed with OPT or CRT-P to have a device implanted or upgrade to a different
device according to disease progression.
The model output obtained with this approach is intended to capture the impact of all treatments received
by the patient over a lifetime, instead of only those of the treatment initially allocated, providing a more
realistic estimation of the consequences of the adoption of a particular technology as initial treatment.
OPT submodel
Device submodel
Stable
Implant
surgery
Perioperative
complications
Transplantation
Dead
SCD
From any state to
another/any state
From a state to
any state
From a state to
another state
Remain in same
state
Death from HF
Death from
surgery
Death from other
causes
New device/
maintenance/
replacement
Hospitalisation
Stable Hospitalisation
Infection
Lead displacement
FIGURE 33 General schematic of the model.
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Relevant patient populations
The baseline cohorts modelled for the economic analysis consist of the three population groups who were
identified in the scope developed by NICE61 for this assessment:
1. patients at increased risk of SCD as a result of ventricular arrhythmias despite receiving OPT
2. patients with HF as a result of LVSD and cardiac dyssynchrony despite receiving OPT
3. patients with both conditions.
Baseline characteristics (age, sex and, when relevant, proportion in each NYHA class) for the modelled
cohorts were based on values reported in relevant clinical trials providing data to populate the model.
Treatment pathways
Population 1: patients at increased risk of sudden cardiac death as a result of
ventricular arrhythmias despite receiving optimum pharmacological therapy
The treatment pathways modelled for each cohort of population 1 patients are shown in Table 93.
Receiving an implantable cardiac defibrillator and optimum pharmacological therapy Patients
enter this arm of the model undergoing ICD implantation surgery. Patients undergoing surgery experience
a risk of procedure-related death. Those who survive surgery and have a successful implantation can
become stable with the device or be hospitalised because of HF, perioperative complications (including
mechanical failures as well as operative complications such as haematoma or pneumothorax), lead
displacement, infection or battery failure. Patients who experience unsuccessful implantation are referred
for reimplantation and are subject to the same risks of surgical failure and any complications, such as
surgical complications, infection or lead displacement, as those who attempt implantation for the
first time.
Stable ICD patients can be hospitalised because of HF, severe arrhythmias, lead displacement, infection or
battery failure. ICD patients who are hospitalised may continue to be hospitalised, return to the stable with
ICD state after treatment or be referred for heart transplantation (if hospitalised for HF). Stable ICD
patients are also subject to periodic battery replacement. As with initial implant surgery and
reimplantation, these routine replacement procedures expose the patient to a risk of procedure-related
death, perioperative complications and unsuccessful implantation.
Receiving optimum pharmacological therapy In this arm, patients enter the model in a stable health
state in which they are treated with OPT to prevent major ventricular arrhythmia. Stable OPT patients
can remain stable, be hospitalised because of HF or be hospitalised because of major arrhythmia and
therefore referred for ICD implantation. Hospitalised patients can return to the stable health state after
treatment, be referred for ICD implantation (if hospitalised for major arrhythmia) or be referred for
transplantation (if hospitalised for HF). Patients referred for ICD implantation are assumed to follow the
same pathway described above for the cohort who enter the model receiving an ICD+OPT and to be
subject to the same risk of events.
TABLE 93 Treatment pathways for population 1
Cohort
Treatment
First Second
OPT OPT ICD+OPT
ICD+OPT ICD+OPT –
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Model assumptions for population 1 Being an adaptation of the economic model developed by Fox
and colleagues64 for TA120,43 our model relies on some of the assumptions underlying Fox and colleagues’
model that were validated by clinical advice:
l patients being managed with OPT alone who experience hospitalisation because of non-fatal
arrhythmia are assumed to be referred to and undergo ICD implantation
l patients receiving OPT and hospitalised because of HF who experience a serious arrhythmic event are
assumed to be implanted with an ICD and to become stable with the device or be hospitalised because
of HF, perioperative complications, lead displacement or infection in the following cycle.
For modelling simplicity and given the exceptional nature of some events, some assumptions underlying
our model were incorporated following clinical advice:
l patients with lead displacements are assumed to have no risk of surgical failure as these interventions
do not require a new device
l patients with an unsuccessful implantation are assumed to have reimplantation attempted in the
following cycle
l patients undergoing reimplantation are assumed to be subject to the same risks of events as those who
attempt implantation for the first time
l the model assumes no risk of return to management with OPT alone because of unsuccessful
ICD implantation.
Population 2: patients with heart failure as a result of left ventricular
systolic dysfunction and cardiac dyssynchrony despite receiving optimum
pharmacological therapy
Table 94 summarises the treatment pathways modelled for each cohort of population 2 patients.
Receiving optimum pharmacological therapy Patients enter the model in a stable health state being
treated with OPT to prevent HF. Stable OPT patients may remain stable or be hospitalised because of HF or
severe arrhythmia. OPT patients who are hospitalised may return to the stable health state with OPT after
treatment or be referred for CRT-P implantation, CRT-D implantation or transplantation. Patients referred
for CRT devices follow a similar pathway to those described below for patients entering the model
undergoing CRT-P or CRT-D implantation.
TABLE 94 Treatment pathways for population 2
Cohort
Treatment
First Second Third Fourth
OPT OPT CRT-P+OPT CRT-D+OPT ICD+OPT
OPT CRT-D+OPT ICD+OPT OPT
CRT-P CRT-P+OPT CRT-D+OPT ICD+OPT OPT
CRT-P+OPT OPT CRT-P+OPT CRT-D+OPT
CRT-P+OPT OPT CRT-D+OPT ICD+OPT
CRT-D CRT-D+OPT ICD+OPT OPT CRT-P+OPT
CRT-D+OPT ICD+OPT OPT CRT-D+OPT
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Receiving CRT-P and optimum pharmacological therapy Patients with HF enter the model undergoing
CRT-P implantation surgery. They may experience procedure-related mortality or survive the implantation
procedure. Patients who survive the procedure may have successful or unsuccessful implantation. Patients
with a successful CRT-P implantation may experience perioperative complications, lead displacement,
infection and hospitalisation because of HF or severe arrhythmia; those who do not experience any of
these events transition to the stable state with CRT-P alongside OPT. Patients who have an unsuccessful
CRT-P implantation may return to the OPT stable health state or be hospitalised because of HF or severe
arrhythmia, and then progress onwards according to the pathway described above for patients receiving
OPT alone.
Stable CRT-P patients may be hospitalised if they experience HF, lead displacement, infection or battery
failure. CRT-P patients who are hospitalised may return to the stable with CRT-P after treatment state,
remain hospitalised, be referred for an upgrade to CRT-D if they experience serious arrhythmias or be
referred for a heart transplant if they experience worsening HF.
Receiving CRT-D and optimum pharmacological therapy Patients with HF enter the model
undergoing CRT-D implantation surgery. Similar to patients who enter the model undergoing CRT-P
implantation surgery, those who receive CRT-D may die from surgery or survive the implantation
procedure. Patients who survive with a successful CRT-D implantation may experience perioperative
complications, lead displacement, infection and hospitalisation because of HF or severe arrhythmia; those
who do not experience any of these events transition to the stable state with CRT-D alongside OPT.
Patients who survive an unsuccessful CRT-D implantation are assumed to undergo an ICD implantation.
These patients may die from ICD implantation surgery. Those who survive ICD implantation and have a
successful implantation can become stable with the device or be hospitalised because of HF or severe
arrhythmia, perioperative complications, lead displacement, infection or battery failure. Those with an
unsuccessful ICD implantation are assumed to be managed with OPT alone and follow the pathway
described earlier for population 2 receiving OPT.
Patients who are stable with CRT-D alongside OPT can be hospitalised if they experience HF or severe
arrhythmia, lead displacement, infection or battery failure. CRT-D patients who are hospitalised may return
to the stable with CRT-D after treatment state, remain hospitalised or be referred for a heart transplant if
they experience worsening HF.
Model assumptions for population 2 Some of the assumptions underlying our model for population 2
derive from the adaptation of the economic model developed by Fox and colleagues64 for TA12043
following clinical validation:
l patients with CRT-P who experience a serious arrhythmic event are assumed to be referred for
CRT-D implantation
l patients who survive an unsuccessful CRT-P implantation are assumed to return to being managed with
OPT alone
l patients who are hospitalised because of HF and who are referred for a device upgrade are assumed to
be implanted and become stable with the device or to be hospitalised because of HF, perioperative
complications, lead displacement or infection in the following cycle.
Other assumptions were incorporated according to clinical advice:
l patients who survive an unsuccessful CRT-D implantation are assumed to undergo an ICD implantation
l for consistency with an unsuccessful CRT-P implantation, patients who survive an unsuccessful ICD
implantation are assumed to return to being managed with OPT alone.
ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
194
Population 3: patients with both conditions
For population 3, four cohorts were modelled receiving initially CRT-D+OPT, CRT-P+OPT, ICD+OPT or
OPT alone. All of these strategies allow for subsequent device implants and upgrades. The treatment
pathways modelled for each cohort of population 3 patients are presented in Table 95.
Receiving CRT-D and optimum pharmacological therapy Patients with both conditions who enter the
model undergoing CRT-D implantation surgery follow a pathway which is similar to that described earlier
for population 2 receiving CRT-D+OPT. Patients who survive an unsuccessful CRT-D implantation are also
assumed to undergo an ICD implantation. However, patients with an ICD who become hospitalised
because of HF are referred for CRT-D reimplantation.
Receiving CRT-P and optimum pharmacological therapy Patients with both conditions who enter the
model undergoing CRT-P implantation surgery follow a similar pathway to that of population 2 receiving
CRT-P+OPT described earlier.
Receiving implantable cardiac defibrillator and optimum pharmacological therapy Patients enter
this arm of the model undergoing ICD implantation surgery. Those who survive with a successful ICD
implantation can become stable with the device or be hospitalised because of HF, a serious arrhythmic
event, perioperative complications, lead displacement, infection or battery failure. Those hospitalised for HF
are upgraded to a CRT-D implant. Those with an unsuccessful ICD implantation are assumed to be
managed with OPT alone and follow the pathway described below for those receiving OPT.
Receiving optimum pharmacological therapy Patients with both conditions who enter the model
being managed with OPT alone may remain stable with OPT or be hospitalised because of HF or severe
arrhythmia. Patients hospitalised for HF may return to the stable health state with OPT after treatment or
be referred for CRT-P implantation, CRT-D implantation or transplantation. OPT patients who are
hospitalised because of serious arrhythmias are referred for CRT-D implantation. Patients referred for CRT
devices follow a similar pathway to those described above for population 3 patients entering the model
receiving CRT-P+OPT or CRT-D+OPT.
TABLE 95 Treatment pathways for population 3
Cohort
Treatment
First Second Third Fourth
OPT OPT CRT-D+OPT ICD+OPT OPT
OPT CRT-P+OPT CRT-D+OPT ICD+OPT
ICD+OPT ICD+OPT CRT-D+OPT ICD+OPT OPT
ICD+OPT OPT CRT-D+OPT ICD+OPT
ICD+OPT OPT CRT-P+OPT CRT-D+OPT
CRT-P+OPT CRT-P+OPT CRT-D+OPT ICD+OPT OPT
CRT-P+OPT OPT CRT-D+OPT ICD+OPT
CRT-P+OPT OPT CRT-P+OPT CRT-D+OPT
CRT-D+OPT CRT-D+OPT ICD+OPT OPT CRT-P+OPT
CRT-D+OPT ICD+OPT OPT CRT-D+OPT
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Model assumptions for population 3 Some of the assumptions underlying the model of Fox and
colleagues,64 which were validated by clinical advice, were used in our model:
l patients being managed with OPT alone who experience a serious arrhythmic event are assumed to be
referred for CRT-D implantation
l patients with CRT-P who experience a serious arrhythmia are assumed to be referred for CRT-D
implantation
l patients with an ICD who are hospitalised because of HF are assumed to be referred for a CRT-D
l patients who are hospitalised because of HF and who are referred for a device upgrade are assumed to
be implanted and to become stable with the device or be hospitalised because of HF, perioperative
complications, lead displacement or infection in the following cycle.
Clinical experts confirmed the reasonability of other assumptions used in our model:
l patients who survive an unsuccessful CRT-D implantation are assumed to undergo an ICD implantation
l for consistency with an unsuccessful CRT-P implantation, patients who survive an unsuccessful ICD
implantation are assumed to return to being managed with OPT alone.
Pathways common to all populations
For each population modelled, patients being managed with a device can be in hospital because of
perioperative complications, lead displacement, routine device replacement or infection. The pathways
subsequent to each of these events are common to all populations:
l Perioperative complications: patients with perioperative complications can become stable with the
device or continue to be hospitalised because of HF, lead displacement, battery failure or infection.
l Heart failure: patients hospitalised because of HF can return to the stable state with the device,
continue to be hospitalised because of HF, experience a device-related infection or a lead displacement
or be referred for a heart transplant. Concerning populations 2 and 3 exclusively, patients receiving
CRT-P who are hospitalised because of HF can be referred for an upgrade to CRT-D if they experience
a major arrhythmia or need a routine device replacement.
l Lead displacement: patients experiencing lead displacement will undergo surgery to replace the lead(s)
and are assumed to be subject to the same risks of surgical death, surgical failure and any
complications as for an initial implantation.
l Routine device replacement: patients will undergo re-surgery to replace the device because of battery
failure. Devices are assumed to work for a fixed period and all patients stable with the device at the
end of that period are assumed to have a new device fitted.
l Infection: to treat a device-related infection, patients will undergo explantation of the device, treatment
for the infection and reimplantation of a new device. These patients are assumed to have the same
risks of surgical death, surgical failure and any complications as for an initial implantation.
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Model assumptions common to all populations
As the models developed for each population follow a similar structure, the following assumptions are
common to all of them:
l patients can die from any health state in the model
l patients in health states involving a surgical procedure can also die from surgery
l the probability of death post transplant is assumed to be lower than the probability of death for
non-transplanted patients, except in the first cycle
l only patients who are hospitalised because of HF are assumed to be at risk of a heart transplant
l patients referred for transplantation are assumed to remain in this health state until they die
l patients hospitalised because of HF while being managed with OPT are assumed to have a null
probability of remaining hospitalised because of HF in the following cycle
l patients hospitalised because of perioperative complications are assumed to have no risk of surgical
death or surgical failure
l all patients undergoing surgery (as a result of the initial implantation, a reattempt at implantation,
routine device replacement or infection) are assumed to have the same risk of surgical failure.
Discounting
In accordance with current NICE guidance,67 future costs and benefits were discounted at a rate of 3.5%.
The impact of discounting using rates of 0% and 6% were explored in sensitivity analysis.
Presentation of the results for the base-case analyses
We report the findings on the cost-effectiveness of interventions based on analysis of cohorts of patients
having the age and sex characteristics discussed earlier. For population 1 (people at increased risk of SCD
as a result of ventricular arrhythmias despite OPT), comparisons for ICD+OPT are made against OPT.
For population 2 (people with HF as a result of LVSD and cardiac dyssynchrony despite receiving OPT),
comparisons for CRT-P+OPT are made against OPT and comparisons for CRT-D+OPT are made against
CRT-P+OPT and OPT. For population 3 (people with both conditions), comparisons for CRT-D+OPT are
made against OPT, ICD+OPT and CRT-P+OPT.
The base-case results are reported in terms of estimated costs and QALYs accrued for each intervention, as
well as incremental costs and QALYs gained for each comparison.
Assessment of uncertainty
Deterministic sensitivity analysis is used to address particular areas of uncertainty in the model related to
model structure, methodological assumptions and parameters around which there is considerable
uncertainty or which may be expected, a priori, to have a disproportionate impact on the study results.
The purpose of this analysis is to identify clearly the impact of this uncertainty and to test the robustness
of the cost-effectiveness results to variation in structural assumptions and parameter inputs.
Parameter uncertainty is addressed using probabilistic sensitivity analysis.220 Probability distributions
are assigned to the point estimates used in the base-case analysis and values from these distributions are
sampled during the probabilistic analysis. The derivation of point estimates for state transitions, costs and
health state utilities is described in the following section. Appendix 15 reports the variables included in the
probabilistic sensitivity analysis, the form of distribution used for sampling and the parameters of
the distribution.
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Data sources and parameter estimates
Population 1: patients at increased risk of sudden cardiac death as a result of
ventricular arrhythmias despite optimum pharmacological therapy
Effectiveness data
Mortality and relative risks Survival estimates over time for use in the model were derived from data
reported for the relevant trials included in our systematic review. Three trials with the longest reported
follow-up (AVID,71 MADIT II101 and SCD-HeFT105) were included in this analysis. According to the evidence
found in Chapter 4 (see People at risk of sudden cardiac death as a result of ventricular arrhythmias),
patients who survived cardiac arrest or sustained VT are likely to be those for whom ICDs have consistently
shown benefit. As the AVID trial71 was the largest trial found for this population, the results of this trial
were used for our base-case analysis of patients at increased risk of SCD as a result of ventricular
arrhythmia. MADIT II101 was the trial with largest number of patients with remote MI and was considered
representative of a relevant group who might benefit from ICDs for primary prevention of SCD. Similarly,
the results from the SCD-HeFT trial105 were used to inform a subgroup analysis of patients with mild to
moderate HF with an indication for an ICD. An additional subgroup analysis was conducted for patients
with cardiomyopathy using as a baseline the all-cause mortality reported for the SCD-HeFT105 subgroup of
patients with non-ischaemic CHF in the placebo arm.
Kaplan–Meier curves for overall survival for the OPT arms (the control groups) of the relevant trials were
used to derive the baseline mortality risk of patients receiving OPT in the population 1 model. Parametric
models were fitted to these curves to derive approximate hazard functions and were assessed visually.
Those showing better goodness of fit were used to estimate survival beyond trial follow-up. Hence,
baseline time-dependent transition probabilities for transition to the all-cause mortality health state for the
model OPT arm were calculated from the estimated hazard functions.220 For patients receiving ICD+OPT,
death transition probabilities were estimated by applying the RRs estimated for ICD+OPT in our systematic
review of clinical effectiveness (see Chapter 4, People at risk of sudden cardiac death as a result of
ventricular arrhythmias, All-cause mortality) to the baseline transition probabilities of the OPT arm.
Weibull approximations were fitted to the Kaplan–Meier curve for overall survival of patients from the
AVID trial,71 the MADIT II trial101 and the SCD-HeFT trial.105 Details of the regression analyses and
comparison between the regression results and the observed survival in these trials are shown in
Appendix 15. The Weibull distribution is defined according to two parameters: the scale parameter (λ)
and the shape parameter (γ). These parameters were fitted using linear regression of transformations of
the Kaplan–Meier estimates (see Appendix 15 for further details). To do this, scanned images of the
Kaplan–Meier curves were imported in Engauge software (Engauge Digitizer – Digitizing software
version 4.1; see http://digitizer.sourceforge.net/) and the extracted data points were then exported to
Microsoft Excel for further analysis. Table 96 shows the parameters of the Weibull functions used in the
model to estimate time-dependent mortality for the OPT arm of the population 1 model.
TABLE 96 Weibull model parameters for all-cause mortality: population 1
Parameter
Mean (SE)
AVID71 (R2= 0.994)
MADIT II101
(R2= 0.9903)
SCD-HeFT105
(R2= 0.993)
SCD-HeFT105 non-ischaemic CHF
subgroup (R2= 0.985)
ln(λ) –3.380 (0.026) –4.628 (0.047) –5.288 (0.039) –4.821 (0.037)
γ 0.696 (0.009) 1.007 (0.017) 1.083 (0.011) 0.883 (0.011)
Weibull model: ln(–ln(S))= ln(λ)+ γln(t); S(t)= exp(–λ.t^γ).
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The effect of an ICD compared with OPT on all-cause mortality of patients at increased risk of SCD is
captured in the model by the RRs reported in Chapter 4 (see People at risk of sudden cardiac death as a
result of ventricular arrhythmias, All-cause mortality). For the base-case analysis (secondary prevention of
cardiac arrest), the pooled RR of 0.75 (95% CI 0.61 to 0.93) was used. For the subgroup analysis of
patients with remote MI, a pooled RR from the MADIT I99 and MADIT II103 trials of 0.57 (95% CI 0.33 to
0.97) was used. The SCD-HeFT105 RR of 0.77 (95% CI 0.66 to 0.89) was used for the subgroup of patients
with mild to moderate HF, and a pooled RR of 0.74 (95% CI 0.58 to 0.93) was used for patients with
cardiomyopathy (derived from the SCD-HeFT105 non-ischaemic CHF subgroup and the three
cardiomyopathy trials69,82,90).
Hospitalisation
Hospitalisation because of heart failure MADIT II is the only RCT included in our systematic review
(see Chapter 4, People at risk of sudden cardiac death as a result of ventricular arrhythmias, Assessment of
effectiveness) reporting HF hospitalisations for patients at increased risk of SCD. The number of admissions
per total number of trial participants (221 out of 1232 patients in the OPT and ICD arms) is reported for a
20-month follow-up period. The model accounts therefore for a risk of hospitalisation for HF of 0.0082
(95% CI 0 to 0.0202) per cycle for patients at risk of SCD being managed with OPT or ICD therapy,
assuming that ICD therapy has no effect on HF hospitalisations.
Hospitalisation because of non-fatal arrhythmia The number of hospitalisations because of non-fatal
arrhythmia is not reported by the trials included in our systematic review for population 1 (see Chapter 4,
People at risk of sudden cardiac death as a result of ventricular arrhythmias, Assessment of effectiveness)
and the number of patients who experienced arrhythmic events that is reported by some of the included
trials is small. Following clinical advice, in our model the baseline probability that a patient at increased risk
of SCD managed with OPT will be hospitalised for a non-fatal arrhythmia is assumed to be the same as
that for patients with HF (0.0075, 95% CI 0.0002 to 0.0148), derived from the number of events in both
arms (OPT and CRT-P) of the MIRACLE trial.121 The sensitivity of the cost-effectiveness results to this
assumption is explored later in this chapter (see Results of the independent economic analysis,
Population 1: patients at increased risk of sudden cardiac death as a result of ventricular arrhythmias
despite optimal pharmacological therapy) with a scenario analysis using the risk of ventricular arrhythmia
for population 3 patients.
Device implantation after hospitalisation Patients being managed with OPT who experience
hospitalisation because of non-fatal arrhythmias are assumed to be referred for ICD implantation
(estimation described earlier). Patients hospitalised because of HF while being managed with OPT alone are
assumed to be subject to a probability of being referred for ICD implantation of 0.0018 (95% CI 0 to
0.0059), the same as that for population 2 patients in the CARE-HF trial109 OPT arm who were referred for
CRT-D implantation (see Data sources and parameter estimates, Population 2: patients with heart failure as
a result of left ventricular systolic dysfunction and cardiac dyssynchrony despite receiving optimum
pharmacological therapy).
Adverse events Adverse events in patients being managed with ICDs were categorised into those
occurring at the time of implantation (or during the initial inpatient stay) and a set of longer-term adverse
events that could occur around the time of implantation and during all subsequent cycles. The former set
of adverse events includes procedure-related mortality, surgical complications and implant failure whereas
the latter set includes lead displacements, infections and device malfunctions and dislodgements. As noted
in the systematic review (see sections on adverse events in Chapter 4), reporting of individual adverse
events in the included trials is limited.
Procedure-related death Most trials of patients at increased risk of SCD in which surgical death was
included explicitly as an outcome (MADIT II,103 DEFINITE,90 DINAMIT,95 DEBUT89) report no deaths related to
the implantation procedure, with only the CASH trial reporting 5/99 perioperative deaths. A pooled
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probability of procedure-related death of 0.003 (95% CI 0 to 0.055) was used in the base-case analysis,
based on five procedure-related deaths among 1449 patients.
Implant failure Two trials included in our systematic review of clinical effectiveness report implant failure
as an outcome of the ICD implantation procedure. This is taken to indicate a failure to achieve the
required outcome, rather than mechanical failure of the device or failure/dislodgements of leads (which are
reported separately). The AVID trial71 reports unsuccessful initial implant in approximately 1% of patients
(5/507) in the defibrillator arm of the trial, corresponding to a probability of implant failure of 0.0098
(95% CI 0 to 0.0962). The SCD-HeFT trial108 reports a lower proportion of patients with unsuccessful
implantation (1/829 patients). However, it is not clear whether this was failure of the initial implantation or
followed revision of the initial implant procedure. The systematic review of RCTs and observational studies
by Ezekowitz and colleagues221 reports a probability of implant failure of 0.011 (95% CI 0.009 to 0.013),
which was used in the model.
Complications Given the inconsistent reporting of perioperative and postoperative complications related
to use of ICDs among the trials included in our systematic review, estimates from the systematic review of
RCTs and observational studies by Ezekowitz and colleagues221 were used in the model. Table 97 presents
the probabilities used for each type of event.
Epidemiological data
Distribution of patients by New York Heart Association class The distribution of patients at increased
risk of SCD by NYHA class was sourced from the baseline distribution of participants in the trials selected
for our base case and alternative patient group analyses: the AVID trial71 for the secondary prevention of
SCD and the MADIT II101 and SCD-HeFT105 trials for the primary prevention of SCD (Table 98).
A summary of the clinical variables in the model for population 1 is provided in Table 99.
TABLE 97 Peri- and postoperative complications with ICDs
Event Riska 95% CI
Perioperative complication
Mechanical complication 0.053 0.046 to 0.062
Postoperative complications
Lead problems 0.0012 0.0010 to 0.0014
Infections 0.0005 0.0004 to 0.0006
a Risk estimates for postoperative complications per 100 patient-years reported by Ezekowitz et al.221 were converted to
risk per 4-week cycle.
TABLE 98 Distribution of the participants of the AVID, MADIT II and SCD-HeFT trials by NYHA class at baseline
NYHA class
AVID71 MADIT II101 SCD-HeFT105
AAD ICD OPT ICD OPT ICD
No HF, % 45 40 0 0 0 0
I, % 48 48 39 35 0 0
II, % 48 48 34 35 70 70
III, % 7 12 23 25 30 30
IV, % 7 12 4 5 0 0
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Population 2: patients with heart failure as a result of left ventricular
systolic dysfunction and cardiac dyssynchrony despite receiving optimum
pharmacological therapy
Effectiveness data
Mortality and relative risks Following the approach of Fox and colleagues,64 the population 2 model
accounts for cardiac mortality (SCD and morality from worsening HF) and non-cardiac mortality.
Cardiac mortality The CARE-HF trial111 is the trial with the longest follow-up period (mean 37.4 months)
of those included in the clinical effectiveness review for people with HF as a result of LVSD and cardiac
dyssynchrony despite receiving OPT. The CARE-HF trial reports survival curves for SCD and death from
worsening HF; hence, baseline time-dependent probabilities of SCD and death from HF were derived from
CARE-HF survival curves in the control group. The methodology used to derive baseline mortality is
described in the previous section and further details can be found in Appendix 15.
Weibull approximations were fitted to the Kaplan–Meier curves for SCD and death from worsening HF in
patients from the CARE-HF trial. The scale (λ) and the shape (γ) parameters that define the Weibull models
used for the estimation of SCD and HF deaths for the OPT arm are shown in Table 100. Time-dependent
death probabilities for population 2 patients receiving devices (CRT-P, CRT-D or ICD) were then derived by
applying device-specific HRs or RRs to the baseline probabilities (OPT arm).
TABLE 99 Key clinical parameters used in the model for population 1
Parameter type Parameter
Source estimate
DistributionMean SE LL UL
All-cause mortality ln(λ) –3.381 0.0257 –3.431 –3.330 Normal
γ 0.696 0.0092 0.678 0.714 Normal
HR ICD 0.75 0.0816 0.61 0.93 Log-normal
All-cause mortality by age HR 18–59 0.62 0.0459 0.54 0.72 Log-normal
HR 75+ 1.41 0.0051 1.40 1.42 Log-normal
Death as a result of surgery DFS_ICD 0.0034 0.0262 0 0.0548 Normal
Probability of surgical death
from transplantation
DFS_TRP 0.122 0.007 0.109 0.136 Normal
Event probabilities (per cycle)
Hospitalisation for HF OPT 0.0082 0.0061 0 0.0201 Beta
RR ICD 1 0.1 0.804 1.196 Beta
Probability of transplant following
HF hospitalisation
HF_TRP 0.0014 0.0025 0 0.0062 Beta
Non-fatal arrhythmia
requiring hospitalisation
HA_OPT 0.0075 0.0037 0.00016 0.0148 Beta
HA_ICD 0.0075 0.0037 0.00016 0.0148 Beta
Probability of surgical failure SF_ICD 0.011 0.001 0.009 0.013 Beta
Device replacement interval ln(λ) –15.784 0.203 –16.182 –15.385 Normal
γ 1.942 0.0273 1.889 1.996 Normal
Upgrade after HF hospitalisation OPT to ICD 0.0018 0.002 0 to 0.0059 Beta
LL, lower limit; UL, upper limit.
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The relative effect of CRT-P on HF deaths was obtained from the meta-analysis in Chapter 4 (see People
with heart failure as a result of left ventricular systolic dysfunction and cardiac dyssynchrony, Assessment of
effectiveness, Heart failure deaths) (encompassing the CARE-HF109 and COMPANION116 trials; RR 0.67;
95% CI 0.51 to 0.88). That for CRT-D patients was sourced from the COMPANION trial116 (HR 0.73,
95% CI 0.47 to 1.11). The estimate for the RR of SCD for CRT-P patients obtained in the meta-analysis in
Chapter 4 (see People with heart failure as a result of left ventricular systolic dysfunction and cardiac
dyssynchrony, Assessment of effectiveness, Sudden cardiac death) (pooled from the CARE-HF,109
COMPANION116 and MUSTIC125 trials ) is 0.97 (95% CI 0.44 to 2.14). Given its wide 95% CI, a RR of 1
was used in our economic model and this estimate was assumed to range between the mean estimates of
RR reported in the most relevant trials (0.54 from CARE-HF109 and 1.13 from the COMPANION116). The RR
of SCD for CRT-D patients was sourced from the COMPANION trial116 (HR 0.44, 95% CI 0.23 to 0.86).
For population 2 patients who were using an ICD because of CRT-D implant failure, the RRs for SCD and
death from worsening HF were sourced from the SCD-HeFT trial.108 This was considered to be the most
representative study from the systematic review of ICDs, as it included a broad population of patients with
mild to moderate HF. A RR of 1.14 (95% CI 0.88 to 1.48) is reported for non-arrhythmic cardiac death
(assumed to be that due to HF) and 0.44 (95% CI 0.31 to 0.61) for SCD. Considering that population 2
patients are expected to be at higher risk of death from HF and lower risk of SCD than the SCD-HeFT
participants (population 1), these parameters were subject to sensitivity analysis (see Results of the
independent economic analysis, Population 2).
Non-cardiac mortality Non-cardiac-related death rates were derived from the 2010 mortality statistics for
England and Wales from the Office for National Statistics.4 All deaths not allocated an International
Classification of Diseases, 10th edition,5 code I00–I52 (for heart disease) were included. Table 101 shows
the non-cardiac death rates by age used in the model for population 2. Proportions of UK patients with HF
were estimated based on the 2011 statistics for incidence of HF by gender reported by the British
Heart Foundation.222
Hospitalisation
Hospitalisation because of heart failure The hospitalisation baseline risk estimate (0.037, 95% CI
0.025 to 0.049) was pooled from the number of events reported for the OPT arm in the relevant trials
included in the systematic review of clinical effectiveness: CARE-HF109 (252/404 events in 29.4 months),
MIRACLE121 (50/225 patients in 6 months), MUSTIC125 (9/29 events in 3 months) and COMPANION116
(235/308 events in 11.9 months).
The RR of hospitalisation because of HF for patients receiving CRT-P compared with those receiving OPT
was estimated to be 0.58 (95% CI 0.35 to 0.96), pooling risks from the CARE-HF,109 COMPANION,116
MIRACLE121 and MUSTIC125 trials as described in Chapter 4 (see People with heart failure as a result of left
TABLE 100 Weibull model parameters for SCD and HF mortality: population 2
Parameter Mean 95% CI
SCD
ln(λ) –6.069 –6.173 to –5.964
γ 1.140 1.107 to 1.173
HF
ln(λ) –6.115 –6.256 to –5.974
γ 1.223 1.179 to 1.266
Weibull model: ln(–ln(S))= ln(λ)+ γln(t); S(t)= exp(–λ.t^γ)
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ventricular systolic dysfunction and cardiac dyssynchrony, Assessment of effectiveness). The COMPANION
trial116 reports a RR of 0.77 (95% CI 0.63 to 0.93; p= 0.008) for patients receiving CRT-D compared with
those receiving OPT. As per Fox and colleagues,64 the risk of hospitalisation because of HF for patients
with an ICD was assumed to be the same as for patients receiving OPT (RR= 1).
Hospitalisation because of non-fatal arrhythmia Fox and colleagues64 report using the number of
severe arrhythmic events reported in the MIRACLE trial121 (26/532 participants) to estimate the risk of
hospitalisation for non-fatal arrhythmic events. Considering the 6-month follow-up of the trial, this
corresponds to a rate of 0.0977 events per patient-year and a 0.0075 (95% CI 0.0002 to 0.0148)
probability of experiencing an arrhythmic event per cycle. This probability was assumed to be the same for
patients being managed with OPT and for patients receiving CRT-P. Given the lack of evidence on
hospitalisation for arrhythmia for population 2 patients receiving CRT-D or an ICD, these patients have
been assumed to be at the same risk as those being managed with CRT-P or OPT alone.
Device-related adverse events Adverse events occurring in patients being managed with CRT were
categorised in a similar way to those occurring with ICDs, that is, into those occurring at the time of
implantation or initial inpatient stay (procedure-related deaths, implant failures and perioperative
complications) and longer-term adverse events (lead displacements, infections and device malfunctions).
Procedure-related death The probability of death related to the surgical procedure for CRT implantation
was derived from the number of events reported in patients randomised to the CRT-arm in the trials
included in our systematic review of clinical effectiveness. The CARE-HF trial109 reported one death in
409 patients, the MIRACLE trial121 one death in 571 patients, the MUSTIC tial125 one death in 64 patients
and the COMPANION trial116 five deaths in 617 patients. A probability of procedure-related death of 0.048
(95% CI 0.0015 to 0.0081) per cycle is therefore considered in the model for CRT-P. The COMPANION
trial116 also reports three procedure-related deaths out of 595 patients in the CRT-D arm, which
corresponds to a probability of procedure-related death of 0.005 (95% CI 0 to 0.0107) per cycle.
Implant failure The probability of implant failure for patients who attempt CRT implantation was derived
from the relevant trials included in the systematic review. A pooled probability of implant failure of 0.084
(95% CI 0.070 to 0.097) per cycle was estimated for patients undergoing CRT-P implantation from four
trials: CARE-HF109 (19/409), MIRACLE121 (43/571), MUSTIC125 (5/64) and COMPANION116 (78/617). The
COMPANION trial116 reports 54 implant failures in 595 patients undergoing CRT-D implantation; thus, a
probability of implant failure of 0.087 (95% CI 0.064 to 0.109) per cycle is used in the model for CRT-D.
Perioperative complications Given the limited and heterogeneous reporting of surgical complications
related to CRT implantation among the trials included in our systematic review, the probability of patients
having an operative complication from a CRT implant was sourced from Fox and colleagues,64 who report
TABLE 101 Non-cardiac mortality by age
Age group (years) Probability of non-cardiac death per cycle
15–24 0.000027
25–34 0.000045
35–44 0.000088
45–54 0.000177
55–64 0.000449
65–74 0.001084
75–84 0.002896
≥ 85 0.008566
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a pooled risk of complications from the CARE-HF,109 MIRACLE,121 MUSTIC125 and CONTAK-CD126 trials and
both CRT arms of the COMPANION trial.116 A probability of perioperative complications of 0.1063
(SE=mean/10) was used for both CRT-P and CRT-D.
Lead displacement Three trials included in the systematic review of clinical effectiveness reported the
number of lead-related complications that occurred with CRT-P during the follow-up periods: CARE-HF109
(24/409), MIRACLE121 (30/571) and MUSTIC125 (8/58). These were used to estimate a pooled risk of lead
displacement of 0.0037 (95% CI 0.0004 to 0.0071) for use in the model for patients being managed with
CRT-P or CRT-D.
Infection A probability of 0.0006 (95% CI 0 to 0.002) for device-related infections in patients being
managed with CRT-P was derived from the relevant trials included in the systematic review of clinical
effectiveness that explicitly reported this outcome: CARE-HF109 (3/409 in 29.4 months) and MIRACLE121
(7/528 in 6 months). For CRT-D, a probability of infection of 0.0006 (95% CI 0 to 0.0015) was derived
similarly, using the events reported in the CONTAK-CD126 (7/517 in 6 months), RethinQ142 (6/172 in
6 months), RHYTHM ICD144 (4/205 in 15.1 months), MADIT-CRT130 (12/1089 in 28.8 months) and RAFT140
(21/888 in 40 months) trials.
Device upgrade after hospitalisation Following hospitalisation, patients being managed with OPT can
be referred for CRT-P or CRT-D implantation, whereas patients being managed with CRT-P can be referred
for CRT-D implantation. The probabilities of device upgrade after hospitalisation were derived from
the CARE-HF trial,111 assuming that the upgrades reported occurred after hospitalisation due to HF. For the
OPT arm (n= 404), the CARE-HF trial111 reports 43 upgrades to CRT-P and 23 upgrades to CRT-D in
29.4 months of follow-up, whereas in the CRT-P arm (n= 409) eight patients upgraded to CRT-D. This
corresponds to a probability of 0.0033 (95% CI 0 to 0.009) for upgrading from OPT to CRT-P, 0.0018
(95% CI 0 to 0.0059) for upgrading from OPT to CRT-D and 0.0006 (95% CI 0 to 0.003) for upgrading
from CRT-P to CRT-D.
Clinical advice indicated that patients with HF as a result of LVSD and cardiac dyssynchrony despite
receiving OPT would upgrade to an ICD only in case of failure of CRT-D implantation, which can be
estimated by multiplying the probability of upgrading from OPT to CRT-D (0.001, 95% CI 0 to 0.003) by
the probability of CRT-D implant failure (0.087, 95% CI 0.064 to 0.109).
For population 2 patients who end up receiving an ICD, our model considers the same data for ICD-related
adverse events reported earlier for population 1.
Epidemiological data
Distribution of patients per New York Heart Association class The distribution of HF patients by
NYHA class used (Table 102) is the same as that used in the previous model by Fox and colleagues,64 who
derived the distribution of patients per NYHA class at baseline and 90 days from the CARE-HF trial109 and
the conference proceedings of the Brescia study by Curnis and colleagues.223
A summary of the clinical variables in the model for population 2 is shown in Table 103.
Population 3: patients with both conditions
Effectiveness data
Mortality and relative risks Estimates of survival over time were derived from Kaplan–Meier curves
reported for relevant trials included in the systematic review. The two largest trials reporting the longest
follow-up periods and comparing events between groups statistically (MADIT-CRT130 and RAFT140) were
included in this analysis. As reported in Chapter 4, length of follow-up was an average of 28.8 months in
ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
204
TABLE 102 Distribution of patients by NYHA class
NYHA class Mean (%) LL (%) UL (%)
OPT
Proportion at baseline
IIIa 93.8 75.42 100.00
IVb 6.2 4.98 7.42
Proportion at 90 days
Ia 10.1 8.12 12.08
IIa 29.9 24.04 35.76
III 54.8 44.06 65.54
IV 5.2 4.18 6.22
Proportion at 18 months
Ic 12.7 10.21 15.19
IIa 37.3 29.99 44.61
III 45.7 36.74 54.66
IV 4.3 3.46 5.14
CRT/ICDd
Proportion at baselinee
III 93.8 75.42 100.00
IV 6.2 4.98 7.42
Proportion at 90 days
Ia 29.5 23.72 35.28
IIa 41.5 33.37 49.63
III 27.2 21.87 32.53
IV 1.8 1.45 2.15
Proportion at 18 months
Ic 31.5 25.33 37.67
II 44.4 35.70 53.10
III 22.5 18.09 26.91
IV 1.5 1.21 1.79
a 95% CIs were derived assuming SE=mean/10.
b Assumed to be equal to 1 minus the proportion of patients in NYHA class III.
c From Curnis et al.223 conference proceeding.
d Assumed to be the same for any device type: CRT-P, CRT-D and ICD.
e Assumed to be the same as for OPT.
Source: CARE-HF trial.109
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TABLE 103 Key clinical parameters used in the model for population 2
Parameter type Parameter
Source estimate
DistributionMean SE LL UL
Death from HF, age 65–74 years, OPT ln(λ) –6.115 0.070 –6.253 –5.977 Normal
γ 1.223 0.022 1.180 1.265 Normal
HR CRT-P 0.67 0.094 0.51 0.88 Log-normal
HR CRT-D 0.73 0.163 0.47 1.11 Log-normal
HR ICD 1.14 0.153 0.88 1.48 Log-normal
Post-transplant mortality RR TRP 0.35 0.035 0.281 0.419 Log-normal
SCD ln(λ) –6.069 0.053 –6.173 –5.964 Normal
γ 1.140 0.017 1.107 1.173 Normal
HR CRT-P 1.00 0.1505 0.54 1.13 Log-normal
HR CRT-D 0.44 0.1607 0.23 0.86 Log-normal
HR ICD 0.44 0.0765 0.31 0.61 Log-normal
All-cause mortality RR by age (years) 18–64 0.62 0.05 0.54 0.72 Log-normal
75+ 1.41 0.01 1.40 1.42 Log-normal
Event probabilities (per cycle)
Surgical mortality ICD 0.003 0.026 0.000 0.055 Beta
CRT-P 0.005 0.002 0.001 0.008 Beta
CRT-D 0.005 0.003 0.000 0.011 Beta
TRP 0.122 0.007 0.109 0.136 Beta
Hospitalisation for HF OPT 0.037 0.006 0.025 0.049 Beta
RR ICD 1 0.1 0.804 1.196 Beta
RR CRT-P 0.58 0.1556 0.35 0.96 Beta
RR CRT-D 0.77 0.0765 0.63 0.93 Beta
Transplant following HF hospitalisation TRP 0.001 0.002 0.000 0.006 Beta
Non-fatal arrhythmia requiring hospitalisation OPT 0.007 0.004 0.000 0.015 Beta
ICD 0.007 0.004 0.000 0.015 Beta
CRT-P 0.007 0.004 0.000 0.015 Beta
CRT-D 0.007 0.004 0.000 0.015 Beta
Probability of upgrade after HF hospitalisation OPT to ICD 0 0 0 0 Beta
OPT to CRT-P 0.003 0.003 0.000 0.009 Beta
OPT to CRT-D 0.002 0.002 0.000 0.006 Beta
CRT-P to CRT-D 0.001 0.001 0.000 0.003 Beta
Surgical failure ICD 0.011 0.001 0.009 0.013 Beta
CRT-P 0.084 0.007 0.070 0.097 Beta
CRT-D 0.087 0.012 0.064 0.109 Beta
TRP, transplant.
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the MADIT-CRT trial130 and 40 months in the RAFT trial.140 Survival estimates from the trial with the
longest follow-up (RAFT) were used for the base-case analysis and those from MADIT-CRT were used in
scenario analysis.
Both trials report Kaplan–Meier curves for all-cause mortality for CRT-D+OPT and ICD+OPT. As CRT-D+
OPT was the intervention scoped by NICE for population 3,61 we used its mortality estimates as the
baseline for this population and used HRs and RRs to derive all-cause mortality for patients receiving OPT
alone, ICD+OPT and CRT-P+OPT.
The methodology used to derive baseline mortality is similar to that described earlier for populations 1 and
2; further details can be found in Appendix 15. Table 104 presents the parameters of the Weibull models
obtained using data from the RAFT140 and MADIT-CRT trials.130
Relative risk for implantable cardiac defibrillators The risk of all-cause mortality for patients with an
ICD relative to those receiving CRT-D was derived from the pooled RR of 0.84 (95% CI 0.73 to 0.96)
estimated in Chapter 4 (see People with both conditions, Assessment of effectiveness, All-cause mortality)
for CRT-D compared with ICD therapy. A RR of 1.19 (95% CI 1.04 to 1.37) for ICD therapy compared with
CRT-D was used to estimate all-cause mortality in the ICD arm.
Relative risk for optimum pharmacological therapy In the systematic review of clinical effectiveness
studies of people with both conditions, only RCTs comparing CRT-D with ICD therapy were found.
However, the COMPANION trial116 reports the HR for all-cause mortality for patients with HF as a result of
LVSD and cardiac dyssynchrony, from which we derived the HR of 1.56 (95% CI 1.16 to 2.08) for OPT
compared with CRT-D, assuming that the same relative effect would be expected in population 3.
Relative risk for CRT-Ps Given the lack of RCTs in people with both conditions directly comparing CRT-P
with CRT-D or assessing interventions other than CRT-D or ICDs, we used the evidence available on the
clinical effectiveness of CRT-P and CRT-D in patients with HF as a result of LVSD and cardiac dyssynchrony.
The only trial comparing CRT-P with CRT-D was the COMPANION trial.116 A non-statistically significant RR
of 1.20 (95% CI 0.96 to 1.52) for all-cause mortality was reported for CRT-P compared with CRT-D.
However, the COMPANION trial116 was not powered for this comparison. Considering the lack of robust
evidence for this comparison, the risk of all-cause mortality for patients with CRT-P was assumed to be
the same as for those with CRT-D (RR= 1). This assumption was subject to sensitivity analysis by varying
the parameter between the assigned upper and lower limits of the 95% CI (0.80 to 1.20).
Hospitalisation because of heart failure The trials included in the systematic review of clinical
effectiveness (see Chapter 4, People with both conditions, Assessment of effectiveness, Hospitalisations
related to heart failure) do not report the number of hospitalisations because of HF. Instead, the
TABLE 104 Weibull model parameters for all-cause mortality: population 3
Parameter Mean 95% CI
RAFT140
ICD-CRT arm (R2= 0.9894)
ln(λ) –6.334 –6.467 to –6.202
γ 1.243 1.20 to 1.27
MADIT–CRT130
Men, CRT-D arm (R2= 0.989)
ln(λ) –6.935 –7.005 to –6.865
γ 1.287 1.266 to 1.308
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CONTAK-CD,126 Piccirillo and colleagues138 and RAFT140 trials report the number of patients receiving
CRT-D hospitalised for HF (at least once during the trial). In 6 months of follow-up, the CONTAK-CD trial126
reported that 32 of 245 patients in the CRT-D arm were hospitalised; Piccirillo and colleagues138 reported
that none of 16 patients in the CRT-D arm, who were followed for 12 months, were hospitalised; and the
RAFT trial140 reported that 174 of 894 patients in the CRT-D arm were hospitalised during the 40 months
of follow-up. The number of patients experiencing at least one hospitalisation during the follow-up period
of the trials provides a minimum number of hospitalisations from which we derived a baseline risk of
hospitalisation because of HF (probability of event occurring 0.0077, 95% CI 0.0027 to 0.0128). Given
that our model is likely to be underestimating the total number of hospitalisations, and consequently the
resource use involved, the probability of hospitalisation because of HF was subject to sensitivity analysis
(see Results of the independent economic analysis).
The RR of hospitalisation because of HF for patients with an ICD compared with those receiving CRT-D
was estimated to be 1.33 (95% CI 1.14 to 1.56), the reverse of the RR of 0.75 (95% CI 0.64 to 0.88)
obtained in Chapter 4 (see People with both conditions, Assessment of effectiveness, Hospitalisations
related to heart failure) by pooling risks from the CONTAK-CD,126 Piccirillo and colleagues138 and
RAFT140 trials.
The COMPANION trial116 reports no significant differences in hospitalisations because of HF between CRT-P
and CRT-D for patients with HF (see Chapter 4, People with heart failure, Assessment of effectiveness,
Hospitalisations because of heart failure). Hence, assuming that no significant differences would be
expected either in patients with both conditions (at risk of SCD as a result of ventricular arrhythmias and
with HF as a result of LVSD and cardiac dyssynchrony), the risk of hospitalisation because of HF estimated
for CRT-D (0.0077) was used for CRT-P (RR= 1).
Evidence on the RR of hospitalisation for HF in patients receiving OPT compared with CRT-D was found
only for patients with HF (population 2). The COMPANION trial116 reported a statistically significant
difference in HF hospital admissions per patient between the CRT-D arm and the OPT arm (0.43 vs. 0.73
admissions per patient-year respectively). The RR estimated for hospitalisations because of HF for OPT
compared with CRT-D was 1.67 (95% CI 1.51 to 1.86, p< 0.00001).
Hospitalisation because of non-fatal arrhythmia The baseline risk of hospitalisation for arrhythmia
used in the model (probability of event occurring 0.029, 95% CI 0.015 to 0.042) was derived from trials
included in the systematic review of clinical effectiveness (see Chapter 4, People with both conditions,
Assessment of effectiveness) reporting the number of patients receiving CRT-D who experienced at least
one episode of VF: MIRACLE ICD136 (42/187), MICACLE ICD II137 (19/85), CONTAK-CD126 (36/245) and the
trial by Pinter and colleagues139 (7/36). Similar to the estimation of hospitalisations for HF, our model is
likely to be underestimating the total number of hospitalisations for arrhythmic events and the value used
was therefore subject to sensitivity analysis (see Results of the independent economic evaluation).
The meta-analysis (see Chapter 4, People with both conditions, Assessment of effectiveness) found a
non-statistically significant difference between CRT-D and ICD in the number of patients experiencing at
least one arrhythmic event (RR 0.90, 95% CI 0.71 to 1.14, p= 0.38). Hence, the inverse RR of 1.11
(95% CI 0.88 to 1.41) for ICD compared with CRT-D was used in the model.
No evidence to derive a measure of relative effect was found for hospitalisations for arrhythmia comparing
CRT-P or OPT with CRT-D. The COMPANION trial116 states that hospitalisations because of other cardiac
causes were not significantly different between the OPT group and the CRT group. Therefore, our model
assumes that the risk of hospitalisation because of arrhythmia for patients managed with OPT alone or
CRT-P is the same as that for patients managed with CRT-D (RR= 1).
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Device-related adverse events Given the inconsistent reporting and lack of clear definitions of
device-related adverse events reported in the relevant trials included in the systematic review of clinical
effectiveness for people with both conditions (population 3), our model assumes the same risks for
population 3 as for population 2 (people with HF).
Epidemiological data
Distribution of patients per New York Heart Association class The RAFT trial140 reported the number
of patients by NYHA class at baseline (Table 105). No evidence on the effect of the devices on HF
progression was found; hence, the model assumes no effect on patient distribution by NYHA class. An
alternative scenario was created to explore the impact of accounting for the potential benefit of CRT
devices for population 3, assuming that 50% of patients with a CRT device improve by one NYHA class at
6 months of treatment (see Results of the independent economic analysis).
A summary of the clinical variables in the model for population 3 is provided in Table 106.
Parameters common to all populations
Age-related mortality
The variation of risk of death according to age was incorporated in our model using the same estimates as
those used by Fox and colleagues,64 who derived the RR of death from the publication by Shahar and
colleagues.224 The RR of death for patients aged < 65 years compared with those aged 65–74 years is 0.62
(95% CI 0.54 to 0.72). For those aged ≥ 75 years compared with those aged 65–74 years the RR is 1.41
(95% CI 1.40 to 1.42).
Distribution of patients eligible for implantable cardiac defibrillator and cardiac
resynchronisation therapy by age
The distribution of heart device implants by age was derived from a report commissioned by the British
Cardiovascular Society, the British Heart Foundation and the Cardio & Vascular Coalition on access to
cardiac care in the UK.225 Table 107 shows the estimated distribution of implanted devices by age.
The distribution of patients with ICD implants was deemed to be a good proxy for population 1 patients at
increased risk of SCD, whereas the distribution of CRT implants was used for population 2 patients with
HF. For population 3 with both conditions, the distribution of both ICD and CRT devices was used in
the model.
TABLE 105 Distribution of patients by NYHA class
NYHA class
Proportion at baseline, n (%)
ICD (n= 904) CRT-D (n= 894)
II 730 (80.8) 708 (79.2)
III 174 (19.2) 186 (20.8)
Source: RAFT trial.140
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TABLE 106 Key clinical parameters used in the model for population 3
Parameter type Parameter
Source estimate
DistributionMean SE LL UL
All-cause mortality, baseline – CRT-D ln(λ) –6.334 0.068 –6.467 –6.202 Normal
γ 1.234 0.018 1.199 1.270 Normal
HR CRT-P 1 0.100 0.804 1.196 Log-normal
HR ICD 1.190 0.084 1.042 1.370 Log-normal
HR OPT 1.563 0.235 1.163 2.083 Log-normal
All-cause mortality RR by age (years) 18–64 0.621 0.046 0.54 0.72 Log-normal
75+ 1.410 0.005 1.4 1.42 Log-normal
Event probabilities (per cycle)
Hospitalisation for HF CRT-D 0.008 0.003 0.003 0.013 Beta
RR ICD 1.333 0.133 1.136 1.563 Log-normal
RR CRT-P 1 0.1000 0.804 1.196 Log-normal
RR OPT 1.67 0.0893 1.51 1.86 Log-normal
Non-fatal arrhythmia requiring
hospitalisation
CRT- D 0.029 0.007 0.015 0.042 Log-normal
RR ICD 1.111 0.111 0.880 1.410 Log-normal
RR CRT-P 1 0.1 0.804 1.196 Log-normal
RR OPT 1 0.1 0.804 1.196 Log-normal
Probability of upgrade after HF
hospitalisation
OPT to ICD 0.002 0.002 0 0.006 Beta
OPT to CRT-P 0.003 0.003 0 0.009 Beta
OPT to CRT-D 0.002 0.002 0 0.006 Beta
CRT-P to CRT-D 0.001 0.001 0 0.003 Beta
ICD to CRT-D 0.007 0.003 0.001 0.013 Beta
Surgical mortality ICD 0.003 0.026 0 0.055 Beta
CRT-P 0.005 0.002 0.001 0.008 Beta
CRT-D 0.005 0.003 0 0.011 Beta
Surgical failure ICD 0.011 0.001 0.009 0.013 Beta
CRT-P 0.084 0.007 0.070 0.097 Beta
CRT-D 0.087 0.012 0.064 0.109 Beta
Device lifetime ICD ln(λ) –15.784 0.203 –16.182 –15.385 Normal
ICD γ 1.943 0.027 1.889 1.996 Normal
CRT-P ln(λ) –14.222 0.242 –14.697 –13.747 Normal
CRT-P γ 1.677 0.032 1.613 1.740 Normal
CRT-D ln(λ) –15.465 0.273 –16 –14.931 Normal
CRT-D γ 1.935 0.036 1.863 2.006 Normal
LL, lower limit; UL, upper limit.
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Heart transplantation
Procedure-related mortality The model takes into account that patients subject to heart transplantation
have a procedure-related risk of death of 12.2% (95% CI 10.9% to 13.6%), the 30-day mortality rate
estimated by the UK Cardiothoracic Transplant Audit226 from data for all patients transplanted between
1995 and 2011.
Post-transplant mortality The risk of death post transplantation was incorporated using the estimate
derived by Fox and colleagues.64 The RR of death from all causes for patients who had a heart transplant
(0.35) was derived from the median survival estimates reported by Hussey and colleagues227 for UK
patients receiving a heart transplant (10.6 years) and those on OPT (3.7 years).
Transplant following hospitalisation for heart failure Abraham and colleagues121 report two heart
transplants in 532 participants in the MIRACLE trial. As in Fox and colleagues,64 for population 2 we
assumed that these patients were referred for transplantation after hospitalisation for HF, estimating a
0.0014 (95% CI 0 to 0.0062) probability of transplantation per cycle for patients hospitalised for HF.
Given the paucity of data regarding the number of transplants after hospitalisation for HF in the trials for
populations 1 and 3, our model assumes the same risk as that for patients with HF (population 2).
Health-related quality of life
Utility values for the several health states modelled were used to estimate the benefit of each intervention
in terms of QALYs. Overall, the HRQoL of patients in stable health states was modelled to vary according
to their NYHA class. A specific utility value was used for hospitalisation and decrements were applied to
health states involving surgery (including for initial device implantation, device-related complications and
device replacement) or infection.
Utilities by New York Heart Association class The utility values by NYHA class used in the model
(Table 108) were from one study214 (described earlier in the systematic review of HRQoL studies) that
reported utility values for all NYHA classes.
Hospitalisation and heart transplant One observational analysis within the UK27 was also included
in the systematic review. Holland and colleagues27 reported utility estimates per NYHA class at baseline in
patients with HF following emergency hospital admission, estimating an average score of 0.57
(see Table 108). This utility value is similar to that estimated by McAlister and colleagues194 and used
in Fox and colleagues’ model.64 Our model also assumed that the proportion of time hospitalised was on
average one-quarter of the month.
TABLE 107 Heart device implantation by age in the UK population
Age group (years) ICDs, % CRTs, % ICDs/CRTs, %
0–34 5.9 1.5 3.8
35–44 6.4 2.4 4.5
45–54 13.0 9.7 11.4
55–64 22.6 21.7 22.1
65–74 30.9 36.7 33.7
75–84 19.8 25.3 22.5
85+ 1.4 2.7 2.0
Total 100.0 100.0 100.0
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As in Fox and colleagues’ model,64 utility estimates for transplantation were assumed to be similar to those
for hospitalised patients and post-transplanted patients were assumed to have a similar HRQoL to NYHA
class I patients.
Surgery and infection None of the studies found in the systematic review reported the impact of surgery
or infection on the QoL of patients eligible for ICD or CRT. As per Fox and colleagues,64 decrements of
0.05 for the impact of surgery and of 0.1 for infection were assumed.
Health-related quality of life associated with implantable cardiac defibrillators One study153
reporting utilities for UK patients at increased risk of SCD as a result of ventricular arrhythmias was
included in the systematic review of HRQoL studies described earlier. Buxton and colleagues153 concluded
that there was no evidence that self-reported HRQoL changes substantially over time. Therefore, we
assumed that the NYHA class of modelled patients was constant over the modelled time horizon.
The distribution of patients by NYHA class reported at baseline in the relevant trials for population 1
was used in our model in combination with utility values by NYHA class from Gohler and colleagues214
(see Table 108) to estimate a NYHA class-weighted average utility value.
Buxton and colleagues153 also found that patients who had suffered inappropriate ICD shocks had
significantly lower HRQoL, reporting mean utility values of 0.7 and 0.8 for patients with at least one
inappropriate shock and with no shocks respectively. Patients who experience inappropriate shocks are
expected to be hospitalised and have their HRQoL affected. The impact of inappropriate shocks on HRQoL
and costs was implicitly accounted for in our economic model through the hospitalisation rates used.
Following clinical advice, we incorporated the probability of hospitalisation for severe arrhythmia in
patients with an ICD. Although there is limited evidence on hospitalisations for severe arrhythmia in the
trials included in our systematic review for population 1, we assumed that patients with an ICD are as
likely to be hospitalised for non-fatal arrhythmia as patients being managed with OPT alone (see Data
sources and parameter estimates, Population 1).
Health-related quality of life associated with cardiac resynchronisation therapy For population 2,
the impact of CRT on the HRQoL of patients with HF over time was captured in the model by changes in
the distribution of patients with HF by NYHA class derived from the relevant trials (see Data sources and
parameter estimates, Population 2, Distribution of patients per New York Heart Association class).
Given that evidence of the impact on the distribution of patients by NYHA class was available only for
population 2 patients receiving CRT-P or OPT alone, the model assumed the same effect for any CRT
device and ICDs were assumed to have the same impact as OPT alone.
For population 3, robust evidence of the effect of the devices on HF progression was not found; hence,
CRT and ICD devices were assumed to have no impact on the distribution of patients by NYHA class over
time (i.e. this distribution was assumed constant). The distribution of patients by NYHA class reported in
TABLE 108 Utilities for patients with HF
Health state NYHA class Utility value (95% CI) Source
Stable I 0.855 (0.845 to 0.864) Gohler et al.214
II 0.771 (0.761 to 0.781)
III 0.673 (0.727 to 0.765)
IV 0.532 (0.48 to 0.584)
Hospitalisation and heart transplantation 0.57 Holland et al.27
Decrement due to surgery 0.05 Assumption64
Decrement due to infection 0.1 Assumption64
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the relevant trials for the CRT-D and ICD arms at baseline (see Data sources and parameter estimates,
Population 3) was applied to patients receiving CRT-P and OPT alone, respectively, in the model. As both
arms of the trial show a similar distribution (approximately 80% and 20% for NYHA classes II and III
respectively), the model assumes similar utility values for patients receiving CRT, an ICD or OPT alone
(e.g. 0.75 for patients who are stable with therapy). Therefore, this base-case approach might be
underestimating the benefit of CRT devices for HRQoL in population 3. To estimate the impact of
accounting for this potential benefit of CRT devices on the cost-effectiveness results for population 3,
an alternative approach was adopted in the scenario analysis (see Results of the independent economic
analysis), assuming that 50% of patients with a CRT device improve by one NYHA class at 6 months
of treatment.
Utility values by NYHA class from Gohler and colleagues214 were then used to estimate NYHA
class-weighted average utility values for patients for all populations. Table 108 summarises the utility
values used in our model and their sources.
Resource use and costs
Resource use and cost estimation aimed to cost all relevant resources consumed in the care of patients in
the three populations being studied. Similar to the previous model for the assessment of CRT devices,64
the resources considered in the current model include medication and resources involved in device
implantation, device-related complications and maintenance, hospitalisation for HF or severe arrhythmia
and heart transplantation.
The economic model estimates resource use associated with each intervention based on event rates and
patient transition probabilities among the different health states. Unit costs associated with each resource
used are then applied for estimation of the total cost per intervention.
Device costs The device-related costs used in the economic model (Table 109) correspond to the
estimates provided in the MS. These were derived from average selling prices aggregated across all
manufacturers for ICD, CRT-P and CRT-D devices and for leads sold in the UK to the NHS.
TABLE 109 Device costs
Device component Mean cost (£) Lower value (£)a Upper value (£)a
Whole system
CRT-P 3411 2742 4080
CRT-D 12,293 9884 14,702
ICD 9692 7792 11,592
Leadsb
CRT-P 811 652 970
CRT-D 541 435 647
ICD 543 437 649
Battery
CRT-P 2600 2090 3110
CRT-D 11,752 9449 14,055
ICD 9149 7356 10,942
a Lower and upper values were estimated assuming SE=mean/10.
b Lead cost was estimated from the difference between the whole system cost and the generator unit cost.
Source: MS.151
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Estimates of device longevity were also sourced from the ABHI joint submission, which reports the
Kaplan–Meier plots of time to device replacement derived from data submitted to CCAD. Estimates of
mean time to replacement were derived from the reported survival functions for use in the model.
Table 110 presents the parameters of the Weibull approximations obtained for each device type and the
respective mean lifetimes. Clinical advice indicated that the longevity of the devices might be
overestimated; hence, these parameters were subject to sensitivity analysis and a scenario of shorter
device longevity was explored (see Results of the independent economic analysis).
Procedure-related costs Costs associated with device implantation, complications or maintenance were
sourced from the 2012–13 UK NHS tariff,229 whereas the costs of hospitalisations and transplantation
were derived from the 2010–11 NHS Reference Costs (NHS trusts and primary care trusts combined
HRG data).218
Table 111 presents the procedure costs used in the economic model. Only elective care estimates were
used to derive the mean cost of device-related procedures. For HRGs concerning non-device-related
procedures, the mean cost was estimated as a weighted average of the national average unit costs
reported for elective and long-stay non-elective care. Lower and upper values of all procedure costs were
derived from the 2010–11 NHS reference costs218 as a weighted average of the lower and upper quartile
unit costs reported for elective and long-stay non-elective care.
Hospitalisation The economic model developed for the current assessment accounts for hospitalisation
for HF and hospitalisation for severe arrhythmia. According to Fox and colleagues,64 fewer resources are
expected to be used to manage hospitalised patients with a device than hospitalised patients receiving
OPT. Thus, the conservative approach of assuming the same resource use for all groups was taken.
The costs associated with the management of hospitalisation for HF and arrhythmia were derived
from the 2010–11 NHS Reference Costs218 and are presented in Table 111.
The HRG codes EB03H and EB03I refer to HF or shock events with or without complications respectively;
hence, a weighted average of the national average unit costs reported for each HRG was estimated
including both elective and long-stay non-elective care. Similarly, EB07H and EB07I concern arrhythmia or
TABLE 110 Mean device lifetime
Parameter Mean 95% CI
ICDs
ln(λ) –15.784 –16.182 to –15.385
γ 1.943 1.889 to 1.996
Device longevity (years) 8.20 12.76 to 5.40
CRT-P
ln(λ) –14.222 –13.747 to –14.697
γ 1.677 1.613 to 1.74
Device longevity (years) 11.81 22.22 to 6.58
CRT-D
ln(λ) –15.465 –16.000 to –14.931
γ 1.935 1.863 to 2.006
Device longevity (years) 7.19 13.05 to 4.14
Mean replacement frequency calculated as (1/λ)^((1/γ)) × Γ(1+ (1/γ)) where Γ is the mathematical gamma function
(see Tappenden et al.228).
Source: MS.151
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conduction disorders with or without complications. The cost of hospitalisation for arrhythmia was
estimated in the same way as the cost of hospitalisation for HF.
Transplantation The cost of a heart transplant was estimated as a weighted average of the national
average unit costs reported for elective and long-stay non-elective care (HRG code EA02Z).
Device implantation Device implantation involves a surgical procedure and device-related resources;
hence, the costs of a whole system and of the implantation procedure (see Tables 109 and 111) were
included. The HRG code specific for ICD implantation is EA12Z and the code for biventricular
resynchronisation therapy procedures is EA07Z. The CRT-D implantation cost was assumed to be the
same as that for ICD implantation (a conservative approach was taken given the higher cost of EA12Z
than EA07Z).
Upgrades and routine replacements Device upgrades and routine/maintenance replacements were
assumed to be similar in terms of resource use and costs to the initial implantation.
Operative complications The resources used for managing operative complications were also accounted
for in the economic model. The definition of operative complications and the detail of their reporting
varied among the RCTs included in our systematic review of clinical effectiveness. Therefore, the rates of
operative complications were sourced from the RAFT trial,140 a large RCT of patients who are at risk of SCD
as a result of ventricular arrhythmia and with HF as a result of LVSD and cardiac dyssynchrony, managed
with CRT-D or ICD devices. For the estimation of an average cost of operative complications, we assumed
TABLE 111 Procedure costs
Procedure
Mean
cost (£)
Lower
value (£)
Upper
value (£) Source
Device-related procedures
Implantation, reimplantation and lead displacement/replacement
CRT-P 4870 3356 7816 UK tariff 2012–13229 elective EA07Z and MS151a
CRT-D 5556 5363 18,267 UK tariff 2012–13229 elective EA12Z
ICD 5556 5363 18,267 UK tariff 2012–13229 elective EA12Z
Explant
CRT-P 2748 2153 4542 UK tariff 2012–13229 elective EA39Z
CRT-D 2748 2153 4542 UK tariff 2012–13229 elective EA39Z
ICD 2748 2153 4542 UK tariff 2012–13229 elective EA39Z
Battery failure/device replacement
CRT-P 2748 2153 4542 UK tariff 2012–13229 elective EA39Z
CRT-D 5556 5363 18,267 UK tariff 2012–13229 elective EA12Zb
ICD 5556 5363 18,267 UK tariff 2012–13229 elective EA12Zc
Hospitalisation
HF 2308 1669 2578 NHS Reference Costs 2010–11218 EB03H/EB03I
Arrhythmia 1372 922 1601 NHS Reference Costs 2010–11218 EB07H/EB07I
Heart transplant 35,606 21,449 43,315 NHS Reference Costs 2010–11218 EA02Z
a Difference between the UK tariff for EA07Z and the CRT-P whole-system cost in the MS.151
b Clinical advice indicated that the battery replacement cost for CRT-D should be the same as that for an ICD.
c As in Fox et al.,64 the cost of ICD battery replacement was assumed to be the same as the cost of initial implantation.
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these to be a combination of lead displacements, infections and device-related problems requiring
intervention or device substitution. Thus, the cost of operative complications was estimated as a weighted
average of these events using the proportions presented in Table 112 for each device type.
The unit cost estimation for lead displacements, infections and device malfunctions is described in the
following section. The unit cost for complications requiring intervention was assumed to be that of lead
displacements, and device-related problems requiring replacement were assumed to cost as much as an
initial implant.
Device-related complications Management of device-related problems requires a different approach
according to each type of event, as different components of the device may need replacement or
adjustment and different lengths of hospital admission might be necessary. Fox and colleagues64
considered lead displacement or failure, lead infection and battery replacement or failure to be the most
frequent device-related complications. All types of devices (ICD and CRT) are assumed to have the same
types of problems and these are assumed to require similar management regardless of device type. Only
costs (device and procedural) are expected to differ according to the type of device.
Lead displacement or replacement Managing a lead displacement/failure occurrence is assumed to
require a surgical intervention to adjust or replace the lead, which is expected to use similar resources to
those used for initial implantation. For cost estimation, the cost of the leads and of implantation surgery
were considered.
Lead infection The treatment of lead infections usually requires surgery for explant of the infected device,
a prolonged hospital stay to control the infection, a post-discharge outpatient visit to confirm the absence
of infection and the implantation of a new system. The resource use and costs involved in the treatment of
infections are provided in Table 113.
The HRG code EA39Z includes procedures for removal of the cardiac pacemaker system and it was applied
as the explant cost for all types of devices. Mean length of stay was derived as a weighted average of the
length of stay reported for elective and long-stay non-elective care. The lower limit corresponds to an
average length of stay for elective care, whereas the upper limit is the average length of stay for long-stay
non-elective care. The cost of each additional bed-day was derived from the excess bed-day national
average unit costs for elective and long-stay non-elective care for explants (EA39Z). The post-discharge
outpatient visit cost was assumed to be a weighted average of those reported for single and
multiprofessional visits of Service 320 – Cardiology under non-admitted face-to-face consultant-led
follow-up attendance (TPCTCLFUSFF and TPCTCLFUMFF).
Battery replacement and device malfunctions Battery replacement or failure and device malfunctions
are assumed in the model to require a short admission to hospital to replace the device. As the battery is
part of the generator unit of the device, its replacement is implied. Following the approach of Fox and
TABLE 112 Proportions of operative complications in the RAFT trial
Complications CRT, n (%) ICD, n (%)
Device-related problems requiring replacementa 4 (4) 1 (2)
Complications requiring interventionb 75 (75) 31 (65)
Infections 21 (21) 16 (33)
Total 100 48
a Reported as device pocket problems requiring revision.
b Includes lead-displacement and device pocket haematoma requiring intervention.
Source: RAFT trial.140
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colleagues,64 the cost of the procedure for battery replacement for an ICD was assumed to be the same as
the cost of initial implantation (HRG code EA12Z), whereas that for CRT-P was assumed to the same as the
cost of device explant (HRG code EA39Z). Clinical advice indicated that the cost of the procedure for
battery replacement for CRT-D should be the same as that for an ICD.
Device-related total costs
Table 114 summarises the device-related total costs used in the economic model. These include the costs
of device components and procedure by event.
Drug costs
Patients with HF being managed with a device or with OPT alone receive a combination of drugs of several
classes for this condition according to their NYHA class. The approach for estimation of drug use by
NYHA class and of costs is similar to that taken by Fox and colleagues64 and the MS,151 in which a given
proportion of patients in each NYHA class is assumed to consume a selected range of drugs. The drugs,
daily doses and proportions chosen for our base-case analysis are those reported in the MS,151 based on
the systematic review and expert opinion. These are presented in Table 115.
Unit costs for the selected drugs were derived from BNF 61.219 The 4-week cycle cost was assumed to be
that of the 28-tablet pack (assuming one tablet per day) for all drugs except furosemide, for which the
cost of three packs of 28 tablets (20mg) was used. The drug cost by NYHA class is presented in Table 116.
The cost of OPT for population 1 patients without HF was assumed to be the same as that for NYHA
class I patients.
Results of the independent economic analysis
Population 1: patients at increased risk of sudden cardiac death as a result of
ventricular arrhythmias despite optimal pharmacological therapy
Base-case analysis: implantable cardiac defibrillators for secondary prevention
of sudden cardiac death
The AVID trial71 provided the estimates for all-cause mortality and the distribution of patients by NYHA
class used for our base-case analysis of patients at increased risk of SCD as a result of ventricular
arrhythmias, as it was the largest trial of patients who were resuscitated from near-fatal VF or symptomatic
sustained VT with hemodynamic compromise. Appendix 15 presents all variables used in the model for the
TABLE 113 Resource use and costs associated with the treatment of infection
Item
Mean
(£)
Lower
limit (£)
Upper
limit (£) Source
Explant cost 2748 2153 4542 UK tariff 2012–13229 elective EA39Z
Extra bed-day cost 316 190 370 NHS Reference Costs 2010–11218 EA39Z
Length of stay (days) 4.43 2.65 7.12 NHS Reference Costs 2010–11218 EA39Z
Outpatient visit cost 123 94 148 NHS Reference Costs 2010–11218 – Service
320 – Cardiology
Total cost of infectiona
CRT-P 12,553 7285 15,265
CRT-D 21,580 17,202 38,966
ICD 18,977 15,109 35,853
a Includes explant, whole device system, extra inpatient stay and implantation costs detailed in Tables 109 and 111.
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TABLE 115 Drug use (OPT) by NYHA class
Drug (mg/day)
Proportion of patients by NYHA class, %
I II III IV
Atorvastatin (10) 20 20 20 20
Simvastatin (20) 55 55 55 55
Warfarin (1) 10 15 25 40
Clopidogrel (75) 15 15 15 15
Ramipril (10) 90 90 90 90
Carvedilol (25) 85 85 75 70
Spironolactone (25) 0 30 30 30
Digoxin (125)a 5 25 25 25
Furosemide (60) 75 80 90 95
Eplerenone (25) 0 30 30 30
a Dosing measured in µg per day.
TABLE 114 Device-related total costs used in the model
Event
Mean
cost (£)
Lower
value (£)
Upper
value (£) Components
Initial implant and reimplantation
CRT-P 8281 6098 11,895 Whole system and implantation costs
CRT-D 17,849 15,246 32,969
ICD 15,248 13,155 29,858
Lead displacement/replacement
CRT-P 5681 4008 8786 Lead and initial implantation costs
CRT-D 6097 5798 18,914
ICD 6099 5799 18,916
Battery failure/replacement
CRT-P 5348 3884 6974 Generator and battery replacement costs (EA39Z)
CRT-D 17,308 14,811 32,322 Generator and battery replacement costs (EA12Z)
ICD 14,705 12,718 29,209
Infection
CRT-P 12,553 7285 15,265 Includes explant, reimplantation, extra bed-days and
outpatient visits
CRT-D 21,580 17,202 38,966
ICD 18,977 15,109 35,853
Operative complicationsa
CRT-P 4884 2442 9768 Includes device-related problems requiring replacement
(initial implantation cost), complications requiring
intervention (lead replacement cost) and infections
(infection cost)
CRT-D 6634 3317 13,268
ICD 3432 1716 6864
a Arbitrary range used for lower and upper values assuming half and double the mean cost.
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base-case analysis. The estimated base-case results for a mixed-gender cohort of 65-year-old patients are
reported in Table 117 in terms of estimated costs and QALYs accrued for patients managed with OPT or
ICD, as well as incremental costs and QALYs gained with ICD+OPT compared with OPT.
A gain of 0.80 QALYs (equivalent to 290 days in full health) is estimated for the addition of ICD to the
management of patients at increased risk of SCD with OPT, at an incremental cost of £15,492 and an
ICER of £19,479 per QALY gained.
The costs and QALYs estimated for each intervention are plotted in Figure 34.
Model outputs and validation Overall survival estimated in the model was compared with that reported
in the relevant trials (see Appendix 16 for details).
Events The number of major events estimated in the economic model for the base-case analysis is
presented in Table 118 for both strategies being compared for population 1. Initially managing patients
with OPT alone is estimated to lead to 454 ICD implants in patients hospitalised for a serious arrhythmic
event and patients who are referred for an ICD following hospitalisation for HF. As the number of
implanted patients in the OPT alone arm is much smaller than the number in the ICD+OPT arm, less
replacements and complications requiring a new device are estimated for this arm. The risks of
hospitalisation because of HF and arrhythmia are similar for patients being managed with OPT alone and
TABLE 116 Drug costs (OPT) by NYHA class
Drug (mg/day)
Cost (£) per 4 weeks by NYHA class
I II III IV
Atorvastatin (10) 0.38 0.38 0.38 0.38
Simvastatin (20) 0.50 0.50 0.50 0.50
Warfarin (1) 0.09 0.13 0.21 0.34
Clopidogrel (75) 0.35 0.35 0.35 0.35
Ramipril (10) 1.25 1.25 1.25 1.25
Carvedilol (25) 1.37 1.37 1.21 1.13
Spironolactone (25) 0 0.43 0.43 0.43
Digoxin (125)a 0.05 0.25 0.25 0.25
Furosemide (60) 1.8 1.92 2.16 2.28
Eplerenone (25) 0 12.82 12.82 12.82
Total 5.78 19.39 19.56 19.73
a Dosing measured in µg per day.
TABLE 117 Base-case results for a cohort of 65-year-old patients from the AVID trial:71 population 1
Intervention Cost (£) Life-years QALYs
Incremental
cost (£)
Incremental
life-years
Incremental
QALYs
ICER
(£/QALY
gained)
OPT 15,890 7.32 5.95 – – – –
ICD+OPT 31,382 8.25 6.75 15,492 0.93 0.80 19,479
Discounted costs and benefits.
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patients being managed with ICD+OPT; thus, the numbers of these events are similar between arms
as well.
The percentage of time spent in the main health state categories by an average patient for each strategy is
presented in Table 119. Patients in both arms spend most of their time in the stable with therapy health
state, and the proportions were similar between arms. A reduced proportion of time was then spent in the
device-related intervention and hospitalisation health states.
Deterministic sensitivity analysis
Deterministic sensitivity analyses was undertaken to explore the effect of uncertainty related to key
parameters and methodological and structural assumptions on the cost-effectiveness results. Scenario
analyses were performed to explore modelling relevant population groups as well as using alternative
utility estimates to derive QALYs. Univariate sensitivity analyses were also conducted on parameters
expected a priori to be influential on results.
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FIGURE 34 Cost-effectiveness plane: population 1.
TABLE 118 Number of eventsa for cohorts of 1000 patients: population 1
Event
Strategy
OPT ICD+OPT
Initial implant 0 1000
Upgradeb 454 0
Implant reattemptc 10 22
Hospitalisation 1966 2244
Routine replacement 541 921
Postoperative complications 58 114
Lead displacement 77 171
Infection 32 71
Total no. of devicesd 1037 2014
a Undiscounted number of events.
b ICD implants in patients initially managed with OPT alone.
c Following surgical failure.
d Sum of initial implants, upgrades, reattempts from surgical failures, routine replacements and infections
(required new device).
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Mixed-age cohort Cost-effectiveness results were estimated for a scenario of a mixed-age and
mixed-gender cohort of patients eligible for ICD for the secondary prevention of SCD. The distribution of
ICD implants by age in the UK reported by the British Cardiovascular Society, the British Heart Foundation
and the Cardio and Vascular Coalition225 was used as a proxy for the distribution of patients at increased
risk of SCD as a result of ventricular arrhythmia. Age-dependent variables in the population 1 model were
those that determined all-cause mortality (baseline risk and RR of death by age group). Table 120 shows
the results for the mixed-age cohort and per age group.
Overall, the ICER increases with age as the QALY gain with ICD+OPT decreases compared with OPT alone
as the decrement in incremental benefits from treatment over time is steeper than that for incremental
costs. The ICER of £24,967 per QALY gained for the mixed-age cohort shows that ICD+OPT is within the
WTP range of £20,000–30,000 per QALY gained.
TABLE 120 Base-case results by age and for a mixed-age cohort: population 1
Starting age (years) OPT costs (£) ICD costs (£) OPT QALYs ICD QALYs ICER (£/QALY gained)
30 27,207 43,410 9.74 10.69 17,083
40 25,982 41,968 9.33 10.23 17,856
50 23,535 39,238 8.54 9.35 19,228
60 16,947 32,673 6.29 7.15 18,182
70 14,268 29,361 5.41 6.12 21,298
80 9681 24,129 3.85 4.36 28,211
90 5382 18,232 2.40 2.45 288,611
Mixed 16,559 31,838 6.17 6.91 24,967
TABLE 119 Overall distribution of an average patient’s lifetime by health state category: population 1
Health state category
% of remaining life
OPT ICD+OPT
Stable with therapy 97.61 96.50
OPT 47.78 0.00
ICD 49.83 96.50
Hospitalisation 1.19 1.55
Implant surgery 0.37 0.71
Routine replacement 0.43 0.63
Postoperative complications 0.06 0.12
Lead displacement 0.05 0.08
Infection 0.03 0.05
Device-related interventionsa 0.93 1.59
a Sum of occupancy in implant surgery, postoperative complications, routine replacement, lead displacement
and infection.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
221
Implantable cardiac defibrillator for the primary prevention of sudden cardiac death
The MADIT II trial The MADIT II trial101 was the trial with the largest number of patients with a remote
MI and was considered representative of a relevant group who might benefit from ICD therapy for the
primary prevention of SCD. Cost-effectiveness results for the subgroup analysis of patients with a remote
MI, using MADIT II all-cause mortality for a cohort of 64-year-old patients and a pooled RR of 0.57
(effect of ICD+OPT on all-cause mortality relative to OPT), are presented in Table 121.
An increment of 1.18 QALYs per patient is estimated using ICD+OPT for the primary prevention of SCD
at an additional cost of £16,800. The health benefit estimated from using ICD+OPT for the primary
prevention of SCD in patients remote from their MI instead of OPT alone is greater than that for secondary
prevention, in accordance with the lower pooled RR (0.57) estimated for patients with a remote MI than
that used in the base-case analysis (RR= 0.75). The estimated ICER for this patient group is £14,231 per
QALY gained.
The SCD-HeFT trial The all-cause mortality rate in the placebo arm, the RR for ICDs of 0.77 (95% CI 0.66
to 0.89) and the distribution of patients by NYHA class from the SCD-HeFT trial105 were used to inform an
analysis of 60-year-old patients with mild to moderate HF with an indication for an ICD. Table 122 shows
the cost-effectiveness results for this subgroup analysis.
An additional benefit of 0.49 QALYs (approximately 180 days in full health) is estimated for ICD+OPT for
the primary prevention of SCD in patients with mild to moderate HF at an additional cost of £14,655
compared with OPT alone. The estimated ICER for this subgroup of patients (£29,756 per QALY gained) is
just below the WTP threshold of £30,000 per QALY gained.
The two cohorts initially managed with OPT alone or ICD+OPT for the primary prevention of SCD showed
higher costs and slightly longer life expectancy than in the base-case analysis (secondary prevention of
SCD). However, given the greater severity of HF in these patients (see distribution by NYHA class in Data
sources and parameter estimates, Population 1), both cohorts gained fewer QALYs than secondary
prevention patients (base-case analysis).
Patients with cardiomyopathy The all-cause mortality rate reported for the SCD-HeFT105 subgroup of
patients with non-ischaemic CHF in the placebo arm was used as the baseline mortality rate for a
subgroup analysis of 60-year-old patients with cardiomyopathy. The mortality preventative effect of ICDs
was incorporated using a pooled RR of 0.74 (95% CI 0.58 to 0.93) from the non-ischaemic subgroup of
the SCD-HeFT,105 AMIOVIRT,69 CAT82 and DEFINITE90 trials. The SCD-HeFT105 distribution of patients by
NYHA class was also used. Table 123 reports the estimated cost-effectiveness results for this subgroup.
TABLE 122 The SCD-HeFT trial105 subgroup analysis results
Intervention Cost (£) Life-years QALYs ICER (£/QALY gained)
OPT 17,760 7.84 5.79 –
ICD 32,416 8.51 6.28 29,756
TABLE 121 The MADIT II trial101 subgroup analysis results
Intervention Cost (£) Life-years QALYs ICER (£/QALY gained)
OPT 14,783 6.77 5.17 –
ICD+OPT 31,583 8.36 6.35 14,231
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The primary prevention of SCD with ICD+OPT in patients with cardiomyopathy is expected to cost
£15,373 more than initial prevention with OPT alone and subsequent implantations for an incremental
benefit of 0.59 QALYs (216 days in full health). Compared with the base case (secondary prevention of
SCD), both treatment strategies for patients with cardiomyopathy have a higher cost and provide a greater
benefit (about £9000 more for 1.67 or 1.88 QALYs more with ICD+OPT or OPT alone respectively) over a
lifetime. The ICER estimated for the cardiomyopathy subgroup is £26,028 per QALY.
Univariate sensitivity analysis Table 124 shows the results of the univariate sensitivity analyses
conducted on key inputs in the model, allowing the estimation of their impact on the cost-effectiveness
results. The range used for most parameters was their 95% CI.
The univariate sensitivity analyses for the structural parameters did not result in large changes to the ICER,
apart from that for the model time horizon. The only analysis that increased the ICER to > £30,000 per
QALY gained was that in which the time horizon was shortened to the survival follow-up period reported
in the AVID trial71 (as very few health benefits are accrued over that time period compared with the
incremental cost of ICD implantation).
Among the mortality-related estimates, the model results showed particular sensitivity to the HR for
all-cause mortality associated with the ICD+OPT arm, more than tripling to £78,268 per QALY gained
when the upper limit of the HR (0.93) was used.
The event-related estimates that had the greatest impact on the ICER were the risk of surgical death
during ICD implantation and the device lifetime. When the risk of death from ICD surgery was varied
according to the 95% CI the ICER ranged from £18,950 to £32,605 per QALY gained, and when the
device lifetime was changed from 8 years to 13 years or 5 years the ICER ranged from £16,456 to £24,706
per QALY gained respectively.
Hospitalisation for arrhythmia There is limited reporting of the number of hospitalisations for non-fatal
arrhythmia in the trials included in our systematic review for population 1 (patients at increased risk of
SCD). Following clinical advice, our base-case analysis assumes the same risk as that for patients with
HF (probability of event occurring 0.0075, 95% CI 0.0002 to 0.0148), derived from the MIRACLE trial.121
As this is likely to be an underestimate of the risk for population 1 patients, a scenario analysis was
conducted using the risk of hospitalisation for ventricular arrhythmia for population 3 patients with an ICD
(also at increased risk of SCD as a result of ventricular arrhythmia).
In the population 3 model, the risk of hospitalisation because of arrhythmia for patients with an ICD is
0.032 (probability of event occurring; 95% CI 0.017 to 0.046), obtained by applying the pooled RR of 1.11
to the baseline risk of patients managed with CRT-D (0.029) derived in Chapter 4 (see People with both
conditions, Assessment of effectiveness, Arrhythmias). For the population 1 scenario, the risk of
hospitalisation because of arrhythmia was assumed to be 0.032 for patients with an ICD and for patients
being managed with OPT alone. Table 125 summarises the cost-effectiveness results for this scenario.
Compared with the base-case analysis, a slightly lower ICER (£18,185 per QALY gained) is estimated using
a higher risk of hospitalisation for arrhythmia, as the OPT arm shows a substantial gain in QALYs compared
with the ICD+OPT arm, despite the greater increase in cost.
TABLE 123 Cardiomyopathy subgroup analysis results
Intervention Cost (£) Life-years QALYs ICER (£/QALY gained)
OPT 24,845 10.59 7.83 –
ICD 40,218 11.39 8.42 26,028
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TABLE 124 Univariate sensitivity analysis: population 1
∫ Parameter Base-case value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Base case – – 15,492 0.80 19,479
Structural parameters
Time horizon Lifetime AVID trial
follow-up
(3 years)71
13,330 0.09 141,235
Discount rates of costs and
benefits (%)
3.5, 3.5 0, 0 16,836 1.18 14,271
6, 1.5 14,908 0.99 15,069
Survival and HRs
Baseline all-cause mortality,
ln(λ), γ
–3.381, 0.696 –3.431, 0.678 15,496 0.78 19,854
–0.330, 0.714 15,449 0.80 19,416
All-cause mortality HR (ICDs) 0.75 0.61 17,126 1.37 12,480
0.93 13,772 0.18 78,268
Age-related RR of death,
> 75 years
1.41 1 15,551 0.81 19,241
2 15,367 0.76 20,137
Event probabilities
Risk of hospitalisation for
HF (OPT)
0.008 0 15,251 0.79 19,197
0.020 15,869 0.80 19,920
RR of hospitalisation for
HF (ICDs)
1 0.804 15,262 0.80 19,184
1.196 15,723 0.80 19,773
Risk of implantation following
HF hospitalisation
0.002 0 15,506 0.80 19,484
0.006 15,461 0.79 19,466
Risk of surgical death (ICDs) 0.003 0 15,491 0.82 18,950
0.055 15,507 0.48 32,605
Risk of surgical death
(transplant)
0.122 0.109 15,492 0.80 19,476
0.136 15,492 0.80 19,481
Risk of surgical failure 0.011 0.009 15,464 0.80 19,442
0.013 15,521 0.80 19,516
Risk of perioperative
complications
0.053 0.046 15,469 0.80 19,448
0.062 15,523 0.80 19,518
Risk of lead infections 0.0005 0.0004 15,371 0.80 19,321
0.0006 15,614 0.80 19,636
Risk of lead displacements 0.0012 0.001 15,415 0.80 19,372
0.0014 15,570 0.80 19,585
Device lifetime, ln(λ), γ –15.78, 1.94
(∼ 8 years)
–16.182, 1.889
(∼13 years)
13,158 0.80 16,456
–15.385, 1.996
(∼5 years)
19,467 0.79 24,706
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Utilities In the base-case analysis, NYHA class-weighted average utility estimates of 0.81 and 0.82 were
used for the OPT arm and the ICD arm, respectively, using the distribution of patients per NYHA class in
the AVID trial.71 A scenario analysis was conducted using a mean utility estimate of 0.75 irrespective of
NYHA class and treatment arm as per Buxton and colleagues.153 This lower average utility value led to an
estimated 0.69 QALY gain (instead of the 0.80 QALY gain estimated for the base case). Therefore, the
ICER of ICD+OPT compared with OPT alone for the secondary prevention of SCD increased to £22,372
per QALY gained.
Device-related costs All device-related costs (i.e. costs associated with implantation, perioperative
complications, treatment of lead displacement, infection and device replacement) were varied to the lower
and upper limits of their 95% CI, for example the ICD implantation cost was reduced by 14% to £13,155.
For this scenario the ICER ranged from £16,888 to £37,832 per QALY gained.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was performed for the base case to estimate the impact of joint parameter
uncertainty on the model’s cost-effectiveness results. Appendix 15 reports the variables (mean values and
CIs) included in the probabilistic sensitivity analysis, the form of distribution used for sampling and the
parameters of the distribution. Probabilistic sensitivity analysis results of 10,000 iterations are presented in
Figure 35 in terms of cost and QALYs for each strategy. The probabilistic mean ICER is £20,479 per QALY
gained [interquartile range (IQR) £9857 to £61,685 per QALY gained].
Figure 36 shows the variation in the probability of cost-effectiveness for both interventions as the WTP
threshold increases from £0 to £50,000 per QALY gained. The addition of ICD to OPT for SCD secondary
prevention has a 51% probability of being cost-effective at a WTP threshold of £20,000 per QALY gained
and a 82% probability of being cost-effective at a WTP threshold of £30,000 per QALY gained.
TABLE 125 Hospitalisation because of arrhythmia scenario analysis results
Intervention Cost (£) Life-years QALYs ICER (£/QALY gained)
OPT 29,759 7.78 6.34 –
ICD 37,120 8.26 6.74 18,185
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FIGURE 35 Cost-effectiveness scatterplot: population 1.
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Population 2: patients with heart failure as a result of left ventricular systolic
dysfunction and cardiac dyssynchrony despite receiving optimum
pharmacological therapy
People with HF as a result of LVSD and cardiac dyssynchrony despite receiving OPT were modelled
receiving initially OPT alone or CRT-P or CRT-D alongside OPT. This allowed the estimation of the relative
cost-effectiveness of these treatment strategies, and results for the comparisons specified in the NICE
scope61 (CRT-P+OPT vs. OPT, CRT-D+OPT vs. OPT, and CRT-D+OPT vs. CRT-P+OPT) are given in
this section.
Base-case analysis
For our base-case analysis, a 70-year-old mixed-gender cohort of patients with HF was modelled receiving
the relevant treatment strategies. Table 126 presents the estimated discounted costs, life-years and QALYs
accrued for patients managed with OPT, CRT-P+OPT or CRT-D+OPT as well as the incremental cost per
QALY gained for the relevant comparisons.
The ICERs for initial management with CRT-P or CRT-D alongside OPT compared with initial management
with OPT alone were similar (£27,584 and £27,899 per QALY gained respectively). The addition of CRT-P
to OPT results in a gain of 0.68 QALYs at a cost of £18,845 compared with OPT, and the addition of
CRT-D to OPT yields a gain of 1.09 QALYs at a cost of £30,548 compared with OPT. CRT-D+OPT was
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FIGURE 36 Cost-effectiveness acceptability curve: population 1.
TABLE 126 Base-case summary of the cost-effectiveness results: population 2
Strategy Cost (£) Life-years QALYs
Incremental
cost (£)
Incremental
life-years
Incremental
QALYs
ICER
(£/QALY
gained)
Vs. next best optiona
OPT 7615 4.86 3.48 – – – –
CRT-P+OPT 26,460 5.51 4.17 18,845 0.66 0.68 27,584
CRT-D+OPT 38,163 7.21 4.58 11,703 1.69 0.41 28,420
Vs. OPT
CRT-D+OPT 38,163 7.21 4.58 30,548 2.35 1.09 27,899
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated.
Discounted costs and benefits.
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more costly (by £11,703) and more effective (resulting in an increase of 0.41 QALYs) than CRT-P+OPT,
resulting in an ICER of £28,420 per QALY gained compared with CRT-P+OPT. The costs and QALYs
estimated for each intervention are plotted in Figure 37.
Model outputs and validation Heart failure deaths and SCDs estimated in the model were compared
with those reported in the CARE-HF trial109 (see Appendix 16 for details).
Events The percentage of time spent in the main health states by an average patient in each strategy is
presented in Table 127. Patients in each strategy spent most time in the stable with therapy health state.
The cohort initially managed with OPT alone spent slightly more time in the stable with therapy health
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FIGURE 37 Cost-effectiveness plane: population 2.
TABLE 127 Overall distribution of an average patient’s lifetime by health state category: population 2
Health state category
% of remaining life
OPT CRT-P+OPT CRT-D+OPT
Stable with therapy 95.15 94.17 93.44
OPT 93.85 7.90 0.15
CRT-P 0.54 55.86 0
CRT-D 0.67 26.86 83.06
ICD 0.09 3.54 10.24
Hospitalisation 4.22 2.80 3.63
OPT 4.18 0.36 0.01
CRT-P 0.01 1.26 0
CRT-D 0.03 1.02 3.14
ICD 0.00 0.17 0.48
Implant surgery 0.03 1.70 1.24
Routine replacement 0.01 0.32 0.56
Lead displacement 0.00 0.33 0.34
Postoperative complications 0.00 0.25 0.22
Infection 0.00 0.06 0.06
Device-related interventionsa 0.05 2.65 2.42
a Sum of occupancy in implant surgery, postoperative complications, routine upgrade, lead displacement and infection.
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state, but it is also the strategy with the highest proportion of remaining life spent in hospital. The CRT
cohorts spent slightly less time hospitalised; however, they spent more time in the device-related
intervention health state (i.e. because of implant surgery, postoperative complications, routine upgrades,
lead displacements and infections). About 27% of the lifetime of patients initially managed with
CRT-P+OPT was spent stable with a CRT-D device as result of the upgrade.
Table 128 shows the number of events for each cohort of population 2 patients. The cohorts initially
managed with CRT alongside OPT (CRT-P+OPT or CRT-D+OPT) are estimated to require a similar total
number of devices (comprising initial implants, upgrades, infections and replacements) over a lifetime.
Although the CRT-P+OPT group required fewer device replacements than the CRT-D+OPT group given
the longer lifetime of CRT-P, more upgrades were needed than in the CRT-D+OPT arm. The 228 ICDs
reported as upgrades from CRT-D in the CRT-D+OPT strategy in Table 128 are assumed to be successful
ICD implants after CRT-D implant failures.
Deterministic sensitivity analysis
The effect of uncertainty related to key parameters and methodological and structural assumptions on the
cost-effectiveness results was explored through subgroup, univariate and scenario analyses.
Mixed-age cohort Cost-effectiveness results were estimated for a scenario of a mixed-age and
mixed-gender cohort of patients with HF. The distribution of patients with HF by age group reported by
Cowie and colleagues20 was used, and the proportion of men with HF was derived from the prevalence of
HF per sex in the UK from British Heart Foundation Statistics.29 Age-dependent variables in the population
2 model were those that determined SCD, HF death, other-cause mortality and RR of death by age group.
The model results for different starting ages are detailed in Table 129. These results show that the ICER
increases non-linearly with age and the ICERs of the three comparisons are consistently similar among age
groups. For most age groups, CRT-P+OPT compared with OPT alone is the strategy with the lowest ICER
and CRT-D+OPT compared with CRT-P+OPT is the strategy with the highest ICER. The exception is for
80-year-old patients, for whom the opposite is estimated to occur, as CRT-D+OPT compared with
CRT-P+OPT shows a smaller QALY gain (0.33) at a lower cost (£10,757) than that estimated for
CRT-P+OPT relative to OPT alone (0.49 QALYs gained at a cost of £16,000).
Univariate sensitivity analysis Tables 130–132 present the results of the deterministic sensitivity analyses
of the most influential parameters for each of the relevant comparisons (i.e. those that when varied
between the 95% CI limits caused a variation > £10,000 per QALY in the ICER). The other parameters
were varied but had a smaller impact on the results.
Table 130 shows that the risk of hospitalisation for a serious arrhythmic event for HF patients managed
with CRT-P, the RRs of HF death for patients managed with CRT-P and CRT-D, and the RR of SCD for HF
patients managed with CRT-P have the most impact on the cost-effectiveness results for the comparison
between CRT-P+OPT and OPT alone as initial treatment.
The results for this comparison are particularly sensitive to the risk of hospitalisation for non-fatal
arrhythmia for HF patients managed with CRT-P, as the ICER decreases to £15,780 per QALY gained when
the lower limit of the 95% CI of the estimate is used. On the other hand, the ICER rises to £31,978 per
QALY gained when the upper limit of the 95% CI is used, as the cost of the CRT-P+OPT cohort increases
substantially whereas that for the OPT alone cohort stays the same. Patients being managed with CRT-P
who are hospitalised because of arrhythmias are assumed to be referred for CRT-D implantation. The cost
increment for the CRT-P cohort is hence accompanied by a small health gain.
The RR of SCD for patients managed with CRT-P was varied between the RRs reported in the CARE-HF109
and COMPANION116 trials, as these indicate a relative effect in opposite directions. The ICER for
CRT-P+OPT compared with OPT alone decreases to £19,825 per QALY gained when the RR of SCD for
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TABLE 128 Number of eventsa for cohorts of 1000 patients: population 2
Event
Strategy
OPT CRT-P+OPT CRT-D+OPT
Initial implant 0 1000 1000
ICD 0 0 0
CRT-P 0 1000 0
CRT-D 0 0 1000
Hospitalisation 3043 2349 3385
OPT 3013 299 6
CRT-P 9 1057 0
CRT-D 18 854 2929
ICD 3 140 450
Upgrade 20 421 156
ICD 1 58 156
CRT-P 10 1 0
CRT-D 8 362 0
Surgical complications 3 208 204
ICD 0 5 13
CRT-P 1 132 0
CRT-D 2 71 191
Lead displacement 3 275 315
ICD 0 4 12
CRT-P 2 183 0
CRT-D 2 88 303
Infection 0.6 46.3 55.7
ICD 0.0 1.6 5.1
CRT-P 0.3 29.9 0.0
CRT-D 0.3 14.8 50.7
Replacement 6.6 269.3 523.9
ICD 0.7 29.6 66.7
CRT-P 1.1 32.6 0.0
CRT-D 4.8 207.2 457.2
Total no. of devicesb 27 1737 1736
ICD 2 89 228
CRT-P 11 1063 0
CRT-D 14 584 1508
a Undiscounted number of events.
b Sum of initial implants, upgrades, infections (required new device) and replacements.
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patients managed with CRT-P from the CARE-HF trial109 (0.54) is used, that is, when CRT-P is assumed to
considerably reduce the risk of SCD. A cost of £30,925 per QALY gained is estimated when the RR from
the COMPANION trial116 (1.13) is used, a scenario in which CRT-P would increase the risk of SCD.
Generally, the results for the addition of CRT-D to OPT were robust to the variation of most of the
parameters (see Table 131) compared with the results for the other two comparisons (CRT-P+OPT vs. OPT
and CRT-D+OPT vs. CRT-P+OPT). They were mainly sensitive to the RR of HF death and the RR of SCD
for patients managed with CRT-D, and to the lifetime of the CRT-D device, confirming that the
cost-effectiveness of the addition of CRT-D to OPT is determined by the survival benefit associated with
this device. The most influential parameter for this comparison was the RR of HF death associated with
CRT-D (0.73). Varying the RR between 0.47 and 1.11 resulted in the ICER ranging between £20,671 and
£52,082, respectively, a difference of £31,411. When the upper limit of this estimate is considered (1.11),
the preventative benefit of CRT-D for HF death disappears and the ICER for CRT-D+OPT compared with
OPT alone rises to > £50,000 per QALY gained.
TABLE 129 Base-case results by age and for a mixed-age cohort: population 2
Starting
age (years) Strategy Cost (£) Life-years QALYs
ICER (£/QALY gained)
vs. OPT
ICER (£/QALY gained)
vs. CRT-P+OPT
30 OPT 12,614 7.98 5.77 – –
CRT-P+OPT 40,482 9.30 7.05 21,678 –
CRT-D+OPT 54,997 15.65 7.69 22,065 22,848
40 OPT 12,419 7.80 5.63 – –
CRT-P+OPT 39,572 9.00 6.82 22,870 –
CRT-D+OPT 53,849 13.44 7.40 23,413 24,519
50 OPT 11,862 7.47 5.39 – –
CRT-P+OPT 37,713 8.51 6.45 24,444 –
CRT-D+OPT 51,531 12.17 6.97 25,106 26,447
60 OPT 10,081 6.39 4.60 – –
CRT-P+OPT 32,755 7.22 5.47 26,029 –
CRT-D+OPT 45,486 9.76 5.91 26,953 28,771
70 OPT 7615 4.86 3.48 – –
CRT-P+OPT 26,460 5.51 4.17 27,584 –
CRT-D+OPT 38,163 7.21 4.58 27,899 28,420
80 OPT 5882 3.77 2.69 – –
CRT-P+OPT 21,882 4.23 3.18 32,656 –
CRT-D+OPT 32,639 5.33 3.52 32,598 32,511
90 OPT 4075 2.64 1.87 – –
CRT-P+OPT 16,509 2.78 2.08 61,057 –
CRT-D+OPT 25,261 3.15 2.20 64,917 71,322
Mixed OPT 8218 5.23 3.75 – –
CRT-P+OPT 28,016 5.91 4.47 28,928 –
CRT-D+OPT 39,932 7.93 4.88 29,416 30,321
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The results for the comparison between CRT-D and CRT-P alongside OPT were the most sensitive to the
variation of individual parameters, with eight parameters that made the ICER range by > £10,000
(see Table 132). The most influential parameter for this comparison was the RR of HF death for patients
managed with CRT-D compared with OPT alone, followed by the RRs of SCD for both CRT-D and CRT-P
devices relative to OPT alone.
The estimate of the RR of HF death for patients managed with CRT-D was sourced from the COMPANION
trial116 (RR 0.73, 95% CI 0.47 to 1.11). When a higher risk of HF death for CRT-D than for OPT alone is
assumed (RR= 1.11), the incremental benefit of CRT-D+OPT is almost null relative to CRT-P+OPT (0.01),
resulting in an extremely high ICER.
The ICER for CRT-D+OPT compared with CRT-P+OPT also becomes extremely high when the RR of SCD
for patients managed with CRT-P is changed to the lowest limit. The pooled RR of SCD for CRT-P patients
of 0.97 (95% CI 0.44 to 2.14) was obtained in the meta-analysis reported in Chapter 4 (see People with
heart failure, Assessment of effectiveness, Sudden cardiac death). Given its wide 95% CI, a RR of 1 was
TABLE 131 Univariate sensitivity analysis for CRT-D+OPT vs. OPT: population 2
Parameter
Base-case
value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Base case – – 30,548 1.09 27,899
RR of HF death (CRT-D) 0.73 0.47 33,541 1.62 20,671
1.11 27,381 0.53 52,082
RR of SCD (CRT-D) 0.44 0.23 32,147 1.38 23,283
0.86 27,962 0.63 44,659
Device lifetime (CRT-D), ln(λ), γ –15.465, 1.935
(∼7 years)
–16.000, 1.863
(∼13 years)
25,309 1.12 22,643
–14.931, 2.006
(∼4 years)
39,322 1.05 37,363
DSA, deterministic sensitivity analysis.
TABLE 130 Univariate sensitivity analysis for CRT-P+OPT vs. OPT: population 2
Parameter
Base-case
value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Base case – – 18,845 0.68 27,584
Risk of hospitalisation for
non-fatal arrhythmia (CRT-P)
0.0075 0.0002 8765 0.56 15,780
0.0148 24,169 0.76 31,978
RR of HF death (CRT-P) 0.67 0.51 19,575 0.84 23,307
0.88 17,993 0.50 36,019
RR of HF death (CRT-D) 0.73 0.47 19,788 0.84 23,522
1.11 17,836 0.51 34,720
RR of SCD (CRT-P) 1 0.54 20,471 1.03 19,825
1.13 18,443 0.60 30,925
DSA, deterministic sensitivity analysis.
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used in the model and this value was varied in the sensitivity analysis between the mean estimates of RR
reported in the most relevant trials (0.54 from the CARE-HF trial109 and 1.13 from the COMPANION
trial).116 Under the CARE-HF trial scenario, the preventative effect of CRT-P on SCD becomes higher than
that of CRT-D, that is, the incremental benefit of CRT-D+OPT relative to CRT-P+OPT (0.06) is much
smaller than in the base case (0.41).
Similarly, if the RR of SCD for patients managed with CRT-D is increased to 0.86 (the upper limit of its
95% CI, sourced from the COMPANION trial),116 only 0.08 incremental QALYs are estimated for
CRT-D+OPT compared with CRT-P+OPT, resulting in a particularly high ICER.
Varying the life expectancy of the CRT-D device, the RR of HF death for patients managed with CRT-P and
the risk of hospitalisation for severe arrhythmia for patients managed with CRT-P also had a substantial
influence on the ICER, making it range by > £20,000. The ICER for CRT-D+OPT compared with
CRT-P+OPT decreased substantially when a longer device lifetime was used (13 years) for CRT-D, the RR
of HF death with CRT-P was increased or the risk of hospitalisation for arrhythmia with CRT-P was higher.
Overall, the ICERs for the comparisons relevant for population 2 are sensitive mainly to survival-related
parameters that determine the incremental benefit of the devices for patient survival, such as the RRs of
SCD and HF death for CRT-P and CRT-D, the risk of hospitalisation because of arrhythmia for CRT-P and
the lifetime of the device for CRT-D. Device lifetime was also influential because of the incremental costs
incurred if a device needs replacing more frequently.
TABLE 132 Univariate sensitivity analysis for CRT-D+OPT vs. CRT-P+OPT: population 2
Parameter
Base-case
value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY
gained)
Base case – – 11,703 0.41 28,420
RR of HF death (CRT-D) 0.73 0.47 13,754 0.78 17,602
1.11 9545 0.01 793,839
RR of SCD (CRT-P) 1 0.54 10,063 0.06 169,196
1.13 12,108 0.50 24,250
RR of SCD (CRT-D) 0.44 0.23 12,817 0.62 20,180
0.86 9912 0.08 129,220
Device lifetime (CRT-D), ln(λ), γ –15.465, 1.935
(∼7 years)
–16, 1.863
(∼13 years)
8608 0.43 20,238
–14.931, 2.006
(∼4 years)
17,811 0.38 46,640
RR of HF death (CRT-P) 0.67 0.51 10,966 0.25 43,231
0.88 12,563 0.60 21,042
Risk of hospitalisation for
non-fatal arrhythmia (CRT-P)
0.0075 0.0002 21,857 0.54 40,450
0.0148 6335 0.34 18,707
Baseline mortality from HF,
ln(λ), γ
–6.115, 1.223 –6.253, 1.180 12,546 0.52 24,157
–5.977, 1.265 10,864 0.31 35,220
Baseline mortality from SCD,
ln(λ), γ
–6.069, 1.140 –6.173, 1.107 11,460 0.33 34,318
–5.964, 1.173 11,924 0.49 24,316
DSA, deterministic sensitivity analysis.
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Scenario analysis
Device longevity Clinical advice indicated that the device longevity estimates used in the base-case
analysis could be overestimated, particularly for CRT-P. Table 133 presents the device lifetime estimates
used in the previous model by Fox and colleagues64 and those used in the current model.
A scenario analysis was conducted using the mean device lifetime estimates used by Fox and colleagues.64
The results for this scenario are presented in Table 134. Compared with the base-case analysis,
higher costs are estimated for CRT-D and CRT-P alongside OPT because of the shorter device lifetime
(by approximately £4500 and £2000 respectively). Also, slightly fewer QALYs (–0.02) are estimated
to be accrued than in the base-case analysis as patients are estimated to spend more time in the
device-related interventions health state and less time stable with therapy.
Utilities A scenario using the utility estimates from the study by Fox and colleagues64 (presented in
Table 135) was explored. The utility estimates used in the base-case analysis can be found in Table 108.
Table 136 shows the cost-effectiveness results for this scenario, with the same costs per strategy as those
estimated for the base-case analysis. In this scenario, fewer QALYs (–0.09) were estimated for OPT alone
and more QALYs were estimated for the CRT strategies (+0.04 and +0.05 for CRT-P and CRT-D
respectively). The lower ICERs presented in this scenario for the comparisons between CRT-P and CRT-D
TABLE 133 Device lifetime estimates
Device
Lifetime (years)
Fox et al.,64 mean SHTAC, mean (95% CI)
ICD 5.0 8.2 (5.4 to 12.8)
CRT-D 5.5 7.2 (4.1 to 13.1)
CRT-P 6.5 11.8 (6.6 to 22.2)
TABLE 134 Shorter device lifetime scenario analysis results: population 2
Strategy Cost (£) Life-years QALYs
ICER (£/QALY gained)
vs. OPT
ICER (£/QALY gained)
vs. CRT-P+OPT
OPT 7652 4.86 3.48 – –
CRT-P+OPT 28,555 5.50 4.15 31,334 –
CRT-D+OPT 42,627 7.18 4.56 32,505 34,416
TABLE 135 Utility values used in the scenario analysis: population 2
Health state Mean utility value Source
NYHA class I 0.93 Kirsch and McGuire 2000210
NYHA class II 0.78 Kirsch and McGuire 2000210
NYHA class III 0.61 Calvert et al.211
NYHA class IV 0.44 Calvert et al.211
Hospitalisation and transplantation 0.57 McAllister et al.194
Decrement from surgery 0.05 Assumption
Decrement from infection 0.1 Assumption
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and OPT alone are explained by the greater differences in QALYs gained among strategies than in the
base-case analysis. As both CRT cohorts had similar QALY increments in this scenario, the ICER for CRT-D
compared with CRT-P in this scenario (£27,893 per QALY gained) does not differ as much from the ICER in
the base case (£28,420 per QALY gained).
Costs All device-related costs (including those associated with implantation, perioperative complications,
treatment of lead displacement, infection and device replacement) were varied as a group to the lower
and upper limits of their 95% CIs (see Table 114). The ICER ranged from £20,977 to £48,486 per QALY
gained for CRT-P+OPT compared with OPT, from £23,652 to £53,556 per QALY gained for CRT-D+OPT
compared with OPT, and from £28,090 to £61,967 per QALY gained for CRT-D+OPT compared with
CRT-P+OPT. Considering a willing-to-pay threshold of £30,000 per QALY gained, when the upper limits
of the device-related costs are used, both CRT strategies become non-cost-effective compared with OPT
alone, and CRT-D+OPT becomes non-cost-effective compared with CRT-P+OPT. The scenario using the
lower limits of the device-related costs resulted in a reduction in costs of > £4500 for both CRT strategies
and of < £100 for OPT alone. Thus, the ICERs for the comparisons between the CRT devices and OPT
alone are reduced much more substantially than the ICER for the comparison between CRT-D and CRT-P.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was performed for the base case to estimate the impact of joint parameter
uncertainty on the model’s cost-effectiveness results. Appendix 15 reports the variables (mean values and
CIs) included in the probabilistic sensitivity analysis, the form of distribution used for sampling and the
parameters of the distribution. Table 137 reports the estimated probabilistic results of 10,000 iterations in
terms of costs and QALYs for each strategy and their relative cost-effectiveness.
The probabilistic results are consistent with the deterministic base-case analysis. Both CRT-P+OPT and
CRT-D+OPT have ICERs of < £30,000 per QALY gained compared with initial management with OPT
alone, as well as CRT-D+OPT compared with CRT-P+OPT. The IQR estimated for the probabilistic ICER
for the comparison between CRT-D+OPT and CRT-P+OPT reflects the overlap in model results for CRT-P
and CRT-D.
The probabilistic sensitivity analysis results are presented in Figure 38 in terms of incremental costs and
QALYs, showing their dispersion on the cost-effectiveness scatterplot and the partial overlap of the
cost-effectiveness results for the three strategies, particularly between CRT-P and CRT-D.
Figure 39 shows the variation in the probability of the three treatment strategies being cost-effective as the
WTP threshold increases from £0 to £50,000 per QALY gained. At a WTP threshold of £20,000 per QALY
TABLE 136 Utilities scenario analysis results: population 2
Intervention Cost (£) Life-years QALYs ICER (£/QALY gained) vs. OPT
ICER (£/QALY gained)
vs. CRT-P+OPT
OPT 7615 4.86 3.39 – –
CRT-P+OPT 26,460 5.51 4.21 22,892 –
CRT-D+OPT 38,163 7.21 4.63 24,580 27,893
TABLE 137 Base-case summary of the probabilistic cost-effectiveness results: population 2
Strategy Cost (£) QALYs
ICER (£/QALY gained)
vs. OPT (IQR)
ICER (£/QALY gained)
vs. CRT-P+OPT (IQR)
OPT 7604 3.48 – –
CRT-P+OPT 25,874 4.14 27,434 (16,314 to 47,527) –
CRT-D+OPT 38,156 4.56 28,158 (17,431 to 49,839) 27,899 (–175 to 159,172)
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gained, the probability of OPT alone (with subsequent upgrades), CRT-P+OPT and CRT-D+OPT being
cost-effective is 83%, 9% and 8% respectively. Above a WTP threshold of £28,000 per QALY gained,
the intervention with the highest probability of being cost effective is CRT-D+OPT (38%). At a WTP
threshold of £30,000 per QALY gained, CRT-D+OPT and CRT-P+OPT have a 46% and 31% probability
of being cost-effective, respectively, whereas OPT alone has a 23% probability of being cost-effective.
Population 3: people with both conditions
Patients with both conditions were modelled receiving initially OPT alone, ICD+OPT, CRT-P+OPT or
CRT-D+OPT, to estimate the relative cost-effectiveness of these four treatment strategies. The relevant
comparisons for this population are therefore CRT-D+OPT compared with OPT alone (allowing for
subsequent device implantations) or CRT-P or ICD alongside OPT.
Base-case analysis
The RAFT trial140 provided the estimates for all-cause mortality and the distribution of patients by NYHA
class used for our base-case analysis for population 3. Table 138 presents the estimated discounted costs,
life-years and QALYs gained for each strategy, as well as the ICERs for the relevant comparisons.
The initial management of population 3 patients with ICD+OPT is estimated to be the least costly and
least effective strategy. Initial management with OPT alone (followed by subsequent device implants as
necessary) had a similar estimated cost (£287 more) to that of ICD+OPT and resulted in 0.10 more
QALYs. Thus, each additional QALY gained with OPT alone is estimated to cost £2824 more. A significant
proportion of population 3 patients initially managed with OPT alone are estimated to be referred for
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FIGURE 39 Cost-effectiveness acceptability curve: population 2.
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CRT-D over their lifetime. These patients will therefore benefit from lower risks of death and hospitalisation
for HF than patients receiving ICD+OPT. They are estimated to spend more time stable with therapy and
to have a slightly higher QALY gain (0.10) than those managed with ICD+OPT.
Similar costs and QALYs are estimated for the CRT-P+OPT and CRT-D+OPT strategies. As a marginally
higher cost and slightly fewer QALYs are estimated for CRT-P+OPT than for CRT-D+OPT, CRT-P+OPT is
dominated by CRT-D+OPT.
Compared with OPT alone, every additional QALY gained with CRT-D+OPT costs £35,193 more.
CRT-D+OPT compared with ICD+OPT has an ICER of £27,195 per QALY gained.
The costs and QALYs gained per strategy are presented graphically in Figure 40, in which the proximity
between the CRT strategies and the proximity between the OPT alone and ICD+OPT strategies
is noticeable.
Model outputs and validation The overall survival estimated in the model was compared with that
reported in the relevant trials (see Appendix 16 for details).
Events The percentage of time spent in the main health state categories by an average patient for each
strategy is presented in Table 139. All strategies being compared show similar occupancies for the stable
with therapy health state (most of the patient’s lifetime) or the device-related interventions health state
(implant surgery, postoperative complications, routine replacements, lead displacements and infections).
The model also estimates small differences between strategies in the time spent in hospital.
The numbers of the most relevant events estimated for each arm of the population 3 model are presented
in Table 140. The cohort of patients initially managed with OPT alone is estimated to receive 1850
implants (1552 CRT-D, 297 ICD and one CRT-P), of which 820 are estimated to be associated with routine
replacements according to the estimated battery lifetime. In the cohort initially implanted with an ICD,
47 are expected to upgrade to CRT-D and nine are expected to receive an ICD subsequently because of
CRT-D implant failure. Both strategies in which the defibrillator function is implanted initially (ICD+OPT
and CRT-D+OPT) involve fewer device upgrades, with the reported ICD upgrades resulting from CRT-D
implant failure.
TABLE 138 Base-case summary of the cost-effectiveness results: population 3
Strategy Cost (£) Life-years QALYs
Incremental
cost (£)
Incremental
life-years
Incremental
QALYs
ICER
(£/QALY
gained)
Vs. next best optiona
ICD+OPT 39,719 7.45 5.57 – – – –
OPT 40,006 7.59 5.67 287 0.14 0.10 2824
CRT-P+OPT 51,202 7.96 5.94 11,196 0.37 0.27 Dominated
CRT-D+OPT 50,911 8.01 5.98 10,906 0.42 0.31 35,193
Vs. ICD +OPT
CRT-P+OPT 51,202 7.96 5.94 11,483 0.51 0.37 Dominated
CRT-D+OPT 50,911 8.01 5.98 11,193 0.56 0.41 27,195
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated.
Discounted costs and benefits.
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Deterministic sensitivity analysis
Mixed-age cohort Cost-effectiveness results were estimated for a scenario of a mixed-age and
mixed-gender cohort of population 3 patients. The distribution of ICD and CRT implants by age in the UK
reported by the British Cardiovascular Society, the British Heart Foundation and the Cardio & Vascular
Coalition225 was used as a proxy for the distribution of population 3 patients. Age-dependent variables in
the population 3 model were those that determined all-cause mortality (baseline risk and RR of death by
age group).
TABLE 139 Overall distribution of an average patient’s lifetime by health state category for population 3
Health state categories
% of remaining life
OPT ICD CRT-P CRT-D
Stable with therapy 94.32 93.28 93.53 93.33
OPT 22.68 0.42 1.99 0.07
ICD 10.52 89.70 10.44 13.00
CRT-P 0.03 0 20.59 0
CRT-D 61.10 3.15 60.50 80.26
Hospitalisation 3.07 4.08 2.95 3.62
Implant surgery 0.78 0.87 1.54 0.91
ICD 0.13 0.84 0.13 0.15
CRT-P 0.00 0 0.76 0
CRT-D 0.65 0.04 0.65 0.76
Routine replacement 0.66 0.54 0.67 0.70
Lead displacement 0.25 0.13 0.33 0.33
Postoperative complications 0.17 0.09 0.26 0.20
Infection 0.05 0.05 0.06 0.06
Device-related interventionsa 1.90 1.67 2.85 2.19
a Sum of occupancy in implant surgery, postoperative complications, routine upgrades, lead displacements and infections.
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FIGURE 40 Cost-effectiveness plane for population 3.
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TABLE 140 Number of eventsa for cohorts of 1000 patients: population 3
Event
Strategy
OPT ICD CRT-P CRT-D
Initial implant 0 1000 1000 1000
ICD 0 1000 0 0
CRT-P 0 0 1000 0
CRT-D 0 0 0 1000
Hospitalisation 5446 4957 4797 4790
OPT 1171 21 110 4
ICD 578 4776 603 757
CRT-P 808 15 1072 3
CRT-D 2889 144 3012 4025
Upgrade 974 56 1025 203
ICD 160 9 169 195
CRT-P 1 0 0 0
CRT-D 812 47 856 8
Surgical complications 212 107 343 259
ICD 17 96 17 20
CRT-P 0 0 119 0
CRT-D 196 11 206 239
Lead displacement 313 151 432 435
ICD 17 137 17 22
CRT-P 0 0 106 0
CRT-D 296 15 309 413
Infection 57 59 76 78
ICD 7 57 7 9
CRT-P 0 0 17 0
CRT-D 50 2 52 69
Replacement 820 647 874 919
ICD 130 609 137 148
CRT-P 0 0 4 0
CRT-D 690 38 733 771
Number of devicesb 1850 1762 2974 2201
ICD 297 1674 313 353
CRT-P 1 0 1021 0
CRT-D 1552 88 1640 1848
a Undiscounted number of events.
b Sum of number of initial implants, upgrades, infections (required new device) and replacements.
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Table 141 summarises the model results for different starting ages. For most age groups, ICD+OPT is the
strategy with the least estimated benefit. Compared with the next best option or with ICD+OPT in most
age groups, OPT alone is the strategy with the lowest ICER, CRT-P+OPT is dominated and CRT-D+OPT is
that with the highest ICER.
TABLE 141 Results by age and for a mixed-age cohort: population 3
Starting
age (years) Strategy Cost (£) Life-years QALYs
ICER (£/QALY gained)
vs. next best optiona
ICER (£/QALY gained)
vs. ICD+OPT
30 OPT 55,173 10.67 7.98 18,499 18,499
ICD+OPT 51,560 10.40 7.78 – –
CRT-P+OPT 66,193 11.01 8.23 Dominated Dominated
CRT-D+OPT 65,417 11.08 8.28 34,236 28,020
40 OPT 54,428 10.51 7.86 19,094 19,904
ICD+OPT 51,012 10.26 7.68 – –
CRT-P+OPT 65,414 10.84 8.10 Dominated Dominated
CRT-D+OPT 64,637 10.90 8.15 34,872 28,887
50 OPT 52,222 10.02 7.49 19,708 19,708
ICD+OPT 49,165 9.81 7.34 – –
CRT-P+OPT 63,107 10.34 7.72 Dominated Dominated
CRT-D+OPT 62,323 10.40 7.77 36,881 30,672
60 OPT 46,012 8.77 6.55 13,715 13,715
ICD+OPT 43,844 8.55 6.39 – –
CRT-P+OPT 56,718 9.05 6.75 Dominated Dominated
CRT-D+OPT 55,951 9.09 6.79 41,328 30,376
70 OPT 38,026 7.21 5.38 835 835
ICD+OPT 37,938 7.06 5.27 – –
CRT-P+OPT 49,140 7.56 5.64 Dominated Dominated
CRT-D+OPT 48,856 7.61 5.68 36,625 27,196
80 OPT 33,517 6.35 4.74 Dominant Dominant
ICD+OPT 35,152 6.30 4.70 – –
CRT-P+OPT 44,963 6.77 5.05 Extendedly dominated Extendedly dominated
CRT-D+OPT 45,139 6.82 5.08 33,761 26,092
90 OPT 29,415 5.37 4.00 – Extendedly dominated
ICD+OPT 32,257 5.42 4.05 Extendedly dominated –
CRT-P+OPT 40,388 5.68 4.23 Extendedly dominated Extendedly dominated
CRT-D+OPT 40,599 5.72 4.26 43,438 38,916
Mixed OPT 41,612 7.92 5.92 6489 6489
ICD+OPT 40,888 7.77 5.81 – –
CRT-P+OPT 52,673 8.27 6.17 Dominated Dominated
CRT-D+OPT 52,297 8.32 6.21 36,697 28,330
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated.
Discounted costs and benefits.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
239
The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronisation
Therapy trial All-cause mortality reported for men in the CRT-D arm of the MADIT-CRT trial130 and the
respective HR for ICD therapy for the whole population of the MADIT-CRT trial (1.00, 95% CI 0.69 to
1.44) were used as an alternative scenario to the outcomes from the RAFT trial140 used in the base-case
analysis. Table 142 summarises the cost-effectiveness results for this scenario.
Generally, most strategies became more costly and yielded a greater health benefit in this scenario than
in the base case. OPT alone (and subsequent device implants) is the least costly and least effective
strategy in this scenario. ICD+OPT is slightly more costly but yields a greater benefit than OPT alone.
As CRT-P+OPT and CRT-D+OPT are less effective than ICD+OPT and much more costly, both CRT
strategies are dominated by ICD+OPT compared with OPT alone. Therefore, the results obtained with the
MADIT-CRT trial data indicate that ICD+OPT is the most cost-effective strategy, with an ICER of £154 per
QALY gained compared with OPT alone.
As the MADIT-CRT trial found no statistically significant difference in all-cause mortality between the ICD
arm and the CRT-D arm, for this scenario the model assumed the same risk of death for the ICD and
CRT-D cohorts. A similar benefit was therefore estimated for the ICD+OPT and CRT-D+OPT strategies
(the 0.04 difference in QALYs gained is because less time is spent in the device-related interventions health
state in the ICD+OPT cohort than in the CRT-D+OPT cohort). A much lower cost was estimated for
ICD+OPT than for CRT-D+OPT as the first is estimated to involve fewer device upgrades
and replacements.
Univariate sensitivity analysis Comprehensive univariate sensitivity analyses were performed on the
parameters informing the population 3 model. Tables 143–146 present the sensitivity analysis results for
the most influential parameters (i.e. those that when varied between the 95% CI limits caused a variation
of > £20,000 per QALY in the ICER) for each of the relevant comparisons: CRT-D+OPT compared with
OPT alone (allowing for subsequent device implantations), CRT-D+OPT compared with CRT-P+OPT and
CRT-D+OPT compared with ICD+OPT.
The cost-effectiveness results for the comparison between initial treatment with CRT-D+OPT and initial
treatment with OPT alone (see Table 143) were quite robust to the variation of the parameters in the
model, with only two parameters varying the ICER by > £20,000. The comparison between CRT-D+OPT
and OPT alone showed great sensitivity to the RR of all-cause mortality for the OPT alone arm. The ICER
for CRT-D+OPT decreased to £22,240 per QALY gained when a greater risk of death is assumed for OPT
than for CRT-D+OPT (because of the incremental QALY gain with the latter). When a shorter time horizon
was considered (assuming the same as the lifetime of the CRT-D device), less benefit from CRT-D+OPT
relative to OPT alone was accrued and therefore the ICER increased.
Table 144 shows the univariate sensitivity analysis results for CRT-D+OPT compared with ICD+OPT. The
most influential parameters for this comparison were the RR of all-cause mortality for patients managed
with an ICD and the lifetime of the CRT-D and ICD devices.
Assuming a lower RR of death for patients managed with an ICD would substantially increase the ICER for
CRT-D+OPT compared with ICD+OPT, as there is a very small QALY gain (0.07). Also, assuming a
4-year device lifetime for the CRT-D device would almost double the ICER for CRT-D+OTP compared
with ICD+OPT.
Varying the lifetime of the ICD device also had a substantial impact on the incremental cost of CRT-D
compared with ICD. When the ICD was assumed to have a longer lifetime (13 years), a higher incremental
cost for CRT-D was estimated and this strategy became non-cost-effective (ICER £35,034 per QALY
gained). The opposite happened when the ICD was assumed to have a lifetime of 5 years (alongside the
7-year lifetime of the CRT-D device).
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Table 145 shows the univariate sensitivity analysis for CRT-D+OPT compared with CRT-P+OPT, with
10 parameters that made the ICER range by > £20,000. As the estimated costs and benefits of these
strategies are so similar, the comparison between CRT-D+OPT and CRT-P+OPT is sensitive to the
variation of more parameters. Overall, this comparison showed greater sensitivity to parameters related to
the preventative effect of the devices on arrhythmia (baseline risk of hospitalisation for arrhythmia with
CRT-D and RR of hospitalisation for arrhythmia of CRT-P) and the lifetime of the CRT-D device.
TABLE 144 Univariate sensitivity analysis for CRT-D+OPT vs. ICD+OPT
Parameter Base-case value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY gained)
Base case – – 11,193 0.41 27,195
RR of all-cause
mortality (ICD)
1.19 1.04 9407 0.07 127,299
1.37 12,981 0.75 17,262
Device lifetime
(CRT-D), ln(λ), γ
–15.465, 1.935
(7 years)
–16.000, 1.863
(13 years)
3841 0.44 8784
–14.931, 2.006
(4 years)
22,019 0.37 59,421
Device lifetime (ICD),
ln(λ), γ
–15.78 1.94
(∼8 years)
–16.182, 1.889
(∼13 years)
14,285 0.41 35,034
–15.385, 1.996
(∼5 years)
5951 0.42 14,218
DSA, deterministic sensitivity analysis.
TABLE 142 The MADIT-CRT trial130 scenario analysis results: population 3
Strategy Cost (£) Life-years QALYs ICER (£/QALY gained) vs. next best optiona
OPT 49,908 9.59 7.17 –
CRT-P+OPT 60,736 9.89 7.39 Dominated
CRT-D+OPT 60,051 9.97 7.45 Dominated
ICD+OPT 49,957 10.01 7.49 154
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated
TABLE 143 Univariate sensitivity analysis for CRT-D+OPT vs. OPT
Parameter Base-case value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY gained)
Base case – – 10,906 0.31 35,193
RR of all-cause
mortality (OPT)
1.563 1.163 9109 0.07 124,733
2.083 12,972 0.58 22,240
Time horizon Lifetime CRT-D lifetime
(7 years)
9347 0.15 63,837
DSA, deterministic sensitivity analysis.
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
241
For the base-case analysis, the baseline risk of hospitalisation for arrhythmia for patients managed with
CRT-D (0.0285) was derived from the relevant trials included in the systematic review. As no evidence on
hospitalisation for arrhythmia was found for the comparison between CRT-P and CRT-D, the risk for
patients managed with CRT-P was assumed to be the same as that for CRT-D, given that clinical advice
suggested that population 3 patients are likely to be hospitalised for arrhythmia irrespective of whether or
not they have a device with a defibrillator function implanted. When a lower baseline risk of hospitalisation
for arrhythmia is used, the ICER for CRT-D+OPT compared with CRT-P+OPT increases significantly as the
incremental cost of CRT-D is estimated to increase with no additional benefit. Under this scenario, all
strategies show a reduction in the estimated costs; however, the costs of strategies without a defibrillator
function (CRT-P and OPT alone) are reduced by more (about £10,000 less) than the cost of those with a
defibrillator function (CRT-D and ICD), which incur costs of about £5000 less than in the base case. When
the RR of hospitalisation for arrhythmia for patients managed with CRT-P is assumed to be less than the
baseline risk, the cost of the CRT-P+OPT strategy decreases and this strategy is no longer dominated by
CRT-D+OPT.
TABLE 145 Univariate sensitivity analysis for CRT-D+OPT vs. CRT-P+OPT
Parameter
Base-case
value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY gained)
Base case – – –291 0.04 Dominant
Baseline risk of hospitalisation
for non-fatal arrhythmia (CRT-D)
0.0285 0.0146 3993 0.04 93,501
0.0424 –1823 0.04 Dominant
Device lifetime (CRT-D), ln(λ), γ –15.465,
1.935
(∼7 years)
–16, 1.863
(∼13 years)
–866 0.04 Dominant
–14.931,
2.006
(∼4 years)
1840 0.03 58,794
RR of hospitalisation for non-fatal
arrhythmia (CRT-P)
1 0.80 1374 0.04 38,915
1.20 –1457 0.04 Dominant
Risk of lead displacement (CRT-D) 0.004 0.0004 –926 0.05 Dominant
0.0071 313 0.03 9393
RR of all-cause mortality (OPT) 1.563 1.163 –460 0.02 Dominant
2.083 –97 0.07 Dominant
Discount rates of costs and
benefits (%)
3.5, 3.5 0, 0 –1054 0.05 Dominant
6, 1.5 207 0.05 4370
Risk of surgical mortality with CRT-P 0.0048 0.0015 –450 0.02 Dominant
0.0081 –131 0.06 Dominant
Risk of lead infections (CRT-D) 0.0006 0 –659 0.04 Dominant
0.0015 243 0.04 6432
Risk of lead displacement (CRT-P) 0.0037 0.0004 188 0.03 5513
0.0071 –764 0.04 Dominant
Time horizon Lifetime CRT-D lifetime
(7 years )
–613 0.02 Dominant
DSA, deterministic sensitivity analysis.
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As for the previous comparison of two strategies both involving initial treatment with a device, varying the
lifetime of the CRT-D device had a great impact on the ICER for the comparison between CRT-D+OPT
and CRT-P+OPT. The incremental cost associated with a 4-year time period for replacement led to an
ICER of £58,794 per QALY gained.
The comparison between OPT and ICD+OPT was also sensitive to many parameters (see Table 146),
given that the estimated costs and QALYs for these strategies were very similar. It showed particular
sensitivity to the time horizon, the lifetime of the CRT-D and ICD devices, the baseline risk of hospitalisation
for non-fatal arrhythmia (CRT-D) and the RR of hospitalisation for non-fatal arrhythmia (OPT and ICD).
Assuming a shorter time horizon resulted in a substantial increase in the ICER for the comparison between
OPT alone and ICD+OPT, as the first strategy showed a cost saving associated with a very small reduction
in the health benefits accrued. When the 8-year ICD lifetime was assumed as the time horizon for the
model, there was an increase in the incremental cost for OPT alone and less benefit compared with
TABLE 146 Univariate sensitivity analysis for OPT alone vs. ICD+OPT
Parameter
Base-case
value DSA value
Incremental
cost (£)
Incremental
QALYs
ICER
(£/QALY gained)
Base case – – 287 0.10 2824
Time horizon Lifetime CRT-D lifetime
(7 years)
–4395 –0.05 94,341
Device lifetime (CRT-D), ln(λ), γ –15.465,
1.935
(∼7 years)
–16, 1.863
(∼13 years)
–6129 0.12 Dominant
–14.931,
2.006
(∼4 years)
8653 0.07 123,385
Device lifetime (ICD), ln(λ), γ –15.78,
1.94
(∼ 8 years)
–16.182,
1.889
(∼13 years)
3505 0.10 35,868
–15.385,
1.996
(∼5 years)
–5086 0.11 Dominant
Baseline risk of hospitalisation for
non-fatal arrhythmia (CRT-D)
0.0285 0.0146 –4565 –0.09 49,987
0.0424 2086 0.19 10,896
RR of hospitalisation for non-fatal
arrhythmia (OPT)
1 0.8 –1978 0.04 Dominant
1.2 1923 0.15 13,107
RR of hospitalisation for non-fatal
arrhythmia (ICD)
1.11 0.88 2330 0.10 22,346
1.41 –2334 0.10 Dominant
Baseline risk of all-cause mortality
(CRT-D), ln(λ), γ
–6.334,
1.234
–6.467,
1.198
2047 0.14 14,124
–6.202,
1.270
–1092 0.06 Dominant
Risk of lead displacement (CRT-D) 0.0037 0.0004 –1083 0.11 Dominant
0.0071 1600 0.09 17,916
Discount rates of costs and
benefits (%)
3.5, 3.5 0, 0 3183 0.22 14,529
6, 1.5 –1212 0.16 Dominant
DSA, deterministic sensitivity analysis.
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ICD+OPT. This increase in incremental cost with OPT alone is mainly a result of referrals for CRT-D
implants because of severe arrhythmic events.
A substantial increase in the incremental cost for OPT alone compared with ICD+OPT is also estimated
when CRT-D devices are assumed to require replacement every 4 years, associated with a small reduction
in incremental QALYs compared with the base case, resulting in an ICER of £123,385 per QALY gained.
When the lifetime of the ICD device is assumed to be longer than in the base case (13 years), the
incremental cost of OPT increases but the same incremental benefit is estimated relative to the base case.
The baseline risk of hospitalisation for arrhythmia and the relative effects of the alternative treatments
also had noticeable impacts on the comparison between OPT alone and ICD+OPT. With a lower baseline
risk of hospitalisation, the estimated costs and QALYs for all strategies decreased (strategies without a
defibrillator function have a greater reduction in costs than those with a defibrillator function) compared
with the base case. Mainly because of fewer referrals for CRT-D implants, OPT alone (followed by the
subsequent implants) was the strategy that was the most cost saving relative to the base case and also
the one with the greatest loss of QALYs accrued, hence the high ICER estimated for it compared with
ICD+OPT when a lower baseline risk of hospitalisation for severe arrhythmia was used. The ICER for OPT
alone compared with ICD+OPT also increases when the RR of hospitalisation for arrhythmia is assumed
to be higher for OPT or lower for ICD+OPT, as the additional cost associated with OPT increases
substantially (and the additional benefit rises slightly or does not change respectively).
Table 147 presents the parameters that result in a change in the most cost-effective strategy as their
value is varied between their 95% CI limits. These relate mainly to the longevity of the devices with a
defibrillator function (these have a shorter estimated lifetime relative to that of CRT-P), the RR of all-cause
mortality for ICD and OPT, the baseline risk of hospitalisation for arrhythmia for CRT-D and the RR of
hospitalisation for arrhythmia for ICD, and the discount rates for costs and benefits.
Overall, ICD+OPT becomes the most cost-effective strategy at a WTP threshold of £20,000 per QALY
gained when an 8-year time horizon (the lifetime of an ICD device), a shorter CRT-D device lifetime
(approximately 4 years), a longer ICD device lifetime (approximately 13 years), a lower RR of all-cause
mortality for patients managed with ICD (RR= 1.04), a higher RR of all-cause mortality for patients
managed with OPT (RR= 2.08) or a lower RR of hospitalisation for arrhythmia for patients managed with
ICD (RR= 0.88) is used.
Under a scenario of not discounting future costs and benefits or of discounting future costs at a higher
rate (6%) than future benefits (1.5%), CRT-D+OPT would become the most cost-effective strategy
at a WTP threshold of £30,000 per QALY gained (ICERs of £25,602 and £29,650 per QALY gained,
respectively, compared with OPT alone). If a higher RR of all-cause mortality for patients being managed
with OPT compared with those being managed with CRT-D is used (RR= 2.08), CRT-D becomes the optimal
strategy at a WTP threshold of £30,000 per QALY gained, with an ICER of £22,240 per QALY gained.
The strategy of CRT-P+OPT became the most cost-effective strategy at a WTP threshold of £30,000 per
QALY gained when the lower limit of the baseline risk of hospitalisation for arrhythmia for patients
managed with CRT-D was used (ICER of £26,200 per QALY gained compared with OPT alone).
Scenario analysis
Device longevity Clinical advice indicated that device longevity estimates in the base-case analysis
could be overestimated. A scenario analysis using the mean device lifetime estimates used by Fox and
colleagues64 (see Table 133) was conducted and the results are presented in Table 148. In this scenario,
initial management with OPT alone (and subsequent upgrades) was less costly and more effective than
with ICD+OPT (i.e. OPT alone dominated ICD+OPT). CRT-P+OPT is more costly and more effective than
OPT alone; however, the ICER for CRT-P+OPT compared with OPT alone is higher (£43,274 per QALY
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gained) than that for CRT-D+OPT compared with OPT alone (£39,318 per QALY gained). CRT-P+OPT is
therefore extendedly dominated by CRT-D+OPT compared with OPT alone. Compared with ICD+OPT,
CRT-D+OPT has an ICER of £23,690 per QALY gained and CRT-P+OPT is also extendedly dominated in
this case.
Effect of cardiac resynchronisation therapy devices on heart failure progression The population 3
base-case analysis is based on the conservative assumption that CRT devices have no impact on the
distribution of patients by NYHA class over time. This scenario analysis assumes similar HF progression as
used in the population 2 model. The population 2 model assumes a given initial distribution of patients by
NYHA class (initially more severe than that in the population 3 model). At 9 months and 18 months,
TABLE 147 Most cost-effective strategies according to the variation of the most influential parameters
Parameter
Base-case
value DSA value
Most cost-effective
strategy at
£20,000/QALY
Most cost-effective
strategy at
£30,000/QALY
Base case – – OPT OPT
Time horizon Lifetime 8 years
(ICD lifetime)
ICD+OPT ICD+OPT
Device lifetime (CRT-D),
ln(λ), γ
–15.465,
1.935
(∼7 years)
UL: –14.934,
2.006
(∼4 years)
ICD+OPT ICD+OPT
Device lifetime (ICD),
ln(λ), γ
–15.784,
1.943
(∼8 years)
LL: –16.182,
1.889
(∼13 years)
ICD+OPT ICD+OPT
RR of all-cause
mortality (ICD)
1.19 LL: 1.04 ICD+OPT ICD+OPT
RR of all-cause
mortality (OPT)
1.563 UL: 2.08 ICD+OPT CRT-D+OPT
Discount rates of costs and
benefits (%)
3.5, 3.5 0, 0 OPT CRT-D+OPT
6, 1.5 OPT CRT-D+OPT
Baseline risk of
hospitalisation for
arrhythmia (CRT-D)
0.029 LL: 0.015 OPT CRT-P+OPT
RR of hospitalisation for
arrhythmia with ICD
1.11 LL: 0.88 ICD+OPT OPT
DSA, deterministic sensitivity analysis; LL, lower limit; UL, upper limit.
TABLE 148 Shorter device lifetime scenario analysis results: population 3
Strategy Cost (£) Life-years QALYs
ICER (£/QALY gained)
vs. next best optiona
ICER (£/QALY gained)
vs. ICD+OPT
ICD+OPT 47,068 7.44 5.56 – –
OPT 44,567 7.57 5.65 Dominant –
CRT-P+OPT 56,135 7.94 5.92 Extendedly dominated Extendedly dominated
CRT-D+OPT 56,601 7.99 5.96 39,318 23,690
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated.
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different distributions by NYHA class (derived from the CARE-HF trial109 and the BRESCIA study223) are
assumed, capturing the effect of CRT on patients’ HRQoL.
Table 149 shows the cost-effectiveness results for this scenario. The results show an ICER of £27,396 per
QALY gained for CRT-D+OPT compared with OPT alone, similar to that seen in the population 2 model
(£27,899 per QALY gained).
Utilities A scenario using the utility estimates used by Fox and colleagues64 (presented in Table 135) was
explored. Table 150 shows the cost-effectiveness results for this scenario. Using the same utility values as
Fox and colleagues did not effect the model results significantly (a reduction of 0.02 QALYs for OPT alone
and 0.03 QALYs for all of the strategies beginning with implantation of a device). The ICERs obtained with
this scenario are similar to those in the base-case analysis.
Costs All relevant comparisons showed great sensitivity to costs when these were varied as a group
between the lower and upper limits of their 95% CIs (see Table 114). When all costs were varied, the
range in the ICER was > £25,000 per QALY gained for all relevant comparisons except for OPT compared
with ICD+OPT, which showed a small variation. The ICER ranged from £22,271 to £50,824 per QALY
gained for CRT-D+OPT compared with ICD+OPT, from £13,829 to £43,853 per QALY gained for
CRT-D+OPT compared with CRT-P+OPT, and from £28,200 to £60,864 for CRT-D+OPT compared with
OPT alone.
Under a scenario using the upper limit of all costs, ICD+OPT and OPT alone are the most cost-effective
strategies at a WTP threshold of £20,000 and £30,000 per QALY gained respectively. When the lower limit
of all costs (including device-related costs, health state costs and pharmacological therapy costs) is used,
the most cost-effective strategy at a threshold of £30,000 per QALY gained is CRT-D+OPT.
TABLE 149 The effect of CRT devices on HF scenario analysis results: population 3
Strategy Cost (£) Life-years QALYs
Incremental
ICER (£/QALY gained)Cost (£) Life-years QALYs
Vs. next best optiona
ICD+OPT 39,719 7.45 5.37 – – – –
OPT 40,006 7.59 5.68 287 0.14 0.31 936
CRT-P+OPT 51,202 7.96 6.04 11,196 0.37 0.36 Dominated
CRT-D+OPT 50,911 8.01 6.08 10,906 0.42 0.40 27,396
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated.
Discounted costs and benefits.
TABLE 150 Utilities scenario analysis results: population 3
Strategy Cost (£) Life-years QALYs
ICER (£/QALY gained) vs.
next best optiona
ICER (£/QALY gained)
vs. ICD+OPT
ICD+OPT 39,719 7.45 5.55 – –
OPT 40,006 7.59 5.64 3,033 –
CRT-P+OPT 51,202 7.96 5.91 Dominated Dominated
CRT-D+OPT 50,911 8.01 5.95 35,515 27,859
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated.
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Probabilistic sensitivity analysis
Table 151 reports the base-case probabilistic sensitivity analysis for population 3. Appendix 15 reports the
variables (mean values and CIs) included in the probabilistic sensitivity analysis and the form of distribution
used for sampling and the parameters of the distribution. Overall, the probabilistic results are consistent
with the deterministic results. The results show that an additional QALY gained with OPT alone is
estimated to cost £13,053 more than with ICD+OPT. The estimated ICER for CRT-D+OPT compared with
OPT alone is £34,988 per QALY gained. Compared with ICD+OPT, the ICER for CRT-D+OPT is £23,133
per QALY gained.
The probabilistic sensitivity analysis results of 10,000 iterations are presented in Figure 41 in terms of
average costs and QALYs, showing the overlap of the results for the different strategies on the scatterplot.
Figure 42 shows the variation in the probability of being cost-effective for the different treatment
strategies as the WTP threshold increases from £0 to £50,000 per QALY gained. At a WTP threshold of
£20,000 per QALY gained, the probability of OPT alone, ICD+OPT, CRT-D+OPT and CRT-P+OPT being
cost-effective is 57%, 37%, 3% and 3% respectively. Above a WTP of £42,000 per QALY gained, the
intervention with the highest probability of being cost effective is CRT-D+OPT (31%). At a WTP threshold
of £30,000 per QALY gained, OPT alone, ICD+OPT, CRT-D+OPT and CRT-P+OPT have a probability of
being cost-effective of 44%, 31%, 15% and 10% respectively.
TABLE 151 Base-case summary of the probabilistic cost-effectiveness results: population 3
Strategy Cost (£) QALYs
ICER (£/QALY gained)
vs. next best optiona (IQR)
ICER (£/QALY gained)
vs. ICD+OPT (IQR)
ICD+OPT 44,310 5.58 – –
OPT 38,732 5.63 13,053 (–515,869 to 471,462) –
CRT-P+OPT 51,286 5.94 Extendedly dominated Extendedly dominated
CRT-D+OPT 51,690 5.98 34,988 (–191,681 to 264,108) 23,133 (–196,334 to 222,149)
a Treatments compared with the preceding best option, that is, the preceding treatment that is neither dominated nor
extendedly dominated.
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FIGURE 41 Cost-effectiveness scatterplot: population 3.
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Summary of the independent economic evaluation
Population 1
l The addition of ICD to OPT for the secondary prevention of SCD has an ICER of £19,479 per QALY
gained compared with OPT alone. Its probability of being cost-effective at a WTP of £20,000 and
£30,000 per QALY gained is 51% and 82% respectively.
l The ICER for the mixed-age cohort is slightly higher (£24,967 per QALY gained) as it increased with
age and 52% of these patients are expected to be aged > 65 years.
l Subgroup analysis using MADIT II trial data shows that ICD+OPT is cost-effective (ICER of £14,231 per
QALY gained) for the primary prevention of SCD in patients with remote MI.
l For the SCD-HeFT trial data (patients with mild to moderate HF), the estimated ICER for ICD +OPT is
£29,756 per QALY gained compared with OPT alone.
l For patients with non-ischaemic cardiomyopathy the ICER was £26,028 per QALY gained.
l The parameters that have the greatest impact on the ICER were the time horizon, the HR for all-cause
mortality associated with the ICD+OPT arm, the risk of surgical death during ICD implantation and the
lifetime of the device.
Population 2
l The addition of CRT-P to OPT (in the initial stage of management of HF) resulted in an ICER of £27,584
per QALY gained compared with initial management with OPT alone (allowing for subsequent
implants). Similarly, initial implantation of a CRT-D device alongside OPT resulted in an ICER of £27,899
per QALY gained compared with OPT alone. When comparing CRT-D+OPT with CRT-P+OPT, a
slightly higher ICER was estimated (£28,420 per QALY gained).
l At a WTP of £20,000 per QALY gained, initial management with OPT alone followed by implantation
of the clinically necessary devices is the strategy with the highest probability of being cost-effective
(81%). Above a WTP of £28,000 per QALY, the strategy with the highest probability of being cost
effective is CRT-D+OPT (38%).
l The incremental cost-effectiveness results for the comparisons relevant for population 2 seem to be
sensitive mainly to device-related costs and to parameters that determine the incremental benefit of the
devices for patient survival, such as the RRs of SCD and HF death for patients managed with CRT-P.
The lifetime of the CRT-D device was also particularly influential because of the incremental costs
incurred when it became shorter.
l In a scenario assuming the upper limit estimates of device-related costs or the lower limit estimates for
the longevity of all devices, both CRT-P+OPT and CRT-D+OPT became non-cost-effective compared
with initial management with OPT alone (followed by the subsequent upgrades).
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FIGURE 42 Cost-effectiveness acceptability curve: population 3.
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Population 3
l In the base case the most cost-effective strategy for people with both conditions at a WTP of
£20,000–30,000 per QALY is initial management with OPT alone (followed by device implantation and
subsequent upgrades as necessary). Both strategies including initial implantation of a CRT device have
ICERs that are greater than the WTP range of £20,000–30,000 per QALY gained compared with OPT
alone (CRT-D £35,193 per QALY gained; CRT-P £41,414 per QALY gained). Costs and QALYs for
CRT-D and CRT-P are similar.
l CRT-D+OPT is cost-effective compared with ICD+OPT at a WTP of £30,000 per QALY (ICER of
£27,195 per QALY gained).
l At a WTP of £30,000 per QALY, OPT alone, ICD+OPT, CRT-D+OPT and CRT-P+OPT have a
probability of being cost-effective of 44%, 31%, 15% and 10% respectively. Above a WTP of £42,000
per QALY, the intervention with the highest probability of being cost effective is CRT-D+OPT (31%).
l In an alternative scenario analysis using MADIT-CRT trial data, CRT-P and CRT-D are dominated by
ICD+OPT, which is the most cost-effective strategy (ICER of £154 per QALY gained vs. OPT).
l Overall, the relative cost-effectiveness of the strategies compared for population 3 was most sensitive
to costs and the lifetime of the CRT-D device. The risk of all-cause mortality for OPT relative to CRT-D
was the most influential parameter for the comparison between CRT-D+OPT and OPT alone (followed
by the subsequent updates). Similarly, the preventative effect on all-cause mortality estimated for ICD
therapy was particularly important for the comparison between CRT-D+OPT and ICD+OPT.
The preventative effect of the devices on hospitalisation for arrhythmia, as well as the longevity of the
CRT-D device, were particularly prominent for the comparison between CRT-D+OPT and CRT-P+OPT.
The most influential parameters for the comparison between OPT alone (and subsequent device
implantations) and ICD+OPT were the lifetime of the CRT-D and ICD devices and the risk of
hospitalisation for arrhythmia associated with CRT-D, ICD and OPT.
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Chapter 6 Assessment of factors relevant
to the NHS and other parties
Factors relevant to service provision
The possible extension of indications for ICD and CRT devices is likely to lead to an increase in the demand
for their use. This will have the potential to impact on the organisation and provision of the service and the
cost of the service to the NHS. The implications are likely to be greater given the recognition that current
rates of implantation of the devices remain below national targets in the UK (see Table 3), there are
regional variations in utilisation55 and there is a growing ageing population that is likely to place additional
pressure on the service. Any development will need to take account of the reasons for the low
implantation rates as well as increasing provision for any extension of the indications. Factors thought to
underlie the low implantation rates include a shortage of implantation centres and electrophysiologists,
poorly developed referral strategies/care pathways and problems with specialist health-care investment.60
Further expansion to accommodate any additional development in the service would necessitate an
increase in appropriately trained cardiologists, associated clinical staff and technicians, and properly
equipped implantation centres. Access to service provision and location of services are issues
for consideration.
Factors relevant to patients and carers
The sudden death of a wage earner results in costs to his or her relatives that are difficult to quantify but
are important nonetheless. With an ICD, individuals and their families feel reassured. The improvements
associated with CRT are expected to lessen the impact of HF on the lives of individuals and their families.
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Chapter 7 Discussion
Statement of principal findings
Clinical effectiveness
People at risk of sudden cardiac death: implantable cardiac defibrillators
compared with optimum pharmacological therapy
Thirteen RCTs were included that compared ICDs with medical therapy, four RCTs in people at increased
risk of SCD because of previous ventricular arrhythmias (secondary prevention) and nine RCTs in people
who have not suffered a life-threatening arrhythmia but who are at risk (primary prevention). Risk of bias
was noted in the RCTs, specifically performance bias because of lack of blinding, detection bias with
regard to QoL outcomes and possible selection bias because of inadequate reporting. Length of follow-up
varied from 18 to 57 months in the four RCTs on secondary prevention and from 20 to 37 months in the
nine RCTs on primary prevention. Sample size ranged from 66 to 1016 in the four RCTs on secondary
prevention and from 103 to 2521 in the nine RCTs on primary prevention. Most participants suffered from
CHF, with 50–80% of those in the secondary prevention RCTs in NYHA classes I and II and 50–66% in the
primary prevention RCTs in NYHA class II or II/III. LVEF varied from 30% to 70% in the secondary
prevention RCTs and from 22% to 35% in the primary prevention RCTs. The studies were synthesised
according to the criteria that they used to identify people at risk of SCD.
Ventricular arrhythmia/cardiac arrest (secondary prevention)
Four RCTs compared ICDs with AAD. Meta-analysis found that ICDs significantly reduced the risk of
all-cause mortality (four RCTs; RR 0.75, 95% CI 0.61 to 0.93; p= 0.01), SCD (four RCTs; RR 0.49, 95% CI
0.34 to 0.69; p< 0.001) and total cardiac deaths (two RCTs; RR 0.74, 95% CI 0.61 to 0.91; p= 0.004). No
significant differences were found between ICDs and AAD for non-arrhythmic cardiac deaths (two RCTs;
RR 0.97, 95% CI 0.72 to 1.31; p= 0.83) or other non-cardiac causes of death (two RCTs; RR 0.79, 95% CI
0.45 to 1.37; p= 0.40). Two RCTs reported significant benefits for ICDs compared with AAD for overall
survival at 3 years (difference 11%; p< 0.02), survival free of cardiac death at 2 years (difference 4%;
p= 0.004), survival from arrhythmic death at 2 years (difference 5%, p= 0.0002) and survival free of
sudden death at 57 months (HR 0.423; p= 0.005). In terms of QoL, one RCT found significant
improvements in the SF-36 PCS and MCS and patient concerns checklist for both groups up to the 1-year
follow-up, with no significant between-group differences. Using the MHI and NHP, another RCT showed
benefits for ICDs but not OPT at 1 year of follow-up. Both RCTs showed a worsening QoL with increasing
numbers of shocks. Prespecified subgroup analyses for age, LVEF, cause of arrhythmia and qualifying
arrhythmia demonstrated no significant difference from each other or the overall population for all-
cause mortality.
One RCT (DEBUT) was included in the present review in addition to those included in the previous TAR.62
The population in this trial, SUDS survivors, differed from those of the other RCTs. Despite this difference,
the results from the present review concur with those of the previous review.62
People with a recent myocardial infarction (within 6–41 days or ≤ 31 days)
Two RCTs compared ICD+OPT with OPT. Meta-analysis of two trials found no difference between the
groups for all-cause mortality (RR 1.04, 95% CI 0.86 to 1.25; p= 0.69), total cardiac deaths (RR 0.97,
95% CI 0.79 to 1.20; p= 0.8) and non-cardiac deaths (RR 1.39, 95% CI 0.86 to 2.27; p= 0.18).
People with an ICD+OPT had a lower risk of SCD (RR 0.45, 95% CI 0.31 to 0.64; p< 0.0001) but a
higher risk of non-arrhythmic cardiac death (RR 1.77, 95% CI 1.30 to 2.40; p= 0.0002) than people
receiving OPT alone. One trial reporting cumulative mortality found no statistically significant difference
between groups. QoL was not reported. One trial reported no significant differences for 13 prespecified
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subgroups
(age, sex, CHF on admission, criterion of inclusion, ST-elevation MI, early reperfusion for
ST-elevation MI, number of vessels, smoking and NYHA class at discharge, diabetes, hypertension,
lipid abnormalities, number of risk factors) for all-cause mortality.
These trials were not included in the previous TAR.62
People with remote myocardial infarction (> 3 weeks or > 1month previously)
Meta-analysis of the two trials in this group found a reduction in all-cause mortality (RR 0.57, 95% CI 0.33
to 0.97; p= 0.04), total cardiac deaths (RR 0.59, 95% CI 0.42 to 0.83; p= 0.003) and SCDs (RR 0.36,
95% CI 0.23 to 0.55; p< 0.00001) with ICD+OPT compared with OPT. There was no difference between
the groups in non-arrhythmic cardiac deaths (RR 0.95, 95% CI 0.41 to 2.18; p= 0.1) or non-cardiac
deaths (RR 1.06, 95% CI 0.58 to 1.95; p= 0.84). One trial reporting hospitalisations found higher rates
per 1000 months’ follow-up among people receiving an ICD (11.3 vs. 9.4; p= 0.09), with higher HF
hospitalisations (19.9% vs. 14.9%; p-value not reported). One trial assessed QoL using the HUI3, finding
a worsening QoL for both the ICD+OPT group and the OPT group annually over 3 years, with no
statistically significant differences. One trial reported prespecified subgroup analyses for all-cause mortality.
The HRs in all 12 of the subgroups (age, sex, ejection fraction, NYHA class or QRS interval, hypertension,
diabetes, LBBB, atrial fibrillation, the interval since the most recent MI, type of ICD, and blood urea
nitrogen) were similar, with no statistically significant interactions.
Both of these trials were included in the previous TAR62 and no additional RCTs in this population were
identified in the present review.
People with non-ischaemic or idiopathic dilated cardiomyopathy
Three RCTs compared ICD+OPT with OPT or ICD+OPT with amiodarone+OPT. Meta-analysis found no
significant difference between the groups in all-cause mortality (RR 0.77, 95% CI 0.52 to 1.15; p= 0.20),
total cardiac deaths (RR 2.03, 95% CI 0.17 to 23.62; p= 0.57), non-arrhythmic cardiac deaths (RR 1.13,
95% CI 0.42 to 3.03; p= 0.81) or non-cardiac deaths (RR 0.65, 95% CI 0.13 to 3.29; p= 0.60). However,
a statistically significant reduction was found in SCDs (RR 0.26, 95% CI 0.09 to 0.77; p= 0.02) with ICD
therapy. No statistically significant differences were found for measures of survival or QoL using the QWBS,
STAI, SF-12 MCS or PCS and MLWHFQ. One trial reported six prespecified subgroup analyses for all-cause
mortality (age, sex, LVEF, QRS interval, NHYA class and history of atrial fibrillation). None of the differences
between subgroups was statistically significant
An additional meta-analysis was undertaken on the advice of clinical experts, combining data on all-cause
mortality from the non-ischaemic CHF subgroup of the SCD-HeFT trial with data from the three
cardiomyopathy trials. The SCD-HeFT non-ischaemic subgroup strongly influenced the analysis and a
statistically significant effect in favour of ICDs with no statistical heterogeneity was found for all-cause
mortality (RR 0.74, 95% CI 0.58 to 0.93; p= 0.01).
Only one of the three cardiomyopathy RCTs (CAT) was included in the previous TAR;62 the other two RCTs
(AMIOVIRT, DEFINITE) were excluded from the previous TAR62 on the basis of the populations included in
the trials. There were no SCDs in either group in the CAT trial. However, the inclusion of the comparatively
large DEFINITE trial in the present review strongly influences the results, demonstrating a significant
reduction in SCDs with ICDs in people with non-ischaemic cardiomyopathy and moderate to severe left
ventricular dysfunction.
People scheduled for coronary artery bypass graft surgery
No significant difference between groups was found in all-cause mortality (RR 1.08, 95% CI 0.85 to 1.38;
p= 0.53), total cardiac deaths (HR 0.97, 95% CI 0.71 to 1.33; p= 0.84), non-arrhythmic cardiac deaths
(RR 1.26, 95% CI 0.87 to 1.82; p= 0.21), non-cardiac deaths (RR 1.50, 95% CI 0.82 to 2.73; p= 0.19) or
actuarial mortality at 4 years’ follow-up (HR 1.07, 95% CI 0.81 to 1.42; p= 0.64) in one trial. Rates of
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SCD were lower in the ICD group but this did not reach statistical significance (HR 0.55, 95% CI 0.29
to 1.03; p= 0.06). HRQoL was higher among people receiving OPT for all measures and this was
statistically significant for some: perception of health transition, emotional role function, mental health,
satisfaction with appearance and satisfaction with scar. HRs for ICDs compared with the control for
all-cause mortality were found to be similar among 10 prespecified subgroups (age, sex, HF, NYHA class,
LVEF, diabetes mellitus, QRS complex duration, use of ACE inhibitors, use of class I or class III AADs and
use of beta-adrenergic-blocking drugs).
This trial was included in the previous TAR62 and no additional RCTs in this population were identified in
the present review.
People with mild to moderate heart failure
All-cause mortality was significantly lower in the ICD+OPT group than in the placebo+OPT group
(HR 0.77, 97.5% CI 0.62 to 0.96; p= 0.007) in one trial. A significant reduction in total cardiac deaths
(HR 0.76, 95% CI 0.60 to 0.95; p< 0.018) and SCDs (compared with the placebo and amiodarone groups
combined; RR 0.44, 95% CI 0.31 to 0.61; p< 0.00001) was also found for ICDs. There was no statistically
significant difference in non-arrhythmic cardiac deaths (RR 1.14, 95% CI 0.88 to 1.48; p= 0.32) or deaths
from non-cardiac causes (RR 0.92, 95% CI 0.66 to 1.27; p= 0.60) between the ICD+OPT group and the
placebo and amiodarone groups combined. QoL was assessed using the DASI, MHI and global health
status measures, with either a limited difference or no long-term difference between the interventions.
ICD shock resulted in a significant decrease in QoL. Prespecified subgroup analyses found no interaction
between ICD therapy (p= 0.68) and the cause of CHF (ischaemic or non-ischaemic) for all-cause mortality,
cardiac deaths, sudden deaths presumed to be ventricular tachyarrhythmic, HF deaths or non-cardiac
deaths. There was a statistically significant interaction between ICD therapy and NYHA class, with ICDs
reducing the risk of all-cause mortality, cardiac mortality and sudden death presumed to be ventricular
tachyarrhythmic in people in NYHA class II but not in those in NYHA class III. The interaction between ICD
therapy and NYHA class was not statistically significant for HF or non-cardiac deaths.
This trial was in progress at the time of the previous TAR.62
All four RCTs of people with previous ventricular arrhythmias reported adverse events, showing higher
rates for the ICD groups (up to 30%), with most related to the placement and operation of the device.
The nine primary prevention RCTs reported adverse event rates of between 5% and 61% for people
with an ICD, depending on the definition of adverse event and length of follow-up. Adverse event
rates for the comparator treatment were between 12% and 55% in the three RCTs reporting this.
Lead-, electrode- or defibrillator generator-related problems affected 1.8–14% of people in five trials.
People with heart failure as a result of left ventricular systolic dysfunction
and cardiac dyssynchrony: CRT-P or CRT-D compared with each other or with
optimum pharmacological therapy
Four RCTs were included that compared CRT-P with OPT in people with HF as a result of LVSD and cardiac
dyssynchrony. One of these RCTs included a third arm (CRT-D). No other RCTs comparing CRT-P with OPT
or with CRT-D were identified. There was some risk of bias in the trials, although the risk of bias was
unclear in some cases because of inadequate reporting. Length of follow-up in the four RCTs varied:
3 months, 6 months, a median of 11.9–15.7 months and a mean of 37.4 months including an extension
period, respectively. Sample size ranged from 58 to 1520 participants. The majority of participants had
NYHA class III symptoms; the remaining few had NYHA class IV symptoms. The eligibility cut-off for LVEF
was ≤ 35% in the trials, with an average baseline LVEF of 22–25% where this was reported. QRS interval
was required to be ≥ 120milliseconds (two trials), ≥ 130milliseconds or > 150milliseconds. The average
baseline QRS interval was between 160milliseconds and 175milliseconds. Where reported, the proportion
of participants with ischaemic heart disease varied from around 40% to around 60%.
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CRT-P compared with optimum pharmacological therapy
Meta-analysis found that CRT-P reduced the risk of all-cause mortality (RR 0.75, 95% CI 0.58 to 0.96,
p= 0.02), HF deaths (RR 0.67, 95% CI 0.51 to 0.88, p= 0.004) and HF hospitalisations (RR 0.61, 95% CI
0.44 to 0.83, p= 0.002). Combining three RCTs in a meta-analysis demonstrated no significant difference
in SCDs (RR 0.97, 95% CI 0.44 to 2.14, p= 0.94). One RCT reported no statistically significant
difference in total cardiac deaths (CRT-P 17.7% vs. OPT 18.8%, p= 0.334) or non-cardiac deaths
(CRT-P 2.3% vs. OPT 3.6%, p= 0.122).
More people receiving CRT-P had an improvement of one or more NYHA class (RR 1.68, 95% CI
1.52 to 1.86, p< 0.00001). One RCT reported change in LVEF and reported a statistically significant
improvement with CRT-P compared with OPT (4.6% vs. –0.2%, p< 0.001) at 6 months. There was a
greater improvement in exercise capacity with CRT-P, as measured by the distance walked in 6 minutes
(meta-analysis of three trials; change from baseline or final values: MD 38.14m, 95% CI 21.74 to 54.54m,
p< 0.00001). A statistically significant improvement in VO2max was also reported by two of these RCTs.
All four RCTs found statistically significant improvements in QoL (using the MLWHFQ) with CRT-P (change
from baseline or final values: MD –10.33, 95% CI –13.31 to –7.36). One trial also reported a statistically
significant improvement in EQ-5D score and increased QALYs with CRT-P.
One trial reported prespecified subgroup analysis. A significant interaction between CRT-P and aetiology
was found, with people with non-ischaemic heart disease having a greater change in LVEF. There was
little difference in the effect of CRT-P on the composite outcome (death from any cause or unplanned
hospitalisation for a major cardiovascular event) for 16 predefined subgroups (age, sex, NHYA class,
dilated cardiomyopathy, systolic blood pressure, N-terminal pro-B-type natriuretic peptide, ejection fraction,
end-systolic volume index, QRS interval, interventricular mechanical delay, mitral regurgitation area,
glomerular filtration rate, beta-blocker use, spironolactone use, loop diuretics use, digoxin use).
CRT-D compared with optimum pharmacological therapy
One (three-arm) trial compared CRT-D with OPT. All-cause mortality (HR 0.64, 95% CI 0.48 to 0.86;
p= 0.003), total cardiac deaths (RR 0.68, 95% CI 0.50 to 0.93; p= 0.02), SCDs (HR 0.44, 95% CI 0.23 to
0.86; p= 0.02) and HF hospitalisations (RR 0.77, 95% CI 0.63 to 0.93; p= 0.008) were reduced with
CRT-D compared with OPT. There was no significant difference in HF deaths (HR 0.73, 95% CI 0.47 to
1.11; p= 0.143) or non-cardiac deaths (CRT-D 2.3% vs. OPT 3.6%; p= 0.717) between the CRT-D group
and the OPT group. The proportion of people with an improvement of one or more NYHA class (57% vs.
38%; p< 0.001) and the improvements in exercise capacity [change in 6-minute walk distance: 46m
(SD 98m) vs. 1m (SD 93m); p< 0.001] and QoL score (using the MLWHFQ) [–26 (SD 28) vs. –12 (SD 23);
p< 0.001] were statistically significantly greater with CRT-D than with OPT.
CRT-P compared with CRT-D
One three-arm trial compared both CRT-P and CRT-D with OPT, but the trial was not powered for a
statistical comparison of CRT-P with CRT-D. Direct statistical comparisons between CRT-P and CRT-D have
been undertaken for the purposes of this review but should be viewed with caution.
Total cardiac deaths (RR 1.38, 95% CI 1.06 to 1.81; p= 0.02) and SCDs (RR 2.72, 95% CI 1.58 to 4.68;
p= 0.0003) were higher with CRT-P than with CRT-D. All-cause mortality (RR 1.20, 95% CI 0.96 to 1.52;
p= 0.12), HF deaths (RR 0.98, 95% CI 0.68 to 1.42; p= 0.93) and HF hospitalisations (28% vs. 29%) were
similar between the CRT-P group and the CRT-D group. Changes in NYHA class, exercise capacity and QoL
were also similar for CRT-P and CRT-D.
Adverse events Two trials randomised people with successful implantation only. The other two trials
reported a rate of device-related deaths of between 0.2% and 0.8% for those receiving CRT-P and 0.5%
for those receiving CRT-D. The rate of moderate or severe adverse events related to the implantation
procedure was reported by one trial as 10% for those receiving CRT-P and 8% for those receiving CRT-D,
with 13% and 9% of CRT-P and CRT-D implantations being unsuccessful respectively. Moderate or severe
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adverse events from any cause were more common among those receiving CRT-D than among those
receiving OPT (CRT-D 69%, CRT-P 66%, OPT 61%; CRT-D vs. OPT p= 0.03, CRT-P vs. OPT p= 0.15).
Reported complications included lead displacements, infections and coronary sinus dissections.
No trials in addition to those included in the previous TAR64 were identified. However, one trial
(CONTAK-CD) that was included in the previous report was not included in this section of the present
report as the population, intervention and comparator were more appropriately considered in the section
on people with both conditions. Despite this difference, the results from the present review concur with
those of the previous review.64
People with both conditions: CRT-D compared with optimum
pharmacological therapy, CRT-P or implantable cardiac defibrillator
Nine RCTs were included that compared CRT-D with ICD in people at risk of SCD as a result of ventricular
arrhythmias and with HF as a result of LVSD and cardiac dyssynchrony. No RCTs comparing CRT-D with
OPT or with CRT-P were identified for this population. The risk of bias was low in some of the included
trials but was unclear in others because of inadequate reporting. Length of follow-up was 6 months in
five trials, 1 year in two trials and an average of 2.4 years and 3.3 years in the remaining two trials. Sample
size ranged from 31 to 1820 participants. The trials differed in their eligibility criteria for HF: the majority of
participants were in NYHA class II in three trials, in NYHA class III in four trials, described as having mild to
moderate HF in one trial (NYHA class not reported) and in NYHA class IV in one trial. The eligibility cut-off
for LVEF was ≤ 35% in seven trials and ≤ 30% in two trials, with a mean LVEF at baseline of between
21% and 26%. One trial (RethinQ) differed from the others in the criteria used to define cardiac
dyssynchrony, recruiting people with a narrow QRS interval (< 130milliseconds) and evidence of
mechanical dyssynchrony on ECG. Of the other trials, the QRS interval was ≥ 120milliseconds (four trials),
≥ 130milliseconds (three trials) or ≥ 150milliseconds (one trial). The mean QRS interval at baseline was
107milliseconds in one trial (RethinQ) and between 156milliseconds and 169milliseconds in the remaining
trials where reported. The proportion of participants with ischaemic heart disease varied from just over
50% to 100%.
Meta-analysis found that CRT-D reduced the risk of all-cause mortality (RR 0.84, 95% CI 0.73 to 0.96;
p= 0.01), total cardiac deaths (RR 0.82, 95% CI 0.67 to 1.00; p= 0.05) and HF hospitalisations (RR 0.75,
95% CI 0.64 to 0.88; p= 0.0005) compared with ICD therapy. Fewer trials reported HF deaths or SCDs
separately, and no HF deaths or SCDs occurred in some of these trials. Combining three RCTs in a
meta-analysis found little difference in SCDs between the CRT-D group and the ICD group (RR 1.45,
95% CI 0.43 to 4.92; p= 0.55).
Meta-analysis of four trials found no statistically significant difference between groups in the proportion
of people experiencing at least one episode of VT or VF (RR 0.90, 95% CI 0.71 to 1.14; p= 0.38).
An improvement in average NYHA class (MD –0.19, 95% CI –0.34 to –0.05; p= 0.008) and in the
proportion of people who improved by one or more NYHA class (RR 1.81, 95% CI 0.91 to 3.60; p= 0.09)
and in average LVEF (MD 2.15%, 95% CI 0.45 to 3.86%; p= 0.01), left ventricular end-diastolic
volume (MD –19.7ml, 95% CI –32.1 to –7.3ml; p< 0.0.002) and left ventricular end-systolic volume
(MD –20.9ml, 95% CI –32.9 to –8.8ml; p< 0.0007) was found with CRT-D. There was no overall
difference in end-diastolic diameter (MD –0.29mm, 95% CI –1.67 to 1.08mm; p= 0.67) or end-systolic
diameter (MD –1.88mm, 95% CI –4.39 to 0.62mm; p= 0.14). Substantial statistical heterogeneity was
present for these outcomes and some trials reported median values, which may indicate skewed data.
One trial of people with moderate to severe HF found a significantly greater reduction in QRS interval with
CRT-D than with ICD (–20milliseconds vs. 0milliseconds; p< 0.001). The QRS interval was similar in the
CRT-D and ICD groups in two trials of people with mild or mild to moderate HF.
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There was a greater improvement in exercise capacity (change in peak VO2: MD 0.75ml/kg/minute,
95% CI 0.23 to 1.27ml/kg/minute; p= 0.005; change in 6-minute walk distance: MD 14.5m, 95% CI 2.9
to 26.1m; p= 0.01) and QoL (change in MLWHFQ score: MD –6.9, 95% CI –10.4 to –3.4; p= 0.0001)
with CRT-D than with ICD. One small trial of people with mild to moderate HF reporting other measures of
QoL (DASI, one-item Global Visual Analogue Scale and SF-36) found that the comparisons of baseline to
6-month changes were statistically significantly different for the general health component of the SF-36 only.
When the large RAFT trial contributed data to the meta-analyses, the results were strongly influenced by it.
The RAFT trial included people with mild to moderate HF despite receiving OPT, a LVEF of ≤ 30% from
ischaemic or non-ischaemic causes, a wide QRS interval and planned ICD implantation for indicated
primary or secondary prevention of SCD.
The extent of reporting of adverse events varied between the trials. Some trials reported adverse events for
all people undergoing implantation attempts, but only randomised people who had a successful implant.
Only three trials reported adverse events according to the device received. The large RAFT trial reported
adverse events for all implanted participants and found that the rate of device- or implantation-related
complications within 30 days of implantation was significantly higher in the CRT-D group than in the ICD
group (13.3% vs. 6.8%; p< 0.001), as was the rate of device-related hospitalisations (20% vs. 12.2%,
HR 1.68, 95% CI 1.32 to 2.13; p< 0.001).
Three trials reported prespecified subgroup analyses. Two trials reported that CRT-D was associated
with a greater benefit in people with a QRS duration of ≥ 150milliseconds than in those with a QRS
duration of < 150milliseconds; the third trial found a significant increase in the proportion of people with
an improvement in peak oxygen uptake among those with a QRS duration of ≥ 120milliseconds but not
among those with a QRS duration of < 120milliseconds. CRT-D was associated with a greater benefit
in women than in men (one trial) and with a greater benefit in people with LBBB than in those with
non-specific intraventricular conduction delay (one trial). One trial found a statistically significant
improvement with CRT-D in distance walked in 6 minutes for those with non-ischaemic cardiomyopathy
(55.0m vs. 2.5m; p= 0.01) but not for those with ischaemic cardiomyopathy (4.2m vs. 5.8m; p= 0.57).
Other evaluated subgroups showed no statistically significant effects.
This evidence (apart from the CONTAK-CD trial) has not been previously evaluated in a TAR.62,64
Summary of the industry-submitted individual patient data network
meta-analysis
The MS reported an IPD NMA that assessed the effectiveness of ICDs, CRT-P and CRT-D compared with
OPT for people with HF. As people with HF vary considerably, the NMA aimed to identify subgroups who
may benefit from the different interventions. The NMA assessed the outcomes of all-cause mortality,
all-cause hospitalisation and HRQoL, with the findings informing the economic model presented in the MS.
The focus of the NMA differed from that specified in the scope for the appraisal, trying to establish which
subgroups may benefit from the interventions rather than assessing their effectiveness in the groups
identified in the original decision problem.
The NMA was based on a network of evidence identified from a systematic review presented in the MS.
It included 13 of 22 trials (95% of patients in the network) from the network for which IPD were available.
The network excluded seven RCTs identified in this report. The evidence base for the different outcomes
varied (all-cause mortality: 13 trials, all-cause hospitalisation: 11 trials and HRQoL: three trials), resulting
in limited and, on occasions, skewed data that affected the results of the NMA. The MS outlined the
methods followed in the different stages of the NMA; however, it did not provide comprehensive results
from each stage to allow a full appraisal of the decisions made and their effect on the results. The IPD
NMA used meta-regression to assess the clinical effectiveness of the different interventions, allowing the
impact of different patient characteristics to be taken into account in the analysis (i.e. baseline risks and
treatment modifiers). The NMA followed a two stage process: first, baseline rates were estimated for
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patients randomised to the comparator treatment of OPT independent of treatment effects; second,
device-specific treatment effects were estimated from relevant IPD trials to allow comparison with the
baseline rates. Baseline risk and treatment effect modifiers (i.e. patient characteristics) were included in
both stages to allow subgroups to be identified. When possible, the MS assessed the validity of the results
against other evidence, making adjustments when considered necessary because of counterintuitive results
or a lack of data.
The results of the NMA showed that there was a benefit for people receiving a device compared with OPT
for the three outcomes; however, the extent of the benefit and the subgroups most affected remained
uncertain. Fixed-effects NMA without the covariables for all-cause mortality estimated HRs that showed
a statistically significant benefit for all devices compared with OPT (commercial-in-confidence information
has been removed). HRs showed a statistically significant benefit for CRT-D compared with CRT-P
(commercial-in-confidence information has been removed) and ICD (commercial-in-confidence information
has been removed). NMA models including covariables (treatment modifiers) reported findings that were
more equivocal and the MS states that they should be interpreted with caution. Although HRs showed that
all devices appeared to have a beneficial effect compared with OPT, rarely were the differences statistically
significant. CRT-D appeared to have a statistically significant effect for people with QRS duration of
≥ 150milliseconds. It also had an effect for people with a QRS duration from ≥ 120milliseconds to
< 150milliseconds, which was statistically significant for women and marginally insignificant for men. ICDs
had a statistically significant benefit for men aged < 60 years and men aged ≥ 60 years with a QRS duration
from ≥ 120milliseconds to < 150milliseconds and without LBBB. CRT-P provided a statistically significant
effect for women with a QRS duration of ≥ 150milliseconds and LBBB. Similar benefits from all devices
when compared with OPT were shown for all-cause hospitalisations, although limited data meant that
some comparisons were not possible. All-cause hospitalisations were reduced in people in NYHA classes I–III
receiving an ICD (commercial-in-confidence information has been removed), in NYHA classes III and IV with
CRT-P (commercial-in-confidence information has been removed) and in all NYHA groups with CRT-D
(commercial-in-confidence information has been removed). Results for HRQoL were less clear because of
the scarcity of data available for the NMA. Although the use of the devices led to improvements in EQ-5D
values, some comparisons could not be made and others produced counterintuitive results. As a
consequence, the MS adjusted values to show that ICDs had benefit for people in NYHA class I/II and that
CRT-P and CRT-D had the same effect for people in NYHA classes III and IV. Given that most utility values
were changed and that limited comparisons can be made with other evidence, these data should be
interpreted with caution.
The IPD NMA provides an opportunity to undertake a more detail analysis of the effectiveness of ICDs,
CRT-P and CRT-D in relation to the comparator treatment of OPT, evaluating the benefits for specific
groups of people with HF. Unfortunately, limitations in the data available and lack of detail concerning the
methods used render the findings uncertain. It is clear that all of the devices are beneficial compared with
OPT for all-cause mortality. They also appear to have benefit for the outcomes of all-cause hospitalisation
and HRQoL, although the extent of the effect is less clear. However, the benefits for specific subgroups
remain unclear. When some benefits are shown, the warnings in the MS concerning the analysis cause
some concern. In addition, the subgroups identified in the NMA differ from those outlined in the scope
for the appraisal, making translation of the results between them difficult.
Cost-effectiveness
Summary of previously published economic evaluations
The systematic review of the cost-effectiveness of ICDs for the treatment of arrhythmia and of CRT for
treatment of HF identified 51 studies (36 studies of ICDs and 17 of CRT). Most of the evaluations
employed state transition models to estimate long-term outcomes extrapolated from short-term outcomes
in trials. Almost half of the studies reported that ICDs were cost-effective, with the remaining studies
finding that ICDs were cost effective only in high-risk groups or were not-cost effective or that it was
uncertain whether they were cost-effective. One high-quality study was conducted for a UK setting and
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
259
perspective and reported a mean ICER for ICDs compared with AADs for an average UK secondary
prevention patient over a 20-year time horizon of £76,139 per QALY gained. However, these results may
not be applicable to current UK practice as some data used in the model are now out of date. Almost all
studies reported that CRT was cost-effective, with only two studies uncertain whether it was cost-effective.
One high-quality study was conducted for a UK setting and estimated an ICER of £16,735 per QALY
gained for CRT-P compared with OPT and an ICER of £40,160 per QALY gained for CRT-D compared
with CRT-P.
Summary of the systematic review of quality-of-life studies
The systematic review found six relevant HRQoL studies that measured EQ-5D in HF, stratified by NYHA
class, or that reported on patients who had previously received an ICD. Two studies were conducted in
patients who had received an ICD. One study of UK patients who responded to a postal questionnaire
found that mean EQ-5D score did not change with time after implant; the other study of volunteers
attending a defibrillator clinic in the USA reported no difference between the EQ-5D scores of primary and
secondary prevention patients and that QoL for ICD patients was similar to that of the general population.
Four cohort studies reported EQ-5D scores in HF, with baseline scores ranging from 0.44 to 0.66
depending on NYHA classification. Overall, the results show decreased EQ-5D scores in HF compared
with those of the general population, particularly in NYHA classes III and IV.
Summary of the industry-submitted economic evaluation
One submission was received from ABHI. The general approach taken in the MS seems reasonable,
with the model structure consistent with the current understanding of HF and ventricular arrhythmia.
Assumptions over costing are also consistent with current clinical practice. However, there is limited
reporting in the MS on some sources of evidence used in the model. Uncertainty is not comprehensively
assessed as the sensitivity analyses presented are limited to few scenarios and the methodology used
for the probabilistic sensitivity analysis is not described in sufficient detail to determine whether or not joint
parameter uncertainty was properly assessed. The cost-effectiveness results presented in the submission
(according to subgroups specified by ABHI) do not directly address questions posed in NICE’s scope,61 as it
is unclear how the subgroups selected relate to the groups scoped by NICE. Overall, the results show that
for most subgroups there is at least one device with an ICER of < £30,000 per QALY gained, and in some
cases a different device might have an ICER of < £20,000 per QALY gained.
Summary of the independent economic model
We developed an independent state transition model based on that created by Fox and colleagues64 for
TA120.43 The care pathways and assumptions have been adapted according to new evidence and clinical
advice to allow for the assessment of the cost-effectiveness of ICDs, CRT-P and CRT-D for people at risk of
SCD as a result of ventricular arrhythmias and/or HF as a result of LVSD and cardiac dyssynchrony.
People at risk of sudden cardiac death
The current economic model indicates that the initial management of patients at increased risk of SCD
with an ICD alongside OPT is a cost-effective strategy compared with initial treatment with OPT alone
(ICER £19,479 per QALY). The use of ICDs for the secondary prevention of SCD had a 51% and 82%
probability of being cost-effective at a WTP of £20,000 and £30,000 per QALY gained respectively. ICDs
were also estimated as being cost-effective (within the WTP range of £20,000–30,000 per QALY gained)
for the primary prevention subgroups analysed (people with remote MI, a broad population with mild to
moderate HF, and non-ischaemic cardiomyopathy patients). The parameters with the greatest impact on
the cost-effectiveness results were the time horizon, the HR for all-cause mortality associated with the
ICD+OPT arm, the risk of surgical death during ICD implantation and the lifetime of the device.
People with heart failure as a result of left ventricular systolic dysfunction and
cardiac dyssynchrony
For patients with HF as a result of LVSD and cardiac dyssynchrony, the base-case analysis found that the
addition of either CRT-P or CRT-D to OPT (in the initial stage of management of HF) may be considered
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cost-effective at a WTP of £30,000 compared with OPT alone (allowing for subsequent device
implantation), with ICERs of £27,584 per QALY and £27,899 per QALY respectively. The use of
CRT-D+OPT compared with CRT-P+OPT was also likely to be cost-effective (ICER £28,420 per QALY).
At a WTP of £20,000 per QALY, initial management with OPT alone (followed by the clinically necessary
device implants) was the strategy with the highest probability of being cost-effective (81%). Above a WTP
of £28,000 per QALY, the strategy with the highest probability of being cost effective was CRT-D+OPT
(38%). At £30,000 per QALY, CRT-D+OPT and CRT-P+OPT had a 46% and 31% probability of being
cost-effective, respectively, whereas OPT alone had a 23% probability of being cost-effective.
The parameters with the most influence on the model results for the comparison between CRT-P and OPT
were the risk of hospitalisation for a serious arrhythmic event for patients receiving CRT-P, the risk of HF
death for both patients receiving CRT-P and patients receiving CRT-D and the risk of SCD for patients
receiving CRT-P. The results of the comparison between CRT-D and OPT were most influenced by the risks
of HF death and SCD death in CRT-D patients and the lifetime of the device. The results of the comparison
between CRT-D and CRT-P were the most sensitive to the variation of individual parameters, with eight
parameters causing the ICER to range by > £10,000, the most influential being the risk of HF death for
CRT-D patients and the risk of SCD for both CRT-D and CRT-P patients.
People with both conditions
The base-case analysis found that the most cost-effective strategy for people with both conditions at a
WTP of £20,000–30,000 per QALY was initial management with OPT alone (followed by device
implantation and subsequent upgrades as necessary), with an ICER of £2824 per QALY compared
with ICD+OPT (the least costly and least effective strategy). Costs and QALYs for CRT-D+OPT and
CRT-P+OPT were similar. CRT-D had an ICER of < £30,000 when compared with ICD+OPT
(ICER £27,195 per QALY) but not when compared with initial management with OPT alone (ICER £35,193
per QALY). At a WTP of £30,000 per QALY, OPT alone, ICD+OPT, CRT-D+OPT and CRT-P+OPT had a
44%, 31%, 15% and 10% probability of being cost-effective respectively. Above a WTP of £42,000 per
QALY, the intervention with the highest probability of being cost effective was CRT-D+OPT (31%).
However, the results differ when using an alternative scenario from the MADIT-CRT trial. In this case,
ICD+OPT is slightly more costly but yields a greater benefit than OPT alone. As CRT-P+OPT and
CRT-D+OPT are less effective than ICD+OPT and much more costly, both CRT strategies are dominated
by ICD+OPT compared with OPT alone. Therefore, the results obtained with the MADIT-CRT data indicate
that ICD+OPT is the most cost-effective strategy, with an ICER of £154 per QALY gained compared with
OPT alone. The cost-effectiveness results for the comparison between CRT-D+OPT and ICD+OPT were
quite robust to the variation of input parameters. The most influential parameters for this comparison were
the RR of all-cause mortality for ICD patients and the lifetime of the CRT-D and ICD devices.
Exploration of differences in results between population 2 and population 3
In response to comments querying the face validity of the results for population 3 compared with
population 2, the differences were explored.
The baseline mortality risk for population 2 was higher than that for population 3, although the RR
improvement with CRT-P compared with OPT was similar in the two populations. In the original analyses
there was a greater benefit in terms of survival for population 2 than for population 3 because of the high
numbers of crossovers to CRT-D in the OPT group in population 3. A new scenario for population 3 was
conducted using a higher baseline risk, similar to the risk of all-cause mortality for population 2. All-cause
mortality for population 3 was 50% higher (all-cause mortality yearly probability: OPT 0.105, CRT-D
0.065), giving a similar ICER to the baseline ICER (£34,964 vs. £35,193).
The approach to modelling changes in QoL also differed between population 2 and population 3. The
population 2 model assumed a given initial distribution of patients by NYHA class (initially more severe
than that in the population 3 model). At 9 and 18 months, different distributions by NYHA class (derived
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from the CARE-HF and Brescia studies) were assumed to capture the effect of CRT on patients HRQoL.
In the population 3 model, the HRQoL of patients was kept constant over time, assuming an initial
distribution of patients per NYHA class as reported for the RAFT trial at baseline. The effect of these
differences is that there is more QoL benefit in population 2 than in population 3 for patients receiving
CRT-D. It is likely that these differences in HF progression explain some of the differences between the
results for populations 2 and 3. A scenario analysis was undertaken assuming that population 3 has the
same HF progression as population 2. This resulted in an ICER of £27,396 per QALY gained for CRT-D
compared with OPT, similar to that in the population 2 model (£27,899 per QALY).
Strengths and limitations of the assessment
Strengths
This review has the following strengths:
l It is independent of any vested interest.
l It has been undertaken following the principles for conducting a systematic review. The methods were
set out in a research protocol that defined the research question, inclusion criteria, quality criteria,
data extraction process and methods to be employed at different stages of the review.
l A multidisciplinary advisory group has informed the review from its initiation. The research protocol
was informed by comments received from the advisory group and the advisory group has reviewed and
commented on the final report.
l The review brings together within one assessment report the most up-to-date evidence for the clinical
effectiveness and cost-effectiveness of ICDs, CRT-P and CRT-D for people at risk of SCD as a result of
ventricular arrhythmias and/or HF as a result of LVSD and cardiac dyssynchrony. This evidence has
been critically appraised and presented in a consistent and transparent manner.
l An economic model has been developed de novo following recognised guidelines and systematic
searches have been conducted to identify data for the economic model. The main results have been
summarised and presented.
Limitations
In contrast, this assessment also has certain limitations.
Limitations of the included trials
l Randomised patients with successful implantation may overestimate the benefits and underestimate
adverse effects.
l Trials have not been conducted in the UK and may not be generalisable.
l The time horizon of the included trials may be inadequate.
l Blinding of participants and health-care providers is impossible in trials that compare devices and drugs;
however, it is important to acknowledge the bias that may occur as a result of this. It would be
possible to blind outcome assessors in these trials.
l The definition of OPT has changed over time; therefore, the pharmacological therapy used in some of
the included trials would not be considered optimal by current standards.
Limitations of the systematic review of clinical effectiveness
l Three populations were defined by the NICE scope;61 however, there are no accepted a priori criteria
that could be used to categorise trials. Clinical experts were consulted to allocate trials to the
population groups and pragmatic decisions were taken to allocate trials and ensure that all relevant
RCT evidence comparing eligible interventions and comparators was included.
l A decision was made to also include trials in which medical therapy would not be considered optimal
by current standards. Pharmacological therapy varied between the trials and was described in detail.
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l The MUSTT and MAVERIC trials were excluded from the systematic review as the intervention did not
meet the scope of the review (many participants in the intervention arm did not receive an ICD);
however, these trials presented subgroup data for the comparison between ICD therapy and no ICD
therapy. These trials were not subjected to formal data extraction and quality assessment but were
presented for information.
l Significant statistical heterogeneity was shown between trials for some outcomes; therefore, the
pooled data should be viewed with caution. Some trials reported median values and CIs rather than
mean values. Median values are similar to mean values when the distribution of data is symmetrical
and so can be used directly in the meta-analyses.65 However, means and medians can be very different
from each other if the data are skewed. The use of median values in some of the meta-analyses may
have contributed to statistical heterogeneity.
l The review included only subgroup analyses specified a priori by the trials. However, subgroup analysis
lacks statistical power and may be misleading, for example because of problems of multiplicity.
Subgroup analyses should therefore be viewed with caution.
Limitations of the independent economic model
The independent model for the current appraisal was developed to address the decision problem specified
in the NICE scope for the appraisal61 and followed recommended guidance provided in the NICE Guide to
the Methods of Technology Appraisal.67 It was based on an adaptation of a model structure used in the
previous appraisal of CRT for HF (TA12043), developed by Fox and colleagues,64 providing a consistent
approach and comparability. Despite following recognised guidance on developing economic models,67,68
the evaluation has some limitations:
l As the independent model was based on an adaptation of a model developed by Fox and colleagues,64
it relies on some of the same assumptions made with regard to the structure of the model. These
relate to the referral of patients receiving particular treatment options, whether the comparator or an
intervention, to receive an alternative intervention following occurrence of a particular event (e.g. a
non-fatal arrhythmia for a patient on OPT or a serious arrhythmic event for a patient on CRT-P or an
unsuccessful CRT-P implantation). As these were validated by Fox and colleagues by clinical advice and
considered during previous appraisals, it was felt that they were of limited concern.
l Additional structural assumptions were made with regard to the risks and timing of the reimplantation
of devices, alternative options for those patients with unsuccessful implantation, and perioperative
complications, surgical failure, heart transplantation and death. As with the assumptions in the model
by Fox and colleagues,64 these were incorporated following clinical advice.
l Survival estimates over time for the model were derived from relevant trials with the longest follow-up.
These were identified in the systematic review of clinical effectiveness produced for this assessment.
Given the heterogeneous nature of the studies included, it is possible that the studies used in the
analysis did not encompass the differences in the patient groups. To limit any possible effects,
base-case and subgroup analyses were carried out to try and encompass the different patients
included. Also, follow-up varied (range 18–45.5 months) in the different studies used, affecting the
extent to which survival curves had to be extrapolated.
l Parameter values for the clinical effectiveness of the interventions were sourced, where possible, from
the systematic review undertaken for this assessment. Unfortunately, limitations in the evidence base
meant that some parameters either were not available for the specific populations being modelled or
were presented in a single study that may not have encompassed the inherent variability in
heterogeneous patient populations being assessed (e.g. hospitalisation rates, complications). When
necessary, parameter values were obtained from studies in other population groups included within the
appraisal or from other studies or sources outside of the systematic review. These were assumed to
be representative.
l The evidence base for patients who had both HF and an increased risk of SCD (population 3) was
limited, with most studies assessing CRT-D or ICDs. In particular, the lack of a direct comparison
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between CRT-P and CRT-D meant that evidence had to be used from studies on the clinical
effectiveness of CRT-P and CRT-D in patients with HF as a result of LVSD and cardiac dyssynchrony
(population 2).
l The availability of HRQoL data varied for the effects of the different devices and for additional
procedures or adverse events. Baseline utility values were available by NYHA class. Data were not
identified for the effects of transplantation, surgery or infections and assumptions were made following
those used by Fox and colleagues.64 Device-related utility values were assessed through their effect on
changes in the distribution of patients by NYHA class. Data were available only for patients receiving
CRT-P or OPT alone for population 2 and so the effects of CRT-D were assumed to be the same as for
CRT-P devices. Robust evidence on HRQoL was not found for population 3 and so CRT and ICD devices
were assumed to have no impact on utility and baseline values were maintained. These assumptions
may underestimate the benefits of the devices for HRQoL.
l Resource use and costs were obtained from routinely published sources. As some costs were not
specifically identified in the routine sources, assumptions were made. These included the costs of the
implantation of the devices, the costs of upgrades and routine replacements, the costs of operative
complications and device-related complications and drug costs. Alternative data were sourced from Fox
and colleagues,64 the MS and clinical advice.
l The model structure allows patients initially managed with OPT or CRT-P to have a device upgraded to
a different device according to disease progression. The result of this assumption is that there are a
large number of upgrades in some population arms. This is most evident in population 3. These
upgrades occur in patients who experience hospitalisation because of non-fatal arrhythmia (and then
undergo ICD/CRT-D implantation) and are based on the previous modelling structure in the study by
Fox and colleagues.64
When limitations have arisen in the evaluation, these have been identified in the report. Assumptions
made or data identified from alternative sources have been checked through clinical advice, and the
effects parameters thought to be influential on the results have been assessed through sensitivity analyses.
Comparison of the independent economic evaluation with other evaluations
For patients in the UK at increased risk of SCD, Buxton and colleagues153 estimated an ICER of £76,139
per QALY gained for ICD+OPT compared with OPT for the secondary prevention of SCD over a 20-year
time horizon. As some data used in the model are now out of date, these results may not be applicable to
current UK practice and may not be comparable with the results of the current model. Different modelling
structures and different data inputs were used in the current model, as well as different approaches to
estimate HRQoL. Both models estimated similar utility values for the OPT and ICD+OPT cohorts; however,
the average utility values estimated in the current model for OPT alone (0.81) and ICD+OPT (0.82) are
higher than the 0.75 assumed for both arms by Buxton and colleagues. Scenario analysis using the same
average utility values as used by Buxton and colleagues153 resulted in an ICER of £22,372 per QALY gained
for ICD+OPT compared with initial management with OPT alone for the secondary prevention of SCD.
For patients with HF, Fox and colleagues64 estimated ICERs of £16,735 per QALY gained for CRT-P
compared with OPT, £22,231 per QALY gained for CRT-D compared with OPT and £40,160 per QALY
gained for CRT-D compared with CRT-P. The current model estimates a slightly higher cost and QALY gain
for all strategies. However, the estimated incremental benefit of CRT-P compared with OPT is less than
that in the previous model and is associated with a higher incremental cost; hence, an ICER of £25,779 per
QALY gained is estimated for CRT-P compared with OPT. As a greater incremental benefit is estimated
with CRT-D compared with CRT-P at a similar cost, a smaller ICER (£24, 943 per QALY) is estimated for
CRT-D compared with CRT-P. The same incremental benefit is estimated for CRT-D compared with
OPT but the current model estimates a higher incremental cost for CRT-D; thus, a higher ICER (£27,899
per QALY) is estimated for CRT-D compared with OPT.
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The differences in results between models can be explained by using updated costs, different estimates
of the lifetime of the devices, a different set of utilities by NYHA class and structural differences between
models (such as referring patients being managed with OPT alone for CRT-P implantation in case of
hospitalisation for HF, instead of ICD, or for CRT-D following hospitalisation for arrhythmia). Using the
same utility values as in the model of Fox and colleagues64 increases the incremental benefit of both CRT-P
and CRT-D compared with OPT and with each other and therefore reduces the ICERs to £22,892 per
QALY gained for CRT-P compared with OPT, £24,580 per QALY gained for CRT-D compared with OPT and
£27,893 per QALY gained for CRT-D compared with CRT-P. The scenario using the same device lifetime
estimates as in the study by Fox and colleagues64 resulted in higher ICERs for CRT devices compared with
OPT because of higher costs and slightly fewer QALYs estimated for both CRT-D+OPT and CRT-P+OPT.
The joint economic evaluation submitted by ABHI151 concluded that for most subgroups there is at least
one device with an ICER of < £30,000 per QALY gained and in some cases a different device might have
an ICER of < £20,000 per QALY gained. The general approach taken in the MS seems reasonable as
the model structure is consistent with the current understanding of HF and ventricular arrhythmia and the
assumptions over costing are also consistent with current clinical practice. However, the cost-effectiveness
results presented in the MS (according to subgroups specified by ABHI) do not directly address questions
posed in NICE’s scope,61 as it is unclear how the subgroups selected relate to the groups scoped by
NICE. The independent economic model was developed to address NICE’s scope and was based on the
published clinical evidence and on previously published evaluations. Hence, a different modelling approach
was taken and the limited data available did not allow for the analysis of the subgroups defined by
ABHI. It is therefore unclear how the cost-effectiveness results of the current model compare with those
from the MS.
Other recent systematic reviews/meta-analyses
Huang and colleagues230 presented a meta-analysis comparing CRT-D with no CRT-D (CRT-P, ICD or OPT)
and found that all-cause mortality was reduced in CRT-D patients. However, three of the trials included
were not RCTs. Subgroup analysis comparing CRT-D with ICD therapy is also presented but includes
only three of the nine relevant trials identified by the current review. Without the large RAFT trial, the
meta-analysis by Huang and colleagues230 found no significant difference in all-cause mortality between
CRT-D and ICD therapy. Al-Majed and colleagues231 assessed CRT in people with advanced HF and those
with less symptomatic disease. The inclusion criteria for their systematic review differed from those in
the present review (eligible comparators were inactive pacing, right or left ventricular pacing alone and
ICD therapy); therefore, there are some differences in the trials included in the meta-analyses and the
results are not directly comparable. The meta-analyses found that CRT-D reduced all-cause mortality and
HF hospitalisations in subgroups with NYHA class I/II and class III/IV symptoms. Functional outcomes
were improved in people with NYHA class III/V but not class I/II symptoms. A systematic review and
meta-analysis by Wells and colleagues232 compared CRT-D with ICD therapy or OPT and conducted
subgroup analysis for NYHA class. All-cause mortality was reduced with CRT-D compared with ICD therapy
or OPT. Compared with ICD therapy, CRT-D reduced all-cause mortality for people with NYHA class I or II
but not class III or IV symptoms. The differences in effects for the NYHA class subgroups between these
the two meta-analyses231,232 are due to the different comparators and trials included. A meta-analysis by
Bertoldi and colleagues233 also found a significant reduction in all-cause mortality with CRT-P compared
with OPT and with CRT-D compared with ICD therapy, despite including slightly different trials.
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Uncertainties
l No new evidence comparing CRT-P and CRT-D devices was identified; therefore, the relative clinical
effectiveness and cost-effectiveness of the devices in people with HF as a result of LVSD and cardiac
dyssynchrony, with or without an established indication for an ICD, remains uncertain.
l No robust evidence was identified on the effect of CRT and ICD devices on HF progression in people
with both conditions.
l No evidence was found on the RR of hospitalisation because of arrhythmia for CRT-P devices compared
with CRT-D devices in people with both conditions; hence, CRT devices were assumed to have the
same preventative effect on severe arrhythmia. New evidence would reduce the uncertainty associated
with this parameter, to which the comparison between CRT-D+OPT and CRT-P+OPT showed
particularly sensitivity.
l Utility data were not identified for patients with both conditions or for patients receiving CRT-D or an
ICD. Also, no utility decrements were found for the effects of transplantation, surgery or infections.
l Routine cost data were not available for the implantation of devices, upgrades and routine device
replacements or for operative complications.
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Chapter 8 Conclusions
Implications for service provision
Implantable cardioverter defibrillators were found to reduce all-cause mortality in people who were at
increased risk of SCD as a result of ventricular arrhythmias, in which increased risk was defined as previous
ventricular arrhythmias/cardiac arrest, MI > 3 weeks previously, non-ischaemic cardiomyopathy (depending
on the data included) or ischaemic or non-ischaemic CHF and a LVEF of ≤ 35%. No benefit from an ICD
was found in people who were scheduled for CABG surgery. A significant reduction in SCD was found in
people with a recent MI, but there was no difference in all-cause mortality. No significant differences
between prespecified subgroups were reported by most of the trials reporting these. The addition of ICD
to OPT was cost-effective at a WTP threshold of £30,000 for all of the scenarios modelled, and at a WTP
threshold of £20,000 in some cases.
Cardiac resynchronisation therapy – pacer and CRT-D both reduced the risk of mortality and HF
hospitalisations in people with HF as a result of LVSD and cardiac dyssynchrony when compared with OPT.
Improvements in NYHA class, exercise capacity and QoL were also found with both devices. The risk of
SCD was lower with CRT-D than with CRT-P, but other outcomes, including all-cause mortality, were
similar between the devices. Both CRT-P and CRT-D had ICERs of < £30,000 per QALY gained compared
with OPT, as did the comparison between CRT-D and CRT-P.
Compared with ICD, CRT-D reduced the risk of all-cause mortality and HF hospitalisation in people with
both conditions. An improvement in LVEF, exercise capacity and QoL was also found with CRT-D
compared with ICD. Device or implantation complications were more common with CRT-D. The costs and
QALYs for CRT-D and CRT-P were similar. The ICER was < £30,000 per QALY for the comparison of
CRT-D+OPT with ICD+OPT (unless no difference in all-cause mortality was assumed) but not for the
comparison with initial management with OPT alone.
The conclusions should be considered in light of the limitations of this evaluation, such as the approach
of allocating heterogeneous trials to three population groups and the uncertainties in the
economic evaluation.
Suggested research priorities
One three-arm trial comparing CRT-D and CRT-P with OPT in people with HF as a result of LVSD and
cardiac dyssynchrony was identified by the systematic review. The trial was not designed to directly
compare CRT-D and CRT-P and no additional trials of this comparison were identified. Furthermore, the
trial excluded people meeting the general indications for an ICD. A RCT comparing CRT-D and CRT-P in
people with HF as a result of LVSD and cardiac dyssynchrony is required, for both those with and those
without an ICD indication.
The evidence base for ICD therapy in cardiomyopathy is limited. A trial is needed into the benefits of ICDs
for non-ischaemic cardiomyopathy in the absence of dyssynchrony.
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Appendix 1 Comparison of inclusion
criteria in previous and present technology
assessment reports
Parameter ICD TAR62 CRT TAR64 Present TAR
Population Adults at high risk of SCD as a
result of arrhythmia:
‘Secondary prevention’:
(i) cardiac arrest as a result of
either VT or VF; (ii) spontaneous
sustained VT causing syncope or
significant haemodynamic
compromise; (iii) sustained VT
without syncope/cardiac arrest,
and who have an associated
reduction in LVEF (< 35%)
but who are no worse than
NYHA class III
(a) ‘Primary prevention’:
(i) a history of previous MI
and (a) non-sustained VT on
Holter (24-hour ECG)
monitoring, (b) inducible VT
on electrophysiological
testing, (c) left ventricular
dysfunction with an LVEF
< 35% and no worse than
NYHA class III; (ii) a history of
previous MI and depressed
heart function (LVEF ≤ 30%);
(iii) non-ischaemic (dilated)
cardiomyopathy with
arrhythmia at high risk of
SCD and depressed heart
function (LVEF ≤ 30%)
People with HF (any NYHA class)
as a result of LVSD with evidence
of cardiac dyssynchrony (QRS
duration > 120milliseconds) and
LVSD (LVEF ≤ 35%)
People at increased risk of SCD as
a result of ventricular arrhythmias
despite OPT; people with HF
as a result of LVSD and cardiac
dyssynchrony despite OPT;
people with both conditions
described above
Intervention ICD CRT-P or CRT-D ICD, CRT-P, CRT-D
Comparator AAD or placebo/control OPT alone, CRT-P vs. CRT-D OPT, CRT-P vs. CRT-D, CRT-D
vs. ICD
Outcomes Mortality, QoL, adverse effects Mortality, number of people with
HF hospitalisations, exercise
capacity, NYHA class, number
with adverse effects, QoL
Mortality, adverse effects, QoL,
symptoms and complications
related to tachyarrhythmias and/or
HF, HF hospitalisations, change in
NYHA class, change in LVEF
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Appendix 2 Sources of information,
including databases searched and search terms
A ll databases searched for the systematic reviews of clinical effectiveness and cost-effectiveness arepresented in the following table. Searches were updated in November 2012.
Database searched
Clinical
effectiveness searches
Cost effectiveness and
QoL searches
Cochrane Central Register of Controlled Trials (CENTRAL,
The Cochrane Library)
All available years
Cochrane Database of Systematic Reviews (CDSR, The
Cochrane Library)
All available years
Database of Abstracts of Reviews of Effects (DARE, CRD) All available years All available years
EMBASE All available years 1990–2011
HTA database (CRD) All available years All available years
MEDLINE (Ovid) All available years All available years
MEDLINE In-Process & Other Non-Indexed Citations (MEIP) Searched 13 November 2012 Searched 13 November 2012
NHS Economic Evaluation Database (NHS EED, CRD) All available years
Web of Science (Science Citation Index Expanded and
Conference Proceedings)
All available years All available years
Biosis Previews (ISI Web of Knowledge) All available years All available years
Zetoc (Mimas) 1990–2012
Searched for ongoing trials
NIHR Clinical Research Network (NIHR CRN Portfolio, formally UKCRN website)
Current Controlled Trials (CCT)
ClinicalTrials.gov
World Health Organization International Clinical Trials Registry Platform (ICTRP)
The MEDLINE search strategy (presented in the following section) for the systematic review of clinical
effectiveness was adjusted as necessary for the other electronic databases for both the clinical effectiveness
and the cost effectiveness (including QoL information) searches. Search strategies for the systematic review
are available from the authors on request. Citations identified by the searches were added to a Reference
Manager database (version 12; Thomson ResearchSoft, San Francisco, CA, USA).
MEDLINE search strategy
1. Defibrillators, Implantable/ (9092)
2. (implant* adj2 (defibrilat* or defibrillat*)).tw. (7371)
3. ICDs.tw. (1750)
4. (S-ICD or S-ICDS).mp. (10)
5. subcutaneous ICD*1.tw. (14)
6. (implant* adj5 ICD*1).tw. (3365)
7. (CRT or CRT-D or CRT-P).mp. (5381)
8. dual chamber ICD.tw. (100)
9. single chamber ICD.tw. (33)
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10. resynch* therap*.tw. (2776)
11. ((heart or cardiac or myocardial or coronary) adj2 (resynch* or depolari* or repolari*)).tw. (4300)
12. (atriobiventricular adj10 pac*).mp. [mp= title, abstract, original title, name of substance word, subject
heading word, protocol supplementary concept, rare disease supplementary concept, unique
identifier] (13)
13. (atriobiventricular adj10 stimulat*).mp. (1)
14. BVP.tw. (166)
15. (biventricular adj10 pac*).mp. (1222)
16. (biventricular adj10 stimulat*).mp. (149)
17. (cardiover* or “cardio-ver*” or cardioconver* or “cardio-conver*” or “cardio conver*”).tw. (10,472)
18. or/1-17 (23,443)
19. exp arrhythmia/ (149,057)
20. Tachycardia, Ventricular/ or Arrhythmias, Cardiac/ or Tachycardia/ or Ventricular Fibrillation/ (79,877)
21. Atrial Fibrillation/ (27,947)
22. Heart Ventricles/bs, in [Blood Supply, Injuries] (878)
23. exp Ventricular Dysfunction, Left/ (18,010)
24. exp cardiomyopathy, dilated/ (11,764)
25. ventricula* remodel*.tw. (2958)
26. bundle-branch block/ (6995)
27. Heart Failure/ (73,266)
28. exp heart failure, congestive/ (74,453)
29. Death, Sudden, Cardiac/ (9241)
30. Heart Arrest/ (20,135)
31. (ventricul* adj2 (tachycardia* or fibril* or arrhythmia*)).tw. (34,555)
32. ((heart or cardiac or myocardial or coronary) adj2 (failur* or arrest* or sudden)).tw. (116,912)
33. ((cardiac or ventricular or intraventricular) adj5 asynchron*).tw. (438)
34. ((cardiac or ventricular or intraventricular) adj5 dyssynchron*).tw. (844)
35. tachyarrhythmia*.tw. (6663)
36. “abnormal heart rhythm*”.tw. (37)
37. (“unexpected death” or “sudden death”).tw. (16,602)
38. (cardiomyopathy or cardiomyopathies).tw. (38,422)
39. Myocardial Infarction/ (128,452)
40. “heart attack*”.tw. (3218)
41. Long QT Syndrome/ (4998)
42. Syncope/ (8267)
43. (syncope adj2 (cardiogenic or heart or cardiac or myocardial)).tw. (519)
44. (atrial adj2 (fibril* or flutter*)).tw. (30,606)
45. ( “sudden cardiac death” or “sudden arrhythmic death”).tw. (7232)
46. “unstable heart rhythm*”.tw. (2)
47. “left ventricular systolic dysfunction”.tw. (1601)
48. ((reduced or reduction or impair*) adj2 left ventricular ejection fraction).tw. (572)
49. LVSD.tw. (238)
50. ((heart or cardiac or myocardial) adj2 dysfunction*).tw. (10,374)
51. exp cardiomyopathies/ (64,726)
52. Brugada syndrome.tw. (1352)
53. arrhythmogenic right ventricular dysplasia.tw. (777)
54. ARVD.tw. (378)
55. (surg* adj5 “congenital heart disease”).tw. (1327)
56. ((familial or genetic or inherited) adj “heart disease”).tw. (53)
57. (“heart failure” or “cardiac failure” or “ventricula*1 failure”).tw. (93,943)
58. Heart Defects, Congenital/su [Surgery] (12,194)
59. Heart Conduction System/ (26,125)
60. exp Cardiac Pacing, Artificial/ (18,111)
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61. exp Pacemaker, Artificial/ (21,156)
62. exp Heart-Assist Devices/ (6947)
63. or/19-62 (502,075)
64. 18 and 63 (17,567)
65. Randomized Controlled Trials as Topic/ (75,979)
66. randomized controlled trial.pt. (315,877)
67. controlled clinical trial.pt. (83,182)
68. Controlled Clinical Trial/ (83,182)
69. random allocation/ (72,622)
70. Double-Blind Method/ (111,942)
71. Single-Blind Method/ (15,496)
72. (random* adj2 allocat*).tw. (16,697)
73. placebo*.tw. (131,568)
74. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw. (109,548)
75. Research Design/ (64,180)
76. ((random* or control*) adj5 (trial* or stud*)).tw. (414,902)
77. random*.tw. (534,613)
78. exp Placebos/ (30,269)
79. Meta-Analysis/ (30,726)
80. meta analysis.pt. (30,726)
81. meta analys*.tw. (34,905)
82. (systematic adj2 (review* or overview*)).tw. (30,123)
83. Technology Assessment, Biomedical/ (7447)
84. or/65-83 (1,030,489)
85. 64 and 84 (2873)
86. (comment or editorial or letter).pt. (1,090,861)
87. 85 not 86 (2728)
88. limit 87 to english language (2501)
89. limit 88 to (cats or cattle or chick embryo or dogs or goats or guinea pigs or hamsters or horses or
mice or rabbits or rats or sheep or swine) (94)
90. patient*.tw. (3,739,049)
91. 89 not 90 (68)
92. 88 not 91 (2433)
Reference lists
The reference lists of retrieved articles were examined for additional studies.
Other searches
The expert advisory group was contacted to obtain information about additional references and any
ongoing studies.
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British societies and conferences (sources checked
November 2012)
Heart Rhythm in press articles
Heart Rhythm Society conferences 2010–12
www.arrhythmiaalliance.org.uk/
www.actionheart.com/
www.cardiomyopathy.org/
www.bhf.org.uk/
www.scst.org.uk/pages/default.asp
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Appendix 3 Economic evaluation checklist
No. Item Study Comments
1 Is there a clear statement of the decision problem?
2 Is the comparator routinely used in the UK NHS?
3 Is the patient group in the study similar to those of interest in the UK NHS?
4 Is the health-care system comparable to that of the UK?
5 Is the setting comparable to that of the UK?
6 Is the perspective of the model clearly stated?
7 Is the study type appropriate?
8 Is the modelling methodology appropriate?
9 Is the model structure described and does it reflect the disease process?
10 Are assumptions about model structure listed and justified?
11 Are the data inputs for the model described and justified?
12 Is the effectiveness of the intervention established based on a systematic review?
13 Are health benefits measured in QALYs?
14 Are health benefits measured using a standardised and validated generic instrument?
15 Are the resource costs described and justified?
16 Have the costs and outcomes been discounted?
17 Has uncertainty been assessed?
18 Has the model been validated?
Questions are answered as yes, no or unclear.
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Appendix 4 List of excluded clinical
effectiveness studies and recent abstracts
Excluded studies and reasons for exclusion
Adamson PB, Kleckner KJ, VanHout WL, Srinivasan S, Abraham WT. Cardiac resynchronization therapy
improves heart rate variability in patients with symptomatic heart failure. Circulation 2003;108:266–9.
[Reason for exclusion: outcomes.]
Alonso C, Ritter P, Leclercq C, Mabo P, Bailleul C, Daubert JC, et al. Effects of cardiac resynchronization
therapy on heart rate variability in patients with chronic systolic heart failure and intraventricular
conduction delay. Am J Cardiol 2003;91:1144–7. [Reason for exclusion: outcomes and study design.]
Aranda JM Jr, Conti JB, Johnson JW, Petersen-Stejskal S, Curtis AB. Cardiac resynchronization therapy
in patients with heart failure and conduction abnormalities other than left bundle-branch block: analysis
of the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Clin Cardiol 2004;27:678–82.
[Reason for exclusion: study design.]
Are implantable cardioverter-defibrillators or drugs more effective in prolonging life? The Antiarrhythmics
Versus Implantable Defibrillators (AVID) Trial Executive Committee. Am J Cardiol 1997;79:661–3.
[Reason for exclusion: patient group, intervention, outcomes and study design.]
Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, et al. Long-term clinical effect of
hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular
conduction delay. J Am Coll Cardiol 2002;39:2026–33. [Reason for exclusion: comparator.]
Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, et al. Clinical efficacy of cardiac
resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of
ventricular conduction delay. J Am Coll Cardiol 2003;42:2109–16. [Reason for exclusion: comparator.]
Auricchio A, Metra M, Gasparini M, Lamp B, Klersy C, Curnis A, et al. Long-term survival of patients with
heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. Am J Cardiol
2007;99:232–8. [Reason for exclusion: population, comparator and study design.]
Barsheshet A, Moss AJ, McNitt S, Jons C, Glikson M, Klein HU, et al. Long-term implications of cumulative
right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm
2011;8:212–18. [Reason for exclusion: study design.]
Barsheshet A, Wang PJ, Moss AJ, Solomon SD, Al-Ahmad A, McNitt S, et al. Reverse remodeling and the
risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation
Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol 2011;57:2416–23. [Reason for exclusion:
study design.]
Beshai JF. Resynchronization therapy in patients with narrow QRS (RethinQ). ACC Cardiosource Rev J
2007;16:30. [Reason for exclusion: abstract (insufficient details).]
Beshai JF, Daubert J-C. RethinQ (the Resynchronization Therapy in Normal QRS Study). Clin Cardiol
2008;31:89–90. [Reason for exclusion: abstract (insufficient details).]
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Beshai JF, Truong Q. Resynchronization therapy in patients with narrow QRS (RethinQ). ACC Cardiosource
Rev J 2008;17:44. [Reason for exclusion: study design.]
Birnie DH, Ha A, Higginson L, Green M, Thibault B, Wells G, et al. Importance of QRS duration and
morphology in determining response to cardiac resynchronization therapy: results from the
Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). 64th Annual Meeting
of the Canadian Cardiovascular Society, Vancouver, Canada, 22–26 October 2011. [Reason for
exclusion: outcomes.]
Boerrigter G, Costello-Boerrigter LC, Abraham WT, Sutton MG, Heublein DM, Kruger KM, et al. Cardiac
resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration
rate. J Card Fail 2008;14:539–46. [Reason for exclusion: study design.]
Brachmann J, Freigang K, Saggau W. Coronary Artery Bypass Graft Patch trial. Pacing Clin Electrophysiol
1993;16:571–5. [Reason for exclusion: comparator and outcomes.]
Breithardt G. MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization
Therapy): cardiac resynchronization therapy towards early management of heart failure. Eur Heart J
2009;30:2551–3. [Reason for exclusion: outcomes and study design.]
Brenyo A, Link MS, Barsheshet A, Moss AJ, Zareba W, Wang PJ, et al. Cardiac resynchronization therapy
reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic
Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol
2011;58:1682–9. [Reason for exclusion: outcomes.]
Brodine WN, Tung RT, Lee JK, Hockstad ES, Moss AJ, Zareba W, et al. Effects of beta-blockers on
implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy
(from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol 2005;96:691–5.
[Reason for exclusion: comparator and study design.]
Brodsky MA, McAnulty J, Zipes DP, Baessler C, Hallstrom AP, AVID investigators. A history of heart failure
predicts arrhythmia treatment efficacy: data from the Antiarrythmics Versus Implantable Defibrillators
(AVID) study. Am Heart J 2006;152:724–30. [Reason for exclusion: study design.]
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the
prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia
Trial investigators. N Engl J Med 1999;341:1882–90. [Erratum published in N Engl J Med 2000;342:1300.]
[Reason for exclusion: intervention and comparator (although the study is excluded, some details of the
study are discussed in the report.)]
Campbell P, Bourgoun M, Shah A, Foster E, Brown MW, Moss AJ, et al. Effect of baseline right ventricular
function on outcomes after CRT: an analysis of the MADIT-CRT population. J Am Coll Cardiol
2011;57(Suppl. 14):E205. [Reason for exclusion: outcomes.]
Campbell P, Takeuchi M, Bourgoun M, McNitt S, Goldenberg I, Zareba W, et al. Relationship between
change in ventricular size and function and BNP in patients undergoing CRT therapy: MADIT-CRT.
J Card Fail 2011;17(Suppl. 8):S57. [Reason for exclusion: abstract (insufficient details).]
Cappato R, Boczor S, Kuck KH; CASH investigators. Response to programmed ventricular stimulation and
clinical outcome in cardiac arrest survivors receiving randomised assignment to implantable cardioverter
defibrillator or antiarrhythmic drug therapy. Eur Heart J 2004;25:642–9. [Reason for exclusion:
study design.]
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Cardiomyopathy trial. The Cardiomyopathy Trial Investigators. Pacing Clin Electrophysiol 1993;16:576–81.
[Reason for exclusion: outcomes.]
Cawley PJ, Al-Khatib SM. Amiodarone versus implantable cardioverter defibrillator for asymptomatic
nonsustained ventricular tachycardia in nonischemic dilated cardiomyopathy. Am Heart J 2004;147:790–1.
[Reason for exclusion: intervention, comparator, outcomes and study design.]
Chung ES, Menon SG, Weiss R, Schloss EJ, Chow T, Kereiakes DJ, et al. Feasibility of biventricular
pacing in patients with recent myocardial infarction: impact on ventricular remodeling. Congest Heart Fail
2007;13:9–15. [Reason for exclusion: population.]
Chung ES, Mazur W, Menon SG, Schloss EJ, Chow T, Kereiakes DJ. Peri-infarct pacing with CRT in the
early postinfarct phase to attenuate long-term remodeling. J Cardiovasc Transl Res 2009;2:126–9.
[Reason for exclusion: outcomes.]
Chung ES, Dan D, Solomon SD, Bank AJ, Pastore J, Iyer A, et al. Effect of peri-infarct pacing early after
myocardial infarction: results of the prevention of myocardial enlargement and dilatation post myocardial
infarction study. Circ Heart Fail 2010;3:650–8. [Reason for exclusion: population.]
Cleland JGF. New results from the CARE-HF programme. ESC Congress Report 2005, p. 13. URL: www.
escardio.org/congresses/esc_congress_2005/Documents/ESC-Congress-HotLines-and-CTU-Reports-2005.pdf
(accessed January 2014). [Reason for exclusion: abstract (insufficient details).]
Cleland JG, Ghosh J, Freemantle N. Can cardiac-resynchronization therapy reduce mortality in patients
suffering from advanced chronic heart failure? Nat Clin Pract Cardiovasc Med 2004;1:10–11.
[Reason for exclusion: Outcome and study design.]
Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, et al. Clinical trials update and cumulative
meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE,
STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail
2004;6:501–8. [Reason for exclusion: study design (review).]
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Baseline
characteristics of patients recruited into the CARE-HF study. Eur J Heart Fail 2005;7:205–14. [Reason for
exclusion: outcomes.]
Cleland JG, Freemantle N, Daubert JC, Toff WD, Leisch F, Tavazzi L. Long-term effect of cardiac
resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study.
Heart 2008;94:278–83. [Reason for exclusion: study design.]
Curtis AB, Cannom DS, Bigger JT Jr, DiMarco JP, Estes NA III, Steinman RC, et al. Baseline characteristics of
patients in the coronary artery bypass graft (CABG) Patch trial. Am Heart J 1997;134:787–98. [Reason for
exclusion: outcomes.]
Cygankiewicz I, Gillespie J, Zareba W, Brown MW, Goldenberg I, Klein H, et al. Predictors of long-term
mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) patients with implantable
cardioverter-defibrillators. Heart Rhythm 2009;6:468–73. [Reason for exclusion: comparator and
study design.]
Cygankiewicz I, McNitt S, Thomsen PEB, Kautzner J, Moss AJ, Zareba W. Heart rate turbulence predicts
heart failure events in MADIT-CRT patients. 64th Annual Meeting of the Canadian Cardiovascular Society,
Vancouver, Canada, 22–26 October 2011. [Reason for exclusion: comparator, outcomes and study design.]
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Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al. Inappropriate implantable
cardioverter-defibrillator shocks in MADIT II. J Am Coll Cardiol 2008;51:1357–65. [Reason for exclusion:
comparator and study design.]
Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, et al. Prevention of disease progression
by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular
dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in
Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009;54:1837–46. [Reason for exclusion:
population and intervention.]
De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, et al. Impact of cardiac
resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart
failure with QRS prolongation: COMPANION trial sub-study. J Card Fail 2008;14:9–18. [Reason for
exclusion: intervention.]
Domanski MJ, Sakseena S, Epstein AE, Hallstrom AP, Brodsky MA, Kim S, et al. Relative effectiveness of
the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of
left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators.
Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999;34:1090–5. [Reason for
exclusion: study design.]
Domanski MJ, Epstein A, Hallstrom A, Saksena S, Zipes DP. Survival of antiarrhythmic or implantable
cardioverter defibrillator treated patients with varying degrees of left ventricular dysfunction who survived
malignant ventricular arrhythmias. J Cardiovasc Electrophysiol 2002;13:580–3. [Reason for exclusion:
study design (comparator).]
Dorian P, Hohnloser SH, Thorpe KE, Roberts RS, Kuck KH, Gent M, et al. Mechanisms underlying the lack
of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent
myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT).
Circulation 2010;122:2645–52. [Reason for exclusion: study design.]
Filho MM, Pedrosa AA, Costa R, Nishioka SA, Siqueira SF, Tamaki WT, et al. Biventricular pacing
improves clinical behavior and reduces prevalence of ventricular arrhythmia in patients with heart failure.
Arq Bras Cardiol 2002;78:110–13. [Reason for exclusion: comparator.]
Foley PW, Patel K, Irwin N, Sanderson JE, Frenneaux MP, Smith RE, et al. Cardiac resynchronisation therapy
in patients with heart failure and a normal QRS duration: the RESPOND study. Heart 2011;97:1041–7.
[Reason for exclusion: abstract.]
Foster E, Solomon SD, McNitt S, Heintze J, Vogt J, Almendral J, et al. MADIT CRT: who are
the super responders to cardiac resynchronisation therapy? Europace 2010;12:i50. [Reason for
exclusion: comparator.]
Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, et al. Risk of
thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial
(SCD-HeFT). Circulation 2007;115:2637–41. [Reason for exclusion: population and design.]
Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, et al. Risk stratification and clinical
outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia
and coronary disease: a prospective single-center study. Am J Cardiol 1997;80:3–9F. [Reason for exclusion:
intervention and study design.]
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Appendix 5 Ongoing trials
F ive relevant trials in progress were identified by the searches:
l ICD2 (Implantable Cardioverter Defibrillator in Dialysis patients) trial – ‘A prospective randomised
controlled trial to evaluate the prevention of sudden cardiac death using implantable cardioverter
defibrillators in dialysis patients’ (ISRCTN20479861). This trial aims to determine whether or not ICD
therapy in dialysis patients aged 55–80 years will result in a significant reduction in sudden cardiac
(arrhythmic) death rates compared with no ICD therapy. This is a multicentre RCT carried out in the
Netherlands. Start date: 1 April 2007; end date: 1 April 2017. Funding: Biotronik Nederland BV.
l DANISH (Efficacy of ICD in Patients with Non-Ischemic Systolic Heart Failure) trial – ‘Efficacy of
implantable cardioverter defibrillator in patients with non-ischemic systolic heart failure on mortality’
(NCT00542945 and NCT00541268). The comparator is OPT only. This is a multicentre RCT carried out
in Denmark. Start date: December 2007; end date: December 2012. Funding: not stated.
l REFINE-ICD (Risk Estimation Following Infarction, Noninvasive Evaluation) trial – ‘Efficacy of implantable
defibrillator therapy after a myocardial infarction’ (NCT00673842). This trial aims to determine whether
prophylactic ICD therapy reduces mortality in MI survivors with better-preserved left ventricular function
compared with standard medical care and standard post-MI treatment. This is a multicentre RCT carried
out in Canada. Start date: March 2011; end date: February 2018. Funding: not stated but collaborators
are Alberta Innovation and Science, Medtronic and GE Healthcare.
l EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial (NCT00683696). This trial
aims to evaluate the effects of CRT-D on mortality and morbidity of patients with HF as a result of
LVSD, already receiving OPT, with a narrow QRS width and echocardiographic evidence of ventricular
dyssynchrony, compared with OPT only and CRT-D off. This is an international multicentre RCT
(including Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Israel,
Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the USA). Start date: August
2008; end date: December 2012. Funding: Biotronik, Inc.
l ADOPT trial – ‘Assessment of efficacies of cardiac resynchronization therapies (CRT-P/D) for heart
failure patients in China’ (ChiCTR-TRC-09000574). This trial aims to evaluate whether CRT-P/D in
addition to OPT can further reduce mortality, improve congestive HF symptoms and enhance QoL
compared with OPT alone in Chinese congestive HF patients. This is a multicentre RCT carried out in
China. Start date: October 2008; end date: December 2012. Funding: Medtronik, Inc.
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Appendix 6 Hospitalisations: total, cardiac
and non-cardiac
People with heart failure as a result of left ventricular systolic
dysfunction and cardiac dyssynchrony
Number of patients hospitalised
The CARE-HF trial109 reported unplanned hospitalisations for a major cardiovascular event and this
was the primary outcome of the study. In addition, the study reported mean number of days in hospital by
3 months, mean days in hospital after 3 months and mean days in hospital overall during the entire
study (median 29.6 months). The COMPANION trial120 reported data for all hospital admissions,
cardiac admissions and non-cardiac admissions.
CRT-P compared with optimum pharmacological therapy
In the CARE-HF trial109 there were statistically significantly fewer unplanned hospitalisations for a major
cardiovascular event with CRT-P than with OPT (31% vs. 46% respectively; HR 0.61, 95% CI 0.49 to 0.77;
p< 0.001). The mean number of days in hospital overall was also lower with CRT-P than with OPT, but no
statistical comparisons for these outcomes were reported (Table 152). Similarly, in the COMPANION trial,120
the rates of all hospital admissions (CRT-P 63% vs. OPT 65%; p= 0.02) and cardiac admissions (CRT-P
49% vs. OPT 53%; p< 0.01) were both statistically significantly lower with CRT-P than with OPT.
However, the rate of non-cardiac hospital admissions was higher with CRT-P than with OPT (36% vs. 27%
respectively), but no statistical comparison was reported.
CRT-D compared with optimum pharmacological therapy
All hospital admissions (CRT-D 63% vs. OPT 65%; p= 0.03) and cardiac hospital admissions (CRT-D 48%
vs. OPT 53%; p< 0.01) were statistically significantly lower with CRT-D than with OPT in the COMPANION
trial (see Table 152).120 However, non-cardiac hospital admissions were higher with CRT-D than with OPT
(35% vs. 27% respectively), but no statistical comparison was reported.
CRT-P compared with cardiac CRT-D
The authors of the COMPANION trial120 state that no significant differences were found in any of the
hospital end points for CRT-P compared with CRT-D, but no statistics were reported (see Table 152).
Number of events/days of admission
CRT-P compared with optimum pharmacological therapy
The CARE-HF trial109 reported 222 unplanned hospitalisations for a major cardiovascular event in the CRT-P
group (n= 409) and 384 in the OPT group (n= 404) (Table 153). The COMPANION trial120 found
statistically significantly fewer admissions per patient-year for a cardiac procedure for those receiving CRT-P
(CRT-P 0.13 vs. OPT 0.24; p< 0.01). The number of average admissions per patient-year of follow-up was
lower for those receiving CRT-P (CRT-P 1.25 vs. OPT 1.59). The average number of hospital days per
patient-year of follow-up was also lower for CRT-P (CRT-P 8.3 vs. OPT 11.0), with the average length of
hospital stay per admission similar for both treatment groups (CRT-P 6.7 days vs. OPT 6.9 days). The
average number of hospital admissions per patient-year of follow-up was lower with CRT-P for cardiac
causes (CRT-P 0.79 vs. OPT 1.20) but higher for non-cardiac causes (CRT-P 0.46 vs. OPT 0.39 admissions).
Average number of hospital days per patient-year of follow-up for cardiac (CRT-P 5.2 vs. OPT 8.1) and
non-cardiac (CRT-P 3.2 vs. OPT 2.8) causes, and average length of stay per hospital admission for cardiac
(CRT-P 6.5 vs. OPT 6.8 days) and non-cardiac (CRT-P 6.9 vs. OPT 7.1 days) causes were similar between
treatment groups.
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TABLE 152 All hospitalisations: number of patients
Study Outcome and follow-up CRT-P, n/N (%) OPT, n/N (%) Effect
95% CI;
p-value
CARE-HF109 Major cardiovascular event, 29.4 monthsa 125/409 (31) 184/404 (46) HR
0.61
0.49 to
0.77,
< 0.001
Mean days in hospital by 3 months 7.5, median 4
(IQR 2–8)
3.4, median 0
(IQR 0–1)
– –
Days in hospital after 3 months 222 384 – –
Mean days in hospital overall during entire
study (reported as median of 29.6 months)
20.7, median 9
(IQR 4–26)
22.4, median 9
(IQR 0–31)
– –
MIRACLE121 Hospitalisations unrelated to HF or
function of left ventricular lead
37/228 (16.2) 33/225 (14.7) – –
COMPANION120b All admissions, CRT-P 16.2 months,
OPT 11.9 monthsc
388/617(63) 199/308 (65) – 0.02
Cardiac admissions 301/617 (49) 164/308 (53) – < 0.01
Non-cardiac admissions 222/617 (36) 84/308 (27) – –
CRT-D, n/N (%) OPT, n/N (%)
All admissions, CRT-D 15.7 months,
OPT 11.9 monthsc
372/595 (63) 199/308 (65) – 0.03
Cardiac admissions 284/595 (48) 164/308 (53) – < 0.01
Non-cardiac admissions 207/595 (35) 84/308 (27) –
a Mean.
b The authors of the COMPANION trial116 state that no significant differences were found in any of the end points for
CRT-P vs. CRT-D (no p-values reported).
c Median.
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TABLE 153 All hospitalisations: number of events and/or of days of admission
Study Outcome and follow-up CRT-P OPT Effect
95% CI;
p-value
CARE-HF109 No. of unplanned hospitalisations for a
major cardiovascular event, 29.4 monthsa
222 384 – –
COMPANION120b No. of admissions (% of total admissions), no. of average admissions per patient-year of follow-up;
CRT-P 16.2 months, OPT 11.9 monthsa
All admissions 993 (n/a), 1.25 516 (n/a), 1.59 – –
Cardiac 628 (63), 0.79 338 (75), 1.20 – –
Non-cardiac 365 (37), 0.46 126 (24), 0.39 – –
Average hospital days per patient-year of follow-up (average length of stay per admission in days);
CRT-P 16.2 months, OPT 11.9 monthsa
All admissions 8.3 (6.7) 11.0 (6.9) – –
Cardiac 5.2 (6.5) 8.1 (6.8) – –
Non-cardiac 3.2 (6.9) 2.8 (7.1) – –
No. of admissions per patient-year for a
cardiac procedure
0.13 0.24 – < 0.01
CRT-D OPT
No. of admissions (% of total admissions), no. of average admissions per patient-year of follow-up;
CRT-D 15.7 months, OPT 11.9 monthsa
All admissions 919 (n/a) 1.20 516 (n/a) 1.59 – –
Cardiac 580 (63) 0.76 338 (75) 1.20 – –
Non-cardiac 339 (37) 0.44 126 (24) 0.39 – NS
Average hospital days per patient-year of follow-up (average length of stay per admission in days);
CRT-D 15.7 months, OPT 11.9 monthsa
All admissions 8.6 (7.2) 11.0 (6.9) – –
Cardiac 5.5 (7.2) 8.1 (6.8) – –
Non-cardiac 3.8 (8.8) 2.8 (7.1) – –
No. of admissions per patient-year for a
cardiac procedure
0.09 0.24 – < 0.01
n/a, not applicable; NS, not significant.
a Median.
b The COMPANION trial116 states that no significant differences were found in any of the end points for CRT-P vs. CRT-D
(no p-values reported).
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CRT-D compared with optimum pharmacological therapy
The COMPANION trial120 reported statistically significantly fewer hospital admissions per patient-year for a
cardiac procedure in those receiving CRT-D (CRT-D 0.09 vs. 0.24 OPT; p< 0.01). The number of average
admissions per patient-year of follow-up was lower in those receiving CRT-D (CRT-D 1.20 vs. 1.59 OPT).
The average number of hospital days per patient-year of follow-up was also lower in those receiving CRT-D
(8.6 days vs. 11.0 days OPT), with the average length of hospital stay per admission similar for both
treatment groups (CRT-D 7.2 days vs. OPT 6.9 days). Those receiving CRT-D had fewer average hospital
admissions per patient-year of follow-up for cardiac causes (CRT-D 0.76 vs. OPT 1.20), but more
admissions for non-cardiac causes (CRT-D 0.44 vs. OPT 0.39). Average hospital days per patient-year of
follow-up for cardiac (CRT-D 5.5 days vs. OPT 8.1 days) and non-cardiac (CRT-D 3.8 days vs. OPT 2.8 days)
causes, and average length of stay per hospital admission for cardiac (CRT-D 7.2 days vs. OPT 6.8 days)
and non-cardiac (CRT-D 8.8 days vs. OPT 7.1 days) causes were similar for both treatment groups
(see Table 153).
CRT-P compared with CRT-D
The authors of the COMPANION study120 state that no significant differences were found in any of the
hospitalisation end points for CRT-P vs. CRT-D, but statistics were not reported.
People with both conditions
The RAFT study140 reported that a similar proportion of participants (about 56%) in each group were
hospitalised at least once (Table 154), and the majority were hospitalised for a cardiac cause (CRT-D
47.3%, ICD 44.7%; p= 0.56). All-cause hospitalisations were also similar in the MIRACLE ICD study,136
although the mean length of stay was slightly reduced with CRT-D [mean 4.8 days (SD 4.9 days) vs. mean
5.4 days (SD 4.7 days); p= 0.06]. All-cause hospitalisations were slightly lower with CRT-D in the Pinter
study139 (30.6% vs. 36.1%).
TABLE 154 All hospitalisations
Study Outcome and follow-up
CRT-D,
n/N (%)
ICD,
n/N (%) Effect
95% CI;
p-value
MIRACLE
ICD136
Hospitalisation, 6 months 85/187
(45.5)
78/182
(42.9)
– –
Length of hospital stay (days), mean (SD) 4.8
(4.9)
5.4
(4.7)
– 0.06
Pinter139 Patients hospitalised, 6 months 11/36a
(30.6)
13/36a
(36.1)
– –
RAFT140 One or more hospitalisations during follow-up
(mostly cardiovascular reasons), 40 (SD 20) monthsb
509/894
(56.9)
509/904
(56.3)
– –
Hospitalisation: cardiac cause 423/894
(47.3)
404/904
(44.7)
HR 1.04 0.56
a Numerator calculated by reviewer.
b Mean.
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Appendix 7 Data extraction: people at risk
of sudden cardiac death as a result of
ventricular arrhythmias
Amiodarone Versus Implantable Cardioverter-Defibrillator
Randomized Trial (AMIOVIRT)
Reference
and design Intervention and comparator Participants Outcome measures
Strickberger
et al. 2003,69
Wijetunga and
Strickberger,
200370
Study design:
RCT
Country: USA
No. of centres:
10
Funding:
unrestricted
research grant
from the
guidant
corporation
Intervention: ICD+OPT
(ICDs were inserted using
conventional non-thoracotomy
techniques)
Comparator:
Amiodarone+OPT
(dose: 800mg/day for first
week, 400mg/day for 1 year
and then 300mg/day)
Other interventions used: OPT
with ACE inhibitors,
beta-blockers and
potassium-sparing diuretics was
strongly encouraged and
attempted throughout the
duration of the study for
both groups
Indication for treatment:
NIDCM and asymptomatic
NSVT
No. of randomised participants:
103; ICD: 51 OPT: 52
Inclusion criteria: age ≥
18 years; NIDCM
(left ventricular dysfunction
in the absence of,
or disproportionate to the
severity of, coronary artery
disease); LVEF ≤ 0.35;
asymptomatic NSVT (three or
more consecutive ventricular
premature depolarisations with
a rate of > 100 beats per
minute, lasting < 30 seconds
and not associated with
symptoms of cerebral
hypofusion); NYHA class I–III
Exclusion criteria: syncope;
pregnancy; a contraindication
to amiodarone or defibrillator
therapy or concomitant therapy
with a class I AAD; or NIDCM
diagnosed within 6 months70
Primary outcome: total mortality
Secondary outcomes: SCD,
non-SCD, non-cardiac death,
syncope, arrhythmia-free
survival, QoL and costs
Method of assessing outcomes:
stored ECGs and all available
clinical data were used to
determine the appropriateness
of ICD therapy. Causes of death
were determined by an events
committee, with each of the
three members independently
evaluating all information
available regarding each death.
Differences in the cause of
death were adjudicated and a
consensus reached
QoL: completed by patients
both at the time of
randomisation and during
follow-up visits:
l QWBS – score range 0–110
(higher level of general
well-being associated with
a higher value)
l STAI – score range 40–160
(higher value associated
with lower level of anxiety)
Cost analysis: in- and outpatient
costs for the 24 patients based
on University of Michigan health
system for 1 year starting at
study entry (not data extracted)
continued
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Reference
and design Intervention and comparator Participants Outcome measures
Amiodarone group: assessed for
thyroid function and aspartate
and alanine transaminase
plasma levels; chest radiograph
obtained at baseline and every
4 months during follow-up;
serum concentrations of
amiodarone and
desethylamiodarone were
obtained 4 months and 1 year
after initiation of treatment
(until 30 June 2001)
ICD group: defibrillator
follow-up was performed every
4 months, including evaluation
of stored ECGs and sensing and
pacing functions
Definitions: arrhythmia-free
survival: freedom from death,
syncope, appropriate ICD
therapy and sustained VT or VF
Length of follow-up: mean
duration 2.0 years (SD 1.3 years,
range 0.1–4.8 years);
ICD 2.2 years (SD 1.2 years);
amiodarone 1.8 years
(SD 1.4 years), p= 0.4
Recruitment:
August 1996–September 2000
NIDCM, non-ischaemic dilated cardiomyopathy.
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Participant characteristics
Characteristic ICD (n= 51) Amiodarone (n= 52) p-value
Age (years), mean (SD) 58 (11) 60 (12) 0.5
Sex, % male 67 74 0.3
Ethnicity NR NR
NYHA classification, % 0.9
I 18 13
II 64 63
III 16 24
LVEF, mean (SD) 0.22 (0.10) 0.23 (0.08) 0.5
Heart rate (bpm), mean (SD) 80 (17) 78 (14) 0.7
RBBB, % 16 8 0.2
LBBB, % 42 53 0.3
Electrophysiology findings
No. of beats of NSVT, mean (SD) 8 (7) 12 (21) 0.2
NSVT (bpm), mean (SD) 160 (27) 151 (20) 0.4
NSVT identified, % 0.7
ECG 6 8
Event monitor 26 29
Holter monitor 6 2
Hospital telemetry 62 61
Current pharmacological therapy NR NR
Duration of NIDCM (years), mean (SD) 2.9 (4.0) 3.5 (3.9) 0.6
CAD > 70%,a n/N (%) 2/41 (4.9) 3/27 (11.0) 0.3
Cardiac history
Previous treatment NR NR
Comorbidities
Diabetes mellitus, % 31 36 0.6
Hypertension, % 58 67 0.4
QWBS, mean (SD) 67 (15) 70 (17) 0.5
STAI, mean (SD) 75 (25) 79 (21) 0.5
bpm, beats per minute; CAD, coronary artery disease; NIDCM, non-ischaemic dilated cardiomyopathy; NR, not reported;
RBBB, right bundle branch block.
a CAD> 70%= one major epicardial coronary artery with stenosis ≥ 70%.
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Results
Outcome ICD (n= 51) Amiodarone (n= 52) p-value
Primary outcome total mortality, n (%) 6 (11.8) 7 (13.5) 0.8
Secondary outcomes
Cardiac deaths, n (%) 4 (67) 5 (71) 0.9
SCD 1 (25) 2 (40) 0.7
Non-SCD 3 (75) 3 (60) 0.7
Survival rate, %
At 1 year 96 90 0.8
At 3 years 88 87
Arrhythmia-free survival rate, %
At 1 year 78 82 0.1
At 3 years 63 73
Non-cardiac death, n (%) 2 (33) 2 (29) 0.9
Cardiac transplant, n (%) 1 (2) 2 (4) 0.8
Syncope, % 3.9a 5.8 0.7
HRQoL
QWBS 1 year, mean (SD) 74 (19) 70 (22) 0.5b
STAI 1 year, mean (SD) 61 (17) 67 (20) 0.4b
a VT or VF was the cause of syncope in each ICD patient in whom it occurred.
b p-values were also reported within groups (not data extracted).
Comments
l Kaplan–Meier estimates of cumulative survival and arrhythmia-free survival also displayed in figures for 0–55 months.
l At 1 year, the QWBS and STAI scores were not significantly different between patients treated with an ICD who
did [67 (SD 15) and 73 (SD 22) respectively] and did not [68 (SD 16) and 82 (SD 31) respectively; both p= 0.05)]
receive appropriate ICD therapies.
l Cost of medical care reported but not data extracted.
Concomitant drug therapy at last follow-up
Drug therapy ICD (n= 51) Amiodarone (n= 52) p-value
Beta-blocker, % 53 50 0.5
ACE inhibitor, % 90 81 0.4
Digoxin, % 71 67 0.5
Diuretic, % 71 67 0.5
Spironolactone, % 20 19 0.9
Comment
l Amiodarone group: mean dose at the conclusion of the study: 303 (SD 93) mg/day. The serum concentrations of
amiodarone and desethylamiodarone at 4 and 12 months were also reported (not data extracted).
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Adverse effects of treatment
25 patients discontinued amiodarone because of adverse side effects (mean 17.8, SD 13.3, range 1.2–43.8 months)a
a States in the discussion that amiodarone was discontinued in one-third of patients but data not reported per
treatment group.
Comments
l All ICD implants were successful.
l An appropriate ICD therapy was delivered in 16 patients for ventricular arrhythmias, which had a mean rate of 218
(SD 40, range 170–284) beats per minute.
Comments
Methodological comments
l Allocation to treatment groups: randomisation was stratified by centre (patients who refused study
participation were followed in a voluntary registry).
l Blinding: unblinded trial. Assessors for causes of death were blinded (independent events review
committee) and all references to amiodarone or ICD therapy were removed from the reviewed documents
(including the death certificate, other relevant medical records and interviews with family members).
l Comparability of treatment groups: There were no statistically significant differences at baseline between
the treatment groups.
l Method of data analysis: patients who underwent cardiac transplantation were censored from data analysis
beginning on the day of transplantation. All analyses were based on ITT. Primary and secondary end points
were compared between the two groups with a log-rank test, and survival curves were constructed using
Kaplan–Meier methods. Continuous variables are expressed as mean± 1 SD and were compared using the
Student’s t-test, except for comparisons between baseline and 1-year QoL scores within the two study
groups, which were compared with a paired t-test. A chi-squared or Fisher’s exact test was used to
compare nominal variables. A p-value of < 0.05 was considered statistically significant. A data safety
monitoring board evaluated the results every 10 deaths. Prospectively determined stopping rules consisted
of a mortality difference at a significance level of < 0.025, or a significance level of> 0.025 (90% power)
based on a power calculation conditional on holding outcomes stable and assuming enrolment of
600 patients. At the first interim analysis in September 2000, the study enrolment was discontinued
because the prospective stopping rule for the inability to demonstrate statistical significance was reached.
l Sample size/power calculation: during the anticipated follow-up duration of 2 years, the expected total
mortality rates were 20% in the amiodarone group and 10% in the ICD group. An 80% power to identify
a reduction in total mortality from 20% to 10% was calculated to require 219 patients in each group
(p< 0.05, two-sided t-test).
l Attrition/dropout: states that no patients were lost to follow-up. Amiodarone: crossover from amiodarone
to ICD (n= 8): near-syncope with documented VT (n= 2), cardiac arrest (n= 2) or amiodarone intolerance
(n= 4); ICD insertion (months): mean 26.1 (SD 16.9) after study entry. ICD patients also receiving
amiodarone (n= 11): frequent appropriate defibrillator therapies (n= 1; 200mg/day, SD 0mg/day), atrial
fibrillation (n= 8; 200mg/day, SD 0mg/day), other reasons (n= 2; 150mg/day, SD 71mg/day).
General comments
l Generalisability: only to patients with NIDCM and asymptomatic NSVT.
l Outcome measures: appear appropriate.
l Intercentre variability: not reported.
l Conflict of interests: none reported, but supported by grant from Guidant Corporation.
NIDCM, non-ischaemic dilated cardiomyopathy.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence
generation
Unclear Randomly assigned and stratified by centre, but no details of
sequence generation
Allocation concealment Unclear Not reported
Performance bias
Blinding of participants and personnel
Mortality High No blinding
QoL High May be influenced by lack of blinding
Detection bias
Blinding of outcome assessment
Mortality Low Members of independent events review committee assessing causes of death
were blinded
QoL High May be influenced by lack of blinding
Attrition bias
Incomplete outcome
data addressed
Low States that all analyses were based on ITT; no patients lost to follow-up
Reporting bias
Selective reporting Low No study protocol available but results for specified primary and secondary
outcomes were reported
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Antiarrhythmics Versus Implantable Defibrillators (AVID) trial
Reference
and design
Intervention
and comparator Participants Outcome measures
AVID investigators
1997,71 1999,72
Hallstrom 1995,73
Schron et al.
200274
Study design: RCT
Countries: USA
and Canada
No. of centres: 56
(53 USA, three
Canada)
Funding: National
Heart, Lung, and
Blood Institute,
Bethesda, MD;
contract
N01-HC-25117
Intervention: ICDs; investigators
chose any ‘state-of-the-art’ ICD
meeting prespecified criteria
Comparator: best
contemporary AADs.
Consideration of the use of
sotalol left to physician
judgement. If patients eligible
for sotalol a second
randomisation assigned them
to either amiodarone
(doses determined empirically)
or sotalol (guided by
electrophysiological testing,
Holter monitoring or both)
Other interventions used:
aspirin, beta-blockers and
ACE inhibitors when
clinically appropriate
Indication for treatment:
resuscitated from near-fatal VF;
or symptomatic sustained VT
with hemodynamic compromise
No. of randomised participants:
1016; ICD: 507 (93%
non-thoracotomy lead system,
5% epicardial system, 2% no
device implanted), AAD: 509
[356 began immediate
treatment with amiodarone;
remaining 153 randomised to
amiodarone (n= 79) or sotalol
(n= 74)]
QoL substudy:74 800; ICD: 416,
AAD: 384
Inclusion criteria: VF, VT with
syncope or VT without syncope
but with ejection fraction
≤ 0.40 and systolic blood
pressure < 80mmHg, chest
pain or near syncope.73 If
patients underwent
revascularisation their ejection
fraction had to be ≤ 0.40
Exclusion criteria:
contraindication to amiodarone
or ICD therapy, transient or
correctable cause identified for
the arrhythmia, CABG or
percutaneous transluminal
coronary angioplasty planned
and ejection fraction > 0.40,
left ventricular aneurysm
surgery planned or performed
since index event, recent
amiodarone exposure
(definition provided), long QT
syndrome, atrial fibrillation or
other supraventricular
arrhythmia requiring class I or III
antiarrhythmic agents,
bradycardia or heart block
without permanent pacemaker,
NYHA class IV HF, life
expectancy < 1 year73
Primary outcome:
overall mortality
Secondary outcomes:
cost, QoL
Other: ICD shock, sustained
arrhythmia, syncope
Method of assessing
outcomes: patients evaluated
every 3 months and at the
time of events. Cause of death
reviewed by events committee
QoL substudy74 at baseline
(before randomisation) and 3,
6 and 12 months
after randomisation:
l SF-36: overall score, PCS
and MCS, score range
0–100; higher scores
indicate superior QoL
l the 46-item patient
concerns checklist (disease
specific), score range
0–46; higher sores indicate
increased concern and
poorer QoL
l cardiac version of the QoL
index, score range 0–30;
higher score indicates
superior QoL (this measure
administered at baseline
and 12 months only)
Defibrillator shocks categorised
as appropriate or inappropriate
on the basis of clinical
presentation, R–R intervals
and ECGs
Length of follow-up: mean
18.2 (SD 12.2) months. For
QoL substudy74 follow-up was
1 year
Recruitment: 1 June 1993 to
7 April 1997
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Main study
Participant characteristics
Characteristic ICD (n= 507) AAD (n= 509) p-value
Age (years), mean (SD) 65 (11) 65 (10)
Sex, % male 78 81
Ethnicity, % white 87 86
Index arrhythmia VF, n 226 229
Index arrhythmia sustained VT, n 281 280
CHF at enrolment, %
No CHF 45 40
NYHA class I or II 48 48
NYHA class IIIa 7 12
Angina at enrolment, %
No angina 64 65
CCS class I or II 34 33
CCS class III 2 2
LVEF, mean (SD) 0.32 (0.13) 0.31 (0.13)
Median time from index event to measurement (days) 3 3
Findings on baseline ECGb
Heart rate (bpm), mean (SD) 77 (18) 78 (17)
PR interval (milliseconds), mean (SD) 178 (37) 183 (37)
QRS complex (milliseconds), mean (SD) 116 (26) 117 (26)
Corrected QT interval (milliseconds), mean SD 441 (40) 445 (39)
Paced, % 3 4
Bundle branch block, % 23 25
Clinical history before index arrhythmia, %
Atrial fibrillation or fluttera 21 26
VF 5 5
VT 14 15
Unexplained syncope 11 15
Coronary artery disease 81 81
MI 67 67
CHF 46 47
Hypertension 55 56
Diabetes 25 24
Angina 48 50
Peripheral vascular disease 16 15
AAD therapy 16 15
Coronary revascularisation during hospitalisation for the
index arrhythmia, %
10 12
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ICD (n= 497) AAD (n= 496)
Therapy at discharge, %c
ICD 98.6 1.4
Amiodarone 1.8 95.8
Sotalol 0.2 2.8
Beta-blocker 42.3 16.5 < 0.001d
Calcium channel blocker 18.4 12.1
Both beta-blocker and calcium channel blocker 5.3 2.4
Digitalis 46.8 40.6 0.04d
Diuretic agent 48.2 50.7
Other AAD 4.2 1.2
ACE inhibitor 68.8 68.2
Nitrate 36.4 37.0
Other antihypertensive agent 7.6 8.8
Lipid-lowering agent 13.2 11.5
Acetylsalicylic acid (aspirin) 60.7 59.2
Warfarin 21.9 34.8
bpm, beats per minute; CCS, Canadian Cardiovascular Society.
a Paper stated that baseline characteristics are similar in the two groups except for NYHA class III HF and history of atrial
fibrillation or flutter.
b Recorded when patients were taking no AADs and without cardiac pacing.
c 23 patients are excluded: 19 who died while in hospital after the index event and four who were still in hospital at the
termination of the study.
d Unclear in paper whether p-value applies at discharge or 12 or 24 months’ follow-up or overall.
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Results
Outcome ICD (n= 507) AAD (n= 509) p-value
Deaths, n/N 80/507 122/509 < 0.012
Cause of death, n72
Cardiac death 63 94
Arrhythmic 24 55
Non-arrhythmic 39 39
Non cardiac death 17 28 (three attributed to
pulmonary toxicity
from amiodarone)
0.053; RR 1.78
(95% CI 0.98
to 3.26)
Crude death rate (±95% CI) over mean
follow-up of 18.2 (SD 12.2) months, %
15.8 (±3.2) 24.0 (±3.7)
Survival free of cardiac death72 (non-cardiac
deaths censored), %
0.0042
At 1 year 90.9 85.1
At 2 years 85.0 81.2
Survival to arrhythmic death72 (non-cardiac
and non-arrhythmic deaths censored), %
0.0002
At 1 year 96.6 91.9
At 2 years 94.2 89.1
Survival free of non-arrhythmic cardiac
death (non-cardiac and arrhythmic
deaths censored)
Presented in figure only Presented in figure only 0.8039
Overall survival through the course of
study, %
< 0.02 in favour
of ICD
Patients surviving at 1 year 89.3 82.3
Patients surviving at 2 year 81.6 74.7
Patients surviving at 3 year 75.4 64.1
Cumulative % of patients with any
activation of the ICD (antitachycardia pacing
or shock)
Index VFa Index VTa < 0.001 for VT
vs. VF
At 3 months 15 36
At 1 year 39 68
At 2 years 53 81
At 3 years 69 85
% of patients rehospitalised
(denominator n= 1011)
0.04
At 1 year 59.5 55.6
At 2 years 74.8 64.7
At 3 years 83.3 75.5
Change in NYHA class NR NR
Change in LVEF NR NR
Exercise capacity outcomes NR NR
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Outcome ICD (n= 507) AAD (n= 509) p-value
Crossover rate, %
At 1 year 17.7 12.6 < 0.001
At 2 years 25.7 18.9
At 3 years 33.7 24.3
Therapy at follow-up, % 12 months
(n= 338)
24 months
(n= 171)
12 months
(n= 306)
24 months
(n= 162)
ICD 97.9 95.7 9.5 9.8
Amiodarone 8.3 9.3 84.7 82.4
Sotalol 1.8 3.1 5.8 8.5
Beta-blocker 38.1 39.4 11.0 10.1
Calcium channel blocker 22.9 19.4 16.6 14.1
Both beta-blocker and calcium
channel blocker
6.8 5.6 2.1 0.7
Digitalis 45.8 44.4 37.9 32.3
Diuretic agent 56.0 56.9 59.3 56.4
Other AAD 7.1 10.0 3.8 4.0
ACE inhibitor 68.4 68.1 65.5 63.1
Nitrate 29.1 28.1 27.9 29.5
Other antihypertensive agent 9.0 10.0 9.4 6.1
Lipid-lowering agent 19.5 23.1 17.2 19.5
Acetylsalicylic acid (aspirin) 55.4 62.5 55.4 56.4
Warfarinftsa 24.8 22.5 35.4 30.2
NR, not reported.
a Numbers not reported. It is not clear whether events reported are for the ICD group only or for the whole trial
population (i.e. including participants in the AAD group who received an ICD during the course of the study).
Comments
l A Kaplan–Meier plot of overall survival is presented. The survival figures represent a decrease in death rate
(±95% CI) of 39± 20%, 27± 21% and 31± 21% at 1, 2 and 3 years respectively. The authors note that the accuracy
of long-term data is limited because few patients had been followed beyond 2 years at the time that the study ended.
The average unadjusted length of additional life with an ICD (not clear if just those in the ICD group or all those with
an ICD in the study) was 2.7 months at 3 years.
l The location of death (in hospital or out of hospital) and whether or not death was witnessed was also reported but
has not been data extracted. Causes of non-cardiac death were also reported but have not been data extracted.
l A plot of time to first rehospitalisation is presented but has not been data extracted. Five patients are excluded
(baseline overall n= 1011) because they were still hospitalised for the index arrhythmia at the time that the study was
stopped. The groups that these patients were in are not reported.
l The study reports the daily maintenance doses of amiodarone and sotalol received by participants during follow-up;
however, it is not clear whether these data are reported only for those in the ADD group or for the whole trial
population. The mean (SD) daily dose of amiodarone decreased during the study [389 (112) mg at 3 months,
331 (99) mg at 1 year, 294 (94) mg at 2 years, 256 (95) mg at 3 years]. Of the patients receiving amiodarone at
discharge, 87% continued it at 1 year and 85% at 2 years. These percentages differ from those given above (therapy
at follow-up). The mean (SD) daily dose of sotalol was stable during the study [258 (81) mg at 3 months, 248 (88) mg
at 1 year, 280 (121) mg at 2 years, 240 (113) mg at 3 years].
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Adverse effects of treatment
Adverse effect ICD Amiodarone Sotalol p-value
Non-fatal torsade de pointes VT, n 1
Suspected pulmonary toxicity in patients treated with amiodarone, %
At 1 year 3
At 2 years 5
Death from pulmonary toxicity, n 1
Thyroid replacement medication, %
At 1 year 1 10
At 2 years 1 16
Death within 30 days of initiation of therapy, n/N (%)a 12/507 (2.4) 18/509 (3.5) 0.27
Bleeding requiring reoperation or transfusion, n 6
Serious haematoma, n 13
Infection, n 10
Pneumothorax, n 8
Cardiac perforation, n 1
Early dislodgement or migration of leads, n 3
Unsuccessful first attempt at ICD implantation without
thoracotomy, n
5b
Overall rate of non-fatal complications of implantation, %
(reported in discussion)
5.7
a Or by the time of hospital discharge if discharge occurred later than 30 days after therapy began.
b Unsuccessful in four patients because of an excessively high defibrillation threshold and in one because of cardiac
perforation. Three of the five patients subsequently underwent successful implantation.
Comments
l Two linked excluded studies, Kron et al.234,235 provide data on lead- and device-related complications, including time-to-
event data with Kaplan–Meier curves, but these data have not been extracted.
l A linked excluded study, Klein et al.,236 provides data on events triggering ICD or antitachycardia pacing, reviewing
whether therapy was appropriate and what the results were. This has not been data extracted.
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Subgroup data71
Subgroup HR 95% CI p-value
Age (years)
< 60 0.57 0.31 to 1.05
60–69 0.63 0.38 to 1.04
≥ 70 0.67 0.44 to 1.00
LVEF
> 0.35 0.86 0.47 to 1.61
≤ 0.35 0.57 0.41 to 0.79
Cause of arrhythmia
Coronary artery disease 0.62 0.46 to 0.86
Other 0.62 0.28 to 1.35
Rhythm
VF 0.57 0.38 to 0.86
VT 0.68 0.46 to 1.02
Overall 0.62 0.47 to 0.83
Comments
l HRs and 95% CIs estimated from a figure in the paper using Enguage digitising software. Numbers in each subgroup
were not reported.
l No subgroup differed significantly from the entire population. The early termination of the study diminished its power
to detect differences between the subgroups.
l Multivariate analysis showed that the beneficial effect of the implantation of an ICD persisted after adjustment for
other factors (e.g. age, beta-blockers, CHF, ejection fraction). Revascularisation after the index arrhythmia did not alter
survival (data not reported in paper).
l When the Cox model was used to adjust for baseline differences in the presence or absence of HF, the ejection fraction
and history of atrial fibrillation, the estimates indicated that reductions in mortality (±95% CIs) attributable to the
ICD were 37± 22% at 1 year, 24± 22% at 2 years and 29± 33% at 3 years. Estimates adjusted for the use of
beta-blockers were unchanged from the unadjusted values (data not reported in paper).
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Subgroup data72
Outcomes
Index arrhythmia VF
(n= 455 at baseline)
Index arrhythmia VT
(n= 561 at baseline) p-value
Survival free of arrhythmic death Improved by the ICD for patients whose presenting arrhythmia was VT
(p= 0.025) or VF, with twice as many deaths in the AAD group
(p= 0.0019). Survival curves presented but not extracted
Non-arrhythmic cardiac death No difference in survival between ICD and AAD groups in patients with
either VT (p= 0.72) or VF (p= 0.98)
Quality-of-life substudy74
Participant characteristics
Characteristic ICD (n= 416) AAD (n= 384) p-value
Age (years), mean (SD) 64.3 (10.5) 64.7 (10.1) 0.5
Sex, % male 81.3 80.5 0.8
Ethnicity, % white 89.7 88.0 0.5
Live with spouse partner, % 72.6 70.6 0.5
High-school graduate, % 74.0 74.5 0.9
Index arrhythmia VF, % 43.5 42.4 0.8
LVEF, mean (SD) 0.33 (0.13) 0.32 (0.14) 0.6
History of HF, % 44.5 41.1 0.3
Discharge beta-blocker use, % 43.0 16.4 < 0.001
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Results
Outcome ICD (n= 416) AAD (n= 384) p-value
SF-36 PCS score, mean (SD)
Baseline 37.4 (10.9) 36.5 (11.2) 0.3
12 months 40 (10.5) 38 (17)
SF-36 MCS score, mean (SD)
Baseline 45.9 (11.8) 47.5 (11.5) 0.006
12 months 49 (16.5) 48 (17)
Patient concerns checklist, mean (SD)
Baseline 15.9 (8.6) 16.2 (8.9) 0.06
Follow-up NR NR 0.1
QoL index baseline, mean (SD) 22.1 (4.9) 21.9 (5.0) Similar at baseline
and follow-up
Impact of adverse symptoms on QoLa
SF-36 PCS score –2.25 (–3.32, –1.18),
p< 0.001
–1.64 (–2.89, –0.41),
p= 0.009
SF-36 MCS score –2.32 (–3.76, –0.88),
p= 0.002
–0.51 (–1.97, 0.94),
p= 0.5
Patient concerns 1.84 (0.91, 2.76),
p< 0.001
0.91 (0.07, 1.75),
p= 0.03
Impact of ICD shocks on QoLa,b
SF-36 PCS score –1.45 (–2.74, –0.18),
p= 0.03
SF-36 MCS score –1.82 (–3.56, –0.08),
p= 0.04
Patient concerns 2.15 (1.07, 3.23),
p< 0.001
ICD shocksb
Experienced one or more shocks during first
year of follow-up, n/N (%)
144/373 (39)
Experienced one or two shocks 71/144 (49)
Experienced three or more shocks 73/144 (51)
Proportion of shocks considered appropriate, % 94
NR, not reported.
a Multivariate analysis with model comparing any adverse events/ICD shock vs. none. Model includes age, sex, race, index
arrhythmia, ejection fraction, history of HF and use of beta-blockers at hospital discharge. Unit for outcome not given;
assumed to be mean impact (change) in QoL score with 95% CI.
b Complete data on shocks available for 373/416 (90%) ICD recipients in the QoL substudy.
Comments
l Values in italics obtained from figure in paper using Enguage software. Subgroup analysis of patients discharged with
and without beta-blockers not data extracted.
l The occurrence of one or more vs. no shocks was independently associated with significant reductions in mental
well-being and physical functioning and an increase in patient concerns. The development of more frequent shocks
(three of more vs. less than three) was associated with similar alterations in self-perceived QoL (numerical data not
presented in paper).
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Comments
Methodological comments
l Allocation to treatment groups: stratified by clinical site and index arrhythmia.73 AAD group subrandomised
to empirical amiodarone or Holter-/electrophysiology-guided sotalol (if no contraindications to sotalol,
otherwise assigned to amiodarone).71
l Blinding: not stated but presume unblinded because only one group received an ICD and implantation of
this requires an operation. The primary end point of overall mortality not likely to be affected by bias.
Cause of death analysis was blinded. All references to therapy with either ICD or AAD were removed from
medical records sent to the clinical trial centre. In addition, ‘sham blinding’ was performed to try and mimic
the removal of items that would have been deleted if the patient had been randomised to the alternative
arm. The committee judging cause of death knew that sham blinding could occur.
l Comparability of treatment groups: described as similar except for history of atrial fibrillation or flutter and
NYHA class III HF. Also, more patients were taking beta-blockers (p< 0.001) and slightly more were taking
digitalis (p= 0.04) in the ICD group at discharge than in the AAD group (see footnote d in Participant
characteristics). Adjusting for the difference in beta-blocker use in the Cox regression analysis slightly
reduced the estimated beneficial effect of ICD on survival (unadjusted HR for ICD vs. AAD 0.62, adjusted
HR 0.67). In the QoL substudy baseline characteristics were similar except that patients in the ICD group
were more often discharged with beta-blocker therapy.
l Method of data analysis: the null hypothesis was that there was no difference in overall mortality between
therapy with an ICD and AAD therapy. Analysis was by ITT for overall mortality, QoL and costs;73 however,
it is clear from the numbers reported that for other outcomes analysis was not by ITT. Significance was
based on a two-sided alpha level of 0.05 for comparisons of survival distributions. At the end of the pilot
phase sequential data monitoring was performed every 6 months. Criteria for termination of the study
were based on an O’Brien–Fleming spending function, which requires a substantial difference between
treatment groups to stop the study early (referenced). Subgroup analyses were to be specified early in the
course of the second phase (after the pilot phase with the first 200 participants), and the intention was to
limit severely the numbers of a priori subgroup analyses.73 Two subgroup analyses are specified: index
arrhythmia (VF vs. VT) and cardiac substrate (coronary artery disease vs. cardiomyopathy). In the QoL
substudy74 both appropriate and inappropriate shocks were included in the analysis. Because follow-up QoL
values cannot be reliably defined for patients who die before reassessment the primary analyses were
limited to patients who survived for 1 year after randomisation. Secondary sensitivity analyses included all
QoL substudy participants. A chi-squared test or t-test was used for pairwise comparisons. Generalised
estimating equations were used to model change in QoL scores over time to account for correlation of
individual values and to deal with missing follow-up data. Separate models were used for PCS, MCS and
patient concerns checklist scores. Models were adjusted for baseline characteristics of age, sex, race, living
alone vs. with a spouse or partner, index arrhythmia, ejection fraction, history of HF and beta-blocker use
to assess the independent relationship of variables with QoL. All analyses were ITT and p≤ 0.05 was
considered significant.
l Sample size/power calculation: a sample size of 1200 patients was estimated, assuming an average
follow-up of 2.6 years and an event rate of 40% in the AAD group at 4 years, to detect a 30% decrease
in mortality. The data and safety monitoring board recommended stopping the trial on 7 April 1997
when analysis revealed that the difference in the primary outcome variable between the two groups had
crossed the statistical boundary for early termination of the study (1016 patients had been randomised).
l Attrition/dropout: in 2% of the ICD group no device was implanted. In the AAD group 13/74 patients
assigned to sotalol had adequate suppression of arrhythmia and were receiving sotalol at discharge. The
remaining 61/74 patients randomised to sotalol received amiodarone (n= 58), another AAD (n= 1) or an
ICD (n= 2). 25.7% of ICD group and 18.9% of AAD group crossed over to the other therapy by 24
months. The crossover rate was higher among those initially assigned to therapy with an ICD (p< 0.001).
States that rates of crossover did not compromise the power of the study and that most crossovers
occurred because arrhythmia recurred, rather than because of intolerance to either drugs or devices.
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QoL substudy:74 of the 1016 participants randomised in the main study, 905 (89%) completed at least one QoL
assessment in the first year of follow-up and most of these (800/905, 88%) survived for 1 year and were
included in the analyses of QoL (n= 416 in the ICD group and n= 384 in the AAD group). Complete QoL data
were available for most patients at each time point; more data were missing at later compared with earlier
assessments. Most (49%) incomplete data were missing because collection fell outside the specified time
period. Details reported (not extracted) for whole study (but not for treatment groups).
General comments
l Generalisability: in the discussion of the paper it is noted that data in the AVID registry show that the
clinical characteristics of patients included in the trial were similar to those who were not included and
therefore the AVID study authors believed that the population studied was representative of the general
population of patients who are resuscitated from VF or who have symptomatic, sustained VT.
QoL substudy:74 there were differences between the 905 participants who completed at least one QoL
assessment and those in the trial as a whole. QoL substudy participants were younger on average
(65 vs. 68 years) and more likely to be male (81% vs. 70%), white (88% vs. 70%) and living with a spouse or
partner (71% vs. 51%) and to have graduated from high school (73% vs. 42%) than 111 non-participants.
Also reports differences between those who died in the first year vs. those who survived.
l Outcome measures: appear appropriate. For the QoL substudy74 definitions and categorisation of
symptoms provided.
l Intercentre variability: not discussed.
l Conflict of interests: no conflicts of interest statement made.
l Other: a registry was maintained for all patients who qualified for the study but did not undergo
randomisation to compare the randomised and non-randomised patients. The registry also followed
patients with VF or VT who were not eligible for randomisation. Data on long-term mortality among the
non-randomised patients could be obtained from the National Death Index.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear ‘Allocation is stratified by clinical site and index arrhythmia (ventricular
fibrillation or ventricular tachycardia)’.73 No other information provided
Allocation concealment Unclear No information provided
Performance bias
Blinding of participants
and personnel
High Not explicitly stated but presume unblinded (because only one of the
two groups received an ICD). QoL self-assessment by participants at risk
of bias because of knowledge of intervention received
Detection bias
Blinding of outcome assessment
Overall mortality and cause
of death
Low For overall mortality outcome risk of bias likely to be low in an
unblinded study. Committee judging causes of death were blinded to
the participant group
QoL High
Attrition bias
Incomplete outcome data
addressed – overall mortality
Low ‘Analysis was performed according to the intention-to-treat principle’.71
Although there were crossovers between groups, no dropouts are
recorded in the paper
Incomplete outcome data
addressed – QoL
High The QoL substudy did not include all randomised participants and there
were some differences between those completing the QoL substudy and
the whole trial population. In addition, data from those who completed
the baseline QoL assessment but died within a year could not be
included in the QoL assessment, which may be another source of bias
Reporting bias
Selective reporting Low Paper available describing rationale, design and methods for the study
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Coronary Artery Bypass Graft (CABG) Patch trial
Reference and design
Intervention
and comparator Participants Outcome measures
Bigger et al. 1997,75–78
Namerow et al. 1999,80
Spotnitz et al. 199879
Study design: RCT
Countries: USA and
Germany
No. of centres: 37 (USA 35,
Germany two)
Funding: National Heart
Lung and Blood Institute
grants HL-48120 and
HL-48159 and a grant from
Guidant Corporation/CPI,
St Paul, MN
Intervention: ICD: epicardial
defibrillator. Leads and
pulse generators provided
by Guidant Corporation/CPI
(St Paul, MN). Most were
committed devices
(i.e. deliver a shock even if the
arrhythmia stops before the
end of charging) that were
not capable of storing ECGs
Comparator: control group,
OPT (subject to caveats
described below). No
defibrillator therapy75 and
no specific therapy for
ventricular arrhythmias237
Other interventions used:
ICD group: the protocol
prohibited the use of AADs
for asymptomatic
ventricular arrhythmias and
specified that patients
without contraindications
should be treated with
aspirin. Clinical advice has
indicated that, although the
drug therapy received was
lower than current
standards (especially for
statin use) for a trial
conducted at this time,
it would have been
considered OPT
Indication for treatment:
patients scheduled for
CABG surgery and at risk
for sudden death (LVEF
< 0.36 and abnormalities
on an ECG). Prophylactic
No. of randomised
participants: 900;
ICD: 446, control: 454
Inclusion criteria:
scheduled for CABG
surgery, < 80 years old,
LVEF < 0.36, marker of
arrhythmia: abnormalities
on an ECG (duration
filtered QRS complex
≥ 114milliseconds;
root mean square
voltage in the terminal
40milliseconds of the QRS
complex < 20 µV; or
duration of the terminal
filtered QRS complex at
< 40 µV> 38milliseconds)
Exclusion criteria: history
of VT or VF, diabetes
mellitus with poor blood
glucose control or
recurrent infections,
previous or concomitant
aortic or mitral valve
surgery, concomitant
cerebrovascular surgery,
serum creatinine > 3mg/dl
(265mmol/l), emergency
coronary bypass surgery,
non-cardiovascular
condition with expected
survival < 2 years, inability
to attend follow-up visits
Primary outcome: mortality
Secondary outcomes: not
explicitly stated but QoL and
adverse events reported
Method of assessing
outcomes: follow-up visits
every 3 months
QoL study:80 single
assessment at 6 months
included (1) seven of the
subscales of the SF-36:
general health, physical
functioning, physical role
functioning, bodily pain,
social functioning,
emotional role functioning,
mental health; for each
subscale a raw score is
transformed to a 0–100
scale; (2) health transition
variable with five response
categories (higher score
represents perception that
heath status has become
worse); (3) items on
employment status and
body image (two two-item
scales: satisfaction with
appearance and satisfaction
with scar; higher scores=
greater satisfaction)
Length of follow-up:
mean of 32 months
Recruitment: pilot study
from 14 August 1990,
full-scale study from 1993.
Final enrolment 5 February
1996.80 Study data reported
on 30 April 1997 for main
trial publication75
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Participant characteristics
Characteristica ICD (n= 446) Control (n= 454) p-value
Age (years), mean (SD) 64 (9) 63 (9)
Sex, male/female, n 386/60 373/81
Ethnicity, %80 NS
White 88 86
African American 7 10
Other 5 4
LVEF, mean (SD) 0.27 (0.06) 0.27 (0.06)
Heart rate (bpm), mean (SD) 79 (15) 79 (14)
Findings on 12-lead ECG, %
Duration of QRS complex> 100milliseconds 71 74
LBBB 10 12
Q-wave MI 52 53
Cardiovascular history, %
Cigarette smoking at any time 79 76
Angina pectoris 76 76
MI 83 82
Two or more previous MIs 30 33
HF 51 49
Treatment for HF 49 47
NYHA functional class II or III 71 74
Treatment for hypertension 54 52
Diabetes mellitus 36 40
Diabetes treated with insulin 17 20
Treatment for ventricular arrhythmias 7 7
PTCA or atherectomy 11 11
CABG surgery 12 10
Electronic cardiac pacemaker 2 2
Systolic blood pressure (mmHg), mean (SD) 126 (19) 123 (19)
Pulmonary rales, % 20 25
S3 gallop, % 14 11
Left ventricular end-diastolic pressure (mmHg), mean (SD) 21 (10) 22 (10)
Findings on coronary angiography, %
One-vessel disease 8 9
Two-vessel disease 36 36
Three-vessel disease 55 55
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Characteristica ICD (n= 446) Control (n= 454) p-value
ICD (n= 430) Control (n= 442)
Drug therapy at hospital discharge, % of patientsb
Oral AADs
None 63.3 65.2
Class I drugs 16.7 12.0
Amiodarone 3.7 3.2
Sotalol 0.5 0.2
Beta-blockers (not sotalol) 17.9 24.0
ACE inhibitors 54.7 53.8
Diuretics 57.2 47.1
Digitalis 68.6 64.5
Nitrates 8.1 8.1
Calcium channel blockers 10.5 7.0
Antiplatelet drugs 82.8 85.1
Oral anticoagulants 15.3 14.7
Lipid-lowering drugs 9.5 8.4
bpm, beats per minute; NS, not significant; PTCA, percutaneous transluminal coronary angioplasty.
a Baseline data for marital status, educational attainment, employment status and occupational status are reported in the
paper describing QoL outcomes;80 these characteristics did not differ between the groups and have not been
data extracted.
b Data were not available for all patients.
Comment
l States that there was no significant difference between the two groups for the variables listed. States that the use of
cardiac drugs was similar at the time of discharge.
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Results
Outcome ICD (n= 446) Control (n= 454) p-value
Deaths in the first 30 days after
randomisation, n (%, calculated
by reviewer)
24 (5.4) 20 (4.4) 0.60
aDeaths during mean (SD) follow-up of
32 (16) months,78 n
102 96
Mechanism of death,78 n/N (%)
Cardiac 76/102 (74.5) 79/96 (82.3)
Primary arrhythmic 13/102 (12.7) 22/96 (22.9) Arrhythmic deaths
15% vs. 29%,
χ2= 5.10, p= 0.024Secondary arrhythmic 2/102 (2) 6/96 (6.3)
Non-arrhythmic, cardiac 57/102 (55.9) 46/96 (47.9)
Myocardial pump failure 30/102 (29.4) 23/96 (24.0) χ2= 0.75, p= 0.358
Cardiac procedure 27/102 (26.5) 23/96 (24.0)
Unwitnessed, cardiac 0 2/96 (2.1)
Uncertain, cardiac 4/102 (3.9) 3/96 (3.1)
Non cardiac 25/102 (24.5) 17/96 (17.7)
Unknown 1/102 (1.0) 0
RR (95% CI) of cause-specific death by treatment assignment78
Cardiac 0.97 (0.71 to 1.33) 0.84
Arrhythmic 0.55 (0.29 to 1.03) 0.06
Non-arrhythmic, cardiac 1.24 (0.84 to 1.84) 0.28
Myocardial pump failure 1.28 (0.74 to 2.22) 0.37
Procedure death 1.20 (0.69 to 2.10) 0.52
Non-cardiac 1.49 (0.80 to 2.76) 0.21
Total 1.07 (0.81 to 1.42) 0.63
Actuarial mortality by 4 years’
follow-up (%)
27 24 0.64
HR (95% CI) for death per unit time 1.07 (0.81 to 1.42)
HR (95% CI) from Cox regression model
stratified by clinical centre and LVEF
1.02 (0.76 to 1.35)
HR (95% CI) from Cox model beginning
30 days after randomization
1.03 (0.75 to 1.41)
Received a shock within 1 year of ICD
implantation (actuarial incidence
presented in a figure), %
50
Received a shock within 2 years of ICD
implantation (actuarial incidence
presented in a figure), %
57
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR
HF hospitalizations NR NR
Change in NYHA class NR NR
Change in LVEF NR NR
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Outcome ICD (n= 446) Control (n= 454) p-value
Exercise capacity outcomes
(e.g. 6-minute walk distance,
total exercise time, peak VO2)
NR NR
3 months
(n= 403)
1 year
(n= 374)
3 months
(n= 411)
1 year
(n= 373)
Drug therapy after CABG, %b
Oral AADs
None 70.7 70.3 70.1 72.9
Class I drugs 8.2 7.5 5.8 4.8
Amiodarone 4.2 6.1 3.6 2.9
Sotalol 1.0 0.8 0.5 0.5
Beta-blockers (not sotalol) 16.4 16.0 21.7 19.8
ACE inhibitors 60.3 64.2 63.7 67.8
Diuretics 61.3 64.7 57.2 55.2
Digitalis 70.7 70.6 62.5 60.1
Nitrates 10.9 15.8 12.2 16.9
Calcium channel blockers 9.2 12.0 7.1 9.7
Antiplatelet drugs 78.2 79.1 83.7 82.6
Oral anticoagulants 20.6 20.1 16.8 16.6
Lipid-lowering drugs 12.9 23.0 13.4 23.3
NR, not reported.
a Total number of deaths and number of cardiac deaths reported differs slightly between the main trial publication75
and that specifically reporting mechanism of death.78 Results from the latter paper are reported above (main trial
publication75 reported 101 (71 from cardiac causes) in the ICD group and 95 (72 from cardiac causes) in the
control group).
b Drug therapy – data were not available for all patients.
Comments
l The HR (95% CI) derived from a Cox model after adjustment for the 10 prespecified covariates was stated to be similar
to the value obtained without adjustment but data are not reported in the paper.
l Separate Cox regression analyses for each of the 10 prespecified covariates showed no significant interaction with ICD
therapy (i.e. HRs for the ICD group compared with the control group were similar among the predefined subgroups).
l Kaplan–Meier figures for analysis of the probability of death and the probability of the discharge of the first shock from
the ICD in the ICD group are presented but have not been data extracted.
l States use of cardiac drugs was similar in the two groups at 3 months and 1 year after hospital discharge. Rates of use
of class I or III AADs and beta-blockers were similar in the two groups throughout the trial.
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Quality-of-life outcomes
Outcome ICD (n= 262) Control (n= 228) p-valuea
HRQoL at 6 months, mean (SD)80
Perception of health
General health status 54.8 (22.9) 58.3 (23.6) NS
Perception of health transitionb 2.4 (1.2) 2.1 (1.2) 0.030
Physical limitations 41.7 (42.3) 49.2 (42.8) 0.055
Bodily pain 57.4 (24.6) 58.8 (24.8) NS
Ability to function
Employment status 0.25 (0.4) 0.29 (0.5) NS
Physical role functioning 58.3 (27.5) 61.8 (28.3) NS
Emotional role functioning 55.4 (43.4) 67.3 (39.9) 0.003
Social functioning 70.5 (27.2) 70.8 (26.4) NS
Psychological well-being
Mental health 72.5 (18.3) 77.2 (17.0) 0.004
Satisfaction with appearance 6.0 (1.3) 6.3 (1.1) 0.008
Satisfaction with scar 7.0 (1.2) 7.2 (1.1) 0.040
Received a shock before completing the
6-month QoL instrument, n/N (%)
101/262 (38.5)
ICD device did not
fire (n = 161)
ICD device
fired (n = 101)
Control
(n = 228)
Control vs. ICD
fired (95% CI)c
HRQoL at 6 months, mean (SD)80
Perception of health
General health status 56.6 (23.3) 52.1 (22.1) 58.3 (23.6) NS
Perception of health transitionb 2.3 (1.2) 2.5 (1.3) 2.1 (1.2) –0.73 to –0.01d
Physical limitations 44.8 (42.9) 36.8 (41.1) 49.2 (42.8) 0.31 to 24.6e
Bodily pain 57.8 (24.1) 56.8 (25.3) 58.8 (24.8) NS
Ability to function
Employment status 0.30 (0.5) 0.18 (0.4) 0.29 (0.5) NS
Physical role functioning 61.5 (27.5) 53.2 (27.0) 61.8 (28.3) 0.7 to 16.6
Emotional role functioning 59.5 (43.4) 49.1 (42.8) 67.3 (39.9) 6.2 to 30.1
Social functioning 71.6 (26.9) 68.8 (27.7) 70.8 (26.4) NS
Psychological well-being
Mental health 73.6 (43.4) 70.6 (18.5) 77.2 (17.0) 1.5 to 11.6
Satisfaction with appearance 6.0 (1.3) 6.0 (1.4) 6.3 (1.1) –0.01 to 0.71
Satisfaction with scar 7.0 (1.2) 7.1 (1.2) 7.2 (1.1) NS
Rate of rehospitalisation before date of
6-month QoL assessment (%)
36.0 55.5 33.8
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Outcome ICD (n= 262) Control (n= 228) p-valuea
ICDs explanted before completing
6-month QoL assessment, n/N
12/262
At patient request 1
Because of infection 8
Other reason 3
NS, not significant.
a p-values for QoL outcomes represent significance of t-tests comparing mean scores of control vs. ICD patients.
b Lower score reflects a tendency to rate heath as better now relative to 1 year ago. For all other QoL measures higher
scores represent a more favourable score.
c 95% CIs control the experiment-wise type 1 error rate to be 0.5 using Tukey’s method.
d F-test for analysis of variance (ANOVA) has p-value of 0.0507.
e F-test for ANOVA has p-value of 0.0549.
Comments
l QoL outcomes grouped into three categories: perception of health status, ability to function and psychological
well-being.
l Paper states that control group and ICD group patients whose devices had not fired did not differ on any of the
reported QoL measures. ICD group patients whose devices had not fired and ICD group patients who had received a
shock from their ICD did not differ significantly from each other.
l A graph showing the cumulative incidence of ICD discharges is presented but has not been data extracted.
l Discussion states that, although hospitalisation affects perceived QoL, the differences in QoL scores between control
patients and ICD patients whose devices had fired persisted even when rehospitalisation was controlled for in
regression analyses.
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Adverse effects of treatment
Adverse effect ICD (n= 446) Control (n= 454) p-valuea
Postoperative complications, %
MI 4.0 3.5
Sustained VT 5.8 6.8
VF 3.4 5.3
Bradycardia 2.9 4.4
Atrial fibrillation 22.9 20.7
Shock 9.2 7.5
New or more severe HF 15.7 12.6
Conduction defect 14.1 14.5
Residual central nervous system deficit 3.6 2.0
Bleeding treated with surgery 4.9 3.1
Postpericardiotomy syndrome 0.9 0.7
Deep sternal wound infection 2.7 0.4 0.01< p< 0.05
Infection at wound or catheter site 12.3 5.9 0.01< p< 0.05
Pneumonia 8.5 4.0 0.01< p< 0.05
Other infection 6.3 3.3
Renal failure 6.7 4.8
Events during long-term follow-up, %
Angina pectoris 27.0 27.5
MI 0.5 4.2 0.01< p< 0.05
New or worsening HF 42.5 42.5
Ventricular arrhythmias 19.4 14.3
Atrial fibrillation 14.7 10.1
Hospitalisation 61.4 55.2
Repeat CABG surgery 0.0 0.7
PTCA or atherectomy 2.9 2.1
Permanent cardiac pacemaker 2.9 4.9
ICD removed, nb 40
Infection 19
ICD reached end of service period and not replaced 5
Patient request 5
PTCA, percutaneous transluminal coronary angioplasty.
a p-values have no adjustment for multiple comparisons.
b Reason for every ICD removal not reported.
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Comments
Methodological comments
l Allocation to treatment groups: two independent randomisation schedules were set up for each hospital,
one for patients with a LVEF ≤ 0.2 and the other for those with a LVEF of 0.21–0.35. Randomisation
therefore stratified by LVEF and also by centre.76 Patients randomly assigned to ICD or control group within
randomly permuted blocks. Randomisation took place in the operating room after completion of CABG
surgery and patients were on partial cardiopulmonary bypass. The attending surgeon had the option not to
have the patient randomly assigned if he or she thought that implanting and testing an ICD in the patient
was too risky. Assignment supplied by data co-ordinating centre in opaque envelopes sealed with a
validating label.
l Blinding: no blinding; states that the nature of the intervention precluded the blinding of investigators
or patients.
l Comparability of treatment groups: states that baseline characteristics of the two study groups were similar.
There was no baseline assessment for QoL because informed consent was obtained just hours before
surgery, which made it impossible to obtain preoperative QoL data.
l Method of data analysis: data were reviewed by an independent data and safety monitoring board. Four
interim analyses were scheduled and performed. These were based on sequential monitoring procedures
for the groups, with prospective stopping rules defined by a Lan–DeMets boundary with an
O’Brien–Fleming spending function. Cumulative survival curves were estimated by the Kaplan–Meier
method. Cox proportional hazards regression models were used to estimate HRs. Log-rank tests, stratified
according to LVEF and clinical centre, were used to test hypotheses about between-group differences.
Secondary analyses (also based on Cox models) examined survival after surgery and treatment interactions
for prespecified subgroups. Ten prospectively selected covariates [age, sex, presence/absence of HF, NYHA
functional class, LVEF, presence/absence of diabetes, duration of QRS complex (> 100milliseconds or
≤ 100milliseconds), use of ACE inhibitors, use of class I or class III AADs and use of beta-adrenergic
blocking drugs] were evaluated for their interaction with the effect of ICD on risk of death. All analyses
used the ITT principle. The last of the four interim analyses of mortality data was on 2 April 1997; 76% of
the anticipated information was available. This fourth analysis showed no difference between the ICD
group and the control group and a negligible chance that a difference would ever be found. The board
therefore recommended that the data on the primary end point be reported as of 30 April 1997 while the
trial continued to pursue its secondary objectives.
l QoL substudy:80 Comparisons of scales based on t-tests. Analysis of variance models were used to
test for differences in QoL scales between three groups: (1) control, (2) ICD – device did not fire and
(3) ICD – device did fire. If a significant difference was found between the three groups based on an F-test,
subsequent pairwise comparisons of each group to the others were made adopting Tukey’s method to
maintain an overall 0.05 type 1 error probability. There was no correction or testing of the several scales
from the QoL instrument. All tests were two-tailed.
l Sample size/power calculation: design ensured that the study had a power of > 80% to detect a difference
of 26% in mortality between the groups, a difference that corresponded to a 40% reduction in the hazard
rate for death from all causes in the ICD group compared with the control group (allowing for anticipated
crossovers). Originally the protocol was for 800 patients to be recruited and monitored for a minimum of
2 years. Many would have needed their ICD pulse generators to be replaced during follow-up. However, a
clarification of the Medicare reimbursement policy for investigational use of devices caused a protocol
change which meant that ICDs would not be replaced at the end of service life because of battery
depletion. This change would have decreased the average follow-up time and statistical power. Mortality
was also lower than expected in the control group. Therefore, in October 1994 the data and safety
monitoring board recommended that power be restored by increasing recruitment from 800 to 900
patients and lengthening the minimum follow-up to 42 months (which is the average service time of a
Ventak P pulse generator). ICDs with battery depletion before 39 months were replaced.77
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l Attrition/drop-out: of 1422 eligible patients, 1055 (74%) signed a consent form. Of these, 155 were
not randomised (n= 67 found to meet one or more criteria for exclusion between enrolment and
randomisation, n= 88 not randomised because surgeon decided intraoperative events made ICD
implantation too risky). There were 70 crossovers during follow-up: 18 control group patients had an ICD
implanted; 12 patients assigned to the ICD group did not receive one because of death or hemodynamic
instability in the operating room; 40 ICD group patients had the ICD removed (see Adverse events).
At 42 months the cumulative rate of crossover to the control group was 10% and the cumulative rate of
crossover to the ICD group was < 5%. QoL substudy:29 Of the 900 participants randomised in the main
study, only 719 were expected to complete the 6-month QoL instrument [study authors presumed that
death (43%), language difficulties (19%) (those whose first language was not English were not expected to
complete the instrument) and completing 6 months of follow-up (38%) prior to the development of the
QoL instrument would cause some participants to be unable to contribute data]. Of the 719 expected to
have completed the instrument, 490 did so (68% of those expected, 54% of total trial population). A
comparison of the characteristics of those who completed vs. those who did not complete the instrument is
presented (not data extracted). This showed that completers differed by race, educational attainment,
occupational attainment and randomisation group (higher rate of completion in ICD group).
l Other: QoL substudy:80 ICD patients were recommended not to participate in the enrolling centre’s ICD
support group meetings because their ICDs had been placed prophylactically and therefore they differed
from those receiving ICDs for conventional reasons. It was anticipated that the meeting might cause trial
participants to become confused and anxious.
General comments
l Generalisability: this study found that the study population did not benefit from an ICD. In the discussion
section of the paper75 the authors indicate that they enrolled a high proportion of eligible patients from a
well-characterised population. However, mortality in this population differed from that in the AVID71 and
MADIT99,101 trials and this leads the study authors to conclude that there must be differences between the
enrolled populations. The authors speculate that the indicator for arrhythmia used may be the important
factor and that the occurrence of either natural or induced sustained ventricular arrhythmias is a better
marker for an at-risk population than abnormalities on a signal-averaged ECG, as was used in this study.
Revascularisation may be another factor contributing to differences between this and other studies. The
QoL part of the study80 notes that the ICDs in this study were older generation, which were larger and
more intrusive than current devices. Thus, outcomes on satisfaction with appearance may not apply to new
generation devices. In addition, the QoL findings are based on English-speaking, predominantly white male
participants and so the results may not be generalisable to other groups, and other differences between
those who did and did not complete the QoL study may also impact on generalisability.
l Outcome measures: appear appropriate although not all (e.g. QoL outcomes) were ITT.
l Intercentre variability: not discussed.
l Conflict of interests: not explicitly stated. The leads and pulse generators were provided by the device
manufacturer, Guidant Corporation/CPI, who also provided part of the grant funding for the study.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random
sequence generation
Unclear States ‘randomised’ and also mentions ‘randomly permuted blocks’ but no
detail about how randomisation schedule was set up
Allocation concealment Low Central allocation, opaque sealed envelopes
Performance bias
Blinding of participants
and personnel
High ‘The nature of the intervention precluded the blinding of investigators
or patients’75
Detection bias
Blinding of outcome assessment
Mortality Low ‘The nature of the intervention precluded the blinding of investigators or
patients’.75 Death unlikely to be influenced by lack of blinding
QoL High
Attrition bias
Mortality Low States analysed according to the ITT principle. Methods for handling censored
data not described but bias unlikely, particularly as no significant difference
between groups and trial was expecting to find one
QoL High Not all participants contributed data; those who did differed from those who
did not and there was a higher rate of completion in the ICD group
Reporting bias
Selective reporting Unclear Protocol76 states primary outcome and lists 11 of the secondary outcomes but
does not indicate how many secondary outcomes there would be overall.
Most outcomes appear to have been reported
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Cardiac Arrest Study Hamburg (CASH)
Reference
and design
Intervention
and comparator Participants Outcome measures
Kuck et al. 200081
Study design: RCT
Country: Germany
No. of centres:
multicentre but
number of centres
not reported
Funding: supported
by a grant from
CPI/Guidant
Corporation and
ASTRA GmbH
Intervention: ICD Cardiac
Pacemakers, Inc. devices were
used (Ventak AID, Ventak
AICD, Ventak P, Ventak PRx,
Ventak Mini). From recruitment
start to June 1991 participants
received an epicardial device
(n= 55). From July 1991
participants received an
endocardial device (n= 44). If
patients required surgical
revascularisation, implantation
of an epicardial or endocardial
device was performed at the
time of or 7–15 (mean 10± 3)
days after CABG surgery
respectively
Comparator: AAD, either
amiodarone or metoprolol
(propafenone arm originally
included but eliminated).
Amiodarone oral loading dose
of 1000mg/day for 7 days,
followed by maintenance dose
of 200–600mg/day.
Metoprolol initiated at
12.5–25mg/day and increased
within 7–14 days to a
maximum of 200mg/day if
tolerated. Details reported for
propafenone (study arm
terminated early as a result of
interim analysis) in other
publications238–240 – excluded
comparator
Other interventions used:
concurrent therapies at
discharge reported (see below)
but doses not provided
Indication for treatment:
patients resuscitated from
cardiac arrest secondary to
documented sustained
ventricular arrhythmias. Index
arrhythmia VF in 293/349
(84%) patients and VT in
56/349 (16%) patients (entire
group before termination of
propafenone arm)
No. of randomised participants:
349, but this dropped to 288
after termination of the
propafenone arm;
ICD: 99, amiodarone: 92,
metoprolol: 97. Some evidence
for error in participant
numbers and/or missing data.
Details in methodological
comments
Inclusion criteria: not reported.
Rate was the only criterion
selected for detection of a
sustained ventricular
arrhythmia
Exclusion criteria: cardiac arrest
occurred within 72 hours of an
acute MI, cardiac surgery,
electrolyte abnormalities or
proarrhythmic drug effect
Primary outcome: all-cause
mortality
Secondary outcomes: sudden
death, recurrence of cardiac
arrest at 2-year follow-up
Method of assessing
outcomes: evaluations at 2, 4,
6, 12, 18 and 24 months then
every 12 months thereafter.
Sudden death defined as
death within 1 hour of the
onset of symptoms or an
unwitnessed death. Cardiac
arrest defined as sudden
circulatory collapse requiring
resuscitation
Length of follow-up:
minimum of 2 years, study
terminated March 1998.
Mean 57 (SD 34) months
Recruitment: from March 1987
to March 1992 (propafenone
arm terminated early) or to
1996 (remaining study arms)
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Participant characteristics
Characteristic
ICD
(n= 99)
Amiodarone
(n= 92)
Metoprolol
(n= 97) p-value
Age (years), mean (SD) 58 (11) 59 (10) 56 (11)
Sex, % male 79 82 79
Ethnicity NR NR NR
Underlying disease, %
Coronary artery disease 73 77 70
Dilated cardiomyopathy 12 10 14
Others 6 2 5
No heart disease 9 11 11
CHF at enrolment, %
NYHA class I 23 25 32
NYHA class II 59 57 55
NYHA class II (drug arms combined) 56
NYHA class III 18 18 13
LVEF, mean (SD) 0.46 (0.19) 0.44 (0.17) 0.47 (0.17)
0.46 (0.17)
Heart rate (bpm), mean (SD) 81 (17) 80 (17) 76 (16)
Findings on baseline ECG
Corrected QT interval (milliseconds), mean (SD) 437 (42) 430 (51) 430 (48)
Bundle branch block, % 17 23 19
Concurrent therapies at discharge, n
ICD 99 0 0
Amiodarone 0 90 0
Metoprolol 0 0 96
Digitalis 26 23 15
Diuretic agents 33 25 30
Nitrates 29 27 24
Calcium channel blockers 26 15 12
ACE inhibitors 45 40 40
Acetylsalicylic acid (aspirin) 57 41 40
Warfarin 9 6 9
Coronary revascularisation during hospitalisation after index
event, %
19 21
Cardiac history NR NR NR
Previous treatment NR NR NR
Comorbidities NR NR NR
Exposure time to primary events (months) 4767.36 4169.41 5078.40
bpm, beats per minute; NR, not reported.
Comment
l Daily maintenance doses throughout the study were 225± 75mg of amiodarone and 85± 73mg of metoprolol.
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Results
Outcome ICD (n= 99)
Amiodarone
(n= 92)
Metoprolol
(n= 97) p-value
Crude death rate during mean (SD) follow-up of
57 (34) months, % (CIa)
36.4
(26.9 to 46.6)
44.4
(37.2 to 51.8)
43.5
(33.2 to 54.2)
45.4
(35.2 to 55.8)
0.845b
Overall survival (ICD vs. antiarrhythmic therapy) HR 0.766 (97.5% CI upper bound 1.112);c survival
curve presented but not data extracted
0.081d
Crude sudden death rate, % (CIa) 13.0
(7.9 to 19.6)
33.0
(27.2 to 41.8)
29.5
(19.4 to 40.8)
35.1
(25.2 to 48.8)
0.467b
Survival free of sudden death (ICD vs.
antiarrhythmic therapy)
HR 0.423 (97.5% CI upper bound 0.721); survival
curve presented but not data extracted
0.005d
Crude rate of non-fatal cardiac arrest, % (CIa) 11.1
(6.9 to 16.5)
19.5
(12.2 to 25.6)
Survival free of cardiac arrest (ICD vs.
antiarrhythmic therapy)
HR 0.481 (97.5% CI upper bound 1.338); no survival
curve presented
0.072d
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR NR
HRQoL NR NR NR
HF hospitalisations NR NR NR
Change in NYHA class NR NR NR
Change in LVEF fraction NR NR NR
Exercise capacity outcomes NR NR NR
NR, not reported.
a Level of the CI not reported.
b For the comparison between amiodarone and metoprolol.
c A 23% non-significant reduction in all-cause mortality in ICD patients.
d One-sided p-value unadjusted for multiple looks for survival or survival free of the event for the comparison between ICD
and antiarrhythmic therapy.
Comments
l Survival curves presented for long-term overall survival in ICD and AAD groups; long-term overall survival in
amiodarone and metoprolol groups; long-term survival free of sudden death in ICD and AAD groups; long-term survival
free of sudden death in amiodarone and metoprolol groups.
l Kaplan-Maier estimates of the decrease in death rates at years 1–9 of follow-up were 41.9%, 39.3%, 28.4%, 27.7%,
22.8%, 11.4%, 9.1%, 10.6% and 24.7% respectively.
l The Kaplan-Maier estimates of the percentage reduction in sudden death for ICD patients at years 1–9 of follow-up
were 81.8%, 86.7%, 76.2%, 78.3%, 80.8%, 73.1%, 64.3%, 56.7% and 60.6% respectively.
l The decrease in cardiac arrest rates for patients assigned to ICD were 61.8%, 65.5%, 59.2%, 53.8%, 50.4%, 58.6%,
49.2%, 52.8% and 42.1% at years 1–9 of follow up respectively.
l Death rates for the subgroups of patients with either inducible sustained ventricular arrhythmia at baseline or
non-inducible ventricular arrhythmia at baseline are reported but have not been data extracted. Over a mean follow-up
of 37± 26 months a similar outcome (data not reported) was observed for the ICD arm patients who received an
epicardial device and those who received an endocardial device (p= 0.189).
l States that there were no significant differences in the HRs for death from any cause for subgroups defined by LVEF,
NYHA class and presence of organic heart disease. Data presented but not extracted. A trend towards a higher benefit
from ICDs for subgroups with a lower LVEF and higher NYHA function class is reported.
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Adverse effects of treatment
Adverse effect ICD (n= 99)
Amiodarone
(n= 92)
Metoprolol
(n= 97) p-value
Drug-related pulmonary toxicity, n 0 NR
Hyperthyroidism, n (%) 3 (3.3)
Drug discontinuation required, n (%) 9 (9.8) 10 (10.3)
Perioperative death or, for drug arms,
deaths within the same time frame, n (%)
5 (5.1); 3 (5.4) epicardial
ICD, 2 (4.5) endocardial ICD
2 (1.1) p= 0.029
2 0
Other complications, n
Infection 3 (explantation required
for 2)
Haematoma or seroma 6
Pericardial effusion 1
Pleural effusion 3
Pneumothorax 1
Dislodgement or migration of
system leads
3
Device dysfunction 5
Overall complication rate, % 23.0 (including an
explantation rate of 2.1%)
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Comments
Methodological comments
l Allocation to treatment groups: randomisation ratio ICD : AAD= 1 : 3
(ICD : amiodarone : metoprolol : propafenone= 1 : 1 : 1 : 1). All patients assigned to the AAD arm underwent
repeat predischarge 24-hour Holter monitoring, PES and exercise testing. Response to serial drug testing
did not affect the therapy assignment obtained by randomisation.
l Blinding: not reported.
l Comparability of treatment groups: described as similar in the two treatment groups (ICD and AAD) but
data presented separately for amiodarone and metoprolol groups. Baseline characteristics were not
reported for the suspended propafenone arm.
l Method of data analysis: analysis by ITT. An interim analysis was required by the safety monitoring board in
March 1992 because of the unexpectedly long recruitment time and subsequent data in the literature
showing life-threatening proarrhythmic effects by class Ic antiarrhythmic agents. The aim of this analysis
was to prevent further patients being assigned to a possibly harmful treatment. However, as no precautions
had been stated concerning multiple group comparisons and multiple looks into the data at the study start
the interim analysis meant that the overall significance level for comparisons of the ICD group with each of
the three drug groups was adjusted according to Bonferroni inequality. Time to clinical events (i.e.
mortality, sudden death, cardiac arrest recurrence) for ICD vs. AAD was analysed using the Kaplan–Meier
method. Cumulative survival functions were compared using the log-rank (Mantel–Cox) test. The Cox
proportional regression model was used for calculation of HRs with the patients groups as randomised (ITT).
l Sample size/power calculation: based on an assumption that ICDs would in the worst case be as effective
as AADs. The alpha-level for comparison of survival distributions between the ICD and drug arms was
based on a one-sided test; the significance test was at a 0.025 level. Design had a power of 80% to detect
a difference of 19 percentage points in 2-year mortality rates between the two arms (50% expected
mortality rate in patients assigned to the drug arm, 31% in the ICD arm). Sample size of 390 with a 1 : 3
(ICD : drug therapy) ratio for randomisation estimated to be sufficient. States that the 19.6% 2-year all-
cause mortality rate observed in the amiodarone and metoprolol groups was less than half the mortality
rate used to calculate the trial sample size, thus rendering the trial underpowered to test the working
hypothesis. Note that data were presented and analysed separately for the two drugs and it is unclear
whether the study was powered for this.
l Attrition/dropout: three participants are unaccounted for from the description of numbers of participants.
Overall, 349 included (293 VF+ 56 VT) but 58 receiving propafenone were eliminated from the trial after
an interim analysis found a higher all-cause mortality rate in this arm. This should leave 291 participants;
however, it is stated that 288 remained in the continuing three study arms. Two in the amiodarone group
refused to start drug therapy (table 2 in the paper indicates that these are included among the 92 in the
amiodarone group). During follow-up six (6.1%) patients in the ICD arm and 11 (5.8%) in the drug arm
crossed over or added the other therapy by 24 months. Three (3.0%) patients in the ICD arm and none of
those assigned to amiodarone received beta-blockers during follow-up.
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General comments
l Generalisability: the study authors suggest that the mean LVEF for the whole study population (0.46)
suggests that there may have been a disproportionate representation of relatively healthy patients in the
trial. The effect of this on the generalisability of the results to more typical patients is unclear but the
authors suggest that the benefit of ICD therapy may have been underestimated in the trial
l Outcome measures: appear appropriate.
l Intercentre variability: unclear as the number of centres and their characteristics not reported. The
discussion section of the paper does note as a limitation the small number of participating centres and their
reluctance to enrol patients for potential ICD therapy in the early phase of the study and to deny ICD
therapy in the late phase of the study.
l Conflict of interests: not stated.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence
generation
Unclear No information provided
Allocation concealment Unclear No information provided
Performance bias
Blinding of participants
and personnel
High No information provided, assume none
Detection bias
Blinding of outcome
assessment
Low No information provided but mortality unlikely to be influenced by lack
of blinding
Attrition bias
Incomplete outcome
data addressed
Low ‘For calculation of hazard ratios, the Cox proportional regression model was
used with the patients grouped as randomised (intention to treat)’81
Crossovers or addition of the other treatment was similar in the two groups
(ICD 6.1%, AAD 5.8%)
Reporting bias
Selective reporting Low The study protocol is not available but primary and secondary outcomes are
specified and defined. The outcomes are the outcomes expected
Other bias
Other sources of bias Unclear Study authors note that centres were reluctant to enrol patients for potential
ICD therapy in the early phase of the study and to deny ICD therapy in the late
phase of the study. It is not clear whether or not this could have introduced
any bias
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Cardiomyopathy Trial (CAT)
Reference
and design
Intervention
and comparator Participants Outcome measures
Bänsch et al.
2002,82 German
Dilated
Cardiomyopathy
Study investigators
199283
Study design: RCT
(pilot phase)
Country: Germany
No. of centres: 15
Funding: grant
from Guidant
Corporation,
Giessen, Germany
Intervention: ICD+OPT.
Transvenous electrode systems
(Endotak, Cardiac Pacemakers,
Inc.). Pulse generators Ventak
P2, P3, PrX II, CPI.
Defibrillation threshold of
< 20 J mandatory. VT zone
with detection rate of
200 bpm programmed for
all patients. All shocks
programmed to maximum
output 30 J. Pacemaker rate
40 bpm
Comparator: OPT
Other interventions used:
both groups received
pharmacological treatment
throughout the trial (details in
Participant characteristics). No
changes in ACE inhibitor,
digitalis and diuretic
medications between baseline
and 2-year follow-up
were documented
Indication for treatment:
recent-onset idiopathic dilated
cardiomyopathy (DCM) and
impaired LVEF and without
documented symptomatic VT
No. of randomised
participants: 104; ICD: 50,
control: 54
Inclusion criteria: NYHA class II
or III, LVEF ≤ 30%, LVEDD not
reported, QRS interval not
reported, aged 18–70 years,
symptomatic DCM ≤ 9 months
Exclusion criteria: coronary
artery disease (coronary
stenosis > 70%), previous
history of MI, myocarditis or
excessive alcohol consumption,
symptomatic bradycardia, VT,
VF, on heart transplant list,
significant valvular disease,
hypertrophic or restricted
cardiomyopathy, NYHA class I
or IV, mentally unable to
understand protocol
Primary outcomes: all-cause
mortality at 1 year
Secondary outcomes: heart
transplantation, cardiac
mortality (sudden and
non-sudden cardiac death),
sustained VT (adequate ICD
therapy), symptomatic
ventricular tachyarrhythmias
requiring antiarrhythmic
treatment, complications
Method of assessing
outcomes: visits every
3 months and encouraged to
make additional visit if the first
shock, cluster of shocks or
syncope had occurred. ECGs
stored on devices
Length of follow-up: 2 years
Recruitment: 1991–7
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter.
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Participant characteristics
Characteristic ICD (n= 50) Control (n= 54) p-value
Age (years), mean (SD) 52 (12) 52 (10) NS
Sex, male/female, n 43/7 40/14 NS
Ethnicity NR NR
NYHA class, %
I 66.7 64.1 NS
III 33.3 35.8
Duration of symptoms (months), median 3.0 2.5 NS
LVEF (%), mean (SD) 24 (6) 25 (8) NS
Heart rate NR NR
Echocardiographya
Left ventricular end-diastolic volume (mm), mean (SD) 69 (7) 69 (8) NS
Left ventricular end-systolic volume (mm), mean (SD) 58 (9) 59 (10) NS
ECG rhythm, % NS
Sinus 79.6 86.8
Atrial fibrillation/flutterb 20.4 11.3
Paced 0 1.9
QRS morphology, % NS
Normal 72.9 55.1
Not normal 27.1 44.9
LBBB 84.6 81.8
RBBB 7.7 0
Other or undefined bundle branch block 7.7 18.2
QRS widthc (milliseconds), mean (SD) 102 (29) 114 (29) NS
Patients with NSVT, % 53.1 58.0 NS
Median duration of NSVT (seconds) (25th–75th percentile) 5 (3.0–6.5) 3.5 (2.3–6.0) NS
Rate of NSVT (bpm), mean (SD) 175 (39) 157 (23) NS
Bradycardias, % 2.1 18.8 0.015
Sinoatrial block 0 4.2
Atrioventricular block 2.1 14.6 NS
Inducible VT, % 6.1 0 NS
Inducible VF, % 16.0 3.7 NS
continued
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Characteristic ICD (n= 50) Control (n= 54) p-value
Current pharmacological therapy, %
Beta-blocker 4.0 3.7 NS
Calcium antagonist 16.0 7.4 NS
Digitalis 86.0 75.9 NS
Diuretics 88.0 85.2 NS
Nitrates 32.0 25.9 NS
ACE inhibitor 94.0 98.1 NS
Warfarin 24.0 35.2 NS
Cardiac history NR NR
Previous treatment NR NR
Comorbidities NR NR
Follow-up (months) (per protocol), mean (SD) 22.7 (4.5) 22.9 (4.2) NS
Follow-up (years) (per August 2000), mean (SD) 5.7 (2.2) 5.2 (2.1) NS
bpm, beats per minute; NR, not reported; NS, not significant; NSVT, non-sustained VT; RBBB, right bundle branch block.
a States echocardiographic M-mode data available only for 70 patients; no asterisk in table to indicate which
characteristics this relates to but believed to be these.
b Chronic or intermittent.
c Patients with pacemakers not included.
Comment
l The following baseline characteristics were reported but not extracted: baseline violators, orthopnoe, oedema, left
ventricular end-diastolic pressure, QT duration, baseline AH interval a (interval between atrial electrogram and His
bundle electrogram) and HV interval (interval between His bundle electrogram and ventricular electrogram).
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Results
Outcome ICD (n= 50) Control (n= 54) p-value
All-cause mortality after 1 year (primary end point),a n 4 (all cardiac) 2 (both
non-cardiac)b
0.3672
All-cause mortality after mean (SD) 5.5 (2.2) years’
follow-up, n
13 17
Cumulative survival, %
2 year 92 93 0.554
4 years 86 80
6 years 73 68
HRQoL NR NR
Symptoms and complications related to tachyarrhythmias
and/or HF
NR NR
HF hospitalisations NR NR
Change in NYHA class NR NR
Change in LVEF NR NR
Exercise capacity outcomes (e.g. 6-minute walk distance,
total exercise time, peak VO2)
NR NR
Received adequate therapy from ICD for VTs > 200 bpm, n 11 NA
Syncope during VT, n 6
bpm, beats per minute; NA, not applicable; NR, not reported.
a No sudden death occurred in either group.
b States both control group deaths are non-cardiac in text but table 1 shows one cardiac death.
Comments
l A Kaplan–Meier plot of cumulative survival is presented but has not been extracted.
l Predictors of mortality (based on baseline characteristics) have not been data extracted as this analysis is not defined a
priori in the study design paper.83
l All-cause mortality for subgroups of patients with and without adequate therapies in the ICD group reported but
not extracted.
Adverse effects of treatment
Adverse effect ICD (n= 50) Control (n= 54) p-value
Complications caused by ICD therapy
Deaths within 30 days of ICD implantation, n 0
Device dislocation and bleeding requiring revision, n 2
Electrode dislocation requiring revision, n 2
Complications in 24 months of follow-up 10 in 7 patients
Electrode dislocation and sensing/isolation defects, n 7
Infection with total device replacement, n 2
Perforation, n 1
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Comments
Methodological comments
l Allocation to treatment groups: random assignment performed centrally. Closed envelopes with the
assigned study group were sent to each centre. Envelopes opened when a patient was enrolled.
l Blinding: none reported so presume no blinding.
l Comparability of treatment groups: no differences between groups except for bradycardias caused by sinus
arrest and atrioventricular block I and II (Wenckebach), which were more common in the control group
(18.8%) than the ICD group (2.1%) (p= 0.015) during Holter monitoring. Any other differences observed
between groups were not statistically significant.
l Method of data analysis: no statement made regarding whether analysis ITT or not. Blind interim analysis
after inclusion of 100 patients at 1 year of follow-up was planned because of considerable variation in the
all-cause mortality rate in different studies that had informed the sample size calculation. Interim analysis
conducted in 1997 showed overall 1-year mortality rate of only 5.6% (well below the assumed 30%). As
difference between the groups was only 2.6%, randomisation was stopped (as per protocol) and scheduled
follow-up of 2 years completed by randomised patients. Survival rates presented as Kaplan–Meier curves
and compared with log-rank statistics. Cox proportional regression models calculated to estimate
prognostic relevance of patient characteristics. Data described by mean (SD) if normally distributed or
otherwise by median (25%–75% percentiles). Quantitative comparisons between groups performed using
two-sided analysis using Mann–Whitney exact test; qualitative characteristics compared using the exact
Fisher chi-squared test.
l Sample size/power calculation: all-cause mortality rate assumed to be 30% in the first year with 40% of
deaths being sudden. On this assumption 1348 patients had to be enrolled to show a 1-year survival
benefit of 6% for ICD treatment, with a power of 80% and a probability value of 0.05.
l Attrition/dropout: no details reported.
General comments
l Generalisability: as the trial was stopped because of futility after 1 year because of the low event rate,
results are not likely to be generalisable.
l Outcome measures: appear appropriate although the secondary outcome of heart transplantation was not
commented on.
l Intercentre variability: not commented on.
l Conflict of interests: no statement other than support was by a grant from Guidant Corporation.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear States ‘were randomly assigned’ but no further description
Allocation concealment Unclear Envelopes used but does not state whether these were opaque and
sequentially numbered
Performance bias
Blinding of participants
and personnel
High Blinding unlikely
Detection bias
Blinding of
outcome assessment
Low Blinding unlikely but the outcome of all-cause mortality is unlikely to
be affected
Attrition bias
Incomplete outcome
data addressed
Unclear No details reported regarding attrition
Reporting bias
Selective reporting High Incidence of heart transplantation specified as a secondary outcome but
no reporting on this
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Canadian Implantable Defibrillator Study (CIDS)
Reference and design
Intervention
and comparator Participants Outcome measures
Connolly et al. 199385 and
2000,84 Irvine et al. 2002,87
Sheldon et al. 200086 (no
additional data extracted),
Bokhari et al. 200488
Study design: RCT
Countries: Canada,
Australia, USA
No. of centres: Canada: 19,
Australia: 3, USA: 2
Funding: Medical Research
Council of Canada
Intervention: ICD. Implant
criteria met with three
consecutive successful
defibrillations at ≥ 10 J
below maximum device
output. Either thoracotomy
or non-thoracotomy lead
systems used
Comparator: amiodarone
≥ 1200mg/day for ≥ 1
week in hospital, ≥ 400mg/
day for ≥ 10 weeks then
≥ 300mg/day. Dose could
be lowered to a minimum
of 200mg/day for
intolerable side effects
Other interventions used:
AADs could be used in both
groups to control
supraventricular or NSVTs
that were symptomatic or
might cause discharge of
the ICD
Indication for treatment:
previous sustained
ventricular arrhythmia
No. of randomised
participants: ICD
randomised: 328, ICD
received implant: 310,
amiodarone: 331. For QOL:
317 randomised and
eligible, 287 survived to
12 months, 178 had data at
6 and 12 months
Inclusion criteria: any of
following in the absence of
either recent acute MI
(≤ 72 hours) or electrolyte
imbalance: documented VF;
out-of-hospital cardiac arrest
requiring defibrillation or
cardioversion; documented
sustained VT causing
syncope; other documented
sustained VT at a rate
≥ 150 bpm causing
presyncope or angina in a
patient with a LVEF ≤ 35%;
or unmonitored syncope
with subsequent
documentation of either
spontaneous VT
≥ 10 seconds or sustained
(≥ 30 seconds)
monomorphic VT induced by
programmed ventricular
stimulation. Ventricular
tachyarrhythmias induced in
laboratory met criteria if
patient had previous
spontaneous documented
sustained VT and the
induced arrhythmia was
monomorphic
sustained VT
Exclusion criteria:
amiodarone or ICD not
considered appropriate,
excessive perioperative risk
for ICD implantation,
previous amiodarone
therapy for ≥ 6 weeks,
non-arrhythmic medical
condition making 1-year
survival unlikely, long
QT syndrome
Primary outcomes: death
from any cause
Secondary outcomes:
arrhythmic death (based on
clinical classification of
cardiac deaths by Hinkle
and Thaler (reference
provided), QoL,87 side
effects, arrhythmia
recurrence
Method of assessing
outcomes: 2 and 6 months
after randomisation then
every 6 months. All deaths
adjudicated by an external
validation committee not
blinded to treatment
QoL study:87 emotional
functioning: Rand
Corporations 38-item MHI;
HRQoL: NHP. Assessed in
hospital before or just after
randomisation (people after
randomisation may have
started therapy), then by
mailed questionnaire at 2, 6
and 12 months
Length of follow-up:
ICDs: mean 3.0 years;
amiodarone: mean 2.9 years
For long-term follow-up of
subset of patients from one
centre:88 follow-up until
April 2002, mean 5.6
(SD 2.6) years, median 5.92
(range 0.08–11.08) years
Recruitment:
October 1990–January 1997
bpm, beats per minute.
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Participant characteristics
Characteristic
ICD
(n= 328)
Amiodarone
(n= 331) p-value
Age (years), mean (SD) 63.3. (9.2) 63.8 (9.9)
Sex, % male 85.4 83.7
Ethnicity NR NR
Index arrhythmia, %
VF or cardiac arrest 45.1 50.1
VT with syncope 15.9 10.6
Other VT 23.8 26.9
Unmonitored syncope 15.2 12.4
Primary cardiac diagnosis, %
Ischaemic heart disease with MI 75.6 73.1
Ischaemic heart disease without MI 7.3 9.1
Dilated cardiomyopathy 8.5 10.6
Valvular heart disease 1.2 3.0
Other heart disease 3.7 2.4
No heart disease 3.7 1.8
CHF, %
None 51.2 49.5
NYHA class I or II 37.8 39.9
NYHA class III or IV 11.0 10.6
LVEF (%), mean (SD) 34.3 (14.5) 33.3 (14.1)
LVEF < 20%, % 11.3 13.3
Heart rate NR NR
Baseline electrophysiological study
Ever done, % 62.2 62.8
Inducible VT or VF, n/N (%) 154/204 (75.7) 147/208 (70.7)
Coronary angiography, %
Ever done 75.6 78.2
Three-vessel disease 19.0 18.9
Chest radiography, %
Interstitial abnormality (document on previous
standard chest radiography report)
15.5 17.6
Other abnormality 31.4 34.6
Current pharmacological therapy NR NR
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Characteristic
ICD
(n= 328)
Amiodarone
(n= 331) p-value
Cardiac history, %
Angina pectoris 51.2 57.1
MI 77.1 75.8
CABG surgery 31.4 28.1
Previous treatment NR NR
Medical conditions, %
Liver disorder 1.5 2.7
Respiratory disease 17.5 17.8
Thyroid disease 5.8 3.9
NR, not reported.
Comment
l Baseline characteristics are also presented for 317 English-speaking participants undertaking QoL assessment.87
QoL results reported for 178 of these.
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Results
Outcome
ICDs
(n= 328)
Amiodarone
(n= 331) RRRa (95% CI) (%), p-value
30-day mortality in implanted patients (n= 310), n/N (%)
Patients with thoracotomy (n= 33) 1/33 (3.3)
Patients with non-thoracotomy lead
system (n= 277)
1/277 (0.36)
Outcome event rate summary, no. of events
[rate/year (%)]
All-cause mortality 83 (8.3) 98 (10.2) 19.7 (–7.7 to 40.0), 0.142
Arrhythmic death 30 (3.0) 43 (4.5) 32.8 (–7.2 to 57.8), 0.094
Other cardiac death 37 (3.7) 40 (4.2) 13.5 (–35.4 to 44.7), 0.526
Non-cardiac vascular death 3 (0.3) 2 (0.2) –36.6 (–719.8 to 77.2), 0.732
Non-vascular death 13 (1.3) 13 (1.4) 4.5 (–106.1 to 55.7), 0.908
Total cardiac death (6.7) (8.6) 23.4 (–5.7 to 44.5), 1.04
ARR, RRR (%)
Cumulative risks over time, %
Total mortality
1 year 9.46 11.18 1.72, 15.4
2 years 14.75 20.97 6.22, 29.7
3 years 23.32 27.03 3.71, 13.7
Arrhythmic mortality
1 year 4.37 6.23 1.86, 29.9
2 years 6.68 9.74 3.06, 31.4
3 years 9.77 11.88 2.11, 17.8
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR
HF hospitalisations NR NR
Change in NYHA class NR NR
Change in LVEF NR NR
Exercise capacity outcomes NR NR
Concomitant antiarrythmic medications, % patients
Beta-blocker (other than sotalol)
Hospital discharge 33.5 21.4
1 year 37.0 21.2
3 years 33.3 19.0
5 years 29.6 22.4
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Outcome
ICDs
(n= 328)
Amiodarone
(n= 331) RRRa (95% CI) (%), p-value
Sotalol
Hospital discharge 19.8 1.5
1 year 21.5 2.5
3 years 23.3 4.9
5 years 24.1 4.1
Digoxin
Hospital discharge 29.6 22.7
1 year 34.5 21.9
3 years 34.7 22.5
5 years 33.3. 24.5
Class I AAD (any Vaughan Williams class I)
Hospital discharge 5.5 2.4
1 year 8.4 2.8
3 years 10.0 2.1
5 years 9.3 2.0
ARR, absolute risk reduction; NR, not reported.
a Treatment effect adjusted for LVEF stratification. Total patient-years of follow-up were 957 for amiodarone group and
995 for ICD group.
Comments
l Percentage of ICD patients who were receiving amiodarone at 1 year: 17.4%; 3 years: 21.7%; 5 years: 28.1%.
Mean dose of amiodarone in these patients at 3 years was 277mg/day.
l Percentage of amiodarone group receiving amiodarone at 2 months: 96.2%; 1 year: 88.7%, 3 years: 80.3%;
5 years: 85.4%. Mean doses 390, 306, 262 and 255mg/day respectively.
l 52/331 in the amiodarone group received an ICD.
l Cumulative proportion of the amiodarone group receiving an ICD at 1, 3 and 5 years was 9.0%, 18.6% and
21.4% respectively.
l States significantly more drugs were used in patients randomised to ICD treatment (statistical significance not reported)
and the imbalance was most marked for sotalol.
l Kaplan–Meier curve of cumulative risk of death from any cause over 4 years presented but not data extracted.
l Figure of HRs and 95% CIs for all-cause mortality for various subgroups of baseline characteristics presented (no data
presented, figure only). Although the plot showed no statistically significant difference between ICDs and amiodarone,
it was not stated whether subgroup analysis was prespecified and so it was not data extracted.
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Health-related quality of life87
QoL measure ICD (n= 86) Amiodarone (n= 92) Time by group p-value (ANOVA)
Domains of MHI, mean (SD)
Total indexa
Baseline 173.2 (25.5) 180.4 (27.8)
6 months 183.1 (30.2) 180.2 (31.1)
12 months 184.3 (27.9) 178.3 (28.7) 0.001
Psychological distressb
Baseline 51.3 (14.1) 47.8 (16.5)
6 months 45.1 (17.6) 47.6 (18.3)
12 months 43.4 (15.9) 48.8 (16.8) 0.001
Psychological well-beinga
Baseline 58.5 (12.7) 62.2 (12.3)
6 months 62.2 (13.4) 61.8 (14.1)
12 months 61.7 (13.2) 61.3 (13.3) 0.03
Domains of NHP, mean (SD)
Energy levelb (n= 83) (n= 88)
Baseline 27.5 (32.2) 24.4 (32.4)
6 months 18.6 (30.1) 27.8 (32.1)
12 months 17.7 (26.1) 36.8 (37.3) 0.0001
Physical mobilityb (n= 84) (n= 90)
Baseline 10.9 (12.0) 13.2 (20.5)
6 months 10.5 (13.7) 15.1 (19.2)
12 months 9.1 (13.6) 17.7 (19.2) 0.002
Social isolationb (n= 81) (n= 88)
Baseline 8.5 (15.4) 9.9 (17.7)
6 months 9.8 (18.6) 12.2 (22.4)
12 months 8.5 (18.4) 11.1 (22.6) 0.9
Emotional reactionsb (n= 76) (n= 86)
Baseline 17.3 (18.1) 14.3 (20.1)
6 months 11.1 (18.2) 15.3 (22.4)
12 months 8.3 (16.6) 14.5 (19.6) 0.002
Painb (n= 83) (n= 90)
Baseline 4.4 (7.9) 7.5 (15.1)
6 months 7.5 (17.1) 6.3 (13.6)
12 months 4.5 (9.9) 8.2 (15.4) 0.52
Sleep disturbanceb (n= 78) (n= 88)
Baseline 31.4 (27.4) 29.6 (31.5)
6 months 25.0 (29.7) 30.8 (31.0)
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QoL measure ICD (n= 86) Amiodarone (n= 92) Time by group p-value (ANOVA)
12 months 23.9 (29.4) 30.2 (32.4) 0.02
Life impairmentb (n= 78) (n= 83)
Baseline 2.0 (1.9) 1.6 (1.7)
6 months 1.6 (1.8) 1.9 (1.9)
12 months 1.6 (1.3) 1.8 (1.9) 0.005
ANOVA, analysis of variance.
a Higher values represent better functioning.
b Higher values represent poorer functioning.
Effect of implantable cardiac defibrillator shocks on Mental Health
Inventory and Nottingham Health Profile scores87
QoL measure
ICDs,
no shocks
(n= 66)
ICDs, one to
four shocks
(n= 27)
ICDs, five
or more
shocks
(n= 15)
Amiodarone,
no ICD
(n= 95)
Between-
group
p-value
Domains of MHI, mean (SD)
Total indexa
Baseline 175.9 (26.5) 171.7 (22.7) 171.2 (32.0) 177.9 (27.1)
12-month follow-up 186.2 (26.9)b,c 186.6 (21.7)b,c 168.8 (41.2) 175.6 (29.2) 0.001
Within-group p-value 0.001 0.001 0.725
Psychological distressd
Baseline 50.2 (15.2) 50.8 (12.3) 51.9 (18.1) 49.8 (16.3)
12-month follow-up 42.5 (15.3)b,c 41.4 (11.7)b,c 52.7 (25.2) 50.9 (17.5) 0.001
Within-group p-value 0.001 0.001 0.833
Psychological well-beinga
Baseline 60.1 (12.5) 56.6 (11.6) 57.1 (15.0) 61.7 (12.0)
12-month follow-up 62.8 (13.1) 62.1 (10.9)c 55.6 (16.8) 60.6 (13.3) 0.02
Within-group p-value 0.074 0.004 0.642
Domains of NHP, mean (SD)
Energy leveld (n= 64) (n= 27) (n= 15) (n= 90)
Baseline 28.6 (32.5) 28.5 (30.5) 22.6 (34.2) 24.3 (30.8)
12-month follow-up 19.5 (27.1)b 24.8 (33.4)b 23.5 (29.5) 37.0 (37.6) 0.003
Within-group p-value 0.02 0.115 0.859
Physical mobilityd (n= 65) (n= 27) (n= 15) (n= 93)
Baseline 13.1 (15.0) 12.4 (10.2) 7.1 (9.8) 13.18 (20.1)
12-month follow-up 9.3 (12.4)b 15.5 (17.3) 8.0 (13.3) 17.2 (19.1) 0.02
Within-group p-value 0.05 0.638 0.747
Social isolationd (n= 66) (n= 27) (n= 15) (n= 92)
Baseline 10.6 (16.7) 4.3 (9.2) 8.9 (16.1) 11.8 (18.5)
12-month follow-up 8.8 (19.5) 6.4 (15.5) 12.8 (23.9) 12.5 (23.0) 0.57
Within-group p-value 0.03 0.991 0.817
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QoL measure
ICDs,
no shocks
(n= 66)
ICDs, one to
four shocks
(n= 27)
ICDs, five
or more
shocks
(n= 15)
Amiodarone,
no ICD
(n= 95)
Between-
group
p-value
Emotional reactionsd (n= 61) (n= 27) (n= 14) (n= 90)
Baseline 16.2 (17.4) 16.3 (17.1) 21.6 (21.1) 16.3 (19.8)
12-month follow-up 7.1 (14.6)b,c 6.8 (10.2)b 22.0 (31.0) 15.9 (20.3) 0.001
Within-group p-value 0.001 0.02 0.886
Paind (n= 66) (n= 27) (n= 15) (n= 92)
Baseline 6.8 (11.8) 4.0 (8.5) 5.3 (8.3) 8.5 (15.6)
12-month follow-up 6.4 (14.7) 5.4 (11.7) 5.5 (7.1) 7.7 (14.5) 0.71
Within-group p-value 0.086 0.710 0.721
Sleep disturbanced (n= 62) (n= 27) (n= 14) (n= 89)
Baseline 30.0 (26.9) 36.3 (31.4) 27.3 (27.1) 30.4 (30.5)
12-month follow-up 22.1 (28.1) 29.1 (33.9) 34.6 (35.4) 30.1 (33.6) 0.3
Within-group p-value 0.002 0.042 0.680
Lifestyle impairmentd (n= 65) (n= 26) (n= 14) (n= 82)
Baseline 2.0 (2.0) 2.4 (1.9) 2.2 (1.9) 1.7 (1.6)
12-month follow-up 1.3 (1.5)b 1.4 (1.5)b 1.4 (1.6) 1.9 (1.9) 0.03
Within-group p-value 0.061 0.033 0.334
a Higher values represent better functioning.
b Groups that differed significantly from the amiodarone without an ICD group (p< 0.05).
c Groups that differed significantly from the ICD five or more shocks group (p< 0.05).
d Higher values represent poorer functioning.
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Adverse effects of treatment
Adverse effect ICD (n= 328)
Amiodarone
(n= 331) p-value
ICD permanently or temporarily explanted because of infection,
heart transplantation or patient preference, n/N
16/310
Adverse experiences ever reported, n/N (%)
Pulmonary infiltrate 18/331 (5.7)
(1.9% per year)a
Visual symptoms (blurred, halo or decreased) 48/331 (14.5)
Bradycardia 10/331 (3.0)
Skin discolouration 21/331 (6.3)
Photosensitivity 34/331 (10.3)
Ataxia 97/331 (17.2)a
Tremor 91/331 (15.4)a
Insomnia 64/331 (19.3)
Peripheral neuropathy 1/331 (0.3)
ICD product discomfort, n/N (%) 25/328 (7.6)
ICD malfunction, n/N (%) 2/328 (0.6)
ICD pocket infection, n/N (%) 15/328 (4.6)
(1.4% per year)
ICD dislodgement/fracture, n/N (%) 8/328 (2.4)
a The numerator, denominator and percentages are as reported by the primary publication. They are incorrect; however,
it is not clear where the error lies.
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Long-term follow-up of subset of patients from one centre88
Participant characteristics
Characteristic ICD (n= 60) Amiodarone (n= 60) p-value
Age (years), mean (SD) 64 (9.2) 64 (8.7) NS
Sex, male, n (%) 50 (83) 50 (83) NS
Index arrhythmia, %
VF 18 27 NS
VT 35 23 0.044
Syncope/inducible VT, % 7 10 NS
History of MI, n (%) 36 (60) 31 (52) NS
Coronary artery disease, n (%) 48 (80) 48 (80) NS
NYHA class I or II, n (%) 57 (95) 57 (95) NS
NYHA class III or IV, n (%) 3 (5) 3 (5) NS
LVEF (%), mean (SD) 33.9 (12.5) 32.1 (11.1) NS
CABG surgery, n (%) 19 (32) 22 (37) NS
Percutaneous coronary
intervention, n (%)
4 (7) 2 (3) NS
Beta-blockers, n (%) 23 (38) 21 (35) NS
Diabetes mellitus, n (%) 7 (12) 11 (18) NS
Hypertension, n (%) 13 (22) 14 (23) NS
NS, not significant.
Results
Outcome ICD (n= 60) Amiodarone (n= 60) p-value
Total deaths, n (%) 16 (27) 28 (47) 0.0231
Total mortality per year, % 2.8 5.5 HR 2.011
(95% CI 1.087 to
3.721, p= 0.0261)a
Presumed arrhythmic death, % 2 12 0.049
Cardiac death, % 8 11
Vascular death, % 1 1
Non-cardiac death, % 5 4
Symptomatic non-fatal arrhythmia recurrence, n 12
a States p= 0.0261 in text but p= 0.0231 in legend of a figure.
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Adverse effects of treatment
Adverse effect ICD (n= 60) Amiodarone (n= 60) p-value
Side effects related to amiodarone, n patients (%) 49 (82)
Side effects requiring dose reduction or discontinuation,
n patients (%)
30 (50)
Serious adverse effects requiring discontinuation,
n patients
13
Severe side effects requiring permanent removal of the ICD
and crossover to amiodarone
0
Procedures performed in addition to initial implants,
n procedures
68
Defibrillators replaced 50
Battery end of life 41
Pocket infections 3
Other reasons 6
Leads replaced 18
Lead fracture 16
Lead failure/dislodgement 2
Patients undergoing two or more procedures to replace
device or change a lead (up to seven procedures, details
reported), n
41
Perioperative death, n 0
Pneumothorax, n 1
Deep-vein thrombosis, n 1
Pocket haematoma postoperatively, n 1
ICD turned off at patients request because of
terminal cancer
2
Inappropriate therapy, n (%) 30 (50)
Comments
l 19/60 amiodarone group crossed over to ICD group because of adverse events (n= 12) or arrhythmia (n= 7).
l 26/60 ICD group were receiving or had received amiodarone by the end of follow-up.
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Comments
Methodological comments
l Allocation to treatment groups: central randomisation was stratified by clinical centre and LVEF (≤ 35%
and > 35%).
l Blinding: ‘all deaths adjudicated by an External Validation Committee whose members had no other
affiliation to study. Despite best efforts, it was not always possible to blind Committee to
treatment allocation’.84
l Comparability of treatment groups: described as well-balanced.
l Method of data analysis: states analysis based on the ITT principle. Study planned as a one-sided
comparison with the hypothesis that ICDs would be superior to amiodarone. Two-sided statistics presented
in response to review process. Cumulative mortality summarised as Kaplan–Meier survival curves. Curves
compared using Mantel–Haenszel test incorporating stratification for LVEF. Cox’s proportional hazards
method used to adjust for imbalances in baseline prognostic risk and to investigate potential subgroup
effects. External safety and efficacy monitoring committee reviewed the unblinded study data every
6 months for safety and did three formal interim analyses of efficacy with the intention of stopping the
study early in favour of ICD if one-sided p≤ 0.001. For QoL study,87 analysis of variance with repeated
measures used. Significant time changes and group effects followed up by means of post-hoc tests (Tukey
honestly significant difference test). Scores on the NHP were normalised by use of a log plus 1
transformation. Effects of the number of ICD shocks on QoL were assessed using analysis of covariance.
Analysis based on the ITT principle.
l Sample size/power calculation: study originally designed with a primary outcome of arrhythmic death; this
was changed in 1993 to all-cause mortality because of concerns that the ICD might prevent some
arrhythmic deaths but, because of completing risks, have little effect on overall survival. This change led to
an increase in the patient enrolment target from 400 to 650 patients, which provided 90% power to
detect a relative reduction in all-cause mortality of 33% with the ICD with an anticipated 3-year mortality
rate of 30% on amiodarone. Crossover rates of 5% per year for both treatment groups were anticipated.
QoL study87 was conducted with the original 400 patients only because of cost. Of these, 317 spoke
English; participation rate was 79%. In the QoL study, 9/92 receiving amiodarone received an ICD and
14/86 with an ICD received amiodarone by 12 months. The long-term follow-up of a subset of patients
from one centre would not be adequately powered.88
l Attrition/dropout: of the entire trial population, 328 were randomised to the ICD group and 310 (94.5%)
received an ICD. Of the 18 who did not receive an ICD, seven died in hospital awaiting ICD surgery and 10
decided against an ICD (patient or physician) after randomisation; in addition, there was one technical
problem. A total of 16 patients had their ICD explanted permanently or temporarily because of infection,
heart transplantation or patient preference; 52/331 (15.7%) patients randomised to amiodarone received
an ICD. For QoL,87 of the original 400 participants, 317 spoke English; participation rate was 79%. Of the
317 recruited, 287 (90.5%) were alive at the 12-month assessment; 22/287 (7.7%) were missing the
baseline QoL assessment (11 from each group) and 127/287 (44%) were missing data at one of the
follow-up assessments (63 amiodarone, 64 ICD). Missing baseline date were replaced by the mean
for the variable across both treatment groups and 2-month data were excluded, resulting in a sample of
178/287 (62.0%) participants with 6- and 12-month data. In total, 9/92 in the amiodarone group received
an ICD within the first 12months and 14/86 in the ICD group were taking amiodarone at 12 months. For
the subset of patients from a single centre87 it is stated that follow-up was complete in the ICD group and
3/60 patients were lost to follow-up in the amiodarone group. In the amiodarone group 19/60 crossed over
to the ICD group because of adverse events (n= 12) or arrhythmia recurrence (n= 7). For those with an ICD,
26/60 were receiving amiodarone during follow-up.88
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General comments
l Generalisability: included people with VF, sustained VT or unmonitored syncope likely because of VT.
Most participants from centres in Canada.
l Outcome measures: mortality, QoL and adverse events only.
l Intercentre variability: not reported.
l Conflict of interests: not stated. Amiodarone supplied by Wyeth-Ayerst Pharmaceuticals, Ltd.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random
sequence generation
Unclear ‘Central randomisation was stratified by clinical centre and LVEF (≤ 35% and
> 35%)’.84 Method not stated
Allocation concealment Low ‘Central randomisation’.84 No further details given but assume allocation
concealed by central allocation
Performance bias
Blinding of participants
and personnel
High No details reported but assume participants and personnel not blinded
Detection bias
Blinding of outcome assessment
Mortality Low ‘All deaths adjudicated by an External Validation Committee whose members
had no other affiliation to study. Despite best efforts, it was not always possible
to blind Committee to treatment allocation’.84 Mortality unlikely to be
influenced by lack of blinding
QoL High
Attrition bias
Incomplete outcome
data addressed
Unclear Changes to intervention reported but missing data not reported. Crossover
rates higher than anticipated in planned analysis. For QoL subgroup, missing
data did not differ between treatment groups
Reporting bias
Selective reporting High Study design paper published,85 which specifies secondary outcome events:
‘nonfatal recurrence of ventricular fibrillation or sustained ventricular
tachycardia causing syncope or cardiac arrest requiring cardioversion or
defibrillator, other than by an ICD’. Publication of these outcomes for the
whole group not identified by the systematic review
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Defibrillator versus Beta-Blockers for Unexplained Death in
Thailand (DEBUT) trial
Reference
and design
Intervention
and comparator Participants Outcome measures
Nademanee et al.
200389
Study design:
RCT; pilot study and
main study
Country: Thailand
No. of centres:
not reported
Funding: Grant-in-Aid
from Cardiac Rhythm
Management and
Guidant Corporation,
St Paul, MN
Intervention: ICD (Guidant
Corporation, St Paul, MN)
Comparator: beta-blockade
(long-acting propranolol
40mg/day up to 160mg/day)
Other interventions used:
other beta-blocking agents or
amiodarone permitted if
intolerable side effects of
propranolol or if frequent
shocks from recurrent
VF developed
Indication for treatment: SUDS
survivors or probable survivors
No. of randomised participants:
pilot study: 20 (ICD: 10,
beta-blockers: 10); main study:
66 (ICD 37, beta-blockers: 29)
(155 screened, 88 not
randomised, one randomised
but refused ICD)
Inclusion criteria: SUDS survivor
defined as a healthy subject
without structural heart disease
who had survived unexpected VF
or cardiac arrest after successful
resuscitation. Probable SUDS
survivor defined as a subject
without structural heart disease
who experienced symptoms
indicative of the clinical
presentation of SUDs, especially
during sleep, including agonal
respiration, transient episodes of
stress, abnormal respiration
associated with grasping and
groaning, syncope or seizure-like
symptoms. ECG abnormalities
showing RBBB-like pattern with
ST elevation in right precordial
leads and inducible VT/VF in
electrophysiological testing
Exclusion criteria:
no further detail
Primary outcome: death
from all causes
Secondary outcomes:
recurrent VT/VF or cardiac
arrest
Method of assessing
outcomes: first month
and at 3-month intervals
Length of follow-up:
maximum 3 years after
randomisation. Median
follow-up not reported
Recruitment: Pilot study
January 1995 to April 1997;
main study May 1997 to
December 2000
(trial terminated by data
safety monitoring board)
RBBB, right bundle branch block.
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Participant characteristics
Pilot study
Characteristic ICD (n= 10) Beta-blocker (n= 10) p-value
Age (years), mean (SEM) 44 (11) 48 (15) 0.63
Sex, male, n (%) 10 (100) 10 (100)
Ethnicity NR NR
SUDS survivors, n 8 6
Probable SUDS survivors, n 2 4
NYHA class I, n (%) 10 (100) 10 (100)
LVEF (%), mean (SEM) 67 (12) 69 (6) 0.66
RVEF (%), mean (SEM) 60 (8) 58 (8) 0.76
Received CPR, n 9 6 0.30
Received defibrillation, n 8 5 0.35
Symptoms during index event, n
Loss of consciousness, intervention 8 6 0.63
Loss of consciousness, spontaneous recovery 2 3 0.99
Near syncope 0 1 0.99
Agonal respiration during sleep 0 0
Seizure 0 0
Difficult to arouse with signs of distress 0 0
Rhythm at time of recording, n 0.10
VF 7 6
VT 0 0
Unknown or not documented 0 4
ECG abnormalities manifesting as RBBB and ST elevation at
the precordial lead (V1–V3), n (%)
NR NR
Heart rate (bpm), mean (SEM) 67 (12) 64 (7)
PR interval (milliseconds), mean (SEM) 166 (26) 169 (30)
QRS interval (milliseconds), mean (SEM) 98 (29) 92 (12)
QT interval (milliseconds), mean (SEM) 396 (51) 387 (31)
Induced VF (≥ 300 bpm), n (%) 1 (13) 1 (10)
Induced polymorphic VT (≤ 300 bpm), n (%) 4 (50) 8 (80)
Non-inducible VF/VT, n (%) 3 (37) 1 (10)
Electrophysiological study not carried out, n 2 0
Atrio-His conduction time (milliseconds), mean (SEM) 94 (10) 94 (12)
His-Purkinje conduction time (milliseconds), mean (SEM) 58 (18) 54 (3)
Signal-averaging ECG performed, n (%) 5 8
Positive 4 (80) 4 (50)
Negative 1 (20) 4 (50)
bpm, beats per minute; CPR, cardiopulmonary resuscitation; NR, not reported; RBBB, right bundle branch block;
RVEF, right ventricular ejection fraction.
Comment
l No differences in baseline characteristics or index arrhythmic events.
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Main study
Characteristic ICD (n= 37) Beta-blocker (n= 29)
Age (years), mean (SEM) 40 (11) 40 (14) 0.95
Sex, male, n (%) 35 (95) 29 (100) 0.5
Ethnicity NR NR
SUDS survivors, n 22 20
Probable SUDS survivors, n 15 9
NYHA class I, n (%) 37 (100) 28 (100)a
LVEF (%), mean (SEM) 66 (10) 67 (7) 0.55
RVEF (%), mean (SEM) 62 (13) 60 (8) 0.6
Received CPR, n 26 20 0.92
Received defibrillation, n 17 18 0.17
Symptoms during index event, n
Loss of consciousness, intervention 26 21 0.85
Loss of consciousness, spontaneous recovery 5 4 0.99
Near syncope 2 1 0.99
Agonal respiration during sleep 3 3 0.99
Seizure 0 5 0.01
Difficult to arouse with signs of distress 2 4 0.67
Rhythm at time of recording, n 0.74
VF 9 11
VT 2 2
Unknown or not documented 26 16
ECG abnormalities manifesting as RBBB and ST elevation at
the precordial lead (V1–V3), n (%)
23 (62) 16 (55)
Heart rate (bpm), mean (SEM) 64 (11) 66 (12) 0.48
PR interval (milliseconds), mean (SEM) 180 (98) 163 (27) 0.48
QRS interval (milliseconds), mean (SEM) 99 (30) 95 (16) 0.43
QT interval (milliseconds), mean (SEM) 404 (43) 394 (31) 0.33
Induced VF (≥ 300 bpm), n (%) 8 (22) 8 (30) 0.70
Induced polymorphic VT (≤ 300 bpm), n (%) 15 (40) 11 (41)
Non-inducible VF/VT, n (%) 14 (38) 8 (30)
Electrophysiological study not carried out 0 2
Atrio-His conduction time (milliseconds), mean (SEM) 100 (22) 96 (22) 0.58
His-Purkinje conduction time (milliseconds), mean (SEM) 51 (8) 49 (11) 0.47
Signal-averaging ECG performed, n (%) 29 21 0.74
Positive 11 (38) 7 (33)
Negative 18 (62) 14 (67)
bpm, beats per minute; CPR, cardiopulmonary resuscitation; RBBB, right bundle branch block; RVEF, right ventricular
ejection fraction.
a Reported in paper as 28 (100%); however, 28/29 would be (96.5%). Not clear which is correct.
Comment
l No differences in baseline characteristics or index arrhythmic events.
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Results
Pilot study
Outcome ICD (n= 10) Beta-blocker (n= 10) p-value
Died before main trial, n 1
Death during follow-up, n 0 3 (2 SUDS survivors, 1 probable
SUDS survivor) at 5.4, 11.8
at 24.6 months
0.07
Multiple VF episodes successfully treated
by ICD, n
5
Adverse effects of treatment
Adverse effect ICD (n= 10) Beta-blocker (n= 10) p-value
Operative mortality, n 0
Adverse effects, n/N (%) 2/10 (20)
Defibrillation discharges caused by
supraventricular tachycardia or
sinus tachycardia
1
T-wave oversensing 0
ICD replaced because of insulation break, n 1
Main study
Outcome ICD (n= 37) Beta-blocker (n= 29) p-value
Mortality during 3-year follow-up, n (%) 0 4 (14) 0.02
Annual death rate 0 About 10%
Survival (months), mean (SEM) 26.2 (1.4)
Recurrent VF (effectively treated by ICD),
n (%)
7 (19)
Comment
l Kaplan–Meier survival curve presented.
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Adverse effects of treatment
Adverse effect ICD (n= 37) Beta-blocker (n= 29) p-value
Operative mortality 0
Adverse effects, n/N (%) 11/37 (30) 4 (14)
Minor complications, corrected by reprogramming devices without major intervention, n
Defibrillation discharges caused by
supraventricular tachycardia or sinus
tachycardia
7
T-wave oversensing 3
Pocket erosion requiring removal of ICD, n 1
Side-effects in beta-blocker group, n
Impotence/decrease in libido 1
Fatigue 1
Profound bradycardia 1
Hypotension plus central nervous system
side effect
1
Comment
l Medication compliance in beta-blocker group 98%.
Pilot and main study combined
Outcome ICD (n= 47) Beta-blocker (n= 39) p-value
Sudden death, n 0 7
Multiple VF episodes and defibrillation shocks, n 12
Annual rate of VF episodes or sudden death (%) 20 10
Comment
l Kaplan–Meier survival curve of composite of primary and secondary end points (sudden death or VF episodes) for pilot
and main trial data presented.
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Comments
Methodological comments
l Allocation to treatment groups: randomisation stratified by SUDS survivor vs. probable SUDS survivor.
l Blinding: not reported.
l Comparability of treatment groups: groups similar.
l Method of data analysis: interim analyses planned after half of patients and three-quarters of patients had
been randomised. Trial planned to be stopped after first interim analysis if survival analysis was p< 0.005
and after second analysis if p< 0.006. Final statistical analysis at the 0.048 significance level. Trial stopped
at first interim analysis by data safety monitoring board even though analysis did not reach level of
significance, based on cumulative weight of all evidence gained from data (including pilot study) that ICDs
were superior. Baseline characteristics compared and any significantly different factors were used as
covariates in subsequent analysis. States ITT analysis used to contrast mortality rates and used Kaplan–Meier
methods for calculating survival curves, log-rank method for comparing survival curves and Cox regression
methods for comparing survival curves adjusting for covariates found to be different between
treatment arms.
l Sample size/power calculation: from the pilot study it was estimated that 114 patients needed to be
randomised, based on an expected annual mortality rate of 20% for the SUDS population. Assuming that
the annual mortality rate would be reduced 10-fold (i.e. by up to 2%) in the ICD arm, 57 patients per
treatment arm were required to produce the expected difference at 80% power and 0.05 two-sided
significance level. Note that only 66 patients were randomised. The annual death rate in the beta-blocker
arm was about 10%, half that used for the sample size calculation.
l Attrition/dropout: in total, 155 people were screened, 64 had probable SUDS, either non-inducible or
unclear marker, 10 refused to be enrolled, one was randomised to the ICD group but refused, two
preferred ICD treatment, five had brain anoxic encephalopathy, six had presence of heart disease and one
entered after the trial was stopped. Attrition/dropout after randomisation not reported. Not clear if all
66 participants were followed for 3 years.
General comments
l Generalisability: small trial stopped early. Population differs significantly from that in other trials as
participants are survivors of sudden unexplained death with otherwise normal hearts with no HF. All
participants were of Thai origin, mostly men. Participants similar to those with Brugada syndrome (a genetic
disorder characterised by abnormal ECG findings and increased risk of SCD); study findings should also
apply to this group of people.
l OPT used: the use of beta-blockers is low in the ICD group (exact numbers in main trial not clear, but 8/47
in the main trial and pilot study combined). The study used an active comparator.
l Outcome measures: limited to death from all causes, VT/VF episodes and adverse events.
l Intercentre variability: not reported.
l Conflict of interests: not stated. Supported by grant-in-aid from Cardiac Rhythm Management and Guidant
Corporation, St Paul, MN.
l Other: paper reports the results of a pilot study and main study.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Details not reported
Allocation concealment Unclear Details not reported
Performance bias
Blinding of participants and personnel High Not reported but unlikely to be blinded because of surgical
intervention in one arm
Detection bias
Blinding of outcome assessment Low Not reported but assessment of mortality unlikely to be
influenced by lack of blinding
Attrition bias
Incomplete outcome data addressed Unclear States ITT analysis but loss to follow-up not reported.
Follow-up for maximum 3 years; not clear how many
participants followed for this length of time
Reporting bias
Selective reporting Low
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Defibrillators in Non-Ischemic Cardiomyopathy Treatment
Evaluation (DEFINITE)
Reference and design
Intervention
and comparator Participants Outcome measures
Kadish et al. 200091 and
2004,90 Schaechter et al.
200392 Ellenbogen et al.
2006,93 Passman et al.
200794
Study design: RCT
Countries: USA and
Israel
No. of centres:
48 (USA 44, Israel 4)
Funding: St
Jude Medical
Intervention: ICD+ standard
oral medical therapy for HF
(OPT). Single chamber device.
Programmed to back up VVI
pacing at a rate of 40 bpm
and to detect VF at a rate of
180 bpm
Comparator: OPT. Medical
therapy in both groups for HF
included ACE inhibitors
unless contraindicated (then
hydralazine, nitrates or ARBs)
and beta-blocker therapy
(unless not tolerated) with
carvedilol. Doses of ACE
inhibitors and beta-blockers
adjusted to recommended
levels for HF patients or to
highest tolerated doses.
Digoxin and diuretics used
when necessary to manage
clinical symptoms. Use of
AADs (e.g. amiodarone)
discouraged but allowed for
some patients with
symptomatic atrial fibrillation
or supraventricular
arrhythmias. No other
AADs used
Other interventions used:
none reported
Indication for treatment:
non-ischaemic
cardiomyopathy and
moderate to severe left
ventricular dysfunction
No. of randomised
participants: 458; ICD+OPT:
229, OPT: 229
Inclusion criteria: NYHA class
not reported, LVEF < 36%,
LVEDD not reported, QRS
interval not reported,
presence of ambient
arrhythmias (episode of
non-sustained VT 3–15 beats
at a rate of> 20 bpm or an
average of at least 10
premature ventricular
complexes per hour on
24-hour Holter monitoring),
history of symptomatic HF,
presence of non-ischaemic
dilated cardiomyopathy,
absence of clinically
significant coronary artery
disease, age 21–80 years93
Exclusion criteria: NYHA class
IV, not a candidate for an
ICD, electrophysiological
testing within the last
3 months, permanent
pacemaker, cardiac
transplantation appeared
imminent, familial
cardiomyopathy associated
with sudden death, acute
myocarditis, congenital
heart disease
Primary outcome: death from
any cause
Secondary outcomes: sudden
death from arrhythmia, QoL94
Method of assessing
outcomes: at 3-month
intervals. Cause of death
used Epstein classification;
therefore, patients with
progressive symptomatic
deterioration of pump failure
who died from terminal VF
were not considered to have
had sudden death from
arrhythmia. ICD shocks
assessed at each follow-up or
when indicated by
symptoms.94 QoL assessed
with self-administered SF-12
and the MLWHFQ at
baseline, 1 month after
randomisation and every
3 months thereafter
(to 63 months)94
Length of follow-up:
duration computed from
randomisation to death or to
the date of the 68th death
for those who did not die.
Mean (SD) 29.0 (14.4)
months
Recruitment:
July 1998 to June 2002
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter.
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Participant characteristics
Characteristica ICD+OPT (n= 229) OPT (n= 229) p-value
Age (years), mean (range) 58.4 (20.3–83.9) 58.1 (21.8–78.7)
Sex male, n (%) 166 (72.5) 160 (69.9)
Self-reported ethnicity, n (%)
White 154 (67.2) 154 (67.2)
Black 59 (25.8) 59 (25.8)
Hispanic 13 (5.7) 13 (5.7)
Pacific Islander 1 (0.4) 0
Asian 0 1 (0.4)
Other 2 (0.9) 2 (0.9)
Qualifying arrhythmia, n (%)
NSVT only 51 (22.3) 52 (22.7)
PVCs only 21 (9.2) 22 (9.6)
NSVT and PVCs 157 (68.6) 155 (67.7)
Severity of disease, e.g. NYHA classification
NYHA class I, n (%) 58 (25.3) 41 (17.9)
NYHA class II, n (%) 124 (54.2) 139 (60.7)
NYHA class III, n (%) 47 (20.5) 49 (21.4)
LVEF (%), mean (range) 20.9 (7–35) 21.8 (10–35)
Heart rate NR NR
QRS interval (milliseconds), mean (range) 114.7 (78–196) 115.5 (79–192)
LBBB, n (%) 45 (19.7) 45 (19.7)
RBBB, n (%) 8 (3.5) 7 (3.1)
continued
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Characteristica ICD+OPT (n= 229) OPT (n= 229) p-value
Pharmacological therapy, n (%)
ACE inhibitor 192 (83.8) 200 (87.3)
Beta-blocker 196 (85.6) 193 (84.3)
Carvedilol 129 (56.3) 134 (58.5)
Metoprolol 59 (25.8) 43 (18.8)
Other 8 (3.5) 16 (7.0)
Diuretic 200 (87.3) 197 (86.0)
ARB 31 (13.5) 20 (8.7)
Amiodarone 9 (3.9) 15 (6.6)
Digoxin 95 (41.5) 97 (42.4)
Nitrate 21 (9.2) 30 (13.1)
Duration of HF (years), mean (range) 2.39 (0.0–21.33) 3.27 (0.0–38.5) 0.04
History of diabetes, n (%) 52 (22.7) 53 (23.1)
History of atrial fibrillation, n (%) 52 (22.7) 60 (26.2)
Distance walked in 6 minutes (m), mean (range) 311.2 (29–1143) 328.3 (18–1317)
ICD+OPT (n= 227) OPT (n= 226)
HRQoL94a
Physical score (MLWHFQ), mean (SD) 20 (12) 20 (12) 0.98
Emotional score (MLWHFQ), mean (SD) 11 (8) 10 (8) 0.59
PCS (SF-12), mean (SD) 37 (11) 38 (10) 0.47
MCS (SF-12), mean (SD) 45 (11) 47 (11) 0.14
NR, not reported; PVC, premature ventricular complex; RBBB, right bundle branch block.
a Separate participant characteristics are reported for the QoL study, which excluded five patients with no data, but only
data for baseline SF-12 and MLHFQ scores have been extracted. In common with the data above, the only significant
difference between the groups was for duration of HF > 1 year (p= 0.01).
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Results
Outcome
ICD+OPT
(n= 229)
OPT
(n= 229) HR (95% CI) p-value
All-cause mortality, n 28 40 0.65 (0.40 to 1.06),a 0.08
All-cause mortality rate at 1 year, % 2.6 6.2
All-cause mortality rate at 2 years, % 7.9 14.1
Sudden death from arrhythmia, n 3 14 0.20 (0.06 to 0.71), 0.006
Death from HF, n 9 11
Receipt of appropriate ICD shocksb 41 patients,
91 shocks
Receipt of inappropriate ICD shocksb 49 patients
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR
HF hospitalisations NR NR
Change in NYHA class NR NR
Change in LVEF NR NR
Exercise capacity outcomes (e.g. 6-minute
walk distance, total exercise time, peak VO2)
NR NR
ICD+OPT
(n= 227)
OPT
(n= 226) p-value
HRQoL94
Long-term MCS score 0.89
Long-term PCS score NS, p-value not reported
Long-term MLWHFQ subscale score NS, p-value not reported
NR, not reported; NS, not significant.
a HR for death among ICD patients compared with OPT patients. The HR was unchanged after adjustment for duration
of HF.
b Unclear whether these data are for the ICD group only or whether participants from the OPT group who had received
an ICD are also included. Inappropriate shocks were primarily for atrial fibrillation or sinus tachycardia. More detailed
reporting on shocks received is presented by Ellenbogen et al.93 but these data, which differ from those reported in the
main study paper,90 have not been extracted. The reason(s) for the difference between the two papers is not discussed
in either paper.
Comments
l Mortality presented for treatment actually received not data extracted.
l Kaplan–Meier plots for death from any cause and sudden death from arrhythmia presented but not extracted.
l One death in the OPT group was thought to be from cardiac causes but an arrhythmic or non-arrhythmic cause could
not be distinguished from the available information.
l 26 deaths classified as non-cardiac were not reported by treatment group (10 from cancer, seven from pneumonia,
five from stroke, one each to drug overdose, suicide, liver failure and renal failure).
l Four deaths (two in each group) could not be classified (insufficient information).
l Pairwise comparisons of unadjusted MLWHFQ and SF-12 scores by treatment group were evaluated but none reached
statistical significance. This indicated no detectable difference in QoL between the groups for this period. Results are
presented in a figure and data have not been extracted.
l SF-12 scores adjusted by time in trial are presented in a figure but have not been data extracted. Higher scores
represent better QoL. Numerical data for short-term (approx. 3 months) changes within groups showed a statistically
significant improvement from baseline for the ICD group and a non-statistically significant trend towards improvement
in the OPT group. After this short-term improvement scores in both groups declined slowly (statistically significant)
towards baseline values.
l MLWHFQ scores adjusted by time in trial are also presented in a figure but have not been data extracted. Significant
improvements in the emotional and physical scale scores occurred from enrolment to the second follow-up visit. After
initial improvement, scores remained stable for the emotional scale in both groups; scores for the physical scale
decreased equally toward baseline values.
l Potential interaction between QoL and patient variables was assessed but the results implied that clinical variables
cannot be used to identify patients who are likely to show a decline in QoL after ICD implantation.
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Adverse effects of treatment
Adverse effect ICD+OPT (n= 229) OPT (n= 229) p-value
Complications during implantation of ICD,a n (%) 3 (1.3)
Haemothorax 1
Pneumothorax 1
Cardiac tamponade 1
Procedure-related deaths, n 0
Complications during follow-up, n (%) 10 (4.4)
Lead dislodgement or fracture 6
Venous thrombosis 3
Infection 1
Receipt of ICD upgrade during follow-up, n 13
Dual chamber ICD because of development of
sinus node dysfunction
2
Biventricular device for NYHA class III or IV HF
and prolonged QRS interval
11
a All resolved with medical therapy or drainage.
Prespecified subgroup analyses
Subgroup analysis RR (95% CI) p-value
RR of death from any cause after receipt of ICD in comparison to OPT
For men 0.49 (0.27 to 0.90) 0.018
For NYHA class III HF patients 0.37 (0.15 to 0.90) 0.02
Comments
l Six prespecified subgroup analyses (age, sex, LVEF, QRS interval, NHYA class and history of atrial fibrillation) are
presented in a figure, with data reported for men and NYHA class III only. The 95% CIs crossed 1.0 apart from for
men, NYHA class III and LVEF ≥ 20% (favours ICD, data in figure only).
l None of the differences between subgroups were significant.
l The study was not powered to detect differences within subgroups.
l Kaplan–Meier survival curves for NYHA class III patients in the ICD and OPT groups are provided, but have not been
data extracted.
l The QoL paper94 reports an analysis of the impact of shocks on QoL (comparing those receiving shocks with those not
receiving shocks); however, this analysis is not mentioned in either of the two available papers on study design and
organisation.91,92 Therefore, it is assumed that these are post hoc analyses and they have therefore not been
data extracted.
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Comments
Methodological comments
l Allocation to treatment groups: randomisation stratified by centre and by the use or non-use of
amiodarone for supraventricular arrhythmias.
l Blinding: cause of death determined by an events committee unaware of patients’ treatment assignments.
Blinding process included editing information from progress notes or laboratory reports that could have
identified the presence of an ICD.
l Comparability of treatment groups: similar apart from duration of HF [ICD+OPT mean 2.39 (range
0.0–21.33) years, OPT mean 3.27 (range 0.0–38.5) years, p= 0.04].
l Method of data analysis: all analyses ITT. Data collection and analysis independently performed at
Northwestern University, IL. Interim analyses performed after 22, 34, 45, 50 and 56 deaths. Critical values
for interim and final analyses assumed an O’Brien–Fleming type of spending function. For patient safety,
stopping boundaries were defined in favour of the null hypothesis of no effect of the ICD on the risk of
death at each interim analysis. No boundaries were crossed at any of the five interim analyses so the report
presents the final analysis results at the time of the 68th death. The p-value for significance in the final
analysis was 0.041 on the basis of a two-sided test. Baseline characteristics were compared using two-
sample t-tests for continuous variables and chi-square tests for categorical variables. Log-rank test was used
to compare Kaplan–Meier survival curves. Cox proportional hazards model was used to adjust for covariates
and to estimate the HR for death and corresponding 95% CI in the ICD group vs. the OPT group. Data for
patients receiving a heart transplant were censored at the time of transplantation. All reported p-values are
two-tailed. QoL outcomes were compared using hierarchical linear regression. QoL analyses were controlled
for baseline differences and predetermined characteristics (sex, age, NYHA class, ethnicity, ejection fraction,
duration of HF, history of atrial fibrillation). Covariates were entered into and removed from the model
stepwise at the group level with α= 0.05 and α= 0.10 as the criterion for entry and removal respectively.94
l Sample size/power calculation: designed to have statistical power of 85% based on a one-sided test.
Two-year mortality rate of 15% assumed in the comparator group and 7.5 in the ICD group with
enrolment of 458 patients and 56 deaths. To report results with the use of two-sided tests and 85%
statistical power, follow-up was extended to include 68 deaths.
l Attrition/dropout: prespecified criteria meant that the OPT group patients received an ICD if they had a
cardiac arrest or an episode of unexplained syncope consistent with the occurrence of an arrhythmic event.
Overall, 23 (10%) of the OPT group received an ICD during follow-up, primarily for this reason (no further
details provided). Two ICD group participants declined implantation of the device after randomisation.
Additionally, one patient had the ICD explanted and one had the device inactivated. All four were included
in the ICD group (ITT analysis). In the QoL analysis, missing months of data were treated following a full
information restricted maximum likelihood estimation approach.94 The QoL analysis excluded five patients
who did not provide any data (two from the ICD group, three from the OPT group). QoL data were missing
from one or two visits for 130 patients, and 178 patients had missing QoL data from more than two visits.
States no relationship between QoL and varying length of follow-up or dropping out of the study. No
significant differences between complete and incomplete QoL data by patient age, sex or NYHA class but
patients without missing data are more likely to be white and have a better ejection fraction and less likely
to have diabetes than those with missing data (all p< 0.05). Those with complete data were more likely to
report a better baseline QoL. No interactions between data completeness and treatment group (p= 0.2).
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General comments
l Generalisability: focus was on primary prevention of sudden death in patients with non-ischaemic
cardiomyopathy and moderate to severe left ventricular dysfunction. Results unlikely to be generalisable to
higher-risk groups, e.g. secondary prevention of sudden death.
l Outcome measures: appear appropriate.
l Intercentre variability: randomisation stratified by centre but no comments regarding intercentre variability.
l Conflict of interests: states study sponsor did not have access to the data. Three of the authors had
received fees from one or more of Medtronic, Guidant Corporation and St Jude Medical.
l Other: included after receiving advice from experts who indicated that it was similar to the AMIOVERT trial
investigating whether ICDs reduce mortality in a high-risk population with cardiomyopathy and no coronary
disease. Note that mean QRS interval is < 120milliseconds in each group so on average no
cardiac dyssynchrony.
Criteria for assessment of risk of bias in randomised controlled trials65
Judgementa Support for judgement
Selection bias
Random sequence generation Unclear No details about sequence generation
Allocation concealment Unclear No details reported
Performance bias
Blinding of participants and personnel High Not reported
Detection bias
Blinding of outcome assessment
Mortality Low Events committee determining cause of death blinded
QoL High
Attrition bias
Incomplete outcome data addressed Low ITT analysis and attrition for each group reported
with reasons
Reporting bias
Selective reporting High A cost analysis is listed in both papers reporting on
study design and organisation91,92 but no cost
outcomes are reported in the identified papers
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Defibrillator in Acute Myocardial Infarction Trial (DINAMIT)
Reference and design
Intervention
and comparator Participants Outcome measures
Hohnloser et al. 200096 and
200495
Study design: RCT
Countries: 12 countries
worldwide
No. of centres: 73
(Canada 25, Germany 21,
UK 4, Slovakia 2, Poland 4,
France 8, Czech Republic 1,
Austria 2, Switzerland 1,
Sweden 2, Italy 1, USA 2)
Funding: Supported by a
grant from St Jude Medical
Intervention: ICD+OPT
(supplied by St Jude
Medical). Single-chamber
ICD implanted within
1 week of randomisation.
Implanted leads were
required to achieve an
R wave of < 4.9mV, a
pacing threshold of
> 2.1 V at 0.5milliseconds
and a defibrillation
threshold with a safety
margin of at least 10 J.
Postoperatively, the ICD was
set to detect VT and VF.
The detection rate for
tachycardia was set at
≥ 175 bpm per minute for
≥ 16 beats. The device was
programmed to deliver all
discharges at maximal
output in the VF zone
(≥ 200 bpm). Bradycardia
pacing was programmed for
activation at a minimum of
40 bpm. Antitachycardia
pacing within the VT zone
(175–200 bpm) could be
activated to deliver four
bursts of six to 10 beats
beginning at 81% of the
tachycardia cycle length,
with 10-milliseconds
decrements between bursts
Comparator: OPT (best
conventional medical
therapy)
Other interventions used:
Best conventional medical
therapy. Investigators were
encouraged to treat all
study patients with ACE
inhibitors, beta-blockers,
aspirin and lipid-lowering
drugs as appropriate
(reasons for not giving
these medications
were documented)
Indication for treatment:
Recent MI (within
6–40 days), reduced
LVEF and impaired cardiac
autonomic function
No. of randomised
participants: 674; ICD: 332,
OPT: 342
Inclusion criteria: Age
18–80 years, recent MI
(within 6–40 days),
LVEF ≤ 0.35, SD of
normal-to-normal
R–R intervals of
≤ 70milliseconds or
a mean R–R interval of
≤ 750milliseconds (HR
≥ 80 bpm) over a 24-hour
period as assessed by
24-hour Holter monitoring
performed at least 3 days
after the infarction
Exclusion criteria: CHF or
NYHA class IV at time of
randomisation, non-cardiac
disease that limited life
expectancy, CABG
performed since the
qualifying infarction or
planned to be performed
within 4 weeks of
randomisation, three-vessel
percutaneous coronary
intervention performed
since the qualifying
infarction, name on a
waiting list for a heart
transplant, current ongoing
ICD therapy, previous
implantation of a
permanent pacemaker,
requirement for an ICD
(i.e. sustained VT or VF
> 48 hours after the
qualifying infarction), low
probability that the study
ICD could be implanted
within 7 days of
randomisation, expected
poor compliance with
the protocol
Primary outcome: Death
from any cause
Secondary outcome: Death
from cardiac arrhythmia
Method of assessing
outcomes: Cause of death
ascertained by local
investigators and
documentation based on
information obtained from
witnesses, family members,
death certificates, hospital
records and autopsy reports
when available, not from ICD
telemetry. All deaths were
reviewed by a committee and
classification of each death
was agreed based on clinical
circumstances of death and
not ICD information. Deaths
were classified as either
arrhythmic or non-arrhythmic
in nature (based on criteria
from Hinkle and Thaler,
reference provided).
Follow-up visits were
scheduled at 3 and 6 months
after randomisation and at
6-monthly intervals
thereafter. Follow-up ended
in September 2003, about
15 months after last patient
was recruited
Length of follow-up:
Mean follow-up 30 (SD 13)
months, maximum 4 years
from randomisation
Recruitment:
April 1998–June 2002
bpm, beats per minute.
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Participant characteristics
Characteristic ICD (n= 332)a OPT (n= 342)a p-value
Age (years), mean (SD) 61.5 (10.9) 62.1 (10.6) NR
Sex male, n (%) 252 (75.9) 262 (76.6) NR
Ethnicity NR NR
CHF with index MI, n (%) 156 (47.0) 167 (48.8) NR
NYHA class I 21 (13.5) 20 (12.0) NR
NYHA class II 95 (60.9) 98 (58.7) NR
NYHA class III 40 (25.6) 49 (29.3) NR
LVEF, mean (SD) 0.28 (0.05) 0.28 (0.05) NR
Heart rate NR NR
Electrophysiology
QRS duration (milliseconds), mean (SD) 107 (24) 105 (23) NR
Peak creatine kinase (U/l), mean (SD) 2329 (3837) 2138 (2349) NR
New Q-wave infarction, n (%) 240 (72.3) 256 (74.9) NR
SD of normal-to-normal RR intervals (milliseconds), mean (SD) 61 (21) 61 (22) NR
24-hour RR interval (milliseconds), mean (SD) 745 (106) 747 (105) NR
Beta-blockers, n (%) 289 (87.0) 296 (86.5) NR
ACE inhibitors, n (%) 315 (94.9) 323 (94.4) NR
Antiplatelet agents, n (%) 306 (92.2) 315 (92.1) NR
Lipid-lowering agents, n (%) 255 (76.8) 272 (79.5) NR
Cardiac history, n (%)
Previous MI 123 (37.0) 111 (32.5) NR
Previous CABG 25 (7.5) 24 (7.0) NR
Previous PTCA 49 (14.8) 38 (11.1) NR
Location of index MI, n (%)
Anterior 239 (72.0) 247 (72.2) NR
Other 93 (28.0) 95 (27.8) NR
In-hospital therapy for MI, n (%)
Any 208 (62.7) 212 (62.0) NR
PTCA only 87 (26.2) 92 (26.9) NR
Thrombolysis only 88 (26.5) 76 (22.2) NR
Both PTCA and thrombolysis 33 (9.9) 44 (12.9) NR
None 115 (34.6) 111 (32.5) NR
Unknown 9 (2.7) 19 (5.6) NR
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Characteristic ICD (n= 332)a OPT (n= 342)a p-value
Comorbidities, n (%)
Diabetes mellitus 102 (30.7) 98 (28.7) NR
Hypertension 155 (46.7) 154 (45.0) NR
NR, not reported; PTCA, percutaneous transluminal coronary angioplasty.
a Not all percentages total 100 because of rounding.
Comments
l Authors state that there were no significant differences between the treatment groups in baseline characteristics.
l The average time from MI to randomisation was 18 days and was similar in both groups.
l The average time between randomisation and ICD implantation was 6.3 (SD 7.3) days.
l The average time between implantation and hospital discharge was 4.7 (SD 6.4) days.
Results
Outcome ICD (n= 332) OPT (n= 342) HR (95% CI),a p-valueb
Mortality rate, n [rate (%/year]c,d
Primary outcome: death from any cause 62 (7.5) 58 (6.9) 1.08 (0.76 to 1.55), 0.66
Secondary outcome: death from arrhythmia 12 (1.5) 29 (3.5) 0.42 (0.22 to 0.83), 0.009
Secondary outcome: non-arrhythmic causes 50 (6.1) 29 (3.5) 1.75 (1.11 to 2.76), 0.02
Cardiac, non-arrhythmic 34 (4.1) 20 (2.4) 1.72 (0.99 to 2.99), 0.05
Vascular, non-cardiac 5 (0.6) 3 (0.4) 1.69 (0.40 to 7.06), 0.47
Non-vascular 11 (1.3) 6 (0.7) 1.85 (0.68 to 5.01), 0.22
Percutaneous or surgical coronary revascularisation, n (%) 33 (9.9) 50 (14.6) p= 0.08
Prescribed amiodarone, n (%) 27 (8.1) 46 (13.5) p= 0.04
a HRs are for the ICD group vs. the OPT group.
b p-values are two-sided.
c Average follow-up 30 (SD 13) months.
d The data were analysed with use of the Cox model.
Comments
l Kaplan–Meier curves also reported for cumulative risk of death from any cause, cumulative risk of death from
arrhythmia and cumulative risk of death from non-arrhythmic causes.
l HRs for death from any cause also reported according to selected clinical characteristics (age, sex, diabetes, NYHA class,
LVEF, rhythm, QRS duration, NSVT, heart rate, SD of normal RR intervals and early reperfusion).
l States that for each outcome the ICD effect remained consistent and did not differ significantly between or
among subgroups.
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Adverse effects of treatment
Adverse effect ICD (n= 332)
Death related to device implantation, n 0
In-hospital device-related complications,a n 25/310
a Most common complications were lead dislodgement, pneumothorax and inappropriate shocks.
Comments
Methodological comments
l Allocation to treatment groups: central randomisation was performed at the study co-ordinating and
methods centre. Patients were randomly assigned in a 1 : 1 ratio. The randomisation sequence was
stratified according to centre and balanced within randomly varying blocks of two, four or six patients.
l Blinding: unblinded study; blinding reported for independent review committee.
l Comparability of treatment groups: described as well balanced for baseline clinical characteristics and early
use of reperfusion therapy (states no significant differences). The ICD group had slightly higher percentages
for previous MI and percutaneous transluminal coronary angioplasty (PTCA) and in-hospital therapy for
‘thrombolysis only’. The OPT group had slightly higher percentages for NYHA class III as well as in-hospital
therapy for ‘both PTCA and thrombolysis’ and ‘unknown’. Average time from MI to randomisation was
18 days – similar between groups (no p-value reported). Amiodarone use was higher in the OPT group.
l Method of data analysis: the primary study outcome was evaluated according to the ITT principle. The
cumulative risks of death from any cause and from specific causes over time were estimated separately for
each treatment group with the use of the Kaplan–Meier procedure and were compared between groups
with the use of the Mantel–Haenszel test. A single interim analysis of efficacy was performed by an external
safety and efficacy monitoring committee after 66deaths (about half the anticipated number) had occurred.
A one-sided p-value of < 0.001 would have resulted in early termination of the study. Before unblinding, a
decision was made to use two-sided statistical testing.
l Sample size/power calculation: on the basis of mortality data from similar populations of patients, it was
anticipated that the OPT group would have a 3-year mortality rate of 30.0% and that 40.0% of these
deaths would be caused by arrhythmias. The net effect of preventing 80.0% of these deaths from
arrhythmias with the use of an ICD would be to reduce the total mortality rate to 20.4%. Based on a
one-sided test at an alpha level of 0.05, 525 patients would be required for the study to have 80% power
to identify a difference between the groups. Because mortality rates were lower than expected during the
study, the target enrolment was increased to 674 patients. States that it is unlikely that the similarity
between the two groups in the rate of death from all causes represents a false-negative result because of
an inadequate sample size.
l Attrition/dropout: four patients in the OPT group had only partial follow-up data available. ICD received:
310/332; 20/332 patients refused ICD implantation, 2/332 died before receiving the ICD.
General comments
l Generalisability: limited to high-risk patients with a recent MI, reduced LVEF and impaired cardiac
autonomic function.
l Outcome measures: limited to mortality. No adverse event data for the OPT group and limited adverse
event data for the ICD group.
l Intercentre variability: not reported.
l Conflict of interests: Drs Hohnloser, Kuck, Dorian and Connolly are consultants to and have received lecture
fees from St Jude Medical. Dr Fain is an employee of St Jude Medical. Data analysis was performed at the
Hamilton Civic Hospitals Research Centre by two of the authors (Mr Roberts and Dr Gent). All investigators
had full access to the data.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear The randomisation sequence was stratified according
to centre and balanced within randomly varying
blocks of two, four or six patients. No details of
sequence generation
Allocation concealment Low Central randomisation
Performance bias
Blinding of participants and personnel High Described as an unblinded study
Detection bias
Blinding of outcome assessment Low Assessment of causes of death by unblinded local
investigators, but all causes of deaths were reviewed
by an independent blinded central validation committee
Attrition bias
Incomplete outcome data addressed Low Primary outcome was evaluated according to the ITT
principle; unclear how partially missing follow-up data
for four OPT patients were accounted for in relation
to secondary outcomes
Reporting bias
Selective reporting High QoL mentioned in protocol but data not reported
Other bias
Other sources of bias High Block randomisation in unblinded trial can lead to
prediction of allocation
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Immediate Risk Stratification Improves Survival (IRIS) trial
Reference
and design
Intervention
and comparator Participants Outcome measures
Steinbeck et al.
200498 and 200997
Study design: RCT
Countries: Austria,
the Czech Republic,
Germany, Hungary,
Poland, the Russian
Federation, Slovakia
No. of centres: 92
Funding: grants
from Medtronic
Bakken Research
Center, AstraZeneca
and R Becker
Intervention: ICD+OPT. In
total, 78% received Medtronic
models of the GEM® family,
11% Micro Jewel II, 8%
Maximo and 3% Marquis.
A total of 81% were
single-chamber ICDs. A Fidelis
lead was used in 21% of
patients. Protocol required two
consecutive terminations of VF
at 10 J below the maximum
ICD output and VVI pacing at
40 bpm, with maximal shock
energy turned on for
treatment of VF (threshold
≥ 200 bpm) and treatment for
VT turned off initially
Comparator: OPT
(not described further)
Other interventions used:
Not stated
Indication for treatment:
Recent MI (within ≤ 31days)
and predefined markers of
elevated risk
No. of randomised
participants: 898; ICD: 445,
OPT: 453
Inclusion criteria: Predefined
markers of elevated risk: at
least one of heart rate
≥ 90 bpm on the first available
ECG (within 48 hours of MI)
and LVEF ≤ 40% (on one of
days 5–31 after MI); NSVT of
three or more consecutive
ventricular premature beats
during Holter ECG monitoring,
with a heart rate of ≥ 150 bpm
(on days 5–31)
Exclusion criteria: Ventricular
arrhythmia before the index MI
or > 48 hours after the event
and required treatment, NYHA
class IV, interval > 31 days
between the MI and
presentation, no ECG within
48 hours of chest pain onset,
indication for CABG surgery,
psychiatric disorder, severe
concomitant disease, history of
poor compliance with
treatment, current
participation in another trial,
unstable clinical condition
Primary outcome: Overall
mortality
Secondary outcomes: SCD
[death occurred within
minutes of onset of acute
symptoms, resulted from a
documented cardiac
arrhythmia or was not
witnessed and occurred
unexpectedly and without
recognisable causes
(e.g. during sleep)], non-SCD,
non-cardiac death
Method of assessing
outcomes: 3 and 6 months
after randomisation and then
at 6-month intervals
Length of follow-up: Average
37 (range 0–106) months
Recruitment:
June 1999–October 2007
bpm, beats per minute.
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Participant characteristics
Characteristic ICD (n= 445) OPT (n= 453) p-value
Age (years), mean (SD) 62.8 (10.5) 62.4 (10.6)
Sex, male, n (%) 345 (77.5) 344 (75.9)
Ethnicity NR NR
Criteria for inclusion, n (%)
Criterion 1 only (heart rate and LVEF) 299 (67.2) 303 (66.9)
Criterion 2 only (NSVT) 99 (22.2) 109 (24.1)
Criteria 1 and 2 47 (10.6) 41 (9.1)
LVEF (%), mean (SD) 34.6 (9.3) 34.5 (9.4)
Criterion 1 only 32.2 (6.3) 31.9 (6.7)
Criterion 2 only 45.9 (10.8) 44.8 (11.0)
Criteria 1 and 2 29.6 (7.0) 31.4 (6.7)
Heart rate NR NR
Electrophysiology findings NR NR
Medical therapy on admission n/N (%)
Antiplatelet agents 438/443 (98.9) 442/452 (97.8)
Beta-blockers 394/442 (89.1) 388/453 (85.7)
ACE inhibitors 361/443 (81.5) 373/453 (82.3)
STEMI, n (%) 341 (76.6) 348 (76.8)
Reperfusion in STEMI, n/N (%)
None 43/340 (12.6) 48/348 (13.8)
PTCA 243/340 (71.5) 253/348 (72.7)
Thrombolytic therapy, with or without PTCA 54/340 (15.9) 47/348 (13.5)
Anterior wall MI, n/N (%) 282/439 (64.2) 300/449 (66.8)
HF on admission n/N (%) 197/444 (44.4) 209/453 (46.1)
Previous MI, n/N (%) 77/444 (17.3) 89/453 (19.6)
Atrial fibrillation, n/N (%) 60/445 (13.5) 61/453 (13.5)
LBBB, n/N (%) 45/445 (10.1) 29/453 (6.4) 0.05
Hypertension, n/N (%) 296/444 (66.7) 300/453 (66.2)
Diabetes mellitus, n/N (%) 165/444 (37.2) 137/453 (30.2) 0.03
continued
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Characteristic ICD (n= 445) OPT (n= 453) p-value
NYHA class at discharge (in 885 surviving patients), n (%)
I 247 (28)
II 531 (60)
III 106 (12)
IV 1 (0.1)
Discharge medication, % of patients
Antiplatelet agents 96.1 95.8
Beta-blockers 97.1 95.3
ACE inhibitors 90.9 91.1
Statins 91.6 91.5
AADs (mainly amiodarone) 13.4 17.4 0.11
NR, not reported; PTCA, percutaneous transluminal coronary angiography; STEMI, ST-elevation myocardial infarction.
Comments
l Characteristics described as well balanced although diabetes and LBBB more frequent in the ICD group.
l Randomised to study treatment a mean (SD) of 13 (7) days after infarction. Implantation performed ‘as soon as
possible’ after randomisation.98
l Implantation performed during hospitalisation for index infarction in 378 (91.1%) in the ICD group.
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Results
Outcome ICD (n= 445) OPT (n= 453) HR (95% CI) (unadjusted), p-value
Cause of death,a n/n (%)
Any cause 116/445 (26.1) 117/453 (25.8) 1.04 (0.81 to 1.35), 0.15
SCD 27/445 (6.1) 60/453 (13.2) 0.55 (0.31 to 1.00), 0.049
Non-SCD 68/445 (15.3) 39/453 (8.6) 1.92 (1.29 to 2.84), 0.001
Non-cardiac death 21/445 (4.7) 18/453 (4.0) 1.23, 0.51
Cumulative 1-year death rate, %b 10.6 12.5
Cumulative 2-year death rate, %b 15.4 18.2
Cumulative 3-year death rate, %b 22.4 22.9
HRQoL NR NR
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR
HF hospitalisations NR NR
Change in NYHA class NR NR
Change in LVEF NR NR
Exercise capacity outcomes
(e.g. 6-minute walk distance, total
exercise time, peak VO2)
NR NR
NR, not reported.
a Average follow-up of 37 (range 0–106) months.
b States that no significant difference in survival was detected between the groups; p-value of 0.76 given, which may
relate to these data but reporting is unclear.
Comments
l 13 prespecified subgroups and one post hoc subgroup. HRs and p-values for death from any cause in nine (age, sex,
CHF on admission, criterion of inclusion, ST-elevation MI, early reperfusion for ST-elevation MI only, number of vessels,
smoking and NYHA class at discharge) of 13 subgroups presented in figure only but not data extracted. Four other
prespecified subgroups (diabetes, hypertension, lipid abnormalities, number of risk factors) not shown in figure. The
p-values ranged from 0.01 (smoking) to 0.92 (amiodarone at discharge – post hoc subgroup). The p-value for smoking
was the only one that was < 0.05. States that a neutral effect of the ICD on overall mortality was seen in all three
prespecified subgroups (patients meeting criterion 1 or 2 or both).
l Kaplan–Meier plots for all-cause mortality, risk of SCD and risk of non-SCD are presented but have not been
data extracted.
l Cause of death also reported separately for participants meeting inclusion criterion 1 or 2 only or both criteria but
these data have not been extracted. States that the effects were almost identical in these three predefined subgroups
(interaction p= 0.99 or p= 0.71 for SCD or non-SCD respectively).
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Adverse effects of treatment
Adverse effect ICD (n= 445) OPT (n= 453) p-value
No. of ICDs actually implanted 415 39 (median 7.6 months
after randomisation)
Inserted lead entangled in tricuspid valve,
removed surgically
1/415 patients
ICD explanted or permanently deactivated
during follow-up (median 6.8 months
after implantation)
14/415 patients
Clinically significant complications requiring
hospitalisation, surgical correction or
intravenous drug administration
65/415 (15.7%) patients,
76 complications
Up to 30 days after implantation 19 (4.6%) patients
During follow-up 48 (11.6%) patients
Lead-related problems requiring surgical
revision (included in the above complications)
10 patients (four had
lead replacements)
Died within 30 days of implantation, n 7 (MI 4, HF 3)
Died within 30 days of randomisation, n 9 11
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Comments
Methodological comments
l Allocation to treatment groups: randomisation by the data co-ordinating centre with risk stratification to
ensure a balanced number of patients with ST elevation and non-ST elevation MI between the ICD and
control groups within these strata.98 No further details on allocation.
l Blinding: an adverse event committee unaware of treatment assignment classified deaths. An independent
data co-ordinating centre undertook unblinding, data collection and statistical analysis.
l Comparability of treatment groups: comparable for most characteristics.
l Method of data analysis: primary analysis was ITT including all randomised patients with written informed
consent obtained. Conducted by an independent data co-ordinating centre and independently repeated by
one of the authors. Subdistribution hazard analyses performed using R software. Baseline comparisons
were carried out using Fisher’s exact tests, chi-squared tests or Wilcoxon tests as appropriate. Cumulative
risks of death estimated using the Kaplan–Meier method and compared between groups using the log-rank
test. Cumulative mortality by year and annual rates calculated using an inverse Kaplan–Meier analysis.
Calculation of HRs and subgroup analysis performed on the basis of Cox proportional hazards models.
Proportional hazards assumption tested on the basis of Schoenfeld residuals. Subgroup analyses (13
prespecified and one post hoc added for the effect of amiodarone) were performed one by one, with use
of a corresponding interaction test for comparison of the treatment effect between subgroups. Causes of
death were analysed on the basis of proportional subdistribution hazard models (as causes of death
represent competing risks).
l Sample size/power calculation: the 2-year survival rate was assumed to be 70.6% for the medical therapy
group and 79.4% for the ICD group (RRR approximately 30% in the ICD group). Assumed two-sided alpha
error of 5%, beta error of 20%, 30-month recruitment period and 2-year minimum follow-up. With a loss
to follow-up of 1% per year and accounting for group sequential design the number of patients required in
each group was 350. Recruitment time was more than doubled because the percentage of screened
patients excluded was unexpectedly high. In December 2005 the data and safety monitoring board,
because of lower than anticipated mortality, recommended increasing the required number of patients to
900 and extending follow-up until the last patient had been in the study for 1 year.
l Attrition/dropout: 415/445 ICD group patients actually received an ICD: 14 withdrew consent; 11 refused
ICD implantation; five died before implantation could take place. ICDs were removed in 15 patients and 39
in the OPT group were given ICDs.
l Other: to increase recruitment two modifications to the protocol were made: (1) non-ST elevation MI
included from June 2002; (2) qualifying heart rate on the first ECG was reduced from 100 bpm to 90 bpm
from October 2004.
General comments
l Generalisability: people within 31 days of a MI.
l Outcome measures: appear appropriate.
l Intercentre variability: not reported.
l Conflict of interests: sponsors were informed of the trial outcome after the evaluation had been completed.
Sponsors had an opportunity to review and provide comments on the predefined final analysis plan and the
manuscript but did not have a role in study design, data analysis or the interpretation of results.
bpm, beats per minute.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Details not reported
Allocation concealment Low Randomisation by data co-ordinating centre
Performance bias
Blinding of participants and personnel High No blinding
Detection bias
Blinding of outcome assessment Low No blinding but outcomes not likely to be influenced
(deaths classified by blinded committee)
Attrition bias
Incomplete outcome data addressed Low Primary analysis according to the ITT principle
Reporting bias
Selective reporting High Protocol paper98 indicates that the SF-36 will be used to
determine QoL but this outcome is not reported
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Multicenter Automatic Defibrillator Implantation
Trial (MADIT) I
Reference
and design Intervention and comparator Participants Outcome measures
Moss et al. 1996,99
MADIT Executive
Committee 1991100
Study design: RCT
Countries: USA and
Europe
No. of centres: 32
(USA 30, Europe 2)
Funding: research
grant from CPI/
Guidant Corporation,
St Paul, MN
(also donated ICDs)100
Intervention: ICD+medical
therapy. Pulse generators
(monophasic n= 79; biphasic
n= 11) and lead systems
supplied by CPI/Guidant
Corporation. Non-thoracotomy
transvenous leads included in
1993. Late in the trial, a small
number of patients had pulse
generators with ECG storage
implanted (number not
reported). Defibrillators were
implanted using standard
techniques and testing was
carried out during the
implantation procedure
(endeavoured to achieve
defibrillation within a 10-J
safety margin)
Comparator: conventional
medical therapy. Attending
physician elected medical
therapy and use of
FDA-approved AADs in
both groups
Other interventions used:
none reported
Indication for treatment:
previous MI and left ventricular
dysfunction
No. of randomised participants:
196; ICD: 95 (transthoracic
stratum 45, transvenous
stratum 50), OPT: 101
(transthoracic stratum 53,
transvenous stratum 48). Total
transthoracic stratum: 98, total
transvenous stratum: 98
Crossovers: 16; ICD: 5 (no ICD
fitted), deactivated ICD: 2, OPT:
11 (ICD fitted)
Loss to follow up: ICD: 1,
OPT: 2
Inclusion criteria: age
25–80 years, NYHA class I,
II or III, LVEF ≤ 0.35, Q-wave or
enzyme-positive MI > 3 weeks
before entry, a documented
episode of asymptomatic,
unsustained VT (run of 3–30
ventricular ectopic beats at a
rate > 120 bpm) unrelated to
an acute MI, no indications for
CABG surgery or coronary
angioplasty within the past
3 months, sustained VT or VF
reproducibly induced and
not suppressed after the
intravenous administration of
procainamide (or equivalent)
Exclusion criteria: previous
cardiac arrest or VT causing
syncope not associated with an
acute MI, symptomatic
hypotension while in a stable
rhythm, MI within the past
3 weeks, CABG surgery within
the past 2 months or coronary
angioplasty within the past
3 months, non-contraceptive-
taking women of childbearing
age, advanced cerebrovascular
disease, any condition other
than cardiac disease associated
with a reduced likelihood of
survival for the duration of the
trial, participating in other
clinical trials
Primary outcome: death
from all causes
Secondary outcomes:
none specified
Other outcomes reported:
prevalence of medications,
adverse events, impact of
11 preselected baseline
characteristics and
medication type on
observed HR for overall
mortality
Method of assessing
outcomes: causes of death:
categorised as either
cardiac or non-cardiac
(Hinkle and Thaler
classification, reference
provided) by two people
reviewing information
on deaths on or before
24 March 1996. Cardiac
causes further categorised
into arrhythmic,
non-arrhythmic or
uncertain
Follow-up visits: clinical
evaluation, recorded use
of medication, test of
defibrillator; 1 month after
randomisation, thereafter
3-monthly until trial was
stopped. Final evaluation
1 month after end of trial
Length of follow-up:
< 1 month to 61 months
(average 27 months).
Average 37 months for
earlier transthoracic
stratum (n= 98),
16 months for later
transvenous stratum
(n= 98)
Recruitment:
27 December 1990
bpm, beats per minute.
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Participant characteristics
Characteristic ICD (n= 95) OPT (n= 101) p-value
Age (years), mean (SD)a 62 (9) 64 (9) NR
Sex, % male/femalea 92/8 92/8 NR
Ethnicity NR NR
NYHA class II or III, %a 63 67 NR
Cardiac findings at enrolment, %
Pulmonary congestion (defined radiographically as
mild, moderate or severe)
18 20 NR
Blood urea nitrogen > 25mg/dl (8.92mmol/l)a 22 21 NR
Cholesterol > 200mg/dl (5.17mmol/l) 41 49 NR
LBBB, %a 7 8 NR
LVEF, mean (SD)a 0.27 (0.07) 0.25 (0.07) NR
Qualifying unsustained VT (no. of consecutive beats),
mean (SD)
10 (9) 9 (10) NR
Electrophysiology – initial induction, %
Monomorphic VT 87 91 NR
Polymorphic VT 7 7 NR
VF 6 2 NR
Electrophysiology – induction after antiarrhythmic challenge, %
Monomorphic VT 92 94 NR
Polymorphic VT 7 5 NR
VF 1 1 NR
Cardiac history, %
Two or more previous MIsa 34 29 NR
Treatment for ventricular arrhythmias 42 35 NR
Treatment for CHFa 52 51 NR
Treatment for hypertensiona 48 35 NR
CABG surgerya 46 44 NR
Coronary angioplasty 17 27 NR
Implanted pacemaker 2 7 NR
Interval of ≥ 6 months between most recent MI
and enrolmenta
75 76 NR
Insulin-dependent diabetic, % 7 5 NR
Cigarette smoking (any time), % 79 73 NR
NR, not reported.
a Denotes 11 preselected variables for inclusion in a Cox regression analysis.
Comments
l States baseline characteristics of the two treatment groups were similar; no p-values reported.
l States that the distribution of the qualifying Q-wave MIs in terms of anterior, inferior and posterior locations was similar
in the two treatment groups; no p-values reported.
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Results
Outcome ICD (n= 95) OPT (n= 101) HR (95% CI), p-value
Mortality: cause of death, n
Cardiac cause 11 27 NR
Primary arrhythmia 3 13 NR
Non-arrhythmia 7 13 NR
Uncertain 1 1 NR
Non-cardiac cause 4 6 NR
Unknown cause 0 6 NR
Total 15 39 0.46 (0.26 to 0.82), 0.009
NR, not reported.
Comments
l HR= ratio of the risk of death per unit of time among patients randomly assigned to ICD to that among patients
randomly assigned to OPT. HR takes into account the stopping rule, not adjusted for covariates.
l Kaplan–Meier cumulative survival curves presented.
l Authors note that there were more deaths from non-arrhythmic causes in the OPT group than in the ICD group and
suggest that this could be due to an inaccuracy in the classification of cause of death or the higher rate of amiodarone
use in this group.
Cardiac medication
Medication
1 montha Last contactb
p-valueICD (n= 93) OPT (n= 93) ICD (n= 86) OPT (n= 82)
AADs, %
Amiodarone 2 74 7 45 NR
Beta-blockers 26 8 27 5 NR
Class I antiarrhythmic agents 12 10 11 11 NR
Sotalol 1 7 4 9 NR
Beta-blockers or sotalol 27 15 31 14 NR
No antiarrhythmic medication 56 8 44 23 NR
Other cardiac medication, %
ACE inhibitors 60 55 57 51 NR
Digitalis 58 38 57 30 NR
Diuretics 53 52 52 47 NR
NR, not reported.
a Data missing for two patients in the ICD group and eight patients in the OPT group.
b Last contact defined as the last recorded contact with the patient at the end of the trial, at the last clinic visit before
death or at the last clinic visit before the patient was lost to follow-up.
Comments
l Separate Cox regression analyses revealed that neither medication nor any of the 11 preselected baseline variables had
any ‘meaningful influence’ on the HR (p> 0.2 for all interactions). However, the authors acknowledge that the power
of the analysis is limited because of the small patient numbers for some of the variables.
l ICD effects did not differ between those with transthoracic leads and those with transvenous leads (p= 0.78).
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Adverse effects of treatment
Adverse effect ICD (n= 95)a OPT (n= 101)a p-value
Operative deaths in the first 30 days, n 0 0
Hypotension, n 0 1
Syncope, n 1 5
Hypothyroidism, n 0 1
Sinus bradycardia, n 3 3
Pulmonary fibrosis, n 0 3
Pulmonary embolism, n 1 1
Atrial fibrillation, n 4 0
Pneumothorax, n 2 0
Bleeding, n 1 0
Venous thrombosis, n 1 0
Surgical infection, n 2 0
Problems with defibrillator lead, n 7 0
Malfunction of defibrillator generator, n 3 2
Total no. of patients with adverse events 19 12
a Some patients had more than one adverse event.
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Comments
Methodological comments
l Allocation to treatment groups: random assignment of eligible patients to either the ICD group or the OPT
group within 30 days of completing the qualifying electrophysiological study. The randomisation scheme
included stratification according to centre and the interval between the most recent MI and enrolment
(< 6 months or ≥ 6 months). The random assignment was made by the co-ordinating centre and
transmitted to the enrolling clinical centre by telephone (hard copy followed).100 After March 1993 and
once non-thoracotomy transvenous leads were approved at a centre, a new stratum consisting of patients
assigned to transvenous ICD or OPT was initiated.
l Blinding: the executive committee was unaware of the results of the study throughout the trial and revised
the sequential design during the trial on two occasions.
l Comparability of treatment groups: baseline characteristics between the two treatment groups described as
similar (no statistical testing reported).
l Method of data analysis: a triangular sequential design, modified for two-sided alternatives, was used with
preset boundaries to permit termination of the trial if the efficacy or inefficacy of ICDs was established, or if
there was evidence that there was no difference in outcome between the ICD group and the OPT group.
Weekly data analysis was used, starting at the point at which 10 deaths had been reported. The trial was
designed to be terminated when the path of the log-rank statistic, measuring imbalance between the
survival curves for the two groups, crossed one of the preset termination boundaries (efficacy, inefficacy
or no difference in outcome) of the sequential design. Because of the slow rate of enrolment from
12 November 1995 (before first enrolled patient had reached the fifth year of the study), patient data were
censored for analytical purposes at 5 years, with subsequent follow-up information on such patients
censored from the ongoing sequential analysis. Analyses were stratified according to the type of device
(transthoracic or transvenous) and followed the ITT principle. All analyses and potential covariates were
prespecified. After termination of the trial, sequential analysis methods were used to calculate a p-value
and HR (median unbiased), along with a 95% CI based on the p-value function. Secondary analyses were
performed with the Cox proportional hazards regression model, adjusted for relevant covariates. Separate
Cox regression analyses were carried out in the transthoracic and transvenous strata, to determine whether
the efficacy of defibrillators was similar in these two groups. Preselected baseline covariates and prescribed
cardiac medications recorded at the 1-month clinic visit were evaluated in the Cox model to determine their
effect on the risk of death per unit of time in the ICD group compared with that in the OPT group (the HR).
Survival curves for patients assigned to ICD treatment and OPT treatment were determined according to
the method of Kaplan and Meier (reference cited). However, a note in the text states that the HR, derived
from the sequential design, takes into account the sequential stopping rule, but was not adjusted
for covariates.
l Sample size/power calculation: the trial was designed to have an 85% power to detect a 46% reduction in
mortality rate among ICD patients compared with a postulated 2-year mortality rate of 30% among the
patients randomly assigned to OPT, with a two-sided significance level of 0.05. After the introduction of
transvenous leads (1 September 1993), the power requirement of the trial was increased from 85% to
90% so ‘as not to compromise the credibility of the study’.
l Attrition/dropout: numbers lost to follow-up reported (ICD n= 1; OPT n= 2). Percentage of patients who
completed the 1838 scheduled follow-up clinic visits was 92% for the ICD group and 86% for the OPT
group. There were 16crossovers, 11 in the OPT group [adverse drug reaction n= 2, unexplained syncope
n= 2, investigator concern about episodes of ventricular tachyarrhythmia n= 6 and aborted cardiac arrest
(VF) n= 1] and five in the ICD group (high defibrillation threshold n= 1 and patient preference n = 4).
Two patients had their defibrillators deactivated during the course of the trial.
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General comments
l Generalisability: authors acknowledge that the change to transvenous leads altered the type of patient
referred for entry into the trial. Generalisability is limited to high-risk patients with CHD and left ventricular
dysfunction, spontaneous asymptomatic unsustained VT and inducible and non-suppressible ventricular
tachyarrhythmia on electrophysiological testing.
l Outcome measures: appear appropriate although unclear if all ITT (cardiac medication).
l Intercentre variability: not reported. However, an evaluation of the consistency of the beneficial effect of
ICDs in eachof the two centres with the highest enrolment (n= 42 and n= 21) and comparison of the
results in the high-enrolment centres with the results in the 30 low-enrolment centres (total n= 133)
showed that the reduction in mortality with ICDs is similar among these groups (no statistical
testing reported).
l Conflict of interests: states that all investigators agreed in writing not to hold stock in CPI/Guidant
Corporation or any other defibrillator-manufacturing company before study participation and to abide by
the conflict of interest standards (reference cited).
l Other: study officially stopped when the efficacy boundary of the sequential design was crossed (when
51 deaths were reported).
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear No details of randomisation procedure in either trial paper99 or
protocol.100 Patients were ‘randomly assigned’ by clinical centre and
chronology of the interval after a previous MI100
Allocation concealment Low Random assignment provided to centres by telephone before receiving
hard copy100
Performance bias
Blinding of participants
and personnel
High Unblinded trial
Detection bias
Blinding of outcome
assessment
Low A two-member end point subcommittee independently reviewed
information on the causes and circumstances of deaths and categorised
them, but does not state blinded to allocation.99,100 Mortality unlikely to
be influenced by lack of blinding
Attrition bias
Incomplete outcome
data addressed
Low Analyses ‘followed the ITT principle’. For the purpose of analysis,
patients were not withdrawn from the trial and every effort was made
to ascertain the occurrence or non-occurrence of the primary end
point.100 Although not a primary outcome, it is unclear how missing
data for type of medication (n= 10) were dealt with in the analysis
Reporting bias
Selective reporting Low Described outcomes reported. Protocol published100
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Multicenter Automatic Defibrillator Implantation Trial
(MADIT) II
Reference and design
Intervention
and comparator Participants Outcome measures
Moss et al. 1999102 and
2002,101 Greenberg et al.
2004,103 Noyes et al.
2007104
Study design: RCT
Countries: USA and
Europe
No. of centres: 76 (USA
71, Europe 5)
Funding: research grant
from Guidant Corporation,
St Paul, MN, to the
University of Rochester
School of Medicine and
Dentistry, NY
Intervention:
ICD+ conventional medial
therapy. Transvenous
defibrillator systems (Guidant
Corporation) and standard
defibrillator implant
techniques were used. ICD
programming and
prescribing medications
were at the discretion of the
patients’ physicians
Comparator: conventional
medical therapy (OPT).
The appropriate use of
beta-blockers, ACE inhibitors
and lipid-lowering drugs was
strongly encouraged in both
study groups
Other interventions used:
none reported
Indication for treatment:
high-risk cardiac patients
with previous MI and
advanced left ventricular
dysfunction
No. of randomised
participants: 1232; ICD:
742, OPT: 490
Crossovers: 54; ICD: 32
[no ICD fitted: 21 (2.8%);
ICD removed: 11 (1.5%)
(nine heart transplants)];
deactivated ICD: 12 (usually
because of terminal illness);
OPT: 22 (4.5%) ICD fitted
Loss to follow-up: ICD: 2,
OPT: 1
Inclusion criteria: age
> 21 years, LVEF ≤ 0.30 in
last 3 months (assessed by
angiography, radionuclide
scanning or ECG), MI
> 1 month before study
entry (documented by an
abnormal Q wave on ECG,
elevated cardiac enzyme
levels on laboratory testing
during hospitalisation for
suspected MI, a fixed defect
on thallium scanning or
localised akinesis on
ventriculography with
evidence of obstructive
coronary disease on
angiography), frequent or
repetitive ventricular ectopic
beats during 24-hour Holter
monitoring from July 1997
until 1 January 1998
(discontinued as majority of
cases had such arrhythmias)
Exclusion criteria: indication
approved by the FDA for an
ICD (and patients who met
the MADIT I criteria for an
ICD102), NYHA class IV at
enrolment, undergone
coronary revascularisation
within the last 3 months,
MI within the past month
(evidenced by measurement
of cardiac enzyme levels),
advanced cerebrovascular
disease, women of
childbearing age not using
medically prescribed
Primary outcome: all-cause
mortality
Secondary outcomes:
adverse events, HRQoL,
economic outcomes,
incidence of SCD, incidence
of cardiac death from
progressive left ventricular
failure
Method of assessing
outcomes: patients followed
up 1 month post
randomisation and at
3-monthly intervals. Causes
of death were assessed
using a modified version of
the Hinkle–Thaler system
(see General comments)
Cause of death definitions:103
SCD (modified Hinkle–Thaler
system): (1) Died suddenly
and unexpectedly within
1 hour of cardiac symptoms
in the absence of progressive
cardiac deterioration; (2) died
unexpectedly in bed during
sleep; (3) died unexpectedly
within 24 hours of last being
seen alive. SCD subclassified
into those with and those
without symptoms of severe
left ventricular dysfunction
NYHA ≥ III HF
Non-SCD: patients who died
of progressive cardiac failure
or patients who did not meet
the time criteria for sudden
death
Progressive cardiac failure:
unstable clinical progression
of deteriorating pump
function in the setting of
active therapy, most often in
an intensive care setting
(patients with advanced HF in
whom death was not
anticipated as imminent
were categorised as sudden
death if their terminal event
met the time criteria)
SCD (clinical classification):
Death within 1 hour of
symptom onset – primary
(without preceding
symptoms) or secondary
continued
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Reference and design
Intervention
and comparator Participants Outcome measures
contraception, any condition
other than cardiac disease
that was associated with a
high likelihood of death
during the trial, not willing
to sign the consent form
(complaint of chest pain
during the hour before
death). Marked ECG changes
indicative of active MI were
absent in any of the reviewed
records
Multiple cause category:
presence of several medical
problems in which CHD
contributed to, but was not
the dominant feature of, the
mortality event
HRQoL:104 HUI3
self-administered during
face-to-face study visits at
baseline and 3, 12, 24 and
36 months. Patients could
complete the HUI3 at home
and mail it back. HUI3 has
eight attributes (vision,
hearing, speech, ambulation,
dexterity, emotion, cognition
and pain discomfort;
–0.0371=worse possible
state, 0= death, 1= best
possible health state)
Length of follow-up: average
20 months (range 6 days to
53 months); HUI3: up to 36
months104
Recruitment: 11 July
1997–20 November 2001
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Participant characteristics
Characteristic ICD (n= 742) OPT (n= 490) p-value
Age (years), mean (SD) 64 (10) 65 (10) NR
Sex, % male/female 84/16 85/15 NR
Ethnicity NR NR
Diagnosis NR NR
NYHA functional class, %a
I 35 39 NR
II 35 34 NR
III 25 23 NR
IV 5 4 NR
LVEF (%), mean (SD) 23 (5) 23 (6) NR
Heart rate NR NR
Blood urea nitrogen > 25mg/dl (8.92mmol/l), % 29 32 NR
Atrial fibrillation, n 9 8 NR
QRS interval ≥ 120milliseconds, n 50 51 NR
Non-specific conduction defect, n 22 26 NR
RBBB, n 9 7 NR
LBBB, n 19 18 NR
Medication at last contact, %b
Amiodarone 13 10 NR
ACE inhibitors 68 72 NR
Beta-blockers 70 70 NR
Calcium channel blockers 9 9 NR
Class I antiarrhythmic agents 3 2 NR
Digitalis 57 57 NR
Diuretics 72 81 NR
Lipid-lowering statin drugs 67 64 NR
Cardiac history
Interval of > 6 months between most recent MI and enrolment, % 88 87 NR
Previous treatment, %
Hypertension 53 53 NR
CABG surgery 58 56 NR
Coronary angioplasty 45 42 NR
Diabetes, % 33 38 NR
Current or former cigarette smoker, % 80 82 NR
NR, not reported; RBBB, right bundle branch block.
a Values reflect the highest NYHA functional class recorded in the 3 months before enrolment; limited to NYHA class I, II
or III at enrolment.
b Mean interval from enrolment to last follow-up visit when medication use was recorded was 18 months in the
ICD group and 17 months in the OPT group.
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Baseline characteristics by subgroup103
Characteristic
ICD OPT
p-value
Alive
(n= 637)
Dead
(n= 105)
Alive
(n= 393)
Dead
(n= 97)
Age (years), mean (SD) 64 (11) 69 (9)a 64 (10) 68 (10)a
Sex, % male 84 82 86 84
NYHA functional class, %b
I 36 27a 41 29a
II 37 27a 36 27a
III 27 46a 23 44a
LVEF (%), mean (SD) 23 (5) 22 (6)a 24 (5) 23 (6)a
Blood urea nitrogen > 25mg/dl (8.92mmol/l), % 25 51a 28 49a
Atrial fibrillation, n 8 12 7 16a
QRS interval ≥ 12 seconds, n 49 57 49 59
RBBB, n 9 7 7 8
LBBB, n 19 28 16 27
Previous treatment, %
Hypertension 53 54 53 55
CABG surgery 58 59 56 56
Coronary angioplasty 47 36 45 31
Cardiac history, %
Interval of > 6 month between most recent MI
and enrolment, %
88 87 87 89
Diabetes, % 32 34 36 43
Cardiac morbidity after enrolment
Hospitalisation for HF, n 20 60a 15 41a
MI, n 4 20a 4 15a
Coronary revascularisation, n 5 6 4 6
RBBB, right bundle branch block.
a p< 0.01 for comparison between alive and dead within each treatment arm.
b Values reflect the highest NYHA functional class recorded in the 3 months before enrolment; limited to NYHA class I, II
or III at enrolment.
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Baseline health-related quality of life104
HRQoL measure
ICD
(n= 658)
OPT
(n= 431) p-value
HUI3 score, mean 0.637 0.646 > 0.10
SF-12 PCS, mean 36.293 36.444 > 0.10
SF-12 MCS, mean 50.505 50.419 > 0.10
Hospitalised at baseline (%), mean 14.7 10.9 > 0.10
Comment
l All other baseline scores for these subgroups were similar to those of the main patient group above. HRQoL was not
measured in European study centres (n= 109).
Results
Outcome
ICD
(n= 742)
OPT
(n= 490) HR (95% CI), p-value
Primary outcome: mortality, no. of deaths (%) 105 (14.2) 97 (19.8) 0.69 (0.51 to 0.93), 0.016a
31% reduction in risk of death
at any interval for ICD compared
with OPT
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR
HF hospitalisations NR NR
Change in NYHA class NR NR
Change in LVEF NR NR
Exercise capacity outcomes (e.g. 6-minute walk
distance, total exercise time, peak VO2)
NR NR
NR, not reported.
a Adjusted for stopping rules.
Comments
l Kaplan–Meier estimates of survival were reported for years 1–4 and difference in survival between the groups was
significant (nominal p= 0.007). The two survival curves began to diverge at around 9 months. Survival curves showed
reductions in the rate of death with ICD use of 12% (95% CI to –27% to 40%) at 1 year, 28% (95% CI 4% to 46%)
at 2 years and 28% (95% CI 5% to 45%) at 3 years.
l There were no significant differences in the effect of defibrillator therapy on survival in subgroup analyses stratified
according to age, sex, ejection fraction, NYHA class or QRS interval (presented in figure).
l There were also no significant differences in the effect of ICDs on survival in subgroup analyses classified according to
the presence or absence of hypertension, diabetes, LBBB or atrial fibrillation; the interval since the most recent MI
(≤ 6 months vs. > 6 months); the type of defibrillator implanted (single chamber vs. dual chamber); or the blood urea
nitrogen level (≤ 25mg/dl vs.> 25mg/dl) (not presented in figure).
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Subgroup analyses103
Outcome ICD (n= 105) OPT (n= 97) p-value
Cause of death by treatment group (modified Hinkle–Thaler scheme), n (%)
Cardiac death
SCD 28 (27) 49 (51) p< 0.01
Without severe left ventricular dysfunction 18 34
With severe left ventricular dysfunction 10 15
Non-SCD 43 (41) 21 (22) p< 0.01
Unclassified cardiac death 8 (8) 10 (10)
Total cardiac death 79 80
Non-cardiac death/non-coronary death 22 (21) 12 (12)
Unknown/unclassified 4 (4) 5 (5)
Nominal death rates, % (n/N)
Cardiac death rate 10.6 (79/742) 16.3 (80/490) p< 0.01
SCD rate 3.8 (28/742) 10.0 (49/490)
Non-SCD rate 5.8 (43/742) 4.3 (21/490)
Total all-cause mortality 14.2 (105/742) 19.8 (97/490)
Clinical classification scheme, cause of death: cardiac death, n (%)
SCD 24 (23) 48 (49) p< 0.01
Primary arrhythmia (without preceding symptoms) 22 41
Secondary arrhythmia (with chest pain symptoms) 2 7
Primary mechanical 40 (38) 19 (20)
Cardiac procedure 1 1
Multiple causes 8 (8) 3 (3)
Non-cardiac/non-coronary death 22 (21) 12 (12)
Unknown/unclassified death 10 (10) 14 (10)
Nominal death rate: cardiac rates, % (n/N)
Cardiac death 9.8 (73/742) 14.5 (71/490) p< 0.01
SCD 3.2 (24/742) 9.8 (48/490) p< 0.01
Primary mechanical cardiac death 5.4 (40/742) 3.9 (19/490)
Total all-cause mortality 14.2 (105/742) 19.8 (97/490) p< 0.01
Nominal death rate out of hospitala 3.8 (28/742) 9.6 (47/490) p< 0.01
Nominal death rate in hospital 5.7 (42/742) 4.5 (22/490)
a ICD vs. OPT; cardiac deaths include only SCD and non-SCD according to the Hinkle–Thaler classification. Also reported
are location and number of SCDs and non-SCDs, as well as chronology of cardiac death by treatment group
(not extracted).
Comments
l Data are presented as the percentage of SCDs and non-SCDs calculated from the total number of deaths in each
treatment group. The nominal cardiac, sudden and non-sudden cardiac death rates are calculated from the numbers
of specified deaths per number of randomised patients in each treatment arm (ICD= 742; OPT= 490), expressed
as a percentage.
l SCD: 35% (28/79) ICD vs. 61% (49/80) OPT, p< 0.001 (chi square).
l Nominal (raw) death rate, SCD: 3.8% ICD vs. 10.0% OPT, p< 0.01; nominal death rate, non-SCD: higher for ICD than
OPT but not significant (p-value not reported).
l Kaplan–Meier: HR for SCD 0.33 (95% CI 0.20 to 0.53), p< 0.0001; HR for non-SCD p= 0.32 (cumulative
Kaplan–Meier curves of SCD rates reported years 0–4).
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Health-related quality of life
HUI3 scores while alive
ICD (n= 658) OPT (n= 431)
0 Year 1 Year 2 Year 3 0 Year 1 Year 2 Year 3
Proportion alive 0.93 0.846 0.767 0.903 0.792 0.667
Mean score 0.637 0.627 0.622 0.601 0.646 0.659 0.667 0.678
Mean annual changea –0.019 –0.027b –0.019c –0.012 –0.011 –0.013
Overall mean score including deathd 0.637 0.584 0.526 0.461 0.646 0.595 0.529 0.452
a Equals (difference from baseline)/year.
b p< 0.05.
c p< 0.10.
d Mean HRQoL score (among n patients) after setting score for death to 0.
Adverse effects of treatment
Adverse effect ICD (n= 742) OPT (n= 490) p-value
Death during implantation, n 0
Lead problems, n (%) 13 (1.8)
Non-fatal infections requiring surgical intervention, n (%) 5 (0.7)
Hospitalisation because of HF, n (%) 148 (19.9) 73 (14.9)
Patients hospitalised per 1000 months of active follow-up 11.3 9.4 p= 0.09
Adverse cardiac events in the week before SCD,103 (%) (n= 28) (n= 49)
Syncope 4 4
Angina pectoris 4 4
MI 4 10
Ventricular arrhythmia 25 10
CHF 43 16
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Comments
Methodological comments
l Allocation to treatment groups: patients were randomly assigned by the co-ordinating centre in a 3 : 2 ratio
to receive an ICD (60.2%) or OPT (39.8%) stratified by clinical centre.
l Blinding: none reported. Authors state that information will be reported periodically to the independent
safety monitoring subcommittee but kept confidential from investigators, executive committee
and sponsors.
l Comparability of treatment groups: authors state that baseline characteristics and prevalence of the use of
various cardiac mediations at the time of the last follow-up visit were similar between the two groups but
no p-values are reported.
l Method of data analysis: analysis was performed according to the ITT principle. A triangular sequential
design modified for two-sided alternatives and corrected for the lag in obtaining data accrued but not
reported before the termination of the trial, for weekly monitoring, with preset boundaries to permit
termination of the trial if ICD was found to be superior to, inferior to or equal to OPT was used. Secondary
analyses were performed with the use of the Cox proportional hazards regression model. Survival curves
were determined according to the Kaplan–Meier method, with comparisons of cumulative mortality based
on logarithmic transformation. P-values were termed nominal when not adjusted for sequential monitoring.
All p-values were two-tailed. Analyses used version 2.0 of the trial database, released on 16 January 2002.
The trial was stopped on 20 November 2001 after analysis revealed that the difference in mortality
between both groups had reached the prespecified efficacy boundary (p= 0.027). Subgroups were
prespecified. Mortality events103 were based on version 3.0 of the database (released 26 July 2002),
chi-squared statistics were used for categorical data, t-test were used for continuous variables (independent
samples), the Kaplan–Meier method was used for cumulative survival curves and the log-rank method was
used for statistical comparison of cumulative mortality. The Cox proportional hazards regression model
was used to calculate the risk of SCD and non-SCD in the total population and in subgroups stratified by
relevant baseline characteristics for patients randomised to ICD compared with OPT. Missing HUI3 scores104
were imputed using a multivariate fixed-effects model, regressing the difference between baseline score
and a score for each subsequent visit on time, treatment, sex, age, death during the trial, death within
6 months of the HRQoL assessment, sudden death within 6 months of the HRQoL assessment, presence of
diabetes, use of diuretics and having NYHA class II–IV symptoms.
l Sample size/power calculation: the trial was designed to have 95% power to detect a 38% reduction in the
2-year mortality rate in the ICD group, given a postulated 2-year mortality rate of 19% among the OPT
group with a two-sided significance level of 0.05. For proportional hazards modelling, power was
maintained for a true HR of 0.63 after allowance for crossover. Originally it was estimated that 1200
patients (720 ICDs and 480 OPT) were needed. On 4 May 2001, the executive committee increased the
enrolment goal to 1500 patients so that enrolment would be ongoing while data on outcomes were
still accruing.
l Attrition/dropout: the percentage of patients who completed the 8749 scheduled follow-up clinic visits was
97% for the ICD group and 94% for the OPT group [authors state that the status of three patients (two
ICD, one OPT) at the termination of the trial is unknown]. Reasons for dropout not reported. HRQoL
assessed in the European study centres (n= 109). Patients with missing data at baseline (n= 22) were
excluded, as were patients with poor data quality (n= 12). Questionnaires returned after trial termination
were also excluded (n= 8), but this number appears to have been accounted for as part of the number of
patients with poor-quality data. In total, 8.5% of the HRQoL data were missing and summary reasons
were provided.
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General comments
l Generalisability: limited to high-risk cardiac patients with a previous MI and advanced left
ventricular dysfunction.
l Outcome measures: appear appropriate.
l Intercentre variability: not reported.
l Conflict of interests: supported by a research grant from Guidant Corporation, St Paul, MN. Drs Cannom,
Daubert and Higgins have given lectures sponsored by the grant provider (Guidant Corporation). Authors
state that all investigators agreed to abide by the conflict-of-interest guidelines and that investigators had
full access to the data and performed the analysis with no limitations imposed by the sponsor.
l Other: ICD patients were not responsible for the incurred costs of the ICD, implantation or hospitalisation
for the procedure.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Patients randomly assigned but no details of procedure
Allocation concealment Unclear Not reported
Performance bias
Blinding of participants
and personnel
High No blinding reported
Detection bias
Blinding of outcome assessment
Mortality Low No blinding reported. Data were independently reviewed but
the committee was not blinded.103 Mortality unlikely to be
influenced by lack of blinding
QoL High
Attrition bias
Incomplete outcome
data addressed
Low Analysis was performed according to the ITT principle.
Missing HUI3 scores were imputed using a multivariate
fixed-effects model (see Methodological comments)
Reporting bias
Selective reporting Unclear Apart from the primary end point, the protocol paper
specifies only four secondary objectives (association of
induced VT with ICD discharge rate; patients at risk of
increased mortality according to prespecified Holter-recorded
electrocardiological parameters at baseline; cost-effectiveness
of ICDs; QoL)
Other bias
Other sources of bias Low No costs in relation to ICDs were incurred by patients
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
Reference and design
Intervention
and comparator Participants Outcome measures
Bardy et al. 2005,105 Packer
et al. 2009,108 Michell et al.
2008,106 Mark et al. 2008107
Study design: RCT
Countries: USA (99%107),
Canada and New Zealand106
No. of centres: 148106
Funding: grants from the
National Heart, Lung, and
Blood Institute, the National
Institutes of Health and
Medtronic, Wyeth-Ayerst
Laboratories and
Knoll Pharmaceuticals
Group 1: ICDs. Single
chamber ICD (Medtronic,
model 7223) programmed
to shock only mode (to treat
only rapid sustained VT or
VF). Detection rate of
≥ 187 bpm. Antitachycardia
pacing therapies not
permitted
Group 2: amiodarone. Dose
partly based on weight.
Loading dose of 800mg
daily for 1 week and then
400mg daily for 3 weeks.
Then, patients > 200 lb
(90.9 kg) received 400mg
daily, patients 150–200 lb
(68.2–90.9 kg) received
300mg daily and patients
< 150 lb (68.2 kg) received
200mg daily. If a patient
had bradycardia the loading
or maintenance dose could
be lowered
Group 3: placebo,
administered in the same
way as amiodarone
Other interventions used: all
participants received optimal
HF medical therapy.108 If
clinically reasonable, all
patients were required to
receive treatment with a
beta-blocker and an ACE
inhibitor. When appropriate,
participants received
aldosterone, aspirin
and statins105
Indication for treatment:
Broad population of
patients with mild to
moderate HF
No. of randomised
participants: 2521; ICD:
829, amiodarone: 845,
placebo:847
Inclusion criteria: NYHA
class II or III chronic stable
CHF from ischaemic or
non-ischaemic causes, LVEF
≤ 35%, ≥ 18 years.
Ischaemic CHF defined as
LVSD associated with
≥ 75% narrowing of at
least one of three major
coronary arteries (marked
stenosis) or a documented
history of MI. Non-
ischaemic CHF defined as
LVSD without marked
stenosis
Exclusion criteria:
None stated
Primary outcomes: death
from any cause. For the QoL
study, the DASI and the
SF-36 MHI-5
Secondary outcomes: other
scales from the SF-36,
number of ‘bed-days’ and
‘disability-days’, MLWHFQ,
health status utility, global
health status
Method of assessing
outcomes: every 3 months
with alternating clinic visits
and telephone calls. Data
downloaded from ICD
memory regularly at visits.
Deaths were classified by an
events committee. Cardiac
deaths were subclassified
as sudden death (VT,
bradyarrhythmic, HF related,
other cardiac causes).
Non-cardiac deaths included
stroke, peripheral arterial
embolism, pulmonary
embolism, aneurysm
rupture, acute haemorrhage
and non-vascular events
(e.g. serious lung, liver,
kidney or other organ
failure, cancer and sepsis)108
QoL:107 measured by
structured interviews at
baseline (before
randomisation) and at
months 3, 12 and 30 (or at
the end of study follow-up).
Interviews at the time of
scheduled clinic visit or by
telephone if visit was
missed. A short proxy form
was used if patients were
too ill, had a language
barrier or were otherwise
unable to participate in a
full interview. The DASI
reflects cardiac-specific
physical functioning (score
0–58, higher scores indicate
better function, a difference
of ≥ 4 points is considered
clinically significant). The
SF-36 MHI-5 reflects
psychological well-being
(score 0–100, higher scores
indicate better function).
A clinically significant
difference was
approximated as
one-quarter of 1 SD
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Reference and design
Intervention
and comparator Participants Outcome measures
(5 points in this study).
Other SF-36 scales were
scored the same way
‘Bed-days’ were defined as
the number of days spent in
bed all or most of the day
in the last 42 days.
‘Disability-days’ were
defined as the number of
days (excluding bed-days)
that the patient cut down
usual activities for health
reasons
MLWHFQ was scored from
0 to 105 (higher scores
indicate worse function,
clinically significant
difference approximately
5 points)
Health status utility
[0 (dead)–1 (excellent)] was
assessed using the time
trade-off technique
Global health was rated on
a scale of 0 (dead)–100
(excellent health) with a
5-point difference
(one-quarter of 1 SD)
approximating clinical
significance
Length of follow-up:
to 31 October 2003.
Median follow-up for
surviving patients 45.5
(range 24–72.6) months
Recruitment: September
1997–July 2001
bpm, beats per minute.
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Participant characteristics
Characteristic
ICD
(n= 829)
Amiodarone
(n= 845)
Placebo
(n= 847) p-value
Age (years), median (IQR) 60.1 (51.9 to 69.2) 60.4 (51.7 to 68.3) 59.7 (51.2 to 67.8)
Sex, male, n (%)a 639 (77) 639 (76) 655 (77)
Non-white race, n (%) 189 (23) 196 (23) 204 (24)
LVEF (%), median (IQR) 24.0 (19.0–30.0) 25.0 (20.0–30.0) 25.0 (20.0–30.0)
Heart rate (bpm), median (IQR) 74 (65 to 84) 72 (64 to 82) 73 (64 to 84)
NSVT,b n (%) 210 (25) 193 (23) 180 (21)
Syncope, n (%) 52 (6) 54 (6) 56 (7)
Systolic blood pressure (mmHg),
median (IQR)
118 (104–131) 118 (106–130) 120 (108–132)
Diastolic blood pressure (mmHg),
median (IQR)
70 (61–80) 70 (62–80) 70 (62–80)
Medication use at enrolment, n (%)
ACE inhibitor 684 (83) 731 (87) 718 (85)
ARB 114 (14) 118 (14) 132 (16)
ACE inhibitor or ARB 783 (94) 822 (97) 827 (98)
Beta-blocker 576 (69) 581 (69) 581 (69)
Diuretic
Loop 676 (82) 696 (82) 692 (82)
Potassium sparing 168 (20) 174 (21) 165 (19)
Thiazide 63 (8) 52 (6) 60 (7)
Digoxin 552 (67) 614 (73) 589 (70)
Acetylsalicylic acid (aspirin) 477 (58) 461 (55) 477 (56)
Warfarin 266 (32) 310 (37) 281 (33)
Statin 312 (38) 334 (40) 319 (38)
Diabetes, n (%) 253 (31) 243 (29) 271 (32)
Pulmonary disease, n (%) 175 (21) 147 (17) 158 (19)
Hypercholesterolaemia, n (%)c 431 (52) 442 (52) 456 (54)
Hypertension, n (%) 453 (55) 469 (56) 478 (56)
Atrial fibrillation or flutter, n (%) 141 (17) 132 (16) 117 (14)
bpm, beats per minute.
a Calculated by reviewer.
b NSVT defined as three or more consecutive ventricular beats at a heart rate > 100 bpm.
c Hypercholesterolaemia defined as low-density lipoprotein cholesterol at enrolment of > 130mg/dl after an
overnight fast.
Comments
l Baseline characteristics of the electrophysiological study, weight, serum sodium and serum creatinine, were reported
but not extracted. Groups were well balanced.
l Overall, 70% of the population had NYHA class II CHF and 30% had class III CHF.
l Selected baseline characteristics are reported for the participants in the QoL study107 (ICD n= 816, amiodarone n= 830,
placebo n= 833) but have not been extracted.
l Baseline characteristics are reported by race106 but have not been extracted. Significant differences in demographic and
clinical data were found between different racial groups.
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Results
Outcome ICD (n= 829)
Amiodarone
(n= 845)
Placebo
(n= 847) HR (95% CI), p-value
Mortality from any cause,
n (%)
182 (22) 240 (28) 244 (29) HR amiodarone vs. placebo 1.06
(97.5% CI 0.86 to 1.30), 0.53; HR ICD
vs. placebo 0.77 (97.5% CI 0.62 to
0.96), 0.007
Kaplan–Meier estimate for
death from any cause,
5-year event rate
0.289 0.340 0.361
Cardiac deaths, n/no.
of deaths (%)108
122/182 (67) 162/240 (68) 167/244 (68) HR amiodarone vs. placebo 1.05 (0.85
to 1.31), NS; HR ICD vs. placebo 0.76
(0.60 to 0.95), 0.018
Tachyarrhythmic 37/182 (20) 75/240 (31) 95/244 (39) HR amiodarone vs. placebo 0.84 (0.62
to 1.13), 0.25; HR ICD vs. placebo
0.40 CI 0.27 to 0.59), p< 0.001
Bradyarrhythmic 1/182 (< 1) 5/240 (2) 3/244 (1)
HF 72/182 (40) 67/240 (28) 66/244 (27) HR amiodarone vs. placebo 1.14 (0.81
to 1.60), NS; HR ICD vs. placebo 1.14
(0.82 to 1.60), NS
Non-arrhythmic, non-HF 9/182 (5) 10/240 (4) 2/244 (1)
Cardiac but unable to
classify further
3/182 (2) 5/240 (2) 1/244 (< 1)
Non-cardiac deaths,
n/no. of deaths (%)108
48/182 (26) 54/240 (23) 53/244 (22) HR amiodarone vs. placebo 1.10 (0.80
to 1.50), NS; HR ICD vs. placebo 0.80
(0.57 to 1.12), NS
Vascular 11/182 (6) 10/240 (4) 12/244 (5)
Non-vascular 37/182 (20) 44/240 (18) 41/244 (17)
Unknown deaths, n/no.
of deaths (%)108
12/182 (7) 24/240 (10) 24/244 (10) NS
Medication use at last
follow-up, n (%)
(n= 822) (n= 840) (n= 838)
ACE inhibitor 576 (70) 594 (71) 619 (74)
ARB 144 (18) 152 (18) 145 (17)
ACE inhibitor or ARB 706 (86) 718 (85) 740 (88)
Beta-blocker 672 (82) 605 (72) 662 (79) < 0.001
Diuretic
Loop 649 (79) 665 (79) 674 (80)
Potassium sparing 261 (32) 236 (28) 278 (33)
Thiazide 80 (10) 95 (11) 88 (11)
Digoxin 512 (63) 496 (59) 524 (62)
Acetylsalicylic
acid (aspirin)
449 (55) 474 (56) 451 (54)
Warfarin 279 (34) 272 (32) 300 (36)
Statin 395 (48) 405 (48) 387 (46)
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Outcome ICD (n= 829)
Amiodarone
(n= 845)
Placebo
(n= 847) HR (95% CI), p-value
ICD shocks, n/N (%)
Received for any cause,
n/N (%)
259/829 (31)
Received for rapid VT or
VF, n/N (%)
177/259 (68)
Annual rate of ICD
shocks during 5-year
follow up, %
7.5
Annual rate of
appropriate shocks
(sustained VT or VF)
during 5-year
follow-up, %
5.1
NS, not significant.
Comments
l As indicated by the HR for the mortality of ICD therapy compared with placebo, the RRR of ICD therapy was 23%.
The absolute reduction at 5 years was 7.2 percentage points.
l Kaplan–Meier curves for mortality from any cause are presented but not extracted.105 Curves are also presented for
classifications of death but are not extracted.108
Adverse effects of treatment
Adverse effect ICD (n= 829) Amiodarone (n= 845) Placebo (n= 847) p-value
Implantation unsuccessful, n (%) 1 (< 1)
ICD removed during follow-up, n (%) 32 (4)
Clinically significant ICD complications,a %
At the time of implantation 5
Later in the course of follow-up 9
At time of last follow-up, %
Increased tremor 4 (amiodarone vs. placebo) 0.02
Increased hypothyroidism 6 (amiodarone vs. placebo) < 0.001
a Defined as clinical events requiring surgical correction, hospitalisation or new and otherwise unanticipated drug therapy.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
414
Prespecified subgroup analyses105,106,108
Outcome
ICD
(n= 829)
Amiodarone
(n= 845)
Placebo
(n= 847) HR (95% CI), p-value
Mortality from any
cause – ischaemic CHF105
HR amiodarone vs. placebo 1.05
(97.5% CI 0.81 to 1.36), 0.66; HR ICD vs.
placebo 0.79 (97.5% CI 0.60 to 1.04), 0.05
Kaplan–Meier estimates of
mortality from any
cause – 5-year event rate
ischaemic CHF105
0.359
(n= 431)
0.417
(n= 426)
0.432
(n= 453)
Cause of death, participants with ischaemic CHF108
Cardiac HR amiodarone vs. placebo 0.96
(0.73 to 1.26); HR ICD vs. placebo 0.80
(0.60 to 1.05)
Sudden tachyarrhythmic HR amiodarone vs. placebo 0.70
(0.48 to 1.03); HR ICD vs. placebo 0.43
(0.27 to 0.67)
HF HR amiodarone vs. placebo 1.17
(0.78 to 1.77); HR ICD vs. placebo 1.11
(0.74 to 1.67)
Non-cardiac HR amiodarone vs. placebo 1.21
(0.88 to 1.94); HR ICD vs. placebo 0.79
(0.50 to 1.22)
Mortality from any
cause – non-
ischaemic CHF105
HR amiodarone vs. placebo 1.07
(97.5% CI 0.76 to 1.51), 0.65; HR ICD vs.
placebo 0.73 (97.5% CI 0.50 to 1.07), 0.06
Kaplan–Meier estimates of
mortality from any
cause – 5-year event rate
non-ischaemic CHF105
0.214
(n= 398)
0.258
(n= 419)
0.279
(n= 394)
Cause of death, participants with non-ischaemic CHF108
Cardiac HR amiodarone vs. placebo 1.23
(0.85 to 1.77); HR ICD vs. placebo 0.68
(0.44 to 1.03)
Sudden tachyarrhythmic HR amiodarone vs. placebo 1.13
(0.68 to 1.85); HR ICD vs. placebo 0.34
(0.17 to 0.70)
HF HR amiodarone vs. placebo 1.06
(0.58 to 1.96) HR ICD vs. placebo 1.21
(0.67 to 2.18)
Non-cardiac HR amiodarone vs. placebo 0.81
(0.48 to 1.36); HR ICD vs. placebo 0.81
(0.48 to 1.37)
Mortality from any
cause – NYHA II105
HR amiodarone vs. placebo 0.85
(97.5% CI 0.65 to 1.11), 0.17; HR ICD vs.
placebo 0.54 (97.5% CI 0.40 to 0.74), < 0.001
Kaplan–Meier estimates of
mortality from any
cause – 5-year event rate
NYHA II105
0.201
(n= 566)
0.264
(n= 601)
0.320
(n= 594)
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Outcome
ICD
(n= 829)
Amiodarone
(n= 845)
Placebo
(n= 847) HR (95% CI), p-value
Cause of death, participants with NYHA class II CHF108
Cardiac HR amiodarone vs. placebo 0.88
(0.66 to 1.17); HR ICD vs. placebo 0.50
(0.36 to 0.70)
Sudden tachyarrhythmic HR amiodarone vs. placebo 0.68
(0.47 to 0.99); HR ICD vs. placebo 0.26
(0.15 to 0.44)
HF HR amiodarone vs. placebo 0.93
(0.56 to 1.54); HR ICD vs. placebo 0.93
(0.56 to 1.54)
Non-cardiac HR amiodarone vs. placebo 0.79
(0.52 to 1.20); HR ICD vs. placebo 0.63
(0.40 to 0.99)
Mortality from any
cause – NYHA III105
HR amiodarone vs. placebo 1.44
(97.5% CI 1.05 to 1.97), 0.010; HR ICD vs.
placebo 1.16 (97.5% CI 0.84 to 1.61), 0.30
Kaplan–Meier estimates of
mortality from any
cause – 5-year event rate
NYHA III105
0.484
(n= 263)
0.528
(n= 244)
0.456
(n= 253)
Cause of death, participants with NYHA class III CHF108
Cardiac HR amiodarone vs. placebo 1.33
(95% CI 0.95 to 1.86); HR ICD vs.
placebo 1.17 (95% CI 0.84 to 1.64)
Sudden tachyarrhythmic HR amiodarone vs. placebo 1.22
(95% CI 0.73 to 2.03); HR ICD vs.
placebo 0.73 (95% CI 0.41 to 1.29)
HF HR amiodarone vs. placebo 1.34
(95% CI 0.84 to 2.11); HR ICD vs.
placebo 1.34 (95% CI 0.86 to 2.09)
Non-cardiac HR amiodarone vs. placebo 1.68
(95% CI 1.03 to 2.73); HR ICD vs.
placebo 1.10 (95% CI 0.66 to 1.85)
Comments
l There was no interaction of either amiodarone therapy (p= 0.93) or ICD therapy (p= 0.68) with the cause of CHF.
l The interaction between amiodarone and NYHA class was significant (p= 0.004). Patients with NYHA class III CHF in
the amiodarone group had a relative 44% increase in the risk of death compared with those in the placebo group
(HR 1.44). For patients with NYHA class II CHF, no excess risk of death was associated with amiodarone therapy
compared with placebo (HR 0.85).
l The interaction between ICD therapy and NYHA class was significant (p< 0.001). Among patients with NYHA class II
CHF there was a 46% relative reduction in the risk of death (HR 0.54) for those in the ICD group compared with the
placebo group. The absolute reduction in mortality among patients in NYHA class II was 11.9% at 5 years. Patients
with NYHA class III CHF had no apparent reduction in risk of death with ICD therapy compared with the placebo
(HR 1.16).
l Kaplan–Meier plots are presented but were not extracted.
l Other subgroup analyses [sex, age, race (white vs. non-white; see next section for white vs. African American), LVEF,
QRS duration, 6-minute walk distance, use of beta-blockers, diabetes] are presented but were not data extracted as not
specified a priori.
l Packer et al.,108 reporting on the impact of type of HF and HF class on mode of death, state that the interaction
between ICD therapy and NYHA class was significant for cardiac mortality (p= 0.0004) and sudden death presumed to
be ventricular tachyarrhythmic (p= 0.0091) but not for HF (p= 0.29) or non-cardiac (p= 0.11) deaths. There was a
significant interaction of amiodarone therapy on non-cardiac mortality between NYHA classes (p= 0.020) but no
significant interaction between amiodarone therapy and HF classes with respect to cardiac mortality (p= 0.064), sudden
death (p= 0.073) or HF mortality (p= 0.30).
l For type of HF (ischaemic/non-ischaemic), Packer et al.108 state that there was no significant interaction of ICD therapy
with the type of HF for cardiac (p= 0.53), sudden tachyarrhythmic (p= 0.58), HF (p= 0.82) or non-cardiac (p= 0.92)
modes of death. Similarly, no interaction was seen between amiodarone therapy and type of HF in cardiac (p= 0.29),
sudden tachyarrhythmic (p= 0.14), HF (p= 0.79) and non-cardiac (p= 0.15) mortality.
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Prespecified analysis by race106
Outcome
ICD Amiodarone Placebo
AA 36% White 33% AA 30% White 34% AA 34% White 33%
Risk
of death
HR ICD vs.
placebo 0.65
(95% CI 0.43
to 0.99),
p = not reported
HR ICD vs.
placebo 0.73
(95% CI 0.58
to 0.90),
p = not reported
HR amiodarone
vs. placebo 1.08
(95% CI 0.71
to 1.64),
p = not reported
HR amiodarone
vs. placebo 1.11
(95% CI 0.90
to 1.37),
p = not reported
ICD
discharges
No significant difference observed
between white and AA
participants, HR 1.10
(95% CI 0.80 to 1.51), p = 0.56
AA, African American.
Quality-of-life study107
Outcome ICD (n= 816)
Amiodarone
(n= 830) Placebo (n= 833)
Difference (95% CI),
p-value
DASI, mean score (SD)
Baseline 24.6 (13.6) (n= 814) 25.3 (14.1) (n= 825) 24.9 (14.1) (n= 829) Amiodarone vs. placebo
0.44 (–0.92 to 1.80);
ICD vs. placebo –0.34
(–1.68 to 1.00)
3 months 26.9 (14.1) (n= 766) 26.2 (14.7) (n= 756) 26.2 (14.3) (n= 768) Amiodarone vs. placebo
–0.01 (–1.47 to 1.45);
ICD vs. placebo –0.69
(–0.73 to 2.11)
12 months 26.8 (14.4) (n= 734) 26.1 (14.5) (n= 676) 26.6 (14.8) (n= 697) Amiodarone vs. placebo
–0.58 (–2.14 to 0.97);
ICD vs. placebo 0.16
(–1.35 to 1.68)
30 months 26.8 (14.3) (n= 665) 27.1 (15.3) (n= 575) 25.9 (15.3) (n= 585) Amiodarone vs. placebo
1.20 (–0.56 to 2.96);
ICD vs. placebo 0.89
(–0.75 to 2.53)
MHI-5, mean score (SD)
Baseline 71.7 (20.5) (n= 814) 72.1 (20.1) (n= 827) 70.0 (21.4) (n= 830) Amiodarone vs. placebo
2.11 (0.11 to 4.11),
≤ 0.05; ICD vs. placebo
1.64 (–0.39 to 3.67)
3 months 74.4 (19.3) (n= 764) 72.9 (20.6) (n= 759) 71.3 (21.5) (n= 767) Amiodarone vs. placebo
1.60 (–0.51 to 3.72);
ICD vs. placebo 3.15
(1.10 to 5.19), ≤ 0.05
12 months 74.5 (18.9) (n= 734) 72.9 (20.5) (n= 674) 70.9 (21.5) (n= 693) Amiodarone vs. placebo
1.99 (–0.24 to 4.22);
ICD vs. placebo 3.68
(1.58 to 5.78), ≤ 0.05
30 months 72.2 (19.1) (n= 654) 73.2 (20.3) (n= 560) 71.0 (21.7) (n= 564) Amiodarone vs. placebo
2.22 (–0.24 to 4.68);
ICD vs. placebo 1.24
(–1.06 to 3.53)
continued
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Outcome ICD (n= 816)
Amiodarone
(n= 830) Placebo (n= 833)
Difference (95% CI),
p-value
MLWHFQ, median
Baseline 41 NR 43 0.77
3 months 30 NR 36 0.006
12 months 32 NR 36 0.07
30 months 32 NR 36 0.05
Global health status, median107
3 months 75 70 0.002
12 months 75 70 0.05
30 months 70 70 0.18
NR, not reported.
Comments
l Median (IQR) scores for DASI reported but not extracted. This also showed no significant difference between the ICD
group and the placebo group at baseline (p= 0.76) and at months 3, 12 and 30 (p> 0.10). There were also no
significant differences at any point between the amiodarone group and the placebo group.
l Median (IQR) scores for MHI-5 also reported but not extracted. This also showed no significant difference between the
ICD group and the placebo group at baseline (p= 0.17) score was better in the ICD group than in the placebo group at
3 months (median scores 80 and 76 respectively, p= 0.01) and 12 months (median scores 80 and 76 respectively,
p= 0.003). There was no significant difference at 30 months (p= 0.79). There were no significant differences at any
point between the amiodarone group and the placebo group.
l Data for each of the other SF-36 scales are presented in a supplementary appendix and have not been extracted. For
each of these scales at least one interval comparison showed a significantly better score in the ICD group. However,
values were clinically similar and did not differ at baseline or at 30 months on any of these scales. Patients in the
amiodarone group had significantly higher scores than patients in the placebo group on the SF-36 pain index at all
four time points.
l Baseline (for the whole sample) but not follow-up data on number of bed-days are reported. Authors state that an
effect of ICD therapy compared with placebo could not be detected for number of bed-days, or disability-days, or for
the proportion of patients who were able to drive a car, manage their finances or maintain employment during the
follow-up period.
l Authors state that there was a significant improvement in the ICD group compared with the placebo group at
3 months in the time trade-off health status utility measure but not at any of the other time points. No numerical data
are presented (baseline utility measure averaged 0.80 at baseline in all three groups).
l Results are presented for an analysis accounting for the improved survival in participants in the ICD group but these
have not been extracted. Authors state that these results were not materially different from the unadjusted
comparisons, which have been extracted.
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Subgroup analyses: quality-of-life study107
Outcome
ICD (n= 816)
p-valueReceived shocka (n= 49) No shock
SF-36 score, mean changeb
General health perceptions –6.3 3.4 0.002
Physical function –8 10.9 < 0.001
Emotional function –11 4.5 0.02
Social function –5.3 4.6 0.009
Self-related health –3.2 6.6 0.009
a 49 participants received a shock up to 1 month before a scheduled QoL assessment.
b Changes in scores for patients who had received a shock are calculated as the value after the shock was delivered minus
the most recent value before the shock. Changes in scores for the non-shock group are calculated as the QoL value at
3 months minus the value at baseline. Authors state that the results were similar when other follow-up time points were
used to calculate the change in scores. A positive change indicates better function.
Comments
l Authors state that the pattern was the same for the 66 participants who had received a shock up to 2 months before a
scheduled QoL assessment, but with smaller differences.
l Authors state that a comparison between 100 surviving patients who received an ICD shock at any time in the first year
and 638 participants who did not receive a shock showed no significant differences. Also, the number of ICD
discharges (above a range of two to five) did not have a significant effect on subsequent QoL. Further details
not reported.
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Comments
Methodological comments
l Allocation to treatment groups: patients assigned to amiodarone or placebo began therapy as outpatients
immediately after randomisation. ICD group patients received the device a median of 3 days after
randomisation (IQR 2-5 days). Permuted-block randomisation was carried out, stratified by clinical site,
cause of CHD (ischaemic vs. non-ischaemic) and NYHA class (II vs. III). Block size randomly chosen as 3 or 6.
l Blinding: placebo and amiodarone administered in double-blind fashion. Wyeth-Ayerst Pharmaceuticals
provided tablets that appeared identical.105 The events committee that adjudicated deaths was blinded to
treatment assignment (a nurse removed all information identifying randomised therapy assignment
from reports).108
l Comparability of treatment groups: authors state that there were no significant differences between the
groups at baseline. By the last follow-up visit there was a difference in use of beta-blockers (p< 0.001).
The median dose of amiodarone and placebo was 300mg/day 3 months after randomisation and remained
so throughout the study. QoL study:107 selected baseline characteristics are reported and described
as well balanced between the groups.
l Method of data analysis: pairwise comparisons (amiodarone vs. placebo; ICD vs. placebo) performed
according to the ITT principle. All statistical tests two-tailed. Cumulative mortality rates calculated using the
Kaplan–Meier method. Event (or censoring) times measured from time of randomisation (time zero).
Differences in mortality rates assessed using the log-rank test, with adjustment for NYHA class and cause of
CHF. RRs expressed as HRs with 97.5% CIs (consistent with an alpha level of 0.025) are derived from the
Cox proportional hazards model (however, 95% CIs are reported by Parker et al.108). Cox model also used
to test the significance of interactions between NYHA class and treatment, and between cause of CHF and
treatment. Six interim analyses were performed and reviewed by the independent data and safety
monitoring board using two-sided, symmetrical O’Brien–Fleming boundaries generated with the
Lan–DeMets alpha-spending function approach to group sequential testing. Because of sequential testing
the level of significance for each major treatment comparison at completion of the study was 0.023.
Some patients may have had ICD discharges that were either not recorded or not reported to the ICD core
laboratory, which would limit the ability to know the true rate of ICD events. QoL study:107 continuous
data described with means (SD) and/or medians (25–75 percentiles). Categorical variables described with
percentages. Pearson’s chi-squared test was used for categorical variable comparisons and the Wilcoxon
rank-sum test was used for continuous variables. The Wilcoxon rank-sum test for changes in scores from
the most recent QoL measurements before a shock occurred was used to compare patients who received a
shock within the month preceding a QoL assessment with those who did not. The analysis was repeated
with 2- and 12-month time frames. To account for potential bias as a result of the significant difference in
mortality between the groups, an estimator for the survival average causal effect was applied in a sensitivity
analysis. All reported p-values were two-sided and no adjustments were made for multiple testing.
l Sample size/power calculation: based on the assumption that the placebo group would have an annual
mortality rate of 10%. Powered at 90% to detect a 25% reduction in death from any cause with
amiodarone or ICD therapy compared with placebo on the basis of an alpha level for each comparison
of 0.025.
l Attrition/dropout: vital status known for all 2521 patients at the time of the last scheduled follow-up visit.
The non-compliance rate for study drug therapy (discontinuation of placebo or amiodarone for any period)
was 27% (458 patients) – 22% of the placebo group (189/847 patients) and 32% of the amiodarone
group (269/845 patients). Crossovers: 125 patients (7%) in the drug groups crossed over to open-label
amiodarone (44 in the amiodarone group and 81 in the placebo group). In the ICD group 113/829 (14%)
patients received open-label amiodarone during some part of the follow-up and 17/829 (2%) patients
assigned to ICD therapy declined to undergo implantation. Crossover to some form of ICD therapy
occurred in 188 patients (11%) in the drug groups during follow-up. Median time from randomisation
to crossover was 26.7 months. QoL study:107 98% completed the baseline QoL questionnaires. At each
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follow-up 93–95% of eligible patients were included; overall, 95% of the questionnaires were collected.
A total of 1.2% of patients declined to complete the questionnaires, 1.4% of the forms were judged
incomplete and in 69/6268 (1.1%) interviews proxy forms were substituted for the full questionnaire.
l Other: none of the 716 patients for whom defibrillation testing data were reported required more than a
30-J shock for defibrillation (the maximum device output).
General comments
l Generalisability: broad population of patients with mild to moderate HF and no exclusions stated. However,
the majority of the participants were American and the racial mix of participants differs to that likely in
the UK.
l Outcome measures: appear appropriate.
l Intercentre variability: for the QoL study specific training was provided at each site to ensure standardisation
of data collection.107 No other details provided.
l Conflict of interests: authors state that companies provided study drugs and ICDs free of charge and
provided additional clinical and research funding. However, neither company had any role in the design,
analysis or interpretation of the study.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random
sequence generation
Unclear States permuted-block randomisation, stratified by clinical site, cause of CHD
and NYHA class, with block size randomly chosen as 3 or 6. However,
no details about generation of sequence
Allocation concealment Unclear No details provided
Performance bias
Blinding of participants
and personnel
High No blinding of ICD arm. QoL: risk of bias between ICD and non-ICD groups
because of knowledge of intervention received
Detection bias
Blinding of outcome assessment
Mortality Low Events committee who adjudicated deaths was blinded to treatment group
QoL High QoL data obtained by structured interview; risk of bias between ICD and
non-ICD groups because of knowledge of intervention received
Attrition bias
Incomplete outcome data addressed
Mortality Low ITT analysis and vital status known for all patients at time of last visit
QoL Unclear Some explanation of missing data but not by treatment group
Reporting bias
Selective reporting Low Protocol not available but papers appear to report all of the expected and
stated outcomes
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Appendix 8 Data extraction: people with
heart failure as a result of left ventricular
systolic dysfunction and cardiac dyssynchrony
Cardiac Resynchronization – Heart Failure (CARE-HF) trial
Reference
and design
Intervention
and comparator Participants Outcome measures
Cleland et al. 2001,110
2005,109 2006,111
2008112 and 2009,113
Gras et al. 2007,36
Gervais et al. 2009,114
Ghio et al. 2009115
Study design: RCT
Countries: European
countries including
the UK, France,
Germany, Switzerland
and Italy109
No. of centres: 82109
Funding: supported by
a grant
from Medtronic
Intervention: CRT-P+medical
therapy (standard
pharmacological therapy).
CRT (Medtronic InSync or
InSync III device) provided
atrial-based, biventricular
stimulation. Standard right
ventricular and Attain
(Medtronic) left ventricular
leads. Back-up atrial pacing
set at 60 bpm, interventricular
delay set at zero,
atrioventricular delay
echocardiographically
optimised109
Comparator: medical therapy
(standard pharmacological
therapy) only109
Other interventions used:
none reported. Standard
medications adjusted if
needed at follow-up visits
Indication for treatment:
NYHA class III or IV from LVSD
and cardiac dyssynchrony
receiving standard
pharmacological therapy109
No. of randomised
participants: 813;
CRT-P+medical therapy: 409,
medical therapy alone: 404109
Inclusion criteria: NYHA class
III or IV despite standard
pharmacological therapy,
LVEF ≤ 35%, LVEDD ≥ 30mm
(indexed to height), QRS
interval ≥ 120milliseconds
(patients with QRS interval of
120–149milliseconds required
to meet two of three
additional criteria for
dyssynchrony: aortic
pre-ejection delay
> 140milliseconds,
interventricular mechanical
delay > 40milliseconds,
delayed activation of
posterolateral left ventricular
wall), age ≥ 18 years,
HF for ≥ 6 weeks109
Exclusion criteria: major
cardiovascular event in
previous 6 weeks,
conventional indications for a
pacemaker or an ICD, HF
requiring continuous
intravenous therapy,
atrial arrhythmias109
Primary outcomes: composite
of death from any cause or an
unplanned hospitalisation for
a major cardiovascular event
(only first hospitalisation
counted).109 For extension
phase, death from any
cause111
Secondary outcomes: death
from any cause, composite of
death from any cause and
unplanned hospitalisation for
HF, 90-day NYHA class,
90-day QoL.109 For extension
phase, mode of death111
Method of assessing
outcomes: assessment at
baseline and 1, 3, 6, 9, 12
and 18 months, then at
6-month intervals. For QoL,113
assessment at baseline and
3 months, then disease-specific
instrument only at 18 months
and study end
QoL: patient assessed using
the disease-specific MLWHFQ
(score range 0–105, higher
score indicates lower QoL)
and the generic EQ-5D (score
range –0.594 to 1.0, lower
score indicates lower QoL,
negative scores considered
worse than death)
Length of follow-up: mean
29.4 months (range
18.0–44.7 months).109 For
QoL,113 median 29.6 months
(IQR 23.6–34.6 months).
After 8-month extension
phase, mean 37.4 months
(range 26.1–52.6 months),
median 37.6 months (IQR
31.5–42.5 months)111
Recruitment: January
2001–March 2003109
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter.
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Participant characteristics109
Characteristic
CRT-P+medical
therapy (n= 409)
Medical therapy
(n= 404) p-value
Age (years), median (range) 67 (60–73) 66 (59–72)
Sex, male, n (%) 304 (74) 293 (73)
Ethnicity NR NR
Dilated cardiomyopathy, n (%) 177 (43) 193 (48)
Ischaemic heart disease, n (%) 165 (40) 144 (36)
Heart disease of other causes, n (%) 67 (16) 67 (17)
NYHA class IV, n (%) 23 (6) 27 (7)
LVEF (%), median (range) 25 (21–29) 25 (22–29)
QRS interval (milliseconds), median (range) 160 (152–180) 160 (152–180)
Heart rate (bpm), median (range) 69 (60–78) 70 (61–78)
Left ventricular end-systolic volume index (ml/m2), median (range) 121 (92–151) 117 (94–147)
Interventricular mechanical delay (milliseconds), median (range) 49 (32–67) 50 (30–66)
Mitral regurgitation area (cm2), median (range) 0.21 (0.12–0.33) 0.23 (0.11–0.34)
Use of ACE inhibitor or ARB, n (%) 387 (95) 383 (95)
Use of beta-blocker, n (%) 288 (70) 298 (74)
Use of spironolactone, n (%) 219 (54) 238 (59)
Use of high-dose loop diuretic, n (%) 175 (43) 177 (44)
Use of digoxin, n (%) 165 (40) 181 (45)
Systolic blood pressure (mmHg), median (range) 110 (100–125) 110 (100–125)
Diastolic blood pressure (mmHg), median (range) 70 (60–79) 70 (60–80)
N-terminal pro-brain natriuretic peptide (pg/ml), median (range) 1920 (744–4288) 1806 (719–3949)
Glomerular filtration rate (ml/minute/1.73m2), median (range) 60 (46–73) 61 (46–73)
bpm, beats per minute; NR, not reported.
Comments
l Beta-blockers were taken at some time during the study by 85% of the medical therapy group and 84% of the
CRT-P group.
l Information on associations between baseline EQ-5D score and baseline patient characteristics is reported but has not
been data extracted.113
l Baseline characteristics for the 735 participants who had an analysable echocardiographic examination at baseline are
presented in another paper115 on left ventricular reverse modelling outcomes but have not been data extracted.
The clinical characteristics of these participants are described as similar to those of the whole study population.
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Results
Outcome109
CRT-P+medical
therapy (n= 409)
Medical therapy
(n= 404)
HR or difference in
means (95% CI), p-value
Death or unplanned hospitalisation
for a cardiovascular event
(primary outcome), n/N (%)
159/409 (39) 224/404 (55) HR 0.63 (0.51 to 0.77),
< 0.001
Unplanned hospitalisation for a
cardiovascular event
(primary outcome), n/N (%)a
125/409 (31) 184/404 (46) HR 0.61 (0.49 to 0.77),
< 0.001
Death from any cause, n/N (%) 82/409 (20) 120/404 (30) HR 0.64 (0.48 to 0.85),
< 0.002
Additional deaths during the
extension phase, n111
19 34
Deaths in main study+ deaths in
extension phase, n/N (%)
101/409 (24.7),
7.9% per annum
154/404 (38.1),
12.2% per annum
HR 0.60 (0.47 to 0.77),
< 0.0001
Principal cause of death, n/N deaths (%)
Cardiovascular 167/202 (83)
Non-cardiovascular 34/202 (17)
Not classifiable 1/202 (0.5)
Death attributed to worsening HF,
n/N deaths (%)
33/82 (40) 56/120 (47)
Deaths from HF in main
study+ extension phase, n111
38 (3.0% per annum) 64 (5.1% per annum) HR 0.55 (0.37 to 0.82),
0.003
Death classified as sudden, n/N
deaths (%)
29/82 (35) 38/120 (32)
Sudden deaths in the extension phase,
n/N deaths111
3/19 16/34
Sudden deaths in main
study+ extension phase, n111
32 (2.5% per annum) 54 (4.3% per annum) HR 0.54 (0.35 to 0.84),
0.005
Mortality rate, %
1 year 9.7 12.6
2 years 18.0 25.1
3 years111 23.6 35.1
Death from any cause or unplanned
hospitalisation with worsening HF,
n/N (%)
118/409 (29) 191/404 (47) HR 0.54 (0.43 to 0.68),
< 0.001
Unplanned hospitalisation with
worsening HF, n/N (%)a
72/409 (18) 133/404 (33) HR 0.48 (0.36 to 0.64),
< 0.001
Deaths in the first 90 days, n 12 15
Heart transplantations, nb
Emergency 1 3
Elective 9 6
continued
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Outcome109
CRT-P+medical
therapy (n= 409)
Medical therapy
(n= 404)
HR or difference in
means (95% CI), p-value
MLWHFQ score, mean (SD) at
90 daysc
31 (22) 40 (22) Difference in means
–10 (–8 to –12), < 0.001
EQ-5D score, mean (SD) at 90 daysc 0.70 (0.28) 0.63 (0.29) Difference in means
0.08 (0.04 to
0.12), < 0.001
NYHA class, mean (SD) at 90 days 2.1 (1.0) 2.7 (0.9) Difference in means
0.6 (0.4 to 0.7), < 0.001
NYHA class at 18 months, n
Class I 105 39
Class II 150 112
Class III or IV 80 152
Difference in meansd (95% CI) p-value
LVEF (%)
At 3 monthse +3.7 (3.0 to 4.4) < 0.001
At 18 monthse +6.9 (5.6 to 8.1) < 0.001
Heart rate (bpm)
At 3 months +1.1 (–1.2 to 3.4) 0.33
At 18 months +1.0 (–1.5 to 3.6) 0.43
Systolic blood pressure (mmHg)
At 3 months +5.8 (3.5 to 8.2) < 0.001
At 18 months +6.3 (3.6 to 8.9) < 0.001
Diastolic blood pressure (mmHg)
At 3 months +1.5 (0.1 to 2.9) 0.03
At 18 months +1.3 (–1.8 to 4.4) 0.42
Interventricular mechanical delay (ms)e
At 3 months –21 (–25 to –18) < 0.001
At 18 months –21 (–25 to –17) < 0.001
Left ventricular end-systolic volume index (ml/m2)
At 3 months –18.2 (–21.2 to –15.1) < 0.001
At 18 months –26.0 (–31.5 to –20.4) < 0.001
Mitral regurgitation area (cm2)
At 3 months –0.051 (–0.073 to –0.028) < 0.001
At 18 months –0.042 (–0.070 to –0.014) 0.003
N-terminal pro-brain natriuretic peptide (pg/ml)
At 3 months –225 (–705 to –255) 0.36
At 18 months –1122 (–1815 to –429) < 0.002
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Outcome109
CRT-P+medical
therapy (n= 409)
Medical therapy
(n= 404)
HR or difference in
means (95% CI), p-value
IHD
(n= 168)
Non-IHD
(n= 197)
IHD
(n= 135)
Non-IHD
(n= 235)
p-value
LEVF
Baseline (%), median (IQR)115 25
(22 to 29)
24
(21 to 29)
26
(22 to 30)
24
(21 to 29)
0.1867
(IHD vs. non-IHD)
Mean (SD) change at 18 months
from baseline (%)f
6.1 (1.2) 10.9 (1.5) 1.3 (0.7) 2.4 (1.7) 0.003 for interaction
between CRT and aetiology
bpm, beats per minute; IHD, ischaemic heart disease.
a These events contributed to the primary or secondary outcome.
b All emergency heart transplantation patients died; the elective heart transplantation patients were all alive 7 days after
transplantation, at which point their data were censored from the analysis.
c Difference in means is for the CRT-P group compared with the medical therapy group.
d Differences were not adjusted for the higher mortality rate in the medical therapy group. A plus sign indicates that the
CRT-P value is greater than the medical therapy group-value; a minus sign indicates that the CRT-P value is smaller than
the medical therapy group value.
e Similar but not identical data also presented by Ghio et al.115
f Values estimated from figure by reviewer using digitising software.115 Not stated, but error bars presumed to show SDs.
Comments
l Authors state that there were 384 unplanned hospitalisations for a major cardiovascular event in the medical therapy
group and 222 in the CRT-P group. Although not explicitly stated it is assumed that, as these values differ from those
in the table above, they include all events (not just the first event, which contributed to the outcome above).
l Of the 383 events in the total trial population contributing to the primary outcome of death or unplanned
hospitalisation, death was the primary event in 74 patients and hospitalisation was the primary event in 309 patients.
l 12 CRT-P patients and 10 OPT patients had unplanned hospitalisations for a major cardiovascular event that occurred
within 10 days of randomisation and these hospitalisations were therefore not counted as primary end points.
l Kaplan–Meier estimates of time to primary end point and the principal secondary outcome are presented but have not
been data extracted. Kaplan–Meier-estimates also presented including the extension phase for time to all-cause
mortality, time to death from worsening HF and time to death from sudden death but these have not been
data extracted.
l The 72 CRT-P participants with unplanned hospitalisations with worsening HF had 122 hospitalisations in total,
whereas the 133 participants with unplanned hospitalisations in the medical therapy group had 252 hospitalisations
in total.
l Outcomes from a multivariable analysis112 of 15 baseline variables and eight markers of response, which investigated
whether these factors could predict all-cause mortality, have not been extracted. Similarly, outcomes from single and
multiple variable analyses114 of electrocardiographic measures, which assessed whether a surface ECG can predict
outcomes, have not been data extracted.
l Ejection fraction outcomes for subgroups with or without ischaemic heart disease but not for subgroups with
restrictive/non-restrictive left ventricular filling or measures of right ventricular dysfunction have been extracted from the
left ventricular reverse remodelling paper.115 Other outcomes (end-diastolic and end-systolic volumes, severity of mitral
regurgitation, predictors of long-term response) have not been extracted.
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Quality-of-life results113
Outcome
CRT-P+medical
therapy (n= 409)
Medical therapy
(n= 404) MD (95% CI), p-value
Mean QALYs (95% CI)
3 months 0.16 (0.15 to 0.16) 0.15 (0.14 to 0.15) 0.01 (0.001 to 0.018), 0.285
18 months 0.95 (0.91 to 0.99) 0.82 (0.78 to 0.86) 0.13 (0.07 to 0.018), < 0.0001
End of study 1.45 (1.38 to 1.53) 1.22 (1.15 to 1.29) 0.23 (0.13 to 0.33), < 0.0001
Mean life-years (95% CI)
3 months 0.241 (0.238 to 0.244) 0.241 (0.238 to 0.244) 0.0003 (–0.004 to 0.0045), 0.90
18 months 1.37 (1.34 to 1.40) 1.33 (1.29 to 1.37) 0.04 (–0.01 to 0.09), 0.13
End of study 2.07 (1.99 to 2.15) 1.96 (1.88 to 2.05) 0.10 (–0.01 to 0.22), 0.07a
EQ-5D score (95% CI)
Baseline 0.60 (0.58 to 0.63) 0.60 (0.57 to 0.63) –
3 months 0.69 (0.66 to 0.72) 0.61 (0.59 to 0.64) 0.08 (0.04 to 0.11), < 0.0001
18 months 0.61 (0.58 to 0.64) 0.51 (0.48 to 0.54) 0.10 (0.06 to 0.15), < 0.0001
End of study 0.56 (0.52 to 0.59) 0.43 (0.39 to 0.46) 0.13 (0.08 to 0.18), < 0.0001b
MLWHFQ score (95% CI)
Baseline 44.6 (42.5 to 46.7) 43.7 (41.5 to 45.8) –
3 months 30.1 (27.9 to 32.3) 38.9 (36.6 to 41.2) –10.6 (–8.1 to –13.1), < 0.0001c
18 months 28.4 (26.2 to 30.5) 36.0 (33.5 to 38.5) –10.7 (–7.6 to –13.8), < 0.0001c
End of study 27.2 (24.9 to 29.5) 35.1 (32.6 to 37.6) –10.1 (–6.8 to –13.3), < 0.0001c
Mean [median (IQR)] days in
hospital by 3 months
7.5 [4 (2–8)] 3.4 [0 (0–1)]
Days in hospital after 3 months 222 384
Mean [median (IQR)] days in
hospital overall during entire
study (median 29.6 months)
20.7 [9 (4–26)] 22.4 [9 (0–31)]
a p-value based on restricted mean survival used to estimate QALYs. This is not the best estimator of survival differences
between groups (statistically inefficient); see, instead, all-cause mortality earlier.
b Decline in EQ-5D score despite a maintained effect on the MLWHFQ is because death has a health use of zero on the
EQ-5D and is not included in the MLWHFQ.
c MLWHFQ scores include the last value carried forward for missing items. Patients who died are not included. Difference
between groups accounts for baseline NYHA class and MLWHFQ score.
Comments
l Baseline EQ-5D score (mean 0.60, 95% CI 0.58 to 0.62) is lower than that of representative age-matched general
population (mean 0.78, 95% CI 0.76 to 0.80)
l In the CRT group at 3 months, most QALYs gained in comparison to the control group came from improved QoL. With
longer follow-up deaths in the control group caused a larger proportion of lost QALYs and a larger proportion of the
gain with CRT.
l Data are presented for the proportion of patients with improved, the same or worse EQ-5D scores but these have not
been extracted (incomplete data: 320/409 in CRT group, 315/404 in medical therapy group). Data are presented in a
figure for the proportion of patients with a deterioration in, an improvement in or the same MLWHFQ score but these
have not been extracted.
l A figure showing that by 3 months CRT reduced the proportion of patients reporting problems in all EQ-5D dimensions
has not been data extracted.
l Subgroup analyses (predefined) showing that there was little heterogeneity in the effect of CRT on QALYs are reported
but not extracted.
l In first 3 months the CRT group spent more days in hospital as a result of device implantation but overall spent fewer
days because of the small number of unplanned hospitalisations for major cardiovascular events.
l There are minor differences between the QoL results reported in the main trial publication109 and those reported in this
table.113 The reasons for these minor differences are not clear.
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Adverse effects of treatment109
Adverse effect
CRT-P+medical therapy
(n= 409)
Medical therapy
(n= 404) p-value
Device-related deaths, n 1 (HF aggravated by
lead displacement)
1 (septicaemia after
receiving a device)
Most common adverse device- or procedure-related events, n patients
Lead displacement 24
Coronary sinus dissection 10
Pocket erosion 8
Pneumothorax 6
Device-related infection 3
Worsening HF, n patients 191 263 < 0.001
Atrial arrhythmias or ectopy, n patients 64 41 0.02
Comments
l Frequency of respiratory tract infections, hypotension, falls or syncope, acute coronary syndromes, renal dysfunction,
ventricular arrhythmias or ectopy and neurological events was similar in the two groups; numerical data not presented.
l More detailed reporting of adverse events in the paper by Gras et al.36 suggests that some of the CRT-P group adverse
events reported above may have occurred in participants who crossed over from medical therapy to CRT-P; however;
some of these data do not appear to match those data reported in this table from the main paper109 and thus they
have not been extracted.
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Subgroup analyses109
Subgroup Patients with event/total no. of patients HR (95% CI)
Overall with primary end point 383/813 0.63 (0.51 to 0.77)
Age (years)a
< 66.4 163/406 0.55 (0.40 to 0.75)
≥ 66.4 220/407 0.68 (0.52 to 0.89)
Sex
Male 290/597 0.62 (0.49 to 0.79)
Female 93/215 0.64 (0.42 to 0.97)
NYHA class
III 349/763 0.64 (0.52 to 0.80)
IV 34/50 0.50 (0.25 to 1.01)
Dilated cardiomyopathy
No 238/443 0.68 (0.53 to 0.88)
Yes 145/370 0.51 (0.36 to 0.73)
Systolic blood pressure (mmHg)a
< 117 208/401 0.60 (0.46 to 0.80)
≥ 117 mmHg 170/402 0.66 (0.48 to 0.89)
N-terminal pro-brain natriuretic peptide (pg/ml)
< 214.5 122/366 0.53 (0.36 to 0.76)
≥ 214.5 224/366 0.70 (0.54 to 0.91)
Ejection fraction (%)a
< 24.7 205/372 0.65 (0.49 to 0.86)
≥ 24.7 152/373 0.62 (0.44 to 0.85)
Left ventricular end-systolic volume index (ml/m2)a
< 119.2 156/366 0.71 (0.52 to 0.98)
≥ 119.2 193/366 0.54 (0.40 to 0.73)
QRS interval (milliseconds)
< 160 152/290 0.74 (0.54 to 1.02)
≥ 160 222/505 0.60 (0.46 to 0.79)
Interventricular mechanical delay (milliseconds)a
< 49.2 199/367 0.77 (0.58 to 1.02)
≥ 49.2 147/368 0.50 (0.36 to 0.70)
Mitral regurgitation area (cm2)a
< 0.218 114/302 0.86 (0.60 to 1.25)
≥ 0.218 175/303 0.56 (0.41 to 0.75)
Glomerular filtration rate (ml/minute/1.73m2)a
< 60.3 196/369 0.67 (0.50 to 0.89)
≥ 60.3 142/370 0.57 (0.40 to 0.80)
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Subgroup Patients with event/total no. of patients HR (95% CI)
Beta-blockers
No 131/227 0.72 (0.51 to 1.02)
Yes 252/586 0.59 (0.46 to 0.76)
Spironolactone
No 166/356 0.58 (0.43 to 0.79)
Yes 217/457 0.67 (0.51 to 0.88)
Loop diuretics
< 80mg of furosemide or equivalent 181/461 0.56 (0.42 to 0.76)
≥ 80mg of furosemide or equivalent 202/352 0.69 (0.53 to 0.92)
Digoxin
No 218/467 0.66 (0.50 to 0.86)
Yes 165/346 0.59 (0.43 to 0.81)
a Divided according to the median value in the study population.
Comments
l All analyses were stratified according to NYHA class, except for the subgroup analysis of NYHA class.
l For some data many patients had results at the median value and this led to some inequalities in the sizes of the
subgroups (e.g. QRS interval).
l There were missing baseline data for sex, systolic blood pressure, N-terminal pro-brain natriuretic peptide level, ejection
fraction, end-systolic volume index, QRS interval, interventricular mechanical delay, mitral regurgitation area and
glomerular filtration rate. Consequently, these subgroup numbers do not total 813.
l A similar subgroup analysis was conducted after the extension phase for deaths only (whereas data above are for the
composite primary outcome of death from any cause or an unplanned hospitalisation for a major cardiovascular
event).111 As the extension phase subgroup analysis is not for the primary outcome and because it showed no
heterogeneity of effect, these data have not been extracted.
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Comments
Methodological comments
l Allocation to treatment groups: randomisation stratified by NYHA class and carried out by an independent
clinical research organisation (Quintiles, Dublin) using a minimisation procedure.109
l Blinding: not blinded;109 however, members of the end points committee (who classified all hospitalisations
and some adverse events) were not aware of patients’ treatment assignments. Procedure- or device-related
adverse events classified by an unblinded independent expert.109
l Comparability of treatment groups: baseline characteristics similar.
l Method of data analysis: all prespecified analyses carried out according to the ITT principle. Time to event
calculated using Kaplan–Meier method and analysed with Cox proportional hazard models (baseline NYHA
as a covariate). Continuous data (including QoL113 and ECG outcomes115) analysed using mixed models that
included baseline variables as patient-level covariates and study centres as random effects. Dichotomous
outcomes analysed using non-linear mixed models with NYHA class as a patient-level covariate and study
centres as random effects. Adverse event rates compared using Fisher’s exact test. Two planned interim
analyses were conducted by the data and safety monitoring board with the use of non-symmetrical
stopping rules.109 Missing QoL scores were imputed using EQ-5D and MLWHFQ scores, sex, NYHA class,
interventricular mechanical delay and mitral regurgitation at baseline. A score of zero was assigned at the
time of patient death or time of heart transplantation.113 QALYs calculated for each patient as the area
under the curve estimated through linear interpolation of individual patient-level estimates of health utility
based on EQ-5D scores at baseline, 3 and 18 months and the end of the study.113
l Sample size/power calculation: statistical power of 80% to identify a 14% relative reduction or a 5.7%
point reduction in the rate of events (α= 0.025, 300 events predicted).109
l Attrition/dropout: of the 409 patients assigned to CRT-P, an attempt at implantation was made in 404.
One patient died before the procedure and in the other four cases the patient or the investigator decided
not to proceed with implantation. A CRT-P device was implanted and activated in 390 (95%) patients [six
patients had an unplanned hospitalisation for cardiovascular reasons (reached primary end point) before the
device was activated], and eight patients received CRT-D]. In 43 patients from the medical therapy group
implantation of a CRT-P device was attempted, and in 23 patients implantation of a CRT-D device was
attempted (both attempted in one patient). The device was activated in 50 patients. In 10 cases the device
was programmed to provide standard pacemaker or ICD-only functions to avoid crossover. In the remaining
five patients implantation was unsuccessful. In 19 patients (5%) the device was activated before the
primary end point was reached; eight subsequently reached the primary end point (six died). Among the
31 patients who reached the primary end point before the device was activated, seven subsequently
died.109 At the end of the extension phase the survival of one participant in the medical therapy group was
unknown.111 During the extension phase four patients who had received a device in the main phase had it
activated, and 41 additional patients had a CRT device implanted and activated. Therefore, at the end of
the extension phase a total of 95/404 participants in the medical therapy group had received a CRT device
and had it activated, of whom 22 (23.2%) had died.111 In the paper reporting left ventricular reverse
modelling outcomes,115 baseline ECGs were not analysable for 78 (10%) participants. Reasons for this were
baseline data not received by the core ECG laboratory (n= 36), damaged video tape (n= 4) and
poor-quality examination (n= 38).
l Other: the extension phase was declared before study closure and without knowledge of the results.111
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General comments
l Generalisability: included patients with LVSD and cardiac dyssynchrony who have moderate or severe HF
and who are in sinus rhythm.
l Outcome measures: appear appropriate.
l Intercentre variability: not commented on but data analysis included study centres as random effects as
noted in the method of data analysis, which presumably took this into account.109
l Conflict of interests: all of the authors had conflicts of interest, which are stated at the end of the report.109
The sponsor had no access to the database and did not participate in the analysis of the results or the
writing of the article.
Criteria for assessment of risk of bias in randomised controlled trials65
Judgementa Support for judgement
Selection bias
Random sequence generation Low Randomisation used a minimisation procedure
Allocation concealment Low Allocation by independent organisation
Performance bias
Blinding of participants
and personnel
High Unblinded trial
Detection bias
Blinding of outcome assessment
Mortality and hospitalisation Low End points committee not aware of patients’ treatment assignments
ECG outcomes High Unblinded trial. No indication that core laboratory quantifying these
data were unaware of treatment assignment
Adverse events Unclear Some adverse events (not specified which) were classified by the end
points committee who were unaware of patients’ treatment
assignments but other procedure- or device-related adverse events were
classified by an unblinded independent expert
Attrition bias
Incomplete outcome data addressed
Mortality, hospitalisation,
ECG outcomes
Low Analyses according to the ITT principle. Crossovers reported
QoL Unclear Missing QoL scores imputed but amount of missing data not reported
Left ventricular reverse
remodelling outcomes
Unclear Not all participants were included because not all had a readable
baseline ECG (10% missing). Authors state that clinical characteristics of
groups were similar to those of the total trial population. Reasons for
missing data not reported for each group, only overall, so not clear if
reasons for missing data are similar between groups
Reporting bias
Selective reporting Low Rationale, design and end points paper available.110 Primary and
secondary outcomes appear to have been reported as planned.
Separate papers report outcomes109,111,113,115
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Comparison of Medical Therapy, Pacing and Defibrillation in
Heart Failure (COMPANION) trial
Reference
and design
Intervention
and comparator Participants Outcome measures
Bristow et al. 2000117
and 2004,116
Carson et al. 2005,119
US FDA 2004118
Anand et al. 2009120
Study design: RCT
Country: USA
No. of centres: 128
Funding: Guidant
Corporation,
St Paul, MN
Intervention: OPT and either
CRT-P (Guidant model
1241 Contak TR) or CRT-D
(Guidant model 1823
Contak CD)
Comparator: OPT – loop
diuretics, ACE inhibitors,
spironolactone and
beta-blockers (unless not
tolerated). Also permitted:
booster diuretics, ARBs,
digoxin, alternative
vasodilators, calcium channel
blockers
Other interventions used:
none reported
Indication for treatment:
advanced chronic HF and
intraventricular conduction
delays
No. of randomised
participants: 1520; CRT-P:
617, CRT-D: 595, OPT: 308
Inclusion criteria: NYHA class
III or IV, QRS duration
≥ 120milliseconds, PR
interval > 150milliseconds,
LVEF ≤ 35%, OPT, LVEDD
≥ 60mm, age ≥ 18 years,
sinus rhythm
Exclusion criteria: ICD
indications, life expectancy
< 6 months, chronic atrial
tachyarrhythmias, indications
for antibradycardia pacing,
unexplained syncope,
MI within 60 days of
randomisation, uncontrolled
blood pressure, surgically
uncorrected primary valvular
heart disease, progressive or
unstable angina, pregnancy,
hypertrophic obstructive
cardiomyopathy, amyloid
disease, tricuspid prosthesis,
hospitalisation for HF
> 4 hours in previous
month117
Primary outcomes: all-cause
mortality and all-cause
hospitalisation (composite
end point)
Secondary outcomes: cardiac
morbidity, all-cause mortality,
cardiac hospitalisation,
6-minute walk distance, NYHA
class before and after
treatment, adverse events,
HRQoL (MLWHFQ)
Method of assessing
outcomes: first events for
hospitalisation related to
cardiovascular causes or HF,
use of outpatient intravenous
medication and cause of death
adjudicated by end points
committee. Clinical evaluations
at baseline,
1 week and 1 month,
then 3-monthly117
Length of follow-up, median:
primary end point: CRT-P 16.2
months (vs. OPT, p< 0.001);
CRT-D 15.7 months (vs. OPT,
p< 0.001); OPT 11.9 months.
Mortality: CRT-P 16.5 months
(vs. OPT, p< 0.028); CRT-D
16.0 months (vs. OPT,
p< 0.129); OPT 14.8 months
Recruitment:
January 2000–December 2002
LVEDD, left ventricular end-diastolic diameter.
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Participant characteristics (pre randomisation/implant)
Characteristic CRT-P (n= 617) CRT-D (n= 595) OPT (n= 308) p-value
Age (years), median 67 66 68
Sex, % male 67 67 69
Ethnicity NR NR NR
Severity of HF, %
NYHA class III 87 86 82
NYHA class IVa 13 14 18
QRS interval (ms), median 160 160 158
LVEF, median 0.20 0.22 0.22
LVEDD (mm), median 68 67 67
Heart rate (bpm), median 72 72 72
Blood pressure (mmHg), median
Systolic 110 112 112
Diastolic 68 68 64
Ischaemic cardiomyopathy, % 54 55 59
Pharmacological therapy, %
Beta-blocker 68 68 66
Spironolactone 53 55 55
ACE inhibitor 70 69 69
ACE inhibitor or ARB 89 90 89
Loop diuretic 94 97 94
Left branch bundle block, % 69 73 70
Right branch bundle block, % 12 10 9
Duration of HF (years), median 3.7 3.5 3.6
6-minute walk distance (m), median 274 258 244
Diabetes, % 39 41 45
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter; NR, not reported.
a Calculated by reviewer.
Comments
l Authors state that there are no clinically significant differences between the groups.
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Results
Outcome CRT-P (n= 617) CRT-D (n= 595) OPT (n= 308)
HR (95% CI), p-value:
OPT vs. CRT-P;
OPT vs. CRT-D
Composite end point (all-cause mortality or hospitalisation) (primary end point)a
Events during study, n 414 390 216
12-month event rate, % 56 56 68 0.81 (0.69 to 0.96),
0.014; 0.80
(0.68 to 0.95), 0.010
All-cause mortalitya
Events during study,
n/N (%)
131/617 (21.2) 105/595 (17.6) 77/308 (25.0)
12-month event rate, % 15 12 19 0.76 (0.58 to 1.01),
0.059; 0.64
(0.48 to 0.86), 0.003
Death or hospitalisation from cardiovascular causesa
Events during study, n 338 312 188
12-month event rate, % 45 44 60 0.75 (0.63 to 0.90),
0.002; 0.72
(0.60 to 0.86), < 0.001
Death or hospitalisation from HFa
Events during study, n 237 212 145
12-month event rate, % 31 29 45 0.66 (0.53 to 0.87),
0.002; 0.60
(0.49 to 0.75), < 0.001
Cause of death,119 n (% of patients) [% of deaths]
Cardiacb 109 (17.1) [83.2] 76 (12.8) [72.4] 54 (18.8) [75.3] p= 0.334; p= 0.006
SCDb 48 (7.8) [36.6] 17 (2.9) [16.2] 18 (5.8) [23.4] 1.21 (0.70 to 2.07),
0.485; 0.44
(0.23 to 0.86), 0.020
Pump failureb 53 (8.6) [40.5] 52 (8.7) [49.5] 34 (11.0) [44.2] 0.71 (0.46 to 1.09),
0.112; 0.73
(0.47 to 1.11), 0.143
Ischaemic 2 (0.3) [1.5] 4 (0.7) [3.8] 4 (1.3) [5.2]
Cardiac procedure 6 (1.0) [4.6] 2 (0.3) [1.9] 2 (0.6) [2.6]
Other 0 1 (0.2) [1.0] 0
Vascular 5 (0.8) [3.8] 3 (0.5) [2.8] 0
Non-cardiacb 14 (2.3) [10.7] 21 (3.5) [20.0] 11 (3.6) [14.3] p= 0.122; p= 0.717
Unknown 3 (0.5) [2.3] 5 (0.8) [4.8] 8 (2.6) [10.4]
c,dHospital admissions120
Patients hospitalised at least once, n/N (%)
All hospital admissions 388/617 (63) 372/595 (63) 199/308 (65) p= 0.02;e p= 0.03e
Cardiac 301/617 (49) 284/595 (48) 164/308 (53) p< 0.01;e p< 0.01e
HF 179/617 (29) 166/595 (28) 112/308 (36) p< 0.01;e p< 0.01e
Non-cardiac 222/617 (36) 207/595 (35) 84/308 (27)
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Outcome CRT-P (n= 617) CRT-D (n= 595) OPT (n= 308)
HR (95% CI), p-value:
OPT vs. CRT-P;
OPT vs. CRT-D
No. of admissions (% of total admissions), no. of average admissions per patient-year of follow-up
All hospital admissions 993 (NA), 1.25 919 (NA), 1.20 516 (NA), 1.59
Cardiac 628 (63), 0.79 580 (63), 0.76 338 (75), 1.20
HF 329 (33), 0.41 333 (36), 0.43 235 (46), 0.73
Non-cardiac 365 (37), 0.46 339 (37), 0.44 126 (24), 0.39
Hospitalisation time (days): average days per patient-year of follow-up (average length of stay per admission)
All hospital admissions 8.3 (6.7) 8.6 (7.2) 11.0 (6.9)
Cardiac 5.2 (6.5) 5.5 (7.2) 8.1 (6.8)
HF 3.6 (8.6) 3.8 (8.8) 5.9 (8.2)
Non-cardiac 3.2 (6.9) 3.2 (7.2) 2.8 (7.1) NS
Cardiac procedure,
number of hospital
admissions per
patient-yearf
0.13 0.09 0.24 p< 0.01
CRT implants,
n/N (% of procedures)
33/78 (42)
Electrophysiological
studies,
n/N (% of procedures)
13/78 (17)
Pacer/ICD implants,
n/N (% of procedures)
13/101 (13) 10/78 (13)
Heart transplants,
n/N (% of procedures)
5/78 (6)
Other,
n/N (% of procedures)
15/78 (19)
Lead revision,
n/N (% of procedures)
42/101 (42) 36/69 (52)
Increase in 6-minute walk distance (m), mean change (SD)
3 months (n= 422) 33 (99) (n= 420) 44 (109) (n= 170) 9 (84) p< 0.001; p< 0.001
6 months (n= 373) 40 (96) (n= 378) 46 (98) (n= 142) 1 (93) p< 0.001; p< 0.001
Increase in QoL (%),g mean change (SD)
3 months (n= 510) –24 (27) (n= 514) –24 (28) (n= 243) –9 (21) p< 0.001; p< 0.001
6 months (n= 460) –25 (26) (n= 478) –26 (28) (n= 207) –12 (23) p< 0.001; p< 0.001
Proportion of patients with improvement in NYHA class symptoms, %
3 months (n= 551) 58 (n= 543) 55 (n= 242) 24 p< 0.001; p< 0.001
6 months (n= 489) 61 (n= 497) 57 (n= 199) 38 p< 0.001; p< 0.001
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Outcome CRT-P (n= 617) CRT-D (n= 595) OPT (n= 308)
HR (95% CI), p-value:
OPT vs. CRT-P;
OPT vs. CRT-D
Duration of procedure
(minutes), median
(patients randomised after
1 July 2001)
(n=NR) 164 (n=NR) 176
NA, not applicable; NR, not reported; NS, not significant.
a Kaplan–Meier curves presented.
b Kaplan–Meier curves of time to first event presented but not extracted.
c Total follow-up time for hospital admissions: OPT 324 years, CRT-P 793 years, CRT-D 768 years.
d Predictors of hospitalisation reported but not data extracted.
e Analysis adjusted for multiple hospital admissions, follow-up time and competing risk of death.
f Authors state that after hospitalisations for HF, cardiac procedures were the next most common cause for
hospitalisation. Selected procedures are reported in the paper. Hospitalisation curves presented. Authors state that no
significant differences were found in any of the end-points for CRT-P vs. CRT-D.
g 21 questions rated on a 6-point scale, total score 105; higher score indicates poorer QoL.
Comments
l Subgroup analyses presented according to baseline characteristics – not data extracted.
l Median changes in systolic blood pressure from baseline to 3, 6 and 12 months were significantly better in the CRT-P
and CRT-D groups than in the OPT group. There were no significant changes in diastolic blood pressure in any group
(data presented in figure, not data extracted).
Adverse effects of treatment
Adverse effect CRT-P (n= 617) CRT-D (n= 595) OPT (n= 308)
p-value: CRT-P vs.
OPT; CRT-D vs. OPT
Unsuccessful implantation, n/N (%) 78/617 (13) 54/595 (9)
Deaths from procedural complications,
n/N (%)
5/615 (0.8) 3/595 (0.5)
Mortality rate 30 days after
randomisation, %
1.0 1.8 1.2 0.34; 0.97
Moderate or severe adverse event
from any cause, %a
66 69 61 0.15; 0.03
Moderate or severe adverse event
related to implantation procedure, %
10 8
Coronary venous dissection 0.3 0.5
Coronary venous perforation 1.1 0.8
Coronary venous tamponade 0.5 0.3
Withdrawal rate, %
For all patients 6 7 26
For patients who had not reached
the primary end point
2 2 13
a CRT-P vs. CRT-D, p= 0.042.
Comment
l More detailed adverse event reporting for CRT-D is available in the FDA report.118
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Comments
Methodological comments
l Allocation to treatment groups: randomisation ratio 1 : 2 : 2 (OPT : CRT-P : CRT-D). Randomisation stratified
by centre and beta-blocker use.
l Blinding: patients, physicians, statisticians, data management group and safety and monitoring board not
blinded. Steering committee, end points committee and sponsor were unaware of assignments.
l Comparability of treatment groups: groups similar at baseline.
l Method of data analysis: all analyses were carried out according to the ITT principle. Efficacy analyses were
based on time to first event (unless otherwise stated), differences were determined using the log-rank
statistic and time to event used the Kaplan–Meier method. Nominal p-values and p-values adjusted for
sequential monitoring were reported. HRs were unadjusted for covariates, Wald chi-squared statistic used
for subgroups. Baseline differences were evaluated using the Wilcoxon rank-sum test for continuous and
ordered data and Pearson’s chi-squared test was used for categorical data.
l Sample size/power calculation: trial designed with 2200 participants to detect a reduction of 25% in the
primary end point and rate of death from any cause at an alpha value of 0.02 in the CRT-P group and 0.03
in the CRT-D group, each compared with OPT. With a target of 1000 primary events, the trial had statistical
power of > 90% for the primary end point and 80% for the secondary end point. The trial was stopped
early when pre-established boundaries had been crossed; 1520 participants had been randomised and
1000 primary end points already or almost met.
l Attrition/dropout: substantial withdrawals from the OPT group (see Adverse effects of treatment) to receive
commercially available implants, because of arrhythmia or HF. Patients contacted to consent to collection of
data for the duration of the study; data censored if this information could not be obtained. Status for the
primary end point through to the end of the study known for 91% of the OPT group and 99% of the
other groups; data on mortality complete for 96% of the OPT group and 99% of the other groups.
General comments
l Generalisability: people with advanced HF and increased QRS interval.
l Outcome measures: authors state that the composite end point based on both mortality and hospitalisation
was chosen to avoid the analytical difficulty encountered with competing risk: death precludes subsequent
hospitalisation for chronic HF decompensation.117 Demonstration of a favourable hospitalisation outcome
may be offset by the inability to survive, and benefit of survival may be offset by incremental chronic HF
morbidity requiring recurrent hospitalisations.
l Intercentre variability: not reported.
l Conflict of interests: authors state that sponsor had no role in data analysis.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Details not reported
Allocation concealment Unclear Details not reported
Performance bias
Blinding of participants and personnel High No blinding
Detection bias
Blinding of outcome assessment Low Steering committee and end points committee unaware of
assignment. Outcomes objective and unlikely to be influenced
Attrition bias
Incomplete outcome data addressed Low ITT analysis. Data censored for people who withdrew and for
whom data could not be obtained
Reporting bias
Selective reporting Low Protocol published; no evidence of missing outcomes
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Multicenter InSync Randomized Clinical Evaluation (MIRACLE)
Reference
and design
Intervention
and comparator Participants Outcome measures
Abraham et al.
2000122 and
2002,121 St John
Sutton et al.
2003,124 US FDA
2001123
Study design: RCT
Countries: USA
and Canada
No. of centres: 45
Funding:
Medtronic, Inc.,
Minneapolis, MN
Intervention: optimal medical
therapy and CRT-P on: VDDa
30, InSync model 8040
(Medtronic), three pacing
leads
Comparator: optimal medical
therapy and CRT-P off: VDI 30
(ventrical paced, atrial and
ventricular sensed, no
response to sensing), InSync
model 8040 (Medtronic Inc.)
Other interventions used:
medication for HF for both
groups kept constant
Indication for treatment:
moderate to severe HF and a
prolonged QRS interval
No. of randomised
participants: 453;
CRT-P on: 228, OPT: 225
Inclusion criteria: HF due to
ischaemic or non-ischaemic
cardiomyopathy for
> 1 month, NYHA class III
or IV, LVEF ≤ 35%, LVEDD
≥ 55mm, QRS interval
≥ 130milliseconds,
age ≥ 18 years,
6-minute walk distance
≤ 450m, optimal medical
therapy121,122
Exclusion criteria: pacemaker
or ICD, indication for or
contraindication to cardiac
pacing, cardiac or cerebral
ischaemic event within
≤ 3 months, atrial fibrillation
within ≤ 1 month, severe
primary pulmonary disease,
systolic blood pressure
> 170mmHg or < 80mmHg,
heart rate > 140 bpm, serum
creatinine > 3.0mg/dl, serum
aminotransferase more than
three times the upper limit of
normal, unstable angina, acute
MI or coronary surgery within
≤ 3 months, life expectancy
< 6 months121,122
Primary outcomes: NYHA
class, QoL, 6-minute walk
distance
Secondary outcomes:
all-cause mortality, HF
hospitalisations, exercise
capacity (peak oxygen
consumption, time on
treadmill), LVEF, LVEDD,
QRS duration, severity of
mitral regurgitation, clinical
composite response
(improved, worsened or
unchanged), an analysis of
death or worsening HF
(as safety variables),
number of days spent
in hospital
Method of assessing
outcomes: questionnaires
at baseline and at 1, 3 and
6 months. Clinical events
review committee
adjudicated adverse
events/end points122
Length of follow-up:
6 months
Recruitment: November
1998–December 2000
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter.
a The pacemaker senses atrial and ventricular activity, but paces only in the ventricle.
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Participant characteristics (pre randomisation and ≤ 7 days pre implantation)
Characteristic CRT-P (n= 228) OPT (n= 225)
Age (years), mean (SD) 63.9 (10.7) 64.7 (11.2)
Sex, % male 68 68
Ethnicity, % white 90 91
Ischemia, % 50 58
NYHA class III, % 90 91
LVEF (%), mean (SD) 21.8 (6.3) 21.6 (6.2)
Duration of QRS interval (milliseconds), mean (SD) 167 (21) 165 (20)
Heart rate (bpm), mean (SD) 73 (13) 75 (13)
LVEDD (mm), mean (SD) 70 (10) 69 (10)
Area of mitral regurgitant jet (cm2), mean (SD) 7.6 (6.4) 7.2 (4.9)
Distance walked in 6 minutes (m), mean (SD) 305 (85) 291 (101)
MLWHFQ score,a mean (SD) 59 (20) 59 (21)
Total exercise time (seconds), mean (SD) 484 (209) 462 (217)
Peak oxygen consumption (ml/kg bodyweight/minute), mean (SD) 14.0 (3.5) 13.7 (3.8)
Systolic blood pressure (mmHg), mean (SD) 114 (18) 115 (18)
Diastolic blood pressure (mmHg), mean (SD) 69 (10) 68 (10)
Receiving digitalis, % 78 79
Receiving diuretic agents, % 94 93
Receiving ACE inhibitors or ARBs, % 93 90
Receiving beta-blockers, % 62 55
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter.
a Score range 0–105, higher score indicates more severe impairment.
Comment
l Groups were similar at baseline.
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Results
Outcome (at 6 months) CRT-P (n= 228) OPT (n= 225) HR (CI 95%), p-value
All-cause mortality, n/N 12/228 16/225 0.73 (0.34 to 1.54), 0.40
Hospitalisations for worsening HF
People, n/N 18/228 34/225 0.50 (0.28 to 0.88), 0.02
Events, n 25 50
Total no. of days 83 363
Death or worsening HF
requiring hospitalisation, n/N
28/228 44/225 0.60 (0.37 to 0.96), 0.03
Death or worsening HF
requiring hospitalisation or
intravenous treatment, n/N
36/228 55/225 0.61 (0.40 to 0.93), 0.02
Worsening HF leading to use of intravenous, n/N
Diuretic agents 13/228 24/225 0.51 (0.26 to 1.00), 0.05
Vasodilators or positive
inotropic agents
6/228 14/225 0.41 (0.16 to 1.08), 0.06
Medication for HF 16/228 35/225 0.43 (0.24 to 0.77), 0.004
Change in NYHA class
(primary outcome), n/N (%)
p< 0.001
Improved by two or
more classes
34/211 (16) 12/196 (6)
Improved by one class 109/211 (52) 62/196 (32)
No change 64/211 (30) 115/196 (59)
Worsened 4/211 (2) 7/196 (4)
Change in distance walked in
6 minutes (m), median
(95% CI) (primary outcome)
(n= 214) +39 (26 to 54) (n= 198) +10 (0 to 25) p= 0.005
Change in MLWHFQ score,
median (95% CI)
(primary outcome)
(n= 213) –18 (–22 to –12) (n= 193) –9 (–12 to –5) p= 0.001
Change in peak oxygen
consumption (ml/kg/minute),
median (95% CI)
(n= 158) +1.1 (0.6 to 1.7) (n= 145) +0.2 (–0.2 to 0.8) p= 0.009
Change in total exercise time
(seconds), median (95% CI)
(n= 159) +81 (62 to 119) (n= 146) +19 (–1 to 47) p= 0.001
Absolute change in LVEF (%),
median (95% CI)
(n= 155) +4.6 (3.2 to 6.4) (n= 146) –0.2 (–1.0 to 1.5) p< 0.001
Change in LVEDD (mm),
median (95% CI)
(n= 90) –3.5 (–6 to –1) (n= 98) 0.0 (–1 to 2) p< 0.001
Change in area of mitral
regurgitation jet (cm2),
median (95% CI)
(n= 116) –2.7 (–4.0 to –2.1) (n= 118) –0.5 (–1.1 to 0.0) p< 0.001
Change in QRS duration (ms),
median (95% CI)
(n= 206) –20 (–20 to –12) (n= 192) 0 (–10 to 0) p< 0.001
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Outcome (at 6 months) CRT-P (n= 228) OPT (n= 225) HR (CI 95%), p-value
Clinical composite HF score p< 0.001
Improved, % 67 39
Worsened, % 16 27
LVEDD, left ventricular end-diastolic diameter.
Comment
l States that the magnitude of the effect on the 3 primary endpoints was not influenced by use of a beta-blocker, cause
of HF, (ischaemic or non-ischaemic), configuration of QRS complex (left or right bundle branch block), or baseline
duration of QRS interval (analysed as a continuous variable, p> 0.10 for all interactions).
Adverse effects of treatment
Adverse effect CRT-P (n= 228) OPT (n= 225)
Hospitalised for repositioning or replacement of left
ventricular lead,a n
11 3
Hospitalisations not related to HF or function of left
ventricular lead,a n
37 33
All participants undergoing implantation (n= 571)
Complete heart block requiring permanent cardiac
pacing, n/N
2/571
Death from progressive hypotension, n/N 1/571
Asystole, resuscitated but died 1 month later, n/N 1/571
Coronary sinus dissection, n/N (%) 23/571 (4)
Cardiac vein or coronary sinus perforation (three of
these recovered and continued in the study), n/N (%)
12/571 (2)
Participants who underwent successful
implantation (n= 528)
Left ventricular lead repositioned, n/N 20/528
Left ventricular lead replaced, n/N 10/528
Pacemaker-related infection requiring explantation, n/N 7/528
a Median duration of procedure not data extracted.
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Comments
Methodological comments
l Allocation to treatment groups: randomisation in permuted blocks to ensure balance between groups
within centres. Sealed envelopes used.
l Blinding: patients and physicians treating them for HF and performing study evaluations were unaware of
treatment assignments. An electrophysiologist who was not involved with clinical care opened a sealed
envelope at the time of randomisation, programmed the device and performed all tests that could reveal
the identity of the pacing mode.
l Comparability of treatment groups: authors state that groups were similar with respect to all
baseline characteristics.
l Method of data analysis: authors state that all end points were analysed according to the ITT principle. For
continuous variables, comparisons of changes from baseline to 6 months between groups were evaluated
using the Wilcoxon rank-sum test. The chi-squared test was used for categorical end points. Only patients
with data at baseline and 6 months were included in these analyses, but results were similar if patients with
incomplete data were included, using the last value carried forward. Cumulative survival curves for the risk
of a major clinical event used the Kaplan–Meier method and were tested for significance using the log-rank
statistic. Cox proportional hazards regression models were used to estimate HRs.
l Sample size/power calculation: sample size of 224 patients per group estimated on the basis of the
assumption that the study would have 80% power (two-sided α= 0.0167) to detect a difference in NYHA
class of 0.75, in QoL of 13 points or in distance walked in 6 minutes of 50m.
l Attrition/dropout: in total, 571 agreed to participate, with 528 successfully implanted and 43 not
successfully implanted. Of those who were successfully implanted, two required cardiac pacing, two
became clinically unstable, 71 were enrolled in the initial pilot phase and 453 were randomised to main
study. OPT group: 24/225 did not complete the 6-month follow-up (16 died, two had a heart transplant,
one had complications related to the device and five missed the 6-month visit). CRT-P group: 13/228 did
not complete the 6-month follow-up (12 died and one had complications related to the device). No patient
was lost to follow-up for the analysis of death or worsening HF. In total, 10/225 in the control group
crossed over to the CRT-P group, seven because of worsening HF and three because of bradycardia.
General comments
l Generalisability: only those successfully implanted underwent randomisation. Generalisability limited to
people with moderate to severe HF and a prolonged QRS interval.
l Outcome measures: clinical events review committee adjudicated with regard to adverse events/end points.
QoL was assessed using a validated questionnaire.
l Intercentre variability: not reported.
l Conflict of interests: stated. some of the authors are consultants or investigators for, or employees of,
Medtronic; one author was also on the advisory board of St Jude Medical. Authors state that investigators
had full access to all data and performed analyses without restrictions or limitations from the sponsor.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Randomised in permuted blocks; further details not reported
Allocation concealment Unclear Sealed envelopes used but unclear if they were opaque and
sequentially numbered
Performance bias
Blinding of participants and personnel Low Patients and physicians treating them for HF and performing
study evaluations were unaware of treatment assignments
Detection bias
Blinding of outcome assessment Low Patients and physicians treating them for HF and performing
study evaluations were unaware of treatment assignments
Attrition bias
Incomplete outcome data addressed
Primary outcomes Unclear States ITT analysis used and attrition reported; also reports that
analysis included last value carried forward analysis. However,
numbers are low for NYHA class (primary outcome) without
giving reasons why
Secondary outcomes Unclear Reasons for different sample sizes unclear
Reporting bias
Selective reporting High SF-36 is included in the protocol paper122 but results for this
measure are not reported
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Multisite Stimulation in Cardiomyopathies (MUSTIC) trial
Reference and design
Intervention
and comparator Participants Outcome measures
Cazeau et al. 2001125
Study design: randomised
crossover study
Countries: Europe (France,
Germany, Italy, Sweden,
Switzerland, the UK)
No. of centres: 15
Funding: ELA Recherche,
Medtronic and the Swedish
Heart and Lung Association
and by a grant from the
Swedish Medical
Research Council
Intervention: CRT-P on:
atrioventricular (active)
pacing [Chorum 7336 MSP
(ELA Medical), and InSync
8040 (Medtronic Inc.)]
Comparator: CRT-P off:
ventricular inhibited
(inactive) pacing at a basic
rate of 40 bpm
Other interventions used:
no modification to
medication other than
adjustment of dose of
diuretic permitted. OPT
(n= 67): ACE inhibitors or
equivalent 96%, diuretics
94%, digoxin 48%,
amiodarone 31%,
beta-blockers 28%,
spirololactone 22%
Indication for treatment:
severe HF and major
intraventricular delay but
without standard
indications for a pacemaker
No. of enrolled participants:
67
No. of randomised
participants: 58; group 1
(CRT-P on, CRT-P off): 29,
group 2 (CRT-P off, CRT-P
on): 29
Inclusion criteria: severe HF
because of idiopathic or
ischaemic LVSD, NYHA
class III for ≥ 1 month
whilst on OPT, LVEF
< 35%, LVEDD > 60mm;
QRS interval
> 150milliseconds, in sinus
rhythm, without a standard
indication for a pacemaker
Exclusion criteria:
hypertrophic or restrictive
cardiomyopathy, suspected
acute myocarditis,
correctable valvulopathy,
acute coronary syndrome
lasting < 3 months,
coronary revascularisation
during last 3 months or
scheduled revascularisation,
treatment-resistant
hypertension, severe
obstructive lung disease,
inability to walk, life
expectancy < 1 year not
associated with
cardiovascular disease,
indication for an ICD
Primary outcome: distance
walked in 6 minutes
Secondary outcomes: QoL,
peak oxygen uptake,
hospital admissions because
of decompensated HF,
patient preference, death
Method of assessing
outcomes: assessed at
baseline (4 weeks before
implantation), at
randomisation (2 weeks
after implantation) and at
the end of each crossover
phase. QoL measured using
the MLWHFQ (total score
0–105, higher score
indicates worse QoL). The
6-minute walk test was
carried out according to
Guyatt et al. and Lipkin
et al. (references provided):
two tests at each visit with
an interval of at least
3 hours between them;
the maximal difference
between the two tests was
15% and the value recorded
was the mean of the results
of the two tests. Patient
preference – at the end of
the crossover phase patients
were asked which 3-month
period they preferred
Length of follow-up:
participants received the
intervention and the
comparator for 3 months
each in random order
Recruitment: March
1998–March 1999
LVEDD, left ventricular end-diastolic diameter.
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Participant characteristics (at randomisation 2 weeks post implant)
Characteristic
Group 1 (CRT-P on,
CRT-P off) (n= 29)
Group 2 (CRT-P off,
CRT-P on) (n= 29) p-value
Age (years), mean (SD) 64 (11) 64 (8) 0.91
Sex, male, n/N 19/29 24/29 0.13
Ethnicity NR NR
NYHA class III, % 100 100
Weight (kg), mean (SD) 79 (19) 78 (16) 0.97
Distance walked in 6 minutes (m), mean (SD) 354 (110) 346 (111) 0.82
Peak VO2 (ml/kg of body weight/minute), mean (SD) 13.5 (8.4) 14.1 (4.6) 0.41
QoL score, mean (SD) 48 (19) 46 (25) 0.66
Heart rate (bpm), mean (SD) 75 (12) 75 (14) 0.89
QRS interval (milliseconds), mean (SD) 172 (22) 175 (19) 0.48
NR, not reported.
Comment
l Baseline characteristics for n= 67 at baseline (4 weeks before implantation) are also presented but not extracted.
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Results
Outcome CRT-P on CRT-P off p-value
Mortality over 6-month period
First crossover period: sudden death after 26 days of
active pacing
1
Second crossover period: acute MI few hours after premature
switch to active pacing as a result of severe decompensation
1
Second crossover period: sudden death 2 hours after switching
from inactive to active pacing
1
Distance walked in 6 minutes (m), mean (SD)a
Group 1 (CRT-P on, CRT-P off) (n= 22) 384.1 (78.9) 336.1 (128.3)
Group 2 (CRT-P off, CRT-P on) (n= 24) 412.9 (116.9) 316.2 (141.8)
Both groups (n= 46) 399.2 (100.5) 325.7 (134.4) p< 0.001
Peak VO2 (ml/kg of body weight/minute), mean (SD)
Group 1 (CRT-P on, CRT-P off) (n= 18) 15.9 (5.8) 15.3 (5.9)
Group 2 (CRT-P off, CRT-P on) (n= 20) 16.4 (3.6) 14.8 (3.9)
Both groups (n= 38) 16.2 (4.7) 15 (4.9) p= 0.029
QoL score, mean (SD)
Group 1 (CRT-P on, CRT-P off) (n= 23) 33.3 (22) 42.6 (20.9)
Group 2 (CRT-P off, CRT-P on) (n= 22) 25.7 (20.4) 44 (25)
Both groups (n= 45) 29.6 (21.3) 43.2 (22.8) p< 0.001
HF hospitalisations at 3 months (first crossover period only), n/N 3/29 9/29 p< 0.05
Patient preference after 6 months (n= 48),b n/N (%) 41/48 (85) 2/48 (4) p< 0.001
a In the per-protocol analysis (n= 23), the mean distance walked (CRT-P on vs. CRT-P off) was 424 (SD 83) m vs. 375
(SD 83) m (p< 0.04).
b 48 patients completed both phases of the study. Patient preference: 5/48 (10%) patients had no preference; p-value
reported in the abstract of the paper but not in the results section.
Adverse effects of treatment
Adverse effect CRT-P on CRT-P off p-value
Uncorrectable loss of left ventricular pacing efficacy, n 2
Severe decompensation leading to a premature switch
to active pacing, n
1
Decompensation attributed to rapidly progressive
aortic stenosis, n
1
Decompensation due to persistent atrial fibrillation, n 1
Comments
l Implantation of a left ventricular lead was attempted in 64/67 patients with a 92% (59/64) success rate. The
five failures were not randomised.
l A lateral position was reached in 80% of patients with a mean pacing threshold of 1.4 (SD 1.1) V.
l Early dislodgement occurred in eight patients and was successfully corrected in five.
l Overall, 88% of patients had a functional left ventricular lead at the end of the crossover phase.
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Comments
Methodological comments
l Allocation to treatment groups: randomisation of order of treatment followed a block design with
stratification according to study centre. Authors also state that patients were ‘randomly assigned to and
equally distributed between the two study groups.
l Blinding: described as single blind. Authors state that patients had no knowledge of the order of treatment
but no details are provided.
l Comparability of treatment groups: similar.
l Method of data analysis: authors state that all analyses are based on the ITT principle; thus, all enrolled
patients were included in the analysis but each efficacy end point could be assessed only in patients with
no data missing after the completion of both crossover phases. Baseline characteristics were assessed using
the chi-squared test for dichotomous variables and the Student’s t-test or Wilcoxon non-parametric test for
quantitative or categorical variables. Responses obtained for all criteria assessing clinical efficacy were
compared using the Wilcoxon test and according to a two-period and two-treatment (two-by-two)
crossover design. Period and carry-over effects were checked before the efficacy of treatment was
evaluated. Morbidity and mortality were compared during the first crossover period and were described for
all other phases of the study. The stability of the results was assessed in a per-protocol analysis, which
included only patients without any deviations from the protocol. The authors state that no significant
carry-over and period effects were noted. Threshold of significance 0.05
l Sample size/power calculation: on the basis of previous reports of mortality rates in NYHA class III, a 10%
mortality rate at 6 months was estimated. A 10% failure rate of left ventricular lead implantation and a
20% rate of premature termination because of loss of left ventricular pacing efficacy of unstable HF was
expected. A 10% increase in the distance walked in 6 minutes with active pacing was estimated. The total
target sample needed was estimated to be 22 patients for a study with a 95% confidence level and 95%
power. For the MLWHFQ score, a predicted 10% reduction with active pacing necessitated a 30-patient
sample. Considering mortality and dropouts, 40 patients were needed
l Attrition/dropout: three patients withdrew before implantation, two with unstable HF (one subsequently
died) and one with a pre-existing indication for pacing. Implantation of a left ventricular lead was
attempted in 64 patients. In six patients it was removed before randomisation, five because of failed
implantation of the left ventricular lead and one because of sudden death while the device was inactive. A
total of 10 patients did not complete two crossover periods: first crossover period: one withdrew consent at
randomisation, two had uncorrectable loss of ventricular pacing efficacy, one switched from inactive to
active pacing because of severe decompensation and one died suddenly after 26 days of active pacing;
second crossover period: three had worsening HF (one had decompensation with active pacing, one had
decompensation during inactive pacing), one died suddenly after switching to active pacing and one had
lung cancer
General comments
l Generalisability: patients were randomised 2 weeks after implantation. Only patients who were successfully
implanted were randomised.
l Outcome measures: appropriate but change in NYHA class not reported.
l Intercentre variability: not reported.
l Conflict of interests: part funded by ELA Recherche and Medtronic. Four authors are paid consultants of
Medtronic or ELA Recherche and one author is an employee of ELA Recherche.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Details not reported
Allocation concealment Unclear Details not reported
Performance bias
Blinding of participants and personnel High Authors state that participants had no knowledge of the order
of treatments, but not clear how this was maintained.
Personnel not blinded; 6-minute walk test and QoL outcomes
may be influenced by lack of blinding
Detection bias
Blinding of outcome assessment High States ‘single blind’ so assume only participants were blinded
Attrition bias
Incomplete outcome data addressed Low Numbers and reasons reported
Reporting bias
Selective reporting High Change in NYHA class assessed but data not reported
Other bias
Other sources of bias High Use of block randomisation without blinding means that it
may be possible to predict future assignments. Crossover
design appears appropriate
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Appendix 9 Data extraction: people with
both conditions
CONTAK-CD trial
Reference
and design Intervention and comparator Participants Outcome measures
Higgins et al.
2003,126 Lozano
et al. 2000,128
US FDA 2002,129
Saxon et al. 1999127
Study design:
crossover RCT in
phase I; parallel RCT
in phase II
Country: USA (see
General comments,
Intercentre
variability)
No. of centres: 47
Funding: Guidant
Corporation,
St Paul, MN
Intervention: CRT-D+OPT
Comparator: ICD+OPT
Devices were either Model
1822 Ventak CHF Automatic
Implantable Cardioverter
Defibrillator or Model 1283
Contak CD device (Guidant
Corporation)
Initially, the left ventricle was
paced with a commercially
available epicardial pace/sense
lead. Later, a lead that could
be placed transvenously using
over-the-wire techniques
in the coronary venous
vasculature was introduced. A
cardioversion/defibrillation lead
was implanted in the right
ventricle and a pace/sense lead
was placed in the right atrium
for this three-lead CRT system.
Details of lead positioning are
reported but have not been
data extracted
Randomised therapy
programmed after a minimum
30-day period with no CRT.
During this period investigators
were permitted to optimise
pharmacological therapy. OPT
not defined
Other interventions used:
none stated
Indication for treatment:
patients with symptomatic HF,
intraventricular conduction
delay and malignant
ventricular tachyarrhythmias
(VT/VF) requiring therapy from
an ICD
No. of randomised
participants: 490; CRT-D: 245,
ICD: 245
Inclusion criteria: NYHA class
II–IV, LVEF ≤ 35%, QRS
interval ≥ 120milliseconds,
conventional indications for
an ICD (American College of
Cardiology/American Heart
Association guidelines),126 age
≥ 18 years, symptomatic HF
despite OPT (must include
ACE inhibitors if tolerated)127
Exclusion criteria: atrial
tachyarrhythmias or
conventional indications for a
permanent pacemaker,126
concomitant cardiac surgery,
unable to undergo device
implant, unable to comply
with protocol and follow-up
including exercise testing, life
expectancy < 6 months
because of other conditions,
amyloid disease, hypertrophic
obstructive cardiomyopathy,
requires in-hospital
continuous intravenous
inotropes, use of pre-existing
cardioversion/defibrillation
leads other than those
specified in the protocol,
involved in other
cardiovascular clinical
investigations of active
therapy or treatment127
Primary outcome: progression
of HF, defined as a composite
end point of all-cause
mortality, hospitalisation for
worsening HF, ventricular
tachyarrhythmias requiring
device therapy (initially the
primary outcome was peak
VO2 but this was changed
when the study design
was changed)
Secondary outcomes: VO2,
QoL, 6-minute walk distance,
biventricular antitachycardia
pacing efficacy, defibrillation
therapy safety127
Method of assessing
outcomes: VO2 assessed by
cardiopulmonary exercise
test.127 QoL measured using
the MLWHFQ. A Heart Failure
Events Committee adjudicated
all deaths and hospitalisations.
Operative mortality was
defined as death from any
cause within 30 days of the
implant procedure
Length of follow-up:
maximum of 6 months
(but some patients, presumed
to be all those in phase I,
only 3 months)
Recruitment: February
1998–December 2000
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Participant characteristics
Participant characteristics CRT-D (n= 245) ICD (n= 245) p-value
Age (years), mean (SD)a 66 (11) 66 (11)
Sex, % male 85 83
Ethnicity NR NR
Aetiology ischaemic, % 67 71
NYHA class, %
II 32 33
III 60 57
IV 8 10
LVEF (%), mean (SD)a 21 (7) 22 (7)
QRS interval (milliseconds), mean (SD)a 160 (27) 156 (26)
Intraventricular conduction delay, %
LBBB 54 55
Non-specific 32 33
RBBB 14 12
Diuretic, % 88 83
ACE inhibitor/ARB, % 86 89
Beta-blocker, % 48 46
Digoxin, % 69 68
Peak VO2 (ml/kg/minute), mean (SD)
a 13.8 (4.6) 13.5 (3.8)
QoL score, mean (SD)a 44 (25) 40 (23)
6-minute walk distance (m), mean (SD)a 316 (119) 320 (121)
LVID in diastole (mm), mean (SD)a 71 (11) 70 (10)
LVID in systole (mm), mean (SD)a 59 (11) 58 (11)
Heart rate NR NR
Cardiac history NR NR
Previous treatment NR NR
Comorbidities NR NR
LVID, left ventricular internal diameter; NR, not reported; RBBB, right bundle branch block.
a Data are assumed to be mean (SD) although this is not specifically stated anywhere in the paper.
Comments
l Characteristics are reported for the 490 participants who were randomised at the time of implantation.
l During the 30-day post-implant recovery period, when investigators were permitted to adjust or initiate HF medications,
many patients demonstrated a significant improvement. This meant that, of the 328 patients who presented in NYHA
class III/IV, 131 (40%) improved to NYHA class I or II, whereas 30/162 (19%) NYHA class II patients worsened to NYHA
class III/IV. After optimisation of medical therapy, therefore, 227 patients were in NYHA class III/IV and 263 were in
NYHA class I/II before randomisation.
l Participant characteristics in an earlier paper reporting only on the 222 patients enrolled in phase I of the study128
have not been extracted. It is not clear whether some or all of these participants are included in the data from
Higgins et al.126 reported in this table.
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Results
Outcome CRT-D (n= 245) ICD (n= 245) p-value
Progression of HF, n/N 79/245 94/245 0.35
Mortality 11/245 16/245
HF hospitalisations (at least one) 32/245 39/245
At least one VT/VF event 36/245 39/245
All-cause mortality,a n 109
Death during the study treatment phase
(detail by group below)
27
Death during the long-term follow-up phase 70
Cause of death, n/N (%)
Pump failure 47/109 (43)
Non-cardiac 21/109 (19)
Arrhythmic 9/109 (8)
Ischaemic 2/109 (2)
Cardiac in nature but unknown aetiology 2/109 (2)
Insufficient information for independent events
committee to be able to adjudicate
28/109 (26)
Deaths during the study treatment phase,129 n/N (%) 11/245 (4.5) 16/245 (6.5)
Cardiac, pump failure 4/245 (1.6) 9/245 (3.7)
Cardiac, arrhythmic 1/245 (0.4) 0/245 (0)
Cardiac, other 2/245 (0.8) 1/245 (0.4)
Non-cardiac 2/245 (0.8) 3/245 (1.2)
Unknown 2/245 (0.8) 3/245 (1.2)
Total survival, %
At 1 year 85
At 2 years 74
At 3 years 70
Received appropriate treatment of ventricular
tachyarrhythmias, n/N (%)
36/245 (15) 39/245 (16)
VT alone 25/245 (10) 27/245 (11)
VF alone 7/245 (3) 6/245 (2)
VT and VF 4/245 (2) 6/245 (2)
VT/VF episodes during therapy evaluation phase
(excluding those with no episodes), median
2.5 2
QoL score, mean change (SE)b –7 (2) (n= 234) 5 (2) (n= 225) 0.39
Change in NYHA class, % (n= 109) (n= 116)
Improved by two classes 11 2
Improved by one class 25 30 0.10c
No change 51 51
Worsened 13 17
continued
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Outcome CRT-D (n= 245) ICD (n= 245) p-value
LVEF (%), mean change (SE)b 5.1 (0.7) (n= 222) 2.8 (0.7) (n= 216) 0.020
LVID in diastole (mm), mean change (SE)b –3.4 (0.6) (n= 228) –0.3 (0.6) (n= 219) < 0.001
LVID in systole (mm), mean change (SE)b –4.0 (0.7) (n= 228) –0.7 (0.7) (n= 219) < 0.001
Peak VO2 (ml/kg/minute), mean change (SE)
b 0.8 (0.3) (n= 216) 0.0 (0.3) (n= 201) 0.030
6-minute walk distance (m), mean change (SE)b 35 (7) (n= 224) 15 (7) (n= 220) 0.043
LVID, left ventricular internal diameter.
a Two of these deaths are not accounted for in the division between deaths occurring during treatment and deaths
occurring during long-term follow up.
b Data are assumed to be mean (SE) although this is not specifically stated anywhere in the paper.
c Not clear whether the p-value relates to the specific comparison for improved by one class or to the comparison for
NYHA class changes overall.
Comments
l Results are also presented separately for patients in NYHA class III/IV at randomisation and patients in NYHA class I/II at
randomisation (i.e. at the conclusion of the post-recovery period) but as this appears to be a post hoc analysis these
results have not been data extracted.
l The overall relative reduction in composite HF progression was 15% with CRT.
l Kaplan–Meier curves illustrating time to event for all-cause mortality, all-cause mortality plus HF hospitalisation, and
mortality during the study treatment phase are presented but have not been data extracted.
l Spontaneous monomorphic VT was successfully treated with biventricular antitachycardia pacing in 927/1053
(88%) episodes.
l Results in an earlier paper reporting only on the 222 patients enrolled in phase I of the study128 have not been data
extracted. It is not clear whether some or all these participants are included in the data from Higgins et al.126 reported
in this table.
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Adverse effects of treatment
Adverse effect CRT-D and ICD
Operative mortality126,129 12/567 (2.1%) (95% CI 0.9% to 3.3%)
Causes of death for operative mortality,129 n Implants (n= 501) Attempts (n= 66) Total (n= 567)
Total deaths 10 2 12
Cardiac: pump failure 5 1 6
Cardiac: arrhythmic 2 1 3
Non-cardiaca 2 0 2
Unknown 1 0 1
Overall lead-related adverse event rate n= 75 (unique patients), 14.5% (95% CI 11.5% to 17.5%)
Lead-related, n/N 53/448
Procedure-related, n/N 27/517
Severe device-related events, n patients/N 7/567 (1.2% with at least one event)
Telemetry difficulty; device explanted 2 (0.4%, 95 CI 0.0% to 0.9%)
VT during cardiopulmonary exercise testing 1 (0.2%, 95 CI 0.0% to 0.5%)
Coronary sinus perforation 1 (0.2%, 95 CI 0.0% to 0.5%)
Inappropriate shock because of oversensing 1 (0.2%, 95 CI 0.0% to 0.5%)
Lead dislodgement 1 (0.2%, 95 CI 0.0% to 0.5%)
Anaphylaxis in association with use of pulmonary
artery catheter
1 (0.2%, 95 CI 0.0% to 0.5%)
Device-related complications (only those occurring in > 1% of patients) in all patients implanted (n= 448), n (%)
Loss of left ventricular capture 31 (6.9)
Loss of right atrial capture 7 (1.6)
Ventricular oversensing 6 (1.3)
Extracardiac stimulation 5 (1.1)
Device-related complications (only those occurring in > 1% of patients) in all patients attempted or implanted (n= 517), n (%)
Infections 7 (1.4)
a In Higgins et al.126 two of the 10 ‘implant’ deaths were described as perioperative (one attributed to pulseless electrical
activity resulting from defibrillation threshold testing and one attributed to incessant VT during the implant procedure).
The causes of the remaining eight deaths were pump failure (n= 5), cardiac causes unrelated to pump failure (n= 2) and
unknown (n= 1). Higgins et al.126 state that none of these eight deaths were attributed to the implant procedure.
Comments
l Adverse events reported in the summary of safety and effectiveness129 focus on adverse events related to the Easytrack
leads or the implant procedure required to place an Easytrack lead. In defining adverse event rates the main dominators
used are 517 for adverse events relating to the procedure to implant Easytrack leads and 448 for adverse events
relating to events occurring in participants who were successfully implanted.
l Of the 53 lead-related adverse events the most common (> 1% incidence) were loss of left ventricular capture
(31 patients, 6.9%), ventricular oversensing (11 patients, 2.5%) and extracardiac stimulation (nine patients, 2.0%).
These were typically resolved with surgical intervention.
l Of the 27 procedure-related events the most common (> 1% incidence) were coronary venous trauma (10 patients,
2.0%), transient atrioventricular block (six patients, 1.2%) and transient renal failure (five patients, 1.0%). These events
typically resolved without intervention and with no permanent long-term sequelae.
l The incidence of severe device-related events (1.2%) was reported as significantly less than the hypothesized rate of
20% (p< 0.01).
l The operative mortality rate (2.1%) was reported to be significantly less than the hypothesized rate of 9% (p< 0.01).
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Comments
Methodological comments
l Allocation to treatment groups: not described.
l Blinding: double blind.
l Comparability of treatment groups: groups are described as balanced with no statistically significant
differences with respect to baseline characteristics (no statistical testing reported).
l Method of data analysis: patients from phase I contributed data from a 3-month treatment phase and
patients from phase II contributed data from a 6-month treatment phase for the analysis of the primary end
point. The 3-month treatment phase correlates to the first study period (i.e. before any crossover). Cox
proportional hazards models were fitted for the combination of events with the treatment effect adjusted
for covariates chosen by the Heart Failure Events Committee before the primary end point analysis. The
covariates included NYHA class, QRS interval, ischaemic aetiology, LVEF and bundle branch morphology.
The Wei method (reference provided) was used to calculate a composite effect of the treatment and
covariates. For continuous variables the longitudinal (repeated measures) analysis method (reference
provided) was used to compare the difference in the sample means. This method accounted for the
patterns of missing data and took full advantage of the correlation structure, and all of the data were used
to estimate the model parameters. Model parameters were estimated using maximum likelihood. Values of
p< 0.05 were considered to be significant for all tests. The events contributing to the composite primary
end point appear to be analysed using the ITT principle. It is clear from the numbers reported for the
secondary outcomes that analyses for change in QoL, NYHA class, LVEF, LVID in diastole and in systole,
peak VO2 and 6-minute walk distance are not analysed using the ITT principle. No reasons are given for the
missing data. The study authors do not comment on whether the alteration of the study design between
phase I and phase II of the study was expected to have an impact on the methods of data analysis.
l Sample size/power calculation: not described, although Higgins et al.126 state that it was postulated that the
therapy would reduce the events contributing to the composite primary end point by 25%. However, the
actual event rate observed was approximately half that expected in the original study design and
consequently the authors state that the study was not adequately powered to detect a statistically
significant difference in HF events.
l Attrition/dropout: initially 581 patients were enrolled (248 in phase I and 333 in phase II) but 14 either
withdrew consent or were withdrawn by the investigator (found not to meet eligibility criteria) before an
implant procedure and 66 did not receive the system being used in this trial because of the inability to
place the coronary venous lead. These patients received a conventional ICD instead. Therefore, 501 were
implanted (222 in phase I and 279 in phase II) with the intervention system. Of these, 448/501 (89%)
received a transvenous system and 53/501 (11%) received a transthoracic system (phase I: 51, phase II: 2).
Of the 501 patients implanted, 11 did not enter the randomised part of the study 30 days after the implant
procedure [10 patients died (see Adverse effects) and one withdrew in the 30-day post-implant recovery
period before the randomised therapy was programmed]. As noted above, not all analyses used the ITT
principle and, when data are missing, no reasons for this are provided.
l Other: (1) the study design was modified because of regulatory concerns about morbidity and mortality
associated with CRT and the length of follow-up in the randomised mode of the initial design. This meant
that the design changed from a crossover RCT design (crossover to occur after the first 3 months of
randomised therapy) to a parallel RCT design with 6 months of follow-up in phase II. (2) During the course
of the trial positive clinical trial results led to the widespread adoption of HF medications such as beta-
blockers and spironolactone. There was also an evolution in HF management, focusing on increased
outpatient surveillance. Both of these factors may have contributed to the reduction in the number of HF
events expected. The improvement seen in many patients once medical management was optimised before
randomisation also may have made it more difficult to show a benefit of treatment in healthier patients,
and may have contributed to the reduction in statistical power to show improvement in those patients who
remained in NYHA class III/IV despite optimal HF medication.
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General comments
l Generalisability: the authors point out that the results may not be generalisable to patients with chronic
atrial fibrillation, chronotropic incompetence and sinus bradycardia. The study also only studied CRT
delivered in an atrial synchronous manner (i.e. the VDD modea). Therefore, the effects of atrial pacing as
well as adaptive-rate pacing delivered with the DDD(R) modesb are not known.
l Outcome measures: appear to be appropriate; however, the reason(s) why the study sponsor decided to
change the primary end point from peak VO2 to a composite HF outcome are not provided.
l Intercentre variability: the key paper for this study126 and the summary of safety and effectiveness for the
device used129 state that the centres were based in the USA. However, an earlier paper reporting on phase I
of the study128 states that patients were enrolled from sites in the USA, Europe and Australia (number of
centres not reported). Therefore, it is not clear whether all or only some of the trial centres involved in
phase I contributed data to the key paper for the study.
l Conflict of interests: not stated but note that the study sponsor (manufacturer of the device) chose to
change the primary end point during the course of the study.
l Other: the chief sources of information for this data extraction were the peer-reviewed publications of
Higgins et al.,126 Saxon et al.127 and Lozano et al.128 As operative mortality was the only adverse event
reported by the key trial paper,126 the summary of safety and effectiveness129 submitted by the
manufacturer, Guidant Corporation, to the FDA as part of its approvals process was used as a source of
adverse event data.
LVID, left ventricular internal diameter.
a The pacemaker senses atrial and ventricular activity, but paces only in the ventricle.
b Dual-chamber pacing and sensing, both triggered and inhibited mode, with rate modulation (increases the
patient’s heart rate in response to exercise).
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Study described as randomised controlled study but no
further details provided
Allocation concealment Unclear No details provided
Performance bias
Blinding of participants and personnel Low Study described as double blind. ‘Both the patient and
the heart failure specialist treating the patient are
blinded to the pacing mode’127
Detection bias
Blinding of outcome assessment Low Study described as double blind. ‘Both the patient and
the heart failure specialist treating the patient are
blinded to the pacing mode’127 ‘A Heart Failure Event
Committee (HFEC) adjudicated all deaths and
hospitalisations’.126 It is not clear whether this
committee was blind to the pacing mode. However,
these outcomes are unlikely to have been influenced
by a lack of blinding
Attrition bias
Incomplete outcome data addressed
Primary outcome: progression of HF
(composite including mortality, HF
hospitalisations and VT and VF events)
Low From the data provided these analyses appear to
account for all participants
Change in QoL, NYHA class, LVEF, LVID in
diastole and systole, peak VO2 and 6-minute
walk distance
High It is clear from the numbers provided that there are
missing data. No reasons for missing data are given
Reporting bias
Selective reporting Low A description of the study is available127 and the only
outcome mentioned here that is missing from the
published papers is blood laboratory tests. However,
these are not likely to be a key outcome for
this intervention
Other bias
Other sources of bias Unclear The study design and primary outcome measure were
changed during the course of the study. The length of
follow-up from phase I was 3 months whereas that
from phase II was 6 months. The potential for these
issues to introduce a bias into the results is unknown
LVID, left ventricular internal diameter.
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Multicenter Automatic Defibrillator Implantation Trial with
Cardiac Resynchronization Therapy (MADIT-CRT) trial
Reference
and design
Intervention
and comparator Participants Outcome measures
Moss et al. 2005131 and
2009,130 Solomon et al.
2010,132 Goldenberg et al.
2011,133,134 Arshad et al.
2011135
Study design: RCT
Countries: USA, Canada
and Europe
No. of centres: text states
110: 88 in the USA, 2 in
Canada and 20 in Europe
(the Czech Republic 1,
Denmark 1, France 1,
Germany 4, Hungary 1,
Italy 3, Israel 3, Poland 1,
Spain 2, Switzerland 1,
the Netherlands 3, UK 1).
Inconsistency between
numbers reported in the
text and appendix
Funding: supported by a
research grant from
Boston
Scientific to the University
of Rochester with funds
distributed to the
co-ordination and data
centre, enrolling centres,
core laboratories,
committees and boards
under subcontracts
from the University of
Rochester, NY
Intervention: CRT-ICD.
Programmed mode was
DDD with lower rate of
40 bpm and hysteresis off
Comparator: ICD only.
Programmed pacing mode
was VVI for single-chamber
units and DDIa for
dual-chamber units with
lower rates of 40 bpm and
hysteresis off in both
single- and dual-chamber
units. Commercially
available transvenous
devices (Boston Scientific)
were used
Other interventions used:
OPT for HF131
Indication for treatment:
mild cardiac symptoms, reduced
ejection fraction and wide QRS
complex. All met the guideline
indication for ICD therapy
No. of participants: 1820
(1271 in the USA, 22 in Canada,
527 in Europe); CRT-ICD: 1089,
ICD only: 731
Inclusion criteria: NYHA
class I or II, LVEF ≤ 30%, QRs
interval ≥ 130milliseconds,
age ≥ 21 years with ischaemic
cardiomyopathy (NYHA class I or
II) or non-ischaemic
cardiomyopathy (NYHA class II
only), sinus rhythm, ejection
fraction < 30% and prolonged
intraventricular conduction
with QRs duration of
> 130 milliseconds;
met guideline indication
for ICD therapy
Exclusion criteria: existing
indication for CRT; implanted
pacemaker, ICD or
resynchronisation device;
NYHA class III or IV symptoms;
previous CABG surgery,
percutaneous coronary
intervention or an enzyme-positive
MI up to 3 months before
enrolment; NYHA class I with
non-ischaemic cardiomyopathy;
those with angiographic evidence
of coronary disease who are
candidates for coronary
revascularisation and who are
likely to undergo a procedure in
the foreseeable future; second- or
third-degree heart block;
irreversible brain damage from
pre-existing cerebral disease;
women who are pregnant or
planning to become pregnant;
reversible non-ischaemic
cardiomyopathy; chronic atrial
fibrillation up to 1 month before
enrolment; presence of other
life-limiting disease, e.g. cancer;
participating in other trials;
unwilling to co-operate; living too
distant from clinic for ease of
follow-up visits; unlikely to be
resident in the area for duration
of the trial; unwilling to consent
Primary outcomes: death or
non-fatal HF events
(whichever came first)
Secondary outcomes:
none reported
Method of assessing
outcomes: baseline 12-lead
ECG and echocardiogram;
baseline physical
examination and 6-minute
walk test. Two-dimensional
echocardiography assessed
changes in left ventricular
volumes and ejection
fraction between baseline
and 1-year follow-up.
Volumes were estimated
by averaging those
derived from the
two-chamber and
four-chamber views
according to Simpson’s
method (no reference
provided). States that
ejection fraction was
calculated in the usual
fashion (no further
details or reference)
Diagnosis of HF required
signs and symptoms
consistent with CHF that
was responsive to
intravenous decongestive
therapy (outpatient basis)
or an augmented
decongestive regimen with
oral or parenteral medication
during inpatient hospital stay
Clinical follow-up 1 month
after randomisation and then
at 3-month intervals until
termination of the trial.
Clinical and device testing
carried out at each visit
Length of follow-up: to trial
termination. The trial was
stopped on 22 June 2009.
Average follow-up
was 2.4 years
Recruitment dates:
22 December 2004–
23 April 2008
bpm, beats per minute.
a Pacemaker has dual-chamber pacing and sensing, but inhibited mode only.
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Participant characteristics
Characteristic CRT-ICD (n= 1089) ICD (n= 731)
Age (years), mean (SD) 65 (11) 64 (11)
Sex, male, n (%) 814 (74.7) 553 (75.6)
Ethnicity, n/N (%)
White 979/1083 (90.4) 657/724 (90.7)
Black 87/1083 (8.0) 56/724 (7.7)
Other 17/1083 (1.6) 11/724 (1.5)
Cardiac history and NYHA class, n (%)
Ischaemic heart disease, class I 152 (14.0) 113 (15.5)
Ischaemic heart disease, class II 446 (41.0) 288 (39.4)
Non-ischaemic heart disease, class II 491 (45.1) 330 (45.1)
NYHA class III or IV > 3 months before enrolment, n (%) 109 (10.0) 73 (10.0)
Cardiac findings at enrolment
Blood pressure (mmHg), mean (SD)
Systolic 124 (17) 121 (18)
Diastolic 72 (10) 71 (10)
Blood urea nitrogen ≥ 26mg/dl (9.3 mmol/l), n/N (%) 260/1082 (24.0) 177/721 (24.5)
Creatinine (mg/dl), mean (SD) 1.2 (0.4) 1.2 (0.4)
LBBB, n/N (%) 761/1088 (69.9) 520/729 (71.3)
RBBB, n/N (%) 136/1088 (12.5) 92/729 (12.6)
QRS duration ≥ 150milliseconds, n (%) 699 (64.2) 476 (65.1)
LVEF, mean (SD) 0.24 (0.05) 0.24 (0.05)
6-minute walk distance (m), mean (SD) 359 (107) 363 (108)
Heart rate NR NR
ECG or Doppler findings (ml), mean (SD)
Left ventricular end-diastolic volume 245 (60) 251 (65)
Left ventricular end-systolic volume 175 (48) 179 (53)
Medication, n (%)
Aldosterone antagonist 352 (32.3) 226 (30.9)
Amiodarone 78 (7.2) 51 (7.0)
ACE inhibitor 839 (77.0) 563 (77.0)
ARB 227 (20.8) 148 (20.2)
Beta-blocker 1016 (93.3) 681 (93.2)
Class I antiarrhythmic agent 12 (1.1) 3 (0.4)
Digitalis 291 (26.7) 177 (24.2)
Diuretic 824 (75.7) 533 (72.9)
Lipid-lowering statin 735 (67.5) 491 (67.2)
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Characteristic CRT-ICD (n= 1089) ICD (n= 731)
Previous treatment NR NR
Cardiac risk factors, n/N (%)
Treatment for hypertension 691/1085 (63.7) 461/730 (63.2)
Atrial fibrillation > 1 month before enrolment 118/1063 (11.1) 90/717 (12.6)
Diabetes mellitus 329/1088 (30.2) 223/729 (30.6)
Cigarette smoking 122/1069 (11.4) 92/717 (12.8)
Body mass index ≥ 30 kg/m2 385/1072 (35.9) 263/723 (36.4)
Coronary bypass surgery 317/1088 (29.1) 208/730 (28.5)
NR, not reported; RBBB, right bundle branch block.
Comments
l Evidence for some missing baseline data (in some cases total N differs from total randomised to group).
l Percentages may not sum to 100 because of rounding.
l Baseline characteristics for the subgroup who completed the ECG protocol are reported,132 but not extracted.
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Results
Outcome CRT-ICD (n= 1089) ICD only (n= 731) HR (95% CI), p-value
Death from any cause or non-fatal HF
event, n/N (%)
187/1089 (17.2) 185/731 (25.3) 0.66 (0.52 to 0.84), 0.001
Deaths 36/1089 (3.3) 18/731 (2.5) NR
HF events only 151/1089 (13.9) 167/731 (22.8) 0.59 (0.47 to 0.74), < 0.001
HF events occurring in hospital, n/N 136/151 140/167
HF events outside the hospital, n/N 15/151 27/167
Death at any time,a n/N (%) 74/1089 (6.8) 53/731 (7.3) 1.00 (0.69 to 1.44), 0.99
HRQoL NR NR
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR
HF hospitalisations NR NR
Change in NYHA class NR NR
Left ventricular remodelling
Change in LVEF 0.11 (n= 746) 0.03 (n= 620) < 0.001
Left ventricular end-diastolic volume
average changeb from baseline to
1 year (ml)
–52 (n= 746) –15 (n= 620) < 0.001
Left ventricular end-systolic volume
average changeb from baseline to
1 year (ml)
–57 (n= 746) –18 (n= 620) < 0.001
Exercise capacity outcomes NR NR
NR, not reported.
a Total of 127 deaths including those that occurred after the first HF event; annual rate approximately 3% in each group.
b Average change is not defined further; 95% CIs are represented on a figure but have not been data extracted.
Comments
l Kaplan–Meier estimates of the probability of survival free of HF are presented but have not been data extracted.
l For the primary outcome of death or HF the HR of 0.66 indicates that there was a 34% reduction in the risk of death
or non-fatal HF (whichever occurred first) among patients in the CRT-ICD group compared with patients in the ICD
only group.
l HRs for HF alone and for death at any time for the total population and in the ischaemic and non-ischaemic subgroups
(subgroup data below) indicate that the benefit from resynchronisation therapy was driven by a 41% reduction in the
risk of HF.
l An analysis145 based on ECG data and construction of a response score to identify predictors of response to CRT-D has
not been extracted.
l An assessment of the benefit of CRT-D for the prevention of recurring HF events has been published134 but has not
been data extracted.
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Adverse effects of treatment
Adverse effect CRT-ICD (n= 1089) ICD only (n= 731)
Death in hospital after device implantation, n 1 (pulmonary embolus) –
Serious adverse events in the 30 days after device implantation (% of patients)
Pneumothorax 1.7 0.8
Infection 1.1 0.7
Pocket haematoma requiring evacuation 3.3 2.5
Coronary venous dissection with pericardial effusion
during CRT-D+ ICD implantation, n (%)
5 (0.5) –
Left ventricular coronary vein lead repositioned
during first 30 days, n (%)
44 (4.0%) –
Frequency of serious device-related adverse events
during long-term follow-up after the first 30 days
4.5 per 100
device-months
5.2 per 100
device-months
Removal of device, n (%) 14 (1.3) 5 (0.7)
Subgroup data
Subgroup CRT-ICD ICD only HR (95% CI), p-value
Patients with ischaemic cardiomyopathy
(NYHA class I or II)
(n = 598) (n = 401)
Death from any cause or non-fatal HF event,
n/N (%)
122/598 (20.4) 117/401 (29.2) 0.67 (0.52 to 0.88), 0.003
HF events only 96/598 (16.1) 105/401 (26.2) 0.58 (0.44 to 0.78), < 0.001
Death at any time, n/N (%) 53/598 (8.9) 35/401 (8.7) 1.06 (0.68 to 1.64), 0.80
Patients with non-ischaemic cardiomyopathy
(NYHA class I or II)
(n = 491) (n = 330)
Death from any cause or non-fatal HF event, n (%) 65 (13.2) 68 (20.6) 0.62 (0.44 to 0.89), 0.01
HF events only 55 (11.2) 62 (18.8) 0.59 (0.41 to 0.87), 0.01
Death at any time, n (%) 21 (4.3) 18 (5.5) 0.87 (0.44 to 1.70), 0.68
No. of events/no. of patients HR (95% CI), p-value
Risk of death or HF according to selected clinical characteristics
Age (years)
< 65 142/852 0.80a
≥ 65 230/968 0.60a
Sex
Male 294/1367 0.76 (0.59 to 0.97)
Female 78/453 0.37 (0.22 to 0.61), 0.01
for interaction
continued
DOI: 10.3310/hta18560 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 56
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Colquitt et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
465
Subgroup CRT-ICD ICD only HR (95% CI), p-value
NYHA class
Ischaemic I 53/265 0.76a
Ischaemic II 186/734 0.62a
Non-ischaemic II 133/821 0.60a
QRS duration (ms)
< 150 147/645 1.06 (0.74 to 1.52)
≥ 150 225/1175 0.48 (0.37 to 0.64), 0.001
for interaction
LVEF (%)
≤ 25 101/646 0.70a
> 25 271/1174 0.60a
Left ventricular end-diastolic volume (ml)
≤ 240 184/828 0.70a
> 240 184/969 0.62a
Left ventricular end-systolic volume (ml)
≤ 170 190/835 0.66a
> 170 178/962 0.70a
All patients 372/1820 0.66
a HRs estimated from figure but 95% CIs have not been data extracted.
Comments
l Only data from prespecified subgroups have been extracted.
l Patients with ischaemic cardiomyopathy and those with non-ischaemic cardiomyopathy had a similar benefit from
CRT-ICD therapy.
l CRT-ICD therapy was associated with a greater benefit in women than in men and a greater benefit in patients with a
QRS duration ≥ 150milliseconds than in those with a QRS duration < 150milliseconds. All other interaction p-values
exceeded 0.10.
l No significant interaction effects were identified between the 37 centres with low enrolment (< 10 patients) and the
remaining 73 centres with higher enrolment or between patients with an elevated blood urea nitrogen level
[≥ 26mg/dl (≥ 9.3mmol/l)] and those without an elevated level. No data are presented.
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Subgroup analysis by gender135
Outcome
Women (n= 453) Men (n= 1367)
p-valueCRT-D ICD CRT-D ICD
HF or death (primary end point) 29/275 (11%) 51/178 (29%) 159/814 (20%) 137/553 (25%)
CRT-D vs. ICD HR 0.31
(95% CI 0.19 to 0.50), p< 0.001
CRT-D vs. ICD HR 0.72
(95% CI 0.57 to 0.92), p< 0.01
< 0.01
for interaction
HF only n= 73 events
CRT-D vs. ICD HR 0.30
(95% CI 0.18 to 0.50), p< 0.001
n= 249 events
CRT-D vs. ICD HR 0.65
(95% CI 0.50 to 0.84), p= 0.001
< 0.01
for interaction
Death at any time n= 20 events
CRT-D vs. ICD HR 0.28
(95% CI 0.10 to 0.79), p= 0.02
n= 107 events
CRT-D vs. ICD HR 1.05
(95% CI 0.70 to 1.57), p= 0.83
< 0.03
for interaction
Comments
l Patient characteristics are reported by gender, but have not been extracted.
l The primary end point included 54 deaths and 322 HF events.
l A Kaplan–Meier plot of the probability of the primary end point in women and men receiving CRT-D and ICD therapy
is presented but has not been data extracted. Overall, women receiving CRT-D had a significantly better outcome than
women receiving ICD therapy and men receiving either therapy during an average follow-up of 2.4 years.
l HRs are also provided separately for men and women by disease aetiology, QRS duration and conduction disturbance
but these data have not been extracted.
l Results from the ECG study132 have not been extracted.
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Comments
Methodological comments
l Allocation to treatment groups: randomisation, in a 3 : 2 ratio to CRT-ICD or ICD only, was stratified
according to clinical centre and ischaemic status with the use of an algorithm that ensured near balance in
each stratum. Random assignment was made by the co-ordinating and data centre and transmitted to the
enrolling clinical centre by logging on to a web-based automated program or by telephone with hard copy
to follow.131
l Blinding: treating physicians were aware of study group assignments. Diagnosis of HF and decisions about
therapy or hospital admission for patients with HF were made by physicians aware of study group
assignments. Adjudication of end points was carried out by an independent mortality committee and a HF
committee who was unaware of study group assignments, according to prespecified criteria.
l Comparability of treatment groups: baseline characteristics and use of cardiac medications at enrolment are
described as similar in the two groups.
l Method of data analysis: ITT analysis (except for paired volume and ejection fraction studies). Event
monitoring was prespecified and involved an independent data and safety monitoring board at up to 20
successive multiples of approximately 35 adjudicated events, precisely specified in terms of variance of the
log-rank statistic, with topping boundaries specified for termination of the trial in favour of CRT-ICD
therapy, in favour of ICD only therapy or for no significant difference. Analysis of the primary end point,
based on the statistical log-rank test stratified according to study centre and ischaemic status, was used to
evaluate statistical significance for the trial. A Cox proportional hazards regression model (similarly stratified)
was used to estimate HRs. These analyses were adjusted for the group sequential stopping rule and
incorporated late reported events that occurred before termination of the trial. Cox proportional hazards
regression was used for additional primary analyses for HF alone, death at any time and evaluation of
10 prespecified categorical subgroups and treatment interactions. All p-values were two-tailed and were
not adjusted for the stopping rule (except for the primary end point analysis). Absolute change in left
ventricular volumes and the ejection fraction was evaluated with paired-sample t-tests in patients in each
study group who had paired baseline and 12-month recordings. The trial was stopped on the
recommendation of the independent data and safety monitoring board when the monitoring statistic
reached the prespecified efficacy boundary. The study was then unblinded and analyses were limited to
events occurring before trial termination. A plan for secondary analyses related to recurring HF events and a
number of tertiary analyses was outlined. Of the tertiary analyses, only ECG changes at 1 year are reported.
The authors state that some caution in the interpretation of the subgroup interactions is needed because of
multiple testing but that, given the significance of the comparison, the chance of getting two or more false
positives is small, and the analyses showed a relatively constant treatment effect over time.
l Sample size/power calculation: a Wang–Tsiatis (Δ= 0.1 category) group sequential design (reference
provided) was used with a power of 95% to detect a HR of 0.75 at a two-sided significance level of 0.05.
l Attrition/dropout: in the CRT-ICD arm 11/1089 patients (1.0%) did not receive a device; in the ICD only
arm 19/731 patients (2.6%) did not receive a device. Overall, implantation of a device was achieved in
98.4% of patients, with 95.4% receiving the device to which they had been assigned. During the trial, 173
crossovers occurred for the following reasons: in patients assigned to an ICD only, 91 (12.4%) received
CRT-ICD (30 at discretion of the physician before reaching an end point and 61 after a HF event); in
patients assigned to CRT-ICD, 82 (7.5%) received an ICD only because of technical difficulties (not further
described) in positioning the CRT pacing lead in the coronary vein. During the trial, devices were also
removed for a variety of reasons (as noted in the adverse effects section; reasons not provided). In the
CRT-ICD group, 44 patients (4.0%) declined to continue participating in the study, were withdrawn by a
physician or were lost to follow-up compared with 55 patients (7.5%) in the ICD only group. In total, 201
patients in the CRT-ICD group underwent the 1-year ECG evaluation with the CRT device switched off.
These patients are not included in the paired volume and ejection fraction studies.
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General comments
l Generalisability: the study was designed to investigate the use of combined CRT-ICD in mildly symptomatic
or asymptomatic patients and thus the results are unlikely to be transferable to more severe HF patients.
l Outcome measures: the primary end point was a composite measure but the discussion section describes
this as appropriate and widely used in HF trials. Other outcomes appear appropriate; however, not all were
analysed according to the ITT principle.
l Intercentre variability: authors state that no significant interaction effects were identified between the
37 centres with low enrolment (< 10 patients) and the remaining 73 centres with higher enrolment.
l Conflict of interests: 11/14 authors named on the publication declared one or more potential conflicts of
interest in the form of grant support, lecture fees, consulting fees or institutional fellowships from one or
more company.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear No information provided
Allocation concealment Low ‘Random assignment made by the coordinating and data
centre and transmitted to the enrolling clinical centre by
logging on to a web-based automated program or by
telephone with hard copy to follow’131
Performance bias
Blinding of participants and personnel High ‘The treating physicians were aware of study
group assignments’130
Detection bias
Blinding of outcome assessment High ‘Members of the heart-failure adjudication committee were
unaware of study-group assignments, but the investigators
who decided on therapy or hospital admission for patients
with heart failure were aware of such assignments’.130
Authors acknowledged that ‘it is possible that the
investigators’ knowledge of study-group assignment
contributed in some way to the lower frequency of HF
in the CRT-ICD group’130
Attrition bias
Incomplete outcome data addressed
Survival/HF outcomes Low ‘Data analysis was performed according to the
intention-to-treat principle’130
‘For the purpose of analysis, subjects will not be censored at
withdrawal, and every effort will be made to ascertain the
occurrences or non-occurrence of the primary endpoints’131
Ventricular remodelling outcomes High 201/1820 participants not included in the paired volume and
ejection fraction studies
Reporting bias
Selective reporting Low Paper available describing design and clinical protocol.
Outcomes of interest reported as expected131
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Multicenter InSync ICD Randomized Clinical Evaluation
(MIRACLE ICD)
Reference
and design Intervention and comparator Participants Outcome measures
Young et al.
2003136
Study design:
RCT
Countries: USA
and Canada
No. of centres:
Not stated;
reviewer counted
63 listed
Funding:
Medtronic Inc.
(manufacturer of
the device used
in the trial)
Intervention: ICD-CRT+OPT
Mode programmed that paced
both ventricles simultaneously
following atrial-sensed events at
rate of ≤ 130/minute. ICD
active. Atrial pacing occurred
only for sinus rates < 35/minute
Comparator: ICD+OPT
Mode programmed that
inhibited atrial or ventricular
pacing unless intrinsic rate
< 35/minute. ICD active.
Participants implanted with
Model 7272 InSync ICD
(Medtronic Inc.), which can
deliver atrial-synchronised
biventricular pacing for
cardiac resynchronisation,
antitachycardia pacing through
right ventricular or right
ventricular and left ventricular
leads, and cardioversion and
defibrillation to treat ventricular
tachyarrhythmias delivered
through the right ventricular
lead only
Other interventions used: stable
and appropriate drug regimen,
which included an ACE inhibitor
or ARB, if tolerated, for at least
1 month. A beta-blocker had to
have been initiated at least
3 months before enrolment.
Initiation of a beta-blocker was
not permitted during the
trial period
Indication for treatment:
moderate to severe HF, wide
QRS interval, LVSD and an
established indication
for an ICD
No. of participants: 369;
ICD-CRT+OPT 187,
ICD+OPT 182
Inclusion criteria: indications for
an ICD: cardiac arrest (loss of
consciousness) due to VT or VF
without a transient reversible
cause, patients with recurrent,
poorly tolerated and sustained
VT (spontaneously or induced);
NYHA class III or IV CHF; LVEF
≤ 35%, LVEDD ≥ 55mm; QRS
interval ≥ 130milliseconds;
age ≥ 18 years; stable drug
regimen for ≥ 1 month
Exclusion criteria: life
expectancy < 6 months;
baseline 6-minute walk test
> 450m; bradycardia requiring
pacemaker; unstable angina,
MI, CABG, PTCA, cerebral
vascular accident or transient
ischaemic attack within
previous 3 months; more than
two infusions of inotropic drug
per week; systolic blood
pressure > 170 or < 80mmHg;
resting heart rate > 140 bpm;
serum creatinine > 3.0mg/dl;
hepatic enzymes more than
three times the upper limit of
normal; severe lung disease;
chronic atrial arrhythmias or
cardioversion or paroxysmal
atrial fibrillation within previous
1 month; heart transplant
recipient; severe valvular
heart disease
Primary outcomes: NYHA class,
QoL score, distance walked
covered in 6 minutes
Secondary outcomes: included
peak VO2, treadmill exercise
duration, LVEF, left ventricular
end-systolic and end-diastolic
volumes, LVEDD, severity of
mitral regurgitation, QRS
duration, neurohormone
concentrations and a clinical
composite response (worsened,
improved or unchanged).
Worsened defined as death,
hospitalised because of
worsening HF, permanently
discontinued double-blind
treatment (because of
worsening HF, withdrawal of
consent or other administrative
reason), worsening NYHA class
at LOCF or moderate to
marked worsening of patient
global assessment score at
LOCF; improved defined as not
worsened and demonstrated
improvement in NYHA class at
LOCF or a moderate to marked
improvement in patient global
assessment score at LOCF;
unchanged defined as neither
improved nor worsened
Complication definition: a sign,
symptom, illness or other
medical event that was
resolved invasively (penetrated
the skin, parenteral fluids or
drugs) or resulted in death or
serious injury to patient;
termination of a significant
device function
Method of assessing outcomes:
visits at 1, 3 and 6 months.
At each visit: interrogation of
implanted device, QoL
assessment, 6-minute walk
distance, estimation of NYHA
class and monitoring of drug
regimen. At 6 month visit:
ECG, cardiopulmonary exercise
test and measurement of
plasma neurohormones
Length of follow-up: 6 months
Recruitment: October 1999–
August 2001
bpm, beats per minute; LOCF, last observation carried forward; LVEDD, left ventricular end-diastolic diameter;
PTCA, percutaneous transluminal coronary angiography.
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Participant characteristics
Characteristic ICD-CRT+OPT (n= 187) ICD+OPT (n= 182) p-value
Age (years), mean (SD) 66.6 (11.3) 67.6 (9.2)
Gender, male, n (%) 142 (75.9) 141 (77.5)
Ethnicity NR NR
Underlying heart disease, n (%) 0.02
Ischaemic 119 (64.0) 138 (75.8)
Non-ischaemic 67 (36.0) 48 (26.4)
Indication for ICD, n (%)
Cardiac arrest 17 (9) 20 (11)
Sustained VT 71 (38) 76 (42)
Induced VF and sustained VT 99 (53) 85 (47)
NYHA class, n (%)
III 165 (88.2) 163 (89.6)
IV 22 (11.8) 19 (10.4)
LVEF (%), mean (SD) 24.2 (6.5) 23.9 (6.0)
Resting heart rate/minute, mean (SD) 71.0 (12.4) 71.3 (12.9)
Blood pressure (mmHg), mean (SD)
Systolic 113 (18) 114 (17)
Diastolic 66 (11) 67 (10)
QRS duration (milliseconds), mean (SD) 165 (22) 162 (22)
Isolated right bundle branch block, n (%) 25 (13) 24 (13)
LVEDD (mm), mean (SD) 75.6 (9.6) 76.7 (10.4)
LVESD (mm), mean (SD) 248 (93) 240 (87)
LVEDV (ml), mean (SD) 322 (100) 311 (96)
Mitral regurgitation, average jet area (cm2), mean (SD) 7.5 (5.9) 7.3 (6.7)
QoL life score, mean (SD) 56.8 (22.6) 55.2 (22.6)
6-minute walk distance (m), mean (SD) 243 (129) 243 (117)
Peak VO2 (ml/kg/minute), mean (SD) 13.3 (3.6) 13.4 (3.8)
Exercise duration (seconds), mean (SD) 468 (205) 506 (230)
Baseline medications, n (%)
ACE inhibitor or ACE inhibitor substitute 173 (92.5) 162 (89.0)
Antiarrhythmic 79 (42.3) 60 (33.0)
Beta-locker 116 (62.0) 106 (58.2)
Diuretic 174 (93.1) 172 (94.5)
LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular
end-diastolic volume; NR, not reported.
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Results
Outcomes ICD-CRT+OPT (n= 187) ICD+OPT (n= 182)
Control vs.
CRT p-value
No. of deaths during 6 months 14 15 NR
Sudden deaths 3 3
6-month cumulative survival, % 92.4
(95% CI 87.5 to 95.4)
92.2
(95% CI 87.2 to 95.3)
log-rank
p= 0.96
Primary outcomes (including all patients with data), median change (95% CI), n
Change in QoL scorea –17.5 (–21 to –14), 162 –11 (–16 to –7), 157 0.02
Change in NYHA functional class –1 (–1 to –1), 165 0 (–1 to 0), 162 0.007
Change in 6-minute walk distance (m) 55 (44 to 79), 152 53 (43 to 75), 153 0.36
Primary LOCF analysis (excluding patients who died and those with either no baseline or no follow-up data at 1, 3 and
6 months), median change (95% CI), n
Change in QoL score –17 (–21 to –13), 170 –11 (–16 to –6), 163 0.01
Change in NYHA functional class –1 (–1 to –1), 171 0 (–1 to 0), 166 0.006
Change in 6-minute walk distance (m) 54.5 (40 to 75), 166 52 (40 to 74), 163 0.32
Secondary outcomes, median change (95% CI), n
Cardiopulmonary exercise
Change in peak VO2 (ml/kg/minute) 1.1 (0.7 to 1.6), 120 0.1 (–0.1 to 0.8), 121 0.04
Change in exercise duration (seconds) 55.5 (30 to 79), 120 –11 (–55 to 12), 123 < 0.001
Echocardiographic left ventricular size and function
Change in end-diastolic volume (ml) –19.9 (–39.7 to –6.3), 132 –5.7 (–16.2 to 1.8), 133 0.06
Change in end-systolic volume (ml) –22.2 (–32.8 to –10.7), 132 –8.2 (–19.1 to 0.6), 133 0.06
Change in ejection fraction (absolute %) 2.1 (1.2 to 4.1), 132 1.7 (0.7 to 2.4), 133 0.12
Change in end-diastolic diameter (mm) –0.1 (–0.3 to 0.1), 70 –0.2 (–0.3 to 0), 67 0.81
Change in end-systolic diameter (mm) –0.1 (–0.4 to 0.1), 69 –0.3 (–0.5 to –0.1), 65 0.53
Change in mitral regurgitant jet
area (mm)
–0.55 (–2.00 to 0), 130 –0.33 (–0.85 to 0), 126 0.58
Change in overall clinical status, n (%)
Improved 98 (52.4) 78 (42.9) 0.07
Unchanged 28 (15.0) 43 (23.6)
Worsened 61 (32.6) 61 (33.5)
Change in QRS duration (milliseconds) –20 (–21 to –14), 162 0, n= 160 < 0.001
Changes in plasma neurohormones (pg/ml)
Brain natriuretic peptide –50 (–163 to –6), 119 –68 (–133 to –6), 121 0.77
Dopamine 0, n= 112 0, n= 117 0.37
Norepinephrine (ng/dl) 4 (–12 to 68), 113 –17 (–54 to 49), 117 0.58
Epinephrine 0 (–4 to 0), 112 –3 (–8 to 0), 115 0.05
Big endothelin –2.5 (–6.0 to 1.3), 110 –1.8 (–3.7 to 0.9), 119 0.98
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Outcomes ICD-CRT+OPT (n= 187) ICD+OPT (n= 182)
Control vs.
CRT p-value
Hospitalisations between randomisation and
6-month visit, n/N (%)
85/187 (45.5) 78/182 (42.9)
Length of hospital stay (days), mean (SD) 4.8 (4.9) 5.4 (4.7) 0.06
Probability of hospitalisation for worsening HF
or death from any cause, %
25.7
(95% CI 19.6 to 32.3)
25.9
(95% CI 19.8 to 32.5)
0.69
Risk of death or all cause hospitalisation, % 47.4
(95% CI 40.0 to 54.4)
48.3
(95% CI 40.6 to 55.6)
0.88
Experienced one or more spontaneous episode
of VT or VF, n/N (%)
42/187 (22) 47/182 (26) 0.47
Episode not successfully terminated within
interval determined by device criteria,b n/N (%)
1/678 (0.1) 4/233 (1.7)
Appropriate ICD shocks 89 events, 24/187
patients (13%)
154 events, 26/182
patients (14%)
0.76
Inappropriate ICD shocks 18 events, 8/187
patients (4%)
59 events, 13/182
patients (7%)
0.27
Appropriate: only antitachycardia pacing used 608 events, 33/187
patients (18%)
229 events, 31/182
patients (17%)
0.89
Inappropriate: only antitachycardia
pacing used
35 events, 13/187
patients (7%)
32 events, 8/182
patients (4%)
0.37
Therapy compliance 94% ventricular paced for
≥ 90% of the time
86% received no right
ventricular pacing
NR, not reported.
a For QoL score more negative change scores indicate greater improvement.
b For the spontaneous and treated VT/VF episodes for which outcomes of ICD therapy were recorded. All five episodes
eventually terminated spontaneously.
Comments
l Median duration of successful implantation procedure 2.75 hours (IQR 2.2–3.6).
l In addition to the 6-month median changes in QoL and 6-minute walk distance, changes at 1 and 3 months’ follow-up
are shown in a figure but have not been data extracted.
l An analysis of appropriate and inappropriate ICD treatment by CRT treatment received (not randomised assignment) is
also presented but has not been extracted. Results were broadly similar.
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Adverse effects of treatment
Adverse effect All patients undergoing implant attempt (n= 429)
Experienced complication
from implant to
hospital dischargea
120/429 patients (28%), 159 complications
Complications related to
left ventricular lead
37/159 (23%) (including 15 coronary sinus dissections and 4 cardiac perforations)
HF decompensation 6 patients (received intravenous medication)
Heart block 3 patients (required bradycardia pacing support)
Muscle stimulation 4 patients (required either lead repositioning or replacement)
Pericardial effusion 2 patients (treated with a pericardiocentesis)
Pericarditis 1 patient (received intravenous medication)
Haemo/pneumothorax 3 patients (placement of chest tube)
VT and VF 5 patients (3 received external defibrillation, 2 intravenous medications)
Elevated pacing thresholds or
loss of capture
7 patients (6 received lead repositioning, 1 set screw tightened in connector block)
Died within 30 days of latest
implant attemptb
5/429 (1.2%)
ICD-CRT+OPT (n= 187) ICD+OPT (n= 182)
For patients successfully implanted and randomised: complications after hospital discharge to 6-month follow-up
Left ventricular
lead-related complication
21 complications in 20 patients (11%) 14 complications in
13 patients (7%)
ICD system related 9 complications in 9 patients (5%) 14 complications in
13 patients (8%)
Procedure related 10 complications in 10 patients (5%) 13 complications in
11 patients (6%)
HF decompensation 63 complications in 36 patients (19%) 71 complications in
40 patients (22%)
Other 81 complications in 45 patients (24%) 74 complications in
44 patients (22%)
Total 184 complications in 88 patients (47%) 186 complications in
80 patients (44%)
Crossed over to
alternative treatment
10 (5%) to ICD only (2 ventricular lead
dislodgement, 2 diaphragmatic stimulation,
6 programming errors)
14 (8%) to CRT (11 worsening HF,
2 bradycardia, 1 programming error)
a Not stated but not all complications are reported in detail.
b For those with at least one implant attempt.
Comments
l Adverse events after hospital discharge to 6-month follow-up also shown for 60 participants who had an implant
attempted but who were not randomised (unsuccessful CRT but successful ICD only n= 50; CRT system implanted
n= 10) but these have not been extracted.
l From hospital discharge to 6-month follow-up 175/379 patients (46%) with successful implants experienced 398
complications. States that the rate of device-related events was substantially lower than anticipated in the prespecified
criteria of the original study protocol.
l States that the frequency of adverse events unrelated to the device or to HF did not differ significantly between
the groups.
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Comments
Methodological comments
l Allocation to treatment groups: randomisation occurred within 7 days of successful implantation but after a
cardiopulmonary exercise test. Random assignment in blocked groups of four by centre (to balance CRT
and control assignments at each centre). Random allocation sequence was generated by SAS software
version 8.2 (SAS Institute Inc., Cary, NC, USA). Centres were unaware of randomisation method.
Assignment provided to unblinded electrophysiology staff in consecutively numbered and opaque sealed
envelopes opened at the time of randomisation.
l Blinding: states double blind. Patients and physicians from HF team (not involved in programming of the
device) remained unaware of assignment until after the 6-month visit. Blinded phase of study complete at
6 months. Independent core laboratories, unaware of assignment, interpreted data. Adverse events
classified by clinical events review committee without knowledge of random assignment.
l Comparability of treatment groups: states similar except that the control group had a higher percentage of
participants with ischaemic heart disease.
l Method of data analysis: only participants with both baseline and follow-up data were included in efficacy
analyses. All randomised patients who underwent an implant attempt were included in the adverse event
analysis. For all other analyses all randomised patients were included. States that all end points were
analysed by ITT principle but this appears to conflict with earlier statement that both baseline and follow-up
data were required for participants to be included in efficacy analyses. Data presented as median changes
between baseline and 6-month follow-up. CIs for medians computed using a distribution-free approach.
Mean values presented with SDs. Continuous variable (including NYHA) changes from baseline in control
vs. CRT group and demographic characteristics compared using the Wilcoxon rank-sum test. Differences in
distribution of categorical end points between the two groups compared with Fisher’s exact test. Survival
curves constructed using the Kaplan–Meier method (time zero= date of implant) and differences between
curves examined using the log-rank test statistic. CIs for survival computed on the log-log survival scale.
Objectives considered reached for the three primary efficacy variables if differences between the groups for
all three end points had p≤ 0.05 or if two had p≤ 0.025 or if one had p≤ 0.017, using the Hochberg
criterion. For secondary end points p< 0.05 was considered significant. All p-values were calculated using
two-sided tests. Details of analysis that was not prespecified were not data extracted.
l Sample size/power calculation: estimated based on the assumption that the study would have 80% power
(two-sided α= 0.017) to detect a difference in NYHA class of 0.75, in QoL of 13 points or in 6-minute walk
distance of 50m. There were 112 patients per treatment group. Study was not powered to detect a
morbidity or mortality difference.
l Attrition/dropout: of 639 patients initially enrolled, 210 had mild HF symptoms and as per protocol were
not included in this analysis; 60 NYHA class III or IV patients had an implant attempted but did not enter
the randomised therapy phase. This left 369 patients included in the randomisation. In the CRT-D+OPT
group 10 (5%) crossed over to ICD therapy only (these were included in the analysis), 14 died, six missed
the 6-month follow-up and two received cardiac transplantation (these 22 not included in the analysis),
leaving 165/187 included in the primary efficacy analysis. In the ICD+OPT group 14 (8%) crossed over to
CRT (included in analysis), 15 died and five missed the 6-month follow-up (these 20 not included in the
analysis), leaving 162/182 included in the primary efficacy analysis.
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General comments
l Generalisability: only those with successful implantation were randomised. Generalisable to those with
moderate to severe HF; however, relatively short length of follow-up (6 months) and so results may not be
generalisable over long time periods.
l Outcome measures: appear appropriate but QoL tool not specified.
l Intercentre variability: not commented on.
l Conflict of interests: eight of the 11 listed authors made financial disclosures. The sponsor had responsibility
for the initial study design, day-to-day study operations, data collection, data management and statistical
analysis in conjunction with the co-principal investigators. The study sponsor also participated in
preparation and review of the manuscript for accuracy. States that investigators performed analyses
without restrictions or limitations from sponsors.
l Other: except for ICD indication, patient inclusion criteria and study design were identical to those of the
MIRACLE trial.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random
sequence generation
Low Sequence generated by computer software
Allocation concealment Low Consecutively numbered and opaque sealed envelopes
Performance bias
Blinding of participants
and personnel
Low States double blind, participants and physicians blinded
Detection bias
Blinding of
outcome assessment
Low States double blind, use of independent lab and blinded committee
Attrition bias
Incomplete outcome data addressed
Primary outcomes Unclear Numbers and reasons for missing data are given; appear balanced between
groups for primary outcomes. Crossovers were included as assigned. However,
denominator should be n= 165 for CRT and n= 162 for ICD but this is only
the case for NYHA class and not for the other two primary outcomes QoL and
6-minute walk distance
Secondary outcomes High Amount of missing data varies between different secondary outcomes
although appears to be a similar proportion in each group. Reasons
not provided
Reporting bias
Selective reporting Low Protocol not available but expected outcomes reported
Other bias
Other sources of bias Unclear Study sponsor appears to have been involved in all aspects of the study
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Multicenter InSync ICD II Randomized Clinical Evaluation
(MIRACLE ICD II)
Reference
and design
Intervention
and comparator Participants Outcome measures
Abraham et al.
2004138
Study design: RCT
Countries: USA and
Canada
No. of centres: 63136
Funding: Medtronic,
Inc., St Paul, MN
Intervention: CRT-D+OPT
Combined cardiac
resynchronisation/ICD device
(model 7272 InSync ICD,
Medtronic), with three pacing
leads: standard right atrial
pacing lead, standard right
ventricular pacing/
defibrillation lead, and one of
several left ventricular
transvenous leads positioned
in a distal cardiac vein via
coronary sinus
Device programmed to pace
both ventricles after atrial
sensed events at rates of
≤ 130 bpm. Atrial pacing
occurred only for sinus rates
of ≤ 35 bpm
Comparator: ICD+OPT
Active ICD therapy only.
Device as above. Device
programmed to inhibit atrial
or ventricular pacing unless
intrinsic rate was < 35 bpm
Other interventions used: all
appropriate treatments for HF,
including diuretic, ACE
inhibitor or ARB and usually
digitalis and beta-blocker.
Doses stable for ≥ 1 month
except for beta-blocker, stable
for 3 months
Indication for treatment: mild
NYHA class II HF symptoms, a
wide QRS complex and an
established indication
for an ICD
No. of participants: enrolled
222, implant attempt 210,
successful implant 191,
randomised 186; CRT-D 85,
ICD 101
Completed study: CRT-D 82,
ICD 98
Inclusion criteria: NYHA class
II chronic HF, LVEF ≤ 35%,
LVEDD ≥ 55mm, QRS
interval ≥ 130milliseconds,
indication for ICD
Exclusion criteria: variety of
medical reasons including
having an indication for or
contraindication to
cardiac pacing
Primary outcome: change in
peak VO2
Secondary outcomes:
ventilatory response to
exercise [minute ventilation/
minute carbon dioxide
production (VE/VCO2)], NYHA
class, QoL, 6-minute hall walk
test, left ventricular volume,
LVEF, composite clinical
response (worsened, improved
or unchanged)
Method of assessing
outcomes: 7 days before
implantation: NYHA class,
6-minute hall walk test, QoL
assessed using MLWHFQ,
2-dimensional Doppler ECG,
plasma neurohormone
concentrations, QRS interval
assessed using 12-lead ECG;
before randomisation: exercise
capacity measured using
baseline treadmill
cardiopulmonary exercise test
using modified Naughton
protocol; at 1, 3 and
6 months: interrogation of
CRT-ICD, QoL, 6-minute hall
walk distance, NYHA class,
monitor drug regimen, ECG,
metabolic exercise testing,
plasma neurohormone
measurements at
6-month visit
Adverse events: complication
defined as a sign, symptom,
illness or other medical event
that was resolved invasively or
resulted in death or serious
injury; termination of a
significant device function
Length of follow-up: blinded
phase of study completed at
6-month follow-up. CRT
activated in control group
Recruitment: July 2002
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter.
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Participant characteristics
Characteristic CRT-ICD (n= 85) ICD (n= 101) p-value
Mean (SD) unless stated otherwise
Age (years) 63.0 (12.8) 63.1 (12.1)
Gender, men, n (%) 75 (88.2) 91 (90.1)
Ethnicity NR NR
NYHA functional class II, n (%) 85 (100) 101 (100)
LVEF (%) 24.4 (6.6) 24.6 (6.7)
LVEDD (cm) 7.6 (1.0) 7.5 (1.0)
LVESD (cm) 6.5 (1.2) 6.5 (1.2)
LVEDV (cm3) 337 (147) 329 (108)
LVESV (cm3) 260 (134) 252 (98)
QRS duration (ms) 166 (25) 165 (23)
Mitral regurgitation, average jet area (cm2) 5.9 (6.0) 6.1 (5.3)
QoL score 41.8 (25.1) 39.8 (21.2)
6-min walk test (m) 355 (125) 383 (108)
Peak VO2 (ml/kg/minute) 16.4 (4.4) 16.8 (5.0)
VE/VCo2 (ml/minute) 39.3 (9.7) 38.7 (9.4)
Exercise duration (seconds) 647 (242) 664 (228)
Resting heart rate (bpm) 69.7 (11.5) 68.6 (12.3)
Blood pressure (mmHg)
Systolic 116.2 (15.8) 116.8 (16.8)
Diastolic 69.9 (10.4) 69.4 (10.2)
Underlying heart disease, n (%)
Ischaemic 47 (55.3) 59 (58.4)
Right bundle branch block, n (%) 10 (11.8) 21 (20.8)
Baseline neurohormones (pg/ml)
Brain natriuretic peptide 631 (909) 538 (806)
Norepinephrine 413 (379) 355 (249)
Epinephrine 29 (28) 31 (28)
Big endothelin 15 (12) 18 (15)
Dopamine 23 (51) 12 (7)
Baseline medications, n (%)
ACE inhibitor 83 (97.6) 96 (95.0)
Antiarrhythmic 30 (35.3) 33 (32.7)
Beta-blocker 54 (63.5) 64 (63.4)
Diuretic 74 (87.1) 81 (80.2)
bpm, beats per minute; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume;
LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; NR, not reported.
Comment
l States that all differences between the control group and the CRT group are not statistically significant.
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Results
Outcomes CRT-ICD (n= 85) ICD (n= 101) p-value
Mortality during 6-month follow-up, n 2 (2 cardiac arrests) 2 (1 cardiac arrest, 1 MI with
cardiogenic shock)
Change from baseline to 6 months, mean (SD), n
Change in QoL score –13.3 (25.1), 81 –10.7 (21.7), 96 0.49
Symptoms and complications related to
tachyarrhythmias and/or HF
NR NR
HF hospitalisations NR NR
Change in NYHA class –0.18 (0.61), 82 0.01 (0.63), 98 0.05
Change in peak VO2 (ml/kg/minute) 0.5 (3.2), 66 0.2 (3.2), 79 0.87
Change in exercise duration (seconds) 42 (167), 66 37 (186), 79 0.56
Change in VE/VCO2, (ml/minute) –1.8 (6.2), 66 0.5 (5.2), 78 0.01
Change in 6-minute walk distance (m) 38 (109), 78 33 (98), 93 0.59
Echocardiographic left ventricular size and function
Change in LV end-diastolic volume (ml) –41 (76), 69 –16 (62), 85 0.04
Change in LV end-systolic volume (ml) –42 (77), 68 –14 (57), 85 0.01
Change in LVEF (absolute %) 3.8 (8.0), 68 0.8 (6.2), 85 0.02
Change in mitral regurgitant jet area (mm) –1.7 (4.7), 62 –1.0 (3.7), 84 0.25
Change in overall clinical status, n (%)
Improved 49 (58) 36 (36) 0.01
Unchanged 19 (22) 34 (34) (all)
Worsened 17 (20) 31 (31)
Change in QRS duration –9 (24), 78 –9 (22), 95 0.97
Changes in plasma neurohormones (pg/ml)
Brain natriuretic peptide –195.2 (831.6), 64 –96.3 (581.6), 71 0.81
Dopamine –10.3 (59.7), 60 5.5 (18.2), 71 0.26
Norepinephrine 10.1 (396.0), 60 63.3 (248.3), 71 0.86
Epinephrine –6.5 (34.2), 60 –4.7 (25.8), 71 0.67
Big endothelin –2.3 (15.6), 61 –4.3 (15.6), 70 0.69
One or more appropriately detected,
spontaneous episodes of VT or VF, n/N (%)
19/85 (22) 26/101 (26) 0.61
Percentage of inappropriately detected VT/VF
Treated NR NR 0.21
Shocked NR NR 0.78
NR, not reported; VE/VCO2, ventilatory response to exercise (minute ventilation/minute carbon dioxide production).
Comments
l Primary outcome of study was change in peak VO2.
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Adverse effects of treatment
Adverse effect
From implant to hospital discharge 46/210 (22%) patients,a 56 complications
Complication related to placement of left
ventricular lead
19/56 (34%) (including 3 coronary sinus dissections, 3 cardiac
perforations, 5 lead dislodgements)
Failed initial implant attempt 23/210
From hospital discharge to 6-month follow-up 66/191 (35%) patients,b 109 complications
Complications related to left ventricular lead 19/109 (17%) (including 11 lead dislodgements, 1 cardiac perforation,
3 diaphragmatic muscle stimulation, 4 elevated pacing threshold)
a Note that this is all patients undergoing implantation, not the number randomised.
b Note that this is the number of patients undergoing successful implantation, not the number randomised.
Comments
Methodological comments
l Allocation to treatment groups: patients randomly assigned, in permuted groups for each centre. SAS
software used to generate the random allocation sequence. Method of randomisation not disclosed to
participating centres and was accomplished in blocked groups of four for each centre to ensure balance of
CRT and control assignments at each participating institution. Randomisation occurred after a
successful implant.
l Blinding: patients and physicians treating for HF and performing study evaluations unaware of treatment
assignment. At each site an electrophysiologist unblinded to treatment programmed the device and
performed all tests that could reveal the identity of assigned mode. The clinical events review committee
reviewed and classified adverse events without knowledge of the randomised assignment.
l Comparability of treatment groups: states no statistically significant differences noted between the groups.
l Method of data analysis: states that all end points were analysed according to ITT principle; results were
assessed on the basis of the original treatment assignment. Changes in continuous variables, including
NYHA class, from baseline to 6 months in the control group were compared with changes in the CRT
group using the Wilcoxon rank-sum test. For categorical end points, compared differences in distribution of
responses to treatment at 6 months using Fisher’s exact test, except for inappropriately detected VT/VF
episodes, for which generalised estimating equation methods were used. p< 0.05 was considered
statistically significant. All p-values were calculated using two-sided tests. States that in an analysis that was
not prespecified, potential clinically relevant covariates were analysed by ANOVA with random assignment
as independent variables; however data are not reported in the paper.
l Sample size/power calculation: not reported.
l Attrition/dropout: 222 participants were enrolled and implant was attempted in 210 (reasons for no
implant not reported); 191 (91%) were successfully implanted (reasons for implant failure not reported):
one patient died and four patients had left ventricular lead dislodgements that were not corrected. The
remaining 186 patients were randomised. In each group two patients died and one missed the 6-month
follow-up visit. Five ICD patients (5%) crossed over to CRT-D before 6 months (biventricular pacing was
activated early because of bradycardia in three patients, there was a centre error in one patient and there
was pacemaker dependency after atrioventricular node ablation for atrial flutter in one patient). Two CRT-D
patients (2%) crossed over to no pacing (biventricular pacing was deactivated because of left ventricular
lead dislodgement in one patient and there was diaphragmatic stimulation in biventricular and right
ventricular pacing modes in one patient).
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General comments
l Generalisability: participants had mildly symptomatic class II HF. Exercise capacity was not moderately or
severely impaired at baseline. Randomisation occurred after a successful implant; therefore, patients not
representative of all patients eligible for CRT.
l Outcome measures: appropriate but follow-up only 6 months. Composite outcome not defined in paper
but reference provided. Adverse events not reported separately for treatment groups.
l Intercentre variability: not reported.
l Conflict of interests: study supported by Medtronic, Inc. Conflicts declared by authors, including receiving
honoraria from and/or being a consultant and/or investigator for Medtronic, Guidant, St Jude Medical
and/or GlaxoSmithKline and/or shareholder in Medtronic.
ANOVA, analysis of variance.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Low ‘SAS software (SAS Institute) was used to generate the random
allocation sequence’137
Allocation concealment Low ‘Method of randomisation was not disclosed to
participating centres’137
‘At each site, an electrophysiologist unblinded to treatment
opened a sealed envelope at the time of randomisation,
programmed the device, and performed all tests that could
reveal the identity of the assigned mode’137
Performance bias
Blinding of participants and personnel Low ‘Neither the patients nor the physicians treating them were
aware of the treatment assignment. At each site,
an electrophysiologist unblinded to treatment opened a sealed
envelope at the time of randomisation, programmed the
device, and performed all tests that could reveal the identity
of the assigned mode’137
‘Clinical events review committee reviewed and classified
adverse events without knowledge
of randomised assignment’137
Detection bias
Blinding of outcome assessment Low ‘Cardiopulmonary gas exchange analysis was done at a core
laboratory with personnel blinded to CRT activation status’137
‘Standard protocols used to perform echocardiograms and
collect plasma neurohormones, Independent core laboratories,
blinded to patient study assignment,
interpreted the data’137
‘Clinical events review committee reviewed and classified
adverse events without knowledge
of randomised assignment’137
continued
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Domain Judgementa Support for judgement
Attrition bias
Incomplete outcome data addressed Unclear States ITT but reports various patient numbers for each
outcome. Not clear why these data are missing
Reporting bias
Selective reporting Low Protocol not available but expected outcomes reported.
Analysis described in methods section not reported in the
results section, but not relevant to this review as
not prespecified
Other bias
Other sources of bias Low
a ‘Low risk’ or ‘unclear risk’ of bias.
Piccirillo and colleagues study
Reference and design
Intervention
and comparator Participants Outcome measures
Piccirillo et al. 2006138
Study design: RCT
Country: Italy
No. of centres: one
Funding: not reported
Intervention: CRT-D
Comparator: ICD
Biventricular pacemaker
(Guidant Corporation); the
final pace setting was VDD
with a lower rate well below
the patient’s lowest intrinsic
heart rate to maintain
natural atrial tracking at rest
(setting essential to allow
power spectral analysis of
heart rate variability)
Both groups were taking
standard medications for HF,
including ramipril (2.5–10mg/
day) or losartan (50mg/day),
furosemide (25–250mg/day),
spironolactone (25–50mg/day),
carvedilol (6.25–50mg/day) or
bisoprolol (2.5–5mg/day),
digoxin (0.125mg/day or
0.250mg/day) and
acetylsalicylic acid (100mg/day)
Other interventions used:
none reported
Indication for treatment:
CHF (with low ejection
fraction and prolonged
QRS interval) secondary to
ischaemic dilated
cardiomyopathy
No. of randomised
participants: 31;
CRT-D: 16, ICD: 15
Also reported data for
healthy non-randomised
control group (n= 12).
Data not extracted
Inclusion criteria: LVEF
≤ 35%, QRS interval
> 120milliseconds and sinus
rhythm
Exclusion criteria:
malignancy, primary valve
disease, frequent
extrasystoles (more than one
per minute), atrial fibrillation
or other arrhythmias
requiring a pacemaker
(atrioventricular disturbances)
or defibrillator for
secondary prevention
because of a history of
malignant arrhythmias
Primary/secondary outcome
(not stated which): spectral
indices based on power
spectral analysis and
changes in spectral indices
(not data extracted). Also
reported mortality and
change in NYHA class
Method of assessing
outcomes: details of power
spectral analysis and
assessment of changes in
spectral indices not data
extracted. All ICD shocks
assessed by three expert
cardiologists to evaluate
appropriateness
Length of follow-up: 1 year
Recruitment: not reported
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Participant characteristics
Characteristic CRT-D (n= 16) ICD (n= 15) p-value
Age (years), mean (SD) 65 (4) 65 (8)
Sex, male/female, n 13/3 12/3
Ethnicity NR NR
NYHA class, n
III 5 5
IV 11 10
LVEF (%), mean (SD) 23 (4) 22 (8)
QRS length (milliseconds), mean (SD) 160 (4) 159 (8)
Heart rate (bpm), mean (SD) 79 (4) 81 (8)
Blood pressure (mmHg), mean (SD)
Systolic 112 (12) 109 (19)
Diastolic 68 (8) 69 (11)
Electrophysiology findings
End-systolic diameter (mm), mean (SD) 60 (8) 59 (8)
End-diastolic diameter (mm), mean (SD) 69 (4) 70 (19)
Current pharmacological therapy, n
Digoxin 12 11
Ramipril 16 15
Furosemide 16 15
Spironolactone 9 10
Carvedilol 13 12
Biskoprolol 2 1
Acetylsalicylic acid 16 14
Cardiac history, n
Unstable symptoms of HF 0 0
Hospitalisation 0 0
Recent previous treatment, n
Coronary angioplasty 0 0
Revascularisation procedures 0 0
Change of therapy during the past 3 months, n 0 0
Comorbidities NR NR
Body mass index (kg/m2), mean (SD) 26 (4) 26 (4)
bpm, beats per minute; NR, not reported.
Comments
l Data for the healthy control group not data extracted; p-values for comparison between CHF patients before treatment
and control group not data extracted.
l None of the three CRT-D ‘non-responders’ received ICD shocks.
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Results
Outcome CRT-D (n= 16) ICD (n= 15) p-value
Deaths, n 0 0
HRQoL NR NR
Received appropriate shocks, n 2 4
Sustained VT 1 3
Sustained VF 1 1
Hospitalisation because of worsening CHF, n 0 2
NYHA class after 12 months,a n
I 1 0
II 3a 1
III 6 1
IV 6a 13
LVEF (%),b mean 28 22
Exercise capacity outcomes NR NR
Heart rate (bpm), mean (SD) 75 (4) 76 (4)
Blood pressure (mmHg), mean (SD)
Systolic 115 (4)c 108 (11)
Diastolic 69 (4) 70 (4)
End-systolic diameter (mm), mean (SD) 55 (4)c 61 (4)
End-diastolic diameter (mm), mean (SD) 66 (8)c 72 (11)c
Change in diuretic medication, n 5 reduced 6 increased
bpm, beats per minute; NR, not reported.
a Data for the CRT-D group differ between table 3 and the text (class II amounts to seven in the text and class IV amounts
to two in the text, but three participants were considered as non-responders as their NYHA class did not change).
b SDs reported in text and table 3 differ (CRT-D group: SD 1 in text, SD 4 in table; ICD group: SD 1 in text, SD 8 in table)
(p-value for within CRT-D group comparison from baseline to follow-up not extracted).
c p-values for within-group comparisons from baseline to follow-up not extracted.
Comments
l CRT-D: three patients were considered non-responders as their NYHA class did not change. Text states that, from
baseline, four CRT-D patients improved from NYHA class IV to class II, five improved from NYHA class IV to class III,
three improved from NYHA class III to class II and one improved from NYHA class III to class I; however, these changes
do not correspond with the data presented in table 3.
l ICD: three patients worsened from NYHA class III to class IV and one patient improved from NYHA class III to class II.
l Results from the power spectral analysis for heart rate and blood pressure variability reported, but not extracted.
Adverse effects of treatment
Adverse effect CRT-D (n= 16) ICD (n= 15) p-value
NR NR
NR, reported.
Comment
l Authors state that there were no major complications following implantation.
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Comments
Methodological comments
l Allocation to treatment groups: patients were randomly assigned in a 1 : 1 ratio to ICD or CRT-D.
l Blinding: spectral recording assessment blinded (outcomes not extracted) but no other blinding reported.
l Comparability of treatment groups: authors state that there were no significant differences in age, body
mass index, sex distribution or blood pressure between the two CHF groups and the control group
(no p-values reported; p-values were reported for the CHF groups vs. the control group but were not
data extracted).
l Method of data analysis: linear data expressed as mean± SD. Non-linear data expressed as median (IQR).
ITT analysis not reported. Baseline ICD and CRT-D group data before implantation compared with control
group data. The data for the ICD and CRT-D groups were then compared at baseline and at 1 year.
One-way analysis of variance was used to compare the general characteristics and other linear data
between the study groups. The Kruskal–Wallis test and Mann–Whitney U test were used for non-normally
distributed data. The Wilcoxon test was used for variables with a non-linear distribution. Event-free survival
functions were estimated using the Kaplan–Meier method and differences between the curves were tested
for significance using the log-rank statistic; RRs were computed using a Cox proportional hazards
regression model. As spectral analysis outcomes were not extracted (because not specified for review), the
methods for the analysis of these outcomes were also not extracted.
l Sample size/power calculation: none reported.
l Attrition/dropout: none; all patients completed the study.
General comments
l Generalisability: sample size too small to generalise, but results would be limited to patients with
post-ischaemic dilated cardiomyopathy, excluding primary dilated cardiomyopathy patients.
l Outcome measures: extracted outcome measures appear appropriate.
l Intercentre variability: not applicable, one centre only.
l Conflict of interests: not reported.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random
sequence generation
Unclear Only states randomly assigned in a 1 : 1 ratio; no other details reported
Allocation concealment Unclear No details reported
Performance bias
Blinding of participants
and personnel
High No blinding reported
Detection bias
Blinding of
outcome assessment
High Assessment of spectral recordings blinded (outcomes not extracted), but no
other blinding reported
Attrition bias
Incomplete outcome
data addressed
Low No ITT analysis reported, but all data appear to have been reported and
authors state that all patients completed the study
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Domain Judgementa Support for judgement
Reporting bias
Selective reporting Low No protocol available, but all stated outcomes were reported
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
Pinter and colleagues study
Reference
and design
Intervention
and comparator Participants Outcome measures
Pinter et al. 2009139
Study design: RCT
Country: Canada
No. of centres: 7
Funding: Guidant
Inc., Minneapolis, MN
All patients: CONTAK CD CHF
device, model 1823, or
CONTAK RENEWAL heat
failure device, model H135
(Guidant Corporation).
Standard atrial pacing lead,
ventricular defibrillator lead
and Easytrak left ventricular
pacing lead
(Guidant Corporation)
Intervention: CRT-D (CRT on).
Pacing programmed to
dual-chamber tracking pacing
mode (DDD) with lower rate
limit at 40 bpm and maximum
tracking rate 20 bpm less
than the tachycardia detect
rate. Atrioventricular delay
determined by a proprietary
algorithm. Right ventricular
and left ventricular pacing
were simultaneous
Comparator: ICD (CRT off).
Dual-chamber non-tracking
pacing mode (DDI) with
40 bpm back-up biventricular
pacing
Other interventions used: not
reported but inclusion criteria
state ≥ 2 weeks of treatment
with maximal tolerated doses
of ACE inhibitors or
beta-blockers unless adverse
effects or contraindicated
Indication for treatment: Mild
to moderate HF at high risk of
sudden death and eligible for
an ICD but not a candidate
for CRT based on guidelines
at the time of the study
No. of randomised
participants: 72; CRT-D:
36, ICD: 36
Inclusion criteria: HF:
unequivocal symptoms of
dyspnoea or fatigue on
climbing two or fewer flights
of stairs or a 6-minute walk
distance ≤ 450 m; LVEF
≤ 35% within 6 months of
implant; QRS interval
> 120milliseconds; ≥ 2 weeks
of treatment with maximal
tolerated doses of ACE
inhibitors or beta-blockers
unless adverse effects
or contraindicated;
age 18–80 years
Exclusion criteria: pacing for
symptomatic bradycardia;
not in sinus rhythm; MI or
unstable angina within
6 weeks; CABG surgery
within 4 weeks; Canadian
Cardiovascular Society
class 3 or worse angina;
typical RBBB morphology
in lead V1; pregnant
Primary outcome: LVESV
change from baseline
to 6 months
Secondary outcomes: change
in QoL, stroke volume, cardiac
volume, mitral jet area, cardiac
output, LVEF, serum B-type
natriuretic peptide, average
heart rate, SDANN. Also
reports 6-minute walk
distance, death
and hospitalisations
Method of assessing
outcomes: at baseline and
6 months. LVESV measured
by quantitative resting
radionuclide angiogram
(multigated acquisition scan),
6-minute walk test, 24-hour
Holter monitoring for heart
rate and SDANN. QoL
measured with the MLWHFQ,
SF-36, DASI and one-item
Global Visual Analogue Scale
Length of follow-up: 6 months
Recruitment: not reported
bpm, beats per minute; LVESV, left ventricular end-systolic volume; RBBB, right bundle branch block; SDANN, standard
deviation of adjacent sinus beat intervals.
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Participant characteristics
Characteristic CRT on (CRT-D) (n= 36) CRT off (ICD) (n= 36) p-value
Age (years), mean (SD) 66.3 (8.6) 66.1 (8.8) NS
Sex, % male 77.8 80.6 NS
Ethnicity NR NR
NYHA classification NR NR
Left ventricular measurements by multigated acquisition scan, mean (SD)
LVESV (ml) 242 (96) 251 (147) NS
LVEDV (ml) 314 (108) 335 (156) NS
LVEF (%) 24.2 (7.5) 26.8 (8.4) NS
Left ventricular measurements by ECG, mean (SD)
LVESV (ml) 217 (72) 213 (101) NS
LVEDV (ml) 270 (74) 272 (106) NS
LVEF (%) 21.2 (7.9) 24.0 (8.3) NS
Heart rate (bpm) 68.1 (12.3) 63.6 (11.0) NS
Blood pressure (mmHg), mean (SD)
Systolic 113 (19.6) 114.1 (20.8) NS
Diastolic 65.7 (10.0) 65.2 (10.7) NS
Current pharmacological therapy NR NR
Cardiac history, %
Coronary artery disease 77.8 80.6 NS
Previous MI 66.7 75.0 NS
CABG surgery 38.9 30.6 NS
Coronary angioplasty 8.3 22.2 NS
Dilated cardiomyopathy 16.7 8.33 NS
Valvular disease 16.7 8.33 NS
Mitral regurgitation grade 2/3/4 9/11/1 7/5/1 0.09
Atrial fibrillation 16.7 5.6 NS
Primary arrhythmia, %
Cardiac arrest 25.0 16.7 NS
Sustained VT 58.3 55.5 NS
Prophylactic ICD 16.7 27.8 NS
Hypertension, % 11.1 22.2 NS
Diabetes, % 30.6 25.0 NS
Serum creatinine (µmol/l), mean (SD) 121 (42) 114 (36) NS
Assessment of functional status
6-minute walk distance (m), mean (SD) 314 (114) 338 (110) NS
DASI, mean (SD) 11.3 (9.8) 12.4 (9.3) NS
Global Visual Analogue Scale, mean (SD) 6.4 (2.0) 6.5 (1.9) NS
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Characteristic CRT on (CRT-D) (n= 36) CRT off (ICD) (n= 36) p-value
MLWHFQ, mean (SD)
Complete score 42.3 (20.8) 42.8 (24.9) NS
Physical dimension 20.1 (9.2) 17.7 (9.8) NS
Emotional dimension 8.5 (6.4) 9.1 (7.6) NS
SF-36 health survey subscales, mean (SD)
Physical functioning 46.7 (24.9) 44.5 (26.5) NS
Role physical 14.0 (26.9) 12.4 (23.9) NS
Bodily pain 93.0 (11.4) 95.3 (11.0) NS
General health 59.4 (12.7) 59.0 (9.6) NS
Vitality 43.9 (19.4) 42.8 (25.2) NS
Social functioning 59.4 (27.1) 61.7 (29.0) NS
Role emotional 46.7 (46.0) 54.0 (47.5) NS
Mental health 65.3 (20.0) 69.0 (22.9) NS
SF-36 survey component scores, mean (SD)
PCS 39.5 (5.7) 39.1 (5.7) NS
MCS 43.7 (11.6) 46.0 (13.7) NS
bpm, beats per minute; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume;
NR, not reported; NS, not significant.
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Results
Outcomea CRT on (CRT-D) (n= 36) CRT off (ICD) (n= 36) p-value
Deaths in 6 months’ follow-up from cardiac
causes, n/N
1/36 1/36
Left ventricular measurements by multigated acquisition scan, change from baseline to 6 monthsb
LVESV (ml) (primary outcome) –7 (52) –30 (47) NS
LVEDV (ml) –7 (61) –34 (65) NS
LVEF (%) 1.7 (5.4) 0.6 (6.8) NS
Left ventricular measurements by ECG, change from baseline to 6 monthsb
LVESV (ml) –21 (45) –5 (22) NS
LVEDV (ml) –16 (44) –13 (47) NS
LVEF (%) 3.9 (8.9) 1.9 (6.8) NS
Cardiac output measured by multigated acquisition scan (l/minute)b
Baseline 4.5 (1.6) 5.1 (1.9)
6 months 4.8 (1.8) 4.7 (1.8)
Difference 0.38 (1.5) –0.56 (1.9) 0.033
Patients hospitalised (%)c 30.6 36.1
Jugular venous pressure (cm) above the sternal angleb
Baseline 2.1 (2.3) 2.1 (2.1) NS
6 months 2.9 (2.27) 4.3 (2.5) NR
B-type natriuretic peptide level (ng/l)b
Baseline 198.7 (167.2) 200.9 (208.7)
6 months 119.4 (131.7) 107.6 (99.4) NS
SDANN (milliseconds)
Baseline 83.2 (31.1) 93.7 (29.4) NS
6 months 83.0 (30.6) 109.8 (41.5) NR
Interventricular dyssynchrony (milliseconds)
Baseline 40 (48) 47 (36)
6 months 13 (40) 48 (34)
Horizontal extent of the mitral regurgitation jet area (cm2)b
Baseline 4.79 (3.06) 3.58 (3.66)
6 months 3.90 (3.65) 3.00 (2.74)
QRS duration (milliseconds)b
Baseline 169.1 (22.8) 159.5 (17.4)
6 months 163.3 (24.3) 163.8 (22.3)
Ventricular tachyarrhythmia event requiring
therapy from the device, n (%)
7 (19.4) 6 (16.7) NS
No. of treated VT episodes per patient 5.9 (6.1) 3.4 (2.7) NS
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Outcomea CRT on (CRT-D) (n= 36) CRT off (ICD) (n= 36) p-value
Assessment of functional status, change from baseline to 6 monthsb
6-minute walk distance (m) 53.3 (113.3) 27.3 (71.1) NS
DASI 4.63 (9.20) 1.08 (7.02) NS
Global Visual Analogue Scale –0.07 (2.22) –0.17 (1.64) NS
MLWHFQ
Total score –7.8 (20.1) –0.2 (13.5) NS
Physical dimension –5.0 (12.4) –0.6 (7.9) NS
Emotional dimension –1.3 (5.0) 0.3 (3.4) NS
SF 36, change from baseline to 6 monthsb
Physical functioning 11.2 (24.2) 6.3 (21.2) NS
Role physical 19.6 (43.2) 21.6 (38.1) NS
Bodily pain –3.3 (16.6) –2.3 (13.1) NS
General health –5.8 (14.9) –5.8 (13.6) 0.02
PCS 1.4 (6.4) 1.3 (4.8) NS
Vitality 4.7 (22.7) 2.6 (15.7) NS
Social functioning 12.5 (23.3) 5.4 (32.6) NS
Role emotional 29.5 (48.4) 3.3 (48.2) NS
Mental health 4.5 (14.5) 0.1 (21.8) NS
MCS 5.1 (10.1) 0.5 (12.4) NS
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; NR, not reported;
NS, not significant; SDANN, standard deviation of adjacent sinus beat intervals.
a It is assumed that values are mean (SD) as this is not specified in paper.
b Within-group p-values are reported but not data extracted.
c Authors state that there was no difference in the number of patients hospitalised (statistical significance not reported),
the number of hospitalisations or the reasons for hospitalisations between the two groups (data for the last two
outcomes not reported).
Comments
l Authors state that systolic and diastolic blood pressure and heart rate were similar at baseline in the two groups and
did not change significantly in either group at 6 months (data not presented).
l Authors state that there was no difference in the number of patients receiving a shock from the device or in the
number of shocks per patient (data not presented).
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Adverse effects of treatment
Adverse effect CRT on (CRT-D) (n= 36) CRT off (ICD) (n= 36) p-value
Not reported
Comments
Methodological comments
l Allocation to treatment groups: all patients received a device. Left ventricular pacing was turned off in the
immediate postoperative period. Patients were randomly assigned following completion of baseline
procedures 14–28 days post implant.
l Blinding: patients were blinded to treatment allocation. All post-implant study evaluations were performed
by personnel blinded to treatment allocation.
l Comparability of treatment groups: no significant differences, although there were more patients with
significant mitral regurgitation in the CRT on group (p= 0.09).
l Method of data analysis: primary end point analysed according to ITT principle. Data were analysed using
the unpaired t-test, Wilcoxon signed-rank test and repeated measures analysis of variance as appropriate.
The difference in change from baseline between groups and within groups was analysed using the
Wilcoxon signed-rank test. For some outcomes data are compared within groups only and not between
groups; these p-values have not been extracted.
l Sample size/power calculation: allowing for 10% dropout or crossover rate, it was estimated that
70 patients had to be included to show a clinically meaningful 12% decrease in end-systolic volume with
80% power and a two-tailed alpha of 0.05.
l Attrition/dropout: in total, 75/90 (83.3%) attempted implants were successful. Of these, two were not
randomised because of device-related technical difficulties (double sensing) and one was not randomised
because of worsening HF. Of the 72 randomised, five missed the 6-month visit (one from each group died
from cardiac causes; two crossed over, one from the CRT off group to the CRT on group because of
worsening CHF and one from the CRT on group to the CRT off group because of late left ventricular
capture failure; and one in the CRT on group was too ill). Therefore, 67/72 (93%) completed the study
(CRT on: 33; CRT-off: 34).
General comments
l Generalisability: only those with successful implantation were randomised. This is a study of prophylactic
CRT for patients with mild to moderate HF; patients did not meet guidelines for CRT at the time of the
study but may meet indications for CRT by current standards.
l Outcome measures: radionuclide angiography was selected for the measurement of the primary end point
because of the assumption that it is more accurate than ECG in measuring left ventricular outcomes. NYHA
class and adverse events were not reported.
l Intercentre variability: not reported.
l Conflict of interests: two authors have received honoraria and research funding from Guidant Corporation.
The study was supported by an unrestricted educational grant from Guidant Corporation.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Details not reported
Allocation concealment Unclear Details not reported
Performance bias
Blinding of participants and personnel Low States that patients were blinded, although not clear how this
was maintained
Detection bias
Blinding of outcome assessment Low States that all post-implant study evaluations were performed by
personnel blinded to treatment allocation
Attrition bias
Incomplete outcome data addressed Low Attrition and crossovers reported. ITT analysis performed
Reporting bias
Selective reporting Low No protocol available but outcomes listed in the methods were
reported on
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Resynchronization-Defibrillation for Ambulatory Heart Failure
Trial (RAFT)
Reference and design
Intervention
and comparator Participants Outcome measures
Tang et al. 2009141 and
2010140
Study design: RCT
Countries: Canada,
Europe, Turkey
and Australia
No. of centres: 34
(Canada 24, Europe and
Turkey 8, Australia 2)
Funding: Canadian
Institutes of Health
Research. Medtronic of
Canada (industry partner)
provided funding and
CRT components
Intervention: ICD-CRT
(commercially available
transvenous leads and
devices, Medtronic).
Standard implantation
technique. Programming
standardised to maximise
ventricular pacing
Comparator: ICD.
Programming standardised
to minimise ventricular
pacing
Other interventions used:
OPT for both groups: a
beta-blocker, an ACE
inhibitor or ARB,
spironolactone, aspirin and
statins when appropriate;
uniform arrhythmia
detection and therapy
Indication for treatment:
initially mild to moderate
(NYHA class II or III) HF
despite OPT, later restricted
to NYHA class II HF with
LVSD and a wide QRS
complex
No. of randomised
participants: 1798; ICD-CRT:
894, ICD: 904
Inclusion criteria: NYHA class
II or III (revised in February
2006 to class II only)
symptoms despite receiving
OPT, LVEF ≤ 30% from
ischaemic or non-ischaemic
causes, QRS interval
≥ 120milliseconds or a
paced QRS duration of
≥ 200milliseconds, sinus
rhythm or permanent atrial
fibrillation or flutter with a
controlled ventricular rate
(≤ 60 bpm at rest and
≥ 90 bpm during a 6-minute
walk test) or planned
atrioventricular junction
ablation after device
implantation and planned
ICD implantation for
indicated primary or
secondary prevention of
SCD. Optimal HF
pharmacological therapy141
Exclusion criteria: major
coexisting illness; recent
cardiovascular event
protocol;141 life expectancy
of < 1 year from non-cardiac
cause; expected cardiac
transplantation within 1 year
(status 1); received
intravenous inotropic agent
in the last 4 days; acute
coronary syndrome including
MI can be included if the
patient has had a previous
MI with left ventricular
dysfunction (LVEF ≤ 30%);
in-hospital patients who
have acute cardiac or
non-cardiac illness that
requires intensive care;
uncorrected or uncorrectable
primary valvular disease;
restrictive, hypertrophic or
Primary outcome: composite
outcome of death from any
cause or HF leading to
hospitalisation
Secondary outcomes: death
from any cause at any time
during the study, death from
any cardiovascular cause,
and hospitalisation for HF
among all patients (those
with NYHA class II and
class III HF at baseline)
Method of assessing
outcomes: hospitalisation for
HF was defined as admission
to a health-care facility
lasting > 24 hours with
symptoms of CHF and
subsequent treatment for HF
(admissions for other
medical problems that then
developed into HF in the
hospital were not classified
as hospitalisation for HF).
An adjudication committee
reviewed available
documents and determined
the cause of death and
whether or not
hospitalisations that lasted
> 24 hours were due to the
exacerbation of HF. All
adverse events occurring
within 30 days after ICD
implantation were
adjudicated as related to or
unrelated to the ICD
Follow-up visits 1 month
after device implantation
and then 6-monthly until
≥ 18 months until the end of
the trial, with clinical
assessment and device
interrogation at each visit
Length of follow-up:
minimum of 18 months.
Mean 40 (SD 20) months;
mean follow-up for surviving
patients 44 (SD 18) months
Recruitment: January
2003–February 2009
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Reference and design
Intervention
and comparator Participants Outcome measures
reversible form of
cardiomyopathy; severe
primary pulmonary disease
such as cor pulmonale;
tricuspid prosthetic valve;
patients with an existing ICD
(patients with an existing
pacemaker can be included
if they satisfy all other
inclusion/exclusion criteria);
coronary revascularisation
(CABG or percutaneous
coronary intervention)
< 1 month if previous LVEF
> 30% (more recent
revascularisations can be
included if previous LVEF
≤ 30%); included in other
clinical trial that will affect
the objectives of this study;
history of non-compliance
with medical therapy; unable
or unwilling to provide
informed consent
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Participant characteristics
Characteristics ICD–CRT (n= 894) ICD (n= 904) p-value
Age (years), mean (SD) 66.1 (SD 9.3) 66.2 (SD 9.4) NR
Sex, male, n (%) 758 (84.8) 732 (81.0) NR
Ethnicity NR NR
NYHA class, n (%)
II 708 (79.2) 730 (80.8) NR
III 186 (20.8) 174 (19.2) NR
LVEF (%), mean (SD) 22.6 (5.4) 22.6 (5.1) NR
Atrial rhythm, n (%)
Permanent atrial fibrillation or flutter 114 (12.8) 115 (12.7) NR
Sinus or atrial paced 780 (87.2) 789 (87.3) NR
QRS duration (ms)
Intrinsic
No. of patients 826 837
Mean (SD) 157 (23.6) 158.3 (24.0) NR
Paced
No. of patients 68 67
Mean (SD) 206.5 (24.0) 210.3 (18.3) NR
QRS morphological type, n (%)
RBBB 68 (7.6) 93 (10.3) NR
LBBB 652 (72.9) 643 (71.1) NR
Non-specific intraventricular conduction delay 106 (11.9) 101 (11.2) NR
Ventricular paced 68 (7.6) 67 (7.4) NR
Peripheral vascular disease, n (%) 88 (9.8) 90 (10.0) NR
Underlying heart disease, n (%)
Ischaemic 614 (68.7) 587 (64.9) NR
Non-ischaemic 280 (31.3) 317 (35.1) NR
Hospitalisation for HF in last 6 months, n (%) 238 (26.6) 223 (24.7) NR
Previous treatment, n (%)
Percutaneous coronary intervention 220 (24.6) 208 (23.0) NR
CABG surgery 293 (32.8) 313 (34.6) NR
Comorbidities, n (%)
Diabetes mellitus 293 (32.8) 313 (34.6) NR
Hypertension 402 (45.0) 397 (43.9) NR
Current cigarette smoking, n (%) 121 (13.5) 127 (14.0) NR
Medication, n (%)
Beta-blocker 808 (90.4) 805 (89.0) NR
ACE inhibitor or ARB 859 (96.1) 878 (97.1) NR
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Characteristics ICD–CRT (n= 894) ICD (n= 904) p-value
Spironolactone 372 (41.6) 378 (41.8) NR
Digoxin 301 (33.7) 319 (35.3) NR
Acetylsalicylic acid (aspirin) 584 (65.3) 622 (68.8) NR
Warfarin 310 (34.7) 298 (33.0) NR
Clopidogrel 134 (15.0) 145 (16.0) NR
Statin 607 (67.9) 618 (68.4) NR
Diuretic 757 (84.7) 756 (83.6) NR
Calcium channel blocker 101 (11.3) 83 (9.2) NR
Amiodarone 140 (15.7) 124 (13.7) NR
Other AAD 12 (1.3) 8 (0.9) NR
6-minute walk test
No. of patients 789 765
Distance (m), mean (SD) 351.3 (106.7) 354.9 (110.1) NR
Estimated glomerular filtration rate
No. of patients 885 897
%, mean (SD) 59.5 (19.8) 60.8 (21.9) NR
Rate (ml/minute/1.73m2), n (%)
< 30 57 (6.4) 63 (7.0) NR
30–59 398 (45.0) 383 (42.7) NR
≥ 60 430 (48.6) 451 (50.3) NR
NR, not reported; RBBB, right bundle branch block.
Comment
l Enrolment breakdown: Canada n= 1617, Europe and Turkey n= 137, Australia n= 44.
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Results
Outcome ICD-CRT (n= 894) ICD (n= 904) HR (95% CI), p-value
All patients
Primary outcome: death or hospitalisation for
HF, n/N (%)
297/894 (33.2) 364/904 (40.3) 0.75 (0.64 to 0.87), < 0.001
Secondary outcomes
Death from any cause, n/N (%) 186/894 (20.8) 236/904 (26.1) 0.75 (0.62 to 0.91), 0.003
Death from cardiovascular cause, n/N (%) 130/894 (14.5) 162/904 (17.9) 0.76 (0.60 to 0.96), 0.02
Hospitalisation for HF, n/N (%) 174/894 (19.5) 236/904 (26.1) 0.68 (0.56 to 0.83), < 0.001
Hospitalisation more than once during
follow-up (mostly cardiovascular), n
509 509 NR
Hospitalisation: cardiac cause, n 423 404 HR 1.04, 0.56
Probability of event-free survival at 5 years, % 57.6 48.7 NR
5-year actuarial rate of death (%) 28.6 34.6 NR
ICD-CRT (n= 708) ICD (n= 730)
Patients in NYHA class II
Primary outcome: death or
hospitalisation for HF, n/N (%)
193/708 (27.3) 253/730 (21.1) 0.73 (0.61 to 0.88), 0.001
Secondary outcomes, n/N (%)
Death from any cause 110/708 (15.5) 154/730 (21.1) 0.71 (0.56 to 0.91), 0.006
Death from cardiovascular cause 74/708 (10.5) 100/730 (13.7) 0.73 (0.54 to 0.99), 0.04
Hospitalisation for HF 115/708 (16.2) 159/730 (21.8) 0.70 (0.55 to 0.89), 0.003
ICD-CRT (n= 186) ICD (n= 174)
Patients in NYHA class III
Primary outcome: death or hospitalisation for
HF, n/N (%)
104/186 (55.9) 111/174 (63.8) 0.76 (0.58 to 0.99), 0.04
Secondary outcomes, n/N (%)
Death from any cause 76/186 (40.9) 82/174 (47.1) 0.79 (0.58 to 1.08), 0.14
Death from cardiovascular cause 56/186 (30.1) 62/174 (35.6) 0.77 (0.54 to 1.10), 0.15
Hospitalisation for HF 59/186 (31.7) 77/174 (44.3) 0.63 (0.45 to 0.88), 0.006
Comments
l 12 patients underwent cardiac transplantation before reaching the primary outcome (ICD–CRT n= 7; ICD n= 5).
l 14 patients would be needed to be treated for 5 years with ICD-CRT to prevent one death.
l Kaplan–Meier curves were reported for the composite primary outcome and death from any cause for all patients and
for NYHA class II and class III subgroups (not data extracted).
l For NYHA classes II and III, the two interventions were associated with a similar reduction in the composite primary
outcome (p= 0.91 for interaction), death from any cause and hospitalisation for HF.
l Subgroup analysis on 11 prespecified subgroups showed a significant interaction between treatment and QRS duration
(p= 0.003). ICD-CRT was more effective in those with an intrinsic QRS duration of ≥ 150milliseconds (HR 0.59, 95% CI
0.48 to 0.73) than in those with an intrinsic QRS duration of < 150milliseconds (HR 0.99, 95% CI 0.77 to 1.27,
p= 0.002 for interaction) or those with a paced QRS duration of ≥ 200milliseconds (HR 1.07, 95% CI 0.63 to 1.84,
p= 0.03 for interaction).
l There was a weak interaction between treatment and QRS morphological type (p= 0.046) such that those with LBBB
appeared to have a greater benefit than those with non-specific intraventricular conduction delay (p= 0.04 for interaction).
l HRs for prespecified subgroups were displayed in a figure only and were not data extracted (age: < 65 vs. ≥ 65 years,
p= 0.75; sex: male vs. female, p= 0.09; NYHA class: II vs. III, p= 0.91; underlying heart disease: ischaemic vs.
non-ischaemic, p= 0.90; QRS duration: intrinsic QRS < 150milliseconds vs. intrinsic QRS ≥ 150milliseconds vs. paced
QRS ≥ 200milliseconds, p= 0.003; LVEF: < 20% vs. ≥ 20%, p= 0.05; QRS morphological features: RBBB vs. LBBB vs.
non-specific intraventricular conduction delay vs. paced, p= 0.046; atrial rhythm: permanent atrial fibrillations or flutter
vs. sinus or atrial paced, p= 0.14; diabetes: yes vs. no, p= 0.22; hypertension: yes vs. no, p= 0.84; estimated
glomerular filtration rate (ml/minute/1.73m2): < 60 vs. ≥ 60, p= 0.70).
l Authors state that patients with ischaemic or non-ischaemic causes of HF had a similar benefit from ICD-CRT.
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Adverse effects of treatment
Adverse effect ICD-CRT (n= 888) ICD (n= 899) HR (95% CI), p-value
Death from worsening HF within 24 hours of device
implantation, n
1
Device-related hospitalisation, n (%) 179 (20) 110 (12.2) 1.68 (1.32 to 2.13),
< 0.001
Number of device- or implantation-related
complications during the first 30 days after device
implantation, n/Na
118/888 61/899 – (–), < 0.001
Adverse effects at 30 days after device implantation, n/Na 124/888 58/899 – (–), < 0.001
Haemothorax or pneumothorax, n (%) 11 (1.2) 8 (0.9) 0.47 (–), –
Device pocket haematoma requiring intervention, n (%) 14 (1.6) 11 (1.2) 0.53 (–), –
Device pocket infection requiring intervention, n (%) 21 (2.4) 16 (1.8) 0.39 (–), –
Lead dislodgement requiring intervention, n (%) 61 (6.9) 20 (2.2) – (–), < 0.0001
Device pocket problems requiring revision, n (%) 4 (0.5) 1 (0.1) 0.22 (–), –
Coronary sinus dissection, n (%) 11 (1.2) 0 0.0004 (–), –
Tamponade, n (%) 2 (0.23) 2 (0.22) 1 (–), –
a It is unclear why the numbers of patients in these categories differ for both groups.
Comment
l A left ventricular lead was successfully implanted in 841/888 patients (94.7%) in the CRT-ICD group (during an initial
attempt n= 802; in a subsequent attempt n= 39). Of these, 53 patients (6.0%) did not receive CRT (left ventricular
lead failure n= 47; lead malfunction n= 6).
l A total of 12 patients underwent cardiac transplantation: ICD-CRT group n= 7, ICD group n= 5.
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Comments
Methodological comments
l Allocation to treatment groups: random assignment in a 1 : 1 ratio and stratification according to clinical
centre, atrial rhythm (atrial fibrillation or flutter or sinus atrial pacing) and planned implantation of a
single- or dual-chamber ICD.
l Blinding: described as double blind. Patients and general health-care providers (including the team
responsible for HF management and reporting of clinical events) were blinded, as was the adjudication
committee responsible for reviewing available documents and determining cause of death. Arrhythmia
teams (physicians and caregivers) performing device implantation and device management were not blinded.
l Comparability of treatment groups: authors state that baseline clinical characteristic are similar between the
two groups.
l Method of data analysis: all analyses were conducted according to the ITT principle. Survival analysis
techniques were used to compare the two groups with respect to the primary outcome and principal
secondary outcomes. Survival in each of the two groups was summarised with the use of Kaplan–Meier
product limit estimates. Survival curves were compared using non-parametric log-rank tests. HRs and
associated 95% CIs were calculated with the use of the Cox proportional hazards model. Primary and
secondary outcomes for patients with NYHA class II or III HF were analysed separately as NYHA class III
patients were enrolled only during the first part of the study, before the protocol was revised in February
2006 to include only NYHA class II patients. Cox proportional hazard models were used to test for
interactions in the various planned subgroups. The protocol states that planned subgroup analyses would
include AF compared with no AF and NYHA class II compared with class III (p. 16).141 Chi-squared tests were
used to compare the Kaplan–Meier (actuarial) rate of event-free survival at 5 years. The HR was used to
calculate the number needed to treat to prevent one death or hospitalisation for HF in one patient. Underlying
assumptions for these statistical procedures were assessed (in particular the proportional hazards assumption).
Analyses were conducted with the use of SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA).
l Sample size/power calculation: the study had a statistical power of 85% to detect a 25% relative reduction
in the primary outcome, given a two-sided alpha value of 0.05 and taking into consideration the expected
rate of loss to follow-up and crossover.140 To detect a 20% RRR in the primary end point for CRT-ICD,
given an alpha value of 0.05 (two-sided) and 90% power, a sample size of 1500 patients will be needed
(750 per group). This calculation assumes an exponential survival with all patients followed to the primary
end point or termination of the study, and allows for a 5% inability to implant the left ventricular lead
(based on the most recent data indicating a 96% implant success rate in a worldwide registry) and a 3%
crossover rate from the control group (ICD) to the experimental group (CRT-ICD).141 This sample size will
also be able to detect a 25% RRR in total mortality with the assumption of 11% annual mortality in the
control group, given an alpha value of 0.05 (two-sided) and 80% power.141
l Attrition/dropout: ICD-CRT group: 888/894 (99.3%) received ICD-CRT; leads were successfully implanted in
841/888 (94.7%); 53/888 (60%) did not receive CRT (47 leads failed, six lead malfunctions); of those who
did not undergo implantation, four died and two declined to participate (the patient or physician). ICD
group: 899/904 (99.4%) received ICD; of those who did not undergo implantation, four declined to
participate (patient or physician) and in one there was a lack of venous access. Crossover: ICD to ICD-CRT:
36 (4%) before the occurrence of a primary outcome and 60 (6.6%) after hospitalisation for HF. ICD-CRT
group: eight withdrew, two were lost to follow-up; ICD group: four withdrew, one was lost to follow-up.
l Other: (1) To increase recruitment to 34 patients per month, Medtronic sponsored the expansion to more
centres in Europe and Turkey from the original 21 centres (Canada 21, Germany two, Australia two,
New Zealand one; see protocol, p. 16).141 However, no enrolment for the centre in New Zealand is
reported. (2) Two planned interim analyses were conducted for the data and safety monitoring board
(first planned with 33% enrolled and followed for 2 years; second planned with 66% enrolled and
followed for 2 years141) and an O’Brien–Fleming alpha spending function was used to adjust the sample
size for these interim analyses.
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General comments
l Generalisability: mild to moderate HF patients with LVSD and a wide QRS complex.
l Outcome measures: appear appropriate.
l Intercentre variability: not reported.
l Conflict of interests: medtronic did not participate in the conduct of the trial, the reporting of the data or
the decision to submit the manuscript for publication.
Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Unclear Random assignment in a 1 : 1 ratio with stratification
according to centre. No details on sequence generation
Allocation concealment Unclear No details reported
Performance bias
Blinding of participants and personnel Low Double blind. Patients and general health-care providers were
blinded, but not device caregivers
Detection bias
Blinding of outcome assessment Low Members of the adjudication committee responsible for
reviewing available documents and determining cause of
death were blinded
Attrition bias
Incomplete outcome data addressed Low ITT analysis; CONSORT (Consolidated Standards of Reporting
Trials) flow chart (including numbers analysed) provided in
an appendix
Reporting bias
Selective reporting High The protocol141 described ‘other outcomes’ (e.g. QoL), but no
data for these were reported. However, this is a recent study
and it is possible that further data will be published in
the future
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Cardiac Resynchronization Therapy in Patients with
Heart Failure and Narrow QRS (RethinQ) trial
Reference and design
Intervention
and comparator Participants Outcome measures
Beshai et al. 2007,142
Beshai and Grimm 2007143
Study design: RCT
Country: USA
No. of centres: 34
Funding: St Jude Medical
Intervention: CRT-D
on+OPT (CRT device: Epic
HF or Atlas+ HF, St Jude
Medical) with a standard
right atrial, right ventricular
defibrillator and left
ventricular leads. Detection
and treatment of
tachyarrhythmias turned on143
Comparator: ICD+OPT
(device as above). Detection
and treatment of
tachyarrhythmias turned on143
Other interventions used:
OPT for both groups
defined as a beta-blocker
for a minimum of 90 days
and an ACE inhibitor or
ARB for a minimum of
30 days, unless
contraindicated or not
tolerated (for stable medical
regimen no more than a
100% increase or a 50%
decrease in dose).
Also included: aldactone
inhibitors, diuretics and
cardiac glycosides
(i.e. digoxin) as indicated.
If intolerant to ACE inhibitors
or ARBs or if contraindicated,
alternate therapy as
appropriate, including
afterload reduction agents
(e.g. hydralazine) combined
with nitrates143
Indication for treatment:
standard indication for an
ICD (ischaemic or
non-ischaemic
cardiomyopathy and LVEF
≤ 35%), a narrow QRS
interval and intraventricular
mechanical dyssynchrony
No. of randomised
participants: 172; CRT-D
on: 87, CRT-D off: 85
Inclusion criteria: NYHA
class III caused by either
ischaemic or non-ischaemic
cardiomyopathy, LVEF
≤ 35%, QRS interval
< 130milliseconds, approved
indication for an ICD,
stable conventional medical
regimen, evidence of
mechanical dyssynchrony
on ECG, able to complete
exercise stress testing and a
6-minute walk test (limited
only by cardiac fitness)143
Exclusion criteria: standard
indication for cardiac pacing
or previous treatment with
CRT, standard bradycardic
indication for pacing,
continuous atrial fibrillation
(lasting> 1 month) < 1 year
before enrolment,
cardioversion for atrial
fibrillation in the past
month, ability to walk
> 450m during the 6-minute
walk test, NYHA class I,
II or IV, symptomatic COPD,
classification of status 1 for
cardiac transplantation or
consideration for
transplantation in the next
6 months, recent MI,
unstable angina, cardiac
revascularisation (PTCA or
CABG) within 40 days of
enrolment, recent stroke or
transient ischaemic attack
within 3 months of enrolment,
severe musculoskeletal
disorder/s, pregnant or a
planned pregnancy in the next
6 months, life expectancy of
≤ 6 months, age < 18 years143
Primary outcomes:
proportion of patients with
an increase of ≥ 1.0ml/kg
body weight/minute in
peak oxygen consumption
during cardiopulmonary
exercise testing142 and
survival from CRT-D
system-related
complications143
Secondary outcomes:
QoL and NYHA class
Method of assessing
outcomes: baseline
evaluation 14 days after
successful implantation,
including cardiopulmonary
exercise testing (maximum
exercise tolerance on
treadmill/bicycle
ergonometry measuring
heart rate, minute
ventilation, oxygen uptake
and carbon dioxide
output), NYHA class
assessment, 6-minute walk
distance, QoL evaluation
(MLWHFQ, score from 0 to
105, higher score indicates
poorer QoL), assessment
of medication stability,
ECG for optimisation of
atrioventricular and
interventricular delay and
12-lead ECG. Evaluation
repeated at 6 months
Mechanical dyssynchrony
definition: an opposing
wall delay of
≥ 65milliseconds on tissue
Doppler imaging or a
mechanical dyssynchrony in
the septal to posterior wall
of ≥ 130milliseconds on
M-mode ECG
Length of follow-up:
6 months
Recruitment: August
2005–January 2007
PTCA, percutaneous transluminal coronary angiography
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Participant characteristics
Characteristic CRT-D on+OPT (n= 87) ICD+OPT (n= 85) p-value
Age (years), mean (SD) 60 (12) 58 (14)
Sex, male, n (%) 62 (71) 49 (58)
Ethnicity NR NR
NYHA class III, n (%) 87 (100) 84 (99)
LVEF (%), mean (SD) 25 (5) 26 (6)
End-diastolic diameter (mm), mean (SD) 66 (9) (n= 85) 65 (9) (n= 84)
End-systolic diameter (mm), mean (SD) 56 (9) (n= 85) 53 (9) (n= 84)
End-diastolic volume (ml), mean (SD) 216 (78) 210 (75)
End-systolic volume (ml), mean (SD) 163 (65) 156 (64)
QRS interval (milliseconds), mean (SD) 107 (12) 106 (13)
< 120ms, n (%) 66 (76) 60 (71)
≥ 120ms, n (%) 21 (24) 25 (29)
Underlying heart disease, n (%)
Ischaemic 47 (54) 43 (51)
Non-ischaemic 40 (46) 42 (49)
Indication for ICD, n (%)
Primary prevention 74 (85) 73 (86)
Secondary prevention 13 (15) 12 (14)
Pre-ejection period (milliseconds), mean (SD) 112 (21) (n= 86) 112 (22) (n= 86)
Interventricular mechanical delay (milliseconds), mean (SD) 9 (28) (n= 85) 8 (31) (n= 82)
Intraventricular mechanical dyssynchrony (milliseconds), mean (SD)a
Septal to posterior wall 106 (45) (n= 24) 112 (51) (n= 33)
Septal to lateral wall 81 (39) (n= 85) 86 (38) (n= 85)
Anteroseptal to posterior wall 78 (34) (n= 83) 81 (45) (n= 81)
Mitral regurgitation, n (%)
None or mild 59 (68) 55 (66)
Moderate 25 (29) 23 (28)
Severe 3 (3) 5 (6)
Medication at baseline, n (%)
ACE inhibitor or substituteb 77 (89) 77 (91)
Beta-blocker 84 (97) 79 (93)
Diuretic 73 (84) 74 (87)
AAD 7 (8) 10 (12)
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Characteristic CRT-D on+OPT (n= 87) ICD+OPT (n= 85) p-value
Peak oxygen consumption (ml/kg/minute), mean (SD) 12.1 (3.3) 12.4 (4.5)
Exercise duration (minute), mean (SD) 8.9 (3.0) 9.0 (3.8)
QoL (MLWHFQ) score, mean (SD) 54 (24) 57 (26)
6-minute walk distance (m), mean (SD) 301 (94) 297 (100)
NR, not reported.
a Mechanical delays in the septal to lateral and anteroseptal to posterior walls were measured on tissue Doppler imaging;
mechanical delay in the septal to posterior wall was measured on M-mode ECG.
b Includes ARBs and hydralazine.
Comments
l Authors state that none of the differences between the groups was significant, but no p-values are reported.
l In total, 97% of the left ventricular leads were implanted in a lateral position.
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Results
Outcome
CRT-D on+OPT
(n= 87)
ICD+OPT
(n= 85) p-value
Mortality before 6 months, n/N (%) 5/87 (5.7) 1/85 (1.2)
Unknown cardiac causes 2/87 (2.3)
Pump failure 2/87 (2.3) 1/85 (1.2)
Unknown cause 1/87 (1.2)
Mortality at 7 months, pump failure, n/N (%) 1/85 (1.2)a
Cumulative overall survival at 6 months, % (95% CI) 94.2 (86.7 to 97.6) 98.8 (91.9 to 99.8) 0.11
Cumulative freedom from death caused by worsening HF,
% (95% CI)
97.7 (91.1 to 99.4) 98.9 (91.9 to 99.8) 0.58
Change in peak VO2 (n= 76) (n= 80) 0.63
Median change (ml/kg/minute) (95% CI) 0.4 (–0.6 to 1.2) 0.5 (–0.3 to 1.1)
Primary outcome: increase of ≥ 1.0 ml/kg/minute, n/N (%) 35/76 (46) 33/80 (41)
Change in QoL (MLWHFQ) score (n= 76) (n= 80)
Median change (95% CI) –8 (–10 to –1) –7 (–11 to 3) 0.91
Change in NYHA class, n/N (%) (n= 76) (n= 80) 0.006
Improved by one or more class 41/76 (54) 23/80 (29)
No change 31/76 (41) 51/80 (64)
Worsened 4/76 (5) 6/80 (8)
Change in 6-minute walk distance (m) (n= 75) (n= 79)
Median change (95% CI) 26 (0 to 46) 6 (–17 to 30) 0.23
Change in ejection fraction (%) (n= 68) (n= 74)
Median change (95% CI) 1.2 (–0.4 to 4.4) 2.0 (0.3 to 4.2) 0.83
Change in end-diastolic volume (ml) (n= 68) (n= 74)
Median change (95% CI) –16 (–29 to –8) –11 (–30 to –2) 0.71
Change in end-systolic volume (ml) (n= 68) (n= 74)
Median change (95% CI) –19 (–34 to –12) –18 (–28 to –8) 0.81
Change in end-diastolic diameter (mm) (n= 72) (n= 77)
Median change (95% CI) 0 (–2 to 0) –1 (–2 to 1) 0.49
Change in end-systolic diameter (mm) (n= 72) (n= 77)
Median change (95% CI) –1 (–3 to 0) 0 (–2 to 2) 0.34
Change in degree of mitral regurgitation, n/N (%) (n= 76) (n= 80) > 0.99
Improved by one or more grade 8/76 (11) 9/80 (12)
No change 60/76 (81) 61/80 (80)
Worsened by one or more grade 6/76 (8) 6/80 (8)
a Not included in survival analysis (included in efficacy analysis).
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Adverse effects of treatment
Adverse effect CRT-D on+OPT (n= 87) ICD+OPT (n= 85) p-value
HF events requiring intravenous therapy 24 events in 14/87
patients (16.1%)
41 events in 19/85
patients (22.3%)
Lead dislodgement, n/N (%) 13/172 (7.6)
Left ventricular lead, n/N (%) 5/172 (2.9)
Infection, n/N (%) 6/172 (3.5)
Bleeding or haematoma, n/N (%) 2/172 (1.2)
Loss of pacemaker lead capture, n/N (%) 2/172 (1.2)
Phrenic nerve stimulation, n/N (%) 3/172 (1.7)
Deep venous thrombosis, n/N (%) 3/172 (1.7)
Pneumothorax, n/N (%) 2/172 (1.2)
Pericarditis, n/N (%) 2/172 (1.2)
Coronary sinus perforation, n/N (%) 1/172 (0.6)
Comment
The authors state that the numbers of adverse events did not differ significantly between the two study groups but no
p-values are reported.
Subgroup analysis
Subgroup analysis according to QRS interval at 6 monthsa
Subgroup
CRT-D on+OPT
(QRS ≥ 120milliseconds, n= 17;
QRS < 120milliseconds, n= 59)
ICD+OPT
(QRS ≥ 120milliseconds, n= 25;
QRS < 120milliseconds, n= 55) p-value
Peak VO2, proportion of patients with an increase of at least 1ml/kg body weight/minute from baseline
QRS ≥ 120milliseconds 58.9 19.7 0.02
QRS < 120milliseconds 42.2 51.2 0.45
NYHA class, proportion of patients whose condition improved by at least one class from baseline
QRS ≥ 120milliseconds 70.7 28.0 0.01
QRS < 120milliseconds 49.4 29.3 0.04
QoL, median change from baseline (%)
QRS ≥ 120milliseconds 0 –3.7 0.24
QRS < 120milliseconds –8.9 –7.0 0.63
6-minute walk distance, median change from baseline (m)
QRS ≥ 120milliseconds 0.0 –19.1 0.76
QRS < 120milliseconds 33.7 10.3 0.31
a All values were estimated by the reviewer using Engauge software. The p-values were extracted from the paper.
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Subgroup analysis according to cardiomyopathy classification at 6 monthsa
Subgroup
CRT-D on+OPT
(ischaemic, n= 40;
non-ischaemic, n= 36)
ICD+OPT
(ischaemic, n= 41;
non-ischaemic, n= 39) p-value
Peak VO2, proportion of patients with an increase of at least 1ml/kg body weight/minute from baseline
Ischaemic 40.0 44.2 0.82
Non-ischaemic 52.6 38.4 0.25
NYHA class, proportion of patients whose condition improved by at least one class from baseline
Ischaemic 55.3 29.5 0.02
Non-ischaemic 53.2 28.4 0.04
QoL, median change from baseline (%)
Ischaemic –5.9 –3.6 0.68
Non-ischaemic –10.6 –6.5 0.60
6-minute walk distance, median change from baseline (m)
Ischaemic 4.2 5.8 0.57
Non-ischaemic 55.0 2.5 0.01
a All values were estimated by the reviewer using Engauge software. The p-values were extracted from the paper.
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Comments
Methodological comments
l Allocation to treatment groups: random assignment in a 1 : 1 ratio according to centre and stratified
according to cardiomyopathy classification and QRS interval (< 120milliseconds and ≥ 120milliseconds)
within each centre. Randomisation assignments were created in S-PLUS software (Insightful) and provided
to site personnel (aware of study group assignments) with the use of an interactive voice-response system
at the baseline visit. Participants were randomised after successful implantation and once all baseline
evaluations were completed.
l Blinding: study paper reports that trial was double blind but site personnel provided with randomisation
assignments were aware of study group assignments. Site personnel unaware of study group assignments
administered all evaluations at 6 months. Independent committees whose members were unaware of study
group assignments and investigational centre adjudicated all deaths and adverse events.
l Comparability of treatment groups: authors state that none of the differences between the groups was
significant but no p-values were reported.
l Method of data analysis: all end points were analysed according to the ITT principle. Secondary end points
were each evaluated at a significance level of 0.025 and were considered significant only if the primary
efficacy end point was met with the use of the gatekeeper method. All p-values were calculated with the
use of a two-sided test. Survival curves were constructed according to the Kaplan–Meier method and the
differences between curves were examined by the log-rank statistic. Data for all patients were censored at
196 days, the last day of the 6-month window for clinical visits. CIs for survival were computed on a log–log
scale. For continuous variables, data are presented as median changes between baseline and 6 months. CIs
for the median were computed with the use of a distribution-free approach. Comparisons of changes from
baseline to 6 months between the CRT-D off (control) group and the CRT-D on group were evaluated for
significance by the Wilcoxon rank-sum test. Mean (SD) values are presented. For categorical variables,
differences in the distribution of responses to treatment at 6 months in the two groups were compared by
Fisher’s exact test. CIs for proportions were computed by exact methods. The protocol specified that end
point analyses be performed for patients with data available at 6 months and for those who died, withdrew
or were unable to perform the evaluation at 6 months because of worsening HF. The last group of patients
were included in the analysis with their worst values imputed as follows: 0 ml/kg/minute for peak VO2, a
score of 105 on the QoL scale, NYHA class IV and 0m for the 6-minute walk distance.
l Sample size/power calculation: the study was powered to detect a difference of 23% in the proportion of
patients who achieved the primary end point in the CRT-D on group compared with the CRT-D off group
(control). The proportion who improved in the control group was assumed to be 25%. The sample size
required to detect this difference with a statistical power of 80% at the 0.05 significance level was
76 patients in each group, with the use of Fisher’s exact test. On the basis of an attrition rate of 40%,
the study required a total of 250 participants.
l Attrition/dropout: total recruitment: 250, total randomised: 172 (four unsuccessful implantation, two
deaths, three withdrawals, 69 did not meet inclusion criteria). CRT-D on: three died from other causes than
HF, three withdrew for reasons other than worsening HF, three had < 6 months’ follow-up and two had no
exercise test at follow-up; 76 participants were included in efficacy analyses, two died from HF. CRT-D off:
four had < 6 months’ follow-up, one had no exercise test at 6 months; 80 participants were included in
efficacy analyses, two died from HF and two did not have an exercise test because of worsening HF.
Crossovers: three participants crossed from CRT-D off to CRT-D on because of worsening HF (included in
the control group analysis); there were no crossovers from CRT-D on to CRT-D off.
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General comments
l Generalisability: limited to participants with successful implantation, a QRS interval < 130milliseconds,
NYHA class III symptoms and evidence of mechanical dyssynchrony [authors state that only 4% of patients
were eligible to participate in the study solely on the basis of mechanical dyssynchrony in the septal to
posterior wall of ≥ 130milliseconds on M-mode ECG; 96% qualified on the basis of the tissue Doppler
imaging criterion (i.e. an opposing wall delay of ≥ 65milliseconds)].
l Outcome measures: appear to be appropriate. The primary outcome measure was the proportion of
patients with an increase of 1.0 ml/kg body weight/minute in peak oxygen consumption during
cardiopulmonary exercise testing. The study was not powered for mortality.
l Intercentre variability: not reported.
l Conflict of interests: Drs Beshai, Grimm, Nagueh, Greenberg and Pires received lecture/consulting fees,
support and/or grants from St Jude Medical, Medtronic, GE and/or Boston Scientific. The authors state that
there was no other potential conflict of interest relevant to the publication and that investigators had full
access to all data and performed analyses without restrictions or limitations from the sponsor.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random sequence generation Low Random assignment in a 1 : 1 ratio according to
centre and stratified according to the cardiomyopathy
classification and the QRS interval within each centre.
Randomisation assignments created in S-PLUS
software (Insightful)
Allocation concealment Low Allocation provided to site personnel with the use of
an interactive voice response system at the
baseline visit
Performance bias
Blinding of participants and personnel Unclear Paper states that study was double blind but unclear
who was blinded. Randomisation assignments were
provided to site personnel, unclear if these personnel
continued to be involved in the care of participants
Detection bias
Blinding of outcome assessment Low Site personnel conducting evaluations at 6 months
were unaware of treatment assignments, as were
independent committee members adjudicating all
deaths and adverse events
Attrition bias
Incomplete outcome data addressed
Peak oxygen consumption (primary outcome),
QoL, NYHA class, 6-minute walk distance,
mortality before 6 months
Low Paper states that all end points were analysed
according to the ITT principle. The protocol specified
that end point analyses be performed for patients
with data available at 6 months and for those who
died, withdrew or were unable to perform the
evaluation at 6 months because of worsening HF.
However, analysis was performed with 66 CRT-D
on+OPT group participants and 80 ICD+OPT group
participants, because of some participants not having
completed a cardiopulmonary exercise test for
reasons other than worsening HF. Numbers and
reasons given
Other end points High Missing data; reasons not given
Reporting bias
Selective reporting Low All protocol outcomes reported
Other bias
Other sources of bias Low
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Resynchronization for the HemodYnamic Treatment for Heart
failure Management Implantable Cardioverter Defibrillator
(RHYTHM ICD) trial
Reference and design
Intervention
and comparator Participants Outcome measures
US Food and Drug
Administration 2004144
and 2005145
Study design: RCT
Country: not stated
No. of centres: 50
Funding: not stated but
presumed to be the
device manufacturer,
St Jude Medical
Intervention: CRT-D (device:
St Jude Medical Epic HF
model V-338, maximum
output 30 J, with Aescula
left ventricular leads)
Comparator: ICD
Other interventions used:
not stated
Indication for treatment:
patients indicated for ICD
therapy with NYHA class
III/IV HF and a prolonged
QRS duration
No. of randomised
participants: 205 enrolled,
182 successful implants, 179
baseline visit; CRT-D: 119,
ICD: 60
Inclusion criteria: LVEF
≤ 35%, QRS interval
≥ 150ms, ICD indication for
treatment of life-threatening
VT, symptomatic HF for
≥ 6 months, NYHA class III or
IV despite ≥ 90 days of
appropriate pharmacological
therapy, receiving OPT for
CHF (including ACE inhibitor
and beta-blocker as
tolerated), stable for 30 days
before enrolment, ability to
complete a cardiopulmonary
exercise stress test and
6-minute walk test, able to
consent and comply with
follow-up tests and
evaluations
Exclusion criteria: standard
bradycardic indication for
pacing, chronic atrial
fibrillation (continuous atrial
fibrillation lasting > I month)
within 1 year or
cardioversion for atrial
fibrillation in the past month,
able to walk > 450m in the
6-minute walk test, NYHA
class I or II, contraindication
for an emergency
thoracotomy, candidate for
cardiac transplantation in the
next 6 months, recent
(within 1 month) MI,
unstable angina or cardiac
revascularisation, stroke or
transient ischaemic attack in
the last 3 months, severe
musculoskeletal disorder(s),
pregnancy, participation in
other clinical investigations,
life expectancy < 6 months
Primary outcomes: left
ventricular lead-related
complications at 6 months,
Epic HF system-related
complications at 6 months,
defibrillation system
effectiveness: VF detection/
redetection times, CRT
efficacy (peak VO2)
Secondary outcomes:
improvement at 6 months in
NYHA class, QoL (MLWHFQ)
score and 6-minute walk
test; Aescula left ventricular
lead performance and lead
pacing capture threshold
Method of assessing
outcomes: baseline visit
approximately 2 weeks after
implant. Follow-up at 1, 3
and 6 months. After
6 months crossover to CRT-D
permitted and follow-up
every 3 months
Complications defined as
adverse events that required
invasive intervention.
Observations defined as
adverse events managed
without invasive intervention
(e.g. reprogramming of the
pulse generator)
Length of follow-up:
average 12.1 months
(SD 3.4 months), range
0.3–20.3 patient-months.
Outcomes reported at 6
months
Recruitment: July
2002–October 2003
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Participant characteristics
Participant characteristics CRT-D (n= 119) ICD (n= 59) p-value
Age (years), mean (SD) NR NR
Sex NR NR
Ethnicity NR NR
NYHA class, n (%) 0.61
I 1 (0.8) 2 (3.4)
II 6 (5.0) 4 (6.8)
III 104 (87.4) 50 (84.7)
IV 8 (6.7) 3 (5.1)
LVEF (%), mean (SD), range 25.6 (8.3), 9–48 23.3 (6.4), 11–43 0.07
Heart rate NR NR
QRS duration (milliseconds), mean (SD), range 169 (16), 120–210 167 (15), 130–200 0.40
Left ventricular end-diastolic dimension (mm),
mean (SD), range
66.2 (8.5), 44.7–85.9 66.0 (9.4), 50.1–84.2 0.88
Left ventricular end-systolic dimension (mm),
mean (SD), range
57.1 (9.4), 37.1–76.2 56.9 (10.5), 37.9–78.2 0.93
QoL score, mean (SD), range 48 (24), 0–103 46 (24), 4–100 0.53
6-minute walk distance (m), mean (SD), range 275 (103), 37–561 291 (89), 31–480 0.30
Cardiopulmonary exercise test
Peak VO2 (ml/kg/minute), mean (SD), range 10.8 (3.0), 4.3–26.9 12.3 (3.5), 6.0–23.1 0.006
Exercise time (minutes), mean (SD), range 8.0 (3.2), 0.7–16.5 8.9 (3.6), 2.3–19.8 0.08
Baseline medication, n (%)
ACE inhibitors/substitutes 85 (71.4) 44 (74.6) 0.79
Beta-blockers 95 (79.8) 52 (88.1) 0.24
ARBs 24 (20.2) 10 (16.9) 0.76
Diuretics 103 (86.6) 54 (91.5) 0.47
Positive inotropics/glycoside 73 (61.3) 39 (66.1) 0.65
Nitrates 39 (32.8) 23 (39.0) 0.51
Anticoagulants and antiplatelets 102 (85.7) 48 (81.4) 0.59
Calcium channel blockers 11 (9.2) 9 (15.3) 0.35
AADs 29 (24.4) 13 (22.0) 0.87
NR, not reported.
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Results
Outcome CRT-D (n= 83) ICD (n= 43) p-value
Total deathsa at 6-month visit, average 12.1
(SD 3.4) patient-months of follow-up
9 3
Cardiac arrhythmic 0 0
Cardiac non-arrhythmic 1 1
Cardiac unknown 0 0
Non-cardiac 7 2
Unknown 1 0
Additional deaths after the 6-month visit,144
average 15.1 (SD 4.1) patient-months of follow-up
4 1
Cardiac arrhythmic 0 0
Cardiac non-arrhythmic 1 0
Cardiac unknown 1 0
Non-cardiac 1 1
Unknown 1 0
QoL score, mean (SD)
Baseline 48.3 (24) 42.0 (23)
6-month follow-up 40.4 (22) 45.4 (31)
Change –7.8 (22) 3.4 (31) 0.009
NYHA class, mean (SD)
Baseline 3.01 (0.33) 2.86 (0.52)
6-month follow-up 2.53 (0.69) 2.58 (0.73)
Change –0.48 (0.65) –0.28 (0.63) 0.048
Peak VO2
b (ml/kg/minute), mean (SD) (primary outcome)
Baseline 11.2 (3.0) 12.8 (3.7)
6-month follow-up 11.7 (3.2) 11.4 (5.6)
Change 0.52 (2.5) –1.41 (4.6) 0.001
Per-protocol analysis of change in peak VO2
(ml/kg/minute), mean (SD) at 6 months
(n= 85) 0.52 (2.5) (n= 41) –1.47 (4.7) 0.001
6-minute walk distance (m), mean (SD)
Baseline 284 (105) 298 (94)
6-month follow-up 197 (122) 283 (150)
Change 13 (74) –15 (142) 0.07
Improvement in echocardiography parameters at
6 months, mean (SD)
(n= 82) (n= 40)
LVEDD (mm) –4.3 (5.4) –2.4 (6.5)
LVESD (mm) –4.6 (7.0) –3.0 (6.4)
LVEDV (ml) –43 (69) –37 (53)
LVESV (ml) –43 (58) –36 (47)
LVEF (%) 4.3 (9.9) 2.9 (6.2)
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Outcome CRT-D (n= 83) ICD (n= 43) p-value
MR (grade)c –0.06 (0.74) 0.10 (0.50)
E/A wave point ratio –0.08 (0.8) –0.02 (1.2)
Sphericity index –0.02 (0.1) 0.02 (0.1)
Pre-ejection time (milliseconds) –1.5 (52) 7.3 (33)
Intraventricular mechanical delay (milliseconds) –14.5 (52) –6.4 (48)
Tei Index –0.4 (0.8) –0.05 (0.5)
Contraction interval (milliseconds) –94 (124) –55 (103)
Discontinuations and withdrawals (excluding withdrawals because of deaths and after unsuccessful implant), average of
15.1 (SD 4.1) patient-months of follow-up144
System explant n= 1,d day 1 after implant
Heart transplant n= 1, 75 days after implant
At request of patient n= 1, 28 days after implant;
n= 1, 397 days after implant
At request of patient’s family n= 1, 293 days after implant
LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVESD, left ventricular
end-systolic diameter; LVESV, left ventricular end-systolic volume.
a An additional five deaths (four cardiac non-arrhythmic and one non-cardiac) occurred in patients who did not have a
successful implant or occurred before the baseline visit and randomisation. Total number of deaths is therefore 17, as
detailed in Methodological comments, Attrition/dropout.
b Patients who crossed over from the ICD group to the CRT-D group were analysed according to their original
treatment group.
c MR not defined; presumed to be mitral regurgitation.
d One patient was withdrawn before the baseline visit and randomisation and therefore was not assigned to either group.
Comments
l Mean detection and redetection times for induced VF episodes, Aescula left ventricular lead performance and Aescula
left ventricular lead pacing capture threshold at 6 months have not been extracted because they were not analysed by
treatment group.
l Authors state that the average percentage of biventricular pacing at 6 months in the CRT-D cohort (n= 83) was
95% (SD 6%), range 70–100%.
Adverse effects of treatment
Adverse effect
Reported for the whole
study group before
randomisation (n= 205)a
Total complications, n patients (%), n events; average 12.1
(SD 3.4) patient-months of follow-up145
21 (10.2), 29
Coronary sinus perforation/dissection 2 (1.0), 2
Diaphragmatic/phrenic nerve stimulation 3 (1.5), 3
Lead dislodgement or migration 8 (3.9), 9
Bleeding/haematomab 6 (2.9), 6
Blood clot/thrombosis 1 (0.5), 1
High defibrillation/cardioversion requirements 2 (1.0), 2
Infection 1 (0.5), 1
Noise on EGM post shock (non-SJM right ventricular lead)c 1 (0.5), 1
Pneumothorax 2 (1.0), 2
Retained foreign body (surgical sponge) 1 (0.5), 1
Elevated pacing threshold – left ventricular lead 1 (0.5), 1
continued
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Adverse effect
Reported for the whole
study group before
randomisation (n= 205)a
Total observations, n patients (%), n events; average 12.1
(SD 3.4) patient-months of follow-up145
57 (27.8), 68
Asystolic episode during left ventricular lead placement 1 (0.5), 1
Bleeding/haematomab 10 (4.9), 10
Blood clot/thrombosis 2 (1.0), 2
Coronary sinus perforation/dissection 6 (2.9), 6
Diaphragmatic/phrenic nerve stimulation – left ventricular lead 10 (4.9), 10
Diaphragmatic/phrenic nerve stimulation – right ventricular lead 2 (1.0), 2
Elevated pacing thresholds – left ventricular lead 10 (4.9), 10
Elevated pacing thresholds – right ventricular lead 2 (1.0), 2
Heart block at implant 2 (1.0), 2
High defibrillation/cardioversion requirements 1 (0.5), 1
Hypotension requiring ventilator support 1 (0.5), 1
Inappropriate therapy for SVT 10 (4.9), 13
Infection 3 (1.5), 3
pulmonary embolism 1 (0.5), 1
T-wave sensing 2 (1.0), 3
Pocket inflammation/seroma 1 (0.5), 1
Left ventricular lead-related complications at 6 months 11/155 patients, 13 complications
Epic HF system-related complications at 6 months 13/182 patients, 16 complications
Total complications, n patients (%), n events; average 15.1 (SD 4.1)
patient-months of follow-up (only those complications with added
data detailed below)144
22 (10.7), 31
Lead dislodgement or migration 9 (4.4), 10
Infection 2 (1.0), 2
Total observations, n patients (%), n events; average 15.1 (SD 4.1)
patient-months of follow-up (only those observations with added
data detailed below)144
59 (28.8), 76
Diaphragmatic/phrenic nerve stimulation – left ventricular lead 14 (6.8), 14
Elevated pacing thresholds – left ventricular lead 12 (5.9), 12
Inappropriate therapy for SVT 11 (5.4), 14
Infection 4 (2.0), 4
SJM, St Jude Medical; SVT, supraventricular tachycardia.
a Some patients experienced more than one event; therefore, the number of patients is less than the number of events.
b In total, 15/16 patients with bleeding/haematoma-related events were on active anticoagulation therapy.
c Abbreviations not defined in the publication.
Comment
l A total of 97 adverse events (29 complications and 68 observations) were reported in 70 patients.
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Comments
Methodological comments
l Allocation to treatment groups: states randomised in a ratio of 2 : 1 (CRT-D : ICD).
l Blinding: states double blind.
l Comparability of treatment groups: report does not comment on this; groups appear broadly comparable –
the only significant difference appears to be for peak VO2 for the exercise test for which the ICD group
performed significantly better than the CRT-D group. Note that this measure is a primary outcome.
l Method of data analysis: not stated. Analysed data set was smaller than the randomised data set because
of attrition (see below).
l Sample size/power calculation: not reported.
l Attrition/dropout: in total, 17 (increasing to 22 with additional follow-up144) patients were withdrawn
because of death (patients with unsuccessful implant, n= 3 deaths; death between implant and baseline
visit, n= 2; death between baseline and 6-month visit, n = 8; death after 6-month visit, n= 4); 5/17 deaths
were not attributed to a treatment group as they occurred in patients who did not have a successful
implant (unrelated to implant procedure) or death occurred before the baseline visit and randomisation.
Out of 205 enrolled patients, 23 implants were unsuccessful [unable to cannulate CS, n = 7; unable to
obtain distal lead placement, n= 6; unable to obtain stable lead position, n= 3; high pacing thresholds,
n= 3; CS dissection, n= 3; high defibrillation threshold, n= 1]. Therefore, 182 patients were successfully
implanted; of these, one patient withdrew before baseline, and two (as noted above) died before the
baseline visit, leaving 179 patients. One further patient attended the baseline visit but refused
randomisation and baseline evaluations except for device interrogation and electrical measurements. Thus,
baseline evaluations for 178 patients are presented. Of the 179 patients who attended for the baseline visit
a flow chart shows that 119 were assigned to CRT-D and 60 were assigned to ICD. A further 36 in the
CRT-D group were not included in the analysable patient group for the effectiveness analysis (one refused
the baseline CPET, two were withdrawn, two could not complete the baseline/6-month CPET for
non-cardiac reasons, six died, four had an invalid baseline/6-month CPET and 21 had < 6 months’ follow
up) and 17 were not analysable in the ICD group (one refused the baseline CPET, two died, four had an
invalid baseline/6-month CPET and 10 had < 6 months’ follow-up). Consequently, the analysed data set
included 83 CRT-D participants and 43 ICD participants.
General comments
l Generalisability: uncertain – no indication of age, sex or ethnicity of the participants. Country in which the
trial took place also not reported. Patients had an indication for ICD therapy plus NYHA class III/IV HF and a
prolonged QRS duration. Those with chronic atrial fibrillation were excluded. Baseline evaluation occurred
14 days post implant followed by randomisation; only those with successful implants were randomised.
l Outcome measures: primarily this was a study of safety; effectiveness outcomes were on the whole
secondary measures. Outcomes seem appropriate.
l Intercentre variability: not commented on in the report.
l Conflict of interests: not stated in the report but the study appears to have been funded and conducted by
the device manufacturers.
CPET, cardiopulmonary exercise test; CS, coronary sinus.
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Criteria for assessment of risk of bias in randomised controlled trials65
Domain Judgementa Support for judgement
Selection bias
Random
sequence generation
Unclear No information provided
Allocation concealment Unclear No information provided
Performance bias
Blinding of participants
and personnel
Unclear States double blind but no detail about how this was achieved
Detection bias
Blinding of
outcome assessment
Unclear States double blind but no detail about how this was achieved
Attrition bias
Incomplete outcome
data addressed
Low Although there was a high degree of attrition this has been clearly documented
and appears similar (numbers and reasons) between groups
Reporting bias
Selective reporting Unclear Report is a submission to the FDA and it is not clear whether or not only
selected outcomes have been presented to meet the needs of the FDA
approvals process
Other bias
Other sources of bias Unclear Because of a lack of details, e.g. methodological and details on patient
characteristics, the risks of other sources of bias are unclear
a ‘Low risk’, ‘high risk’ or ‘unclear risk’ of bias.
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Appendix 10 Southampton Health Technology
Assessments Centre’s peer review of the
manufacturers’ submission
Comprehensiveness of ascertainment of published studies
Clinical effectiveness
The MS151 contains a systematic review of clinical effectiveness. In addition, a NMA of IPD is presented (see
table in Southampton Health Technology Assessments Centre’s critical appraisal of the individual patient
data network meta-analysis). The details and results of the studies included in the systematic review were
tabulated. The risk of bias was also assessed and tabulated in appendix 3 of the MS but no narrative
discussion of risk of bias was provided. The studies were not presented according to the population groups
specified in the NICE scope,61 and the inclusion criteria for the systematic review and NMA differ from
those of the NICE scope. The statement of the decision problem defines the population of interest as
‘adults with heart failure (NYHA I to IV) and LVEF ≤ 35%, and/or at risk of sudden cardiac death’ (p. 44).151
The population inclusion criteria for the systematic review are defined as ‘adults with LVEF ≤ 40% or those
who may not have (LVEF) ≤ 40% but are considered to be secondary prevention patients according to TA
95 criteria’ or ‘adults who have experienced prior myocardial infarction or coronary revascularisation; this
must have occurred more than 45 days prior to enrolment’ (p. 51).151 In addition, for the IPD NMA, the
four interventions of interest (OPT, ICD, CRT-P and CRT-D) were not all included as comparators in all of
the patient subgroups (for rationale see table 6, p. 45).151 The MS states that this was either based on
contraindication (e.g. CRT not being recommended for patients with a QRS duration of < 120 milliseconds)
or on a paucity of IPD data (described as ‘proxy for non-use in routine clinical practice’). This differs from
the NICE scope.
l Were databases and dates of searches specified? Yes. Searches were conducted on 27 and 28 June
2011; no update searches were reported. The MS states that timelines initially provided by NICE to all
technology sponsors were followed. MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations,
EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched. The MS
states that searches were restricted to the English language and a start publication date of 1990.
Reference lists of full-text retrieved papers were also scanned.
l Were search strategies supplied? Yes, search strategies for the three databases are presented in
Appendix 1 of the MS.151
l Was enough detail provided for it to be reproducible? Yes.
l Did the manufacturers search for/report on ongoing studies? No.
l Did the manufacturers search for conference proceedings? No, there were no specific searches for
conference abstracts and the MS states that abstracts were excluded from the assessment.
l How much of the data is commercial-in-confidence/academic-in-confidence? There are no
commercial-in-confidence/academic-in-confidence data in the systematic review but the vast majority of
the IPD are marked commercial-in-confidence (no academic-in-confidence data).
Cost-effectiveness
The MS did not report any additional searches for cost-effectiveness studies.
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Studies identified
l Clinical trials (details): 22 RCTs reported in 46 publications (total records identified in the MS: 4749;
total records identified by SHTAC: 4169), plus five trials (reported in 11 publications) of secondary
prevention that were not data extracted.
l Did any meet our inclusion criteria that we have not already included? No additional trials were
identified in the MS. However, there are differences in the included/excluded trials:
¢ People at risk of SCD – the MS did not describe or report data for secondary prevention studies
(listed in appendix 4 of the MS151) and provided justification for this (reduction in implant costs,
absence of new studies since TA95;42 in the MS it is stated that this patient group is believed to lie
outside the scope of the current appraisal). SHTAC included four secondary prevention studies:
AVID,71 CASH,81 CIDS84 and DEBUT.89 Of the primary prevention trials, SHTAC included three trials
that were not included in the MS: DINAMIT,95 IRIS97 and CABG Patch.75 The MS excluded DINAMIT
and IRIS for the ‘inappropriate population’ and one paper linked to the CABG Patch trial was
excluded for its ‘end point’ although other papers from this trial were not mentioned.
¢ People with HF – SHTAC excluded three of the trials included in the MS: (1) RESPOND
(Resynchronization in Patients with Heart Failure and a Normal QRS Duration;241 participants did not
have cardiac dyssynchrony), (2) REVERSE208,242,243 (mixed population receiving the interventions
CRT-P or CRT-D with the comparators OPT or ICD and results not presented separately) and
(3) VECTOR (Ventricular Resynchronization Therapy Randomized Trial;244 FDA report with insufficient
information to allow the assessment of methods and results; no baseline characteristics reported).
¢ The MS excluded ‘patients with familial cardiac conditions with a high risk of SCD, including long
QT syndrome, hypertrophic cardiomyopathy, Brugada syndrome, arrhythmogenic right ventricular
cardiomyopathy, and following surgical repair of Tetralogy of Fallot’ (p. 54).151 SHTAC did not
exclude these patients and therefore included the DEBUT study.89
¢ A list of excluded studies with reasons for exclusion was provided in response to a request
from SHTAC.
Clinical analysis
l Any major differences in evidence reported? Despite the REVERSE trial including a mixed population,
intervention (CRT-P or CRT-D) and comparators (OPT or ICD), the MS presents only patients
randomised to CRT-D compared with ICD in tables for simplicity, and notes this on p. 55 of the MS.151
The 22 trials are tabulated together and not according to the groups defined in the NICE scope. The
narrative synthesis of results often does not refer to the different populations in the studies, for
example those with cardiomyopathy or MI. The MS does not undertake meta-analyses of outcomes
reported by studies included in the systematic review, but reports the meta-analyses undertaken by Fox
and colleagues in 200764 and others.
l Are the MS conclusions similar to those of the SHTAC review? The MS does not explicitly report the
conclusions from the systematic review in the main body of the submission. The executive summary
states that ‘there is a large body of RCT evidence confirming the efficacy and safety of ICD, CRT-P and
CRT-D in patients with HF’ (p. 4).151 There is no comment regarding the comparative effectiveness of
the interventions for the NICE-defined populations. Further conclusions are presented based on the
IPD NMA.
l Any indirect comparisons? No indirect comparisons of the included studies were undertaken in the MS.
However, the MS presents a NMA of IPD combining data from 13 of the 22 included studies.
l Any differences in outcome measures? The MS reports the same outcome measures as the
SHTAC review.
l Any extra adverse event information? A narrative overview of adverse events in the included studies
and information from previous meta-analyses is presented.
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Interpretation
l Does the interpretation of the clinical data match the analyses? The MS does not explicitly provide an
interpretation of the systematic review. The interpretation of the IPD NMA is assessed below.
Questions
l Any areas of uncertainty/discrepancy compared with the SHTAC review?
¢ Inclusion of the REVERSE trial.208
¢ Population not defined according to the NICE scope.1
Southampton Health Technology Assessments Centre’s critical
appraisal of the individual patient data network meta-analysis
Appraisal criteria Criteria met?
A. Conceptual basis
1. Is a justification given for conducting a mixed
treatment comparison?
Yes. The MS correctly identifies that an IPD NMA would be
beneficial in helping to understand the effects of ICDs,
CRT-P and CRT-D on health outcomes for patients with HF.
It is particularly important given the limited direct evidence
for some comparisons. Also, it is helpful in identifying
subgroups within a heterogeneous patient population,
providing the opportunity to capture baseline risks and
relative treatment effects. With published evidence at an
aggregate level, the effectiveness for subgroups is not
addressed by most trials and is inconsistently reported in
others. Provision of confidential IPD by the manufacturers
made such an analysis possible
B. Systematic processes
2. Is a comprehensive and transparent search
strategy reported?
Yes. There was a comprehensive and transparent search
strategy for the systematic review (not separate searches
for the NMA) that provided the basis for the evidence
network. The IPD was based on 14 RCTs from 22 trials
included in the network of evidence from the systematic
review (reported by the MS as 13 as two trials were
combined). IPD were supplied by the manufacturers
3. Are inclusion/exclusion criteria adequately reported? Yes. RCTs for which IPD could be obtained were from the
systematic review. The criteria do not strictly accord with the
decision problem specified in the NICE scope for the
appraisal (see Appendix 9 Comprehensiveness of
ascertainment of published studies)
4. Are the numbers of included/excluded studies from the
mixed treatment comparison reported, with reasons
for exclusions?
Yes. The number of trials excluded (13/22 RCTs, dated
1996–2010) and reasons for exclusion from the evidence
network are reported. Justifications for exclusion include
manufacturers’ IPD data not available (two studies);
available data sets could not be reconciled with the
published data (two studies); two manufacturer-sponsored
studies that the systematic review searches failed to identify
until after the database for the NMA had been assembled
(VECTOR: started in 2000 and details published in a 2005
US FDA report;244 RESPOND: journal article published
February 2011241); and two trials were not sponsored by the
manufacturers contributing to the submission. In addition to
these trials, SHTAC also included seven trials (DINAMIT,95
IRIS97 and CABG Patch75 and four secondary prevention
continued
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Appraisal criteria Criteria met?
RCTs71,81,84,89) that were not included in the MS. Although
the excluded studies account for only 5.3% of the data
(n= 712/13,350), it is unclear what impact their exclusion
has on the results. A flow chart is presented for the
systematic review and numbers excluded from the NMA
are reported
5. Is a visual representation of the data networks provided? Yes. A visual network diagram was provided for the
systematic review (section 4, p. 103, of the MS151). An
explanation is provided for the way that the different trials
were handled within the network. The REVERSE trial208 was
treated as two trials [CRT-P and CRT-D, as well as split
into EU and US populations because of the different
protocol-specific duration of follow-up (24 months and
12 months respectively)]. The CONTAK-CD trial126 was also
treated as two trials as the crossover design was changed to
a 6-month parallel-group trial halfway through (phase 2).
The MIRACLE ICD trial136 was combined with the MIRCALE
ICD II trial137 as the MS states that these were effectively a
single trial. In addition, the MS pooled the data from the
amiodarone and placebo arms in the SCD HeFT trial105
6. Are the data from included studies extracted
and tabulated?
Yes. Baseline information was presented in the systematic
review for the individual trials (see tables 7–11,
pp. 57–72151). A summary table for the IPD trials with
combined participant baseline characteristics per device
(table 35, p. 110151) is presented for comparison with UK
summary data (table 36, p. 111151). The MS suggests that
differences in NYHA class between the two tables are
distorted because of previous NICE decisions about the
devices, differences in the format that other data are
presented in and high levels of missing data in the UK
National Audit. The MS suggests that, despite this, the IPD
is broadly reflective of the UK population. Comparison is
further complicated by QRS data being presented as means
(milliseconds) in the MS table but as percentages
(prolonged) in the UK summary table. A cross-check with
the original trial publications is not possible as this is based
on a large database of IPD
7. Is the quality of the included studies assessed? Yes. All of the NMA trials were critically appraised in the
systematic review. Risk of bias for all 22 studies is presented
in Appendix 3 of the MS,151 but there is no discussion of
this. No studies were excluded because of any potential risk
of bias and the MS fails to address any of the issues arising
from the assessment
C. Statistical analysis
8. Are the statistical procedures adequately described
and executed?
No. Overall procedures used are reported, but specific
details of the analyses for the outcomes of all-cause
mortality, all-cause hospitalisation and HRQoL are omitted.
This limits the opportunity to appraise the NMA. Published
sources are referred to for the methods employed in
statistical analysis
Analysis of the three outcomes follows a similar two-stage
approach, although different types of regression were used.
First, baseline rates were estimated independent of
treatment effect using pooled data from the IPD trials on
OPT (the comparator). Second, device-specific treatment
effects were estimated using relevant IPD trials measuring
the specific outcome in question. Both stages used patient
characteristics as covariables to incorporate baseline risk and
treatment effect modifiers. This allowed subgroups of
patients to be identified for whom the devices may have a
differential effect
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Appraisal criteria Criteria met?
All-cause mortality
For all-cause mortality, a parametric survival analysis was
undertaken to generate estimates of baseline mortality.
Parametric distributions assessed included exponential,
Gompertz, log-logistic, log-normal and Weibull. Covariables
were assessed for inclusion and, when necessary,
transformation undertaken (e.g. age as a time-dependent
covariable). Models were assessed using fitted and
Kaplan–Meier survival curves within trial follow-up, visual
review of the extrapolations and of the shape of the
instantaneous hazard over time, AIC, Cox–Snell residuals,
tests of acceptability of the proportional hazards assumption
or accelerated failure time assumption, comparison against
external data and review by clinical experts. Results of the
tests are not presented. The Weibull distributions formed
the basis for the final baseline model
IPD NMA using meta-regression was undertaken with and
without covariables to estimate relative treatment effects
(i.e. HRs), comparing devices and OPT. Comparisons were
made between the NMA, pairwise meta-analyses and
aggregate trial data to judge whether representative and
the type of analyses that should be undertaken (see
appendix 7151). The MS reports that caterpillar plots,
Brooks–Gelman–Rubin statistics, autocorrelation and DIC
were assessed, although few results are reported.
Covariables were selected through univariate analyses,
multivariate stepwise procedures and exploratory analyses.
Final fixed-effects models using a Cox proportional hazards
approach and stratified for study were estimated
and assessed using proportional hazards tests (see
appendix 8151) and Schoenfeld residual tests (not reported)
All-cause hospitalisations
The analysis focused on ‘expected number of events per
month’ and ‘expected number of days per month spent in
hospital’ (excluding events within 60 days post
randomisation as these were included in the economic
model). Negative binomial regression was used to estimate
baseline rates for OPT patients and the effects of treatment
for all devices. The approach was decided through
measures of goodness of fit (i.e. BIC, AIC and two times
log-likelihood score) and the covariates were incorporated
into the analyses through a stepwise process (included at a
significance level of p= 0.05), although details are not
reported. Limited data resulted in pooling of some
categorical variables (e.g. NYHA groups). Justifications were
provided for decisions and comparisons are made with
previous evaluations
HRQoL
HRQoL was assessed using the EQ-5D, adjusting UK
age- and gender-specific utilities with disease- and
treatment-specific decrements/increments estimated from
the IPD trials reporting EQ-5D. Baseline HRQoL was
estimated using a similar process to that for all-cause
hospitalisation. Before analysis, raw data were transformed
as they were skewed. Derived values were checked against
population norms and trial values. Treatment impact was
estimated through MDs from baseline to first follow-up
(180 days). Limited and skewed data resulted in
counterintuitive results so MLWHFQ 6-month IPD data and
continued
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Appraisal criteria Criteria met?
evidence from the systematic were used to adjust final
values (justifications provided). Duration of effect was
estimated when mean device vs. OPT values showed
no difference
9. Is there a sufficient discussion of heterogeneity? The MS recognises the heterogeneous nature of the trials
included in the IPD NMA. This is reflected in the approach
taken – use of meta-regression to try to account for the
variation, the process for including covariables and the
presentation and the discussion of the results for different
subgroups. There is some limited discussion of measures of
goodness of fit associated with the NMA; however, this is
not related specifically to taking account of heterogeneity.
Some comparisons are made between the NMA, individual
trial results and pairwise meta-analyses, highlighting
differences related to heterogeneous studies
10. Is the type of model used (i.e. fixed or random effects)
reported and justified?
Yes. Comparisons of NMA results from IPD trials and all
trials using both fixed- and random-effects models are
reported and said to be broadly similar (p. 123151), although
random-effects CIs are wider. The MS states for all-cause
mortality that the DIC assessment of model fit supported
the use of the fixed-effect model: all trials: fixed-effects
DIC= 59.0 vs. random-effects DIC= 60.8; IPD trials:
fixed-effects DIC= 1.4 vs. random-effects DIC= 3.0.
Although modelling of all-cause hospitalisation and HRQoL
used a fixed-effects approach and it is indicated that
goodness of fit statistics were assessed, no data or
discussion are presented
11. Was sensitivity analysis conducted? Yes, in relation to the covariables included in the baseline
and treatment effect models through univariate and
multivariate stepwise analyses (see appendix 9151). No
sensitivity analyses were undertaken on the trials included
or the quality of the studies
12. Is any of the programming code used in the statistical
programme provided?
The MS did not provide any programming codes used in the
statistical programme
D. Presentation and interpretation of the evidence
13. Is there a tabulation/illustration of the results for each
intervention and for each outcome?
Results are presented through a series of tabulations and
illustrations, specifically:
All-cause mortality
Baseline model results were presented through
Kaplan–Meier plots of parametric curves and tabulation of
risk models. Treatment effects from the NMA were
presented through forest plots for different devices and
covariables and tabulation of the preferred model
All-cause hospitalisation
Baseline model results were presented through
Kaplan–Meier plots and tabulation of the baseline risk
model. Treatment effects from the NMA were presented
through tabulation of the preferred model and effects on
events per month by device
HRQoL
Outcomes are effect of disease severity on HRQoL at
baseline, treatment effect on HRQoL, explorative analysis of
change in MLWHFQ score at 6 months, HRQoL treatment
benefit duration and addition IPD analyses (long-term
MLWHFQ data from all studies and devices) – results were
presented in tables, histograms and line graphs
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Appraisal criteria Criteria met?
14. Is there a narrative commentary on the results? Yes. The MS presents narrative comments on the results,
putting them into the context of other research and
providing comments on the main limitations [i.e.
dichotomisation may miss some of the heterogeneity in
response to therapy in the 120–150 milliseconds QRS
category (p. 128151); lack of power in the analysis to detect
modest effect modifiers (p. 137151)] or uncertainties
[i.e. treatment effect beyond the included number of years
(p. 137151)]. The MS provides a cautionary note regarding
not overinterpreting individual subgroups as anomalies may
arise as a result of participant-level characteristics not
accounted for (p. 130151)
15. Does the discussion of the results reflect the
data presented?
The discussion of the results for the three outcomes does
reflect the results presented and a warning is provided
about the limitations of the IPD available and the analyses
undertaken. The discussion also places the results in the
context of other evidence
16. Have the authors commented on how their results
compare with other published studies (e.g. MTCs) and
do they offer any explanation for discrepancies?
Partly. The MS comments on how some of the results
compare with those of other reviews, meta-analyses and
studies or with routinely collected data. It also undertakes
additional analyses to check outcomes. In some instances
the MS provides alternative values because of uncertainties
in the results, providing justifications. Importantly, the MS
recognises the limitations in the IPD and NMA undertaken,
providing a note of caution
17. Have the authors discussed whether or not there are
any differences in effects between the direct evidence
and the indirect evidence?
The MS reports that good concordance between pairwise
meta-analysis and NMA suggests reasonable concordance
between the indirect data and the direct data (p. 124151).
Unable to establish if there were any discrepancies in the
IPD data
Southampton Health Technology Assessments Centre’s peer review of
the economic evaluation within the manufacturers’ submission
Study characteristics
Reference
Association of British Healthcare Industries. Implantable Cardioverter Defibrillators for the Treatment of
Arrhythmias and Cardiac Resynchronisation Therapy for the Treatment of Heart Failure (Review of TA95
and TA120). ABHI; 2012.
Health technology
ICD and CRT.
Interventions and comparators
Implantable cardioverter defibrillators and CRT for the treatment of cardiac arrhythmias and HF.
Was a no treatment/supportive care strategy included?
Optimal pharmacological therapy.
Describe interventions/strategies
As above.
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Research question
For adults with HF and a LVEF ≤ 35%, and/or at risk of SCD, which patients should receive an ICD,
a CRT-P or a CRT-D device, based on their clinical parameters.
Study type
Cost–utility analysis.
Study population
Adults with HF (NYHA classes I–IV) and a LVEF ≤ 35%, and/or at risk of SCD.
Institutional setting
Secondary care.
Country/currency
UK pounds.
Funding source
Biotronik, Boston Scientific, Medtronic, Sorin and St Jude Medical.
Analytical perspective
National Health Service and PSS.
Effectiveness
The clinical effectiveness estimates were based on a NMA of IPD from 13 clinical trials (12,638 patients,
followed up for up to 7.5 years). The clinical trials were CARE-HF,109 COMPANION,116 CONTAK-CD,126
DEFINITE,90 MADIT I,99 MADIT II,101 MADIT-CRT,130 MIRACLE,121 MIRACLE ICD,136 RAFT,140 RethinQ,142
REVERSE208 and SCD-HeFT.105 These trials were identified through a systematic review of clinical
effectiveness for all of the interventions. A further nine trials were also identified in the review but IPD
were not available for these trials.
The NMA enabled trials that compared different sets of treatments to be combined within a single analysis
and direct and indirect evidence to be used to inform a comparison between possible treatments.
All-cause mortality
The NMA found CRT-D to have the strongest effect on all-cause mortality with a HR of
(commercial-in-confidence information has been removed). Treatment effects for the individual devices
were (commercial-in-confidence information has been removed).
The parameters used in the cost-effectiveness model are shown in Table 155. This table shows the
predicted treatment effect for each subgroup.
All-cause hospitalisation
Across all NYHA classes, device therapy was associated with a reduction in admission rates. In NYHA
classes I–III, ICDs were associated with a (commercial-in-confidence information has been removed)
reduction in monthly admission rates and CRT with a (commercial-in-confidence information has been
removed) reduction. The effect in NYHA class IV was even more pronounced, with CRT offering a
(commercial-in-confidence information has been removed) reduction in monthly admission rates.
Intervention costs
Individual patient data from the trials were used to estimate the mean number of all-cause hospitalisation
events per month and the mean number of days hospitalised per month. The hospital costs were derived
from the NHS Reference Costs218 and combined with the average mean length of stay. The HF
hospitalisation event cost was £2295 and the non-HF hospitalisation event cost was £2448.
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TABLE 155 Preferred model for the IPD NMA
Variablea HR p-value
ICD Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRT-P Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRT-D Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
QRS < 120 milliseconds Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
QRS ≥ 120 milliseconds Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
LBBB Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
Age ≥ 60 years Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
Gender=male Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
ICD*QRS < 120 milliseconds Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
ICD*QRS ≥ 120 milliseconds Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
ICD*LBBB Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
ICD*Gender=male Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
ICD*Age ≥ 60 years Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTP*QRS ≥ 120 milliseconds Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTP*LBBB Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTP*Gender=male Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTP*Age ≥ 60 years Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTD*QRS ≥ 120milliseconds Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTD*LBBB Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTD*Gender=male Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
CRTD*Age≥ 60 years Commercial-in-confidence information has
been removed
Commercial-in-confidence information has
been removed
a Reference category is a patient with the following characteristics: receiving OPT, < 60 years of age, female, QRS duration
≥ 150milliseconds and with a non-LBBB conduction abnormality.
Note: Main effects for covariables greyed out as not included in cost-effectiveness model.
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Device costs were sourced from the average selling prices from the manufacturers via ABHI. These prices
are an aggregate across all sponsors (manufacturers) for ICD, CRT-P and CRT-D devices and leads sold in
the UK to the NHS. The implantation costs were taken from the HRG tariff values.218 The device-related
infection cost was derived by inflating the value in Fox and colleagues64 to £3139. Device costs, with
implantation costs, are shown in Table 156.
Medication costs
The cost of HF medication cost included for the patients in the model. The proportion of patients using a
range of HF medications, by NYHA class, was derived through a systematic review and expert opinion.
Common values are applied to all four interventions in each month of the model, on the basis of baseline
NYHA values. Recommended doses and purchase costs of the medications were taken from the BNF.219
The total cost of treatment per 1-month model cycle was £14.28 for NYHA class I and between £22.13
and £22.30 for NYHA classes II–IV.
Indirect costs
Not applicable.
Health state valuations/utilities (if study uses quality-of-life adjustments
to outcomes)
The approach taken for HRQoL was (1) to estimate UK-specific age- and gender-specific population
utilities, (2) derive disease-specific decrements using IPD EQ-5D data and (3) derive treatment-specific
increments associated with each device at first follow-up visit by NYHA class.
UK-specific age- and gender-specific population utilities were taken from a study of 3395 individuals
resident in the UK.152 Disease-specific decrements were taken from the CARE-HF,109 MADIT-CRT130 and
RAFT140 trials. For the impact of treatment, the utility increment was calculated as the difference between
baseline and the first follow-up period.
The HRQoL benefit observed at 6 months is maintained up to 5 years and thereafter begins to recede in a
linear manner over the time period 5–10 years. After 10 years the model assumed that the individual with
a CRT or ICD device will have no additional HRQoL benefit over an identical person receiving OPT.
TABLE 156 Device costs used in the model
Item Cost (£) Components
Initial implant operation (ICD) 15,248 ABHI system costs (incl. leads) and UK tariff EA12Z
Initial implant operation (CRT-P) 8281 UK tariff E07Z
Initial implant operation (CRT-D) 17,849 ABHI system costs (incl. leads) and UK tariff EA12Z
Replacement (ICD) 14,705 ABHI system costs (excl. leads) and UK tariff EA12Z
Replacement (CRT-P) 8281 UK tariff E07Z
Replacement (CRT-D) 17,308 ABHI System costs (excl. leads) and UK tariff EA12Z
Device-related infection (ICD) 18,964 See section 5.5.3.3 in the MS151
Device-related infection (CRT-P) 12,541 See section 5.5.3.3 in the MS151
Device-related infection (CRT-D) 21,568 See section 5.5.3.3 in the MS151
Battery replacement (ICD) 12,004 ABHI generator costs (excl. leads) and UK tariff EA39Z
Battery replacement (CRT-P) 8381 UK tariff
Battery replacement (CRT-D) 14,672 ABHI generator costs (excl. leads) and UK tariff EA39Z
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List the utility values used in the evaluation
Individuals in NYHA class I/II have the same HRQoL as an age-equivalent member of the general public
(Table 157). Patients in NYHA classes III and IV have extra decrements by sex and ischaemic aetiology
(Table 158).
TABLE 157 Age- and gender-specific UK EQ-5D population norms [mean (SD)]
Age band (years) Male Female
< 25 0.94 (0.12) 0.94 (0.12)
25–34 0.93 (0.16) 0.93 (0.15)
35–44 0.91 (0.17) 0.91 (0.15)
45–54 0.84 (0.27) 0.85 (0.23)
55–64 0.78 (0.28) 0.81 (0.26)
65–74 0.78 (0.28) 0.78 (0.25)
75+ 0.75 (0.28) 0.71 (0.27)
Reproduced from Kind et al.152
TABLE 158 Negative binomial regression model coefficients used to predict baseline utility decrements
Covariable Beta coefficient SE Z-score e^β
NYHA= III Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
NYHA= IV Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Age Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Ischaemic
aetiology
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Gender=male Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Constant Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
Commercial-in-
confidence information
has been removed
a Variable included despite not being significant on the basis of the underlying disease. Lack of significance likely to have
arisen because of small patient counts.
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Modelling
The model is a survival model with two states for alive and dead. Death is modelled through a series of
covariate-based regression equations for baseline risk and treatment effect using long-term IPD. There is
also a state for all-cause hospitalisation that is aligned to mortality.
The baseline probability of death is for patients who receive OPT but no device, based on a range of
clinical covariates. These probabilities are used in combination with device-specific treatment effects,
derived from the NMA. A similar approach is taken to estimate the probability of all-cause hospitalisation.
HRQoL utility is applied to patients in the model according to their treatment and clinical characteristics.
The model does not include short-term device-related adverse events as the costing approach used to
derive total implant costs covers additional costs such as short-term adverse events.
Results were generated in a two-stage process. In the first, both for patients with and without LBBB, cost
and QALY estimates were derived for all relevant comparators for all 4992 patient profiles [four NYHA
classes × two aetiology status (ischaemic/non-ischaemic) × three QRS categories × four LVEF
categories × LBBB status (yes/no) × two gender groups × 13 age categories]. In the second stage, these
were collapsed to 48 subgroups defined by NYHA class, QRS duration, LBBB status and aetiology. Results
were aggregated over LVEF and age and gender categories.
Extract transition probabilities for [natural history/disease progression]
model and show sources (or refer to table in text)
Mortality For the model the baseline survival curve was derived using the following formulae:
h(t) ¼ exp (−(log (scale)−β  X ) shape) shape tshape (1)
S(t) ¼ exp (−∫ t0h (t)dt) (2)
where h(t) is the instantaneous hazard, S(t) is the survival curve, β are the coefficients on the covariables
and X is the set of covariables (which can be time dependent).
All-cause hospitalisation The derived monthly probabilities are shown in Table 161, using a starting age
of 66 years.
Device lifetime UK device longevity estimates were derived from an analysis of all implants with verified
life status from 2000 to 2011 (∼40,000 implants). Device-specific median survival estimates were used to
TABLE 159 Treatment-specific utility increments used in the economic model
Treatment NYHA I/II NYHA III NYHA IV
OPT Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
ICD Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
CRT-P Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
CRT-D Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
Commercial-in-confidence
information has been removed
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TABLE 160 Preferred baseline risk model
Variable Coefficient
HR for
prognostic variablea p-value
Age (per year) Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Male gender Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
NYHA class III Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
NYHA class IV Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Ischaemic aetiology Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
QRS duration
< 120 milliseconds
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
LVEF > 20% and ≤ 25% Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
LVEF > 25% and ≤ 30% Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
LVEF > 30% Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
log(scale) Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
log(shape) Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
a HR= exp(β/shape).
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inform transition probabilities of device failure in the model. Median time to device failure in the model
was 7.1 years for an ICD device, 10.4 years for a CRT-P device and 5.8 years for a CRT-D device.
What is the model time horizon?
Lifetime.
What discount rates have been applied in the model?
3.5% for costs and benefits.
Results/analysis
What measure(s) of benefit were reported in the evaluation?
The model estimates the total lifetime QALYs for various patient subgroups, but these values are not
presented in the report.
Provide a summary of the costs estimated for each intervention/strategy
assessed in the evaluation
The model estimates the total lifetime costs for various patient subgroups, but these values are not
presented in the report.
Synthesis of costs and benefits
The results of the base-case deterministic cost-effectiveness analysis are presented for 48 subgroups
defined by NYHA class, QRS duration, LBBB status and aetiology (24 subgroups for patients with LBBB and
24 subgroups for patients without) (Tables 162 and 163). All individuals are assumed to have a LVEF
≤ 35%. The authors stated that ischaemia did not substantively impact on cost-effectiveness and so the
results presented are therefore applicable to both ischaemic and non-ischaemic patients
TABLE 161 Monthly probability of hospitalisation by covariate pattern (OPT)
NYHA class I/II NYHA class III NYHA class IV
Non-ischaemic aetiology
QRS < 120 milliseconds Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
QRS 120–149 milliseconds Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
QRS ≥ 150 milliseconds Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Ischaemic aetiology
QRS < 120 milliseconds Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
QRS 120–149 milliseconds Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
QRS ≥ 150 milliseconds Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
Commercial-in-confidence
information has
been removed
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Summary of results
NYHA class I/II
l QRS duration < 120milliseconds: the ICERs for ICD compared with OPT are < £25,200 per
QALY gained.
l QRS duration 120–149milliseconds: ICD is a cost-effective treatment option (ICER< £17,000 per QALY)
for patients with no LBBB. For CRT-D, all ICERs are < £25,000 per QALY gained in LBBB
patients (£20,608–24,343).
l QRS duration ≥ 150milliseconds: CRT-D is a cost-effective treatment with an ICER of < £28,000 per
QALY for all options.
NYHA class III
l QRS duration < 120milliseconds: ICD compared with OPT generates ICERs of < £30,000 per QALY.
l QRS duration 120–149milliseconds: CRT-P is cost-effective. CRT-D generates ICERs of between
£23,900 and £27,400 per QALY gained relative to CRT-P.
l QRS duration > 150milliseconds: CRT-P is cost-effective compared with OPT (ICER < £20,000 per
QALY). Compared with CRT-P, CRT-D generates ICERs of < £30,000 per QALY gained. ICD is either
dominated or extendedly dominated.
NYHA class IV
l QRS duration < 120milliseconds: no comparative analysis was possible in this patient group.
l QRS duration ≥ 120milliseconds: For CRT-P compared with OPT, all ICERs are close to or < £20,000 per
QALY gained. For the comparison of CRT-D with CRT-P, all ICERs are > £30,000 per QALY gained.
The authors reported that, in many cases, there is little difference between the best and second best
options (when viewed in terms of ICERs), and there may be other issues that clinicians wish to take into
account; they conclude that there seems to be a reasonable case for building clinical flexibility into the
recommendations in those cases in which the ICER differences between technologies are small and
the uncertainty over which is the preferred device is high.
Give results of any statistical analysis of the results of the evaluation
Not applicable.
Was any sensitivity analysis performed?
Yes, deterministic sensitivity analysis.
What scenarios were tested in the sensitivity analysis?
The following scenarios were tested in sensitivity analyses: removal of treatment effect tapering
(mortality and HRQoL), use of alternative NYHA-based IPD results and increase in device longevity.
Give a summary of the results of the sensitivity analysis
The following scenarios were tested in sensitivity analyses: removal of treatment effect tapering
(mortality and HRQoL), use of alternative NYHA-based IPD results and increase in device longevity. The
base case assumed that treatment effects on mortality or HRQoL are not constant but diminish over time.
When constant treatment effects for mortality and HRQoL were explored, the ICERs in all patient groups
were lower than in the base case.
According to the MS, there may be a lower mortality treatment effect of CRT-D in patients in NYHA
class IV than in patients in NYHA classes I–III. The economic model was run using the estimated all-cause
mortality treatment effects based on the grouping of NYHA class IV patients compared with
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NYHA class I–III patients. This analysis results in CRT-D becoming dominated in all NYHA class IV groups.
The ICERs for all other groups are lower than in the base case.
Device longevity was investigated by increasing the time to device failure by 10%. This resulted in only
minimal changes to the ICERs.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis
This analysis reconfirms the clinical and economic value of ICD, CRT-P and CRT-D in NYHA class I–IV
HF patients.
What are the implications of the evaluation for practice?
The recommendations from this analysis would lead to a widening of the eligibility criteria for an ICD or a
CRT device and consequently an increase in implant rates. The analysis estimates that the additional
annual expenditure incurred by the NHS would range from £41.6M to £230.2M, depending on the choice
of scenario and year of interest.
Southampton Health Technology Assessments Centre commentary
Selection of comparators
The interventions compared in the MS consist of those included in NICE’s scope.1 However, not all of them
were included as comparators for all patient subgroups:
l ICD was excluded for NYHA class IV
l CRT-P was excluded for NYHA class I/II and QRS duration < 120milliseconds
l CRT-D was excluded for QRS duration < 120milliseconds.
These exclusions seem to conflict with NICE’s scope, for example some patients in the scoped population
with HF and ventricular arrhythmia considered eligible for an ICD are likely to be in NYHA class IV.
Validity of estimate of measure of benefit
Device-specific increments seem similar to those in previous models but the magnitude of the HF-related
decrements is not clear from the regression coefficients reported in the MS.
Validity of estimate of costs
Overall, the derivation of costs and assumptions presented in the MS seem appropriate and consistent with
previous approaches. However, specific searches for resource use or cost studies in the UK are not
reported and the impact of changes to the values and assumptions used was not analysed in the MS.
The estimates in the model seem to cover the relevant resource use, including complications, non-HF
hospitalisations and outpatient visits.
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Appendix 11 List of excluded economic
evaluations
A lcaraz A, Gonzalez ZJ, Augustovski F. Cost-effectiveness of implantable cardioverter-defibrillator inpatients with risk factors for sudden death in Argentina. Value Health 2011;14(Suppl. 1):S33–8.
[Reason for exclusion: language.]
Anderson MH, Camm AJ. Implications for present and future applications of the implantable
cardioverter-defibrillator resulting from the use of a simple model of cost efficacy. Br Heart J
1993;69:83–92. [Reason for exclusion: no comparator.]
Bryant J, Brodin H, Loveman E, Clegg A. Clinical effectiveness and cost-effectiveness of implantable
cardioverter defibrillators for arrhythmias: a systematic review and economic evaluation. Int J Technol
Assess Health Care 2007;23:63–70. [Reason for exclusion: abstract has limited details.]
Feingold B, Arora G, Webber SA, Smith KJ. Cost-effectiveness of implantable cardioverter-defibrillators in
children with dilated cardiomyopathy. J Card Fail 2010;16:734–41. [Reason for exclusion: population.]
Groarke J, Orfali N, Nolan P, Heerey A, Kasim S, Crowley J, et al. Cost effectiveness of implantable
cardioverter defibrillator (ICD) therapy in clinical practice. Eur Heart J 2010;31(Suppl. 1):225. [Reason for
exclusion: abstract.]
Groeneveld PW, Farmer SA, Suh JJ, Matta MA, Yang F. Outcomes and costs of implantable
cardioverter-defibrillators for primary prevention of sudden cardiac death among the elderly. Heart Rhythm
2008;5:646–53. [Reason for exclusion: no economic evaluation.]
Hauer RN, Derksen R, Wever EF. Can implantable cardioverter-defibrillator therapy reduce healthcare
costs? Am J Cardiol 1996;78:134–9. [Reason for exclusion: comparator.]
Kutyifa V, Aidelsburger P, Schauer S, Merkely B, Klein H, Kuniss M, et al. Cost-effectiveness of cardiac
resynchronization therapy in combination with an implantable cardioverter defibrillator in mild heart failure
based on Markov modeling using UK cost approach in MADIT CRT. Eur Heart Jl 2012;33:896. [Reason for
exclusion: abstract.]
L’Agence Nationale d’Accreditation d’Evaluation en Sante (ANAES). Implantable Cardioverter Defibrillators:
Update. Paris: L’Agence Nationale d’Accreditation d’Evaluation en Sante (ANAES); 2001. [Reason for
exclusion: no economic evaluation.]
Linde C, Mealing S, Hawkins N, Eaton J, Brown B, Daubert JC, et al. Cost-effectiveness of cardiac
resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European
cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
Eur Heart J 2011;32:1631–9. [Reason for exclusion: population.]
Maniadakis N, Ekman M, Calvert MJ, Freemantle N, Karamalis M, Vardas P. Cost effectiveness of cardiac
resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure
trial. Europace 2011;13:1597–603. [Reason for exclusion: excluded in error.]
Medical Advisory Service. Internet-based device-assisted remote monitoring of cardiovascular implantable
electronic devices. Ont Health Technol Assess Ser 2012;12(1). [Reason for exclusion: intervention.]
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Mushlin AI, Zwanziger J, Gajary E, Andrews M, Marron R. Approach to cost-effectiveness assessment in
the MADIT trial. Am J Cardiol 1997;80:F33–41. [Reason for exclusion: no economic evaluation.]
Neyt M, Stroobandt S, Obyn C, Camberlin C, Devriese S, De Laet C, et al. Cost-effectiveness of cardiac
resynchronisation therapy for patients with moderate-to-severe heart failure. Value Health 2011;14:A253.
[Reason for exclusion: abstract.]
Health Improvement Scotland. The Use of Cardiac Resynchronization Therapy (CRT) for Heart Failure.
Evidence Note 10. URL: www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/
earlier_evidence_notes/evidence_note_10.aspx (accessed April 2014). [Reason for exclusion: no
economic evaluation.]
Pons JM, Granados A. Implantable Cardioverter Defibrillator: Experience in Catalonia (1989–1995)
and Elements of its Evaluation. Catalonia, Spain: Department of Health; 1997. [Reason for
exclusion: unobtainable.]
Poggio R, Augustovsky F, Caporale J, Irazola V, Miriuka S. Cost-effectiveness of cardiac resynchronization
therapy: perspective from Argentina. Int J Technol Assess Health Care 2012;28:429–35. [Reason for
exclusion: population.]
Pozzolini A. Cost-effectiveness of ICD Therapy in the Prevention of Sudden Death in CAD and/or HF
Patients. Milan: Springer-Verlag Italia; 2007. [Reason for exclusion: unobtainable.]
Shah P, Rongione A, Hewitt P, Rosner C, May C, Burton N, et al. Is cardiac resynchronization therapy a
cost-effective strategy in patients whose ultimate destination is a left ventricular assist device? J Heart Lung
Transplant 2012;31:S50–1. [Reason for exclusion: abstract.]
Taylor R. The Clinical and Cost Effectiveness of Biventricular Pacing for Patients with Severe Heart Failure.
A West Midlands Health Technology Assessment Collaboration Report. Report no. 55. Birmingham:
Department of Public Health and Epidemiology, University of Birmingham; 2005. [Reason for exclusion:
no economic evaluation.]
Wells GA, Coyle D, Nichol G, Coyle K, Talajic M, Tang A. Cost effectiveness of cardiac resynchronization
therapy (CRT) for mild to moderate heart failure. Can J Cardiol 2012;28(Suppl.):S419. [Reason for
exclusion: unobtainable.]
Wever EF, Hauer RN, Schrijvers G, van Capelle FJ, Tijssen JG, Crijns HJ, et al. Cost-effectiveness of
implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in
postinfarct sudden death survivors. A randomized study. Circulation 1996;93:489–96. [Reason for
exclusion: comparator.]
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Appendix 12 Data extraction: cost-effectiveness
Buxton and colleagues 2006153
Country UK
Analysis type Cost–utility analysis/cost-effectiveness analysis
Study type Markov model
Perspective UK NHS
Time horizon 20 years
Discounting (rate) Base-case discount rates were 6% for costs and 1.5% for benefits
Costing year, currency 2001/2 prices, UK pounds
Population Secondary prevention patients at risk of SCD with previously documented cardiac
arrest or VT
Intervention(s), comparator(s) ICD vs. OPT (amiodarone)
Intervention effect Transition probabilities were estimated using IPD from the CIDS trial84
(for OPT patients) and UK sampled observational data (for ICD patients)
Health outcomes A cross-sectional survey collected HRQoL data (using the NHP, SF-36, Hospital Anxiety
and Depression questionnaire and EQ-5D) on a sample of 229 patients
Device cost Cost of ICD (with leads) £16,402
Results Over a 20-year time horizon, the mean discounted incremental cost was £70,900. The
mean discounted incremental gain was 1.24 years or 0.93 QALYs for ICD compared
with OPT. The ICER for an average UK patient was £76,139 per QALY gained
Sensitivity analysis Sensitivity analyses suggested that targeting those patients at greatest risk of SCD,
through either age or poor LVEF, would increase the overall cost-effectiveness of ICD
Authors’ conclusions The results suggest that ICDs, as currently applied in the UK, are not cost-effective by
conventional standards
Reviewer’s comments Sound UK study that included QoL and costing studies for ICD patients
Quality assessment form for economic evaluations
Item Y/N/?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Y
2. Is the setting comparable to the UK? Y
3. Is the analytical and modelling methodology appropriate? Y
4. Are all the relevant costs and consequences for each alternative identified? Y
5. Are the data inputs for the model described and justified? Y
6. Are health outcomes measured in QALYs? Y
7. Is the time horizon considered appropriate? Y
8. Are costs and outcomes discounted? Y
9. Is an incremental analysis performed? Y
10. Is uncertainty assessed? Y
?, unclear; N, no; Y, yes.
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Bond and colleagues 2009,203 derived from Fox and
colleagues 200764
Country UK
Analysis type Cost–utility analysis
Study type Markov model
Perspective UK NHS
Time horizon Lifetime
Discounting (rate) Costs and QALYs 3.5%
Costing year,
currency
2005 UK pounds for all costs except drug costs (2006 UK pounds)
Population A mixed-age cohort of patients with NYHA class III and IV HF, evidence of LVSD (LVEF ≤ 35%) and
evidence of electrical dyssynchrony (QRS duration > 120milliseconds)
Intervention(s),
comparator(s)
CRT vs. OPT;a CRT-Db vs. CRT; OPT vs. CRT vs. CRT–D
Intervention
effectc
RR of death from HF with device: CRT and CRT-D: HR 0.68 (95% CI 0.46 to 0.98); ICD: HR 0.95
(95% CI 0.74 to 1.21)
RR of sudden death with device: CRT: HR 0.75 (95% CI 0.45 to 1.18); CRT–D: HR 0.44 (95% CI 0.23
to 0.86); ICD: HR 0.37 (95% CI 0.27 to 0.50)
Health outcomes Mean model survival was 4.7 years, 5.8 years and 6.2 years for OPT, CRT and CRT-D respectively.
NYHA class-specific estimates of QoL were used to derive time-dependent utility estimates (derived
from the CARE-HF trial109 and the study by Kirsch and McGuire,210 which used EQ-5D and UK
population values) and utility of hospitalisation because of HF (from McAlister et al.194)
Device cost Surgery to implant new system (includes cost of the device): CRT £5074; CRT-D £17,266;
ICD £11,596
Results
Discounted
Mean
cost (£)
Mean
QALYs
Incremental
cost (£)
Incremental
QALYs
ICER (£)
(95% CI) p(CE) (%)
OPT 9367 3.10 – – – –
CRT 20,997 3.80 – – – –
CRT-D 32,687 4.09 – – – –
CRT
vs. OPT
– – 11,630 0.70 16,738
(14,630 to 20,333)
91.3
CRT-D
vs. CRT
– – 11,689 0.29 40,160
(26,645 to 59,391)
26.3
p(CE), probability of being cost-effective at a WTP threshold of £30,000 per QALY.
Sensitivity analysis Deterministic univariate and probabilistic sensitivity analyses were conducted. One-way sensitivity
analyses show the sensitivity of the results to structural parameters, event probabilities and RRs.
In comparison to CRT, CRT-D devices were most likely to be cost-effective when implanted in younger
individuals and in those with a high risk of SCD. A cost-effectiveness probability frontier shows that
CRT is most likely to be the most cost-effective option at WTP thresholds between £17,000 and
£39,000. Above the WTP threshold of £40,000, CRT-D would be the option with the highest
expected net benefit (approximately 50% probability of being cost-effective)
Authors’
conclusions
CRT-D is not cost-effective for LVSD. Instead, CRT alone remains the most cost-effective policy option
in this population. CRT-D is more likely to be cost-effective in the subgroups of younger patients or
those with a high risk of SCD who would qualify for CRT
Reviewer’s
comments
PenTAG’s cost–utility analysis in the UK setting using clinical effectiveness data from accompanying
systematic review and meta-analysis of RCTs
PenTAG, Peninsula Technology Assessment Group.
a Referred to as medical therapy.
b Referred to as CRT-ICD.
c Source: Fox et al.64
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Quality assessment form for economic evaluations
Item Y/N/?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Y
2. Is the setting comparable to the UK? Y
3. Is the analytical and modelling methodology appropriate? Y
4. Are all the relevant costs and consequences for each alternative identified? Y
5. Are the data inputs for the model described and justified? Y
6. Are health outcomes measured in QALYs? Y
7. Is the time horizon considered appropriate? Y
8. Are costs and outcomes discounted? Y
9. Is an incremental analysis performed? Y
10. Is uncertainty assessed? Y
?, unclear; N, no; Y, yes.
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Appendix 13 List of excluded quality-of-life
studies
A lmenar-Pertejo M, Almenar L, Martinez-Dolz L, Campos J, Galan J, Girones P, et al. Study onhealth-related quality of life in patients with advanced heart failure before and after transplantation.
Transplant Proc 2006;38:2524–6. [Reason for exclusion: format of measure.]
Austin J, Williams R, Ross L, Moseley L, Hutchison S. Randomised controlled trial of cardiac rehabilitation in
elderly patients with heart failure. Eur J Heart Fail 2005;7:411–17. [Reason for exclusion: format
of measure.]
Austin J, Williams WR, Ross L, Hutchison S. Five-year follow-up findings from a randomized controlled trial
of cardiac rehabilitation for heart failure. Eur J Cardiovasc Prev Rehabil 2008;15:162–7. [Reason for
exclusion: format of measure.]
Austin J, Williams WR, Hutchison S. Multidisciplinary management of elderly patients with chronic heart
failure: five year outcome measures in death and survivor groups. Eur J Cardiovasc Nurs 2009;8:34–9.
[Reason for exclusion: format of measure.]
Cooper TJ, Dickstein K, Hasselberg N, Comin-Colet J, Filippatos G, Lainscak M, et al. Changes in symptom
and quality-of-life assessments correlate strongly and consistently with changes in functional capacity in
patients with heart failure. Eur J Heart Fail 2011;10(Suppl. 1):S162. [Reason for exclusion: abstract.]
de Rivas B, Permanyer-Miralda G, Brotons C, Aznar J, Sobreviela E. Health-related quality of life in
unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and
determinants of impairment: the INCA study. Qual Life Res 2008;17:1229–38. [Reason for exclusion:
Spanish tariff for EQ-5D.]
Flynn KE, Lin L, Ellis SJ, Russell SD, Spertus JA, Whellan DJ, et al. Outcomes, health policy, and managed
care: relationships between patient-reported outcome measures and clinical measures in outpatients with
heart failure. Am Heart J 2009;158:S64–71. [Reason for exclusion: EQ-5D VAS.]
Iqbal J, Francis L, Reid J, Murray S, Denvir M. Quality of life in patients with chronic heart failure and their
carers: a 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Fail 2010;12:1002–8.
[Reason for exclusion: format of measure.]
Kaplan RM, Tally S, Hays RD, Feeny D, Ganiats TG, Palta M, et al. Five preference-based indexes in cataract
and heart failure patients were not equally responsive to change. J Clin Epidemiol 2011;64:497–506.
[Reason for exclusion: format of measure.]
Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart
disease. Health Econ 2000;9:149–58. [Reason for exclusion: time trade-off measure.]
Kontodimopoulos N, Argiriou M, Theakos N, Niakas D. The impact of disease severity on EQ-5D and SF-6D
utility discrepancies in chronic heart failure. Eur J Health Econ 2011;12:383–91. [Reason for exclusion:
format of measure.]
Linde C, Mealing S, Hawkins N, Eaton J, Brown B, Daubert JC, et al. Cost-effectiveness of cardiac
resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European
cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction).
Eur Heart J 2011;32:1631–9. [Reason for exclusion: utility not reported.]
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Marti B, Delgado J, Oliva J, Llano M, Pascual P, Comin J, et al. Quality of life in chronic symptomatic heart
failure patients in Spain. Value Health 2010;7:A363. [Reason for exclusion: abstract.]
Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, et al. Monitoring clinical
changes in patients with heart failure: a comparison of methods. Am Heart J 2005;150:707–15.
[Reason for exclusion: format of measure.]
Spiraki C, Kaitelidou D, Papakonstantinou V, Prezerakos P, Maniadakis N. Health-related quality of life
measurement in patients admitted with coronary heart disease and heart failure to a cardiology
department of a secondary urban hospital in Greece. Hellenic J Cardiol 2008;49:241–7.
[Reason for exclusion: format of measure.]
Sullivan MD, Newton K, Hecht J, Russo JE, Spertus JA. Depression and health status in elderly patients with
heart failure: a 6-month prospective study in primary care. Am J Geriatr Cardiol 2004;13:252–60.
[Reason for exclusion: uses EQ-5D VAS.]
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Appendix 14 Development of Southampton
Health Technology Assessments Centre model
F rom the review of published economic evaluations, the study by Fox and colleagues64 was found to bethe most adequate for the derivation of a model that would allow the questions of the current
assessment to be addressed, with the necessary adaptations to reflect current clinical practice.
The structure of Fox and colleagues’ model for the OPT arm was considered appropriate for the SHTAC
population 1 model. The Fox and colleagues model structure for the OPT arm allowed patients initially
managed with OPT alone to be upgraded to ICD+OPT in case of hospitalisation for arrhythmia (assumed
direct referral to ICD implantation) or following hospitalisation for HF [given that in the CARE-HF trial109 a
proportion of those in the OPT alone arm who were hospitalised for HF were then referred to a device
with a defibrillation function (CRT-D), Fox and colleagues assumed the same probability for referral to an
ICD]. Clinical advice to SHTAC indicated that referral from OPT alone to ICD implantation would occur in
clinical practice only for population 1 patients. Fox and colleagues’ model structure, including health states
modelled and transitions allowed, was therefore replicated for population 1.
According to clinical advice, population 2 patients would be referred to CRT-P implantation (given their
HF severity) and, in case of also being at high risk of severe arrhythmia, could be referred to CRT-D
implantation. Clinical opinion confirmed that Fox and colleagues’ model structure for the population 2
CRT-P arm was appropriate for the SHTAC population 2 model and that it could form the basis for
modelling population 3.
Adaptations common to all models
Fox and colleagues64 used a specific set of transitions between health states for each of the treatment
arms, that is, patients in each arm were eligible only for some of the available treatments (e.g. HF patients
initially managed with OPT could upgrade only to ICD+OPT whereas those in the CRT-P arm could
upgrade to CRT-D or ICD or explant and be managed with OPT alone). Following feedback from clinical
experts, we decided that all treatment arms in each model should use the same transition matrix, allowing
the modelled cohort of patients to start with the respective treatment and be referred for upgrades
according to probability estimates derived from clinical trials included in SHTAC’s clinical effectiveness
review (see Chapter 4).
For consistency with other surgical procedures and devices modelled and following clinical advice, the risk
of death as a result of transplantation, the risk of hospitalisation for arrhythmia with ICD and CRT-D
therapy, and the risk of lead displacement for ICD therapy were incorporated in the models for
all populations.
The model developed by Fox and colleagues64 assumed that all patients being managed with a device
would be subject to routine device replacement, including patients who were stable with the device, those
having a device-related complication (perioperative, lead displacement or lead infection), those hospitalised
because of HF with a device or those referred for an upgrade following hospitalisation because of HF. For
modelling simplicity and acknowledging the risk of underestimation, in SHTAC’s model only patients who
are stable with the device were subject to routine device replacement, assuming that this allows for a
reasonable estimation of the number of replacements in the patient cohorts over a lifetime.
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Model-specific adaptations
Surgical failure was incorporated in the model for population 1 for consistency with the models for
populations 2 and 3. As clinical advice suggested that returning to management with OPT alone after
unsuccessful ICD implantation would be very unlikely, the population 1 model assumes that patients who
survive unsuccessful ICD implantation reattempt it the following cycle.
In accordance with the model developed by Fox and colleagues,64 in the models for populations 2 and 3,
patients receiving CRT-P who experience lead infection or displacement were assumed to return to being
managed with OPT alone if experiencing surgical failure. For consistency among health states, the risk of
surgical failure was explicitly accounted for in all health states involving surgery (including first device
implantation and routine device replacements). For model simplicity and consistency, patients who survive
unsuccessful ICD implantation were also assumed to return to management with OPT alone. Those with
unsuccessful CRT-D implantation were assumed to undergo ICD implantation.
The model structure for population 2 differs slightly from that in the study by Fox and colleagues.64 The
main variations relate to the transitions allowed for patients managed with OPT alone. In SHTAC’s model,
patients with OPT alone who are hospitalised because of HF or severe arrhythmia can be referred to CRT-P
or CRT-D implantation in the following cycle, according to the probabilities reported in the relevant trials.
Patients can receive an ICD only following unsuccessful CRT-D implantation, as patients who survive
unsuccessful CRT-D implantation are assumed to undergo ICD implantation.
The main adaptation introduced to Fox and colleagues’ model structure for population 3 relates to the
referral of patients to CRT-D implantation. Patients being managed with OPT alone or CRT-P+OPT who
are hospitalised because of a serious arrhythmic event are assumed to undergo CRT-D implantation in the
same cycle. Those being managed with OPT alone because of unsuccessful CRT-P implantation can be
referred to ICD implantation if they experience a life-threatening arrhythmia.
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Appendix 15 Parameters included in the
probabilistic sensitivity analyses
Parameter inputs for the population 1 model
Parameter type Parameter
Source estimate
DistributionMean SE LL UL
All-cause mortality ln(λ) –3.381 0.0257 –3.431 –3.330 Normal
γ 0.696 0.0092 0.678 0.714 Normal
HR ICD 0.75 0.0816 0.61 0.93 Log-normal
All causes multiplier HR 18–59 0.62 0.0459 0.54 0.72 Log-normal
HR 75+ 1.41 0.0051 1.40 1.42
Because of surgery ICD 0.0034 0.0262 –0.0479 0.0548 Normal
Probability of perioperative death Transplant 0.122 0.007 0.109 0.136 Normal
Event probabilities (per cycle)
Hospitalisation for HF OPT 0.0082 0.0061 –0.0036 0.0201 Beta
RR ICD 1 0.1 0.804 1.196
Probability of transplant following
HF hospitalisation
Transplant 0.0014 0.0025 –0.0034 0.0062 Beta
Non-fatal arrhythmia requiring hospitalisation OPT 0.0075 0.0037 0.00016 0.0148 Beta
ICD 0.0075 0.0037 0.00016 0.0148
Probability of surgical failure ICD 0.011 0.0441 –0.07659 0.0962 Beta
Device replacement interval ln(λ) –15.784 0.203 –16.182 –15.385 Normal
γ 1.942 0.0273 1.889 1.996
Upgrade after HF hospitalisation OPT to ICD 0.0018 0.002 –0.0023 0.0059 Beta
LL, lower limit; UL, upper limit.
Parameter inputs for the population 2 model
Parameter type Parameter
Source estimate
LL UL DistributionMean SE
Death from HF, age 65–74 years, OPT ln(λ) –6.115 0.070 –6.253 –5.977 Normal
γ 1.223 0.022 1.180 1.265 Normal
HR CRT-P 0.67 0.094 0.51 0.88 Log-normal
HR CRT-D 0.73 0.163 0.47 1.11 Log-normal
HR ICD 1.14 0.153 0.88 1.48 Log-normal
Post-transplant mortality RR Transplant 0.35 0.035 0.281 0.419 Log-normal
Death from SCD ln(λ) –6.069 0.053 –6.173 –5.964 Normal
γ 1.140 0.017 1.107 1.173 Normal
HR CRT-P 1 0.1505 0.54 1.13 Log-normal
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Parameter type Parameter
Source estimate
LL UL DistributionMean SE
HR CRT-D 0.44 0.1607 0.23 0.86 Log-normal
HR ICD 0.44 0.0765 0.31 0.61 Log-normal
All-cause mortality RR by age (years) 18–64 0.62 0.05 0.54 0.72 Log-normal
75+ 1.41 0.01 1.4 1.42
Event probabilities (per cycle)
Surgical mortality ICD 0.003 0.026 0.000 0.055 Beta
CRT-P 0.005 0.002 0.001 0.008
CRT-D 0.005 0.003 0.000 0.011
Transplant 0.122 0.007 0.109 0.136
Hospitalisation for HF OPT 0.037 0.006 0.025 0.049 Beta
RR ICD 1 0.1 0.804 1.196
RR CRT-P 0.58 0.1556 0.35 0.96
RR CRT-D 0.77 0.0765 0.63 0.93
Transplant following HF hospitalisation Transplant 0.001 0.002 –0.003 0.006 Beta
Non-fatal arrhythmia requiring hospitalisation OPT 0.007 0.004 0.000 0.015 Beta
ICD 0.007 0.004 0.000 0.015
CRT-P 0.007 0.004 0.000 0.015
CRT-D 0.007 0.004 0.000 0.015
Probability of upgrade after HF hospitalisation OPT to ICD 0 0 0 0 Beta
OPT to CRT-P 0.003 0.003 0.000 0.009
OPT to CRT-D 0.002 0.002 0.000 0.006
CRT-P to CRT-D 0.001 0.001 0.000 0.003
Surgical failure ICD 0.011 0.001 0.009 0.013 Beta
CRT-P 0.084 0.007 0.070 0.097
CRT-D 0.087 0.012 0.064 0.109
LL, lower limit; UL, upper limit.
Parameter inputs for the population 3 model
Parameter type Parameter
Source estimate
LL UL DistributionMean SE
All-cause mortality,
baseline – CRT-D
ln(λ) –6.334 0.068 –6.467 –6.202 Normal
γ 1.234 0.018 1.199 1.270 Normal
HR CRT-P 1 0.100 0.804 1.196 Log-normal
HR ICD 1.190 0.084 1.042 1.370 Log-normal
HR OPT 1.563 0.235 1.163 2.083 Log-normal
All-cause mortality RR by
age (years)
18–64 0.621 0.046 0.54 0.72 Log-normal
75+ 1.410 0.005 1.4 1.42
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Parameter type Parameter
Source estimate
LL UL DistributionMean SE
Event probabilities (per cycle) CRT-D 0.008 0.003 0.003 0.013 Beta
Hospitalisation for HF RR ICD 1.333 0.133 1.136 1.563 Log-normal
RR CRT-P 1 0.1000 0.804 1.196
RR OPT 1.67 0.0893 1.51 1.86
Non-fatal arrhythmia
requiring hospitalisation
CRT- D 0.029 0.007 0.015 0.042 Log-normal
ICD RR 1.111 0.111 0.880 1.410
CRT-P RR 1 0.1 0.804 1.196
OPT RR 1 0.1 0.804 1.196
Probability of upgrade after
HF hospitalisation
OPT to ICD 0.002 0.002 0 0.006 Beta
OPT to CRT-P 0.003 0.003 0 0.009
OPT to CRT-D 0.002 0.002 0 0.006
CRT-P to CRT-D 0.001 0.001 0 0.003
ICD to CRT-D 0.007 0.003 0.001 0.013
Surgical mortality ICD 0.003 0.026 0 0.055 Beta
CRT-P 0.005 0.002 0.001 0.008
CRT-D 0.005 0.003 0 0.011
Surgical failure ICD 0.011 0.001 0.009 0.013 Beta
CRT-P 0.084 0.007 0.070 0.097
CRT-D 0.087 0.012 0.064 0.109
Device lifetime ICD ln(λ) –15.784 0.203 –16.182 –15.385 Normal
CD γ 1.943 0.027 1.889 1.996
CRT-P ln(λ) –14.222 0.242 –14.697 –13.747
CRT-P γ 1.677 0.032 1.613 1.740
CRT-D ln(λ) –15.465 0.273 –16 –14.931
CRT-D γ 1.935 0.036 1.863 2.006
LL, lower limit; UL, upper limit.
For all populations: utilities
Parameter type Parameter Mean SE UL LL Distribution
No HF 0.855 0.0048 0.845 0.864 Beta
Per NYHA class NYHA I 0.855 0.0048 0.845 0.864 Beta
NYHA II 0.771 0.0051 0.761 0.781
NYHA III 0.673 0.0097 0.727 0.765
NYHA IV 0.532 0.0265 0.48 0.584
HF hospitalisation Hospitalisation
with HF
0.57 0.0570 0.458 0.682 Beta
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Parameter type Parameter Mean SE UL LL Distribution
Utility decrement Surgery 0.05 0.0255 0 0.1 Beta
Infection 0.1 0.0255 0.05 0.15
Proportion of month hospitalised for
HF (%)
25 0.0255 20 30 Beta
Costs and resource use
Parameter type Parameter Mean (£) SE (£) UL (£) LL (£) Distribution
Implantation CRT-P 8281 1479 6098 11,895 Gamma
CRT-D 17,849 4521 15,246 32,969
ICD 15,248 4261 13,155 29,858
Lead displacement/implantation failure CRT-P 5681 1219 4008 8786 Gamma
CRT-D 6097 3346 5798 18,914
ICD 6099 3346 5799 18,916
Battery failure/device malfunction CRT-P 5348 788 3884 6974 Gamma
CRT-D 17,308 1704 14,811 32,322
ICD 14,705 4207 12,718 29,209
Infection CRT-P 12,553 2036 7285 15,265 Gamma
CRT-D 21,580 5552 17,202 38,966
ICD 18,977 5292 15,109 35,853
Operative complications CRT-P 4884 1869 2442 9768 Gamma
CRT-D 6634 2539 3317 13,268
ICD 3432 1313 1716 6864
Non-elective hospitalisation HF
hospitalisation
2308 232 1669 2578 Gamma
Arrhythmia
hospitalisation
1372 173 922 1601
Transplant Heart transplant 35,606 5578 21,449 43,315 Gamma
Outpatient appointments, 6-monthly Outpatient
cardiology
specialist
follow-up
123 14 94 148 Gamma
OPT drugs, average monthly cost per class NYHA class I 5.78 2.21 2.89 11.56 Gamma
NYHA class II 19.39 7.42 9.695 38.78
NYHA class III 19.56 7.48 9.78 39.12
NYHA class IV 19.73 7.55 9.865 39.46
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Appendix 16 Regression analyses for
deriving model parameters
Kaplan–Meier curves for overall survival were used to derive approximate hazard functions using aWeibull distribution. Transition probabilities, used in the model, can be calculated from the estimated
hazard functions.220 The Weibull distribution is defined according to two parameters: the scale parameter
(λ) and the shape parameter (γ). These parameters were fitted using linear regression of transformations of
the Kaplan–Meier estimates. To do this, scanned images of the Kaplan–Meier curves were imported in
Engauge software and the extracted data points were then exported to Microsoft Excel for further analysis.
For a Weibull distribution the survival function is given by:
S(t) ¼ exp (−λtγ) (3)
with scale parameter λ and shape γ.
Taking the log of both sides gives:
log (S(t)) ¼ −λtγ (4)
Taking the log of both sides again gives:
log (−log (S(t))) ¼ log (λ)þ γlog (t) (5)
which is a linear function and can be fit using least-squares methods to provide estimates of λ and γ.
Population 1
Table 164 shows the parameters derived for estimation of all-cause mortality for the OPT arm in the model
for population 1.
Secondary prevention
Figure 43 shows the Weibull approximation fitted to the Kaplan–Meier curve for overall survival of patients
in the AVID trial,71 who survived VF or sustained VT that had caused haemodynamic compromise.
Goodness of fit can be inspected visually as well as being indicated by the R2 measure close to 1
(R2= 0.994). The shape parameter (γ= 0.70) for the Weibull approximation for the AVID trial is < 1,
indicating that the hazard rate decreases with time.
Primary prevention: remote myocardial infarction
Figure 44 illustrates the curve-fitting process for patients with remote MI and reduced LVEF using data
extracted from the MADIT II trial,101 showing the fitted Weibull approximation. Visual inspection suggests
that the curve fits the data well (R2 from the regression is 0.99). The shape parameter (γ= 1.01) is close
to 1, which indicates that the distribution could potentially be reduced to the exponential form.
Primary prevention: mild to moderate heart failure
The Kaplan–Meier curve for overall survival of patients in the control group with mild to moderate HF at
increased risk of SCD using data extracted from the SCD-HeFT trial105 is shown in Figure 45, as well as its
derived Weibull approximation. The R2 of 0.993 confirms the goodness of fit of the Weibull model to the
Kaplan–Meier curve of the trial. The shape parameter (γ= 1.08) is slightly above 1, indicating that the
hazard rate slightly increases with time.
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TABLE 164 Weibull model parameters for all-cause mortality
Parameter
Mean (SE)
AVID71
(R2= 0.994)
MADIT II101
(R2= 0.9903)
SCD-HeFT105
(R2= 0.993)
SCD-HeFT,105 non-ischaemic CHF
subgroup (R2= 0.985)
ln(λ) –3.380 (0.026) –4.628 (0.047) –5.288 (0.039) –4.821 (0.037)
γ 0.696 (0.009) 1.007 (0.017) 1.083 (0.011) 0.883 (0.011)
Weibull model: ln(–ln(S))= ln(λ)+ γln(t); S(t)= exp(–λ.t^γ).
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FIGURE 43 Kaplan–Meier survival estimates and Weibull approximation for all-cause mortality: AVID
trial population.71
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FIGURE 44 Kaplan–Meier survival estimates and Weibull approximation for all-cause mortality in patients with
remote MI and reduced LVEF: MADIT II trial population.52
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Primary prevention: cardiomyopathy
The SCD-HeFT trial105 reported all-cause mortality for the subgroup of patients with non-ischaemic CHF.
The Kaplan–Meier curve for the placebo arm was used to derive the baseline mortality for the subgroup
analysis of patients with cardiomyopathy (Figure 46). The R2 from the regression (0.99) and visual
inspection of the Weibull approximation suggest that the model fits the Kaplan–Meier estimates well.
Table 165 provides a comparison between the observed survival reported at given years for each trial and
the model predictions.
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FIGURE 45 Kaplan–Meier survival estimates and Weibull approximation for overall survival in patients with mild to
moderate HF: SCD-HeFT trial population.105
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FIGURE 46 Kaplan–Meier survival estimates and Weibull approximation for all-cause mortality in patients with
non-ischaemic CHF: SCD-HeFT trial population.105
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Population 2
Cardiac mortality
The CARE-HF trial111 is the trial with the longest follow-up period of those included in SHTAC’s clinical
effectiveness review for people with HF as a result of LVSD and cardiac dyssynchrony despite receiving
OPT. Hence, baseline time-dependent probabilities of SCD and death from worsening HF were derived
from CARE-HF survival curves.111 Table 166 shows the parameters derived for the estimation of SCD and
HF deaths for the OPT arm.
TABLE 165 Regression results and comparison of observed survival against Weibull model predictions: all-cause
mortality in the AVID,71 MADIT-II101 and SCD-HeFT105 trials
Year
Study report Weibull approximation
AAD ICD AAD ICDa
AVID71 (R2 = 0.994), λ = 0.0340, γ = 0.6962
1 0.823 0.893 0.825 0.881
2 0.747 0.816 0.733 0.814
3 0.641 0.754 0.662 0.762
Conventional medical therapy ICD Conventional medical therapy ICDb
MADIT II101 (R2 = 0.9903), λ = 0.0098, γ = 1.0068
1 0.90 0.91 0.89 0.92
2 0.78 0.84 0.79 0.85
3 0.69 0.78 0.70 0.78
Placeboc ICDc Placebo ICDd
SCD-HeFT105 (R2 = 0.993), λ = 0.0051, γ = 1.0831
1 0.940 0.938 0.928 0.944
2 0.854 0.885 0.854 0.885
3 0.777 0.827 0.783 0.828
4 0.708 0.777 0.716 0.773
5 0.639 0.711 0.653 0.720
a HR (defibrillator vs. AAD) for total mortality is not reported in the AVID trial publication.71 Survival probabilities with a
defibrillator were calculated by applying the RR (0.66) calculated in the systematic review.
b Survival probabilities with a defibrillator were calculated by applying the HR of 0.69 from the trial report101 to the
Weibull approximation.
c Survival probabilities for each year are not reported in the SCD-HeFT trial publication.105 These values were estimated
from the scanned Kaplan–Meier curves.
d Survival probabilities with a defibrillator were calculated by applying the HR of 0.77 from the trial publication105 to the
Weibull approximation.
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Population 3
Mortality and relative risks
Estimates of survival over time were derived from Kaplan–Meier curves reported for relevant trials included
in the systematic review. The two largest trials reporting the longest follow-up and comparing events
between groups statistically (MADIT-CRT135 and RAFT140) were included in this analysis.
Kaplan–Meier curves for all-cause mortality were used to derive approximate hazard functions using a
Weibull distribution. Parameters for the Weibull distribution were fit in Microsoft Excel using linear
regression of transformations of the Kaplan–Meier estimates obtained using Engauge software. Table 167
presents the regression results using data extracted from both trials.135,140
The R2 statistics reported for the regressions in Table 167 confirm that the Weibull models fit the data well.
Figure 47 shows the Weibull approximation to the Kaplan–Meier estimates obtained from the curve
published for the ICD-CRT arm of the RAFT trial.140 The γ value (1.24, 95% CI 1.20 to 1.27) is > 1,
indicating that the probability of death increases over time.
Table 168 provides a comparison between observed survival at times reported for the trials and
model predictions.
TABLE 166 Weibull model parameters for SCD and HF mortality
Parameter Mean 95% CI
SCD
ln(λ) –6.069 –6.173 to –5.964
γ 1.140 1.107 to 1.173
HF
ln(λ) –6.115 –6.256 to –5.974
γ 1.223 1.179 to 1.266
Weibull model: ln(–ln(S))= ln(λ)+ γln(t); S(t)= exp(–λ.t^γ).
TABLE 167 Regression results: parameters used to fit the Weibull models
Parameter Mean 95% CI
RAFT140
ICD-CRT arm (R2= 0.9894)
ln(λ) –6.334 –6.202 to –6.467
γ 1.243 1.20 to 1.27
MADIT-CRT135
Men, CRT-D arm (R2= 0.989)
ln(λ) –6.935 –7.005 to –6.865
γ 1.287 1.266 to 1.308
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FIGURE 47 Weibull approximation to Kaplan–Meier survival for all-cause mortality of patients receiving CRT-D in
the RAFT trial.140
TABLE 168 Comparison between observed survival and Weibull model predictions: all-cause mortality in the
RAFT140 and MADIT-CRT135 trials
Year
Study report Weibull approximation
ICD-CRTa ICDa ICD-CRT ICDb
RAFT140
1 0.954 0.937 0.959 0.945
2 0.902 0.877 0.906 0.876
3 0.860 0.811 0.849 0.804
4 0.797 0.718 0.792 0.733
5 0.714c 0.654c 0.736 0.664
6 0.663 0.553 0.681 0.599
CRT-Da ICDa CRT-D ICDd
MADIT-CRT men135
1 0.974 0.976 0.974 0.975
2 0.946 0.939 0.938 0.941
3 0.889 0.929 0.897 0.901
4 0.855 0.851 0.854 0.858
a Survival probabilities for each year are not reported in the trial publication. These values were estimated from the
scanned Kaplan–Meier curves.
b Survival probabilities with a defibrillator were calculated by applying the reverse HR of 0.75 for ICD-CRT from the trial
report140 to the Weibull approximation.
c Survival probabilities reported in the RAFT trial publication.140
d Survival probabilities with a defibrillator were calculated by applying the reverse HR of 1.05 for men in the ICD-CRT arm
from the trial report135 to the Weibull approximation.
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Appendix 17 Validation of the independent
economic model
Validation against the model developed by Fox
and colleagues64
At an early stage of model development, the OPT arm of the model developed by Fox and colleagues64 for
TA12043 was replicated. The OPT arm consisted of a cohort of patients with HF initially managed with OPT
alone who are eligible for ICD implantation. Table 169 summarises the outputs of the original model and
the replica in terms of life-years and respective discounted QALYs spent in each health state. The same
state occupancy was obtained with both versions of the model.
Having reproduced this model arm, the model was adapted according to clinical advice to reflect disease
progression for the populations defined in the scope developed by NICE61 for this assessment.
Validation against trial data
Population 1
The model was validated against trial data for all-cause mortality from the AVID,71 MADIT II101 and
SCD-Heft105 trials. The model used the all-cause mortality regression parameters calculated for these trials
and the trial RR for ICDs, that is, 0.66 for AVID, 0.71 for MADIT II and 0.77 for SCD-HEFT. Figures 48–50
show the results from these analyses. The model-generated results show a good fit against the AVID trial71
data. The model results show a reasonable fit against the MADIT II and SCD-HeFT trial data, although the
model appears to slightly underestimate the benefit of ICD compared with OPT and therefore may be a
conservative fit.
Population 2
The model was validated against the trial data for all-cause mortality from the CARE-HF trial.111 The model
used the SCD and HF mortality regression parameters calculated for this trial and the trial RR for ICD, that
is 0.55 for HF and 0.54 for SCD. Figure 51 shows the results from this analysis. The model-generated
results show a reasonable fit against the CARE-HF trial111 data, although the model underestimates
all-cause mortality for the OPT arm. This is likely to be an underestimate of non-cardiac mortality for this
group. The model results show a reasonable fit against the CRT arm from the CARE-HF trial, although the
model appears to underestimate the benefit of CRT compared with OPT and therefore may be a
conservative fit.
Population 3
The model was validated against the trial data for all-cause mortality from the RAFT trial.140 The model
used the all-cause mortality regression parameters calculated for this trial and the trial RR of 0.75 for
CRT-D compared with ICD. Figure 52 shows the results from this analysis. The model-generated results
show a good fit against the RAFT trial data.
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TABLE 169 Model outputs for an average 70-year-old patient with HF initially managed with OPT
Health state
Life-years Discounted QALYs
Fox and colleagues64 Replica Fox and colleagues64 Replica
Stable with OPT 3.42 3.42 2.17 2.17
Hospitalised with OPT 0.13 0.13 0.08 0.08
ICD implantation 0.03 0.03 0.02 0.02
Perioperative complications 0.01 0.01 0.00 0.00
Stable with ICD 1.56 1.56 0.98 0.98
Hospitalised with ICD 0.06 0.06 0.04 0.04
Device replacement 0.02 0.02 0.01 0.01
Device-related infection 0.00 0.00 0.00 0.00
Lead displacement 0.00 0.00 0.00 0.00
Transplanted 0.03 0.03 0.02 0.02
Total 5.26 5.26 3.31 3.31
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FIGURE 48 Overall survival curves for OPT and ICD compared with AVID trial data.71 M, model; T, trial.
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FIGURE 49 Overall survival curves for OPT and ICD compared with MADIT II trial data.101
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FIGURE 50 Overall survival curves for OPT and ICD compared with SCD-HeFT trial data.105
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FIGURE 51 Overall survival curves for CRT and OPT compared with CARE-HF trial data.111
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FIGURE 52 Overall survival curves for CRT-D and ICD compared with RAFT trial data.140
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